#Cerebral Cortex Neuroproteomic data

library(readr)
cerebral <- read_delim("C:/Users/abc/Desktop/cerebral.tsv", 
                       "\t", escape_double = FALSE, trim_ws = TRUE)
View(cerebral)

write.csv(cerebral, "/Users/abc/Desktop/CCproteindata.csv", row.names=FALSE)


"Gene","Gene synonym","Ensembl","Gene description","Chromosome","Position","Protein class","Evidence","Antibody","Reliability (IH)","Reliability (Mouse Brain)","Reliability (IF)","Subcellular location","Prognostic p-value","RNA cancer category","RNA tissue category","RNA TS","RNA TS TPM","TPM max in non-specific","RNA cell line category","RNA CS","RNA CS TPM"
"DAB1",NA,"ENSG00000173406","DAB1, reelin adaptor protein","1","56994778-58546734","Predicted intracellular proteins","Evidence at protein level","CAB032329, HPA052033, HPA067495","Enhanced",NA,"Supported","Vesicles",NA,"Mixed","Tissue enhanced",NA,"duodenum: 15.9;seminal vesicle: 13.8;small intestine: 24.8","prostate: 6.4","Cell line enhanced",NA,"fHDF/TERT166: 41.8;HeLa: 12.9;NTERA-2: 23.4;RT4: 25.5;WM-115: 26.3"
"PAFAH1B1","LIS1, MDCR, MDS, NudF, PAFAH","ENSG00000007168","Platelet activating factor acetylhydrolase 1b regulatory subunit 1","17","2593210-2685615","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB004489, HPA020036","Approved",NA,"Enhanced","Centrosome","Renal cancer:3.16e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 178.7","Expressed in all",NA,NA
"CDK5","PSSALRE","ENSG00000164885","Cyclin dependent kinase 5","7","151053812-151058530","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","CAB008909, HPA064535","Enhanced",NA,"Supported","Nucleus<br>Plasma membrane<br>Cell Junctions",NA,"Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 49.9","Expressed in all",NA,NA
"EMX1",NA,"ENSG00000135638","Empty spiracles homeobox 1","2","72916260-72936071","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA006230, HPA006421","Approved",NA,"Approved","Nucleoli","Renal cancer:1.54e-6 (favourable)","Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 8.3;kidney: 15.5;parathyroid gland: 5.0","testis: 2.6","Cell line enhanced",NA,"BEWO: 2.2;CACO-2: 3.1;HEK 293: 7.5"
"NKX2-1","BCH, NKX2A, TITF1, TTF-1, TTF1","ENSG00000136352","NK2 homeobox 1","14","36516392-36521149","Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors","Evidence at protein level","CAB000078, CAB053633, HPA074316","Enhanced",NA,"Uncertain","Golgi apparatus<br>Vesicles",NA,"Group enriched","Group enriched",177,"lung: 101.3;thyroid gland: 103.5","stomach: 0.5","Cell line enriched",36,"SCLC-21H: 119.8"
"NR2E1","TLL, TLX, XTLL","ENSG00000112333","Nuclear receptor subfamily 2 group E member 1","6","108166058-108188809","Nuclear receptors, Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA036954, HPA055642","Enhanced",NA,"Approved","Nuclear bodies",NA,"Tissue enriched","Tissue enriched",46,"cerebral cortex: 11.4","adrenal gland: 0.2","Cell line enhanced",NA,"BEWO: 2.9;U-251 MG: 3.3"
"ADGRG1","GPR56, TM7LN4, TM7XN1","ENSG00000205336","Adhesion G protein-coupled receptor G1","16","57610652-57665580","Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA046065","Uncertain",NA,NA,NA,"Renal cancer:5.52e-7 (favourable), Head and neck cancer:2.53e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 349.0","Cell line enhanced",NA,"SK-MEL-30: 229.9"
"ENC1","ENC-1, KLHL37, NRPB, PIG10, TP53I10","ENSG00000171617","Ectodermal-neural cortex 1","5","74627406-74641424","Cancer-related genes, Predicted intracellular proteins","Evidence at protein level","HPA078061",NA,NA,"Uncertain","Plasma membrane","Renal cancer:2.95e-5 (unfavourable), Breast cancer:3.88e-4 (unfavourable)","Expressed in all","Tissue enriched",15,"cerebral cortex: 461.4","gallbladder: 30.8","Mixed",NA,NA
"LHX6","LHX6.1","ENSG00000106852","LIM homeobox 6","9","122202577-122229626","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA047854, HPA058319","Approved",NA,"Uncertain","Nucleoli fibrillar center<br>Plasma membrane",NA,"Mixed","Mixed",NA,NA,"cerebral cortex: 8.1","Cell line enhanced",NA,"CACO-2: 10.9;NB-4: 11.6;PC-3: 11.4;U-87 MG: 9.4"
"RELN","PRO1598, RL","ENSG00000189056","Reelin","7","103471784-103989516","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA046512",NA,NA,"Approved","Plasma membrane<br>Focal adhesion sites",NA,"Tissue enhanced","Tissue enhanced",NA,"liver: 17.8","cerebral cortex: 7.3","Cell line enhanced",NA,"Hep G2: 43.5;PC-3: 11.6;SCLC-21H: 17.5;SH-SY5Y: 17.2;TIME: 29.6"
"DCX","DBCN, DC, LISX, SCLH, XLIS","ENSG00000077279","Doublecortin","X","111293779-111412429","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA036121",NA,"Supported","Approved","Cytosol",NA,"Tissue enriched","Tissue enhanced",NA,"cerebral cortex: 10.6","endometrium: 2.4","Group enriched",9,"SCLC-21H: 65.0;SH-SY5Y: 24.0"
"TBR1",NA,"ENSG00000136535","T-box, brain 1","2","161416094-161425870","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA051256, HPA078644, HPA078657","Enhanced","Approved",NA,NA,NA,"Not detected","Tissue enriched",30,"cerebral cortex: 30.6","testis: 1.0","Not detected",NA,NA
"PSEN1","AD3, FAD, PS1, S182","ENSG00000080815","Presenilin 1","14","73136418-73223691","Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters","Evidence at protein level","CAB006844, HPA030760, HPA067496","Approved",NA,"Approved","Nucleus<br>Golgi apparatus<br>Cell Junctions","Renal cancer:1.52e-8 (favourable), Liver cancer:1.99e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 66.0","Expressed in all",NA,NA
"ASCL1","ASH1, bHLHa46, HASH1","ENSG00000139352","Achaete-scute family bHLH transcription factor 1","12","102957686-102960516","Predicted secreted proteins, Transcription factors","Evidence at protein level","HPA029217","Enhanced",NA,NA,NA,NA,"Group enriched","Group enriched",8,"cerebral cortex: 16.2;liver: 6.4","adrenal gland: 1.4","Group enriched",23,"SCLC-21H: 63.4;SH-SY5Y: 30.9"
"PEX5","PTS1R, PXR1","ENSG00000139197","Peroxisomal biogenesis factor 5","12","7188685-7218574","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA039259, HPA039260","Enhanced",NA,"Supported","Golgi apparatus<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"testis: 81.3","Expressed in all",NA,NA
"ARX","CT121, EIEE1, ISSX, MRX29, MRX32, MRX33, MRX36, MRX38, MRX43, MRX54, MRX76, MRX87, MRXS1, PRTS","ENSG00000004848","Aristaless related homeobox","X","25003694-25016420","Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors","Evidence at protein level",NA,NA,NA,NA,NA,"Endometrial cancer:3.54e-7 (unfavourable)","Mixed","Tissue enriched",7,"ovary: 97.7","testis: 14.0","Cell line enhanced",NA,"HAP1: 2.0;PC-3: 3.6;U-266/70: 6.3"
"CDK5R1","Nck5a, p35, p35nck5a","ENSG00000176749","Cyclin dependent kinase 5 regulatory subunit 1","17","32486619-32491256","Predicted intracellular proteins","Evidence at protein level","HPA000252",NA,NA,"Supported","Nucleoplasm<br>Vesicles",NA,"Mixed","Tissue enriched",7,"cerebral cortex: 98.4","lymph node: 14.7","Cell line enhanced",NA,"SCLC-21H: 62.8;SK-MEL-30: 30.8"
"DAB2IP","AF9Q34, AIP1, DIP1/2, KIAA1743","ENSG00000136848","DAB2 interacting protein","9","121567057-121785530","Disease related genes, Predicted intracellular proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Renal cancer:4.00e-15 (favourable)","Expressed in all","Mixed",NA,NA,"testis: 33.8","Cell line enhanced",NA,"HaCaT: 72.1"
"DIXDC1","Dixin, KIAA1735","ENSG00000150764","DIX domain containing 1","11","111927144-112022584","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA039658",NA,NA,"Supported","Cytosol","Urothelial cancer:4.19e-5 (unfavourable), Renal cancer:6.89e-5 (favourable)","Expressed in all","Mixed",NA,NA,"seminal vesicle: 49.5","Cell line enhanced",NA,"TIME: 40.5"
"DLX1",NA,"ENSG00000144355","Distal-less homeobox 1","2","172084740-172089677","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA035666, HPA045884","Approved",NA,"Approved","Nucleus<br>Vesicles<br>Cell Junctions",NA,"Tissue enhanced","Tissue enhanced",NA,"adrenal gland: 1.6;cerebral cortex: 5.0","prostate: 0.8","Cell line enhanced",NA,"AN3-CA: 103.9"
"DLX2","TES-1","ENSG00000115844","Distal-less homeobox 2","2","172099439-172102900","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA056965",NA,NA,"Approved","Nuclear speckles",NA,"Mixed","Not detected",NA,NA,"cerebral cortex: 0.8","Group enriched",11,"AN3-CA: 73.7;HEK 293: 46.5"
"EMX2",NA,"ENSG00000170370","Empty spiracles homeobox 2","10","117542444-117549546","Disease related genes, Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA003497, HPA065294","Enhanced","Supported","Approved","Nucleus","Renal cancer:2.28e-13 (favourable), Cervical cancer:2.80e-4 (favourable)","Group enriched","Group enriched",5,"cervix, uterine: 59.5;endometrium: 114.9;epididymis: 115.2;fallopian tube: 73.0;kidney: 38.4;seminal vesicle: 65.3;smooth muscle: 59.8","cerebral cortex: 14.0","Cell line enhanced",NA,"EFO-21: 22.1;fHDF/TERT166: 20.9;RPTEC TERT1: 19.9"
"EOMES","TBR2","ENSG00000163508","Eomesodermin","3","27715949-27722711","Disease related genes, Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA028896","Uncertain",NA,NA,NA,"Renal cancer:9.45e-6 (unfavourable)","Tissue enhanced","Tissue enhanced",NA,"lymph node: 18.2;spleen: 19.4","tonsil: 5.3","Cell line enhanced",NA,"HDLM-2: 7.3;SCLC-21H: 4.9"
"FBXO45","Fbx45","ENSG00000174013","F-box protein 45","3","196568611-196589059","Predicted intracellular proteins","Evidence at protein level","HPA040730","Uncertain",NA,"Approved","Cytosol","Prostate cancer:1.16e-5 (unfavourable), Renal cancer:4.93e-5 (unfavourable), Liver cancer:7.61e-5 (unfavourable), Lung cancer:3.77e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"testis: 22.3","Expressed in all",NA,NA
"FEZF2","FEZL, FKSG36, FLJ10142, TOF, Zfp312, ZNF312","ENSG00000153266","FEZ family zinc finger 2","3","62369681-62374324","Predicted intracellular proteins, Transcription factors","Evidence at transcript level",NA,NA,NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",30,"cerebral cortex: 11.7","colon: 0.3","Cell line enhanced",NA,"AF22: 1.4;NTERA-2: 1.0"
"GLI3","ACLS, GCPS, PAP-A, PAPA, PAPA1, PAPB, PHS, PPDIV","ENSG00000106571","GLI family zinc finger 3","7","41960950-42237870","Disease related genes, Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA005534","Approved",NA,NA,NA,NA,"Mixed","Mixed",NA,NA,"endometrium: 15.9","Cell line enhanced",NA,"AF22: 44.3;WM-115: 32.9"
"RAC1","p21-Rac1, Rac-1, TC-25","ENSG00000136238","Ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1)","7","6374523-6403977","Cancer-related genes, Predicted intracellular proteins, RAS pathway related proteins","Evidence at protein level","CAB035994, HPA047820","Approved",NA,"Approved","Nucleus<br>Nucleoli<br>Cytosol","Liver cancer:1.74e-5 (unfavourable), Pancreatic cancer:4.57e-5 (unfavourable), Renal cancer:2.11e-4 (unfavourable), Lung cancer:4.59e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 281.6","Expressed in all",NA,NA
"SOCS7","NAP4, NCKAP4","ENSG00000274211","Suppressor of cytokine signaling 7","17","38352228-38405593","Predicted intracellular proteins","Evidence at protein level","HPA004475","Approved",NA,"Approved","Cytosol","Breast cancer:7.49e-4 (unfavourable), Endometrial cancer:7.87e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"testis: 54.4","thyroid gland: 13.1","Expressed in all",NA,NA
"CTNNB1","armadillo, beta-catenin, CTNNB","ENSG00000168036","Catenin beta 1","3","41194837-41260096","Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB000108, CAB001950, HPA029159, HPA029160","Enhanced",NA,"Enhanced","Plasma membrane","Colorectal cancer:7.54e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 285.6","Expressed in all",NA,NA
"DRD2",NA,"ENSG00000149295","Dopamine receptor D2","11","113409615-113475691","FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters","Evidence at protein level","HPA015139, HPA015691","Supported","Supported",NA,NA,NA,"Mixed","Tissue enhanced",NA,"adrenal gland: 11.2","smooth muscle: 2.2","Cell line enriched",10,"SCLC-21H: 104.3"
"FGFR2","BEK, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25","ENSG00000066468","Fibroblast growth factor receptor 2","10","121478334-121598458","Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","CAB010886, HPA035305, HPA056562","Uncertain",NA,"Approved","Vesicles","Cervical cancer:8.79e-4 (favourable), Head and neck cancer:9.32e-4 (favourable)","Expressed in all","Mixed",NA,NA,"skin: 129.4","Cell line enhanced",NA,"AN3-CA: 169.6;BEWO: 58.8;HAP1: 61.4;NTERA-2: 58.4"
"FLNA","ABP-280, FLN, FLN1, OPD1, OPD2","ENSG00000196924","Filamin A","X","154348524-154374638","Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters","Evidence at protein level","CAB000356, HPA000368, HPA001016, HPA001115, HPA002925","Enhanced","Approved","Enhanced","Plasma membrane<br>Actin filaments<br>Cytosol","Renal cancer:1.54e-6 (unfavourable), Urothelial cancer:3.88e-4 (unfavourable), Colorectal cancer:7.37e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"smooth muscle: 1051.0","Expressed in all",NA,NA
"KIF14","KIAA0042","ENSG00000118193","Kinesin family member 14","1","200551497-200620734","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA038061, HPA058220","Uncertain",NA,"Supported","Midbody ring<br>Cytosol","Lung cancer:8.64e-4 (unfavourable)","Mixed","Mixed",NA,NA,"testis: 4.6","Mixed",NA,NA
"SMO","FZD11, SMOH","ENSG00000128602","Smoothened, frizzled class receptor","7","129188872-129213545","Cancer-related genes, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins","Evidence at protein level","CAB011446","Approved",NA,NA,NA,NA,"Expressed in all","Mixed",NA,NA,"ovary: 30.4","Cell line enhanced",NA,"AN3-CA: 84.8;NTERA-2: 69.7"
"TSC1","hamartin, KIAA0243, LAM, TSC","ENSG00000165699","Tuberous sclerosis 1","9","132891348-132944633","Cancer-related genes, Disease related genes, Plasma proteins, Predicted membrane proteins","Evidence at protein level","CAB011568, CAB012481, HPA074132","Supported",NA,"Enhanced","Cytosol","Liver cancer:6.03e-6 (unfavourable), Renal cancer:7.91e-4 (favourable), Pancreatic cancer:8.01e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 33.7","Expressed in all",NA,NA
"WDR62","C19orf14, DKFZP434J046, FLJ33298, MCPH2","ENSG00000075702","WD repeat domain 62","19","36054881-36105106","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA043255, HPA043639, CAB046468","Enhanced",NA,"Enhanced","Microtubule organizing center<br>Cytosol",NA,"Mixed","Group enriched",8,"skeletal muscle: 15.9;testis: 76.4","heart muscle: 6.0","Mixed",NA,NA
"YWHAE","FLJ45465","ENSG00000108953","Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein epsilon","17","1344272-1400378","Cancer-related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA008445, CAB016200, CAB021109, CAB047350","Approved",NA,"Uncertain","Cytosol","Endometrial cancer:6.48e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 451.5","Expressed in all",NA,NA
"AKAP5","AKAP75, AKAP79","ENSG00000179841","A-kinase anchoring protein 5","14","64465499-64474503","Plasma proteins, Predicted intracellular proteins, Transporters","Evidence at protein level","CAB004308, HPA053891","Enhanced",NA,"Approved","Nucleoplasm",NA,"Mixed","Tissue enriched",5,"cerebral cortex: 22.5","rectum: 4.2","Cell line enhanced",NA,"CACO-2: 9.0"
"NEFL","CMT1F, CMT2E, NF68, NFL, PPP1R110","ENSG00000277586","Neurofilament light","8","24950955-24957110","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA014850, HPA015021","Enhanced","Supported","Approved","Nuclear speckles<br>Intermediate filaments","Renal cancer:4.91e-4 (unfavourable)","Tissue enhanced","Tissue enriched",10,"cerebral cortex: 289.3","adrenal gland: 29.0","Cell line enhanced",NA,"HEK 293: 544.8;PC-3: 147.7"
"NPY","PYY4","ENSG00000122585","Neuropeptide Y","7","24284163-24291865","Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB016733, CAB034368, HPA036636, HPA044572, HPA056798","Supported","Supported","Enhanced","Golgi apparatus","Endometrial cancer:5.78e-4 (unfavourable)","Tissue enriched","Group enriched",18,"adrenal gland: 153.2;cerebral cortex: 211.6;prostate: 495.0","appendix: 16.1","Cell line enriched",39,"SH-SY5Y: 696.9"
"NTRK2","TRKB","ENSG00000148053","Neurotrophic receptor tyrosine kinase 2","9","84668551-85027070","Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins","Evidence at protein level","HPA007637, CAB010346","Enhanced",NA,"Approved","Cytosol",NA,"Group enriched","Tissue enhanced",NA,"cerebral cortex: 439.6;thyroid gland: 215.7","breast: 82.1","Group enriched",5,"AF22: 9.4;HaCaT: 3.1;RPTEC TERT1: 8.1;SH-SY5Y: 12.9;WM-115: 2.8"
"RNF103","hkf-1, KF1, ZFP103","ENSG00000239305","Ring finger protein 103","2","86603393-86623866","Enzymes, Predicted membrane proteins","Evidence at protein level","HPA057922","Approved",NA,NA,NA,"Urothelial cancer:6.77e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"epididymis: 55.3","Expressed in all",NA,NA
"ATP1A3","DYT12","ENSG00000105409","ATPase Na+/K+ transporting subunit alpha 3","19","41966582-41997497","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters","Evidence at protein level","CAB033630, HPA045367, HPA056446","Enhanced",NA,NA,NA,"Renal cancer:3.02e-6 (unfavourable), Pancreatic cancer:6.15e-5 (favourable), Ovarian cancer:3.44e-4 (unfavourable)","Group enriched","Tissue enhanced",NA,"cerebral cortex: 378.4;heart muscle: 86.0","testis: 54.5","Cell line enhanced",NA,"Daudi: 39.5;SCLC-21H: 148.3;SH-SY5Y: 57.8"
"CNTNAP2","Caspr2, KIAA0868, NRXN4","ENSG00000174469","Contactin associated protein-like 2","7","146116002-148420998","Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA002739","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Group enriched",11,"cerebral cortex: 17.9;prostate: 6.0","fallopian tube: 1.0","Cell line enhanced",NA,"AF22: 7.9;CACO-2: 5.7;NTERA-2: 11.9;SCLC-21H: 28.5"
"KIAA0319","NMIG","ENSG00000137261","KIAA0319","6","24544104-24646155","Disease related genes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA015607, HPA076313","Enhanced",NA,"Uncertain","Vesicles",NA,"Mixed","Tissue enriched",6,"cerebral cortex: 15.8","fallopian tube: 2.8","Cell line enhanced",NA,"HDLM-2: 2.6;SCLC-21H: 5.1;U-266/84: 2.6"
"PRKCZ","PKC2","ENSG00000067606","Protein kinase C zeta","1","2050470-2185395","Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA021851","Enhanced",NA,"Approved","Plasma membrane<br>Cytosol","Renal cancer:1.64e-9 (favourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 99.7","placenta: 62.3","Cell line enhanced",NA,"BEWO: 45.1"
"TH","DYT5b","ENSG00000180176","Tyrosine hydroxylase","11","2163929-2171877","Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins","Evidence at protein level","CAB002522, HPA013768, HPA061003, CAB072340","Enhanced","Supported",NA,NA,NA,"Tissue enhanced","Tissue enriched",81,"adrenal gland: 259.8","adipose tissue: 3.2","Group enriched",26,"PC-3: 54.8;SK-BR-3: 15.7"
"AHSG","A2HS, FETUA, HSGA","ENSG00000145192","Alpha 2-HS glycoprotein","3","186612923-186621318","Cancer-related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA001524, HPA001525, CAB026209","Enhanced",NA,"Supported","Golgi apparatus",NA,"Tissue enriched","Tissue enriched",1903,"liver: 2823.4","testis: 1.4","Cell line enriched",64,"Hep G2: 1410.0"
"CERCAM","CEECAM1, CerCAM, GLT25D3","ENSG00000167123","Cerebral endothelial cell adhesion molecule","9","128411751-128437351","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA021657, HPA051595","Uncertain",NA,"Approved","Nucleus<br>Nucleoli<br>Cell Junctions","Renal cancer:3.33e-16 (unfavourable), Urothelial cancer:3.30e-5 (unfavourable), Ovarian cancer:5.22e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 155.6","Mixed",NA,NA
"CNTN2","AXT, TAG-1, TAX, TAX1","ENSG00000184144","Contactin 2","1","205042937-205078284","Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA001397, HPA012497","Approved",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",7,"cerebral cortex: 81.7","testis: 11.2","Group enriched",7,"NTERA-2: 3.8;SCLC-21H: 11.1"
"GRIN1","GluN1, NMDAR1","ENSG00000176884","Glutamate ionotropic receptor NMDA type subunit 1","9","137138390-137168762","Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters","Evidence at protein level","CAB006831","Approved",NA,NA,NA,NA,"Mixed","Tissue enriched",208,"cerebral cortex: 151.8","prostate: 0.7","Cell line enhanced",NA,"RPMI-8226: 1.8;SCLC-21H: 6.7;SH-SY5Y: 4.2"
"MCPH1","BRIT1, FLJ12847","ENSG00000147316","Microcephalin 1","8","6406592-6648504","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA008238, CAB012177","Supported",NA,"Uncertain","Nucleoplasm<br>Nuclear bodies","Colorectal cancer:8.52e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 19.5","Expressed in all",NA,NA
"NCOA1","bHLHe74, F-SRC-1, KAT13A, NCoA-1, RIP160, SRC1","ENSG00000084676","Nuclear receptor coactivator 1","2","24491914-24770702","Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors","Evidence at protein level","CAB019402, HPA070213, HPA070520","Enhanced",NA,"Enhanced","Nucleoplasm<br>Plasma membrane<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 59.0","Expressed in all",NA,NA
"NDE1","FLJ20101, NDE, nudE","ENSG00000072864","NudE neurodevelopment protein 1","16","15643267-15726353","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA024075","Approved",NA,NA,NA,"Renal cancer:8.19e-4 (unfavourable), Liver cancer:9.92e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"lymph node: 14.8","Expressed in all",NA,NA
"PAX5","BSAP","ENSG00000196092","Paired box 5","9","36833275-37034185","Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors","Evidence at protein level","CAB026269, CAB026869, HPA056394, HPA068498","Enhanced",NA,"Approved","Nucleoplasm<br>Vesicles<br>Cytosol",NA,"Mixed","Tissue enhanced",NA,"lymph node: 48.5;spleen: 26.2;tonsil: 33.2","appendix: 19.5","Group enriched",6,"Daudi: 48.5;REH: 181.0;U-698: 61.2"
"PLCB1","KIAA0581, PLC-I, PLC154","ENSG00000182621","Phospholipase C beta 1","20","8077251-8968360","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","CAB004275, CAB005334, HPA034743, HPA057910","Enhanced",NA,"Approved","Plasma membrane",NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 68.3;parathyroid gland: 121.3","placenta: 28.2","Cell line enhanced",NA,"Hep G2: 46.8"
"SYNE2","DKFZP434H2235, KIAA1011, Nesp2, Nesprin-2, NUA, NUANCE, SYNE-2","ENSG00000054654","Spectrin repeat containing nuclear envelope protein 2","14","63852983-64226433","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA003435, HPA050204","Enhanced",NA,"Enhanced","Nuclear membrane","Renal cancer:3.56e-9 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 197.1","Cell line enhanced",NA,"Daudi: 72.6"
"LRP6","ADCAD2","ENSG00000070018","LDL receptor related protein 6","12","12116025-12267012","Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","CAB004490, HPA029925","Enhanced",NA,NA,NA,NA,"Expressed in all","Mixed",NA,NA,"parathyroid gland: 16.4","Mixed",NA,NA
"AFDN","AF-6, AF6, MLLT4","ENSG00000130396","Afadin, adherens junction formation factor","6","167826922-167972023","Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins","Evidence at protein level","CAB013496, HPA030212, HPA030213, HPA030214, HPA030215, HPA049868","Approved",NA,"Enhanced","Nucleoplasm<br>Plasma membrane<br>Cell Junctions","Breast cancer:7.43e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"esophagus: 110.7","Mixed",NA,NA
"ARHGAP11B","B'-T, FAM7B1","ENSG00000187951","Rho GTPase activating protein 11B","15","30624494-30772993","Predicted intracellular proteins","Evidence at protein level","HPA064479","Uncertain",NA,"Approved","Vesicles",NA,"Mixed","Tissue enhanced",NA,"bone marrow: 2.0","lymph node,testis: 1.1","Mixed",NA,NA
"ASPM","ASP, Calmbp1, FLJ10517, FLJ10549, MCPH5","ENSG00000066279","Abnormal spindle microtubule assembly","1","197084128-197146694","Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB017816","Approved",NA,"Approved","Plasma membrane<br>Cytosol","Liver cancer:1.25e-4 (unfavourable), Endometrial cancer:1.97e-4 (unfavourable), Pancreatic cancer:2.40e-4 (unfavourable), Lung cancer:2.41e-4 (unfavourable)","Mixed","Mixed",NA,NA,"bone marrow: 9.3","Mixed",NA,NA
"ATIC","AICARFT, IMPCHASE, PURH","ENSG00000138363","5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase","2","215311817-215349773","Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB013462, HPA021012","Supported",NA,"Enhanced","Plasma membrane<br>Cytosol","Liver cancer:1.99e-7 (unfavourable), Renal cancer:8.77e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 44.8","Expressed in all",NA,NA
"ATOH1","bHLHa14, HATH1, MATH-1, Math1","ENSG00000172238","Atonal bHLH transcription factor 1","4","93828753-93830964","Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors","Evidence at transcript level",NA,NA,NA,NA,NA,"Colorectal cancer:3.26e-5 (favourable)","Tissue enhanced","Group enriched",9,"colon: 17.6;duodenum: 11.1;rectum: 19.7;small intestine: 22.4","appendix: 1.9","Not detected",NA,NA
"BAD","BBC2, BCL2L8","ENSG00000002330","BCL2 associated agonist of cell death","11","64269830-64284704","Cancer-related genes, Predicted intracellular proteins, RAS pathway related proteins","Evidence at protein level","CAB004205, HPA028185, HPA062105","Approved",NA,"Enhanced","Mitochondria",NA,"Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 48.9","Expressed in all",NA,NA
"BAX","BCL2L4","ENSG00000087088","BCL2 associated X, apoptosis regulator","19","48954815-48961798","Cancer-related genes, Predicted intracellular proteins, Transporters","Evidence at protein level","CAB004206, HPA027878","Approved",NA,NA,NA,"Liver cancer:1.63e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"appendix: 80.3","Expressed in all",NA,NA
"BBS2","BBS","ENSG00000125124","Bardet-Biedl syndrome 2","16","56466836-56520283","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA041315","Approved",NA,NA,NA,"Renal cancer:2.83e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"adrenal gland: 91.3","Expressed in all",NA,NA
"BBS4",NA,"ENSG00000140463","Bardet-Biedl syndrome 4","15","72686179-72738476","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA039418","Approved",NA,"Supported","Cytosol","Endometrial cancer:2.57e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 37.0","Expressed in all",NA,NA
"BCL2A1","ACC-1, ACC-2, ACC1, ACC2, BCL2L5, BFL1, GRS, HBPA1","ENSG00000140379","BCL2 related protein A1","15","79960889-79971446","Cancer-related genes, Predicted intracellular proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Renal cancer:2.77e-5 (unfavourable)","Expressed in all","Tissue enhanced",NA,"appendix: 115.2;bone marrow: 277.0","lymph node: 62.1","Cell line enhanced",NA,"HMC-1: 76.7;SK-MEL-30: 329.3;U-138 MG: 43.6"
"BNIP3","Nip3","ENSG00000176171","BCL2 interacting protein 3","10","131966455-131982013","Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters","Evidence at protein level","HPA003015, CAB011676","Supported",NA,"Uncertain","Cytosol","Renal cancer:4.55e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 84.1","Cell line enhanced",NA,"A-431: 338.9;U-87 MG: 339.6"
"BTBD3","dJ742J24.1, KIAA0952","ENSG00000132640","BTB domain containing 3","20","11890723-11926609","Predicted intracellular proteins","Evidence at protein level","HPA041424, HPA042048","Uncertain",NA,"Supported","Vesicles","Liver cancer:2.51e-5 (unfavourable), Lung cancer:6.94e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 60.1","Cell line enhanced",NA,"AN3-CA: 223.4;HeLa: 128.7"
"C16orf45","FLJ32618","ENSG00000166780","Chromosome 16 open reading frame 45","16","15434295-15625028","Predicted intracellular proteins","Evidence at protein level","HPA041114","Uncertain",NA,"Approved","Nucleoplasm<br>Cytosol","Liver cancer:1.53e-4 (favourable), Renal cancer:1.75e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 171.9","cervix, uterine: 59.6","Cell line enhanced",NA,"fHDF/TERT166: 72.2;U-87 MG: 109.4"
"CCDC85C",NA,"ENSG00000205476","Coiled-coil domain containing 85C","14","99500180-99604026","Predicted intracellular proteins","Evidence at protein level","HPA058346","Uncertain",NA,"Approved","Nuclear speckles<br>Cell Junctions","Renal cancer:2.60e-5 (favourable), Endometrial cancer:1.44e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"esophagus: 31.1","Mixed",NA,NA
"CDH2","CD325, CDHN, NCAD","ENSG00000170558","Cadherin 2","18","27950966-28177446","CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","CAB000141, CAB018580, HPA058574, CAB078686","Enhanced",NA,"Supported","Plasma membrane<br>Cell Junctions",NA,"Expressed in all","Tissue enhanced",NA,"heart muscle: 123.5;parathyroid gland: 126.2","adrenal gland: 87.3","Cell line enhanced",NA,"AF22: 306.2;fHDF/TERT166: 367.9"
"CDK5R2","NCK5AI, P39, p39nck5ai","ENSG00000171450","Cyclin dependent kinase 5 regulatory subunit 2","2","218959655-218962162","Predicted intracellular proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",10,"cerebral cortex: 52.1","adrenal gland: 5.1","Group enriched",10,"SCLC-21H: 21.4;SH-SY5Y: 14.0"
"CDON","CDO, CDON1, ORCAM","ENSG00000064309","Cell adhesion associated, oncogene regulated","11","125955796-126063335","Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB012422, HPA017377","Uncertain",NA,NA,NA,"Renal cancer:1.78e-7 (unfavourable), Breast cancer:1.35e-4 (favourable)","Mixed","Tissue enhanced",NA,"thyroid gland: 75.5","ovary: 53.5","Cell line enhanced",NA,"AF22: 55.0;ASC diff: 47.4;RH-30: 93.1"
"CEP120","CCDC100, FLJ36090","ENSG00000168944","Centrosomal protein 120","5","123344885-123423592","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA028823, HPA051556","Uncertain",NA,"Approved","Microtubules<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"testis: 29.7","Expressed in all",NA,NA
"CHD5",NA,"ENSG00000116254","Chromodomain helicase DNA binding protein 5","1","6101793-6180123","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA015809, HPA055477","Supported",NA,"Supported","Nucleoplasm<br>Nuclear speckles<br>Cytosol",NA,"Mixed","Tissue enriched",7,"cerebral cortex: 42.1","testis: 6.2","Cell line enhanced",NA,"SCLC-21H: 16.0;U-2 OS: 6.3"
"CLASP1","KIAA0622, MAST1","ENSG00000074054","Cytoplasmic linker associated protein 1","2","121337776-121649587","Predicted intracellular proteins","Evidence at protein level","HPA065219","Uncertain",NA,NA,NA,"Renal cancer:6.50e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 34.4","Expressed in all",NA,NA
"CLASP2","KIAA0627","ENSG00000163539","Cytoplasmic linker associated protein 2","3","33496245-33718356","Predicted intracellular proteins","Evidence at protein level","HPA067071",NA,NA,"Supported","Golgi apparatus<br>Cytosol","Renal cancer:1.48e-6 (favourable)","Expressed in all","Tissue enriched",6,"cerebral cortex: 193.2","endometrium: 34.2","Expressed in all",NA,NA
"COL3A1","EDS4A","ENSG00000168542","Collagen type III alpha 1 chain","2","188974320-189012746","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA007583, CAB016766, CAB059993","Approved",NA,NA,NA,"Renal cancer:3.59e-10 (unfavourable)","Expressed in all","Tissue enhanced",NA,"cervix, uterine: 3796.7;gallbladder: 3334.2;smooth muscle: 3029.8","placenta: 2768.0","Cell line enhanced",NA,"AF22: 1344.2;ASC diff: 1690.4;ASC TERT1: 2979.5;fHDF/TERT166: 1406.5;HHSteC: 1419.6;HSkMC: 2318.4"
"CSNK2A2","CK2alpha', CSNK2A1","ENSG00000070770","Casein kinase 2 alpha 2","16","58157907-58197920","Cancer-related genes, Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA077719",NA,NA,"Approved","Nucleoplasm<br>Vesicles<br>Cytosol","Head and neck cancer:1.40e-5 (unfavourable), Liver cancer:1.80e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 237.6","Expressed in all",NA,NA
"DISC1",NA,"ENSG00000162946","Disrupted in schizophrenia 1","1","231626815-232041272","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA048911",NA,NA,"Approved","Intermediate filaments",NA,"Mixed","Mixed",NA,NA,"placenta: 10.5","Mixed",NA,NA
"DMRTA2",NA,"ENSG00000142700","DMRT like family A2","1","50417550-50423500","Predicted secreted proteins, Transcription factors","Evidence at protein level","HPA043098, HPA062958","Uncertain",NA,"Approved","Nucleoplasm<br>Mitochondria",NA,"Tissue enhanced","Not detected",NA,NA,"testis: 0.7","Cell line enhanced",NA,"BEWO: 3.0;HBEC3-KT: 2.3;RH-30: 11.1;SH-SY5Y: 2.6;SiHa: 2.5"
"DRD1",NA,"ENSG00000184845","Dopamine receptor D1","5","175440039-175444208","FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins","Evidence at protein level","HPA013393",NA,"Supported",NA,NA,NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 8.0","prostate: 1.7","Group enriched",10,"RT4: 20.9;U-2 OS: 5.4"
"EFHC1","EJM, EJM1, FLJ10466","ENSG00000096093","EF-hand domain containing 1","6","52362123-52529886","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA035307","Approved",NA,"Uncertain","Plasma membrane<br>Cytosol","Pancreatic cancer:2.33e-4 (favourable), Renal cancer:3.29e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"fallopian tube: 55.6","testis: 31.3","Cell line enhanced",NA,"SCLC-21H: 22.6"
"EGFR","ERBB, ERBB1","ENSG00000146648","Epidermal growth factor receptor","7","55019021-55211628","Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","CAB000035, HPA001200, HPA018530, CAB068186, CAB073534","Enhanced",NA,"Enhanced","Plasma membrane","Urothelial cancer:2.04e-5 (unfavourable)","Expressed in all","Tissue enhanced",NA,"placenta: 100.0","skin: 58.7","Cell line enriched",15,"A-431: 4682.9"
"EZR","VIL2","ENSG00000092820","Ezrin","6","158765741-158819412","Cancer-related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB004035, HPA021616, CAB047324, CAB075739","Enhanced",NA,"Enhanced","Plasma membrane","Renal cancer:9.56e-8 (favourable), Pancreatic cancer:1.70e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 537.0","Expressed in all",NA,NA
"FAT4","CDHF14, CDHR11, FAT-J","ENSG00000196159","FAT atypical cadherin 4","4","125316399-125492932","Cancer-related genes, Disease related genes, Predicted membrane proteins","Evidence at protein level","HPA052819","Approved",NA,"Approved","Cytosol","Renal cancer:1.89e-4 (favourable)","Mixed","Mixed",NA,NA,"parathyroid gland: 9.6","Cell line enhanced",NA,"HUVEC TERT2: 11.5;TIME: 17.8"
"FGF13","FGF2, FHF2","ENSG00000129682","Fibroblast growth factor 13","X","138614731-139222777","Predicted intracellular proteins, RAS pathway related proteins","Evidence at protein level","HPA002809",NA,NA,"Supported","Cytosol",NA,"Mixed","Tissue enhanced",NA,"parathyroid gland: 108.4","cerebral cortex: 47.9","Cell line enhanced",NA,"AF22: 42.4;HAP1: 40.9;U-2197: 64.4;WM-115: 37.0"
"FGFR1","BFGFR, CD331, CEK, FLG, FLT2, H2, H3, H4, H5, KAL2, N-SAM","ENSG00000077782","Fibroblast growth factor receptor 1","8","38411138-38468834","Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","CAB033614, HPA056402, HPA076274","Approved",NA,"Supported","Nucleoli",NA,"Expressed in all","Expressed in all",NA,NA,"cervix, uterine: 109.5","Cell line enhanced",NA,"AN3-CA: 602.2"
"FOXG1","BF1, FKH2, FKHL1, FKHL2, FKHL3, FKHL4, FOXG1A, FOXG1B, FOXG1C, HBF-3, HFK1, HFK2, HFK3, QIN","ENSG00000176165","Forkhead box G1","14","28760330-28770277","Disease related genes, Predicted intracellular proteins, Transcription factors","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enriched","Tissue enriched",6,"cerebral cortex: 29.6","testis: 5.2","Cell line enhanced",NA,"HEK 293: 10.3;SCLC-21H: 34.2;U-138 MG: 17.5;U-251 MG: 15.3"
"FOXP2","CAGH44, SPCH1, TNRC10","ENSG00000128573","Forkhead box P2","7","114086327-114693772","Disease related genes, Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA000382, HPA000383, HPA001679","Enhanced",NA,"Enhanced","Nucleoplasm",NA,"Mixed","Mixed",NA,NA,"endometrium: 13.7","Cell line enhanced",NA,"AF22: 20.9;RH-30: 37.7"
"FUT10",NA,"ENSG00000172728","Fucosyltransferase 10","8","33370824-33473422","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA053970, HPA058655","Uncertain",NA,"Approved","Nucleoplasm<br>Endoplasmic reticulum<br>Golgi apparatus",NA,"Mixed","Mixed",NA,NA,"parathyroid gland: 8.7","Mixed",NA,NA
"GART","PGFT, PRGS","ENSG00000159131","Phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase","21","33503931-33543491","Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA002119, HPA005779","Approved",NA,"Uncertain","Nucleoplasm<br>Mitochondria<br>Cytosol","Renal cancer:3.95e-6 (unfavourable), Head and neck cancer:5.05e-5 (unfavourable), Liver cancer:9.82e-5 (unfavourable), Pancreatic cancer:2.19e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 55.1","Expressed in all",NA,NA
"GDPD5","GDE2, PP1665","ENSG00000158555","Glycerophosphodiester phosphodiesterase domain containing 5","11","75434640-75525903","Predicted membrane proteins","Evidence at protein level","HPA065257, HPA066762, HPA069281","Uncertain",NA,"Approved","Golgi apparatus","Renal cancer:6.59e-9 (unfavourable), Endometrial cancer:1.29e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"spleen: 67.0","testis: 31.2","Cell line enhanced",NA,"HDLM-2: 62.5"
"GNG12",NA,"ENSG00000172380","G protein subunit gamma 12","1","67701466-67833467","Predicted intracellular proteins, RAS pathway related proteins","Evidence at protein level","HPA057790, HPA062208","Enhanced",NA,"Approved","Mitochondria",NA,"Expressed in all","Mixed",NA,NA,"duodenum: 122.4","Mixed",NA,NA
"H2AFX","H2AX","ENSG00000188486","H2A histone family member X","11","119093854-119095467","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB012264, HPA041189, HPA051647","Supported",NA,"Supported","Nucleoplasm<br>Nuclear speckles","Renal cancer:5.47e-9 (unfavourable), Liver cancer:1.51e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"lymph node: 18.7","Expressed in all",NA,NA
"HIF1A","bHLHe78, HIF-1alpha, HIF1, MOP1, PASD8","ENSG00000100644","Hypoxia inducible factor 1 alpha subunit","14","61695513-61748259","Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA000907, HPA001275, CAB017442","Supported",NA,"Supported","Nucleoplasm<br>Nuclear bodies<br>Plasma membrane",NA,"Expressed in all","Expressed in all",NA,NA,"bone marrow: 292.4","Mixed",NA,NA
"HPRT1","HGPRT, HPRT","ENSG00000165704","Hypoxanthine phosphoribosyltransferase 1","X","134460153-134520513","Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA006360, CAB012200","Enhanced",NA,"Supported","Cytosol","Head and neck cancer:1.35e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 139.1","Mixed",NA,NA
"HTR6","5-HT6, 5-HT6R","ENSG00000158748","5-hydroxytryptamine receptor 6","1","19665287-19679562","FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enhanced","Not detected",NA,NA,"cerebral cortex: 0.8","Cell line enhanced",NA,"SH-SY5Y: 2.1"
"ID4","bHLHb27","ENSG00000172201","Inhibitor of DNA binding 4, HLH protein","6","19837386-19840684","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA060800",NA,NA,"Supported","Nucleus","Pancreatic cancer:2.49e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"thyroid gland: 626.0","fallopian tube: 128.5","Cell line enhanced",NA,"AF22: 57.9;AN3-CA: 71.8;EFO-21: 163.7;HEK 293: 91.1;SCLC-21H: 185.5"
"IDI2","IPPI2","ENSG00000148377","Isopentenyl-diphosphate delta isomerase 2","10","1018907-1025859","Enzymes, Predicted intracellular proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Not detected","Tissue enriched",41,"skeletal muscle: 76.3","heart muscle: 1.8","Not detected",NA,NA
"KDM1A","AOF2, BHC110, KDM1, KIAA0601, LSD1","ENSG00000004487","Lysine demethylase 1A","1","23019448-23083689","Disease related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB005884, HPA053660","Supported",NA,"Enhanced","Nucleoplasm<br>Cytosol","Liver cancer:4.47e-12 (unfavourable), Colorectal cancer:6.31e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 163.3","Expressed in all",NA,NA
"LAMB1","CLM","ENSG00000091136","Laminin subunit beta 1","7","107923799-108003255","Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA004056, HPA004132, CAB004256","Enhanced",NA,NA,NA,"Liver cancer:2.07e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"placenta: 263.7","adipose tissue: 161.4","Cell line enhanced",NA,"HSkMC: 640.2"
"LHX2","hLhx2, LH-2","ENSG00000106689","LIM homeobox 2","9","124001670-124033301","Predicted intracellular proteins, Transcription factors","Evidence at transcript level","HPA000838",NA,"Supported","Approved","Nucleoplasm","Cervical cancer:9.52e-4 (favourable)","Group enriched","Tissue enriched",11,"cerebral cortex: 56.3","placenta: 5.1","Cell line enhanced",NA,"AN3-CA: 22.0;HAP1: 24.5;NTERA-2: 29.4"
"LRP1","A2MR, APOER, APR, CD91, LRP, LRP1A","ENSG00000123384","LDL receptor related protein 1","12","57128493-57213351","Candidate cardiovascular disease genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA004182, CAB018621, HPA022903","Supported",NA,"Supported","Nucleoplasm<br>Vesicles","Urothelial cancer:1.29e-5 (unfavourable), Renal cancer:1.52e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"adipose tissue: 123.8","Cell line enhanced",NA,"ASC diff: 333.3;ASC TERT1: 342.9;HSkMC: 232.4"
"LRP8","APOER2, HSZ75190, LRP-8, MCI1","ENSG00000157193","LDL receptor related protein 8","1","53242364-53328070","Disease related genes, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA073031","Enhanced",NA,NA,NA,"Endometrial cancer:3.46e-6 (unfavourable), Lung cancer:7.02e-4 (unfavourable)","Mixed","Group enriched",7,"cerebral cortex: 25.2;testis: 46.9;thyroid gland: 87.5","appendix: 7.7","Expressed in all",NA,NA
"MBOAT7","BB1, hMBOA-7, LENG4, LPIAT","ENSG00000125505","Membrane bound O-acyltransferase domain containing 7","19","54173412-54189882","Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins","Evidence at protein level","HPA055967","Approved",NA,"Approved","Cytosol","Liver cancer:5.55e-6 (unfavourable), Renal cancer:6.62e-5 (unfavourable), Urothelial cancer:4.31e-4 (favourable), Lung cancer:5.13e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 24.3","Cell line enhanced",NA,"HMC-1: 150.7"
"MDK","FLJ27379, MK, NEGF2","ENSG00000110492","Midkine (neurite growth-promoting factor 2)","11","46380756-46383837","Cancer-related genes, Predicted secreted proteins","Evidence at protein level","CAB010055, HPA057126","Uncertain",NA,"Approved","Vesicles","Renal cancer:3.06e-6 (unfavourable), Glioma:9.54e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"ovary: 524.3","Cell line enhanced",NA,"NTERA-2: 890.9;REH: 1226.8;SH-SY5Y: 1163.1"
"MKKS","BBS6","ENSG00000125863","McKusick-Kaufman syndrome","20","10401009-10434222","Disease related genes, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA041071, HPA044233","Enhanced",NA,"Supported","Centrosome","Renal cancer:3.79e-9 (favourable), Liver cancer:9.84e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 70.6","Expressed in all",NA,NA
"NDEL1","MITAP1, NDE1L1, NDE2, NUDEL","ENSG00000166579","NudE neurodevelopment protein 1 like 1","17","8413131-8490411","Predicted intracellular proteins","Evidence at protein level","HPA017916","Approved",NA,NA,NA,NA,"Expressed in all","Expressed in all",NA,NA,"adrenal gland: 81.4","Expressed in all",NA,NA
"NF1",NA,"ENSG00000196712","Neurofibromin 1","17","31094927-31382116","Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins","Evidence at protein level","HPA045502","Uncertain",NA,"Approved","Mitochondria",NA,"Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 33.0","Expressed in all",NA,NA
"NLRP5","CLR19.8, MATER, NALP5, PAN11, PYPAF8","ENSG00000171487","NLR family pyrin domain containing 5","19","55999726-56061813","Predicted secreted proteins","Evidence at protein level","HPA056271","Uncertain",NA,NA,NA,NA,"Not detected","Tissue enriched",51,"parathyroid gland: 22.9","testis: 0.4","Cell line enhanced",NA,"U-2 OS: 3.9"
"PAX6","AN, AN2, D11S812E, WAGR","ENSG00000007372","Paired box 6","11","31784779-31818062","Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors","Evidence at protein level","HPA030775, CAB034143","Supported",NA,"Enhanced","Nucleoplasm",NA,"Tissue enhanced","Group enriched",7,"cerebral cortex: 22.3;stomach: 11.2","testis: 2.5","Cell line enhanced",NA,"AF22: 15.6;AN3-CA: 19.1;HEK 293: 17.3;U-251 MG: 14.4"
"PEX13",NA,"ENSG00000162928","Peroxisomal biogenesis factor 13","2","61017225-61051990","Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters","Evidence at protein level","HPA032141, HPA032142, CAB032689","Enhanced",NA,"Supported","Vesicles","Pancreatic cancer:8.07e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 27.5","Expressed in all",NA,NA
"PKD2","Pc-2, PC2, PKD4, TRPP2","ENSG00000118762","Polycystin 2, transient receptor potential cation channel","4","88007668-88077777","Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels","Evidence at protein level","CAB004544, HPA015794","Approved",NA,"Enhanced","Endoplasmic reticulum",NA,"Expressed in all","Expressed in all",NA,NA,"endometrium: 101.0","Cell line enhanced",NA,"BJ hTERT+: 167.9"
"POU3F2","BRN2, OCT7, OTF7, POUF3","ENSG00000184486","POU class 3 homeobox 2","6","98834592-98839470","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA047081, HPA056261",NA,"Approved","Supported","Nucleus",NA,"Tissue enriched","Tissue enriched",70,"cerebral cortex: 20.4","testis: 0.2","Cell line enhanced",NA,"AF22: 123.9;U-251 MG: 32.8;WM-115: 33.3"
"POU3F3","BRN1, OTF8","ENSG00000198914","POU class 3 homeobox 3","2","104855511-104858574","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA052792, HPA056039, HPA067151","Approved",NA,"Enhanced","Nucleus","Endometrial cancer:4.26e-5 (unfavourable)","Group enriched","Group enriched",45,"cerebral cortex: 43.9;epididymis: 46.3;kidney: 36.6;seminal vesicle: 23.2","skin: 0.8","Group enriched",5,"AF22: 58.4;AN3-CA: 52.7;HEK 293: 20.3;RPTEC TERT1: 50.7;SH-SY5Y: 19.7"
"PPP1R9B","PPP1R6, PPP1R9, SPINO, Spn","ENSG00000108819","Protein phosphatase 1 regulatory subunit 9B","17","50133735-50150630","Predicted intracellular proteins","Evidence at protein level","CAB022461","Approved",NA,NA,NA,"Pancreatic cancer:3.11e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 76.2","Expressed in all",NA,NA
"PTPRS",NA,"ENSG00000105426","Protein tyrosine phosphatase, receptor type S","19","5158495-5340803","Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA054747",NA,NA,"Approved","Plasma membrane<br>Cytosol","Pancreatic cancer:1.07e-4 (favourable), Renal cancer:1.70e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"cerebral cortex: 70.7","Cell line enhanced",NA,"AN3-CA: 112.7;HaCaT: 110.4"
"RAC3",NA,"ENSG00000169750","Ras-related C3 botulinum toxin substrate 3 (rho family, small GTP binding protein Rac3)","17","82031624-82034204","Predicted intracellular proteins, RAS pathway related proteins","Evidence at protein level","HPA047820","Uncertain",NA,NA,NA,"Endometrial cancer:6.21e-5 (unfavourable), Thyroid cancer:4.69e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"testis: 22.7","Expressed in all",NA,NA
"RTN4","ASY, KIAA0886, NOGO, NSP-CL","ENSG00000115310","Reticulon 4","2","54972187-55112621","Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","CAB005388, HPA023977","Supported",NA,"Enhanced","Endoplasmic reticulum","Head and neck cancer:1.00e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 636.8","Expressed in all",NA,NA
"SLC38A2","ATA2, KIAA1382, SAT2, SNAT2","ENSG00000134294","Solute carrier family 38 member 2","12","46358189-46372867","Predicted membrane proteins","Evidence at protein level","HPA035180","Approved",NA,"Approved","Vesicles",NA,"Expressed in all","Expressed in all",NA,NA,"skin: 238.8","Mixed",NA,NA
"SRD5A1",NA,"ENSG00000145545","Steroid 5 alpha-reductase 1","5","6633343-6674386","Cancer-related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins","Evidence at protein level","HPA051402","Approved",NA,NA,NA,"Endometrial cancer:8.73e-6 (unfavourable)","Expressed in all","Mixed",NA,NA,"skin: 16.8","Mixed",NA,NA
"SRGAP2C","SRGAP2P1","ENSG00000171943","SLIT-ROBO Rho GTPase activating protein 2C","1","121184810-121392822","Predicted intracellular proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"parathyroid gland: 34.2","skin: 18.1","Cell line enhanced",NA,"WM-115: 78.0"
"SUN1","FLJ12407, KIAA0810, UNC84A","ENSG00000164828","Sad1 and UNC84 domain containing 1","7","816615-896435","Predicted intracellular proteins, Predicted membrane proteins, Transporters","Evidence at protein level","HPA008346, HPA008461","Enhanced",NA,"Enhanced","Nuclear membrane",NA,"Expressed in all","Expressed in all",NA,NA,"endometrium: 120.7","Expressed in all",NA,NA
"SUN2","UNC84B","ENSG00000100242","Sad1 and UNC84 domain containing 2","22","38734725-38794143","Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA001209","Supported",NA,"Supported","Nuclear membrane",NA,"Expressed in all","Expressed in all",NA,NA,"lymph node: 118.9","Expressed in all",NA,NA
"TACC1",NA,"ENSG00000147526","Transforming acidic coiled-coil containing protein 1","8","38728186-38853028","Predicted intracellular proteins","Evidence at protein level","CAB017041, HPA024702","Approved",NA,NA,NA,"Renal cancer:1.06e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"adipose tissue: 166.8","Expressed in all",NA,NA
"TACC2","AZU-1","ENSG00000138162","Transforming acidic coiled-coil containing protein 2","10","121989174-122254545","Predicted intracellular proteins","Evidence at protein level","HPA031020, HPA031021, HPA061394","Enhanced",NA,"Supported","Nucleoplasm<br>Plasma membrane<br>Cytosol","Renal cancer:2.50e-10 (favourable), Thyroid cancer:8.45e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"skeletal muscle: 112.7","Mixed",NA,NA
"TACC3","ERIC1","ENSG00000013810","Transforming acidic coiled-coil containing protein 3","4","1721490-1745176","Predicted intracellular proteins","Evidence at protein level","HPA005781, HPA006050, CAB010111, HPA022039","Enhanced",NA,"Enhanced","Vesicles<br>Mitotic spindle<br>Microtubule organizing center<br>Centrosome<br>Cytosol","Renal cancer:0.00e+0 (unfavourable), Liver cancer:3.30e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"testis: 74.9","lymph node: 55.8","Expressed in all",NA,NA
"TRA2B","Htra2-beta, PPP1R156, SFRS10","ENSG00000136527","Transformer 2 beta homolog (Drosophila)","3","185915906-185938136","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB011692, HPA063597, HPA064972","Supported",NA,"Enhanced","Nucleoplasm","Ovarian cancer:2.15e-4 (favourable), Liver cancer:8.51e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"appendix: 56.6","Expressed in all",NA,NA
"TRAPPC9","IKBKBBP, KIAA1882, MRT13, NIBP, T1, TRS120","ENSG00000167632","Trafficking protein particle complex 9","8","139730343-140458579","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA026579",NA,NA,"Approved","Nucleoplasm<br>Golgi apparatus<br>Vesicles","Renal cancer:5.11e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 49.7","Expressed in all",NA,NA
"XAB2","HCNP, HCRN, NTC90, SYF1","ENSG00000076924","XPA binding protein 2","19","7619525-7629565","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA048751",NA,NA,"Approved","Nucleus<br>Vesicles","Cervical cancer:4.04e-4 (favourable), Endometrial cancer:4.96e-4 (favourable), Pancreatic cancer:7.47e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 39.3","Expressed in all",NA,NA
"ZNF335","bA465L10.2, NIF-1","ENSG00000198026","Zinc finger protein 335","20","45948653-45972172","Disease related genes, Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA063999, HPA071230",NA,NA,"Enhanced","Nucleoplasm","Renal cancer:2.77e-5 (unfavourable), Liver cancer:1.59e-4 (unfavourable), Head and neck cancer:4.48e-4 (favourable), Prostate cancer:7.04e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"skin: 24.6","Expressed in all",NA,NA
"CTXN1","FLJ25968","ENSG00000178531","Cortexin 1","19","7924485-7926166","Predicted membrane proteins","Evidence at transcript level","HPA016669","Uncertain",NA,"Approved","Nucleoplasm<br>Plasma membrane<br>Cell Junctions",NA,"Expressed in all","Tissue enhanced",NA,"cerebral cortex: 100.4","endometrium: 22.7","Cell line enhanced",NA,"AN3-CA: 86.1;NTERA-2: 70.2;SCLC-21H: 63.8;SH-SY5Y: 96.5"
"CTTNBP2","C7orf8, CORTBP2, KIAA1758, Orf4","ENSG00000077063","Cortactin binding protein 2","7","117710651-117874139","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB009151, HPA044654","Enhanced",NA,"Approved","Midbody ring<br>Cytosol","Renal cancer:3.71e-5 (favourable)","Mixed","Mixed",NA,NA,"parathyroid gland: 19.1","Group enriched",6,"HEL: 50.6;HMC-1: 63.2"
"GAD1","GAD","ENSG00000128683","Glutamate decarboxylase 1","2","170813213-170861151","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","CAB004415, HPA031949, HPA058412, CAB078176","Enhanced","Supported","Approved","Vesicles","Cervical cancer:7.31e-4 (favourable), Endometrial cancer:8.61e-4 (favourable)","Tissue enhanced","Tissue enriched",6,"cerebral cortex: 75.3","parathyroid gland: 11.8","Cell line enhanced",NA,"HEL: 55.7"
"MEF2C",NA,"ENSG00000081189","Myocyte enhancer factor 2C","5","88717117-88904257","Disease related genes, Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA005533, CAB068196, CAB068197","Enhanced",NA,"Supported","Nucleoplasm<br>Vesicles","Renal cancer:1.01e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 197.9","Cell line enhanced",NA,"HEL: 205.2;REH: 238.4;WM-115: 143.4"
"PTK2B","CADTK, CAKB, FAK2, PTK, PYK2, RAFTK","ENSG00000120899","Protein tyrosine kinase 2 beta","8","27311482-27459391","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","CAB003850, HPA026091, HPA026276","Approved",NA,"Enhanced","Plasma membrane<br>Cytosol","Cervical cancer:3.32e-4 (favourable), Thyroid cancer:5.11e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"lymph node: 91.1","Cell line enhanced",NA,"REH: 128.1"
"SEPT5","H5, HCDCREL-1, PNUTL1","ENSG00000184702","Septin 5","22","19714464-19724772","Cancer-related genes, Predicted intracellular proteins","Evidence at protein level","CAB016120, HPA029095, HPA063885","Enhanced",NA,"Approved","Nucleoplasm<br>Actin filaments<br>Cytosol","Renal cancer:6.87e-6 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 386.8","Cell line enhanced",NA,"K-562: 211.0"
"SNCA","alpha-synuclein, NACP, PARK1, PARK4, PD1","ENSG00000145335","Synuclein alpha","4","89724099-89838315","Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters","Evidence at protein level","HPA005459, CAB010877","Enhanced",NA,NA,NA,NA,"Tissue enriched","Group enriched",5,"bone marrow: 160.8;cerebral cortex: 459.2","endometrium: 57.1","Cell line enhanced",NA,"HEL: 198.4;HUVEC TERT2: 218.9;SK-MEL-30: 203.3;TIME: 246.6"
"SPTBN4","KIAA1642, SPTBN3","ENSG00000160460","Spectrin beta, non-erythrocytic 4","19","40466241-40576464","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA054481","Enhanced",NA,"Approved","Nucleus<br>Nucleoli",NA,"Mixed","Tissue enriched",6,"cerebral cortex: 18.6","adrenal gland: 2.8","Cell line enhanced",NA,"K-562: 1.6;Karpas-707: 1.8;SCLC-21H: 4.6;SH-SY5Y: 2.5"
"APP","AD1","ENSG00000142192","Amyloid beta precursor protein","21","25880550-26171128","Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters","Evidence at protein level","CAB000157, HPA001462","Enhanced",NA,"Approved","Golgi apparatus<br>Vesicles","Renal cancer:2.79e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 1203.4","Mixed",NA,NA
"BFSP2","CP47, CP49, LIFL-L, phakinin","ENSG00000170819","Beaded filament structural protein 2","3","133399995-133475222","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA038464, HPA062959","Enhanced",NA,"Uncertain","Plasma membrane<br>Cytosol",NA,"Tissue enriched","Not detected",NA,NA,"lymph node: 0.4","Group enriched",7,"Daudi: 1.5;U-698: 1.7"
"DBN1","D0S117E","ENSG00000113758","Drebrin 1","5","177456608-177474401","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA051452, HPA056940","Enhanced",NA,"Supported","Plasma membrane<br>Actin filaments","Renal cancer:8.28e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 82.9","Mixed",NA,NA
"ERMN","ERMIN, JN, KIAA1189","ENSG00000136541","Ermin","2","157318625-157327713","Predicted intracellular proteins","Evidence at protein level","HPA038295, HPA038296","Enhanced",NA,NA,NA,"Endometrial cancer:6.93e-6 (favourable)","Group enriched","Tissue enriched",27,"cerebral cortex: 227.8","bone marrow: 8.3","Cell line enriched",8,"HAP1: 20.7"
"MARCKS","80K-L, MACS, PKCSL","ENSG00000277443","Myristoylated alanine rich protein kinase C substrate","6","113857362-113863471","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB022062, HPA054820, HPA067595, HPA069443","Enhanced",NA,"Approved","Nucleus<br>Endoplasmic reticulum<br>Plasma membrane<br>Cytosol","Liver cancer:2.78e-8 (unfavourable), Renal cancer:4.85e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 218.8","Cell line enhanced",NA,"AF22: 402.5"
"NSMF","NELF","ENSG00000165802","NMDA receptor synaptonuclear signaling and neuronal migration factor","9","137447570-137459334","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA044316","Enhanced",NA,"Supported","Nucleoplasm","Renal cancer:1.85e-6 (favourable)","Expressed in all","Tissue enriched",5,"cerebral cortex: 189.6","duodenum: 36.2","Mixed",NA,NA
"PDZD4","FLJ34125, KIAA1444, LNX5, LU1, PDZK4, PDZRN4L","ENSG00000067840","PDZ domain containing 4","X","153802166-153830565","Cancer-related genes, Predicted intracellular proteins","Evidence at protein level","HPA003878","Enhanced",NA,NA,NA,"Pancreatic cancer:2.96e-5 (favourable)","Tissue enhanced","Tissue enriched",9,"cerebral cortex: 123.5","seminal vesicle: 13.7","Cell line enhanced",NA,"AF22: 24.1;RH-30: 16.8;SCLC-21H: 34.7;SH-SY5Y: 30.4;U-2 OS: 14.9"
"PNOC","N/OFQ, NOP, PPNOC","ENSG00000168081","Prepronociceptin","8","28316986-28343355","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA044507, HPA056724","Enhanced",NA,NA,NA,"Endometrial cancer:2.94e-6 (unfavourable)","Tissue enriched","Tissue enhanced",NA,"cerebral cortex: 44.2;fallopian tube: 26.3;lymph node: 28.9","tonsil: 21.4","Group enriched",6,"Daudi: 27.2;Karpas-707: 20.9;RPMI-8226: 7.7;U-698: 15.7"
"NECAB1","EFCBP1","ENSG00000123119","N-terminal EF-hand calcium binding protein 1","8","90791550-90959408","Predicted intracellular proteins","Evidence at protein level","HPA023252, HPA023629, HPA025963, HPA031262, CAB068208, CAB068209, CAB068210","Enhanced","Supported","Supported","Nucleoplasm<br>Cytosol",NA,"Mixed","Tissue enriched",10,"cerebral cortex: 79.7","lung: 8.1","Mixed",NA,NA
"ANXA2","ANX2, ANX2L4, CAL1H, LIP2, LPC2D","ENSG00000182718","Annexin A2","15","60347134-60402883","Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters","Evidence at protein level","CAB004311, HPA046964, HPA061798","Enhanced",NA,NA,NA,"Renal cancer:2.11e-6 (unfavourable), Pancreatic cancer:8.47e-6 (unfavourable), Liver cancer:2.54e-5 (unfavourable), Urothelial cancer:6.59e-5 (unfavourable), Endometrial cancer:6.88e-5 (favourable), Lung cancer:7.51e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"esophagus: 1488.4","Expressed in all",NA,NA
"CKAP5","ch-TOG, KIAA0097, TOG, TOGp","ENSG00000175216","Cytoskeleton associated protein 5","11","46743048-46846308","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA039377, HPA040375","Enhanced",NA,"Supported","Nucleoli<br>Plasma membrane<br>Centrosome","Liver cancer:1.03e-6 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 66.2","Expressed in all",NA,NA
"COBL","KIAA0633","ENSG00000106078","Cordon-bleu WH2 repeat protein","7","51016212-51316818","Predicted intracellular proteins","Evidence at protein level","HPA019033, HPA019167","Enhanced",NA,"Approved","Plasma membrane<br>Cell Junctions","Renal cancer:5.21e-12 (favourable)","Mixed","Mixed",NA,NA,"parathyroid gland: 61.9","Cell line enhanced",NA,"BEWO: 31.3;HeLa: 39.5;RPMI-8226: 32.2"
"DBNL","ABP1, HIP-55, SH3P7","ENSG00000136279","Drebrin like","7","44044640-44069456","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA020265, HPA027735","Enhanced",NA,"Supported","Nucleoplasm<br>Cytosol","Glioma:3.20e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"esophagus: 141.9","Expressed in all",NA,NA
"DHCR24","DCE, KIAA0018, seladin-1","ENSG00000116133","24-dehydrocholesterol reductase","1","54849633-54887218","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA017981, CAB037247, HPA063005","Approved",NA,NA,NA,"Endometrial cancer:1.05e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"adrenal gland: 1094.6","Mixed",NA,NA
"FGB",NA,"ENSG00000171564","Fibrinogen beta chain","4","154562956-154571086","Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA001900, HPA001901, CAB008624","Enhanced",NA,"Enhanced","Endoplasmic reticulum","Renal cancer:5.72e-5 (unfavourable)","Tissue enriched","Tissue enriched",556,"liver: 10006.0","kidney: 17.9","Cell line enriched",9,"Hep G2: 184.1"
"FMNL1","C17orf1, C17orf1B, FMNL","ENSG00000184922","Formin like 1","17","45221444-45247320","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA008129, HPA028288","Enhanced",NA,"Approved","Cytosol","Renal cancer:4.23e-8 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"bone marrow: 175.0","Cell line enhanced",NA,"Karpas-707: 137.1;MOLT-4: 110.5;U-266/70: 120.6"
"GLI2","HPE9, THP1, THP2","ENSG00000074047","GLI family zinc finger 2","2","120735623-120992653","Disease related genes, Predicted intracellular proteins, Transcription factors","Evidence at protein level","CAB008558, HPA074275","Approved",NA,"Supported","Nucleus<br>Nucleoli",NA,"Mixed","Tissue enhanced",NA,"ovary: 11.6","gallbladder: 6.0","Cell line enhanced",NA,"AF22: 30.8;U-2 OS: 33.2;WM-115: 27.2"
"HIP1R","FLJ14000, HIP12, HIP3, ILWEQ, KIAA0655","ENSG00000130787","Huntingtin interacting protein 1 related","12","122834453-122862960","Cancer-related genes, Predicted intracellular proteins","Evidence at protein level","CAB017187, HPA038135, HPA038136","Enhanced",NA,"Enhanced","Vesicles<br>Plasma membrane<br>Cytosol","Renal cancer:6.50e-7 (favourable), Urothelial cancer:7.26e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 53.1","Mixed",NA,NA
"MYH9","DFNA17, EPSTS, FTNS, MHA, NMHC-II-A, NMMHCA","ENSG00000100345","Myosin heavy chain 9","22","36281281-36388018","Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA001644, CAB015386, HPA064783","Enhanced",NA,"Supported","Plasma membrane<br>Actin filaments<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"spleen: 308.5","Expressed in all",NA,NA
"MYO10","KIAA0799","ENSG00000145555","Myosin X","5","16661914-16936276","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB015224, HPA024223","Enhanced",NA,"Supported","Nucleoli<br>Plasma membrane<br>Cytosol","Renal cancer:2.75e-4 (favourable), Cervical cancer:4.35e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 68.3","Mixed",NA,NA
"NEDD4","KIAA0093, MGC176705, NEDD4-1, RPF1","ENSG00000069869","Neural precursor cell expressed, developmentally down-regulated 4, E3 ubiquitin protein ligase","15","55826922-55993746","Enzymes, Predicted intracellular proteins, Transporters","Evidence at protein level","CAB001991, HPA039883, CAB072833","Approved",NA,"Approved","Cytosol","Renal cancer:3.74e-6 (unfavourable), Lung cancer:5.14e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"placenta: 22.4","Mixed",NA,NA
"NUMA1",NA,"ENSG00000137497","Nuclear mitotic apparatus protein 1","11","72002864-72080693","Cancer-related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA019841, HPA019859, HPA029912","Enhanced",NA,"Enhanced","Nucleoplasm","Renal cancer:7.92e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 247.9","Expressed in all",NA,NA
"PARD6A","PAR-6, PAR-6A, PAR6alpha, TAX40, TIP-40","ENSG00000102981","Par-6 family cell polarity regulator alpha","16","67660946-67662778","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB009733, HPA041551","Approved",NA,"Supported","Cell Junctions<br>Actin filaments<br>Cytosol","Renal cancer:3.08e-7 (favourable), Breast cancer:5.40e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"testis: 20.2","cerebral cortex: 12.1","Cell line enhanced",NA,"REH: 24.9;SCLC-21H: 25.2"
"PHLDB1","FLJ00141, KIAA0638, LL5a","ENSG00000019144","Pleckstrin homology like domain family B member 1","11","118606440-118658038","Predicted intracellular proteins","Evidence at protein level","HPA037959, HPA038448, HPA061506","Approved",NA,"Approved","Nucleoplasm","Renal cancer:6.36e-6 (unfavourable)","Expressed in all","Mixed",NA,NA,"adipose tissue: 56.5","Cell line enhanced",NA,"ASC TERT1: 74.2"
"PLIN2","ADFP, ADRP","ENSG00000147872","Perilipin 2","9","19108375-19149290","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA016607, CAB037331","Supported",NA,"Supported","Lipid droplets","Thyroid cancer:2.16e-4 (favourable), Renal cancer:3.32e-4 (unfavourable)","Group enriched","Expressed in all",NA,NA,"liver: 450.7","Cell line enhanced",NA,"ASC diff: 1543.1;HHSteC: 1631.5"
"PRKACA","PKACa","ENSG00000072062","Protein kinase cAMP-activated catalytic subunit alpha","19","14091688-14118084","Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins","Evidence at protein level","CAB010361, HPA071185","Approved",NA,"Approved","Cytosol","Cervical cancer:6.28e-6 (favourable), Endometrial cancer:6.26e-5 (unfavourable), Pancreatic cancer:6.47e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"heart muscle: 200.4","Expressed in all",NA,NA
"PTPN11","BPTP3, NS1, PTP2C, SH-PTP2, SHP-2, SHP2","ENSG00000179295","Protein tyrosine phosphatase, non-receptor type 11","12","112418351-112509913","Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins","Evidence at protein level","CAB005377","Approved",NA,"Supported","Nucleus<br>Nucleoli<br>Actin filaments<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 126.0","Expressed in all",NA,NA
"RHOA","ARH12, ARHA, Rho12, RhoA, RHOH12","ENSG00000067560","Ras homolog family member A","3","49359145-49412998","Cancer-related genes, Predicted intracellular proteins, RAS pathway related proteins","Evidence at protein level","CAB005052","Approved",NA,NA,NA,"Renal cancer:3.21e-6 (favourable), Colorectal cancer:3.08e-4 (favourable), Liver cancer:9.15e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"lung: 592.0","Expressed in all",NA,NA
"SPTAN1",NA,"ENSG00000197694","Spectrin alpha, non-erythrocytic 1","9","128552558-128633662","Disease related genes, Predicted intracellular proteins","Evidence at protein level","CAB004581, HPA007927","Enhanced",NA,"Approved","Vesicles<br>Microtubules","Renal cancer:1.84e-12 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 201.9","Expressed in all",NA,NA
"WDPCP","BBS15, C2orf86, fritz, hFrtz","ENSG00000143951","WD repeat containing planar cell polarity effector","2","63121383-63827843","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA044144","Uncertain",NA,"Approved","Cell Junctions",NA,"Mixed","Mixed",NA,NA,"testis: 11.4","Expressed in all",NA,NA
"PRKD1","PKC-mu, PKCM, PKD, PRKCM","ENSG00000184304","Protein kinase D1","14","29576479-30191898","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB018367, HPA029834","Uncertain",NA,"Supported","Plasma membrane<br>Cytosol","Renal cancer:2.44e-5 (favourable), Thyroid cancer:2.91e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"parathyroid gland: 50.3","prostate: 28.5","Mixed",NA,NA
"ADORA2A","ADORA2, RDC8","ENSG00000128271","Adenosine A2a receptor","22","24417879-24442360","Cancer-related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters","Evidence at protein level","CAB001943, HPA065566, HPA075997","Enhanced","Supported",NA,NA,NA,"Not detected","Tissue enhanced",NA,"bone marrow: 24.6;lymph node: 22.7","appendix: 17.8","Cell line enhanced",NA,"Karpas-707: 36.8;SK-BR-3: 55.0;U-266/70: 38.8;U-266/84: 50.0;U-698: 37.2"
"ARHGAP33","FLJ39019, SNX26, TCGAP","ENSG00000004777","Rho GTPase activating protein 33","19","35774532-35788822","Predicted intracellular proteins","Evidence at protein level","HPA030117, HPA030118","Supported",NA,"Approved","Plasma membrane<br>Actin filaments<br>Cytosol","Renal cancer:3.09e-8 (unfavourable)","Expressed in all","Mixed",NA,NA,"cerebral cortex: 25.8","Cell line enhanced",NA,"HMC-1: 50.9"
"MYO7A","DFNA11, DFNB2, NSRD2, USH1B","ENSG00000137474","Myosin VIIA","11","77128264-77215239","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA028918, CAB034059","Uncertain",NA,"Approved","Cytosol","Renal cancer:3.07e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"adrenal gland: 26.8;placenta: 20.8","testis: 17.2","Cell line enhanced",NA,"BEWO: 11.1;RH-30: 20.1;RPMI-8226: 9.7;SK-BR-3: 8.1;U-937: 11.1"
"NRBP1","BCON3, MADM, MUDPNP, NRBP","ENSG00000115216","Nuclear receptor binding protein 1","2","27427790-27442259","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA029527, CAB033078","Supported",NA,"Supported","Cytosol","Liver cancer:2.22e-5 (unfavourable), Renal cancer:5.84e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 125.8","Expressed in all",NA,NA
"SPIRE1","KIAA1135, spir-1","ENSG00000134278","Spire type actin nucleation factor 1","18","12446512-12658134","Predicted intracellular proteins","Evidence at protein level","HPA040737, HPA040942","Uncertain",NA,"Approved","Nucleoplasm<br>Cytosol","Endometrial cancer:2.07e-4 (unfavourable), Stomach cancer:7.92e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"testis: 61.3","cerebral cortex: 50.4","Mixed",NA,NA
"ACTR2","ARP2","ENSG00000138071","ARP2 actin related protein 2 homolog","2","65227753-65271253","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB005083, HPA015050","Approved",NA,"Approved","Cytosol","Liver cancer:4.50e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"appendix: 292.2","Expressed in all",NA,NA
"ADD3","ADDL","ENSG00000148700","Adducin 3","10","109996368-110135565","Disease related genes, Predicted intracellular proteins","Evidence at protein level","CAB009797, HPA035696","Supported",NA,"Supported","Plasma membrane",NA,"Expressed in all","Expressed in all",NA,NA,"thyroid gland: 168.6","Cell line enhanced",NA,"ASC diff: 215.0;ASC TERT1: 204.7"
"AGTR2","AT2, MRX88","ENSG00000180772","Angiotensin II receptor type 2","X","116170722-116174972","G-protein coupled receptors, Predicted membrane proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Group enriched","Group enriched",6,"cervix, uterine: 6.8;endometrium: 13.9;fallopian tube: 3.8;lung: 12.6;smooth muscle: 17.6","adrenal gland: 1.9","Not detected",NA,NA
"AGTRAP","ATRAP","ENSG00000177674","Angiotensin II receptor associated protein","1","11736084-11754802","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA044120","Approved",NA,"Supported","Vesicles","Liver cancer:6.57e-7 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"prostate: 92.6","Expressed in all",NA,NA
"AKAP12","AKAP250, SSeCKS","ENSG00000131016","A-kinase anchoring protein 12","6","151239999-151358557","Cancer-related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA006344, CAB026379, HPA056230","Enhanced",NA,"Supported","Plasma membrane<br>Cytosol","Lung cancer:6.34e-5 (unfavourable), Endometrial cancer:7.08e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 184.5","Cell line enhanced",NA,"REH: 175.6"
"AKAP13","AKAP-Lbc, ARHGEF13, BRX, c-lbc, HA-3, Ht31, LBC, PROTO-LB","ENSG00000170776","A-kinase anchoring protein 13","15","85380571-85749358","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA019773","Approved",NA,"Supported","Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"endometrium: 74.5","Expressed in all",NA,NA
"AKT2",NA,"ENSG00000105221","AKT serine/threonine kinase 2","19","40230317-40285536","Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins","Evidence at protein level","CAB004204, HPA064521","Uncertain",NA,"Supported","Nucleus<br>Vesicles<br>Cytosol","Endometrial cancer:1.05e-6 (unfavourable), Prostate cancer:4.74e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 170.1","Expressed in all",NA,NA
"ANLN","ANILLIN, scra, Scraps","ENSG00000011426","Anillin actin binding protein","7","36389806-36453791","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA005680, CAB033902, HPA050556, CAB062547, CAB068175","Enhanced",NA,"Enhanced","Nucleoplasm<br>Midbody","Renal cancer:0.00e+0 (unfavourable), Liver cancer:5.97e-7 (unfavourable), Pancreatic cancer:2.00e-6 (unfavourable), Lung cancer:6.99e-5 (unfavourable), Endometrial cancer:1.73e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 87.2","bone marrow: 23.1","Expressed in all",NA,NA
"ARF6",NA,"ENSG00000165527","ADP ribosylation factor 6","14","49893092-49897054","Predicted intracellular proteins, RAS pathway related proteins","Evidence at protein level","CAB002778","Approved",NA,NA,NA,"Pancreatic cancer:3.10e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"esophagus: 96.6","Expressed in all",NA,NA
"ARFIP2","POR1","ENSG00000132254","ADP ribosylation factor interacting protein 2","11","6474683-6481479","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB032985, HPA038156","Approved",NA,"Approved","Nucleus<br>Nucleoli fibrillar center<br>Golgi apparatus","Endometrial cancer:2.00e-5 (favourable), Renal cancer:9.53e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 82.5","Expressed in all",NA,NA
"ARHGAP32","GC-GAP, GRIT, KIAA0712, MGC1892, RICS","ENSG00000134909","Rho GTPase activating protein 32","11","128965060-129279324","Cancer-related genes, Predicted intracellular proteins","Evidence at protein level","HPA038382, HPA038389, HPA061505","Approved",NA,"Approved","Nucleoplasm<br>Nucleoli fibrillar center<br>Golgi apparatus","Pancreatic cancer:6.64e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 44.0","Mixed",NA,NA
"ARHGEF7","BETA-PIX, COOL1, DKFZp686C12170, DKFZp761K1021, KIAA0142, Nbla10314, P50, P50BP, P85, P85COOL1, P85SPR, PAK3, PIXB","ENSG00000102606","Rho guanine nucleotide exchange factor 7","13","111114559-111305737","Predicted intracellular proteins","Evidence at protein level","HPA004744","Approved",NA,NA,NA,"Glioma:7.29e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 96.8","Expressed in all",NA,NA
"ARL13B","ARL2L1, DKFZp761H079, JBTS8","ENSG00000169379","ADP ribosylation factor like GTPase 13B","3","93980139-94055668","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA048926","Enhanced",NA,"Uncertain","Microtubules<br>Cytosol",NA,"Expressed in all","Mixed",NA,NA,"thyroid gland: 9.3","Mixed",NA,NA
"ARPC5","ARC16, dJ127C7.3, p16-Arc","ENSG00000162704","Actin related protein 2/3 complex subunit 5","1","183620846-183635757","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA022013, HPA031972","Approved",NA,"Approved","Vesicles<br>Plasma membrane<br>Cell Junctions<br>Cytosol","Renal cancer:1.21e-10 (unfavourable), Liver cancer:3.63e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"appendix: 201.3","Expressed in all",NA,NA
"ASTN2","KIAA0634","ENSG00000148219","Astrotactin 2","9","116425225-117415070","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA027035","Uncertain",NA,"Approved","Nucleoplasm<br>Cytosol","Renal cancer:6.66e-16 (favourable)","Expressed in all","Expressed in all",NA,NA,"prostate: 40.5","Cell line enhanced",NA,"SH-SY5Y: 39.4"
"BFSP1","CP115, CP94, filensin, LIFL-H","ENSG00000125864","Beaded filament structural protein 1","20","17493905-17569220","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA040748, HPA042038","Enhanced",NA,"Supported","Plasma membrane<br>Cytosol","Endometrial cancer:1.39e-4 (favourable)","Mixed","Mixed",NA,NA,"testis: 6.5","Cell line enhanced",NA,"RPTEC TERT1: 14.8"
"C2CD5","CDP138, KIAA0528","ENSG00000111731","C2 calcium dependent domain containing 5","12","22448583-22544546","Predicted intracellular proteins","Evidence at protein level","HPA046194","Approved",NA,"Approved","Microtubule organizing center<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 51.5","Expressed in all",NA,NA
"CABP1",NA,"ENSG00000157782","Calcium binding protein 1","12","120640552-120667324","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA051438","Uncertain",NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",7,"cerebral cortex: 77.4","adipose tissue: 11.2","Cell line enhanced",NA,"NTERA-2: 6.8;SCLC-21H: 3.8;U-87 MG: 8.4"
"CAV1","CAV","ENSG00000105974","Caveolin 1","7","116524785-116561184","Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters","Evidence at protein level","CAB003791, HPA049326","Enhanced",NA,"Supported","Golgi apparatus","Lung cancer:7.17e-5 (unfavourable), Renal cancer:1.29e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"lung: 859.9","adipose tissue: 640.4","Cell line enhanced",NA,"LHCN-M2: 1943.1"
"CD302","BIMLEC, CLEC13A, DCL-1, KIAA0022","ENSG00000241399","CD302 molecule","2","159768630-159798255","CD markers, Predicted membrane proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Mixed","Expressed in all",NA,NA,"liver: 104.7","Cell line enhanced",NA,"ASC diff: 178.2"
"CITED2","MRG1","ENSG00000164442","Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 2","6","139371807-139374620","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB016157, CAB069879","Supported",NA,"Supported","Nucleoplasm","Stomach cancer:3.33e-4 (unfavourable), Renal cancer:3.40e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 379.3","Cell line enhanced",NA,"fHDF/TERT166: 828.8"
"CLIC5","DFNB102","ENSG00000112782","Chloride intracellular channel 5","6","45898451-46080395","Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters","Evidence at protein level","HPA074371",NA,NA,"Supported","Nuclear speckles<br>Plasma membrane",NA,"Tissue enhanced","Tissue enhanced",NA,"lung: 116.1;skeletal muscle: 119.2","heart muscle: 76.0","Group enriched",7,"CAPAN-2: 13.3;EFO-21: 10.0;HDLM-2: 5.7;REH: 13.6;U-266/70: 10.5"
"CLP1","hClp1, HEAB","ENSG00000172409","Cleavage and polyadenylation factor I subunit 1","11","57648992-57661868","Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA057770","Supported",NA,"Supported","Nucleoplasm",NA,"Expressed in all","Expressed in all",NA,NA,"bone marrow: 17.0","Expressed in all",NA,NA
"CNKSR1","CNK, CNK1, KSR","ENSG00000142675","Connector enhancer of kinase suppressor of Ras 1","1","26177403-26189886","Cancer-related genes, Predicted intracellular proteins","Evidence at protein level","HPA030847","Uncertain",NA,"Approved","Cytosol","Urothelial cancer:5.91e-4 (favourable)","Mixed","Mixed",NA,NA,"parathyroid gland: 20.6","Cell line enhanced",NA,"A-431: 15.5;CAPAN-2: 23.4;HaCaT: 17.4"
"COL10A1",NA,"ENSG00000123500","Collagen type X alpha 1 chain","6","116118923-116158747","Disease related genes, Predicted secreted proteins","Evidence at protein level","HPA053268",NA,NA,"Approved","Endoplasmic reticulum",NA,"Tissue enhanced","Tissue enhanced",NA,"gallbladder: 14.5","ovary: 4.9","Cell line enriched",6,"hTEC/SVTERT24-B: 39.7"
"CORO1A","coronin-1, HCORO1, p57","ENSG00000102879","Coronin 1A","16","30182827-30189076","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB046473, HPA051132","Enhanced",NA,"Approved","Cytosol","Renal cancer:5.74e-7 (unfavourable), Head and neck cancer:4.42e-4 (favourable), Endometrial cancer:6.91e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"lymph node: 593.1","Cell line enhanced",NA,"Daudi: 596.0;HMC-1: 850.4;RPMI-8226: 612.4;U-937: 575.5"
"CORT","MGC32686","ENSG00000241563","Cortistatin","1","10449719-10451902","Predicted secreted proteins","Evidence at transcript level",NA,NA,NA,NA,NA,NA,"Mixed","Tissue enriched",24,"cerebral cortex: 24.8","placenta: 1.0","Mixed",NA,NA
"CRIP2","CRP2, ESP1","ENSG00000182809","Cysteine rich protein 2","14","105472962-105480170","Predicted intracellular proteins","Evidence at protein level","HPA042664","Approved",NA,"Approved","Nucleus<br>Nucleoli<br>Plasma membrane",NA,"Expressed in all","Tissue enhanced",NA,"heart muscle: 315.6","fallopian tube: 115.7","Cell line enhanced",NA,"MCF7: 206.8"
"CTGF","CCN2, IGFBP8","ENSG00000118523","Connective tissue growth factor","6","131948176-131951373","Cancer-related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB005123, HPA031075","Approved",NA,NA,NA,"Stomach cancer:5.04e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cervix, uterine: 845.3","Cell line enhanced",NA,"EFO-21: 1511.7;HUVEC TERT2: 1148.6;TIME: 2338.5"
"CTTN","EMS1","ENSG00000085733","Cortactin","11","70398404-70436584","Cancer-related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB011235, HPA057242","Supported",NA,"Supported","Golgi apparatus<br>Vesicles<br>Plasma membrane<br>Cytosol","Head and neck cancer:2.19e-6 (unfavourable), Liver cancer:4.45e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"gallbladder: 108.9","Cell line enhanced",NA,"A-431: 778.5"
"CYTIP","B3-1, CASP, CYBR, CYTHIP, HE, PSCDBP","ENSG00000115165","Cytohesin 1 interacting protein","2","157414619-157488961","Predicted intracellular proteins","Evidence at protein level","HPA007191","Approved",NA,"Approved","Nucleoplasm<br>Cytosol","Endometrial cancer:9.12e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"lymph node: 101.8;tonsil: 102.0","appendix: 92.4","Cell line enhanced",NA,"HDLM-2: 41.0;Karpas-707: 103.6;U-266/70: 185.5;U-266/84: 68.5"
"DAAM1","KIAA0666","ENSG00000100592","Dishevelled associated activator of morphogenesis 1","14","59188646-59371405","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA026605, HPA064789","Uncertain",NA,"Approved","Plasma membrane<br>Cytosol","Renal cancer:3.77e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 52.1","Expressed in all",NA,NA
"DST","BP240, BPA, BPAG1, CATX-15, FLJ13425, FLJ21489, FLJ30627, FLJ32235, KIAA0728, MACF2","ENSG00000151914","Dystonin","6","56457987-56954628","Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA030200","Uncertain",NA,"Approved","Nucleus<br>Microtubules<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"skin: 192.1","Cell line enhanced",NA,"hTCEpi: 351.4;hTERT-HME1: 274.7"
"EPB41","4.1R, EL1","ENSG00000159023","Erythrocyte membrane protein band 4.1","1","28887091-29120046","Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters","Evidence at protein level","HPA028076, HPA028412, HPA028414","Supported",NA,"Supported","Plasma membrane<br>Cell Junctions<br>Cytosol","Renal cancer:1.75e-6 (unfavourable), Endometrial cancer:4.58e-4 (unfavourable), Head and neck cancer:5.87e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"lymph node: 50.6","Mixed",NA,NA
"EPS8",NA,"ENSG00000151491","Epidermal growth factor receptor pathway substrate 8","12","15620158-15882329","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA003897","Approved",NA,"Approved","Golgi apparatus","Renal cancer:1.45e-7 (favourable), Pancreatic cancer:3.33e-7 (unfavourable), Thyroid cancer:5.11e-4 (favourable)","Expressed in all","Mixed",NA,NA,"gallbladder: 88.1","Mixed",NA,NA
"EZH2","ENX-1, EZH1, KMT6, KMT6A","ENSG00000106462","Enhancer of zeste 2 polycomb repressive complex 2 subunit","7","148807383-148884321","Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","CAB009589","Enhanced",NA,"Supported","Nucleoplasm","Renal cancer:8.18e-12 (unfavourable), Liver cancer:2.11e-6 (unfavourable), Melanoma:1.96e-4 (unfavourable), Stomach cancer:6.97e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"testis: 50.5","bone marrow: 30.0","Expressed in all",NA,NA
"FABP1","L-FABP","ENSG00000163586","Fatty acid binding protein 1","2","88122982-88128116","Cancer-related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB002305, HPA028275","Enhanced",NA,"Approved","Nucleoplasm<br>Cytosol",NA,"Group enriched","Group enriched",7,"colon: 4552.0;duodenum: 4123.5;liver: 5672.8;rectum: 3081.5;small intestine: 4506.9","kidney: 602.3","Group enriched",6,"CACO-2: 84.1;Hep G2: 221.3"
"FAM110C",NA,"ENSG00000184731","Family with sequence similarity 110 member C","2","38814-46870","Predicted intracellular proteins","Evidence at protein level","HPA036144, HPA036145","Uncertain",NA,NA,NA,"Glioma:6.77e-4 (unfavourable)","Mixed","Mixed",NA,NA,"seminal vesicle: 29.0","Cell line enhanced",NA,"HaCaT: 11.8;RPTEC TERT1: 13.6;RT4: 20.1"
"FBLIM1","CAL, FBLP-1, migfilin","ENSG00000162458","Filamin binding LIM protein 1","1","15756607-15786594","Predicted intracellular proteins","Evidence at protein level","HPA025287, HPA072750","Approved",NA,"Enhanced","Nucleoli fibrillar center<br>Cell Junctions<br>Focal adhesion sites","Cervical cancer:4.07e-4 (unfavourable), Melanoma:6.15e-4 (unfavourable), Renal cancer:8.64e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"gallbladder: 101.8","Cell line enhanced",NA,"HUVEC TERT2: 210.1;TIME: 323.6"
"FER","PPP1R74, TYK3","ENSG00000151422","FER tyrosine kinase","5","108747822-109196841","Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA007641, CAB022464","Approved",NA,"Supported","Cytosol","Renal cancer:5.55e-4 (favourable)","Expressed in all","Mixed",NA,NA,"parathyroid gland: 19.4","Cell line enhanced",NA,"RPMI-8226: 62.9"
"FERMT2","KIND2, mig-2, PLEKHC1, UNC112B","ENSG00000073712","Fermitin family member 2","14","52857268-52952435","Predicted intracellular proteins","Evidence at protein level","HPA040505","Uncertain",NA,"Supported","Nucleoplasm<br>Focal adhesion sites",NA,"Expressed in all","Mixed",NA,NA,"smooth muscle: 222.9","Mixed",NA,NA
"FGA",NA,"ENSG00000171560","Fibrinogen alpha chain","4","154583126-154590766","Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB016776, HPA051370, HPA064755","Supported",NA,NA,NA,"Renal cancer:4.23e-6 (unfavourable), Liver cancer:7.33e-4 (favourable)","Tissue enriched","Tissue enriched",237,"liver: 9265.4","stomach: 39.0","Cell line enriched",11,"Hep G2: 285.6"
"FGF1","AFGF, ECGF, ECGF-beta, ECGFA, ECGFB, FGF-alpha, FGFA, GLIO703, HBGF1","ENSG00000113578","Fibroblast growth factor 1","5","142592178-142698070","Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins","Evidence at protein level","HPA003265, CAB017519","Enhanced",NA,NA,NA,"Renal cancer:2.59e-5 (favourable), Thyroid cancer:3.45e-5 (favourable)","Tissue enriched","Tissue enhanced",NA,"cerebral cortex: 129.9;kidney: 59.4","heart muscle: 32.8","Cell line enhanced",NA,"BJ: 37.6;BJ hTERT+ SV40 Large T+: 33.4;BJ hTERT+ SV40 Large T+ RasG12V: 43.9;HBF TERT88: 62.3;hTEC/SVTERT24-B: 45.5;U-2 OS: 33.6"
"FGF17","FGF-13","ENSG00000158815","Fibroblast growth factor 17","8","22042398-22048809","Cancer-related genes, Disease related genes, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","HPA052600","Approved",NA,NA,NA,NA,"Tissue enhanced","Mixed",NA,NA,"cerebral cortex: 1.8","Not detected",NA,NA
"FGG",NA,"ENSG00000171557","Fibrinogen gamma chain","4","154604134-154612967","Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA027529, CAB033120","Supported",NA,NA,NA,"Renal cancer:1.00e-6 (unfavourable)","Tissue enriched","Tissue enriched",115,"liver: 8699.0","lung: 75.7","Cell line enriched",42,"Hep G2: 503.3"
"FLNB","ABP-278, FH1, FLN1L, LRS1, TABP, TAP","ENSG00000136068","Filamin B","3","58008400-58172251","Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters","Evidence at protein level","HPA004747, HPA004886, CAB019322","Enhanced",NA,"Supported","Golgi apparatus<br>Plasma membrane<br>Actin filaments<br>Cytosol","Renal cancer:3.45e-6 (favourable), Pancreatic cancer:8.45e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"prostate: 148.3","Expressed in all",NA,NA
"FMN2",NA,"ENSG00000155816","Formin 2","1","240014348-240475189","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA050649",NA,NA,"Approved","Plasma membrane<br>Actin filaments",NA,"Group enriched","Group enriched",6,"cerebral cortex: 53.8;parathyroid gland: 33.5","adrenal gland: 7.0","Cell line enhanced",NA,"BJ: 60.2;fHDF/TERT166: 54.7;LHCN-M2: 63.8;U-138 MG: 48.9;WM-115: 77.8"
"FNBP1","FBP17, KIAA0554","ENSG00000187239","Formin binding protein 1","9","129887187-130043194","Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA019635, HPA019691, HPA022119","Enhanced",NA,NA,NA,"Renal cancer:8.45e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"lymph node: 90.7","Mixed",NA,NA
"FNBP1L","C1orf39, FLJ20275, TOCA1","ENSG00000137942","Formin binding protein 1 like","1","93448131-93554661","Predicted intracellular proteins","Evidence at protein level","HPA065273","Approved",NA,"Supported","Cytosol","Renal cancer:4.72e-7 (favourable), Liver cancer:8.92e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 53.8","Mixed",NA,NA
"FRY","13CDNA73, bA37E23.1, C13orf14, CG003","ENSG00000073910","FRY microtubule binding protein","13","32031300-32299122","Predicted intracellular proteins","Evidence at protein level","HPA041635","Approved",NA,NA,NA,"Renal cancer:9.60e-4 (favourable)","Mixed","Expressed in all",NA,NA,"heart muscle: 33.5","Cell line enhanced",NA,"HUVEC TERT2: 22.7;RT4: 25.4"
"FRYL","AF4p12, DKFZp686E205, KIAA0826, MOR2","ENSG00000075539","FRY like transcription coactivator","4","48497361-48780322","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA031106, HPA031107","Supported",NA,"Approved","Microtubules<br>Cytokinetic bridge<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 51.2","Expressed in all",NA,NA
"GIPC1","C19orf3, GIPC, GLUT1CBP, Hs.6454, NIP, RGS19IP1, SEMCAP, SYNECTIN, TIP-2","ENSG00000123159","GIPC PDZ domain containing family member 1","19","14477760-14496149","Predicted intracellular proteins","Evidence at protein level","HPA043958, HPA061786","Approved",NA,"Approved","Nucleus<br>Plasma membrane<br>Cell Junctions",NA,"Expressed in all","Expressed in all",NA,NA,"esophagus: 103.9","Expressed in all",NA,NA
"GLI1","GLI","ENSG00000111087","GLI family zinc finger 1","12","57460135-57472262","Predicted intracellular proteins, Transcription factors","Evidence at protein level","CAB009460, HPA065172, HPA068903","Uncertain",NA,"Enhanced","Nucleoplasm<br>Cytosol",NA,"Tissue enhanced","Tissue enhanced",NA,"cervix, uterine: 15.1;endometrium: 15.1","gallbladder: 8.5","Cell line enhanced",NA,"AN3-CA: 19.3;RH-30: 59.1"
"GLRX3","bA500G10.4, GLRX4, GRX3, GRX4, PICOT, TXNL2","ENSG00000108010","Glutaredoxin 3","10","130136399-130184521","Predicted intracellular proteins","Evidence at protein level","HPA028941","Approved",NA,NA,NA,"Liver cancer:9.03e-6 (unfavourable), Renal cancer:9.24e-6 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 119.3","Expressed in all",NA,NA
"GM2A","SAP-3","ENSG00000196743","GM2 ganglioside activator","5","151212150-151270440","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA008063","Enhanced",NA,NA,NA,"Liver cancer:1.77e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"skin: 89.5","Expressed in all",NA,NA
"GPSM2","DFNB82, LGN, Pins","ENSG00000121957","G-protein signaling modulator 2","1","108875350-108934545","Disease related genes, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA007327, HPA008408, CAB018962","Uncertain",NA,"Supported","Cytosol","Colorectal cancer:7.86e-5 (favourable), Renal cancer:3.02e-4 (unfavourable), Pancreatic cancer:5.89e-4 (unfavourable)","Mixed","Mixed",NA,NA,"skin: 49.3","Expressed in all",NA,NA
"GRK4","GPRK2L, GPRK4","ENSG00000125388","G protein-coupled receptor kinase 4","4","2963608-3040747","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA028737, HPA057023","Approved",NA,"Supported","Vesicles",NA,"Expressed in all","Tissue enriched",9,"testis: 74.7","cerebral cortex: 8.1","Cell line enhanced",NA,"SCLC-21H: 18.6"
"GRM7","GLUR7, GPRC1G, mGlu7, MGLUR7, PPP1R87","ENSG00000196277","Glutamate metabotropic receptor 7","3","6770001-7741533","G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA015964",NA,NA,"Uncertain","Cytosol",NA,"Not detected","Tissue enhanced",NA,"cerebral cortex: 10.1;parathyroid gland: 7.2","smooth muscle: 3.4","Cell line enriched",12,"SH-SY5Y: 5.0"
"GYS2",NA,"ENSG00000111713","Glycogen synthase 2","12","21536189-21604847","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA039482","Approved",NA,NA,NA,"Liver cancer:7.62e-5 (favourable)","Tissue enriched","Tissue enriched",23,"liver: 91.8","adipose tissue: 3.9","Cell line enhanced",NA,"CACO-2: 1.0"
"HAMP","HEPC, HFE2B, LEAP-1, LEAP1","ENSG00000105697","Hepcidin antimicrobial peptide","19","35280716-35285143","Disease related genes, Potential drug targets, Predicted secreted proteins, Transporters","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Group enriched","Tissue enriched",12,"liver: 259.1","heart muscle: 21.9","Cell line enriched",127,"Hep G2: 135.7"
"HAX1","HCLSBP1, HS1BP1","ENSG00000143575","HCLS1 associated protein X-1","1","154272511-154275875","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA055141, HPA075289","Approved",NA,"Supported","Mitochondria","Renal cancer:1.34e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 114.9","Expressed in all",NA,NA
"HMCN1","ARMD1, FBLN6, FIBL-6, FIBL6","ENSG00000143341","Hemicentin 1","1","185734551-186190949","Disease related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA051677","Uncertain",NA,NA,NA,"Renal cancer:3.59e-7 (unfavourable)","Tissue enriched","Tissue enhanced",NA,"lung: 22.3","prostate: 12.6","Group enriched",6,"fHDF/TERT166: 17.3;MCF7: 58.7;SK-MEL-30: 38.8;U-138 MG: 13.5;WM-115: 43.4"
"HMCN2","DKFZp434P0216, FLJ23816","ENSG00000148357","Hemicentin 2","9","130265882-130434123","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA053903, HPA070647","Enhanced",NA,"Approved","Vesicles",NA,"Mixed","Mixed",NA,NA,"small intestine: 11.4","Cell line enhanced",NA,"HaCaT: 6.9;RH-30: 17.3;SH-SY5Y: 4.4;U-87 MG: 4.0"
"INSC",NA,"ENSG00000188487","Inscuteable homolog (Drosophila)","11","15112424-15247208","Predicted intracellular proteins","Evidence at protein level","HPA039769","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Mixed",NA,NA,"small intestine: 2.7","Cell line enhanced",NA,"ASC TERT1: 8.1;hTERT-HME1: 4.6;TIME: 10.5"
"ITCH","AIP4","ENSG00000078747","Itchy E3 ubiquitin protein ligase","20","34363235-34511393","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA021126, HPA049032","Supported",NA,"Supported","Nucleoplasm",NA,"Expressed in all","Expressed in all",NA,NA,"testis: 73.2","Expressed in all",NA,NA
"ITPR2","CFAP48, IP3R2","ENSG00000123104","Inositol 1,4,5-trisphosphate receptor type 2","12","26336515-26833198","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA059144, HPA062260","Uncertain",NA,"Supported","Nucleus<br>Endoplasmic reticulum",NA,"Expressed in all","Mixed",NA,NA,"parathyroid gland: 26.2","Cell line enhanced",NA,"TIME: 55.9"
"KCNC3","Kv3.3, SCA13","ENSG00000131398","Potassium voltage-gated channel subfamily C member 3","19","50311937-50333515","Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels","Evidence at protein level","HPA018041","Approved",NA,NA,NA,"Renal cancer:1.23e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"parathyroid gland: 39.9","cerebral cortex: 19.8","Cell line enhanced",NA,"HMC-1: 26.4;SK-BR-3: 15.3;T-47d: 18.4;U-2 OS: 13.8"
"KDF1","C1orf172, FLJ34633, RP11-344H11.3","ENSG00000175707","Keratinocyte differentiation factor 1","1","26949562-26960406","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA028639, HPA068312","Uncertain",NA,"Supported","Nucleoplasm<br>Cell Junctions<br>Mitotic spindle","Renal cancer:3.04e-13 (favourable), Urothelial cancer:4.40e-4 (favourable)","Mixed","Mixed",NA,NA,"epididymis: 24.1","Cell line enhanced",NA,"A-431: 22.4;BEWO: 20.8;CAPAN-2: 20.7;HaCaT: 19.6;HBEC3-KT: 21.9;hTCEpi: 28.4;SK-BR-3: 19.3"
"KLHDC3","dJ20C7.3, hPeas, PEAS","ENSG00000124702","Kelch domain containing 3","6","43014103-43021298","Predicted intracellular proteins","Evidence at protein level","HPA030131, HPA030132, HPA030133, HPA030134","Uncertain",NA,"Supported","Nucleoplasm","Endometrial cancer:4.52e-4 (unfavourable), Pancreatic cancer:9.08e-4 (favourable), Cervical cancer:9.15e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 251.9","Expressed in all",NA,NA
"LAMC2","BM600-100kDa, EBR2, EBR2A, kalinin-105kDa, LAMB2T, LAMNB2, nicein-100kDa","ENSG00000058085","Laminin subunit gamma 2","1","183186238-183244900","Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB004257, HPA024638, CAB078165","Enhanced",NA,"Approved","Cytosol","Lung cancer:4.20e-6 (unfavourable), Pancreatic cancer:7.11e-5 (unfavourable)","Tissue enhanced","Tissue enhanced",NA,"fallopian tube: 57.8","lung: 38.9","Cell line enhanced",NA,"A-431: 521.5;CAPAN-2: 460.7;HBEC3-KT: 1872.4;hTERT-HME1: 1202.0;RPTEC TERT1: 464.3"
"LASP1","Lasp-1, MLN50","ENSG00000002834","LIM and SH3 protein 1","17","38869859-38921770","Cancer-related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA012072, CAB022049","Enhanced",NA,"Supported","Plasma membrane<br>Focal adhesion sites<br>Cytosol","Liver cancer:2.41e-4 (unfavourable), Endometrial cancer:4.57e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"small intestine: 181.3","Expressed in all",NA,NA
"MAP2K1","MAPKK1, MEK1, PRKMK1","ENSG00000169032","Mitogen-activated protein kinase kinase 1","15","66386817-66492312","Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins","Evidence at protein level","CAB003834, HPA026430","Approved",NA,"Enhanced","Plasma membrane<br>Cytosol","Glioma:2.68e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 144.4","Expressed in all",NA,NA
"MC3R","MC3","ENSG00000124089","Melanocortin 3 receptor","20","56248732-56249815","G-protein coupled receptors, Predicted membrane proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Not detected","Not detected",NA,NA,"testis: 0.1","Not detected",NA,NA
"MELK","KIAA0175","ENSG00000165304","Maternal embryonic leucine zipper kinase","9","36572862-36677683","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA017214","Uncertain",NA,NA,NA,"Renal cancer:0.00e+0 (unfavourable), Liver cancer:2.91e-7 (unfavourable), Lung cancer:3.99e-4 (unfavourable), Pancreatic cancer:4.58e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"testis: 16.9","lymph node: 11.7","Expressed in all",NA,NA
"MICAL3","KIAA0819","ENSG00000243156","Microtubule associated monooxygenase, calponin and LIM domain containing 3","22","17787649-18024559","Enzymes, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA000639, HPA003421, HPA034882","Uncertain",NA,"Enhanced","Nucleoplasm<br>Plasma membrane<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 71.2","Expressed in all",NA,NA
"MISP","C19orf21, Caprice, DKFZp686H18209, MISP1","ENSG00000099812","Mitotic spindle positioning","19","751126-764318","Predicted intracellular proteins","Evidence at protein level","HPA049511, HPA062232","Enhanced",NA,"Enhanced","Plasma membrane<br>Focal adhesion sites",NA,"Tissue enhanced","Group enriched",6,"colon: 94.7;duodenum: 173.3;rectum: 52.6;small intestine: 217.1","stomach: 21.6","Cell line enhanced",NA,"A549: 110.0;HaCaT: 79.4;hTCEpi: 59.7;SK-BR-3: 101.1"
"MKLN1","TWA2","ENSG00000128585","Muskelin 1","7","131110096-131496636","Predicted intracellular proteins","Evidence at protein level","HPA022817, HPA041810","Approved",NA,"Approved","Vesicles<br>Plasma membrane<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"prostate: 26.0","Expressed in all",NA,NA
"MYH10","NMMHCB","ENSG00000133026","Myosin heavy chain 10","17","8474205-8630761","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB017180, HPA047541, HPA057198","Enhanced",NA,"Enhanced","Actin filaments<br>Mitochondria<br>Cytosol","Renal cancer:1.38e-4 (favourable), Urothelial cancer:6.42e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"lung: 81.0","Cell line enhanced",NA,"AF22: 213.4"
"MYO16","KIAA0865, Myo16b, MYR8, NYAP3, PPP1R107","ENSG00000041515","Myosin XVI","13","108596152-109208007","Predicted intracellular proteins","Evidence at protein level","HPA040110, HPA058769, HPA071948","Uncertain",NA,"Approved","Vesicles",NA,"Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 2.1","testis: 1.0","Cell line enhanced",NA,"SH-SY5Y: 2.4;U-2197: 1.2"
"MYO5B","KIAA1119","ENSG00000167306","Myosin VB","18","49822813-50195093","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA040593, HPA040902, HPA069773","Enhanced",NA,"Approved","Plasma membrane","Renal cancer:1.45e-11 (favourable), Pancreatic cancer:2.26e-5 (unfavourable)","Expressed in all","Mixed",NA,NA,"small intestine: 67.6","Cell line enhanced",NA,"HaCaT: 88.6;RH-30: 147.5"
"MYO6","DFNA22, DFNB37, KIAA0389","ENSG00000196586","Myosin VI","6","75749192-75919537","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB010762, HPA035483","Enhanced",NA,NA,NA,"Renal cancer:1.27e-12 (favourable)","Expressed in all","Mixed",NA,NA,"parathyroid gland: 85.5","Mixed",NA,NA
"MYO9B","CELIAC4","ENSG00000099331","Myosin IXB","19","17075781-17214537","Disease related genes, Predicted intracellular proteins","Evidence at protein level","CAB037190, HPA042043","Approved",NA,"Supported","Cytosol","Renal cancer:5.66e-6 (unfavourable), Ovarian cancer:2.61e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"spleen: 98.8","Expressed in all",NA,NA
"NCL","C23","ENSG00000115053","Nucleolin","2","231453531-231483641","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB004210, HPA023981","Supported",NA,"Enhanced","Nucleus<br>Nucleoli","Liver cancer:1.41e-6 (unfavourable), Endometrial cancer:2.28e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 449.8","Expressed in all",NA,NA
"NDFIP1","MGC10924, N4WBP5","ENSG00000131507","Nedd4 family interacting protein 1","5","142108505-142154443","Predicted membrane proteins","Evidence at protein level","HPA009682","Approved",NA,NA,NA,"Head and neck cancer:2.33e-7 (unfavourable), Renal cancer:2.39e-7 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 246.0","Expressed in all",NA,NA
"NEDD9","CAS-L, CASS2, HEF1","ENSG00000111859","Neural precursor cell expressed, developmentally down-regulated 9","6","11183298-11382348","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB009720, HPA038768, HPA039270","Uncertain",NA,"Approved","Nucleoplasm<br>Plasma membrane<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"lung: 103.4","Cell line enhanced",NA,"EFO-21: 129.1"
"NEUROD2","bHLHa1, NDRF","ENSG00000171532","Neuronal differentiation 2","17","39603536-39609777","Predicted intracellular proteins, Transcription factors","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",142,"cerebral cortex: 14.9","stomach: 0.1","Cell line enriched",302,"SCLC-21H: 30.2"
"NPBWR2","GPR8","ENSG00000125522","Neuropeptides B and W receptor 2","20","64105820-64107171","G-protein coupled receptors, Predicted membrane proteins, Transporters","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Not detected","Not detected",NA,NA,"adrenal gland,cerebral cortex: 0.1","Not detected",NA,NA
"NRG1","GGF, HGL, HRG, NDF, NRG1-IT2","ENSG00000157168","Neuregulin 1","8","31639386-32767959","Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA010964","Uncertain",NA,"Approved","Nucleoplasm",NA,"Tissue enhanced","Mixed",NA,NA,"thyroid gland: 20.0","Cell line enhanced",NA,"A549: 130.4;hTEC/SVTERT24-B: 101.2"
"NRG3",NA,"ENSG00000185737","Neuregulin 3","10","81875314-82987179","Cancer-related genes, Plasma proteins, Predicted membrane proteins","Evidence at protein level","HPA075789",NA,NA,"Approved","Vesicles",NA,"Group enriched","Tissue enhanced",NA,"cerebral cortex: 30.3","fallopian tube: 7.3","Cell line enhanced",NA,"HEK 293: 1.4;SK-MEL-30: 2.6;U-2 OS: 2.9"
"NUBP1","NBP1, NBP35","ENSG00000103274","Nucleotide binding protein 1","16","10743786-10769351","Predicted intracellular proteins","Evidence at protein level","HPA041656, HPA041799","Enhanced",NA,"Supported","Cytosol","Renal cancer:7.61e-8 (favourable), Cervical cancer:2.81e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 55.1","Expressed in all",NA,NA
"OGDH","E1k","ENSG00000105953","Oxoglutarate dehydrogenase","7","44606572-44709066","Citric acid cycle related proteins, Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA019514, HPA020347","Supported",NA,"Enhanced","Mitochondria","Renal cancer:2.22e-14 (favourable)","Expressed in all","Expressed in all",NA,NA,"heart muscle: 147.8","Expressed in all",NA,NA
"OOEP","C6orf156, Em:AC019205.2, KHDC2","ENSG00000203907","Oocyte expressed protein","6","73368555-73395133","Predicted intracellular proteins","Evidence at protein level","HPA055165","Approved",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",11,"testis: 23.1","placenta: 2.0","Cell line enhanced",NA,"BEWO: 2.5;CAPAN-2: 7.2;MCF7: 2.1;U-2 OS: 1.8"
"PARD3","ASIP, Baz, Bazooka, PAR3, PARD3A, PPP1R118","ENSG00000148498","Par-3 family cell polarity regulator","10","34109560-34815325","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA030443","Approved",NA,"Enhanced","Cell Junctions","Liver cancer:1.73e-5 (unfavourable), Urothelial cancer:4.41e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"skin: 68.7","Mixed",NA,NA
"PARD6B","PAR-6B","ENSG00000124171","Par-6 family cell polarity regulator beta","20","50731544-50756795","Predicted intracellular proteins","Evidence at protein level","HPA013376","Uncertain",NA,"Supported","Cytosol","Liver cancer:1.02e-5 (unfavourable), Renal cancer:6.38e-5 (favourable), Pancreatic cancer:8.38e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"kidney: 16.7","Cell line enhanced",NA,"CACO-2: 23.7;MCF7: 39.2;T-47d: 45.5"
"PFN1",NA,"ENSG00000108518","Profilin 1","17","4945652-4949061","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB037134, CAB037140","Enhanced",NA,"Supported","Cytosol","Renal cancer:1.06e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"appendix: 890.4","Expressed in all",NA,NA
"PFN4",NA,"ENSG00000176732","Profilin family member 4","2","24115371-24123477","Predicted intracellular proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Mixed","Tissue enriched",39,"testis: 139.8","thyroid gland: 3.5","Mixed",NA,NA
"PHLDB2","FLJ21791, LL5b, LL5beta","ENSG00000144824","Pleckstrin homology like domain family B member 2","3","111732497-111976517","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA035146, HPA035147","Approved",NA,"Supported","Plasma membrane<br>Cytosol","Renal cancer:7.03e-8 (favourable), Head and neck cancer:2.59e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"placenta: 59.0","Mixed",NA,NA
"PLA2G4C","cPLA2-gamma","ENSG00000105499","Phospholipase A2 group IVC","19","48047843-48110817","Enzymes, Predicted intracellular proteins, RAS pathway related proteins","Evidence at protein level","HPA043083","Approved",NA,"Approved","Cytosol",NA,"Mixed","Mixed",NA,NA,"parathyroid gland: 29.7","Cell line enhanced",NA,"HHSteC: 12.1;TIME: 17.1"
"POTEF","A26C1B, POTE2alpha, POTEACTIN","ENSG00000196604","POTE ankyrin domain family member F","2","130074030-130129222","Cancer-related genes, Predicted intracellular proteins","Evidence at protein level","HPA041264, HPA041271, HPA042822, HPA043260","Uncertain",NA,NA,NA,NA,"Not detected","Tissue enriched",9,"testis: 2.7","breast,placenta,prostate: 0.2","Cell line enhanced",NA,"AN3-CA: 2.3;BEWO: 1.9;CACO-2: 1.9;U-2 OS: 5.6;U-266/70: 2.0"
"PTK2","FADK, FAK, FAK1, PPP1R71","ENSG00000169398","Protein tyrosine kinase 2","8","140657900-141002216","Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA001842, CAB004036, HPA029671","Approved",NA,"Supported","Vesicles<br>Focal adhesion sites<br>Cytosol","Breast cancer:3.21e-4 (unfavourable), Endometrial cancer:9.11e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 107.1","Mixed",NA,NA
"PXN",NA,"ENSG00000089159","Paxillin","12","120210439-120265771","Predicted intracellular proteins","Evidence at protein level","CAB003841, HPA051309","Enhanced",NA,"Enhanced","Focal adhesion sites<br>Centrosome<br>Cytosol","Head and neck cancer:3.72e-5 (unfavourable), Glioma:6.11e-5 (unfavourable), Liver cancer:7.12e-5 (unfavourable), Lung cancer:1.73e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 100.4","Expressed in all",NA,NA
"RAI14","DKFZp564G013, KIAA1334, NORPEG, RAI13","ENSG00000039560","Retinoic acid induced 14","5","34656237-34832627","Predicted intracellular proteins","Evidence at protein level","HPA036949, HPA036950","Supported",NA,"Supported","Nucleus<br>Actin filaments<br>Cytosol","Stomach cancer:2.05e-4 (unfavourable), Renal cancer:9.75e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"endometrium: 92.0","Mixed",NA,NA
"RASAL3","FLJ21438","ENSG00000105122","RAS protein activator like 3","19","15451624-15464571","Predicted intracellular proteins, RAS pathway related proteins","Evidence at protein level","HPA043417","Enhanced",NA,NA,NA,"Renal cancer:1.16e-6 (unfavourable), Endometrial cancer:3.58e-5 (favourable), Head and neck cancer:3.07e-4 (favourable), Cervical cancer:8.75e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"lymph node: 37.5","spleen: 24.6","Cell line enhanced",NA,"HDLM-2: 28.2;HEL: 22.6;HMC-1: 40.9;Karpas-707: 37.6;TIME: 28.9;U-937: 26.4"
"RFX4",NA,"ENSG00000111783","Regulatory factor X4","12","106582907-106762803","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA050527","Enhanced",NA,"Approved","Nucleus",NA,"Tissue enriched","Group enriched",236,"cerebral cortex: 30.8;testis: 135.8","prostate: 0.3","Cell line enriched",13,"AF22: 47.1"
"RIC8B","FLJ10620, hSyn, RIC8","ENSG00000111785","RIC8 guanine nucleotide exchange factor B","12","106774595-106889316","Predicted intracellular proteins","Evidence at protein level","HPA042746","Approved",NA,"Approved","Centrosome<br>Cytosol",NA,"Expressed in all","Mixed",NA,NA,"parathyroid gland: 21.8","Mixed",NA,NA
"RYR1","CCO, MHS, MHS1, PPP1R137, RYR","ENSG00000196218","Ryanodine receptor 1","19","38433699-38587564","Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters","Evidence at protein level","HPA056416","Enhanced",NA,"Approved","Golgi apparatus<br>Vesicles<br>Cytosol",NA,"Mixed","Tissue enriched",31,"skeletal muscle: 572.4","esophagus: 18.6","Cell line enhanced",NA,"HaCaT: 16.8;RH-30: 14.8;SiHa: 32.7;U-2 OS: 13.2"
"SCIN","KIAA1905","ENSG00000006747","Scinderin","7","12570577-12660179","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA020518, HPA024264","Enhanced",NA,"Enhanced","Plasma membrane","Renal cancer:4.26e-8 (favourable)","Tissue enhanced","Tissue enhanced",NA,"placenta: 110.4","kidney: 52.0","Cell line enhanced",NA,"RPTEC TERT1: 71.2;SK-BR-3: 76.9"
"SEPT2","DIFF6, hNedd5, KIAA0158, NEDD5, Pnutl3","ENSG00000168385","Septin 2","2","241315100-241354027","Cancer-related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB017190, HPA018481","Supported",NA,"Supported","Nucleus<br>Actin filaments","Liver cancer:3.66e-4 (unfavourable), Glioma:4.32e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 369.5","Expressed in all",NA,NA
"SERPINI1","neuroserpin, PI12","ENSG00000163536","Serpin family I member 1","3","167735243-167825568","Disease related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA001565, CAB026059, HPA056092","Enhanced",NA,"Approved","Cytosol","Liver cancer:4.25e-4 (unfavourable)","Expressed in all","Tissue enriched",10,"cerebral cortex: 322.1","kidney: 31.3","Mixed",NA,NA
"SPINK5","DKFZp686K19184, FLJ21544, FLJ97536, FLJ97596, FLJ99794, LEKTI, LETKI, NETS, NS, VAKTI","ENSG00000133710","Serine peptidase inhibitor, Kazal type 5","5","148025683-148137289","Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA009067, HPA011351, CAB015347","Enhanced",NA,"Enhanced","Vesicles",NA,"Tissue enhanced","Group enriched",26,"esophagus: 1130.0;skin: 383.9;tonsil: 270.0","breast: 22.9","Cell line enhanced",NA,"HaCaT: 13.2;HeLa: 14.7;Karpas-707: 13.8"
"SPIRE2","KIAA1832, spir-2","ENSG00000204991","Spire type actin nucleation factor 2","16","89818179-89871319","Predicted intracellular proteins","Evidence at protein level","HPA041413, HPA049415","Uncertain",NA,"Approved","Nucleus<br>Vesicles<br>Intermediate filaments","Liver cancer:9.77e-5 (unfavourable)","Expressed in all","Mixed",NA,NA,"stomach: 14.0","Mixed",NA,NA
"SPRR4",NA,"ENSG00000184148","Small proline rich protein 4","1","152970666-152972574","Predicted intracellular proteins","Evidence at protein level","HPA055963","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",6,"skin: 48.3","breast: 7.8","Not detected",NA,NA
"SPTA1","EL2","ENSG00000163554","Spectrin alpha, erythrocytic 1","1","158610706-158686698","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB016193, HPA028048, HPA028253, CAB037246","Supported",NA,NA,NA,NA,"Not detected","Tissue enriched",19,"bone marrow: 47.1","placenta: 2.5","Group enriched",7,"HEL: 7.6;K-562: 34.1"
"SPTB",NA,"ENSG00000070182","Spectrin beta, erythrocytic","14","64746283-64879883","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA003394, HPA003398, CAB015169, CAB016232","Enhanced",NA,"Uncertain","Golgi apparatus<br>Cytosol",NA,"Mixed","Tissue enhanced",NA,"bone marrow: 38.3;skeletal muscle: 43.1","heart muscle: 15.1","Cell line enhanced",NA,"HEL: 35.6;K-562: 43.0;U-937: 11.1"
"SPTBN2","SCA5","ENSG00000173898","Spectrin beta, non-erythrocytic 2","11","66685248-66729226","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB009844, HPA039293, HPA043529","Enhanced",NA,"Supported","Cell Junctions<br>Cytosol","Pancreatic cancer:3.14e-5 (unfavourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 73.0;skin: 59.3;testis: 48.4","parathyroid gland: 24.6","Cell line enhanced",NA,"NTERA-2: 49.7;SCLC-21H: 59.4"
"STOX1","C10orf24, FLJ25162","ENSG00000165730","Storkhead box 1","10","68827541-68895432","Disease related genes, Predicted secreted proteins","Evidence at protein level","HPA037844, HPA037845","Approved",NA,"Supported","Nucleoplasm<br>Nucleoli fibrillar center<br>Cytosol","Breast cancer:3.37e-5 (favourable), Lung cancer:2.08e-4 (favourable)","Mixed","Tissue enhanced",NA,"fallopian tube: 20.0","cerebral cortex: 14.0","Cell line enhanced",NA,"AN3-CA: 8.0;HAP1: 8.3"
"SZT2","C1orf84, FLJ10387, FLJ34502, KIAA0467, RP11-506B15.1, SZT2A, SZT2B","ENSG00000198198","Seizure threshold 2 homolog (mouse)","1","43389882-43454247","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA029012","Approved",NA,"Approved","Nucleoplasm<br>Vesicles<br>Actin filaments","Head and neck cancer:1.47e-7 (favourable), Liver cancer:2.53e-4 (unfavourable), Lung cancer:6.20e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 21.4","Expressed in all",NA,NA
"TCHP","MGC10854, TpMs","ENSG00000139437","Trichoplein keratin filament binding","12","109900264-109983841","Predicted intracellular proteins","Evidence at protein level","HPA038638, HPA061543","Supported",NA,"Supported","Plasma membrane<br>Centrosome<br>Cytosol","Stomach cancer:5.52e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"skin: 32.6","Expressed in all",NA,NA
"TLE6","FLJ14009, GRG6","ENSG00000104953","Transducin like enhancer of split 6","19","2977446-2995184","Disease related genes, Predicted intracellular proteins","Evidence at protein level",NA,NA,NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"thyroid gland: 9.7","placenta: 6.5","Cell line enhanced",NA,"BEWO: 16.5;U-266/70: 11.1"
"TRAF2","TRAP3","ENSG00000127191","TNF receptor associated factor 2","9","136881912-136926607","Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB004603, HPA009972, HPA010634","Uncertain",NA,"Enhanced","Cytosol","Renal cancer:2.09e-4 (unfavourable), Liver cancer:3.06e-4 (unfavourable), Colorectal cancer:9.32e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"lymph node: 22.5","Expressed in all",NA,NA
"TRAF6","RNF85","ENSG00000175104","TNF receptor associated factor 6","11","36487027-36510272","Enzymes, Predicted intracellular proteins","Evidence at protein level","CAB004605, HPA019805, HPA020599","Approved",NA,"Supported","Nucleoli<br>Mitochondria","Renal cancer:1.36e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 16.2","Expressed in all",NA,NA
"TRIP10","CIP4, HSTP, STOT, STP","ENSG00000125733","Thyroid hormone receptor interactor 10","19","6737925-6751526","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA041934, HPA072625, HPA073886","Approved",NA,"Supported","Nucleoplasm<br>Vesicles","Head and neck cancer:1.76e-4 (favourable), Colorectal cancer:3.61e-4 (unfavourable), Renal cancer:4.66e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"skeletal muscle: 129.0","Mixed",NA,NA
"TRNP1","C1orf225, LOC388610","ENSG00000253368","TMF1-regulated nuclear protein 1","1","26993707-27000898","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level",NA,NA,NA,NA,NA,"Liver cancer:1.90e-6 (unfavourable), Renal cancer:7.72e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"stomach: 116.8","esophagus: 49.6","Mixed",NA,NA
"USP2","UBP41","ENSG00000036672","Ubiquitin specific peptidase 2","11","119355215-119381726","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA006777, HPA007222","Approved",NA,"Supported","Plasma membrane<br>Cytosol","Renal cancer:3.09e-11 (favourable)","Expressed in all","Tissue enhanced",NA,"testis: 119.4","skeletal muscle: 59.3","Cell line enhanced",NA,"U-266/70: 43.2"
"WT1","AWT1, GUD, NPHS4, WAGR, WIT-2","ENSG00000184937","Wilms tumor 1","11","32387775-32435630","Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors","Evidence at protein level","CAB000327, HPA035717, HPA053848","Enhanced",NA,"Supported","Nucleoplasm",NA,"Tissue enriched","Tissue enhanced",NA,"endometrium: 112.9;fallopian tube: 126.5;smooth muscle: 80.2","testis: 55.1","Cell line enhanced",NA,"HEL: 23.8;HMC-1: 28.7;K-562: 21.7;NB-4: 40.6;THP-1: 20.5"
"TMEM145","FLJ90805","ENSG00000167619","Transmembrane protein 145","19","42313325-42325062","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA060462","Enhanced",NA,"Approved","Vesicles",NA,"Tissue enhanced","Tissue enriched",6,"cerebral cortex: 38.3","adrenal gland: 5.9","Cell line enhanced",NA,"SCLC-21H: 32.9;SH-SY5Y: 14.2"
"KRT81","Hb-1, KRTHB1","ENSG00000205426","Keratin 81","12","52285913-52291534","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA049778","Supported",NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"breast: 3.8","placenta: 1.5","Cell line enhanced",NA,"A-431: 2684.9;A549: 2072.1;PC-3: 1009.2;U-251 MG: 1766.1"
"KRT83","Hb-3, KRTHB3","ENSG00000170523","Keratin 83","12","52314301-52321398","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA049778","Supported",NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"thyroid gland: 1.7","breast,testis: 0.3","Cell line enhanced",NA,"A549: 2.9;MCF7: 2.0;RPMI-8226: 9.3"
"CALY","CALCYON, DRD1IP, NSG3","ENSG00000130643","Calcyon neuron specific vesicular protein","10","133324072-133336935","FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA042283","Enhanced",NA,NA,NA,"Pancreatic cancer:3.54e-4 (favourable)","Group enriched","Group enriched",13,"adrenal gland: 23.5;cerebral cortex: 77.1","testis: 3.8","Not detected",NA,NA
"CAMK2B","CAM2, CAMK2, CAMKB","ENSG00000058404","Calcium/calmodulin dependent protein kinase II beta","7","44217150-44334577","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","CAB006849, HPA026307, HPA051783, HPA051785, HPA053973","Enhanced","Supported","Supported","Plasma membrane<br>Cell Junctions<br>Cytosol",NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 214.1","skeletal muscle: 46.1","Cell line enriched",12,"SCLC-21H: 88.9"
"CAMSAP2","CAMSAP1L1, KIAA1078","ENSG00000118200","Calmodulin regulated spectrin associated protein family member 2","1","200739558-200860704","Predicted intracellular proteins","Evidence at protein level","HPA026304, HPA026511, HPA027302","Enhanced",NA,"Supported","Microtubule ends<br>Cytosol","Liver cancer:2.11e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"cerebral cortex: 64.5","Cell line enhanced",NA,"hTERT-HME1: 124.5"
"DNAJC6","KIAA0473, PARK19","ENSG00000116675","DnaJ heat shock protein family (Hsp40) member C6","1","65248219-65415869","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA031182, HPA054917","Enhanced",NA,"Approved","Nucleoplasm<br>Plasma membrane<br>Cytosol","Renal cancer:2.81e-4 (favourable)","Tissue enhanced","Tissue enriched",10,"cerebral cortex: 162.8","adrenal gland: 15.6","Cell line enhanced",NA,"HDLM-2: 58.7;HEL: 150.3;K-562: 59.3"
"GAP43","B-50, PP46","ENSG00000172020","Growth associated protein 43","3","115623324-115721490","Plasma proteins, Predicted intracellular proteins, Transporters","Evidence at protein level","CAB004417, HPA013392, HPA015600","Enhanced",NA,"Enhanced","Plasma membrane",NA,"Tissue enriched","Tissue enriched",38,"cerebral cortex: 345.9","appendix: 9.1","Group enriched",6,"AF22: 34.3;NTERA-2: 74.0;SCLC-21H: 55.5;SH-SY5Y: 37.6;U-87 MG: 16.1"
"GFAP","FLJ45472","ENSG00000131095","Glial fibrillary acidic protein","17","44903161-44916937","Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB000039, HPA056030, HPA063513","Enhanced","Supported","Supported","Intermediate filaments",NA,"Tissue enriched","Tissue enriched",398,"cerebral cortex: 3768.4","bone marrow: 9.4","Mixed",NA,NA
"KCNB1","Kv2.1","ENSG00000158445","Potassium voltage-gated channel subfamily B member 1","20","49293394-49484297","Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels","Evidence at protein level","CAB001979, HPA042434","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"adipose tissue: 10.9;cerebral cortex: 21.6","fallopian tube,smooth muscle: 7.4","Cell line enhanced",NA,"CACO-2: 1.8;U-2 OS: 1.8"
"MAP1LC3A","ATG8E, LC3, LC3A, MAP1ALC3, MAP1BLC3","ENSG00000101460","Microtubule associated protein 1 light chain 3 alpha","20","34546854-34560345","Predicted intracellular proteins","Evidence at protein level","HPA007649, CAB037174, HPA052474, HPA052484","Enhanced",NA,NA,NA,"Pancreatic cancer:5.31e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 119.1","Cell line enhanced",NA,"HSkMC: 49.9;SCLC-21H: 52.4;SK-BR-3: 46.8"
"NAPB","SNAP-BETA, SNAPB","ENSG00000125814","NSF attachment protein beta","20","23374519-23421519","Predicted intracellular proteins","Evidence at protein level","CAB037225, CAB037227, HPA046149, HPA050196","Approved",NA,"Uncertain","Cytosol","Renal cancer:1.14e-4 (unfavourable)","Expressed in all","Tissue enriched",9,"cerebral cortex: 303.2","adrenal gland: 32.1","Expressed in all",NA,NA
"NAPG",NA,"ENSG00000134265","NSF attachment protein gamma","18","10525905-10552761","Predicted intracellular proteins","Evidence at protein level","HPA008208, HPA011389","Enhanced",NA,"Approved","Plasma membrane<br>Cytosol","Renal cancer:8.14e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 50.5","Expressed in all",NA,NA
"NPTX1",NA,"ENSG00000171246","Neuronal pentraxin 1","17","80467148-80477843","Predicted secreted proteins","Evidence at protein level","HPA077062","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",28,"cerebral cortex: 122.5","adrenal gland: 4.3","Cell line enhanced",NA,"HAP1: 33.7;SiHa: 44.5;U-138 MG: 85.8;WM-115: 120.6"
"OMG","OMGP","ENSG00000126861","Oligodendrocyte myelin glycoprotein","17","31272013-31297539","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA008206, HPA012693","Enhanced",NA,NA,NA,NA,"Group enriched","Tissue enriched",318,"cerebral cortex: 137.4","bone marrow: 0.4","Not detected",NA,NA
"PPFIA4",NA,"ENSG00000143847","PTPRF interacting protein alpha 4","1","203026498-203078740","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA053419, HPA054132","Enhanced",NA,NA,NA,"Renal cancer:1.73e-8 (unfavourable)","Mixed","Tissue enhanced",NA,"cerebral cortex: 24.8;heart muscle: 14.5","skeletal muscle: 6.5","Cell line enhanced",NA,"RH-30: 13.1;U-87 MG: 12.1"
"S100B","S100beta","ENSG00000160307","S100 calcium binding protein B","21","46598962-46605208","Cancer-related genes, Candidate cardiovascular disease genes, Predicted intracellular proteins, Transporters","Evidence at protein level","CAB000073, HPA015768, CAB078196","Enhanced",NA,"Approved","Nucleus<br>Vesicles",NA,"Group enriched","Group enriched",8,"adipose tissue: 208.2;cerebral cortex: 626.3","seminal vesicle: 49.5","Group enriched",6,"SK-MEL-30: 519.7;WM-115: 1274.2"
"SATB2","FLJ21474, KIAA1034","ENSG00000119042","SATB homeobox 2","2","199269500-199471266","Disease related genes, Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA001042, CAB023669, HPA029543, CAB062562, CAB067751, CAB068229, CAB068230, CAB068231","Enhanced",NA,"Supported","Nucleoplasm","Renal cancer:5.37e-8 (favourable)","Tissue enhanced","Group enriched",5,"cerebral cortex: 22.7;colon: 34.1;rectum: 43.2","small intestine: 6.3","Mixed",NA,NA
"SNAP25","bA416N4.2, dJ1068F16.2, RIC-4, RIC4, SEC9, SNAP, SNAP-25","ENSG00000132639","Synaptosome associated protein 25","20","10218830-10307418","Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Transporters","Evidence at protein level","CAB000360, HPA001830","Enhanced","Supported",NA,NA,NA,"Group enriched","Tissue enriched",31,"cerebral cortex: 1759.0","adrenal gland: 57.2","Cell line enhanced",NA,"SCLC-21H: 92.0;SH-SY5Y: 49.5;U-87 MG: 54.7"
"THOC1","HPR1, P84","ENSG00000079134","THO complex 1","18","214520-268050","Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA019096, HPA019687","Enhanced",NA,"Enhanced","Nuclear speckles","Renal cancer:1.80e-6 (unfavourable), Liver cancer:1.83e-5 (unfavourable), Ovarian cancer:2.89e-5 (favourable), Breast cancer:8.43e-4 (favourable), Urothelial cancer:9.62e-4 (favourable)","Expressed in all","Mixed",NA,NA,"testis: 29.3","Expressed in all",NA,NA
"MAP2K4","JNKK1, MEK4, MKK4, PRKMK4, SERK1","ENSG00000065559","Mitogen-activated protein kinase kinase 4","17","12020824-12143830","Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB007751, HPA060074","Enhanced",NA,"Approved","Nucleoplasm<br>Cell Junctions",NA,"Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 64.0","Expressed in all",NA,NA
"MLC1","KIAA0027, LVM, MLC, VL","ENSG00000100427","Megalencephalic leukoencephalopathy with subcortical cysts 1","22","50059391-50085902","Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters","Evidence at protein level","HPA003040, HPA067533","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",8,"cerebral cortex: 180.8","bone marrow: 23.0","Cell line enhanced",NA,"HL-60: 182.4;NB-4: 133.9;THP-1: 267.0;U-266/70: 101.9;U-266/84: 85.6"
"NTRK3","TRKC","ENSG00000140538","Neurotrophic receptor tyrosine kinase 3","15","87859751-88256768","Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","CAB009233, HPA027484, HPA048065","Enhanced",NA,"Supported","Nuclear membrane<br>Nucleoli",NA,"Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 39.6","testis: 15.2","Cell line enriched",8,"U-138 MG: 99.2"
"PJA2","KIAA0438, Neurodap1, RNF131","ENSG00000198961","Praja ring finger ubiquitin ligase 2","5","109334709-109409994","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA040347, HPA057636","Enhanced",NA,"Supported","Intermediate filaments","Ovarian cancer:8.02e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 254.4","Expressed in all",NA,NA
"ARPP21","ARPP-21, R3HDM3, TARPP","ENSG00000172995","CAMP regulated phosphoprotein 21","3","35638945-35794496","Predicted intracellular proteins","Evidence at protein level","HPA017303","Enhanced",NA,"Approved","Nucleoli<br>Cytosol",NA,"Tissue enhanced","Tissue enriched",6,"cerebral cortex: 127.1","skeletal muscle: 20.2","Group enriched",10,"MOLT-4: 54.6;REH: 34.0;RH-30: 19.9"
"BRWD1","C21orf107, DCAF19, FLJ11315, N143, WDR9","ENSG00000185658","Bromodomain and WD repeat domain containing 1","21","39184176-39321559","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA030943, HPA030944, HPA030945, CAB034184","Approved",NA,"Supported","Nucleus<br>Nucleoli<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 77.7","Expressed in all",NA,NA
"CNP",NA,"ENSG00000173786","2',3'-cyclic nucleotide 3' phosphodiesterase","17","41966741-41977731","Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB002672, HPA023266, HPA023278, HPA023280, HPA023338","Enhanced","Supported","Enhanced","Nucleus<br>Cytosol",NA,"Expressed in all","Tissue enriched",11,"cerebral cortex: 614.8","prostate: 54.9","Expressed in all",NA,NA
"MAP2","MAP2A, MAP2B, MAP2C","ENSG00000078018","Microtubule associated protein 2","2","209424058-209734118","FDA approved drug targets, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB001984, HPA008273, HPA012828","Enhanced","Supported","Supported","Nucleoli<br>Cytosol","Endometrial cancer:1.98e-6 (unfavourable)","Tissue enhanced","Tissue enriched",11,"cerebral cortex: 296.5","thyroid gland: 27.9","Cell line enhanced",NA,"AF22: 293.3;NTERA-2: 106.5;SCLC-21H: 174.9;SH-SY5Y: 88.2"
"NCAM1","CD56, NCAM","ENSG00000149294","Neural cell adhesion molecule 1","11","112961247-113278436","Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB000142, CAB018071, HPA039835","Enhanced",NA,"Enhanced","Plasma membrane<br>Cytosol","Pancreatic cancer:9.11e-6 (favourable), Renal cancer:8.20e-4 (unfavourable)","Tissue enriched","Tissue enhanced",NA,"cerebral cortex: 334.9","heart muscle: 87.5","Cell line enhanced",NA,"RH-30: 128.0;SCLC-21H: 126.2;U-138 MG: 71.8;WM-115: 77.9"
"NCDN","NCDN-1, NCDN-2","ENSG00000020129","Neurochondrin","1","35557473-35567274","Predicted intracellular proteins","Evidence at protein level","HPA023676","Enhanced","Supported","Supported","Cytosol","Liver cancer:1.91e-5 (unfavourable), Pancreatic cancer:3.73e-4 (favourable)","Expressed in all","Tissue enriched",13,"cerebral cortex: 284.4","adrenal gland: 22.7","Expressed in all",NA,NA
"NPTXR",NA,"ENSG00000221890","Neuronal pentraxin receptor","22","38818452-38843982","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA001079","Enhanced",NA,"Approved","Nucleoplasm<br>Plasma membrane<br>Cytosol","Endometrial cancer:2.85e-4 (unfavourable), Cervical cancer:3.93e-4 (favourable)","Expressed in all","Tissue enriched",13,"cerebral cortex: 176.4","prostate: 13.3","Cell line enhanced",NA,"SCLC-21H: 36.6;U-87 MG: 86.8"
"SRGAP3","ARHGAP14, KIAA0411, MEGAP, SRGAP2, WRP","ENSG00000196220","SLIT-ROBO Rho GTPase activating protein 3","3","8980591-9363053","Cancer-related genes, Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA036959, HPA044074","Enhanced",NA,"Approved","Nucleoplasm",NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 26.5;fallopian tube: 17.4","cervix, uterine: 7.9","Cell line enhanced",NA,"AF22: 8.9;HBEC3-KT: 5.7;RT4: 8.6;T-47d: 9.6"
"ADAP1","CENTA1, GCS1L","ENSG00000105963","ArfGAP with dual PH domains 1","7","897901-955407","Predicted intracellular proteins","Evidence at protein level","HPA007033, HPA012049","Enhanced",NA,"Supported","Plasma membrane<br>Cytosol","Renal cancer:4.13e-5 (favourable), Colorectal cancer:5.25e-4 (unfavourable), Head and neck cancer:9.13e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 80.4","colon: 37.9","Cell line enhanced",NA,"A-431: 97.9;CAPAN-2: 69.1;HMC-1: 64.7;THP-1: 87.7"
"ADAR","ADAR1, G1P1, IFI4","ENSG00000160710","Adenosine deaminase, RNA specific","1","154582062-154627999","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA003890, HPA051519, CAB056157","Enhanced",NA,"Enhanced","Nucleus<br>Nucleoli","Renal cancer:7.30e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 121.4","Expressed in all",NA,NA
"AGO3","EIF2C3, FLJ12765, hAGO3","ENSG00000126070","Argonaute 3, RISC catalytic component","1","35930718-36072500","Predicted intracellular proteins","Evidence at protein level","HPA048342, HPA075436","Uncertain",NA,"Supported","Nucleoplasm<br>Cytoplasmic bodies","Endometrial cancer:5.70e-4 (unfavourable)","Mixed","Mixed",NA,NA,"testis: 10.3","Expressed in all",NA,NA
"ARHGAP26","GRAF, KIAA0621, OPHN1L, OPHN1L1","ENSG00000145819","Rho GTPase activating protein 26","5","142770384-143229011","Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA035106, HPA035107","Enhanced",NA,"Approved","Cytosol","Urothelial cancer:2.88e-6 (favourable), Endometrial cancer:5.93e-6 (favourable), Cervical cancer:1.36e-4 (favourable), Breast cancer:2.05e-4 (favourable), Colorectal cancer:6.95e-4 (favourable)","Expressed in all","Mixed",NA,NA,"cerebral cortex: 30.8","Cell line enhanced",NA,"Karpas-707: 61.5"
"BEND6","bA203B9.1, C6orf65, FLJ30162","ENSG00000151917","BEN domain containing 6","6","56955126-57027342","Predicted intracellular proteins","Evidence at protein level","HPA031605, HPA052973","Enhanced",NA,"Approved","Nucleus<br>Plasma membrane",NA,"Tissue enriched","Tissue enriched",6,"cerebral cortex: 39.2","cervix, uterine: 6.6","Mixed",NA,NA
"CAMKV","MGC8407, VACAMKL","ENSG00000164076","CaM kinase like vesicle associated","3","49857988-49870222","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA007656, CAB034931","Enhanced",NA,"Approved","Nucleoplasm<br>Cytokinetic bridge",NA,"Group enriched","Tissue enriched",55,"cerebral cortex: 86.2","testis: 1.5","Cell line enhanced",NA,"AF22: 6.4;HAP1: 8.9;NTERA-2: 30.7;SCLC-21H: 12.2;SH-SY5Y: 7.1"
"CARS","CARS1","ENSG00000110619","Cysteinyl-tRNA synthetase","11","3000922-3057613","Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA002383, HPA002384, CAB075734, CAB075735, CAB075736, CAB075737","Enhanced",NA,"Enhanced","Cytosol","Renal cancer:0.00e+0 (unfavourable), Liver cancer:5.16e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 28.2","Mixed",NA,NA
"CEP170B","Cep170R, FAM68C, KIAA0284","ENSG00000099814","Centrosomal protein 170B","14","104865280-104896770","Predicted intracellular proteins","Evidence at protein level","HPA000871, HPA059017","Enhanced",NA,"Approved","Centrosome<br>Cytosol","Renal cancer:3.26e-4 (favourable), Prostate cancer:4.41e-4 (unfavourable), Liver cancer:6.12e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"skin: 30.5","Mixed",NA,NA
"CKAP4","CLIMP-63, ERGIC-63, P63","ENSG00000136026","Cytoskeleton associated protein 4","12","106237877-106304279","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA000278, HPA000792, HPA001225","Enhanced",NA,"Uncertain","Nuclear speckles<br>Cytosol<br>Cytoplasmic bodies","Renal cancer:0.00e+0 (unfavourable), Liver cancer:6.61e-5 (unfavourable), Lung cancer:5.61e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cervix, uterine: 78.5","Cell line enhanced",NA,"BJ hTERT+: 563.9;fHDF/TERT166: 652.4"
"CKB","CKBB","ENSG00000166165","Creatine kinase B","14","103519659-103523111","Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA001254, CAB047313","Enhanced",NA,"Supported","Cytosol","Renal cancer:4.02e-8 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 475.1","Cell line enhanced",NA,"CACO-2: 340.9;HEK 293: 940.9;SCLC-21H: 678.1"
"COX18","FLJ38991","ENSG00000163626","COX18, cytochrome c oxidase assembly factor","4","73052362-73069755","Predicted membrane proteins","Evidence at protein level","HPA046772, HPA049489","Enhanced",NA,NA,NA,"Renal cancer:8.22e-7 (favourable), Colorectal cancer:6.31e-4 (favourable)","Expressed in all","Mixed",NA,NA,"thyroid gland: 5.4","Expressed in all",NA,NA
"CRYM","DFNA40","ENSG00000103316","Crystallin mu","16","21238874-21303083","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA019086, HPA030619","Enhanced",NA,"Supported","Cytosol",NA,"Tissue enhanced","Group enriched",6,"cerebral cortex: 51.1;heart muscle: 47.8;kidney: 28.4;prostate: 24.7;urinary bladder: 14.8","lung: 5.7","Cell line enhanced",NA,"HEL: 9.4;RPTEC TERT1: 32.9;U-87 MG: 8.7"
"CTNND2","GT24, NPRAP","ENSG00000169862","Catenin delta 2","5","10971840-11904043","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA015077, CAB037339","Enhanced",NA,"Approved","Nucleoplasm<br>Golgi apparatus<br>Cell Junctions",NA,"Tissue enriched","Tissue enriched",18,"cerebral cortex: 103.2","spleen: 5.6","Cell line enhanced",NA,"AF22: 19.5;MCF7: 7.1;SK-BR-3: 4.4;U-266/84: 12.6"
"DCAF17","C2orf37, FLJ13096","ENSG00000115827","DDB1 and CUL4 associated factor 17","2","171434217-171485052","Disease related genes, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA053339, HPA055040","Uncertain",NA,"Supported","Nucleoplasm","Thyroid cancer:7.10e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 17.1","Expressed in all",NA,NA
"DCLK1","DCAMKL1, DCDC3A, DCLK, KIAA0369","ENSG00000133083","Doublecortin like kinase 1","13","35768652-36131306","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","CAB012405, HPA015040, HPA015655","Enhanced",NA,"Approved","Nucleoplasm<br>Cytosol","Renal cancer:4.42e-4 (unfavourable)","Tissue enhanced","Tissue enriched",5,"cerebral cortex: 140.5","smooth muscle: 27.3","Cell line enhanced",NA,"ASC diff: 19.8;ASC TERT1: 19.0;fHDF/TERT166: 18.2;HAP1: 18.4;HSkMC: 18.4;NTERA-2: 36.7"
"DCLK2","DCAMKL2, DCDC3, DCDC3B, DCK2, MGC45428","ENSG00000170390","Doublecortin like kinase 2","4","150078274-150257457","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA015770","Enhanced",NA,NA,NA,"Pancreatic cancer:2.48e-4 (favourable), Ovarian cancer:3.25e-4 (favourable)","Tissue enriched","Tissue enriched",10,"cerebral cortex: 82.6","heart muscle: 7.9","Cell line enhanced",NA,"AF22: 23.3;BJ hTERT+: 20.2"
"DPP6","DPL1, DPPX","ENSG00000130226","Dipeptidyl peptidase like 6","7","153887097-154894285","Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Transporters","Evidence at protein level","HPA050509","Enhanced","Supported",NA,NA,NA,"Tissue enriched","Tissue enhanced",NA,"cerebral cortex: 51.1;endometrium: 27.6","smooth muscle: 15.4","Cell line enriched",9,"NTERA-2: 5.5"
"ENO2",NA,"ENSG00000111674","Enolase 2","12","6913745-6923698","Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB000063, HPA068284, HPA068721, CAB073539, CAB079023","Enhanced","Supported","Supported","Plasma membrane<br>Cytosol","Renal cancer:7.89e-11 (unfavourable), Liver cancer:5.15e-4 (unfavourable), Colorectal cancer:6.96e-4 (unfavourable)","Expressed in all","Tissue enriched",7,"cerebral cortex: 431.0","parathyroid gland: 64.8","Cell line enhanced",NA,"U-87 MG: 368.8"
"EPB41L1","4.1N, KIAA0338","ENSG00000088367","Erythrocyte membrane protein band 4.1 like 1","20","36091504-36232799","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA054104, HPA056817","Enhanced",NA,"Supported","Plasma membrane","Renal cancer:4.39e-10 (favourable), Endometrial cancer:6.46e-5 (unfavourable), Pancreatic cancer:9.30e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"adrenal gland: 162.4","Cell line enhanced",NA,"HaCaT: 212.9"
"ERLEC1","C2orf30, CL25084, ERLECTIN, XTP3-B, XTP3TPB","ENSG00000068912","Endoplasmic reticulum lectin 1","2","53787044-53818819","Predicted secreted proteins, Transporters","Evidence at protein level","HPA031501, HPA031502, HPA031503","Enhanced",NA,NA,NA,NA,"Expressed in all","Expressed in all",NA,NA,"thyroid gland: 121.9","Expressed in all",NA,NA
"FAIM2","KIAA0950, LFG, LFG2, LIFEGUARD, NMP35, TMBIM2","ENSG00000135472","Fas apoptotic inhibitory molecule 2","12","49866896-49904217","Predicted membrane proteins","Evidence at protein level","HPA018790, HPA048800","Enhanced",NA,"Approved","Intermediate filaments",NA,"Tissue enriched","Tissue enriched",7,"cerebral cortex: 369.7","adrenal gland: 55.7","Cell line enhanced",NA,"HHSteC: 10.2;U-87 MG: 37.7"
"FAM171B","FLJ34104, KIAA1946","ENSG00000144369","Family with sequence similarity 171 member B","2","186693971-186765965","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA010639, HPA013434","Approved",NA,"Approved","Nucleus<br>Mitochondria","Renal cancer:9.51e-7 (unfavourable), Urothelial cancer:5.03e-4 (unfavourable)","Tissue enriched","Tissue enriched",6,"cerebral cortex: 114.5","parathyroid gland: 19.3","Mixed",NA,NA
"GABRA1","EJM5","ENSG00000022355","Gamma-aminobutyric acid type A receptor alpha1 subunit","5","161847063-161899981","Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","CAB022502, HPA055746","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",46,"cerebral cortex: 85.0","adrenal gland: 1.8","Not detected",NA,NA
"GAS7","KIAA0394, MGC1348","ENSG00000007237","Growth arrest specific 7","17","9910609-10198551","Cancer-related genes, Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA004838, HPA064678","Enhanced",NA,"Approved","Plasma membrane<br>Actin filaments<br>Focal adhesion sites","Urothelial cancer:6.89e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 154.7","cervix, uterine: 47.6","Cell line enriched",11,"WM-115: 526.3"
"GDAP1","CMT2K, CMT4, CMT4A","ENSG00000104381","Ganglioside induced differentiation associated protein 1","8","74321130-74488872","Disease related genes, Predicted membrane proteins","Evidence at protein level","HPA014266, HPA024334","Enhanced",NA,"Supported","Mitochondria<br>Cytosol","Endometrial cancer:1.82e-4 (unfavourable), Lung cancer:2.68e-4 (favourable), Thyroid cancer:4.54e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 76.7","parathyroid gland: 18.3","Cell line enhanced",NA,"SH-SY5Y: 49.8"
"GPHN","KIAA1385","ENSG00000171723","Gephyrin","14","66507407-67181803","Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA003116, CAB004419, HPA024694","Enhanced",NA,"Uncertain","Cytoplasmic bodies","Renal cancer:5.25e-12 (favourable), Urothelial cancer:4.61e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 30.5","Mixed",NA,NA
"GRIA2","GluA2, GLUR2, GLURB","ENSG00000120251","Glutamate ionotropic receptor AMPA type subunit 2","4","157204182-157366075","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","CAB007812, HPA008441","Enhanced",NA,NA,NA,NA,"Group enriched","Tissue enriched",7,"cerebral cortex: 206.6","endometrium: 27.5","Cell line enriched",8,"SCLC-21H: 19.9"
"HTT","HD, IT15","ENSG00000197386","Huntingtin","4","3074681-3243959","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","CAB002756, HPA026114","Enhanced",NA,"Supported","Nucleoplasm<br>Cytosol","Renal cancer:2.41e-12 (favourable), Head and neck cancer:3.26e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 27.3","Expressed in all",NA,NA
"KCNJ10","Kir1.2, Kir4.1","ENSG00000177807","Potassium voltage-gated channel subfamily J member 10","1","159998651-160070483","Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels","Evidence at protein level","HPA078302","Enhanced",NA,NA,NA,NA,"Tissue enriched","Group enriched",5,"cerebral cortex: 124.7;kidney: 30.6","spleen: 14.5","Cell line enhanced",NA,"Hep G2: 4.5;SK-MEL-30: 1.6;U-266/70: 1.6"
"KIF5A","D12S1889, MY050, NKHC, SPG10","ENSG00000155980","Kinesin family member 5A","12","57549998-57586632","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA004469, HPA073448","Enhanced","Approved","Approved","Nucleoplasm<br>Mitotic spindle<br>Cytosol","Pancreatic cancer:5.23e-4 (favourable)","Tissue enriched","Tissue enriched",28,"cerebral cortex: 325.7","adrenal gland: 11.4","Cell line enhanced",NA,"HDLM-2: 28.1;NTERA-2: 15.0;SCLC-21H: 36.2"
"KRT12","K12","ENSG00000187242","Keratin 12","17","40861303-40867210","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA055217, HPA055835","Enhanced",NA,NA,NA,NA,"Mixed","Not detected",NA,NA,"small intestine: 0.7","Not detected",NA,NA
"LINGO1","FLJ14594, LERN1, LRRN6A","ENSG00000169783","Leucine rich repeat and Ig domain containing 1","15","77613027-77820900","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA074653","Enhanced",NA,"Approved","Plasma membrane","Renal cancer:3.23e-7 (unfavourable)","Expressed in all","Tissue enriched",13,"cerebral cortex: 130.8","placenta: 9.8","Cell line enhanced",NA,"AF22: 23.6;AN3-CA: 18.6;HAP1: 31.4;HEK 293: 19.6;NTERA-2: 56.8"
"LMNB2","LMN2","ENSG00000176619","Lamin B2","19","2427638-2456996","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB022593, HPA047863, HPA062477","Enhanced",NA,"Supported","Nuclear membrane","Renal cancer:9.34e-5 (unfavourable), Prostate cancer:9.53e-5 (unfavourable), Liver cancer:1.32e-4 (unfavourable), Stomach cancer:3.98e-4 (favourable), Melanoma:5.88e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 21.0","Expressed in all",NA,NA
"MAP1A","MAP1L","ENSG00000166963","Microtubule associated protein 1A","15","43510958-43531620","FDA approved drug targets, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA039063, HPA039064, HPA066488","Enhanced",NA,"Approved","Cytosol","Thyroid cancer:1.09e-5 (unfavourable), Urothelial cancer:1.66e-5 (unfavourable), Renal cancer:6.59e-5 (unfavourable)","Tissue enhanced","Tissue enriched",9,"cerebral cortex: 165.6","smooth muscle: 18.9","Cell line enhanced",NA,"fHDF/TERT166: 72.9;U-87 MG: 119.0"
"MBP",NA,"ENSG00000197971","Myelin basic protein","18","76978827-77133683","Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB002300, HPA049222, HPA064368","Enhanced","Supported","Approved","Plasma membrane","Renal cancer:4.48e-12 (favourable)","Group enriched","Tissue enriched",29,"cerebral cortex: 2930.7","parathyroid gland: 99.8","Cell line enhanced",NA,"HL-60: 79.4;SK-MEL-30: 158.4"
"MLF2","NTN4","ENSG00000089693","Myeloid leukemia factor 2","12","6747996-6767475","Predicted intracellular proteins","Evidence at protein level","HPA010811, HPA010859","Enhanced",NA,"Supported","Nucleoplasm<br>Plasma membrane<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 272.5","Expressed in all",NA,NA
"MST1R","CD136, CDw136, PTK8, RON","ENSG00000164078","Macrophage stimulating 1 receptor","3","49887002-49903873","CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA007657, HPA008180, CAB008972","Enhanced",NA,"Approved","Cytosol","Urothelial cancer:2.33e-5 (favourable)","Mixed","Tissue enhanced",NA,"skin: 69.4","stomach: 37.2","Cell line enhanced",NA,"CAPAN-2: 84.1;HaCaT: 46.9;HBEC3-KT: 41.5;hTCEpi: 57.4;RT4: 49.8"
"OLIG2","BHLHB1, bHLHe19, OLIGO2, PRKCBP2, RACK17","ENSG00000205927","Oligodendrocyte transcription factor 2","21","33025845-33029196","Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA003254, CAB019381","Enhanced",NA,"Uncertain","Nucleoplasm<br>Plasma membrane",NA,"Tissue enriched","Tissue enriched",245,"cerebral cortex: 91.0","duodenum: 0.3","Cell line enhanced",NA,"HMC-1: 46.5;NB-4: 25.3;THP-1: 23.2;WM-115: 10.9"
"PCP4L1","IQM1","ENSG00000248485","Purkinje cell protein 4 like 1","1","161258727-161285450","Predicted intracellular proteins","Evidence at protein level","HPA052833","Enhanced","Supported","Approved","Nucleoplasm<br>Mitochondria","Lung cancer:8.10e-5 (favourable)","Group enriched","Tissue enhanced",NA,"cerebral cortex: 45.2;urinary bladder: 39.5","seminal vesicle: 22.7","Cell line enhanced",NA,"RT4: 10.8;T-47d: 8.2"
"PDE2A",NA,"ENSG00000186642","Phosphodiesterase 2A","11","72576141-72674591","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB009752, HPA031192","Enhanced",NA,"Supported","Cytosol","Liver cancer:1.76e-6 (favourable)","Mixed","Tissue enhanced",NA,"cerebral cortex: 141.8;spleen: 184.3","adipose tissue: 62.1","Cell line enriched",6,"HeLa: 340.7"
"PNMA1","MA1","ENSG00000176903","Paraneoplastic Ma antigen 1","14","73711783-73714372","Predicted intracellular proteins","Evidence at protein level","HPA003817, HPA015007","Enhanced",NA,"Supported","Focal adhesion sites<br>Cytosol","Liver cancer:3.00e-5 (unfavourable), Urothelial cancer:4.51e-5 (unfavourable), Head and neck cancer:7.49e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 193.5","Mixed",NA,NA
"PPFIA3","KIAA0654, LPNA3, MGC126567, MGC126569","ENSG00000177380","PTPRF interacting protein alpha 3","19","49119389-49151026","Predicted intracellular proteins","Evidence at protein level","HPA043567, HPA050340","Enhanced",NA,"Uncertain","Nucleoli fibrillar center<br>Vesicles","Head and neck cancer:6.46e-7 (favourable), Liver cancer:2.24e-5 (unfavourable), Breast cancer:3.09e-4 (unfavourable), Endometrial cancer:8.65e-4 (favourable)","Expressed in all","Group enriched",6,"cerebral cortex: 21.5;skin: 20.2","parathyroid gland: 3.6","Cell line enhanced",NA,"PC-3: 33.5"
"PRKCA","PKCA","ENSG00000154229","Protein kinase C alpha","17","66302636-66810743","Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins","Evidence at protein level","CAB003844, HPA006563, HPA006564, CAB016290","Enhanced","Approved","Enhanced","Plasma membrane<br>Cytosol",NA,"Expressed in all","Mixed",NA,NA,"cerebral cortex: 45.0","Cell line enhanced",NA,"U-87 MG: 157.3"
"PRKCE",NA,"ENSG00000171132","Protein kinase C epsilon","2","45651345-46187990","Cancer-related genes, Enzymes, Predicted intracellular proteins","Evidence at protein level","CAB001948, HPA044496, HPA054252","Enhanced",NA,"Approved","Vesicles","Renal cancer:2.63e-7 (favourable), Endometrial cancer:2.42e-4 (unfavourable), Lung cancer:9.62e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 48.3","parathyroid gland: 20.5","Mixed",NA,NA
"PRMT8","HRMT1L3, HRMT1L4","ENSG00000111218","Protein arginine methyltransferase 8","12","3381349-3593973","Predicted intracellular proteins","Evidence at protein level","HPA039747, HPA069769","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",8,"cerebral cortex: 19.9","testis: 2.4","Cell line enriched",11,"hTERT-HME1: 37.3"
"PRRT1","C6orf31, IFITMD7, NG5","ENSG00000204314","Proline rich transmembrane protein 1","6","32148359-32154373","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA055149, HPA059099","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enriched",8,"cerebral cortex: 4.5","ovary: 0.6","Cell line enhanced",NA,"SK-MEL-30: 1.1"
"PTPRZ1","phosphacan, PTP18, PTPRZ, PTPZ, RPTPB","ENSG00000106278","Protein tyrosine phosphatase, receptor type Z1","7","121873089-122062036","Enzymes, Plasma proteins, Predicted membrane proteins","Evidence at protein level","HPA015103, CAB025106, HPA071024","Enhanced","Supported","Supported","Cytosol","Urothelial cancer:9.36e-4 (unfavourable)","Tissue enriched","Tissue enriched",9,"cerebral cortex: 257.9","skin: 30.1","Group enriched",12,"AF22: 420.6;NTERA-2: 119.0;WM-115: 185.9"
"RTN3","ASYIP, HAP, NSPL2, NSPLII, RTN3-A1","ENSG00000133318","Reticulon 3","11","63681446-63759891","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA015649, HPA015650","Enhanced",NA,"Supported","Endoplasmic reticulum","Liver cancer:1.30e-6 (unfavourable), Renal cancer:9.87e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 1030.6","Expressed in all",NA,NA
"SCFD2","FLJ39514, STXBP1L1","ENSG00000184178","Sec1 family domain containing 2","4","52872982-53366075","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA036526, HPA036527","Enhanced",NA,"Approved","Nucleus","Renal cancer:3.81e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 14.7","Expressed in all",NA,NA
"SEMA5B","FLJ10372, KIAA1445, SEMAG, SemG","ENSG00000082684","Semaphorin 5B","3","122909193-123028605","Predicted membrane proteins","Evidence at protein level","HPA066548","Enhanced",NA,"Supported","Cytosol","Renal cancer:7.57e-4 (unfavourable)","Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 11.4","heart muscle: 4.2","Cell line enhanced",NA,"AF22: 79.6;NTERA-2: 15.7;SH-SY5Y: 22.6"
"SGTB","FLJ39002, Sgt2","ENSG00000197860","Small glutamine rich tetratricopeptide repeat containing beta","5","65665928-65723035","Predicted intracellular proteins","Evidence at protein level","HPA044689, HPA063674","Enhanced",NA,"Uncertain","Nucleus",NA,"Expressed in all","Tissue enhanced",NA,"cerebral cortex: 52.0","appendix: 10.4","Expressed in all",NA,NA
"SLC32A1","bA122O1.1, VGAT, VIAAT","ENSG00000101438","Solute carrier family 32 member 1","20","38724462-38729372","Predicted membrane proteins, Transporters","Evidence at protein level","CAB037156, HPA058859, HPA059985","Enhanced","Supported",NA,NA,NA,"Tissue enhanced","Tissue enriched",35,"cerebral cortex: 15.9","testis: 0.4","Cell line enhanced",NA,"MOLT-4: 1.1"
"SLITRK4","DKFZp547M2010","ENSG00000179542","SLIT and NTRK like family member 4","X","143622790-143635777","Predicted membrane proteins","Evidence at protein level","HPA000431","Enhanced",NA,"Uncertain","Microtubules",NA,"Tissue enhanced","Tissue enhanced",NA,"adrenal gland: 13.9;cerebral cortex: 12.8","cervix, uterine: 8.4","Cell line enhanced",NA,"HeLa: 3.9;HHSteC: 2.5;T-47d: 8.3;U-2 OS: 3.5"
"SNAP91","AP180, CALM, KIAA0656","ENSG00000065609","Synaptosome associated protein 91","6","83552880-83709691","Predicted intracellular proteins","Evidence at protein level","CAB009745, HPA029632, HPA029633","Enhanced",NA,"Uncertain","Centrosome<br>Cytosol",NA,"Tissue enhanced","Tissue enriched",7,"cerebral cortex: 152.1","testis: 22.5","Group enriched",16,"SCLC-21H: 27.9;SH-SY5Y: 15.7"
"SOX8",NA,"ENSG00000005513","SRY-box 8","16","981808-986979","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA041640, HPA058665","Enhanced",NA,"Supported","Nucleus",NA,"Tissue enriched","Tissue enriched",29,"cerebral cortex: 109.9","salivary gland: 3.8","Cell line enriched",5,"RH-30: 112.8"
"SS18","SSXT, SYT","ENSG00000141380","SS18, nBAF chromatin remodeling complex subunit","18","26016253-26091217","Cancer-related genes, Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA055741, HPA059539","Supported",NA,"Approved","Nucleoplasm<br>Cytosol","Renal cancer:4.86e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 75.7","Expressed in all",NA,NA
"SYP","MRX96","ENSG00000102003","Synaptophysin","X","49187804-49200259","Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters","Evidence at protein level","CAB000076, HPA002858, CAB055505, CAB078999","Enhanced","Supported",NA,NA,NA,"Group enriched","Tissue enriched",11,"cerebral cortex: 571.4","adrenal gland: 51.1","Cell line enhanced",NA,"SCLC-21H: 116.7;SH-SY5Y: 38.0"
"TNR",NA,"ENSG00000116147","Tenascin R","1","175315194-175743770","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB022343, HPA027134, HPA027150, HPA029859","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",38,"cerebral cortex: 70.6","adrenal gland: 1.8","Cell line enhanced",NA,"SH-SY5Y: 1.9;U-937: 1.1"
"TSSC1",NA,"ENSG00000032389","Tumor suppressing subtransferable candidate 1","2","3188925-3377882","Predicted intracellular proteins","Evidence at protein level","HPA031231, HPA031232, HPA031233, HPA031234","Approved",NA,"Supported","Nucleus<br>Nucleoli<br>Intermediate filaments","Liver cancer:3.67e-7 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 34.8","Expressed in all",NA,NA
"TTC7B","TTC7L1","ENSG00000165914","Tetratricopeptide repeat domain 7B","14","90524564-90816479","Predicted intracellular proteins","Evidence at protein level","HPA058363, HPA059577","Enhanced",NA,"Supported","Plasma membrane","Renal cancer:3.20e-6 (favourable)","Mixed","Expressed in all",NA,NA,"cerebral cortex: 72.6","Mixed",NA,NA
"WIPF2","WICH, WIRE","ENSG00000171475","WAS/WASL interacting protein family member 2","17","40219304-40284136","Predicted intracellular proteins","Evidence at protein level","HPA024000, HPA024001, HPA024467","Enhanced",NA,"Supported","Nucleoplasm",NA,"Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 32.4","Expressed in all",NA,NA
"YWHAB","YWHAA","ENSG00000166913","Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein beta","20","44885676-44908532","Cancer-related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB003759, HPA007925, HPA011212","Enhanced",NA,"Supported","Cytosol","Liver cancer:1.91e-6 (unfavourable), Renal cancer:2.52e-5 (favourable), Endometrial cancer:5.46e-4 (unfavourable), Lung cancer:6.01e-4 (unfavourable), Head and neck cancer:6.14e-4 (unfavourable), Breast cancer:9.18e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 445.0","Expressed in all",NA,NA
"ZFC3H1","CCDC131, CSRC2, KIAA0546, MGC23401, PSRC2","ENSG00000133858","Zinc finger C3H1-type containing","12","71609472-71667725","Predicted intracellular proteins","Evidence at protein level","HPA007072, HPA007151","Enhanced",NA,"Approved","Nucleoplasm<br>Intermediate filaments","Renal cancer:1.48e-5 (unfavourable), Liver cancer:3.63e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"testis: 19.1","Expressed in all",NA,NA
"AATK","AATYK, AATYK1, KIAA0641, LMR1, LMTK1, PPP1R77","ENSG00000181409","Apoptosis associated tyrosine kinase","17","81117295-81166077","Enzymes, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA009073","Enhanced",NA,"Uncertain","Mitochondria",NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 36.4;duodenum: 23.4","small intestine: 18.3","Group enriched",5,"CACO-2: 35.4;SH-SY5Y: 15.1"
"AKR1B1","ALDR1, AR","ENSG00000085662","Aldo-keto reductase family 1 member B","7","134442350-134459284","Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA026425, CAB027391, CAB047353, HPA052751","Enhanced",NA,"Supported","Nucleus<br>Cytosol","Stomach cancer:2.44e-5 (unfavourable), Urothelial cancer:7.00e-4 (unfavourable)","Expressed in all","Tissue enriched",6,"adrenal gland: 2486.1","seminal vesicle: 449.2","Cell line enhanced",NA,"A549: 1469.5;BJ hTERT+: 2394.4"
"ALDOC",NA,"ENSG00000109107","Aldolase, fructose-bisphosphate C","17","28573115-28577264","Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA003282, CAB020828, HPA067442","Enhanced","Supported","Approved","Nucleus<br>Nucleoli fibrillar center<br>Vesicles<br>Cytosol","Renal cancer:1.29e-7 (unfavourable), Head and neck cancer:9.80e-4 (unfavourable)","Tissue enriched","Tissue enriched",7,"cerebral cortex: 766.6","heart muscle: 111.2","Cell line enhanced",NA,"RPMI-8226: 165.2;U-266/70: 119.9"
"DNM1","DNM","ENSG00000106976","Dynamin 1","9","128191655-128255248","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","CAB005920, HPA049910, HPA061801","Enhanced",NA,"Supported","Nucleoplasm",NA,"Mixed","Tissue enriched",14,"cerebral cortex: 364.2","cervix, uterine: 25.6","Cell line enhanced",NA,"A549: 114.8"
"GPR26",NA,"ENSG00000154478","G protein-coupled receptor 26","10","123666355-123694607","G-protein coupled receptors, Predicted membrane proteins","Evidence at protein level","HPA062736","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",16,"cerebral cortex: 4.3","testis: 0.2","Cell line enriched",15,"SCLC-21H: 1.4"
"MARK1","MARK, PAR-1C","ENSG00000116141","Microtubule affinity regulating kinase 1","1","220528183-220664461","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA007421, HPA008061","Uncertain",NA,NA,NA,"Pancreatic cancer:2.23e-5 (favourable), Melanoma:2.63e-4 (unfavourable)","Mixed","Mixed",NA,NA,"cerebral cortex: 21.1","Cell line enhanced",NA,"RT4: 50.7"
"RHBDD2","NPD007, RHBDL7","ENSG00000005486","Rhomboid domain containing 2","7","75842602-75888926","Enzymes, Predicted membrane proteins","Evidence at protein level","HPA045074, HPA051960","Uncertain",NA,"Enhanced","Golgi apparatus","Renal cancer:8.68e-6 (favourable), Colorectal cancer:3.31e-5 (unfavourable), Glioma:1.25e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 258.6","Expressed in all",NA,NA
"SATB1",NA,"ENSG00000182568","SATB homeobox 1","3","18345387-18445588","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Transcription factors","Evidence at protein level","HPA051769, CAB056144","Supported",NA,"Supported","Nucleoplasm<br>Nuclear bodies","Renal cancer:1.96e-7 (favourable), Pancreatic cancer:8.97e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 76.6","Cell line enhanced",NA,"HDLM-2: 421.9;REH: 115.4;THP-1: 129.6"
"ATXN2","ATX2, SCA2, TNRC13","ENSG00000204842","Ataxin 2","12","111452214-111599676","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA018295, HPA020339, HPA021146","Enhanced",NA,"Enhanced","Cytosol","Liver cancer:2.66e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 41.2","Expressed in all",NA,NA
"B3GNT6","B3Gn-T6","ENSG00000198488","UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 6","11","77034398-77041973","Enzymes, Predicted secreted proteins","Evidence at protein level","HPA012158, HPA039805","Enhanced","Approved",NA,NA,"Colorectal cancer:2.31e-4 (favourable)","Group enriched","Tissue enhanced",NA,"colon: 21.7;rectum: 18.2;stomach: 23.5","small intestine: 7.9","Not detected",NA,NA
"CTDP1","FCP1","ENSG00000060069","CTD phosphatase subunit 1","18","79679801-79756623","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","CAB032641, HPA040394, HPA070389","Supported",NA,"Approved","Nucleoplasm<br>Vesicles","Renal cancer:5.51e-5 (favourable), Endometrial cancer:6.43e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 19.6","Expressed in all",NA,NA
"CTRL",NA,"ENSG00000141086","Chymotrypsin like","16","67927640-67932414","Enzymes, Predicted secreted proteins","Evidence at protein level","HPA034504, HPA034505","Enhanced",NA,"Uncertain","Nucleoplasm",NA,"Not detected","Tissue enriched",209,"pancreas: 1629.9","ovary: 7.8","Mixed",NA,NA
"DIP2C","KIAA0934","ENSG00000151240","Disco interacting protein 2 homolog C","10","274190-689668","Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA030264, HPA059325","Enhanced",NA,"Approved","Nucleoplasm<br>Vesicles<br>Cytosol","Renal cancer:2.46e-6 (favourable), Endometrial cancer:8.92e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"cerebral cortex: 23.4","Cell line enhanced",NA,"U-2197: 30.9"
"ELAVL4","HUD, PNEM","ENSG00000162374","ELAV like RNA binding protein 4","1","50048014-50203786","Predicted intracellular proteins","Evidence at protein level","CAB004442, HPA043047","Enhanced",NA,"Approved","Nucleoplasm<br>Vesicles",NA,"Group enriched","Group enriched",9,"adrenal gland: 10.7;cerebral cortex: 53.3;testis: 10.9","appendix: 2.9","Cell line enriched",21,"SH-SY5Y: 131.1"
"FBXL16","C16orf22, Fbl16, MGC33974","ENSG00000127585","F-box and leucine rich repeat protein 16","16","692498-705829","Predicted intracellular proteins","Evidence at protein level","HPA039504, HPA056354","Enhanced",NA,NA,NA,"Endometrial cancer:6.24e-5 (unfavourable), Pancreatic cancer:7.34e-5 (favourable), Renal cancer:1.87e-4 (favourable)","Expressed in all","Tissue enriched",23,"cerebral cortex: 186.4","testis: 8.0","Cell line enhanced",NA,"AN3-CA: 16.9;SCLC-21H: 35.4;SH-SY5Y: 23.8"
"NCOA7","dJ187J11.3, ERAP140, TLDC4","ENSG00000111912","Nuclear receptor coactivator 7","6","125781161-125932030","Predicted intracellular proteins","Evidence at protein level","HPA030289, HPA030290, HPA030291, HPA030292","Approved",NA,"Approved","Nuclear bodies<br>Golgi apparatus","Renal cancer:1.78e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"urinary bladder: 88.4","Expressed in all",NA,NA
"NGEF","ARHGEF27","ENSG00000066248","Neuronal guanine nucleotide exchange factor","2","232878686-233013272","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA008160","Approved",NA,"Uncertain","Plasma membrane<br>Cytosol",NA,"Mixed","Tissue enhanced",NA,"adrenal gland: 66.5;cerebral cortex: 151.4","duodenum: 42.8","Cell line enhanced",NA,"A-431: 46.9;HDLM-2: 42.0;PC-3: 52.8;T-47d: 30.2"
"PRPF8","hPrp8, Prp8, PRPC8, RP13, SNRNP220","ENSG00000174231","Pre-mRNA processing factor 8","17","1650629-1684882","Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB009941, CAB015457","Supported",NA,"Enhanced","Nucleoplasm",NA,"Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 94.4","Expressed in all",NA,NA
"RGN","RC, SMP30","ENSG00000130988","Regucalcin","X","47078355-47093314","Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA029102, HPA029103","Enhanced",NA,"Approved","Nucleus","Renal cancer:5.10e-10 (favourable), Liver cancer:7.55e-4 (favourable)","Tissue enriched","Tissue enhanced",NA,"adrenal gland: 202.7;liver: 196.4","kidney: 57.0","Group enriched",6,"CACO-2: 17.9;fHDF/TERT166: 5.3;Hep G2: 22.3"
"SCO1","SCOD1","ENSG00000133028","SCO1, cytochrome c oxidase assembly protein","17","10672474-10698375","Disease related genes, Predicted membrane proteins","Evidence at protein level","HPA021565, HPA021579","Enhanced",NA,NA,NA,"Renal cancer:9.69e-7 (favourable), Thyroid cancer:7.44e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 22.5","Expressed in all",NA,NA
"SYT1","P65, SVP65, SYT","ENSG00000067715","Synaptotagmin 1","12","78863993-79452008","Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters","Evidence at protein level","HPA008394, HPA064788","Enhanced","Supported",NA,NA,NA,"Mixed","Tissue enriched",13,"cerebral cortex: 476.5","smooth muscle: 36.7","Cell line enhanced",NA,"hTERT-HME1: 29.8;LHCN-M2: 26.5;SH-SY5Y: 32.1;WM-115: 28.3"
"TAC1","NKNA, NPK, TAC2","ENSG00000006128","Tachykinin precursor 1","7","97731908-97740472","Predicted secreted proteins","Evidence at protein level","CAB004588, HPA014429","Approved",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 77.7;spleen: 47.0","appendix: 13.2","Cell line enriched",14,"U-266/70: 16.5"
"TPH2","FLJ37295, NTPH","ENSG00000139287","Tryptophan hydroxylase 2","12","71938846-72186618","Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins","Evidence at protein level","HPA046274, CAB078198","Enhanced","Supported",NA,NA,NA,"Not detected","Tissue enhanced",NA,"cerebral cortex: 1.0","testis: 0.2","Not detected",NA,NA
"RASGEF1A","CG4853, FLJ37817","ENSG00000198915","RasGEF domain family member 1A","10","43194535-43266919","Predicted intracellular proteins","Evidence at protein level","HPA035593","Enhanced",NA,"Approved","Golgi apparatus","Renal cancer:4.11e-7 (unfavourable), Breast cancer:1.86e-5 (favourable), Endometrial cancer:4.28e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"cerebral cortex: 22.7","parathyroid gland: 12.8","Cell line enhanced",NA,"K-562: 15.4;SCLC-21H: 18.4;T-47d: 14.7"
"ACOT7","ACH1, ACT, BACH, CTE-II, hBACH, LACH1, MGC1126","ENSG00000097021","Acyl-CoA thioesterase 7","1","6264269-6394391","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA025735, HPA025762","Enhanced",NA,"Supported","Nucleoplasm<br>Cytosol","Renal cancer:2.55e-6 (unfavourable), Liver cancer:2.31e-5 (unfavourable), Lung cancer:1.29e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 129.2","small intestine: 62.3","Expressed in all",NA,NA
"ACSL4","ACS4, FACL4, LACS4, MRX63, MRX68","ENSG00000068366","Acyl-CoA synthetase long-chain family member 4","X","109624244-109733403","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA000286, HPA005552","Enhanced",NA,"Approved","Golgi apparatus<br>Mitochondria","Urothelial cancer:5.73e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"cervix, uterine: 70.7","Cell line enhanced",NA,"HMC-1: 324.7"
"ADCYAP1R1","PAC1, PAC1R, PACAPR","ENSG00000078549","ADCYAP receptor type I","7","31052461-31111479","G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA030739, HPA049877","Enhanced",NA,"Supported","Vesicles","Endometrial cancer:5.78e-4 (favourable)","Tissue enriched","Tissue enhanced",NA,"cerebral cortex: 137.1;fallopian tube: 46.8","cervix, uterine: 20.7","Group enriched",6,"AF22: 3.6;NTERA-2: 4.9;SCLC-21H: 4.8;SH-SY5Y: 7.8"
"ADD2","ADDB","ENSG00000075340","Adducin 2","2","70607618-70768225","Predicted intracellular proteins","Evidence at protein level","CAB009796, HPA034509, HPA034510","Enhanced",NA,"Approved","Nucleoplasm<br>Plasma membrane<br>Cytosol",NA,"Tissue enhanced","Group enriched",10,"bone marrow: 40.2;cerebral cortex: 44.7","testis: 4.2","Cell line enhanced",NA,"K-562: 41.5;NTERA-2: 86.7;SCLC-21H: 50.4;U-251 MG: 38.9"
"AHR","bHLHe76","ENSG00000106546","Aryl hydrocarbon receptor","7","17298622-17346152","Cancer-related genes, Predicted intracellular proteins, Transcription factors","Evidence at protein level","CAB005072, HPA029722, HPA029723","Enhanced",NA,"Supported","Nucleoplasm<br>Cytosol",NA,"Expressed in all","Mixed",NA,NA,"lung: 56.4","Mixed",NA,NA
"AK5",NA,"ENSG00000154027","Adenylate kinase 5","1","77282051-77559969","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA019128, HPA057255","Enhanced",NA,"Supported","Microtubule organizing center<br>Cytosol","Prostate cancer:3.88e-4 (favourable)","Group enriched","Tissue enriched",9,"cerebral cortex: 220.7","breast: 23.6","Cell line enhanced",NA,"ASC TERT1: 65.9;BJ: 57.0;fHDF/TERT166: 60.0;LHCN-M2: 159.8;U-2 OS: 61.3"
"ALDOA",NA,"ENSG00000149925","Aldolase, fructose-bisphosphate A","16","30053090-30070457","Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA004177, CAB006252","Enhanced",NA,"Supported","Cytosol","Liver cancer:5.79e-5 (unfavourable), Lung cancer:7.32e-5 (unfavourable)","Expressed in all","Tissue enriched",7,"skeletal muscle: 9377.0","esophagus: 1428.8","Expressed in all",NA,NA
"AMER2","FAM123A, FLJ25477","ENSG00000165566","APC membrane recruitment protein 2","13","25161684-25172288","Predicted intracellular proteins","Evidence at protein level","HPA039458","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",53,"cerebral cortex: 72.4","fallopian tube,testis: 1.3","Group enriched",5,"AF22: 3.6;SCLC-21H: 3.5;U-266/70: 5.2"
"APLP1","APLP","ENSG00000105290","Amyloid beta precursor like protein 1","19","35867899-35879791","Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA028970, HPA028971","Enhanced",NA,NA,NA,"Urothelial cancer:2.65e-5 (unfavourable), Endometrial cancer:3.87e-4 (unfavourable)","Tissue enhanced","Tissue enriched",13,"cerebral cortex: 440.4","adrenal gland: 34.5","Cell line enhanced",NA,"AN3-CA: 137.3;SCLC-21H: 100.6;SH-SY5Y: 91.5"
"APOE","AD2","ENSG00000130203","Apolipoprotein E","19","44905754-44909393","Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB008363, HPA065539, HPA068768, CAB069921","Enhanced",NA,"Approved","Vesicles",NA,"Expressed in all","Expressed in all",NA,NA,"adrenal gland: 1801.1","Cell line enhanced",NA,"ASC diff: 1276.1;Hep G2: 626.6;HSkMC: 991.4;SK-MEL-30: 1417.0"
"AQP4","MIWC","ENSG00000171885","Aquaporin 4","18","26852038-26865818","Predicted membrane proteins, Transporters","Evidence at protein level","CAB005079, HPA014784, CAB058689","Enhanced","Supported","Supported","Plasma membrane<br>Cell Junctions",NA,"Tissue enriched","Group enriched",16,"cerebral cortex: 630.0;lung: 171.9","thyroid gland: 24.4","Cell line enhanced",NA,"AF22: 2.4;RPTEC TERT1: 1.0"
"ARHGEF40","FLJ10357, solo","ENSG00000165801","Rho guanine nucleotide exchange factor 40","14","21070270-21090240","Predicted intracellular proteins","Evidence at protein level","HPA030746, HPA030757","Uncertain",NA,NA,NA,NA,"Expressed in all","Expressed in all",NA,NA,"adrenal gland: 32.5","Mixed",NA,NA
"ARHGEF5","GEF5, P60, TIM, TIM1","ENSG00000050327","Rho guanine nucleotide exchange factor 5","7","144355288-144380632","Predicted intracellular proteins","Evidence at protein level","HPA020980, HPA029504, HPA044188, HPA045619, HPA045699","Enhanced",NA,"Approved","Nucleoplasm<br>Plasma membrane<br>Cytosol","Renal cancer:3.28e-7 (favourable)","Mixed","Mixed",NA,NA,"thyroid gland: 42.8","Cell line enhanced",NA,"A-431: 46.6"
"ARL8A","ARL10B, FLJ45195, Gie2","ENSG00000143862","ADP ribosylation factor like GTPase 8A","1","202133404-202144743","Predicted intracellular proteins","Evidence at protein level","HPA038759, HPA040515, HPA045924","Approved",NA,NA,NA,"Colorectal cancer:3.08e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 113.6","Expressed in all",NA,NA
"ARL8B","ARL10C, FLJ10702, Gie1","ENSG00000134108","ADP ribosylation factor like GTPase 8B","3","5122220-5180912","Predicted intracellular proteins","Evidence at protein level","HPA038759, HPA040515, HPA045924","Approved",NA,NA,NA,"Liver cancer:3.68e-6 (unfavourable), Renal cancer:4.84e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 118.6","Expressed in all",NA,NA
"ARNT2","bHLHe1, KIAA0307","ENSG00000172379","Aryl hydrocarbon receptor nuclear translocator 2","15","80404350-80597937","Disease related genes, Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA001056, CAB005081","Enhanced",NA,"Supported","Nucleus","Pancreatic cancer:1.46e-6 (favourable), Renal cancer:7.51e-4 (favourable)","Expressed in all","Tissue enriched",8,"cerebral cortex: 153.7","testis: 18.8","Mixed",NA,NA
"ATAT1","C6orf134, Em:AB023049.7, FLJ13158, MEC17","ENSG00000137343","Alpha tubulin acetyltransferase 1","6","30626842-30646823","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA046816, HPA050999","Approved",NA,"Approved","Golgi apparatus<br>Cytosol","Liver cancer:1.03e-5 (unfavourable), Renal cancer:7.78e-5 (unfavourable), Urothelial cancer:1.35e-4 (favourable)","Expressed in all","Mixed",NA,NA,"epididymis: 4.4","Cell line enhanced",NA,"AF22: 7.3"
"ATG5","APG5, APG5L, ASP, hAPG5","ENSG00000057663","Autophagy related 5","6","106045423-106325791","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB034432, CAB037309, HPA042973","Enhanced",NA,"Approved","Centrosome","Renal cancer:8.73e-4 (unfavourable), Liver cancer:8.84e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 32.3","Expressed in all",NA,NA
"ATL1","AD-FSP, FSP1, SPG3, SPG3A","ENSG00000198513","Atlastin GTPase 1","14","50532509-50633068","Disease related genes, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA027550","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 96.9","smooth muscle: 22.0","Cell line enhanced",NA,"HDLM-2: 18.1;SCLC-21H: 20.2;SiHa: 19.9"
"ATP2B1","PMCA1","ENSG00000070961","ATPase plasma membrane Ca2+ transporting 1","12","89588049-89709300","Enzymes, Plasma proteins, Predicted membrane proteins","Evidence at protein level","CAB005605, HPA011166, HPA012945","Enhanced",NA,"Supported","Plasma membrane","Liver cancer:7.74e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 143.6","Expressed in all",NA,NA
"ATP6V1B2","ATP6B2, HO57, VATB, Vma2, VPP3","ENSG00000147416","ATPase H+ transporting V1 subunit B2","8","20197367-20226819","Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Transporters","Evidence at protein level","HPA008147","Enhanced",NA,"Supported","Vesicles","Renal cancer:8.41e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 304.2","Expressed in all",NA,NA
"B3GAT1","CD57, GlcAT-P, HNK-1, LEU7, NK-1","ENSG00000109956","Beta-1,3-glucuronyltransferase 1","11","134378504-134411918","Enzymes, Predicted intracellular proteins","Evidence at protein level","CAB002500, CAB010893, HPA069468","Enhanced",NA,"Supported","Vesicles",NA,"Group enriched","Tissue enriched",11,"cerebral cortex: 115.4","thyroid gland: 10.3","Cell line enhanced",NA,"AF22: 22.9;HMC-1: 22.4;NTERA-2: 22.3;SH-SY5Y: 9.0"
"B4GALNT1","beta1-4GalNAc-T, GALGT, SPG26","ENSG00000135454","Beta-1,4-N-acetyl-galactosaminyltransferase 1","12","57623410-57633355","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA008968, HPA015128","Enhanced",NA,NA,NA,"Renal cancer:3.18e-14 (unfavourable)","Tissue enriched","Tissue enriched",6,"cerebral cortex: 26.2","seminal vesicle: 4.0","Cell line enhanced",NA,"EFO-21: 33.8;HDLM-2: 29.7"
"BASP1","CAP-23, CAP23, NAP-22, NAP22","ENSG00000176788","Brain abundant membrane attached signal protein 1","5","17065598-17276843","Plasma proteins, Predicted intracellular proteins, Transporters","Evidence at protein level","HPA045218, HPA050333","Enhanced",NA,"Enhanced","Plasma membrane","Renal cancer:5.25e-11 (unfavourable), Head and neck cancer:5.63e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 419.0;epididymis: 369.1","placenta: 130.6","Cell line enhanced",NA,"HeLa: 555.7;SiHa: 845.8"
"BCAN","BEHAB, CSPG7, MGC13038","ENSG00000132692","Brevican","1","156641390-156659532","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA007865, CAB025862","Enhanced","Supported",NA,NA,NA,"Group enriched","Tissue enriched",24,"cerebral cortex: 428.3","epididymis: 18.0","Cell line enhanced",NA,"HDLM-2: 67.3;K-562: 92.6;U-266/84: 84.7"
"BCLAF1","BTF, KIAA0164","ENSG00000029363","BCL2 associated transcription factor 1","6","136256627-136289851","Cancer-related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA006484, HPA006669, HPA027770","Enhanced",NA,"Enhanced","Nuclear speckles","Breast cancer:1.64e-4 (unfavourable), Colorectal cancer:3.44e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"bone marrow: 88.4","Expressed in all",NA,NA
"BDNF",NA,"ENSG00000176697","Brain derived neurotrophic factor","11","27654893-27722058","Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB009564, HPA031440, HPA056104","Enhanced",NA,"Supported","Nuclear speckles<br>Mitochondria",NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 11.9","epididymis: 4.9","Cell line enhanced",NA,"BJ: 37.3;BJ hTERT+ SV40 Large T+: 30.7;HBF TERT88: 30.4;U-138 MG: 45.3"
"BEX5","NGFRAP1L1","ENSG00000184515","Brain expressed X-linked 5","X","102153708-102156057","Predicted intracellular proteins","Evidence at protein level","HPA059058","Enhanced",NA,NA,NA,"Renal cancer:1.97e-4 (favourable), Lung cancer:3.09e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 96.0","epididymis: 34.8","Cell line enhanced",NA,"HAP1: 14.7;Karpas-707: 39.3"
"BORCS8","MEF2BNB","ENSG00000254901","BLOC-1 related complex subunit 8","19","19176903-19192591","Predicted intracellular proteins","Evidence at protein level","HPA045700","Approved",NA,"Approved","Nucleoplasm<br>Vesicles","Pancreatic cancer:4.05e-5 (favourable)","Expressed in all","Mixed",NA,NA,"cerebral cortex: 17.3","Expressed in all",NA,NA
"BRMS1","DKFZP564A063","ENSG00000174744","Breast cancer metastasis suppressor 1","11","66337333-66345125","Cancer-related genes, Predicted intracellular proteins","Evidence at protein level","CAB010824, HPA019637","Approved",NA,"Approved","Centrosome","Liver cancer:6.74e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"skin: 36.3","Expressed in all",NA,NA
"C10orf35",NA,"ENSG00000171224","Chromosome 10 open reading frame 35","10","69630251-69633599","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA034591","Enhanced",NA,"Approved","Nucleus<br>Centrosome<br>Cytosol","Liver cancer:1.03e-4 (unfavourable), Head and neck cancer:8.64e-4 (unfavourable), Urothelial cancer:9.72e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 27.6","testis: 20.2","Cell line enhanced",NA,"PC-3: 53.3"
"CACNA1A","APCA, CACNL1A4, Cav2.1, EA2, FHM, HPCA, MHP, MHP1, SCA6","ENSG00000141837","Calcium voltage-gated channel subunit alpha1 A","19","13206442-13633025","Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels","Evidence at protein level","HPA064258, HPA071902","Enhanced",NA,"Uncertain","Endoplasmic reticulum","Pancreatic cancer:4.32e-4 (favourable)","Mixed","Tissue enhanced",NA,"cerebral cortex: 15.1","stomach: 3.5","Group enriched",7,"SCLC-21H: 56.1;U-87 MG: 26.1"
"CACNG4","MGC11138, MGC24983","ENSG00000075461","Calcium voltage-gated channel auxiliary subunit gamma 4","17","66964910-67033398","Predicted membrane proteins, Transporters","Evidence at protein level","HPA005803, HPA065370","Enhanced",NA,"Approved","Cytosol",NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 48.6;prostate: 20.3","lung: 9.2","Cell line enriched",7,"SH-SY5Y: 436.5"
"CADM2","IGSF4D, Necl-3, NECL3, SynCAM2","ENSG00000175161","Cell adhesion molecule 2","3","84958981-86074429","Predicted membrane proteins","Evidence at protein level","HPA010024","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",14,"cerebral cortex: 86.2","seminal vesicle: 6.2","Cell line enhanced",NA,"AF22: 10.8;AN3-CA: 29.1"
"CADM3","BIgR, FLJ10698, IGSF4B, Necl-1, NECL1, SynCAM3, TSLL1","ENSG00000162706","Cell adhesion molecule 3","1","159171609-159203313","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA002981, CAB025746","Enhanced",NA,NA,NA,"Renal cancer:1.03e-5 (unfavourable), Urothelial cancer:5.75e-4 (unfavourable)","Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 278.5;placenta: 113.9","cervix, uterine: 44.7","Group enriched",7,"HHSteC: 54.6;HSkMC: 158.9;hTERT-HME1: 91.2;U-2 OS: 34.5;WM-115: 59.5"
"CADM4","IGSF4C, Necl-4, SynCAM4, TSLL2","ENSG00000105767","Cell adhesion molecule 4","19","43622368-43639839","Predicted membrane proteins","Evidence at protein level","HPA012612","Enhanced",NA,"Approved","Nucleus<br>Nuclear membrane","Renal cancer:2.28e-6 (favourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 163.6","parathyroid gland: 59.1","Cell line enriched",5,"WM-115: 552.4"
"CAMK1D","CKLiK","ENSG00000183049","Calcium/calmodulin dependent protein kinase ID","10","12349482-12835545","Enzymes, Plasma proteins, Predicted membrane proteins","Evidence at protein level","HPA007266","Enhanced",NA,"Approved","Nucleus<br>Cytosol","Lung cancer:1.67e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 52.0","skin,thyroid gland: 21.9","Cell line enhanced",NA,"HDLM-2: 105.6;U-266/70: 38.2"
"CAMK2A","CAMKA, CaMKIINalpha, KIAA0968","ENSG00000070808","Calcium/calmodulin dependent protein kinase II alpha","5","150219491-150290291","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","CAB004330, HPA051783, HPA051785, HPA053973","Enhanced",NA,"Supported","Plasma membrane<br>Cell Junctions<br>Cytosol",NA,"Tissue enriched","Tissue enriched",9,"cerebral cortex: 283.6","skeletal muscle: 33.3","Cell line enhanced",NA,"SCLC-21H: 6.2;U-87 MG: 4.3"
"CARNS1","ATPGD1, KIAA1394","ENSG00000172508","Carnosine synthase 1","11","67414968-67425607","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA038569","Enhanced",NA,NA,NA,NA,"Group enriched","Group enriched",11,"cerebral cortex: 37.1;skeletal muscle: 25.9","heart muscle: 2.9","Cell line enriched",10,"RPMI-8226: 5.3"
"CASC4","DKFZp459F1927, H63","ENSG00000166734","Cancer susceptibility 4","15","44288729-44415758","Predicted intracellular proteins","Evidence at protein level","HPA043015, HPA049488","Enhanced",NA,"Supported","Golgi apparatus","Renal cancer:1.45e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 141.6","Expressed in all",NA,NA
"CASKIN1","ANKS5A, KIAA1306","ENSG00000167971","CASK interacting protein 1","16","2177180-2196525","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA055990, CAB079050","Enhanced","Supported","Approved","Nucleus<br>Cytosol",NA,"Mixed","Tissue enriched",33,"cerebral cortex: 20.3","testis: 0.6","Cell line enhanced",NA,"HDLM-2: 13.8;SCLC-21H: 7.7"
"CCDC155","FLJ32658, KASH5","ENSG00000161609","Coiled-coil domain containing 155","19","49388218-49417994","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA019937, HPA019940","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",135,"testis: 56.9","pancreas: 0.4","Cell line enhanced",NA,"SCLC-21H: 1.5;U-266/70: 2.7"
"CCSAP","C1orf96, CSAP, FLJ41471","ENSG00000154429","Centriole, cilia and spindle associated protein","1","229321005-229343294","Predicted intracellular proteins","Evidence at protein level","HPA028402, HPA043443","Enhanced",NA,"Supported","Nucleus<br>Plasma membrane<br>Microtubule ends","Renal cancer:4.50e-13 (unfavourable), Liver cancer:1.41e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 54.0","placenta: 18.6","Expressed in all",NA,NA
"CELF2","BRUNOL3, CUGBP2, Etr-3, NAPOR-2","ENSG00000048740","CUGBP Elav-like family member 2","10","10798397-11336675","Predicted intracellular proteins","Evidence at protein level","CAB016395, HPA035813, HPA065098","Enhanced",NA,"Uncertain","Nucleoplasm<br>Microtubules<br>Cytokinetic bridge","Head and neck cancer:7.61e-4 (favourable)","Expressed in all","Mixed",NA,NA,"cerebral cortex: 77.8","Cell line enhanced",NA,"HEL: 179.2;HMC-1: 163.9"
"CELF5","BRUNOL5","ENSG00000161082","CUGBP Elav-like family member 5","19","3224703-3297076","Predicted intracellular proteins","Evidence at protein level","HPA042012, HPA060336","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",7,"cerebral cortex: 38.1","ovary: 5.1","Cell line enhanced",NA,"NTERA-2: 3.5;REH: 4.0;SCLC-21H: 5.2;SH-SY5Y: 2.8"
"CHRM1",NA,"ENSG00000168539","Cholinergic receptor muscarinic 1","11","62908679-62921807","FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins","Evidence at protein level","HPA014101, CAB022366","Enhanced",NA,"Approved","Nucleus<br>Cytosol",NA,"Tissue enriched","Group enriched",8,"cerebral cortex: 39.9;prostate: 42.3;salivary gland: 11.0","adrenal gland: 3.8","Cell line enhanced",NA,"MCF7: 2.7;SK-BR-3: 1.2;T-47d: 1.0"
"CMTM5","CKLFSF5, FLJ37521","ENSG00000166091","CKLF like MARVEL transmembrane domain containing 5","14","23376808-23379772","Predicted membrane proteins","Evidence at protein level","HPA052338","Enhanced",NA,"Approved","Golgi apparatus<br>Vesicles",NA,"Group enriched","Tissue enriched",20,"cerebral cortex: 81.3","seminal vesicle: 4.1","Cell line enriched",6,"HEL: 73.9"
"CNDP1","CN1, CPGL2, HsT2308, MGC10825","ENSG00000150656","Carnosine dipeptidase 1","18","74534440-74587212","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA008933","Enhanced",NA,NA,NA,NA,"Group enriched","Group enriched",12,"cerebral cortex: 101.7;liver: 23.0","duodenum: 5.1","Cell line enriched",68,"U-266/84: 57.1"
"CNTN1","F3, GP135","ENSG00000018236","Contactin 1","12","40692442-41072418","Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB025200, HPA070467","Enhanced",NA,NA,NA,"Urothelial cancer:3.75e-4 (unfavourable)","Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 225.5","ovary: 65.6","Cell line enhanced",NA,"A549: 218.0;HaCaT: 38.4;SCLC-21H: 85.1;SH-SY5Y: 46.5"
"CNTNAP4","CASPR4, KIAA1763","ENSG00000152910","Contactin associated protein like 4","16","76277278-76559238","Predicted membrane proteins","Evidence at protein level","HPA031859, HPA057342","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",21,"cerebral cortex: 35.9","testis: 1.6","Group enriched",6,"Daudi: 7.9;HSkMC: 3.0;Karpas-707: 2.6;RPMI-8226: 4.9"
"CPLX3","CPX-III","ENSG00000213578","Complexin 3","15","74826547-74831802","Predicted intracellular proteins","Evidence at protein level","CAB079003",NA,"Supported",NA,NA,NA,"Not detected","Group enriched",8,"prostate: 143.7;spleen: 74.6","cerebral cortex: 12.8","Cell line enhanced",NA,"Daudi: 1.6;Karpas-707: 1.4;SCLC-21H: 1.0"
"CREG2",NA,"ENSG00000175874","Cellular repressor of E1A stimulated genes 2","2","101345551-101387595","Predicted secreted proteins","Evidence at protein level","HPA038224","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enriched",164,"cerebral cortex: 90.9","fallopian tube: 0.5","Cell line enhanced",NA,"CACO-2: 2.0;HaCaT: 5.6;HeLa: 1.6;PC-3: 2.3"
"CSPG5","NGC","ENSG00000114646","Chondroitin sulfate proteoglycan 5","3","47562239-47580792","Predicted membrane proteins","Evidence at protein level","HPA049529, HPA067818, HPA071779","Enhanced",NA,"Approved","Nucleoplasm<br>Mitochondria","Ovarian cancer:2.14e-4 (favourable)","Tissue enriched","Tissue enriched",56,"cerebral cortex: 156.7","testis: 2.8","Cell line enhanced",NA,"AF22: 32.2"
"CTNNA2","CAP-R, CT114","ENSG00000066032","Catenin alpha 2","2","79185231-80648861","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB037175","Enhanced",NA,NA,NA,NA,"Group enriched","Group enriched",12,"cerebral cortex: 111.6;epididymis: 81.5;testis: 32.2","adrenal gland: 6.3","Cell line enhanced",NA,"AF22: 7.0;Karpas-707: 5.9;NTERA-2: 6.7;SCLC-21H: 4.5;SH-SY5Y: 11.4"
"CUEDC1",NA,"ENSG00000180891","CUE domain containing 1","17","57861243-57955323","Predicted intracellular proteins","Evidence at protein level","HPA023050, HPA024836","Approved",NA,"Uncertain","Centrosome<br>Mitochondria<br>Cytosol","Liver cancer:2.65e-5 (unfavourable), Renal cancer:8.46e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"fallopian tube: 52.4","Mixed",NA,NA
"DAPL1",NA,"ENSG00000163331","Death associated protein like 1","2","158795317-158862781","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA046937, HPA058635","Enhanced",NA,"Approved","Nucleoplasm<br>Nuclear bodies<br>Microtubules","Cervical cancer:8.43e-4 (favourable)","Group enriched","Tissue enhanced",NA,"epididymis: 238.2;esophagus: 243.7;skin: 219.0","fallopian tube: 128.4","Group enriched",5,"HaCaT: 3.5;hTCEpi: 16.6;SCLC-21H: 6.9;U-87 MG: 8.2"
"DDX1","DBP-RB","ENSG00000079785","DEAD-box helicase 1","2","15591178-15631111","Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB012280, HPA034502, HPA034503","Enhanced",NA,"Enhanced","Nucleoplasm<br>Cytosol","Liver cancer:9.09e-9 (unfavourable), Renal cancer:9.69e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 145.1","Expressed in all",NA,NA
"DIP2B","FLJ34278, KIAA1463","ENSG00000066084","Disco interacting protein 2 homolog B","12","50504985-50748667","Predicted intracellular proteins","Evidence at protein level","HPA038472, HPA046133, HPA056045","Enhanced",NA,"Approved","Endoplasmic reticulum","Breast cancer:2.60e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 31.0","Expressed in all",NA,NA
"DLG2","chapsyn-110, PPP1R58, PSD-93, PSD93","ENSG00000150672","Discs large MAGUK scaffold protein 2","11","83455012-85627922","Predicted intracellular proteins","Evidence at protein level","HPA021307, HPA023896, CAB072341","Enhanced",NA,"Approved","Vesicles<br>Plasma membrane",NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 72.8","thyroid gland: 25.8","Cell line enhanced",NA,"BEWO: 7.6;NTERA-2: 5.5;SCLC-21H: 6.4;SH-SY5Y: 8.7;T-47d: 19.2"
"DPF1","BAF45b, NEUD4, neuro-d4","ENSG00000011332","Double PHD fingers 1","19","38211006-38229714","Predicted intracellular proteins","Evidence at protein level","HPA049148","Enhanced",NA,"Approved","Nucleoplasm<br>Mitochondria<br>Cytosol",NA,"Tissue enhanced","Tissue enriched",15,"cerebral cortex: 27.4","testis: 1.8","Cell line enhanced",NA,"SCLC-21H: 26.9"
"DPYD","DPD","ENSG00000188641","Dihydropyrimidine dehydrogenase","1","97077743-97921049","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","CAB033241, HPA045210","Uncertain",NA,NA,NA,"Pancreatic cancer:6.27e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"lung: 44.1","Mixed",NA,NA
"DSCAM","CHD2-42, CHD2-52","ENSG00000171587","DS cell adhesion molecule","21","40010999-40847139","Plasma proteins, Predicted membrane proteins","Evidence at protein level","HPA019324","Enhanced",NA,"Approved","Nucleoplasm<br>Cytosol",NA,"Tissue enriched","Tissue enriched",11,"cerebral cortex: 12.4","placenta,spleen: 1.0","Cell line enhanced",NA,"HBEC3-KT: 2.6;MCF7: 6.2;NTERA-2: 2.2;SCLC-21H: 3.9;T-47d: 2.0"
"DYDC2","bA36D19.6, MGC16186","ENSG00000133665","DPY30 domain containing 2","10","80344745-80368073","Predicted intracellular proteins","Evidence at protein level","HPA038006, HPA038007","Enhanced",NA,NA,NA,"Ovarian cancer:3.54e-4 (favourable)","Tissue enhanced","Tissue enriched",10,"fallopian tube: 153.3","testis: 15.0","Cell line enhanced",NA,"AF22: 2.1;NTERA-2: 3.4;SCLC-21H: 3.4;SH-SY5Y: 2.1;U-2197: 2.0"
"EAF1",NA,"ENSG00000144597","ELL associated factor 1","3","15427355-15450635","Predicted intracellular proteins","Evidence at protein level","HPA059516, HPA060569, HPA069538","Enhanced",NA,"Supported","Nucleoplasm<br>Nuclear bodies<br>Vesicles<br>Cytokinetic bridge","Lung cancer:6.87e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"bone marrow: 33.7","Expressed in all",NA,NA
"EFCAB14","KIAA0494","ENSG00000159658","EF-hand calcium binding domain 14","1","46675159-46719064","Predicted membrane proteins","Evidence at protein level","HPA011224, HPA011938","Supported",NA,"Approved","Nucleoli<br>Golgi apparatus<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 305.3","Expressed in all",NA,NA
"EGR4","NGFI-C, PAT133","ENSG00000135625","Early growth response 4","2","73290929-73293705","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA028983","Enhanced",NA,NA,NA,NA,"Mixed","Group enriched",29,"cerebral cortex: 9.7;testis: 3.2","adipose tissue,appendix: 0.2","Cell line enriched",6,"HMC-1: 1.4"
"EIF2AK2","EIF2AK1, PKR, PPP1R83, PRKR","ENSG00000055332","Eukaryotic translation initiation factor 2 alpha kinase 2","2","37099210-37157065","Enzymes, Predicted intracellular proteins","Evidence at protein level","CAB003845, HPA019795, HPA063893","Approved",NA,"Enhanced","Cytosol","Pancreatic cancer:2.08e-4 (unfavourable), Endometrial cancer:3.77e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 25.4","Mixed",NA,NA
"EIF3I","eIF3-beta, eIF3-p36, eIF3i, EIF3S2, TRIP-1","ENSG00000084623","Eukaryotic translation initiation factor 3 subunit I","1","32221928-32231604","Predicted intracellular proteins","Evidence at protein level","HPA029939, HPA029940","Enhanced",NA,"Uncertain","Nucleoplasm<br>Cytosol","Renal cancer:4.81e-6 (unfavourable), Endometrial cancer:2.14e-4 (favourable), Liver cancer:4.21e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"fallopian tube: 198.1","Expressed in all",NA,NA
"EIF4G3","eIF4GII","ENSG00000075151","Eukaryotic translation initiation factor 4 gamma 3","1","20806292-21176888","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA025031, HPA025039, HPA025041","Enhanced",NA,"Approved","Cytosol","Liver cancer:9.60e-7 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 170.1","Mixed",NA,NA
"ELAVL2","HEL-N1, HuB","ENSG00000107105","ELAV like RNA binding protein 2","9","23690104-23826337","Predicted intracellular proteins","Evidence at protein level","CAB022222, HPA063001","Enhanced",NA,"Approved","Nucleoplasm<br>Cytosol",NA,"Tissue enhanced","Group enriched",32,"cerebral cortex: 37.9;testis: 80.3","adrenal gland: 1.8","Cell line enhanced",NA,"AF22: 36.8;SCLC-21H: 145.6"
"ELAVL3","DKFZp547J036, HUC, HUCL, MGC20653, PLE21","ENSG00000196361","ELAV like RNA binding protein 3","19","11451326-11481046","Predicted intracellular proteins","Evidence at protein level","CAB013066","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",45,"cerebral cortex: 72.8","adrenal gland: 1.6","Group enriched",10,"SCLC-21H: 95.2;SH-SY5Y: 49.4"
"EPHA4","Hek8, TYRO1","ENSG00000116106","EPH receptor A4","2","221418027-221574202","Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB028368","Enhanced",NA,NA,NA,"Renal cancer:5.67e-4 (favourable), Ovarian cancer:9.56e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"cerebral cortex: 41.6","testis: 22.2","Cell line enhanced",NA,"AF22: 77.5;CACO-2: 49.0;U-2197: 35.7"
"EPRS","EARS, GLUPRORS, PARS, QARS, QPRS","ENSG00000136628","Glutamyl-prolyl-tRNA synthetase","1","219968601-220046658","Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA026490, HPA030052","Enhanced",NA,"Enhanced","Cytosol","Urothelial cancer:2.62e-4 (unfavourable), Breast cancer:7.25e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 120.4","Expressed in all",NA,NA
"ERC2","CAST, CAST1, ELKSL, KIAA0378, SPBC110, Spc110","ENSG00000187672","ELKS/RAB6-interacting/CAST family member 2","3","55508308-56468363","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA073739","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enriched",16,"cerebral cortex: 24.6","seminal vesicle: 1.5","Cell line enhanced",NA,"HAP1: 2.7;Karpas-707: 6.2;SH-SY5Y: 2.2;U-266/70: 4.6"
"ERGIC1","ERGIC-32, ERGIC32, KIAA1181, NET24","ENSG00000113719","Endoplasmic reticulum-golgi intermediate compartment 1","5","172834275-172952685","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA018666, HPA018900","Enhanced",NA,"Enhanced","Nucleoplasm<br>Vesicles",NA,"Expressed in all","Expressed in all",NA,NA,"prostate: 238.2","Expressed in all",NA,NA
"FABP7","B-FABP, BLBP","ENSG00000164434","Fatty acid binding protein 7","6","122779475-122784074","Predicted intracellular proteins","Evidence at protein level","CAB025488, HPA028825, CAB058697","Enhanced",NA,NA,NA,"Renal cancer:1.65e-6 (unfavourable), Breast cancer:2.49e-4 (favourable)","Group enriched","Group enriched",13,"breast: 33.1;cerebral cortex: 102.3","skin: 5.2","Group enriched",8,"AF22: 75.1;U-251 MG: 17.6;WM-115: 45.7"
"FAM155A",NA,"ENSG00000204442","Family with sequence similarity 155 member A","13","107163510-107866735","Predicted membrane proteins","Evidence at protein level","HPA039453, HPA058768","Enhanced",NA,"Approved","Nucleus<br>Vesicles<br>Centrosome",NA,"Mixed","Tissue enriched",6,"cerebral cortex: 15.6","seminal vesicle: 2.4","Cell line enhanced",NA,"RPTEC TERT1: 9.3;SCLC-21H: 8.9;SH-SY5Y: 18.1;U-87 MG: 10.5"
"FAM173A","C16orf24, MGC2494","ENSG00000103254","Family with sequence similarity 173 member A","16","720581-722601","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA046262","Enhanced",NA,"Approved","Cytosol","Renal cancer:4.24e-5 (favourable), Head and neck cancer:8.88e-4 (favourable)","Expressed in all","Mixed",NA,NA,"spleen: 9.3","Cell line enhanced",NA,"U-266/70: 49.3"
"FAM81A","MGC26690","ENSG00000157470","Family with sequence similarity 81 member A","15","59372693-59523549","Predicted intracellular proteins","Evidence at protein level","HPA001847, HPA065797","Enhanced",NA,"Approved","Nucleoplasm<br>Cytosol",NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 33.3","fallopian tube: 9.9","Cell line enhanced",NA,"Daudi: 47.3"
"FAM98B","FLJ38426","ENSG00000171262","Family with sequence similarity 98 member B","15","38454127-38487710","Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA008320, HPA008502","Enhanced",NA,"Supported","Nucleoplasm<br>Vesicles",NA,"Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 32.1","Expressed in all",NA,NA
"FKBP3","FKBP-25, PPIase","ENSG00000100442","FK506 binding protein 3","14","45115600-45135319","Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA000864, CAB012232, CAB012520","Supported",NA,"Supported","Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"skeletal muscle: 143.3","Expressed in all",NA,NA
"FNDC1","bA243O10.1, dJ322A24.1, FNDC2, KIAA1866","ENSG00000164694","Fibronectin type III domain containing 1","6","159169397-159272109","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA030962, HPA030963","Approved",NA,"Supported","Nuclear speckles","Renal cancer:1.93e-6 (unfavourable), Endometrial cancer:6.10e-5 (favourable)","Tissue enhanced","Tissue enhanced",NA,"gallbladder: 22.9;thyroid gland: 34.1","smooth muscle: 16.5","Cell line enhanced",NA,"fHDF/TERT166: 2.3"
"FOXO1","FKH1, FKHR, FOXO1A","ENSG00000150907","Forkhead box O1","13","40469953-40666597","Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA001252, CAB022326","Approved","Approved","Supported","Nucleoplasm<br>Cytosol","Renal cancer:1.33e-5 (favourable), Liver cancer:3.74e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"ovary: 80.7","Cell line enhanced",NA,"HSkMC: 39.2;U-698: 40.3"
"FRMD6","C14orf31, EX1, MGC17921, willin","ENSG00000139926","FERM domain containing 6","14","51489100-51730727","Predicted intracellular proteins","Evidence at protein level","HPA001297","Uncertain","Approved","Approved","Mitochondria","Renal cancer:1.28e-4 (unfavourable), Pancreatic cancer:2.66e-4 (unfavourable), Stomach cancer:3.50e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"endometrium: 126.3","Cell line enhanced",NA,"fHDF/TERT166: 644.4"
"FRRS1L","C9orf4, CG-6","ENSG00000260230","Ferric chelate reductase 1 like","9","109130293-109167291","Disease related genes, Predicted membrane proteins","Evidence at protein level","HPA071086","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 47.7","ovary: 14.2","Cell line enhanced",NA,"AF22: 1.6;SH-SY5Y: 4.3"
"G3BP2","KIAA0660","ENSG00000138757","G3BP stress granule assembly factor 2","4","75642782-75724525","Predicted intracellular proteins","Evidence at protein level","HPA018304, HPA018425","Enhanced",NA,"Enhanced","Cytosol","Renal cancer:6.65e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 178.5","Expressed in all",NA,NA
"GABRG3",NA,"ENSG00000182256","Gamma-aminobutyric acid type A receptor gamma3 subunit","15","26971282-27541991","FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA054010","Supported",NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"prostate: 10.6;testis: 16.5","cerebral cortex: 4.2","Cell line enhanced",NA,"K-562: 4.0;PC-3: 5.1;U-87 MG: 14.0"
"GANAB","G2AN, GIIA, GluII, KIAA0088","ENSG00000089597","Glucosidase II alpha subunit","11","62624826-62646726","Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA026874, HPA061426","Enhanced",NA,"Approved","Nuclear membrane<br>Endoplasmic reticulum<br>Cytosol","Liver cancer:1.27e-5 (unfavourable), Urothelial cancer:9.54e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 295.2","Expressed in all",NA,NA
"GARS","CMT2D, DSMAV, GlyRS, SMAD1","ENSG00000106105","Glycyl-tRNA synthetase","7","30594681-30634033","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins","Evidence at protein level","HPA017896, HPA019097","Enhanced",NA,"Supported","Cytosol","Renal cancer:1.70e-5 (unfavourable), Urothelial cancer:3.04e-5 (unfavourable), Liver cancer:8.95e-5 (unfavourable), Breast cancer:1.02e-4 (unfavourable), Endometrial cancer:8.48e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 96.0","Expressed in all",NA,NA
"GIT1",NA,"ENSG00000108262","GIT ArfGAP 1","17","29573469-29594054","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA004059, HPA004186","Approved",NA,"Enhanced","Focal adhesion sites<br>Cytosol","Liver cancer:2.54e-6 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 127.3","Expressed in all",NA,NA
"GNAO1","G-ALPHA-o","ENSG00000087258","G protein subunit alpha o1","16","56191347-56357457","Disease related genes, Predicted intracellular proteins","Evidence at protein level","CAB008387, HPA040878","Enhanced",NA,NA,NA,"Pancreatic cancer:5.93e-4 (favourable)","Tissue enriched","Tissue enriched",7,"cerebral cortex: 166.9","seminal vesicle: 22.6","Cell line enhanced",NA,"BJ hTERT+: 24.8;BJ hTERT+ SV40 Large T+: 18.7;SCLC-21H: 72.2"
"GNAZ",NA,"ENSG00000128266","G protein subunit alpha z","22","23070361-23125037","Predicted intracellular proteins","Evidence at protein level","HPA003011","Enhanced",NA,"Approved","Vesicles","Endometrial cancer:4.85e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 49.7","seminal vesicle: 23.0","Cell line enhanced",NA,"SCLC-21H: 44.4;SH-SY5Y: 24.7"
"GOLGA5","golgin-84, GOLIM5, ret-II, rfg5","ENSG00000066455","Golgin A5","14","92794231-92839963","Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA000992, HPA063876","Enhanced","Supported","Supported","Golgi apparatus",NA,"Expressed in all","Expressed in all",NA,NA,"epididymis: 65.3","Expressed in all",NA,NA
"GPC5",NA,"ENSG00000179399","Glypican 5","13","91398607-92873682","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA040152, HPA044081","Enhanced",NA,"Approved","Nucleus<br>Cytosol","Glioma:5.67e-4 (unfavourable)","Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 15.8;kidney: 8.1;testis: 11.5","lung: 4.9","Group enriched",9,"CACO-2: 41.2;HeLa: 18.9"
"GPR17",NA,"ENSG00000144230","G protein-coupled receptor 17","2","127645864-127652639","G-protein coupled receptors, Predicted membrane proteins","Evidence at protein level","HPA029766","Enhanced","Supported","Approved","Vesicles",NA,"Tissue enriched","Mixed",NA,NA,"spleen: 9.6","Cell line enhanced",NA,"HeLa: 1.7;REH: 4.0;TIME: 3.5;U-2 OS: 1.8;U-2197: 1.8;U-251 MG: 2.1"
"GPR45","PSP24, PSP24A","ENSG00000135973","G protein-coupled receptor 45","2","105241743-105243049","G-protein coupled receptors, Predicted membrane proteins","Evidence at transcript level","HPA055940","Uncertain",NA,NA,NA,NA,"Not detected","Tissue enhanced",NA,"cerebral cortex: 1.8","testis: 0.4","Group enriched",14,"BEWO: 1.3;U-2 OS: 4.5"
"GPR61","BALGR","ENSG00000156097","G protein-coupled receptor 61","1","109539872-109548406","G-protein coupled receptors, Predicted membrane proteins","Evidence at protein level","HPA007326, HPA026088","Approved",NA,NA,NA,NA,"Not detected","Tissue enhanced",NA,"adrenal gland: 1.0;cerebral cortex: 3.4;thyroid gland: 1.2","testis: 0.5","Not detected",NA,NA
"GRB7",NA,"ENSG00000141738","Growth factor receptor bound protein 7","17","39737927-39747291","Cancer-related genes, Predicted intracellular proteins","Evidence at protein level","CAB005226, HPA057084, CAB073538","Approved",NA,"Supported","Plasma membrane","Endometrial cancer:6.60e-7 (unfavourable), Renal cancer:8.23e-5 (favourable), Ovarian cancer:3.10e-4 (unfavourable), Pancreatic cancer:6.90e-4 (unfavourable)","Mixed","Mixed",NA,NA,"fallopian tube: 35.1","Cell line enriched",8,"SK-BR-3: 272.9"
"GRIN2A","GluN2A, NMDAR2A","ENSG00000183454","Glutamate ionotropic receptor NMDA type subunit 2A","16","9753404-10182754","Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins","Evidence at protein level","CAB022725","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 25.8","testis: 6.1","Cell line enhanced",NA,"fHDF/TERT166: 3.3;U-138 MG: 4.4"
"GRIPAP1","DKFZp434P0630, GRASP-1, GRASP1, KIAA1167, MPMGp800B12492Q3","ENSG00000068400","GRIP1 associated protein 1","X","48973720-49002264","Predicted intracellular proteins","Evidence at protein level","HPA000282, HPA000615","Enhanced",NA,"Approved","Vesicles<br>Cytosol","Renal cancer:3.92e-7 (unfavourable), Urothelial cancer:4.63e-7 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 68.5","Expressed in all",NA,NA
"HABP4","IHABP4, SERBP1L","ENSG00000130956","Hyaluronan binding protein 4","9","96450201-96491336","Predicted intracellular proteins","Evidence at protein level","HPA055969","Approved",NA,NA,NA,"Renal cancer:1.10e-7 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 73.8","Mixed",NA,NA
"HCN1","BCNG-1, BCNG1, HAC-2","ENSG00000164588","Hyperpolarization activated cyclic nucleotide gated potassium channel 1","5","45254950-45696498","Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Voltage-gated ion channels","Evidence at protein level","HPA019195","Enhanced",NA,NA,NA,NA,"Not detected","Tissue enriched",8,"cerebral cortex: 4.9","heart muscle: 0.6","Cell line enhanced",NA,"WM-115: 1.0"
"HEPACAM","FLJ25530, GLIALCAM, hepaCAM","ENSG00000165478","Hepatic and glial cell adhesion molecule","11","124919193-124936412","Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters","Evidence at protein level","HPA017613, CAB025486","Enhanced",NA,"Approved","Vesicles",NA,"Tissue enriched","Tissue enriched",5,"cerebral cortex: 80.7","adipose tissue: 15.1","Cell line enriched",27,"Hep G2: 18.8"
"HES5","bHLHb38","ENSG00000197921","Hes family bHLH transcription factor 5","1","2528745-2530245","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA065458, HPA076164","Enhanced",NA,"Approved","Nucleoplasm<br>Nuclear speckles<br>Cytosol",NA,"Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 1.8","skin: 0.9","Cell line enhanced",NA,"HaCaT: 1.1"
"HMGB2","HMG2","ENSG00000164104","High mobility group box 2","4","173331695-173335125","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA003506, CAB037206, HPA053314","Enhanced",NA,"Supported","Nucleus<br>Nucleoli","Renal cancer:7.60e-12 (unfavourable), Liver cancer:3.76e-5 (unfavourable), Melanoma:3.13e-4 (unfavourable), Pancreatic cancer:7.04e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"bone marrow: 1464.0","Expressed in all",NA,NA
"HNRNPA0","hnRNPA0, HNRPA0","ENSG00000177733","Heterogeneous nuclear ribonucleoprotein A0","5","137745651-137754376","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA036569, HPA059404","Enhanced",NA,"Enhanced","Nucleoplasm","Renal cancer:1.99e-4 (favourable), Pancreatic cancer:3.74e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"ovary: 32.8","Expressed in all",NA,NA
"HNRNPDL","HNRPDL, JKTBP, laAUF1","ENSG00000152795","Heterogeneous nuclear ribonucleoprotein D like","4","82422564-82430408","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA056820, HPA063147","Supported",NA,"Enhanced","Nucleoplasm",NA,"Expressed in all","Expressed in all",NA,NA,"endometrium: 422.5","Expressed in all",NA,NA
"HNRNPR","hnRNP-R, HNRPR","ENSG00000125944","Heterogeneous nuclear ribonucleoprotein R","1","23303771-23344336","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB011687, HPA026092","Enhanced",NA,"Enhanced","Nucleoplasm","Liver cancer:1.32e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 66.5","Expressed in all",NA,NA
"HOMER1","HOMER-1B, SYN47, Ves-1","ENSG00000152413","Homer scaffolding protein 1","5","79372636-79514217","Predicted intracellular proteins","Evidence at protein level","CAB004437, HPA036521, HPA036522","Enhanced",NA,"Approved","Cytosol",NA,"Expressed in all","Tissue enhanced",NA,"cerebral cortex: 48.9","thyroid gland: 25.2","Mixed",NA,NA
"HTR7","5-HT7","ENSG00000148680","5-hydroxytryptamine receptor 7","10","90740823-90857698","FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, RAS pathway related proteins","Evidence at protein level","CAB022708, HPA073617","Approved",NA,"Supported","Nuclear speckles<br>Plasma membrane<br>Cytosol",NA,"Group enriched","Group enriched",8,"parathyroid gland: 44.8;testis: 16.1","urinary bladder: 3.8","Cell line enhanced",NA,"hTERT-HME1: 25.8;LHCN-M2: 11.4;WM-115: 12.9"
"ICAM5","TLCN, TLN","ENSG00000105376","Intercellular adhesion molecule 5","19","10289981-10296778","Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA008943, HPA009083, CAB025178","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",10,"cerebral cortex: 21.6","lung: 2.0","Cell line enhanced",NA,"HEL: 14.8;K-562: 12.0;RPMI-8226: 10.5;U-266/70: 13.3;U-87 MG: 10.1"
"INPP4A","INPP4","ENSG00000040933","Inositol polyphosphate-4-phosphatase type I A","2","98444854-98594390","Enzymes, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA001628","Approved",NA,"Approved","Nucleus<br>Nuclear membrane","Endometrial cancer:3.70e-6 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 38.7","Expressed in all",NA,NA
"KCNA2","HK4, Kv1.2","ENSG00000177301","Potassium voltage-gated channel subfamily A member 2","1","110519837-110631474","Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels","Evidence at protein level","CAB001976","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",6,"cerebral cortex: 23.2","thyroid gland: 4.1","Cell line enhanced",NA,"Karpas-707: 4.4;SCLC-21H: 1.8;U-2 OS: 1.4;U-266/70: 1.5;U-266/84: 2.3;WM-115: 1.6"
"KCNC1","Kv3.1","ENSG00000129159","Potassium voltage-gated channel subfamily C member 1","11","17734774-17856804","Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels","Evidence at protein level","HPA047634, HPA048249","Enhanced",NA,"Approved","Nucleus<br>Nuclear membrane<br>Vesicles<br>Cytosol",NA,"Tissue enhanced","Tissue enriched",8,"cerebral cortex: 18.6","testis: 2.2","Cell line enhanced",NA,"RH-30: 3.6;SCLC-21H: 4.2;SH-SY5Y: 2.3"
"KCNF1","IK8, KCNF, kH1, Kv5.1","ENSG00000162975","Potassium voltage-gated channel modifier subfamily F member 1","2","10911937-10914225","Plasma proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels","Evidence at protein level","HPA014738, HPA062278","Enhanced",NA,"Approved","Golgi apparatus",NA,"Tissue enriched","Tissue enriched",32,"cerebral cortex: 37.5","endometrium: 1.1","Cell line enhanced",NA,"A549: 12.9;MCF7: 3.9;T-47d: 5.7"
"KCNJ9","GIRK3, Kir3.3","ENSG00000162728","Potassium voltage-gated channel subfamily J member 9","1","160081570-160090563","Predicted membrane proteins, Voltage-gated ion channels","Evidence at protein level","HPA070478","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",113,"cerebral cortex: 52.3","adrenal gland,testis: 0.4","Not detected",NA,NA
"KCTD16","KIAA1317","ENSG00000183775","Potassium channel tetramerization domain containing 16","5","144170832-144485686","Predicted intracellular proteins","Evidence at protein level","HPA044590, HPA050154","Approved",NA,"Approved","Nuclear speckles",NA,"Tissue enhanced","Group enriched",7,"cerebral cortex: 12.3;testis: 3.0","lung: 1.1","Cell line enhanced",NA,"SCLC-21H: 5.4;TIME: 7.3"
"KEAP1","INrf2, KIAA0132, KLHL19, MGC10630, MGC1114, MGC20887, MGC4407, MGC9454","ENSG00000079999","Kelch like ECH associated protein 1","19","10486120-10503741","Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins","Evidence at protein level","HPA005558, CAB025337","Approved",NA,"Supported","Nucleoplasm<br>Microtubule organizing center<br>Cytosol","Cervical cancer:3.28e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"skeletal muscle: 49.4","Expressed in all",NA,NA
"KHDRBS1","FLJ34027, p62, Sam68","ENSG00000121774","KH RNA binding domain containing, signal transduction associated 1","1","32013829-32060850","Predicted intracellular proteins","Evidence at protein level","CAB005355, HPA051280, HPA056813","Enhanced",NA,"Enhanced","Nucleoplasm","Liver cancer:3.68e-5 (unfavourable), Renal cancer:9.32e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"endometrium: 134.1","Expressed in all",NA,NA
"KHDRBS3","Etle, etoile, SALP, SLM-2, SLM2, T-STAR","ENSG00000131773","KH RNA binding domain containing, signal transduction associated 3","8","135457457-135656722","Predicted intracellular proteins","Evidence at protein level","HPA000275, HPA000500, HPA000981","Enhanced",NA,"Supported","Nucleoplasm","Renal cancer:7.16e-6 (favourable)","Expressed in all","Group enriched",7,"cerebral cortex: 89.1;testis: 285.9","epididymis: 27.8","Cell line enhanced",NA,"WM-115: 83.8"
"KIAA0513",NA,"ENSG00000135709","KIAA0513","16","85027751-85094230","Predicted intracellular proteins","Evidence at protein level","HPA012866, HPA014431","Enhanced",NA,"Uncertain","Nucleoplasm<br>Cytosol","Pancreatic cancer:1.72e-5 (favourable)","Expressed in all","Tissue enriched",7,"cerebral cortex: 102.6","adrenal gland: 14.9","Mixed",NA,NA
"KIAA1462","JCAD","ENSG00000165757","KIAA1462","10","30012800-30115494","Predicted intracellular proteins","Evidence at protein level","HPA017956","Enhanced",NA,"Supported","Vesicles<br>Cell Junctions","Stomach cancer:2.01e-4 (unfavourable), Renal cancer:2.54e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"placenta: 48.7","Cell line enhanced",NA,"HUVEC TERT2: 25.1;TIME: 55.5"
"KIF21A","FEOM1, FLJ20052","ENSG00000139116","Kinesin family member 21A","12","39293228-39443390","Disease related genes, Predicted intracellular proteins","Evidence at protein level","CAB022079, HPA058432","Enhanced",NA,"Supported","Plasma membrane<br>Cytosol","Renal cancer:8.07e-8 (favourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 75.0","fallopian tube: 54.6","Cell line enhanced",NA,"SH-SY5Y: 199.8"
"KIF5C",NA,"ENSG00000168280","Kinesin family member 5C","2","148875250-149026759","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA035210, HPA062272","Enhanced",NA,"Approved","Vesicles",NA,"Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 205.3","prostate: 44.3","Cell line enhanced",NA,"AF22: 38.5;NTERA-2: 39.3;SCLC-21H: 236.2;SH-SY5Y: 49.2"
"KIRREL3","KIAA1867, KIRRE, NEPH2","ENSG00000149571","Kin of IRRE like 3 (Drosophila)","11","126423359-127003460","Disease related genes, Plasma proteins, Predicted membrane proteins","Evidence at protein level","HPA053324, HPA056320","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",11,"cerebral cortex: 20.4","adrenal gland: 1.9","Cell line enhanced",NA,"BJ: 21.4;BJ hTERT+: 12.0;fHDF/TERT166: 14.2;U-138 MG: 11.2;U-251 MG: 11.6"
"KLHL32","BKLHD5, KIAA1900","ENSG00000186231","Kelch like family member 32","6","96924620-97140754","Predicted intracellular proteins","Evidence at protein level","HPA039150","Enhanced",NA,NA,NA,NA,"Mixed","Group enriched",6,"cerebral cortex: 25.3;fallopian tube: 10.3","testis: 3.1","Cell line enhanced",NA,"Daudi: 2.3;HDLM-2: 4.1;SCLC-21H: 2.1;U-266/70: 1.7"
"L1CAM","CD171, HSAS, HSAS1, MASA, MIC5, S10, SPG1","ENSG00000198910","L1 cell adhesion molecule","X","153861514-153909223","CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB010896","Enhanced",NA,"Approved","Nucleoplasm<br>Plasma membrane","Endometrial cancer:8.51e-10 (unfavourable), Lung cancer:2.36e-6 (unfavourable), Renal cancer:1.17e-4 (unfavourable), Head and neck cancer:3.81e-4 (unfavourable)","Tissue enhanced","Tissue enhanced",NA,"adrenal gland: 36.0;cerebral cortex: 66.9","seminal vesicle: 12.8","Cell line enhanced",NA,"BJ hTERT+: 303.8;BJ hTERT+ SV40 Large T+ RasG12V: 195.5;HeLa: 182.1"
"LHPP","HDHD2B","ENSG00000107902","Phospholysine phosphohistidine inorganic pyrophosphate phosphatase","10","124461834-124617888","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA009163, HPA009269","Enhanced",NA,"Supported","Nuclear speckles<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 70.6","Mixed",NA,NA
"LHX5",NA,"ENSG00000089116","LIM homeobox 5","12","113462034-113472280","Predicted intracellular proteins, Transcription factors","Evidence at transcript level","HPA053908","Uncertain",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 1.4","stomach: 0.3","Cell line enhanced",NA,"HMC-1: 1.0"
"LIX1","C5orf11, Lft","ENSG00000145721","Limb and CNS expressed 1","5","97091867-97142872","Predicted intracellular proteins","Evidence at transcript level","HPA058426","Uncertain",NA,"Approved","Vesicles<br>Cytokinetic bridge<br>Cytosol","Endometrial cancer:2.48e-4 (unfavourable)","Tissue enhanced","Tissue enriched",6,"cerebral cortex: 32.8","seminal vesicle: 5.7","Cell line enriched",9,"RPTEC TERT1: 24.5"
"LMTK3","KIAA1883, LMR3, PPP1R101, TYKLM3","ENSG00000142235","Lemur tyrosine kinase 3","19","48485271-48513189","Enzymes, Predicted membrane proteins","Evidence at protein level","HPA040203, HPA077070","Enhanced",NA,"Approved","Nucleoplasm<br>Cell Junctions","Renal cancer:3.18e-8 (favourable)","Mixed","Group enriched",6,"cerebral cortex: 20.3;parathyroid gland: 4.9","duodenum: 2.2","Cell line enhanced",NA,"HMC-1: 6.1;SK-BR-3: 6.2;U-266/70: 5.9"
"LRFN2","FIGLER2, KIAA1246, SALM1","ENSG00000156564","Leucine rich repeat and fibronectin type III domain containing 2","6","40391586-40587465","Predicted membrane proteins","Evidence at protein level","HPA076660","Enhanced",NA,"Supported","Vesicles",NA,"Not detected","Tissue enriched",5,"cerebral cortex: 6.8","testis: 1.3","Cell line enhanced",NA,"REH: 1.5;SH-SY5Y: 5.0"
"LRRC74B",NA,"ENSG00000187905","Leucine rich repeat containing 74B","22","21045960-21064168","Predicted intracellular proteins","Evidence at transcript level","HPA049947","Uncertain",NA,NA,NA,NA,"Not detected","Tissue enhanced",NA,"fallopian tube: 6.0;testis: 1.9","lung: 0.8","Not detected",NA,NA
"LUZP2",NA,"ENSG00000187398","Leucine zipper protein 2","11","24496970-25082631","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA039007, HPA046161","Enhanced",NA,"Approved","Nucleoplasm<br>Plasma membrane<br>Cytosol",NA,"Group enriched","Group enriched",5,"adrenal gland: 8.6;cerebral cortex: 33.0","prostate: 3.8","Group enriched",6,"HaCaT: 9.2;HAP1: 5.4"
"MAD1L1","HsMAD1, MAD1, PIG9, TP53I9, TXBP181","ENSG00000002822","MAD1 mitotic arrest deficient like 1","7","1815793-2233243","Disease related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA003635, CAB015338","Supported",NA,"Supported","Nucleoplasm<br>Nuclear membrane",NA,"Expressed in all","Expressed in all",NA,NA,"lymph node: 23.3","Expressed in all",NA,NA
"MAG","GMA, S-MAG, SIGLEC-4A, SIGLEC4A","ENSG00000105695","Myelin associated glycoprotein","19","35292125-35313804","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB009345, HPA012499","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",6,"cerebral cortex: 163.6","ovary: 27.5","Cell line enriched",31,"WM-115: 35.4"
"MAP1B","MAP5, PPP1R102","ENSG00000131711","Microtubule associated protein 1B","5","72107234-72209570","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB009792, HPA022275","Enhanced",NA,"Enhanced","Cytosol","Urothelial cancer:8.22e-5 (unfavourable)","Tissue enriched","Tissue enriched",5,"cerebral cortex: 187.6","smooth muscle: 36.8","Cell line enhanced",NA,"TIME: 228.1"
"MAPRE2","EB1, EB2, RP1","ENSG00000166974","Microtubule associated protein RP/EB family member 2","18","34976928-35143470","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA016738, HPA016739","Enhanced",NA,"Uncertain","Nucleoplasm",NA,"Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 174.6","Mixed",NA,NA
"MARCH7","AXOT, MARCH-VII, RNF177","ENSG00000136536","Membrane associated ring-CH-type finger 7","2","159712457-159771027","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA014275, HPA022152","Enhanced",NA,"Supported","Plasma membrane<br>Cytosol","Renal cancer:1.84e-4 (unfavourable), Liver cancer:2.41e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 113.1","Expressed in all",NA,NA
"MAST1","KIAA0973, SAST","ENSG00000105613","Microtubule associated serine/threonine kinase 1","19","12833951-12874951","Enzymes, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA028181, HPA073106","Enhanced",NA,"Approved","Vesicles",NA,"Tissue enhanced","Tissue enriched",12,"cerebral cortex: 35.2","testis: 3.0","Cell line enhanced",NA,"AN3-CA: 21.6;SCLC-21H: 47.7;SH-SY5Y: 21.4"
"MATR3","KIAA0723, MGC9105, MPD2, VCPDM","ENSG00000015479","Matrin 3","5","139293648-139331677","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB033552, HPA036564, HPA036565","Enhanced",NA,NA,NA,NA,"Mixed","Expressed in all",NA,NA,"cerebral cortex: 331.3","Expressed in all",NA,NA
"MECP2","MRX16, MRX79, RTT","ENSG00000169057","Methyl-CpG binding protein 2","X","154021573-154137103","Cancer-related genes, Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA000593, HPA001341, CAB037264","Enhanced",NA,"Supported","Nucleus","Renal cancer:7.32e-9 (favourable), Endometrial cancer:8.35e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 29.7","Expressed in all",NA,NA
"MED6","NY-REN-28","ENSG00000133997","Mediator complex subunit 6","14","70581257-70600690","Predicted intracellular proteins","Evidence at protein level","HPA030764, HPA069039","Approved",NA,"Enhanced","Nucleoplasm","Liver cancer:1.04e-4 (unfavourable), Melanoma:2.75e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"lymph node: 28.6","Expressed in all",NA,NA
"MFSD12","C19orf28, MGC20700, PP3501","ENSG00000161091","Major facilitator superfamily domain containing 12","19","3538261-3574290","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA042149, HPA043088","Uncertain",NA,"Approved","Nucleoplasm<br>Mitochondria","Endometrial cancer:5.66e-6 (favourable), Lung cancer:2.34e-4 (unfavourable), Liver cancer:6.61e-4 (unfavourable), Stomach cancer:7.70e-4 (favourable)","Tissue enriched","Expressed in all",NA,NA,"skin: 64.2","Expressed in all",NA,NA
"MOG","BTN6, BTNL11","ENSG00000204655","Myelin oligodendrocyte glycoprotein","6","29656981-29672372","Disease related genes, Predicted membrane proteins","Evidence at protein level","HPA021873","Enhanced",NA,NA,NA,NA,"Tissue enriched","Not detected",NA,NA,"cerebral cortex: 0.8","Not detected",NA,NA
"MPHOSPH10","CT90, MPP10, MPP10P, PPP1R106","ENSG00000124383","M-phase phosphoprotein 10","2","71130314-71150101","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA035059, HPA035060, HPA049907","Enhanced",NA,"Enhanced","Nucleoli","Renal cancer:3.89e-7 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"prostate: 35.3","Expressed in all",NA,NA
"MPP2","DKFZp761D0712, DLG2","ENSG00000108852","Membrane palmitoylated protein 2","17","43875357-43909711","Predicted intracellular proteins","Evidence at protein level","HPA026486","Approved",NA,"Approved","Mitochondria<br>Cytosol","Endometrial cancer:1.87e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"cerebral cortex: 37.9;epididymis: 33.0;parathyroid gland: 43.8","testis: 24.0","Mixed",NA,NA
"MSH2","COCA1, HNPCC, HNPCC1","ENSG00000095002","MutS homolog 2","2","47402969-47562311","Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB009572, HPA066845, CAB070867","Supported",NA,"Supported","Nucleoplasm<br>Vesicles","Liver cancer:1.72e-9 (unfavourable), Endometrial cancer:4.44e-4 (unfavourable), Pancreatic cancer:4.63e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 32.2","Expressed in all",NA,NA
"MT3","GIF","ENSG00000087250","Metallothionein 3","16","56589074-56591088","Predicted intracellular proteins","Evidence at protein level","HPA004011, CAB017779","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",17,"cerebral cortex: 738.6","adrenal gland: 42.9","Group enriched",7,"RPMI-8226: 3.1;SCLC-21H: 8.7;U-87 MG: 12.1"
"NACAD","KIAA0363","ENSG00000136274","NAC alpha domain containing","7","45080438-45088914","Predicted intracellular proteins","Evidence at protein level","HPA020981","Enhanced",NA,"Approved","Nucleus<br>Cytosol","Glioma:2.23e-4 (unfavourable)","Group enriched","Tissue enriched",6,"cerebral cortex: 48.7","ovary: 7.6","Cell line enhanced",NA,"SCLC-21H: 30.5;SH-SY5Y: 19.0"
"NAPA",NA,"ENSG00000105402","NSF attachment protein alpha","19","47487637-47515240","Predicted intracellular proteins","Evidence at protein level","CAB010100, HPA046149, HPA050196","Approved",NA,"Uncertain","Cytosol","Renal cancer:4.26e-9 (favourable)","Expressed in all","Expressed in all",NA,NA,"prostate: 157.4","Expressed in all",NA,NA
"NCAN","CSPG3","ENSG00000130287","Neurocan","19","19211973-19252233","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA036814","Enhanced",NA,"Uncertain","Vesicles<br>Centrosome",NA,"Tissue enriched","Tissue enriched",101,"cerebral cortex: 183.5","testis: 1.8","Cell line enhanced",NA,"AF22: 1.0;SCLC-21H: 2.7;SH-SY5Y: 1.7"
"NCS1","FREQ, NCS-1","ENSG00000107130","Neuronal calcium sensor 1","9","130172578-130237304","Predicted intracellular proteins","Evidence at protein level","CAB018587, HPA019713","Enhanced","Supported","Enhanced","Plasma membrane","Liver cancer:1.11e-4 (unfavourable), Breast cancer:5.40e-4 (unfavourable), Thyroid cancer:8.25e-4 (unfavourable), Endometrial cancer:8.69e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 178.1","seminal vesicle: 92.3","Mixed",NA,NA
"NECAB2","EFCBP2","ENSG00000103154","N-terminal EF-hand calcium binding protein 2","16","83968632-84002776","Predicted intracellular proteins","Evidence at protein level","HPA013998, HPA014144, CAB068211","Enhanced","Supported","Approved","Vesicles","Renal cancer:1.58e-4 (unfavourable)","Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 46.8","kidney: 10.6","Cell line enhanced",NA,"AF22: 10.4;SCLC-21H: 47.1;U-87 MG: 13.8"
"NEFH",NA,"ENSG00000100285","Neurofilament heavy","22","29480230-29491390","Disease related genes, Predicted intracellular proteins","Evidence at protein level","CAB007786, HPA061615","Enhanced",NA,"Approved","Nucleoli<br>Cytosol","Breast cancer:2.33e-6 (favourable)","Group enriched","Tissue enriched",11,"prostate: 405.8","cerebral cortex: 37.3","Cell line enriched",6,"SiHa: 193.4"
"NGB",NA,"ENSG00000165553","Neuroglobin","14","77265483-77271312","Predicted intracellular proteins, Transporters","Evidence at protein level","HPA042615, HPA058596","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Group enriched",5,"adrenal gland: 10.1;cerebral cortex: 4.8;fallopian tube: 2.2","pancreas: 1.0","Group enriched",30,"RPMI-8226: 4.3;SCLC-21H: 14.4"
"NLGN2","KIAA1366","ENSG00000169992","Neuroligin 2","17","7404874-7419860","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA055321, HPA069278","Enhanced",NA,"Approved","Mitochondria","Renal cancer:3.44e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 40.7","endometrium: 21.8","Cell line enhanced",NA,"AF22: 43.3"
"NOMO1","PM5","ENSG00000103512","NODAL modulator 1","16","14833681-14896160","Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","CAB025192, HPA046697, HPA061174","Approved",NA,"Approved","Endoplasmic reticulum","Urothelial cancer:3.15e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"thyroid gland: 11.9","Cell line enhanced",NA,"Hep G2: 80.5;SiHa: 142.9"
"NOVA2","ANOVA, NOVA3","ENSG00000104967","NOVA alternative splicing regulator 2","19","45933734-45973546","Predicted intracellular proteins","Evidence at protein level","HPA045607","Enhanced",NA,"Approved","Nucleoplasm<br>Nuclear bodies<br>Golgi apparatus","Renal cancer:3.04e-4 (unfavourable)","Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 24.3","adipose tissue: 6.0","Cell line enhanced",NA,"AF22: 10.0;HDLM-2: 10.4;HUVEC TERT2: 14.6;TIME: 21.5"
"NPTX2",NA,"ENSG00000106236","Neuronal pentraxin 2","7","98617297-98629868","Predicted secreted proteins","Evidence at protein level","CAB020801, HPA049799, HPA058320","Supported",NA,"Approved","Golgi apparatus<br>Actin filaments<br>Centrosome","Renal cancer:5.46e-9 (unfavourable), Endometrial cancer:5.46e-5 (unfavourable)","Expressed in all","Tissue enhanced",NA,"adrenal gland: 33.5;cerebral cortex: 80.3;testis: 44.3","cervix, uterine: 12.1","Cell line enriched",8,"LHCN-M2: 600.5"
"NRGN","RC3","ENSG00000154146","Neurogranin","11","124739846-124747210","Predicted intracellular proteins","Evidence at protein level","CAB006908, HPA038171","Enhanced",NA,NA,NA,"Renal cancer:1.52e-5 (unfavourable)","Expressed in all","Tissue enriched",17,"cerebral cortex: 961.5","lung: 56.2","Cell line enhanced",NA,"HEL: 133.6;PC-3: 108.8"
"NSD2","KMT3G, MMSET, WHSC1","ENSG00000109685","Nuclear receptor binding SET domain protein 2","4","1871424-1982207","Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA015801, CAB068246, CAB068247","Enhanced",NA,"Supported","Nucleus","Liver cancer:2.61e-4 (unfavourable), Renal cancer:7.19e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 66.6","Expressed in all",NA,NA
"NUDCD3","KIAA1068, NudCL","ENSG00000015676","NudC domain containing 3","7","44379121-44490880","Predicted intracellular proteins","Evidence at protein level","HPA019136, HPA019528, HPA019529","Enhanced",NA,"Approved","Nucleus<br>Plasma membrane<br>Cytosol","Renal cancer:9.16e-4 (favourable)","Expressed in all","Mixed",NA,NA,"cerebral cortex: 12.4","Expressed in all",NA,NA
"NUMBL","CAG3A, CTG3a, NUMB-R, NUMBLIKE, NUMBR, TNRC23","ENSG00000105245","NUMB like, endocytic adaptor protein","19","40665905-40690972","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA058251, HPA058380","Approved",NA,NA,NA,"Renal cancer:7.55e-15 (unfavourable), Ovarian cancer:1.52e-4 (unfavourable), Colorectal cancer:3.49e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 41.7","Expressed in all",NA,NA
"OPHN1","ARHGAP41, MRX60, OPN1","ENSG00000079482","Oligophrenin 1","X","68042344-68433913","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA002919","Approved",NA,"Approved","Nucleus<br>Plasma membrane",NA,"Mixed","Mixed",NA,NA,"cerebral cortex: 20.1","Mixed",NA,NA
"P2RX7","MGC20089, P2X7","ENSG00000089041","Purinergic receptor P2X 7","12","121132819-121188032","Predicted membrane proteins, Transporters","Evidence at protein level","HPA034967, HPA034968, HPA042013, HPA044141","Approved",NA,"Approved","Golgi apparatus","Renal cancer:2.92e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"cerebral cortex: 21.0","Cell line enhanced",NA,"Karpas-707: 28.5;RPMI-8226: 16.7;SK-MEL-30: 31.3;U-266/70: 16.4;U-266/84: 14.0"
"P2RY12","HORK3, P2Y12, SP1999","ENSG00000169313","Purinergic receptor P2Y12","3","151337380-151384812","Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins","Evidence at protein level","HPA013796, HPA014518","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",6,"cerebral cortex: 83.8","lymph node: 13.1","Not detected",NA,NA
"P4HB","DSI, ERBA2L, GIT, P4Hbeta, PDI, PDIA1, PO4DB, PO4HB, PROHB","ENSG00000185624","Prolyl 4-hydroxylase subunit beta","17","81843159-81860694","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB012463, HPA018884","Enhanced",NA,"Supported","Endoplasmic reticulum","Renal cancer:2.30e-11 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"small intestine: 504.4","Expressed in all",NA,NA
"PACSIN1","SDPI","ENSG00000124507","Protein kinase C and casein kinase substrate in neurons 1","6","34466061-34535231","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB009929, HPA028852, HPA055491","Enhanced",NA,"Approved","Nucleus<br>Vesicles",NA,"Mixed","Tissue enriched",32,"cerebral cortex: 133.6","lymph node: 4.1","Cell line enhanced",NA,"MCF7: 9.2;RPMI-8226: 9.7;T-47d: 20.2;U-266/84: 11.7"
"PAK1",NA,"ENSG00000149269","P21 (RAC1) activated kinase 1","11","77321707-77474635","Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins","Evidence at protein level","HPA003565, CAB005312","Enhanced","Supported","Enhanced","Plasma membrane<br>Cytosol","Glioma:9.48e-5 (unfavourable), Colorectal cancer:5.87e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 184.2","Mixed",NA,NA
"PANX2","hPANX2, PX2","ENSG00000073150","Pannexin 2","22","50170731-50180294","Predicted membrane proteins, Transporters","Evidence at protein level","HPA004624, HPA039117","Enhanced",NA,"Approved","Plasma membrane",NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 8.7","seminal vesicle: 2.1","Cell line enhanced",NA,"HDLM-2: 15.5;Hep G2: 13.2;SCLC-21H: 11.5"
"PCDH1","pc42","ENSG00000156453","Protocadherin 1","5","141853111-141879246","Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA047720, HPA050538","Enhanced",NA,"Approved","Nucleus<br>Nucleoli<br>Cell Junctions","Liver cancer:4.96e-5 (unfavourable), Renal cancer:7.55e-5 (favourable), Pancreatic cancer:3.61e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"cerebral cortex: 40.3","Cell line enhanced",NA,"CAPAN-2: 75.4;HaCaT: 95.1;RT4: 59.1;TIME: 60.2;WM-115: 51.1"
"PDP1","PDH, PDP, PPM2A, PPM2C","ENSG00000164951","Pyruvate dehyrogenase phosphatase catalytic subunit 1","8","93857807-93926066","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA018483, HPA019081, HPA021152","Uncertain",NA,"Supported","Nucleoplasm<br>Mitochondria<br>Cytosol","Renal cancer:8.42e-9 (favourable), Breast cancer:8.61e-5 (unfavourable), Ovarian cancer:5.60e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"adrenal gland: 82.3","Expressed in all",NA,NA
"PDXK","C21orf124, C21orf97, FLJ21324, FLJ31940, MGC15873, PKH, PNK, PRED79","ENSG00000160209","Pyridoxal kinase","21","43719094-43762307","Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA030196, HPA030197, HPA030198, CAB033918","Approved",NA,"Enhanced","Nucleus",NA,"Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 47.5","Expressed in all",NA,NA
"PFN2",NA,"ENSG00000070087","Profilin 2","3","149964904-150050788","Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA035611, CAB037073","Enhanced",NA,NA,NA,"Liver cancer:2.19e-7 (unfavourable), Endometrial cancer:2.93e-4 (unfavourable), Head and neck cancer:3.42e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 419.6","Mixed",NA,NA
"PGM2L1","BM32A, FLJ32029","ENSG00000165434","Phosphoglucomutase 2 like 1","11","74330318-74398473","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA056995, HPA060948","Enhanced",NA,"Approved","Mitochondria",NA,"Mixed","Tissue enriched",9,"cerebral cortex: 64.1","endometrium: 7.3","Cell line enhanced",NA,"RH-30: 18.2"
"PHAX","FLJ13193, RNUXA","ENSG00000164902","Phosphorylated adaptor for RNA export","5","126600268-126627252","Predicted intracellular proteins, Transporters","Evidence at protein level","HPA059630, HPA070326","Enhanced",NA,"Enhanced","Nucleoplasm",NA,"Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 17.8","Expressed in all",NA,NA
"PIANP","C12orf53, DKFZp547D2210, PANP","ENSG00000139200","PILR alpha associated neural protein","12","6693792-6700800","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA010631","Enhanced",NA,"Approved","Nucleoplasm",NA,"Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 64.3","endometrium: 13.4","Cell line enhanced",NA,"NTERA-2: 20.8;SH-SY5Y: 20.6;U-2 OS: 11.2"
"PIN1","dod","ENSG00000127445","Peptidylprolyl cis/trans isomerase, NIMA-interacting 1","19","9835257-9849682","Cancer-related genes, Enzymes, Predicted intracellular proteins","Evidence at protein level","CAB004528, CAB009326, HPA068650","Approved",NA,"Enhanced","Nucleoplasm<br>Cytosol","Renal cancer:7.80e-5 (favourable), Pancreatic cancer:3.25e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 136.9","Expressed in all",NA,NA
"PLP1","GPM6C, PLP, SPG2","ENSG00000123560","Proteolipid protein 1","X","103773718-103792619","Cancer-related genes, Disease related genes, Predicted membrane proteins","Evidence at protein level","HPA004128","Enhanced",NA,NA,NA,NA,"Group enriched","Tissue enriched",30,"cerebral cortex: 3216.6","parathyroid gland: 107.9","Group enriched",6,"NTERA-2: 37.4;SK-MEL-30: 184.2;WM-115: 137.4"
"PNMA2","MA2, RGAG2","ENSG00000240694","Paraneoplastic Ma antigen 2","8","26504686-26514092","Predicted intracellular proteins","Evidence at protein level","HPA001936","Enhanced",NA,NA,NA,"Lung cancer:1.81e-4 (favourable), Stomach cancer:6.23e-4 (unfavourable)","Tissue enhanced","Tissue enriched",12,"cerebral cortex: 163.4","adrenal gland: 13.5","Cell line enhanced",NA,"AF22: 59.2;HAP1: 38.7;SH-SY5Y: 45.6"
"PNMAL2","KIAA1183","ENSG00000204851","Paraneoplastic Ma antigen family like 2","19","46486906-46496498","Predicted intracellular proteins","Evidence at protein level","HPA054810","Enhanced",NA,NA,NA,NA,"Mixed","Group enriched",5,"adrenal gland: 12.1;cerebral cortex: 32.9","ovary: 4.3","Cell line enhanced",NA,"AF22: 1.2;AN3-CA: 1.4;SH-SY5Y: 1.3"
"PNMT","PENT","ENSG00000141744","Phenylethanolamine N-methyltransferase","17","39667981-39670475","Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB017029, HPA043412, HPA051005","Enhanced",NA,NA,NA,"Endometrial cancer:3.95e-5 (unfavourable)","Tissue enhanced","Tissue enriched",8,"adrenal gland: 226.6","seminal vesicle: 29.2","Cell line enhanced",NA,"HEL: 4.8;K-562: 10.4;NB-4: 14.5;SCLC-21H: 7.0;SH-SY5Y: 5.8"
"POGZ","KIAA0461, ZNF280E, ZNF635m","ENSG00000143442","Pogo transposable element with ZNF domain","1","151402724-151459465","Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA006800, HPA008781","Enhanced",NA,"Enhanced","Nucleoplasm","Renal cancer:3.92e-5 (unfavourable), Urothelial cancer:4.40e-4 (favourable), Endometrial cancer:8.67e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 76.7","Expressed in all",NA,NA
"POLR1A","DKFZP586M0122, FLJ21915, RPA1, RPO1-4","ENSG00000068654","RNA polymerase I subunit A","2","86020216-86106155","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","CAB010145, HPA031513, HPA049700","Supported",NA,"Supported","Nucleus<br>Nucleoli fibrillar center","Liver cancer:3.70e-9 (unfavourable), Ovarian cancer:3.37e-4 (unfavourable), Thyroid cancer:8.41e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 12.3","Expressed in all",NA,NA
"POU6F1","BRN5, MPOU, TCFB1","ENSG00000184271","POU class 6 homeobox 1","12","51186936-51217708","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA047021, HPA050411","Enhanced",NA,"Supported","Nuclear bodies<br>Actin filaments","Pancreatic cancer:6.61e-4 (favourable)","Expressed in all","Mixed",NA,NA,"cerebral cortex: 10.9","Mixed",NA,NA
"PPP1R10","CAT53, FB19, p99, PNUTS","ENSG00000204569","Protein phosphatase 1 regulatory subunit 10","6","30600400-30618612","Predicted intracellular proteins","Evidence at protein level","CAB025501, HPA047248, HPA056756","Enhanced",NA,"Enhanced","Nucleoplasm<br>Nuclear bodies","Pancreatic cancer:9.74e-5 (favourable), Cervical cancer:4.84e-4 (favourable)","Expressed in all","Mixed",NA,NA,"parathyroid gland: 10.5","Expressed in all",NA,NA
"PPP1R13B","ASPP1, KIAA0771, p53BP2-like, p85","ENSG00000088808","Protein phosphatase 1 regulatory subunit 13B","14","103733752-103847590","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA006394, CAB015454","Approved",NA,"Supported","Nucleoplasm<br>Cytosol","Renal cancer:3.28e-11 (favourable), Lung cancer:1.41e-4 (favourable)","Expressed in all","Mixed",NA,NA,"thyroid gland: 43.9","Mixed",NA,NA
"PRAF2","JM4, Yip6a","ENSG00000243279","PRA1 domain family member 2","X","49071156-49074071","Predicted membrane proteins, Transporters","Evidence at protein level","HPA002859, HPA005504, CAB011655","Enhanced",NA,"Approved","Endoplasmic reticulum<br>Vesicles","Liver cancer:1.66e-6 (unfavourable), Pancreatic cancer:4.88e-6 (favourable), Renal cancer:5.83e-6 (unfavourable), Lung cancer:2.81e-4 (favourable), Cervical cancer:7.42e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"epididymis: 185.0","Expressed in all",NA,NA
"PRKACB","PKACb","ENSG00000142875","Protein kinase cAMP-activated catalytic subunit beta","1","84078062-84238498","Enzymes, Predicted intracellular proteins, RAS pathway related proteins","Evidence at protein level","CAB010363, HPA029754, HPA071185","Approved",NA,"Approved","Cytosol","Renal cancer:1.89e-6 (favourable), Liver cancer:9.49e-4 (unfavourable)","Expressed in all","Tissue enriched",5,"cerebral cortex: 316.3","adrenal gland: 63.1","Mixed",NA,NA
"PRR5","FLJ20185k, PP610, Protor-1","ENSG00000186654","Proline rich 5","22","44668547-44737681","Predicted intracellular proteins","Evidence at protein level","HPA054072","Approved",NA,NA,NA,"Endometrial cancer:2.47e-5 (favourable)","Expressed in all","Mixed",NA,NA,"spleen: 17.5","Cell line enhanced",NA,"U-266/70: 75.3"
"PSD3","DKFZp761K1423, EFA6D, EFA6R, HCA67, KIAA0942","ENSG00000156011","Pleckstrin and Sec7 domain containing 3","8","18527301-19084730","Predicted intracellular proteins","Evidence at protein level","HPA002455","Enhanced",NA,"Approved","Nucleus<br>Vesicles","Endometrial cancer:5.76e-5 (unfavourable), Colorectal cancer:7.55e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 83.3","testis: 29.6","Cell line enhanced",NA,"U-87 MG: 48.5"
"PSIP1","LEDGF, p52, p75, PSIP2","ENSG00000164985","PC4 and SFRS1 interacting protein 1","9","15464066-15511019","Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB013718, HPA019697","Enhanced",NA,"Enhanced","Nucleoplasm",NA,"Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 161.3","Expressed in all",NA,NA
"PSMC5","p45, p45/SUG, S8, SUG-1, SUG1, TBP10, TRIP1","ENSG00000087191","Proteasome 26S subunit, ATPase 5","17","63827152-63832026","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA017871, HPA064293","Enhanced",NA,"Supported","Plasma membrane<br>Cytosol","Renal cancer:3.13e-6 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 251.4","Expressed in all",NA,NA
"PSMD1","P112, Rpn2, S1","ENSG00000173692","Proteasome 26S subunit, non-ATPase 1","2","231056864-231172827","Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB021092, HPA036736, HPA036737","Enhanced",NA,"Approved","Nucleoplasm<br>Actin filaments","Liver cancer:8.63e-12 (unfavourable), Lung cancer:2.34e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 204.0","Expressed in all",NA,NA
"PTN","HBGF8, HBNF, NEGF1","ENSG00000105894","Pleiotrophin","7","137227341-137343865","Cancer-related genes, Predicted secreted proteins","Evidence at protein level","CAB017685","Enhanced",NA,NA,NA,"Renal cancer:1.35e-4 (favourable)","Tissue enriched","Tissue enhanced",NA,"parathyroid gland: 725.3","cerebral cortex: 269.6","Cell line enriched",12,"AF22: 1551.5"
"PTPRT","KIAA0283, RPTPrho","ENSG00000196090","Protein tyrosine phosphatase, receptor type T","20","42072752-43189970","Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA017336, CAB069423","Approved",NA,NA,NA,NA,"Tissue enhanced","Group enriched",5,"cerebral cortex: 24.3;fallopian tube: 17.4","placenta: 4.0","Cell line enhanced",NA,"BEWO: 1.1"
"QKI","QK3","ENSG00000112531","QKI, KH domain containing RNA binding","6","163414000-163578596","Cancer-related genes, Predicted intracellular proteins","Evidence at protein level","HPA019123, CAB022602","Enhanced","Supported","Supported","Nucleoplasm","Renal cancer:2.31e-5 (unfavourable), Liver cancer:1.27e-4 (unfavourable), Stomach cancer:3.69e-4 (unfavourable)","Tissue enriched","Expressed in all",NA,NA,"cerebral cortex: 359.6","Expressed in all",NA,NA
"RAB11FIP3","eferin, KIAA0665, Rab11-FIP3","ENSG00000090565","RAB11 family interacting protein 3","16","425619-523011","Cancer-related genes, Predicted intracellular proteins","Evidence at protein level","HPA028088, HPA028631, HPA030086","Approved",NA,"Supported","Vesicles<br>Cytokinetic bridge<br>Microtubule organizing center","Pancreatic cancer:3.16e-5 (favourable), Liver cancer:9.87e-5 (unfavourable), Endometrial cancer:1.22e-4 (favourable), Renal cancer:7.99e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"kidney: 56.9","Expressed in all",NA,NA
"RAB3A",NA,"ENSG00000105649","RAB3A, member RAS oncogene family","19","18196784-18204074","Predicted intracellular proteins","Evidence at protein level","HPA003160, CAB009949, CAB078998","Enhanced","Supported","Approved","Nucleoplasm<br>Centrosome<br>Cytosol","Renal cancer:6.14e-7 (favourable), Endometrial cancer:3.17e-4 (unfavourable)","Expressed in all","Tissue enriched",12,"cerebral cortex: 250.5","adrenal gland: 20.6","Cell line enhanced",NA,"SCLC-21H: 43.5;U-2197: 23.9"
"RAB3C",NA,"ENSG00000152932","RAB3C, member RAS oncogene family","5","58582221-58859394","Predicted intracellular proteins","Evidence at protein level","HPA003160, HPA048156","Enhanced",NA,"Approved","Cytosol",NA,"Mixed","Group enriched",17,"adrenal gland: 12.0;cerebral cortex: 55.3","small intestine: 2.0","Cell line enhanced",NA,"HEL: 2.2;SCLC-21H: 11.9;SH-SY5Y: 3.9"
"RALYL","HNRPCL3","ENSG00000184672","RALY RNA binding protein-like","8","84182787-84921844","Predicted intracellular proteins","Evidence at protein level","HPA055868, HPA059112","Enhanced",NA,"Approved","Nucleoplasm",NA,"Tissue enhanced","Tissue enhanced",NA,"adrenal gland: 26.1;cerebral cortex: 49.2;kidney: 19.7","gallbladder: 8.1","Cell line enhanced",NA,"AF22: 4.0"
"RAP1GAP2","GARNL4, KIAA1039","ENSG00000132359","RAP1 GTPase activating protein 2","17","2755705-3037739","Predicted intracellular proteins","Evidence at protein level","HPA022148, HPA022896","Approved",NA,"Supported","Nuclear membrane<br>Cytosol","Renal cancer:1.36e-6 (favourable)","Expressed in all","Mixed",NA,NA,"cerebral cortex: 35.2","Cell line enhanced",NA,"SH-SY5Y: 55.4"
"RBFOX1","A2BP1, FOX-1, HRNBP1","ENSG00000078328","RNA binding protein, fox-1 homolog 1","16","6019094-7713338","Predicted intracellular proteins","Evidence at protein level","HPA040809","Enhanced",NA,"Approved","Nucleus<br>Golgi apparatus<br>Cytosol",NA,"Tissue enhanced","Group enriched",5,"cerebral cortex: 110.5;skeletal muscle: 32.9","heart muscle: 13.9","Cell line enriched",18,"RH-30: 26.2"
"RBFOX3","FOX-3, HRNBP3, NeuN","ENSG00000167281","RNA binding protein, fox-1 homolog 3","17","79089345-79516148","Predicted intracellular proteins","Evidence at protein level","HPA030790, CAB078782","Enhanced","Approved","Supported","Nucleoplasm",NA,"Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 62.3;seminal vesicle: 33.2","prostate: 24.1","Group enriched",7,"A549: 14.1;NTERA-2: 13.9;SCLC-21H: 26.0;U-2 OS: 10.8"
"RCN2","E6BP, ERC-55, ERC55, TCBP49","ENSG00000117906","Reticulocalbin 2","15","76931619-76954392","Predicted secreted proteins","Evidence at protein level","HPA030694, HPA030695","Enhanced","Supported","Enhanced","Endoplasmic reticulum","Liver cancer:7.36e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"epididymis: 391.5","Expressed in all",NA,NA
"REPS2","POB1","ENSG00000169891","RALBP1 associated Eps domain containing 2","X","16946691-17153280","Predicted secreted proteins","Evidence at protein level","HPA000565, HPA026073","Uncertain",NA,NA,NA,"Pancreatic cancer:3.24e-4 (unfavourable), Renal cancer:4.08e-4 (favourable), Urothelial cancer:4.56e-4 (favourable), Liver cancer:5.36e-4 (favourable)","Expressed in all","Mixed",NA,NA,"cerebral cortex: 28.8","Cell line enhanced",NA,"HDLM-2: 27.9;Karpas-707: 8.4;RH-30: 8.1"
"RFK","FLJ11149, RIFK","ENSG00000135002","Riboflavin kinase","9","76385517-76394517","Enzymes, FDA approved drug targets, Predicted intracellular proteins","Evidence at protein level","HPA023259, CAB033887, HPA057163","Approved",NA,"Approved","Golgi apparatus",NA,"Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 37.8","Expressed in all",NA,NA
"RGS20","RGSZ1, ZGAP1","ENSG00000147509","Regulator of G-protein signaling 20","8","53851808-53959303","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA070193","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 10.1","thyroid gland: 2.1","Cell line enhanced",NA,"SK-MEL-30: 23.4;U-87 MG: 28.2"
"RGS7",NA,"ENSG00000182901","Regulator of G-protein signaling 7","1","240775515-241357230","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB017561","Enhanced",NA,"Enhanced","Cytosol",NA,"Tissue enhanced","Group enriched",8,"adrenal gland: 10.7;cerebral cortex: 46.4;testis: 10.9","stomach: 2.9","Cell line enhanced",NA,"U-2 OS: 6.8"
"RLBP1","CRALBP","ENSG00000140522","Retinaldehyde binding protein 1","15","89209869-89221751","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA042051, HPA044083","Supported","Approved","Approved","Nucleoplasm<br>Centrosome<br>Cytosol",NA,"Group enriched","Tissue enriched",9,"cerebral cortex: 6.1","testis: 0.6","Cell line enriched",53,"SK-MEL-30: 16.5"
"ROBO2","KIAA1568","ENSG00000185008","Roundabout guidance receptor 2","3","75906695-77649964","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA013371","Approved",NA,"Approved","Nucleus<br>Microtubule organizing center",NA,"Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 33.8","lung: 15.1","Cell line enhanced",NA,"BJ hTERT+: 24.2;HEL: 75.2"
"ROCK2",NA,"ENSG00000134318","Rho associated coiled-coil containing protein kinase 2","2","11179761-11348330","Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA007459, CAB008666, HPA044109","Approved",NA,"Supported","Cytosol","Renal cancer:1.57e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"adipose tissue: 41.0","Expressed in all",NA,NA
"RPP40","bA428J1.3, RNASEP1","ENSG00000124787","Ribonuclease P/MRP subunit p40","6","4994732-5004063","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA035685, HPA035686","Uncertain",NA,"Approved","Nucleoplasm","Renal cancer:7.54e-8 (unfavourable), Endometrial cancer:6.10e-6 (unfavourable), Liver cancer:5.41e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"adrenal gland: 11.9","Expressed in all",NA,NA
"RUFY3","KIAA0871, RIPx, Singar1, ZFYVE30","ENSG00000018189","RUN and FYVE domain containing 3","4","70704204-70807315","Predicted intracellular proteins","Evidence at protein level","HPA022952, HPA022970","Enhanced",NA,"Supported","Cytosol","Pancreatic cancer:8.02e-5 (favourable), Head and neck cancer:1.28e-4 (favourable), Liver cancer:8.95e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 143.0","Expressed in all",NA,NA
"SCG2","CHGC, SgII, SN","ENSG00000171951","Secretogranin II","2","223596940-223602503","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA011893, HPA075062","Enhanced","Supported",NA,NA,"Renal cancer:7.01e-10 (unfavourable), Pancreatic cancer:5.58e-4 (favourable)","Group enriched","Group enriched",8,"adrenal gland: 446.7;cerebral cortex: 232.0","duodenum: 45.1","Cell line enhanced",NA,"ASC TERT1: 35.0;HSkMC: 31.4;SCLC-21H: 52.8;SH-SY5Y: 20.7;WM-115: 32.8"
"SCN2A","HBSCI, HBSCII, Nav1.2, SCN2A1, SCN2A2","ENSG00000136531","Sodium voltage-gated channel alpha subunit 2","2","165194993-165392310","Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels","Evidence at protein level","CAB022567","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",26,"cerebral cortex: 56.6","kidney: 2.1","Cell line enhanced",NA,"U-138 MG: 3.6;U-266/84: 5.7;U-87 MG: 2.2"
"SCRN1","KIAA0193","ENSG00000136193","Secernin 1","7","29920103-29990289","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA024517","Enhanced",NA,"Approved","Cytosol","Renal cancer:1.15e-5 (favourable), Endometrial cancer:4.00e-5 (unfavourable), Urothelial cancer:2.60e-4 (unfavourable), Ovarian cancer:7.27e-4 (unfavourable), Breast cancer:8.32e-4 (unfavourable), Cervical cancer:8.46e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 172.0","parathyroid gland: 129.1","Mixed",NA,NA
"SEMA6B","SEM-SEMA-Y, SEMA-VIB, SEMAN, semaZ","ENSG00000167680","Semaphorin 6B","19","4542593-4559808","Plasma proteins, Predicted membrane proteins","Evidence at protein level","CAB025157, HPA055778, HPA058523","Enhanced",NA,NA,NA,"Renal cancer:3.29e-5 (unfavourable), Thyroid cancer:1.45e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 65.5","spleen: 24.5","Cell line enhanced",NA,"Hep G2: 88.4;HMC-1: 180.6;HUVEC TERT2: 71.3;TIME: 88.7"
"SEZ6L2","FLJ90517, PSK-1","ENSG00000174938","Seizure related 6 homolog like 2","16","29871159-29899547","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA064471","Enhanced",NA,NA,NA,"Colorectal cancer:1.31e-4 (unfavourable), Glioma:7.27e-4 (unfavourable), Cervical cancer:7.46e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 82.4;parathyroid gland: 58.4","adrenal gland: 30.6","Cell line enhanced",NA,"EFO-21: 72.2"
"SFPQ","PPP1R140, PSF","ENSG00000116560","Splicing factor proline and glutamine rich","1","35176378-35193148","Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors","Evidence at protein level","CAB009886, HPA047513, HPA054689","Enhanced",NA,"Enhanced","Nucleoplasm","Liver cancer:7.91e-13 (unfavourable), Breast cancer:9.56e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"bone marrow: 135.5","Expressed in all",NA,NA
"SGSM2","KIAA0397, RUTBC1","ENSG00000141258","Small G protein signaling modulator 2","17","2337498-2381058","Predicted intracellular proteins","Evidence at protein level","HPA021641, HPA024553","Approved",NA,"Approved","Nucleoplasm<br>Cytosol","Pancreatic cancer:9.00e-6 (favourable), Head and neck cancer:3.11e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 78.0","Expressed in all",NA,NA
"SH3GL2","CNSA2, EEN-B1, SH3D2A, SH3P4","ENSG00000107295","SH3 domain containing GRB2 like 2, endophilin A1","9","17579082-17797129","Predicted intracellular proteins","Evidence at protein level","CAB010056, HPA026685, HPA063573","Enhanced","Supported","Approved","Microtubules<br>Cytokinetic bridge<br>Mitotic spindle","Renal cancer:6.68e-12 (favourable)","Tissue enhanced","Tissue enriched",10,"cerebral cortex: 170.1","kidney: 17.5","Cell line enhanced",NA,"HeLa: 14.7;RT4: 34.0;SCLC-21H: 31.7"
"SIRPA","BIT, CD172a, MFR, MYD-1, P84, PTPNS1, SHPS-1, SHPS1, SIRP, SIRP-ALPHA-1, SIRPalpha, SIRPalpha2","ENSG00000198053","Signal regulatory protein alpha","20","1894167-1940592","CD markers, Plasma proteins, Predicted membrane proteins","Evidence at protein level","CAB002776, CAB015122, HPA054437, HPA058511","Enhanced",NA,NA,NA,NA,"Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 207.9","Cell line enhanced",NA,"fHDF/TERT166: 110.5"
"SIRT2","SIR2L","ENSG00000068903","Sirtuin 2","19","38878555-38899862","Cancer-related genes, Predicted intracellular proteins","Evidence at protein level","CAB004573, HPA011165","Approved",NA,"Approved","Nucleus<br>Nucleoli<br>Cytosol","Endometrial cancer:7.20e-7 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 83.9","Expressed in all",NA,NA
"SLC17A6","DNPI, VGLUT2","ENSG00000091664","Solute carrier family 17 member 6","11","22338097-22379503","Predicted membrane proteins, Transporters","Evidence at protein level","CAB037130, HPA039226, CAB078204","Enhanced","Supported",NA,NA,NA,"Not detected","Tissue enriched",65,"cerebral cortex: 6.5","all non-specific tissues: 0.0","Cell line enriched",263,"SCLC-21H: 35.7"
"SLC17A7","BNPI, VGLUT1","ENSG00000104888","Solute carrier family 17 member 7","19","49429401-49442360","Predicted membrane proteins, Transporters","Evidence at protein level","CAB037183, HPA050458, HPA063679","Enhanced","Supported",NA,NA,NA,"Tissue enriched","Tissue enriched",177,"cerebral cortex: 584.4","adipose tissue: 3.3","Cell line enhanced",NA,"HMC-1: 18.2;K-562: 6.2;SCLC-21H: 5.7"
"SLC1A3","EA6, EAAT1, GLAST","ENSG00000079215","Solute carrier family 1 member 3","5","36606355-36688334","Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters","Evidence at protein level","CAB002573, HPA037467, HPA037468","Enhanced",NA,"Approved","Nucleoli<br>Mitochondria",NA,"Tissue enriched","Tissue enriched",16,"cerebral cortex: 518.2","adipose tissue: 31.9","Cell line enhanced",NA,"AF22: 49.5;CACO-2: 68.8;HaCaT: 55.0"
"SLC35F1","C6orf169, dJ230I3.1","ENSG00000196376","Solute carrier family 35 member F1","6","117907526-118317676","Predicted membrane proteins, Transporters","Evidence at protein level","HPA019576","Enhanced",NA,"Approved","Nucleoplasm<br>Microtubule organizing center<br>Cytosol",NA,"Group enriched","Tissue enriched",12,"cerebral cortex: 45.4","epididymis: 3.7","Group enriched",10,"AF22: 47.2;WM-115: 80.1"
"SLC6A17",NA,"ENSG00000197106","Solute carrier family 6 member 17","1","110150486-110202202","Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters","Evidence at protein level","HPA007663, HPA008044","Enhanced",NA,"Approved","Nucleus<br>Golgi apparatus",NA,"Tissue enriched","Tissue enriched",10,"cerebral cortex: 75.4","adrenal gland: 7.9","Cell line enhanced",NA,"SiHa: 6.6;SK-MEL-30: 28.5;U-87 MG: 7.0"
"SLC6A2","NAT1, NET, NET1, SLC6A5","ENSG00000103546","Solute carrier family 6 member 2","16","55655604-55706192","Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters","Evidence at protein level","HPA004057, HPA076311, CAB078195","Enhanced","Supported","Approved","Mitochondria<br>Cytosol",NA,"Tissue enhanced","Tissue enhanced",NA,"adrenal gland: 29.2;placenta: 18.4;skin: 15.7","testis: 11.4","Cell line enriched",35,"SH-SY5Y: 519.4"
"SLC9A6","KIAA0267, NHE6","ENSG00000198689","Solute carrier family 9 member A6","X","135973841-136047269","Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA059445, HPA059590","Enhanced",NA,"Supported","Vesicles",NA,"Expressed in all","Tissue enhanced",NA,"cerebral cortex: 67.9","parathyroid gland: 16.6","Mixed",NA,NA
"SLCO3A1","OATP-D, OATP3A1, SLC21A11","ENSG00000176463","Solute carrier organic anion transporter family member 3A1","15","91853695-92172435","Plasma proteins, Predicted membrane proteins, Transporters","Evidence at protein level","HPA066327","Approved",NA,NA,NA,"Endometrial cancer:6.57e-6 (unfavourable), Cervical cancer:8.61e-4 (favourable)","Expressed in all","Mixed",NA,NA,"parathyroid gland: 27.0","Cell line enhanced",NA,"CAPAN-2: 55.3;HaCaT: 84.3;HMC-1: 48.5"
"SLITRK3","KIAA0848","ENSG00000121871","SLIT and NTRK like family member 3","3","165186720-165197109","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA017636, HPA048042","Enhanced",NA,"Approved","Mitochondria",NA,"Tissue enriched","Tissue enhanced",NA,"cerebral cortex: 17.3;endometrium: 12.3","fallopian tube: 9.8","Cell line enhanced",NA,"AF22: 2.6;HAP1: 2.3;SCLC-21H: 1.7"
"SMARCA2","BAF190, BRM, hBRM, hSNF2a, SNF2, SNF2L2, SNF2LA, Sth1p, SWI2","ENSG00000080503","SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2","9","1980290-2193624","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA029981, CAB037276","Enhanced",NA,"Approved","Nucleoplasm<br>Vesicles<br>Intermediate filaments","Renal cancer:1.26e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 328.7","Cell line enriched",7,"HDLM-2: 1364.0"
"SMIM13","C6orf228","ENSG00000224531","Small integral membrane protein 13","6","11094033-11138733","Predicted membrane proteins","Evidence at protein level","HPA065706","Enhanced",NA,"Approved","Nucleus<br>Nuclear membrane<br>Golgi apparatus","Renal cancer:1.03e-5 (unfavourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 47.1","placenta: 18.9","Expressed in all",NA,NA
"SMIM17",NA,"ENSG00000268182","Small integral membrane protein 17","19","56643145-56655766","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA071857, HPA071861","Enhanced",NA,"Approved","Vesicles",NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 8.7","epididymis: 2.0","Cell line enhanced",NA,"AF22: 2.3;HEK 293: 2.1;SCLC-21H: 2.5"
"SPRYD3","FLJ14800","ENSG00000167778","SPRY domain containing 3","12","53064316-53079420","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA039426, HPA039685","Enhanced",NA,"Approved","Nucleoplasm<br>Actin filaments<br>Cytosol","Renal cancer:1.78e-15 (favourable), Head and neck cancer:9.46e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 144.9","Expressed in all",NA,NA
"SRCIN1","KIAA1684, p140Cap, SNIP","ENSG00000277363","SRC kinase signaling inhibitor 1","17","38530016-38605930","Predicted intracellular proteins","Evidence at protein level","HPA009701, HPA063795","Enhanced",NA,"Approved","Cell Junctions","Urothelial cancer:1.76e-4 (favourable)","Mixed","Tissue enhanced",NA,"cerebral cortex: 22.1","skin: 4.7","Cell line enriched",5,"SCLC-21H: 14.7"
"SRSF7","9G8, AAG3, HSSG1, RBM37, SFRS7, ZCCHC20, ZCRB2","ENSG00000115875","Serine and arginine rich splicing factor 7","2","38743599-38751494","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA043850, HPA056926","Enhanced",NA,"Enhanced","Nucleoplasm","Renal cancer:3.18e-8 (unfavourable), Liver cancer:2.90e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 99.7","Expressed in all",NA,NA
"STRC","DFNB16","ENSG00000242866","Stereocilin","15","43599398-43618800","Disease related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA048083","Enhanced",NA,NA,NA,NA,"Not detected","Tissue enhanced",NA,"cerebral cortex: 1.4;epididymis: 1.6;testis: 1.7","skin: 0.8","Not detected",NA,NA
"STX1A","HPC-1, p35-1, STX1","ENSG00000106089","Syntaxin 1A","7","73699206-73719672","Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters","Evidence at protein level","CAB008372, HPA069176","Enhanced",NA,NA,NA,"Endometrial cancer:1.94e-5 (unfavourable), Cervical cancer:3.63e-4 (unfavourable)","Expressed in all","Tissue enriched",15,"cerebral cortex: 166.6","gallbladder: 10.8","Cell line enhanced",NA,"SCLC-21H: 164.0;U-87 MG: 90.3"
"STXBP1","hUNC18, MUNC18-1, rbSec1, UNC18","ENSG00000136854","Syntaxin binding protein 1","9","127579370-127696027","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA008209, HPA023483, CAB034434","Enhanced",NA,"Approved","Nucleoplasm<br>Cytosol","Head and neck cancer:1.47e-4 (unfavourable), Endometrial cancer:4.78e-4 (unfavourable), Liver cancer:5.73e-4 (unfavourable), Pancreatic cancer:9.81e-4 (favourable)","Expressed in all","Tissue enriched",8,"cerebral cortex: 396.3","fallopian tube: 52.6","Cell line enhanced",NA,"SCLC-21H: 169.1"
"SULT4A1","hBR-STL-1, SULTX3","ENSG00000130540","Sulfotransferase family 4A member 1","22","43824509-43862503","Predicted intracellular proteins","Evidence at protein level","HPA003129","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",35,"cerebral cortex: 143.6","adrenal gland: 4.0","Not detected",NA,NA
"SV2A","KIAA0736, SV2","ENSG00000159164","Synaptic vesicle glycoprotein 2A","1","149903318-149917882","FDA approved drug targets, Predicted membrane proteins","Evidence at protein level","CAB002226, HPA007863","Enhanced",NA,"Approved","Cytosol","Renal cancer:3.22e-4 (unfavourable)","Tissue enriched","Tissue enhanced",NA,"cerebral cortex: 166.9;parathyroid gland: 72.0","epididymis: 28.2","Cell line enhanced",NA,"NTERA-2: 65.6;SCLC-21H: 63.2"
"SYNCRIP","dJ3J17.2, GRY-RBP, hnRNP-Q, HNRNPQ, HNRPQ1, NSAP1","ENSG00000135316","Synaptotagmin binding cytoplasmic RNA interacting protein","6","85607785-85643792","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB010895, HPA041275","Enhanced",NA,"Enhanced","Nucleoplasm<br>Cytosol","Liver cancer:6.28e-5 (unfavourable), Ovarian cancer:5.59e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 132.3","Expressed in all",NA,NA
"SYNJ1","INPP5G, PARK20","ENSG00000159082","Synaptojanin 1","21","32628759-32728048","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA011916","Enhanced",NA,"Approved","Nucleoplasm<br>Centrosome<br>Cytosol","Prostate cancer:2.58e-4 (unfavourable), Head and neck cancer:4.43e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 65.9","testis: 18.4","Expressed in all",NA,NA
"SYNPR","MGC26651, SPO","ENSG00000163630","Synaptoporin","3","63228315-63616921","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA051368, HPA061671","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",27,"cerebral cortex: 78.2","heart muscle: 2.9","Cell line enhanced",NA,"SCLC-21H: 1.2"
"SYT11","DKFZp781D015, KIAA0080, MGC10881, MGC17226","ENSG00000132718","Synaptotagmin 11","1","155859509-155885199","Predicted intracellular proteins","Evidence at protein level","HPA064091","Enhanced",NA,NA,NA,"Endometrial cancer:2.93e-5 (unfavourable)","Tissue enriched","Tissue enriched",14,"cerebral cortex: 402.2","endometrium: 28.4","Cell line enhanced",NA,"Karpas-707: 130.6;SCLC-21H: 84.6;SH-SY5Y: 83.1;U-87 MG: 84.4"
"SYT7","IPCA-7, MGC150517, PCANAP7, SYT-VII","ENSG00000011347","Synaptotagmin 7","11","61515313-61581148","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA012869","Enhanced",NA,NA,NA,"Renal cancer:1.16e-4 (unfavourable), Head and neck cancer:1.20e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 108.7;prostate: 84.8","placenta: 26.6","Cell line enhanced",NA,"hTERT-HME1: 68.9;RT4: 30.1;SCLC-21H: 34.3;SK-BR-3: 31.0;T-47d: 38.2"
"TAF1A","SL1, TAFI48","ENSG00000143498","TATA-box binding protein associated factor, RNA polymerase I subunit A","1","222557902-222589933","Predicted intracellular proteins","Evidence at protein level","HPA054334","Approved",NA,"Supported","Nucleoplasm","Cervical cancer:9.26e-6 (unfavourable)","Expressed in all","Mixed",NA,NA,"testis: 12.0","Expressed in all",NA,NA
"TBCB","CG22, CKAP1, CKAPI","ENSG00000105254","Tubulin folding cofactor B","19","36114289-36125947","Predicted intracellular proteins","Evidence at protein level","HPA041428, HPA041722","Approved",NA,"Supported","Cytosol","Liver cancer:2.09e-4 (unfavourable), Pancreatic cancer:3.11e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 249.9","Expressed in all",NA,NA
"TCEAL7","MGC23947, WEX5","ENSG00000182916","Transcription elongation factor A like 7","X","103330196-103332326","Predicted intracellular proteins","Evidence at protein level","HPA051507, HPA065080","Enhanced",NA,"Supported","Nucleus","Stomach cancer:3.53e-4 (unfavourable), Renal cancer:4.31e-4 (unfavourable)","Tissue enriched","Tissue enhanced",NA,"cerebral cortex: 145.6","endometrium: 76.7","Cell line enhanced",NA,"hTEC/SVTERT24-B: 81.8;SCLC-21H: 242.8"
"TCERG1","CA150, TAF2S, Urn1","ENSG00000113649","Transcription elongation regulator 1","5","146447311-146511961","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA064854, HPA069752, HPA069808","Enhanced",NA,"Enhanced","Nucleoplasm","Renal cancer:4.70e-11 (unfavourable), Liver cancer:5.34e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"lymph node: 20.7","Expressed in all",NA,NA
"TECPR2","KIAA0329","ENSG00000196663","Tectonin beta-propeller repeat containing 2","14","102362963-102502481","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA000658","Enhanced",NA,"Approved","Nucleus","Renal cancer:6.53e-9 (favourable), Liver cancer:5.66e-5 (unfavourable)","Expressed in all","Mixed",NA,NA,"cerebral cortex: 21.4","Mixed",NA,NA
"TENM4","KIAA1302, ODZ4, Ten-M4","ENSG00000149256","Teneurin transmembrane protein 4","11","78652831-79440948","Disease related genes, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA019521, HPA065961","Approved",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"ovary: 20.8;parathyroid gland: 54.0","thyroid gland: 9.7","Cell line enhanced",NA,"PC-3: 9.9;SH-SY5Y: 18.6"
"TIMM21","C18orf55, HSPC154, TIM21","ENSG00000075336","Translocase of inner mitochondrial membrane 21","18","74148511-74160530","Predicted membrane proteins","Evidence at protein level","HPA010587, HPA051543","Uncertain",NA,"Approved","Nucleoplasm","Renal cancer:1.38e-9 (favourable), Liver cancer:9.22e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"heart muscle: 26.2","Expressed in all",NA,NA
"TLN2","ILWEQ, KIAA0320","ENSG00000171914","Talin 2","15","62390526-62844631","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB017194, HPA051828, HPA054787","Enhanced",NA,"Supported","Focal adhesion sites<br>Cytosol","Renal cancer:1.81e-6 (favourable), Breast cancer:6.53e-4 (favourable), Stomach cancer:7.74e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 41.2;kidney: 41.1","thyroid gland: 21.7","Mixed",NA,NA
"TMEM100","FLJ10970, FLJ37856","ENSG00000166292","Transmembrane protein 100","17","55719627-55732121","Predicted membrane proteins","Evidence at protein level","HPA055936","Approved",NA,"Uncertain","Nucleoplasm","Liver cancer:2.67e-5 (favourable), Renal cancer:1.32e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"lung: 131.2;placenta: 78.3","epididymis: 44.5","Cell line enhanced",NA,"ASC diff: 19.9;ASC TERT1: 13.7;HHSteC: 37.7;HSkMC: 15.0;U-87 MG: 13.6;WM-115: 11.8"
"TMEM132A","FLJ20539, GBP, HSPA5BP1","ENSG00000006118","Transmembrane protein 132A","11","60924463-60937159","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA051979, HPA060492","Enhanced",NA,"Approved","Mitochondria","Renal cancer:1.55e-9 (unfavourable), Endometrial cancer:1.98e-5 (favourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 94.2","placenta: 25.0","Cell line enhanced",NA,"EFO-21: 167.6"
"TMEM241","C18orf45, FLJ44259, MGC11386","ENSG00000134490","Transmembrane protein 241","18","23197144-23437961","Predicted membrane proteins","Evidence at protein level","HPA029489, HPA059922","Uncertain",NA,"Approved","Golgi apparatus<br>Vesicles","Urothelial cancer:5.80e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"cerebral cortex: 4.2","Mixed",NA,NA
"TMEM35A","FLJ14084, TMEM35","ENSG00000126950","Transmembrane protein 35A","X","101078720-101096364","Predicted membrane proteins","Evidence at protein level","HPA048583","Enhanced",NA,"Supported","Vesicles<br>Focal adhesion sites<br>Cytosol",NA,"Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 42.4;seminal vesicle: 65.5","prostate: 33.7","Cell line enhanced",NA,"HUVEC TERT2: 40.2;SH-SY5Y: 12.9"
"TOLLIP","IL-1RAcPIP","ENSG00000078902","Toll interacting protein","11","1274371-1309654","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA038621, HPA038622","Enhanced",NA,"Approved","Plasma membrane<br>Cytosol","Renal cancer:1.11e-16 (favourable), Glioma:4.57e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 132.3","Expressed in all",NA,NA
"TPPP","p25, p25alpha, TPPP/p25, TPPP1","ENSG00000171368","Tubulin polymerization promoting protein","5","659862-693395","Predicted intracellular proteins","Evidence at protein level","HPA036575, HPA036576","Enhanced",NA,"Supported","Mitochondria<br>Cytosol","Renal cancer:5.40e-6 (favourable)","Expressed in all","Tissue enriched",10,"cerebral cortex: 166.6","fallopian tube: 16.9","Cell line enhanced",NA,"A549: 6.6;AN3-CA: 5.0;SCLC-21H: 15.6"
"TRIM46","FLJ23229, TRIFIC","ENSG00000163462","Tripartite motif containing 46","1","155173787-155184971","Predicted intracellular proteins","Evidence at protein level","HPA030389, HPA055583","Enhanced",NA,"Approved","Intermediate filaments<br>Cytosol","Endometrial cancer:2.61e-7 (unfavourable)","Mixed","Tissue enhanced",NA,"cerebral cortex: 7.9;epididymis: 4.0","smooth muscle: 1.5","Cell line enhanced",NA,"SH-SY5Y: 11.1"
"TTBK1","KIAA1855","ENSG00000146216","Tau tubulin kinase 1","6","43243680-43288259","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA031735, HPA031736","Enhanced",NA,"Supported","Nucleoplasm<br>Cytosol",NA,"Tissue enhanced","Tissue enriched",6,"cerebral cortex: 18.9","small intestine: 3.1","Group enriched",13,"SCLC-21H: 24.9;SH-SY5Y: 8.7"
"TUBA1A","B-ALPHA-1, FLJ25113, TUBA3","ENSG00000167552","Tubulin alpha 1a","12","49184796-49189324","Cancer-related genes, Disease related genes, FDA approved drug targets, Predicted intracellular proteins","Evidence at protein level","CAB008686, HPA039247, HPA043684, HPA063394","Enhanced",NA,"Enhanced","Microtubules","Renal cancer:2.90e-4 (unfavourable)","Tissue enriched","Expressed in all",NA,NA,"cerebral cortex: 1373.1","Expressed in all",NA,NA
"U2SURP","fSAPa, SR140","ENSG00000163714","U2 snRNP associated SURP domain containing","3","142964497-143060546","Predicted intracellular proteins","Evidence at protein level","HPA037545, HPA037546, HPA061407","Enhanced",NA,"Supported","Nucleoplasm","Renal cancer:8.86e-7 (unfavourable), Liver cancer:3.15e-5 (unfavourable), Urothelial cancer:6.78e-4 (favourable), Endometrial cancer:8.44e-4 (unfavourable), Pancreatic cancer:8.92e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 37.6","Expressed in all",NA,NA
"UBE2K","HIP2, HYPG, UBC1","ENSG00000078140","Ubiquitin conjugating enzyme E2 K","4","39698044-39782792","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA028869, CAB033212, CAB033515","Supported",NA,"Supported","Intermediate filaments<br>Actin filaments<br>Cytosol","Pancreatic cancer:8.60e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 64.7","Expressed in all",NA,NA
"UCHL1","PARK5, PGP9.5, Uch-L1","ENSG00000154277","Ubiquitin C-terminal hydrolase L1","4","41256413-41268455","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","CAB002580, HPA005993, CAB079024","Enhanced","Supported","Enhanced","Nucleoplasm<br>Cytosol","Endometrial cancer:4.08e-5 (unfavourable), Urothelial cancer:1.93e-4 (unfavourable)","Expressed in all","Tissue enriched",7,"cerebral cortex: 785.9","adrenal gland: 107.9","Cell line enhanced",NA,"EFO-21: 912.4;SCLC-21H: 1141.2;U-87 MG: 916.2"
"VAMP1","SYB1, VAMP-1","ENSG00000139190","Vesicle associated membrane protein 1","12","6462237-6470987","FDA approved drug targets, Predicted membrane proteins, Transporters","Evidence at protein level","CAB002779, CAB016119, CAB079000","Approved","Approved",NA,NA,"Renal cancer:1.04e-11 (unfavourable), Colorectal cancer:6.37e-5 (unfavourable), Liver cancer:6.97e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"cerebral cortex: 43.5","Cell line enriched",5,"U-698: 140.4"
"VAMP4",NA,"ENSG00000117533","Vesicle associated membrane protein 4","1","171700160-171742247","Predicted membrane proteins","Evidence at protein level","HPA050418","Enhanced",NA,"Approved","Golgi apparatus","Renal cancer:5.43e-6 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 22.4","Expressed in all",NA,NA
"VGF","SCG7, SgVII","ENSG00000128564","VGF nerve growth factor inducible","7","101162509-101165593","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA055177, HPA072505","Enhanced",NA,"Supported","Golgi apparatus<br>Vesicles","Endometrial cancer:4.25e-4 (unfavourable), Glioma:4.43e-4 (unfavourable)","Tissue enriched","Tissue enriched",22,"cerebral cortex: 46.1","adipose tissue: 2.0","Group enriched",11,"SH-SY5Y: 182.3;SK-MEL-30: 372.7;U-2 OS: 87.3;WM-115: 139.3"
"WNT10B","SHFM6, WNT-12","ENSG00000169884","Wnt family member 10B","12","48965340-48971763","Disease related genes, Predicted secreted proteins","Evidence at protein level","HPA055048, HPA062539","Enhanced",NA,"Approved","Golgi apparatus",NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 11.6","skin: 3.0","Cell line enhanced",NA,"T-47d: 7.6"
"XAGE3","CT12.3a, CT12.3b, GAGED4, PLAC6, pp9012, XAGE-3","ENSG00000171402","X antigen family member 3","X","52862525-52868068","Predicted intracellular proteins","Evidence at protein level","HPA052507, HPA059045, HPA060900","Approved",NA,NA,NA,NA,"Mixed","Tissue enriched",167,"placenta: 575.4","adipose tissue: 3.4","Cell line enhanced",NA,"BEWO: 1.2;U-266/70: 1.6;U-266/84: 1.4"
"XAGE5","CT12.5, GAGED5, XAGE-5","ENSG00000171405","X antigen family member 5","X","52812204-52818301","Predicted intracellular proteins","Evidence at transcript level","HPA052507, HPA055941, HPA059045","Uncertain",NA,"Approved","Nucleoplasm<br>Vesicles",NA,"Tissue enhanced","Tissue enriched",10,"testis: 2.1","skin: 0.2","Cell line enriched",47,"U-2 OS: 22.9"
"YWHAQ","14-3-3, HS1","ENSG00000134308","Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein theta","2","9583972-9631014","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA007925, CAB010286","Approved",NA,"Supported","Nucleoplasm<br>Cytosol","Liver cancer:9.83e-6 (unfavourable), Endometrial cancer:8.20e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 398.1","Expressed in all",NA,NA
"ZDHHC12","FLJ14524, ZNF400","ENSG00000160446","Zinc finger DHHC-type containing 12","9","128720869-128724127","Enzymes, Predicted membrane proteins","Evidence at transcript level","HPA059339","Uncertain",NA,"Approved","Nucleoplasm",NA,"Expressed in all","Expressed in all",NA,NA,"small intestine: 35.8","Mixed",NA,NA
"ZHX2","KIAA0854","ENSG00000178764","Zinc fingers and homeoboxes 2","8","122781394-122974512","Plasma proteins, Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA006769, HPA006996","Enhanced",NA,"Enhanced","Nucleoplasm",NA,"Expressed in all","Expressed in all",NA,NA,"ovary: 32.8","Cell line enhanced",NA,"REH: 47.1"
"ZMAT3","FLJ12296, MGC10613, PAG608, WIG-1, WIG1","ENSG00000172667","Zinc finger matrin-type 3","3","179017223-179072279","Predicted intracellular proteins","Evidence at protein level","HPA027569, HPA028671, HPA054356","Enhanced",NA,"Supported","Nucleoplasm",NA,"Expressed in all","Mixed",NA,NA,"cerebral cortex: 29.0","Expressed in all",NA,NA
"ZNF365","KIAA0844, UAN","ENSG00000138311","Zinc finger protein 365","10","62374192-62672011","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA052446","Enhanced",NA,"Supported","Vesicles<br>Microtubule organizing center",NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 54.5","parathyroid gland: 10.9","Cell line enhanced",NA,"HaCaT: 18.7;PC-3: 12.7;U-251 MG: 14.7"
"ARC","Arg3.1, KIAA0278","ENSG00000198576","Activity regulated cytoskeleton associated protein","8","142611044-142614472","Predicted intracellular proteins","Evidence at protein level","HPA056430, CAB079013",NA,"Supported","Approved","Vesicles<br>Microtubules",NA,"Tissue enriched","Group enriched",7,"adipose tissue: 14.2;adrenal gland: 13.4;cerebral cortex: 14.4;gallbladder: 3.3;seminal vesicle: 5.5","placenta: 1.4","Cell line enhanced",NA,"HEK 293: 9.2;SCLC-21H: 27.7;U-2 OS: 11.9;U-87 MG: 12.5"
"BRI3BP","BNAS1, HCCR-2, HCCRBP-3, KG19","ENSG00000184992","BRI3 binding protein","12","124993700-125031231","Predicted membrane proteins, Transporters","Evidence at protein level","HPA014957","Approved",NA,"Approved","Nucleoplasm<br>Mitochondria","Liver cancer:6.87e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"duodenum: 20.5","Expressed in all",NA,NA
"C12orf10","Gamm1, MYG, MYG1","ENSG00000139637","Chromosome 12 open reading frame 10","12","53299686-53307177","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA038626, HPA038627","Approved","Supported","Supported","Nucleoplasm",NA,"Expressed in all","Expressed in all",NA,NA,"testis: 114.3","Expressed in all",NA,NA
"CLCN5","ClC-5, CLC5, DENTS, hCIC-K2, hClC-K2, NPHL1, NPHL2, XLRH, XRN","ENSG00000171365","Chloride voltage-gated channel 5","X","49922615-50099235","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA000401, HPA003213","Uncertain",NA,"Supported","Golgi apparatus<br>Plasma membrane<br>Cytosol","Renal cancer:2.05e-8 (favourable), Pancreatic cancer:5.20e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"epididymis: 33.7;kidney: 52.0","placenta: 9.6","Cell line enhanced",NA,"CACO-2: 44.1;RH-30: 76.7"
"GPR148","PGR6","ENSG00000173302","G protein-coupled receptor 148","2","130729070-130730336","G-protein coupled receptors, Predicted membrane proteins","Evidence at transcript level","HPA060527","Uncertain",NA,NA,NA,NA,"Not detected","Not detected",NA,NA,"stomach: 0.4","Not detected",NA,NA
"GPR37L1","ETBR-LP-2","ENSG00000170075","G protein-coupled receptor 37 like 1","1","202122858-202133592","G-protein coupled receptors, Predicted membrane proteins","Evidence at protein level","HPA064454","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",65,"cerebral cortex: 34.1","seminal vesicle: 0.5","Cell line enhanced",NA,"HaCaT: 1.1;MCF7: 1.1;T-47d: 3.6"
"KCNG2","KCNF2, Kv6.2","ENSG00000178342","Potassium voltage-gated channel modifier subfamily G member 2","18","79863668-79900184","Predicted membrane proteins, Voltage-gated ion channels","Evidence at protein level","HPA048628","Approved",NA,NA,NA,NA,"Not detected","Not detected",NA,NA,"cerebral cortex: 0.4","Not detected",NA,NA
"KRT85","Hb-5, KRTHB5","ENSG00000135443","Keratin 85","12","52360006-52367481","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA049778","Supported",NA,NA,NA,NA,"Not detected","Not detected",NA,NA,"testis: 0.8","Cell line enhanced",NA,"A549: 2.0"
"KRT86","Hb6, KRTHB6, MNX","ENSG00000170442","Keratin 86","12","52249300-52309163","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA039798, HPA049778","Supported",NA,"Approved","Cytosol",NA,"Mixed","Tissue enhanced",NA,"thyroid gland: 6.9","testis: 2.4","Cell line enhanced",NA,"A-431: 21.8;A549: 23.3;MCF7: 39.4;RPMI-8226: 22.5"
"MAPK10","JNK3, p493F12, p54bSAPK, PRKM10","ENSG00000109339","Mitogen-activated protein kinase 10","4","86010395-86594131","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins","Evidence at protein level","CAB022625","Approved",NA,NA,NA,"Renal cancer:3.11e-4 (favourable), Urothelial cancer:5.57e-4 (favourable)","Mixed","Tissue enhanced",NA,"cerebral cortex: 113.0","seminal vesicle: 38.6","Cell line enriched",16,"AF22: 181.7"
"MRPS25","DKFZp313H0817, FLJ00023, MRP-S25, RPMS25","ENSG00000131368","Mitochondrial ribosomal protein S25","3","15042460-15065335","Predicted intracellular proteins, Ribosomal proteins","Evidence at protein level","HPA043490","Approved",NA,"Enhanced","Mitochondria","Renal cancer:3.60e-7 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 32.9","Expressed in all",NA,NA
"NBEA","BCL8B, FLJ10197, KIAA1544, LYST2","ENSG00000172915","Neurobeachin","13","34942287-35673022","Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA039730, HPA040385","Enhanced",NA,"Supported","Nucleus<br>Nucleoli<br>Golgi apparatus<br>Cytosol","Renal cancer:7.86e-8 (favourable)","Mixed","Tissue enhanced",NA,"cerebral cortex: 30.3","seminal vesicle: 12.2","Cell line enriched",5,"SH-SY5Y: 83.5"
"RAD18","RNF73","ENSG00000070950","RAD18, E3 ubiquitin protein ligase","3","8775402-8963773","Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA006716, HPA006724, HPA008752","Supported","Approved","Enhanced","Nucleoplasm<br>Nuclear bodies","Renal cancer:3.65e-5 (unfavourable), Liver cancer:1.12e-4 (unfavourable), Prostate cancer:3.73e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"duodenum: 10.2","Expressed in all",NA,NA
"RELB","REL-B","ENSG00000104856","RELB proto-oncogene, NF-kB subunit","19","45001430-45038198","Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors","Evidence at protein level","CAB007753, HPA040506","Approved",NA,"Approved","Nucleoplasm<br>Cytosol","Renal cancer:2.99e-6 (unfavourable), Breast cancer:1.55e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"appendix: 25.1","Cell line enhanced",NA,"HDLM-2: 73.5"
"UGGT1","HUGT1, UGCGL1","ENSG00000136731","UDP-glucose glycoprotein glucosyltransferase 1","2","128091200-128195677","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA012761, HPA015127","Enhanced",NA,"Uncertain","Cytosol","Renal cancer:6.37e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"epididymis: 24.3","Expressed in all",NA,NA
"UGT3A1","FLJ34658","ENSG00000145626","UDP glycosyltransferase family 3 member A1","5","35951010-36001028","Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA047697, HPA056290","Uncertain",NA,"Approved","Vesicles<br>Cytosol",NA,"Group enriched","Tissue enhanced",NA,"kidney: 53.4;liver: 29.2","duodenum: 9.5","Cell line enriched",51,"RH-30: 26.5"
"WDR7","KIAA0541, TRAG","ENSG00000091157","WD repeat domain 7","18","56651343-57036606","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA042074, HPA051057","Approved",NA,"Approved","Nucleoplasm<br>Cytosol","Renal cancer:1.13e-5 (favourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 38.6","parathyroid gland: 17.0","Expressed in all",NA,NA
"AK9","AKD1, AKD2, C6orf199, C6orf224, dJ70A9.1, FLJ25791, FLJ42177, MGC26954","ENSG00000155085","Adenylate kinase 9","6","109492856-109691217","Cancer-related genes, Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA030804, HPA030805, HPA031779, HPA031781, HPA036324, HPA036711","Enhanced",NA,"Approved","Nucleoplasm<br>Nuclear membrane",NA,"Mixed","Tissue enhanced",NA,"testis: 31.2","parathyroid gland: 17.1","Expressed in all",NA,NA
"ALPL","HOPS, TNSALP","ENSG00000162551","Alkaline phosphatase, liver/bone/kidney","1","21509372-21578412","Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA007105, HPA008765, CAB020829","Enhanced",NA,"Approved","Cytosol","Melanoma:7.08e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"lung: 78.8","kidney: 47.2","Group enriched",8,"HAP1: 31.9;HSkMC: 126.3;hTEC/SVTERT24-B: 139.0;LHCN-M2: 85.3;NTERA-2: 40.7;SCLC-21H: 103.8"
"AMDHD2","CGI-14","ENSG00000162066","Amidohydrolase domain containing 2","16","2520357-2531422","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA041184, HPA041321","Enhanced",NA,"Approved","Nucleoli<br>Cytosol","Cervical cancer:5.19e-4 (favourable)","Expressed in all","Mixed",NA,NA,"testis: 15.9","Mixed",NA,NA
"AP3B2","NAPTB","ENSG00000103723","Adaptor related protein complex 3 beta 2 subunit","15","82659281-82709914","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA039467, HPA039818","Enhanced",NA,NA,NA,NA,"Mixed","Group enriched",6,"cerebral cortex: 36.2;parathyroid gland: 7.4","adrenal gland: 3.8","Cell line enhanced",NA,"RT4: 11.4;SCLC-21H: 26.6;SH-SY5Y: 18.5"
"APBB1IP","INAG1, RIAM","ENSG00000077420","Amyloid beta precursor protein binding family B member 1 interacting protein","10","26438203-26567803","Predicted intracellular proteins","Evidence at protein level","HPA017009, HPA063903","Enhanced",NA,"Enhanced","Plasma membrane<br>Cytosol","Endometrial cancer:7.48e-4 (favourable)","Expressed in all","Mixed",NA,NA,"appendix: 61.2","Cell line enhanced",NA,"REH: 169.0;U-698: 134.4"
"APEH","D3F15S2, D3S48E, DNF15S2","ENSG00000164062","Acylaminoacyl-peptide hydrolase","3","49674002-49683963","Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA029700, HPA029701, HPA029702, HPA029703","Enhanced",NA,"Enhanced","Cytosol","Renal cancer:3.32e-10 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 101.6","Expressed in all",NA,NA
"ARHGAP20","KIAA1391","ENSG00000137727","Rho GTPase activating protein 20","11","110577042-110713189","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA038458, HPA038459, HPA076303","Uncertain",NA,"Approved","Mitochondria",NA,"Mixed","Mixed",NA,NA,"testis: 15.4","Cell line enhanced",NA,"ASC diff: 16.9;ASC TERT1: 5.7;SiHa: 7.6"
"ARHGEF9","KIAA0424, PEM-2","ENSG00000131089","Cdc42 guanine nucleotide exchange factor 9","X","63634967-63809274","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA035419, HPA055291","Approved",NA,"Supported","Cytosol","Renal cancer:1.02e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 80.1","Mixed",NA,NA
"ATP13A5","FLJ16025","ENSG00000187527","ATPase 13A5","3","193274790-193378843","Predicted membrane proteins","Evidence at transcript level","HPA031771, HPA031774","Uncertain",NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"breast: 17.7","salivary gland: 3.9","Cell line enhanced",NA,"SK-BR-3: 1.2"
"BAZ1B","WBSCR10, WBSCR9, WSTF","ENSG00000009954","Bromodomain adjacent to zinc finger domain 1B","7","73440398-73522278","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","CAB037081, CAB037158, HPA067010","Supported",NA,"Supported","Nuclear bodies",NA,"Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 54.8","Expressed in all",NA,NA
"C1orf131","DKFZp547B1713","ENSG00000143633","Chromosome 1 open reading frame 131","1","231223763-231241187","Predicted intracellular proteins","Evidence at protein level","HPA028452, HPA029920","Enhanced",NA,"Enhanced","Nucleus<br>Nucleoli<br>Cytosol","Renal cancer:2.64e-9 (unfavourable), Urothelial cancer:9.84e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"duodenum: 21.6","Expressed in all",NA,NA
"CACNA1B","CACNL1A5, CACNN, Cav2.2","ENSG00000148408","Calcium voltage-gated channel subunit alpha1 B","9","137877789-138124624","Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels","Evidence at protein level","HPA044347","Uncertain",NA,NA,NA,NA,"Tissue enhanced","Group enriched",8,"adrenal gland: 3.7;cerebral cortex: 14.8;fallopian tube: 4.9;testis: 7.6","prostate: 0.9","Cell line enriched",6,"SCLC-21H: 23.0"
"CCT8","C21orf112, Cctq, PRED71","ENSG00000156261","Chaperonin containing TCP1 subunit 8","21","29055805-29073797","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA018520, HPA021051, HPA029426","Enhanced",NA,"Approved","Nucleus<br>Intermediate filaments<br>Cytosol","Liver cancer:1.56e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"lymph node: 135.9","Expressed in all",NA,NA
"CLPB","ANKCLB, FLJ13152, HSP78, SKD3","ENSG00000162129","ClpB homolog, mitochondrial AAA ATPase chaperonin","11","72292425-72434680","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA039005, HPA039006, HPA064571","Enhanced",NA,NA,NA,"Renal cancer:8.36e-8 (favourable)","Expressed in all","Tissue enriched",10,"testis: 176.6","parathyroid gland: 18.5","Expressed in all",NA,NA
"CPQ","LDP, PGCP","ENSG00000104324","Carboxypeptidase Q","8","96645227-97149654","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA023235, HPA024490","Enhanced",NA,"Supported","Golgi apparatus<br>Vesicles","Renal cancer:5.40e-5 (favourable), Glioma:9.75e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 382.5","Cell line enhanced",NA,"ASC TERT1: 92.2"
"CSF1R","C-FMS, CD115, CSFR, FMS","ENSG00000182578","Colony stimulating factor 1 receptor","5","150053291-150113372","Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","CAB008970, HPA012323","Uncertain",NA,"Supported","Vesicles<br>Plasma membrane","Renal cancer:1.08e-4 (unfavourable), Testis cancer:4.92e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"spleen: 147.7","Group enriched",6,"BEWO: 118.6;SK-BR-3: 35.4"
"CXorf23",NA,"ENSG00000173681","Chromosome X open reading frame 23","X","19912860-19970298","Predicted intracellular proteins","Evidence at protein level","HPA027215","Approved",NA,"Approved","Nucleoplasm","Lung cancer:5.42e-4 (favourable), Urothelial cancer:5.56e-4 (favourable)","Expressed in all","Mixed",NA,NA,"parathyroid gland: 11.8","Expressed in all",NA,NA
"CYP21A2","CA21H, CAH1, CPS1, CYP21, CYP21B, P450c21B","ENSG00000231852","Cytochrome P450 family 21 subfamily A member 2","6","32038265-32041670","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins","Evidence at protein level","HPA048979, HPA053371","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",257,"adrenal gland: 266.4","epididymis: 1.0","Group enriched",5,"HDLM-2: 6.1;Karpas-707: 1.2"
"CYP51A1","CP51, CYP51, CYPL1, LDM, P450-14DM, P450L1","ENSG00000001630","Cytochrome P450 family 51 subfamily A member 1","7","92112151-92142952","Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA041325, HPA043508","Enhanced",NA,"Enhanced","Endoplasmic reticulum","Cervical cancer:6.12e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 174.1","Expressed in all",NA,NA
"DNAJA3","hTid-1, TID1","ENSG00000103423","DnaJ heat shock protein family (Hsp40) member A3","16","4425805-4456775","Predicted intracellular proteins","Evidence at protein level","CAB016095, HPA040875, HPA044229","Approved",NA,"Supported","Mitochondria","Renal cancer:1.79e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 25.4","Expressed in all",NA,NA
"DSG4","CDHF13, LAH","ENSG00000175065","Desmoglein 4","18","31376777-31414912","Disease related genes, Predicted membrane proteins","Evidence at protein level","HPA059456","Supported",NA,NA,NA,NA,"Not detected","Not detected",NA,NA,"testis: 0.8","Cell line enriched",157,"HaCaT: 37.3"
"DTD1","bA379J5.3, bA555E18.1, C20orf88, DUEB, HARS2, MGC119131, MGC41905, pqn-68","ENSG00000125821","D-tyrosyl-tRNA deacylase 1","20","18567453-18763917","Predicted intracellular proteins","Evidence at protein level","HPA040981, HPA042653","Uncertain",NA,"Uncertain","Nucleoli<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 55.8","Mixed",NA,NA
"EEF1A2","EEF1AL, HS1, STN, STNL","ENSG00000101210","Eukaryotic translation elongation factor 1 alpha 2","20","63488013-63499315","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB034019, HPA051759, HPA053862, HPA056990","Approved",NA,"Enhanced","Nucleoli<br>Cytosol","Endometrial cancer:2.90e-5 (unfavourable), Head and neck cancer:9.11e-4 (unfavourable)","Expressed in all","Group enriched",6,"cerebral cortex: 409.3;heart muscle: 425.6;skeletal muscle: 1372.7","adrenal gland: 127.7","Cell line enhanced",NA,"MCF7: 899.8;SCLC-21H: 694.7;T-47d: 410.5;U-2 OS: 431.5"
"FAH",NA,"ENSG00000103876","Fumarylacetoacetate hydrolase","15","80152490-80186946","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA041370, HPA044093","Enhanced",NA,"Approved","Cytosol","Head and neck cancer:8.51e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"liver: 151.9","Cell line enhanced",NA,"HHSteC: 261.9"
"FAM213B","C1orf93, MGC26818","ENSG00000157870","Family with sequence similarity 213 member B","1","2586491-2591469","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA006403","Approved","Approved","Approved","Nucleoplasm<br>Plasma membrane<br>Cytosol","Renal cancer:1.28e-4 (favourable), Liver cancer:1.62e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"small intestine: 14.6","Mixed",NA,NA
"FDX1","ADX, FDX","ENSG00000137714","Ferredoxin 1","11","110429883-110464881","Predicted intracellular proteins","Evidence at protein level","HPA041630, HPA062087","Enhanced",NA,"Enhanced","Mitochondria","Renal cancer:3.58e-7 (favourable), Stomach cancer:2.53e-4 (favourable)","Expressed in all","Tissue enriched",11,"adrenal gland: 387.5","seminal vesicle: 36.5","Expressed in all",NA,NA
"FYB","FYB-120/130, SLAP-130","ENSG00000082074","FYN binding protein","5","39105236-39274528","Predicted intracellular proteins","Evidence at protein level","CAB025336, HPA026796","Enhanced",NA,NA,NA,"Renal cancer:2.24e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"appendix: 127.4;lymph node: 109.8;spleen: 114.9","tonsil: 64.3","Cell line enhanced",NA,"HEL: 61.3;MOLT-4: 171.5;REH: 58.5;U-937: 68.8"
"GRM2","GPRC1B, mGlu2, MGLUR2","ENSG00000164082","Glutamate metabotropic receptor 2","3","51707070-51718613","G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA027868, HPA065166","Approved","Supported",NA,NA,NA,"Tissue enhanced","Tissue enriched",10,"cerebral cortex: 4.4","testis: 0.4","Cell line enriched",7,"SCLC-21H: 7.3"
"IGSF6","DORA","ENSG00000140749","Immunoglobulin superfamily member 6","16","21639537-21652660","Predicted membrane proteins","Evidence at protein level","HPA041023, HPA041072","Uncertain",NA,NA,NA,"Endometrial cancer:1.54e-5 (favourable), Cervical cancer:4.92e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"appendix: 15.2;spleen: 18.1","lung: 8.0","Not detected",NA,NA
"KRT31","Ha-1, KRTHA1","ENSG00000094796","Keratin 31","17","41393724-41397592","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA049550, HPA055194","Supported",NA,NA,NA,NA,"Group enriched","Group enriched",6,"esophagus: 4.6;skin: 14.4","skeletal muscle: 1.5","Not detected",NA,NA
"KRT34","Ha-4, KRTHA4","ENSG00000131737","Keratin 34","17","41377650-41382403","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA055194, HPA072208","Supported",NA,"Approved","Nucleus<br>Vesicles",NA,"Tissue enhanced","Tissue enriched",8,"cervix, uterine: 4.2","testis: 0.5","Cell line enhanced",NA,"BJ: 170.4;BJ hTERT+ SV40 Large T+ RasG12V: 45.2;HBF TERT88: 41.4"
"KRTAP11-1","KAP11.1","ENSG00000182591","Keratin associated protein 11-1","21","30880644-30881555","Predicted intracellular proteins","Evidence at protein level","HPA054008","Supported",NA,NA,NA,NA,"Group enriched","Not detected",NA,NA,"skin: 0.1","Not detected",NA,NA
"LZTS3","KIAA0552, ProSAPiP1","ENSG00000088899","Leucine zipper tumor suppressor family member 3","20","3162617-3173592","Predicted intracellular proteins","Evidence at protein level","HPA031008, HPA031009","Approved",NA,"Approved","Vesicles","Renal cancer:5.92e-8 (favourable), Endometrial cancer:7.26e-4 (unfavourable), Lung cancer:7.98e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 58.6","parathyroid gland: 20.3","Cell line enhanced",NA,"SCLC-21H: 21.3"
"MAPK11","p38-2, p38Beta, PRKM11, SAPK2","ENSG00000185386","Mitogen-activated protein kinase 11","22","50263713-50270767","Enzymes, FDA approved drug targets, Predicted intracellular proteins","Evidence at protein level","CAB012961, HPA045069","Approved",NA,"Approved","Mitochondria","Renal cancer:6.02e-6 (unfavourable)","Expressed in all","Mixed",NA,NA,"cerebral cortex: 27.7","Mixed",NA,NA
"MCM9","C6orf61, dJ329L24.3, FLJ20170, MCMDC1, MGC35304","ENSG00000111877","Minichromosome maintenance 9 homologous recombination repair factor","6","118813442-118935162","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA031137","Approved",NA,"Approved","Nucleoplasm",NA,"Expressed in all","Mixed",NA,NA,"epididymis: 15.5","Expressed in all",NA,NA
"NBR1","1A1-3B, CA125, KIAA0049, M17S2","ENSG00000188554","NBR1, autophagy cargo receptor","17","43170481-43211689","Predicted intracellular proteins","Evidence at protein level","HPA022944, HPA022999, HPA023999","Approved",NA,"Supported","Nucleoplasm<br>Nuclear bodies<br>Vesicles","Renal cancer:2.00e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 259.6","Expressed in all",NA,NA
"NFS1","IscS, NifS","ENSG00000244005","NFS1, cysteine desulfurase","20","35668055-35699359","Enzymes, Predicted intracellular proteins","Evidence at protein level","CAB034314, HPA051801, HPA054755","Enhanced",NA,"Supported","Nucleoplasm<br>Cytosol","Renal cancer:4.72e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"kidney: 43.7","Expressed in all",NA,NA
"NPAS2","bHLHe9, MOP4, PASD4","ENSG00000170485","Neuronal PAS domain protein 2","2","100820152-100996829","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA019674","Uncertain","Supported","Approved","Nucleoplasm","Renal cancer:3.55e-7 (unfavourable), Liver cancer:2.07e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"esophagus: 27.5","Cell line enhanced",NA,"PC-3: 102.3"
"NUP43","bA350J20.1, FLJ13287","ENSG00000120253","Nucleoporin 43","6","149724315-149749665","Predicted intracellular proteins, Transporters","Evidence at protein level","HPA027126, HPA027291, HPA028500","Enhanced",NA,NA,NA,"Liver cancer:7.13e-7 (unfavourable), Breast cancer:2.08e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 18.6","Expressed in all",NA,NA
"OTUD6B","CGI-77, DUBA5","ENSG00000155100","OTU domain containing 6B","8","91070196-91087095","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA024046, HPA024503, HPA024772","Enhanced","Approved","Approved","Nucleoplasm<br>Golgi apparatus<br>Cytosol","Breast cancer:7.50e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"cerebral cortex: 17.2","Expressed in all",NA,NA
"OXR1","TLDC3","ENSG00000164830","Oxidation resistance 1","8","106359476-106752694","Predicted intracellular proteins","Evidence at protein level","HPA027375, HPA027380, HPA027395","Enhanced",NA,"Supported","Vesicles","Renal cancer:5.82e-5 (favourable), Pancreatic cancer:3.85e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 110.7","Expressed in all",NA,NA
"PCDHA1",NA,"ENSG00000204970","Protocadherin alpha 1","5","140786136-141012347","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA035969","Enhanced",NA,"Approved","Plasma membrane",NA,"Not detected","Tissue enhanced",NA,"cerebral cortex: 2.8;testis: 1.4","adrenal gland: 0.4","Cell line enriched",6,"T-47d: 8.6"
"PDCD11","ALG-4, KIAA0185, RRP5","ENSG00000148843","Programmed cell death 11","10","103396648-103446292","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA017924, CAB026472","Approved",NA,"Supported","Nucleoli<br>Vesicles","Liver cancer:2.79e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 27.9","Expressed in all",NA,NA
"PGC",NA,"ENSG00000096088","Progastricsin","6","41736711-41754109","Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA031717, HPA031718","Enhanced",NA,"Supported","Nucleus",NA,"Tissue enhanced","Tissue enriched",17,"stomach: 22276.5","duodenum: 1302.2","Cell line enriched",11,"Hep G2: 171.0"
"PGR","NR3C3, PR","ENSG00000082175","Progesterone receptor","11","101029624-101130524","Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors","Evidence at protein level","CAB000068, HPA004751, HPA008428, HPA017176, CAB055100","Enhanced",NA,NA,NA,"Endometrial cancer:5.76e-8 (favourable)","Group enriched","Group enriched",6,"cervix, uterine: 96.2;endometrium: 172.3;fallopian tube: 53.3;smooth muscle: 114.9","ovary: 19.5","Cell line enriched",349,"T-47d: 157.7"
"PKN3","PKNbeta, UTDP4-1","ENSG00000160447","Protein kinase N3","9","128702523-128720918","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA045390, HPA058305","Uncertain",NA,"Approved","Vesicles",NA,"Expressed in all","Mixed",NA,NA,"adipose tissue: 7.6","Cell line enhanced",NA,"HeLa: 45.8"
"PLD3","HU-K4","ENSG00000105223","Phospholipase D family member 3","19","40348456-40380439","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA012800, CAB020812","Approved",NA,NA,NA,"Renal cancer:2.21e-4 (favourable), Pancreatic cancer:6.44e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 494.9","Expressed in all",NA,NA
"POLR2C","RPB3","ENSG00000102978","RNA polymerase II subunit C","16","57462387-57472010","Predicted intracellular proteins, RNA polymerase related proteins","Evidence at protein level","HPA040919, HPA041826","Enhanced",NA,"Supported","Nucleoplasm<br>Microtubules<br>Cytosol","Renal cancer:3.03e-6 (favourable), Head and neck cancer:1.48e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"epididymis: 68.2","Expressed in all",NA,NA
"PON2",NA,"ENSG00000105854","Paraoxonase 2","7","95404863-95435329","Candidate cardiovascular disease genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB025430, HPA029193","Enhanced",NA,NA,NA,"Renal cancer:4.30e-8 (unfavourable), Cervical cancer:1.43e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 226.2","Mixed",NA,NA
"POU3F4","BRN4, DFN3, DFNX2, OTF9","ENSG00000196767","POU class 3 homeobox 4","X","83508250-83512127","Disease related genes, Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA031984, HPA062295","Uncertain",NA,"Supported","Nucleus",NA,"Tissue enriched","Tissue enriched",11,"cerebral cortex: 7.9","kidney: 0.7","Cell line enriched",96,"AF22: 9.6"
"PPHLN1",NA,"ENSG00000134283","Periphilin 1","12","42238447-42459715","Predicted intracellular proteins","Evidence at protein level","HPA038902, HPA038903","Enhanced",NA,"Enhanced","Nucleoplasm<br>Golgi apparatus","Liver cancer:1.28e-7 (unfavourable), Renal cancer:5.06e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 102.1","Expressed in all",NA,NA
"PPP1R14A","CPI-17, PPP1INL","ENSG00000167641","Protein phosphatase 1 regulatory inhibitor subunit 14A","19","38251237-38256591","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB005044, CAB009803, HPA042097, HPA054534","Enhanced",NA,"Supported","Nucleoplasm<br>Nuclear bodies","Renal cancer:1.25e-5 (unfavourable), Stomach cancer:7.12e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"seminal vesicle: 110.8","Cell line enhanced",NA,"A549: 89.9;EFO-21: 78.3;K-562: 38.3"
"PRSS12","BSSP-3, MRT1","ENSG00000164099","Protease, serine 12","4","118280038-118353003","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins","Evidence at protein level","HPA035054, HPA035055","Uncertain",NA,"Approved","Nucleus<br>Actin filaments","Head and neck cancer:1.03e-4 (favourable), Glioma:1.53e-4 (favourable)","Mixed","Mixed",NA,NA,"cervix, uterine: 22.4","Cell line enhanced",NA,"SH-SY5Y: 228.5;THP-1: 67.4"
"PSMA5","ZETA","ENSG00000143106","Proteasome subunit alpha 5","1","109399031-109426427","Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA028392, HPA028398, HPA028441","Approved",NA,"Approved","Cytosol","Colorectal cancer:1.45e-5 (favourable), Liver cancer:2.28e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"cerebral cortex: 14.9","Cell line enhanced",NA,"MOLT-4: 36.7"
"RPS6KA2","HU-2, RSK, RSK3","ENSG00000071242","Ribosomal protein S6 kinase A2","6","166409364-166906451","Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB026243, HPA045061, HPA054237, CAB069428","Approved",NA,"Supported","Nucleoplasm","Renal cancer:2.86e-5 (favourable), Ovarian cancer:8.63e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 74.4","Cell line enhanced",NA,"ASC diff: 147.2;HHSteC: 133.3;hTERT-HME1: 133.1"
"RTCA","RPC, RTC1, RTCD1","ENSG00000137996","RNA 3'-terminal phosphate cyclase","1","100266207-100292769","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA027982, HPA027990, HPA028151","Uncertain",NA,"Enhanced","Nucleus","Liver cancer:2.76e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"kidney: 35.8","Expressed in all",NA,NA
"SMAD3","HsT17436, JV15-2, MADH3","ENSG00000166949","SMAD family member 3","15","67063763-67195195","Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors","Evidence at protein level","CAB008094, HPA046386, HPA067203, CAB069409","Approved",NA,"Enhanced","Nucleoplasm<br>Cytosol","Pancreatic cancer:2.48e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"esophagus: 54.2","Expressed in all",NA,NA
"SOAT1","ACAT, SOAT, STAT","ENSG00000057252","Sterol O-acyltransferase 1","1","179293714-179358680","Enzymes, FDA approved drug targets, Predicted membrane proteins","Evidence at protein level","CAB009533, HPA047171","Enhanced",NA,"Enhanced","Endoplasmic reticulum",NA,"Expressed in all","Tissue enhanced",NA,"adrenal gland: 218.2","prostate: 45.1","Expressed in all",NA,NA
"STAP2","BKS, STAP-2","ENSG00000178078","Signal transducing adaptor family member 2","19","4324043-4342786","Predicted intracellular proteins","Evidence at protein level","HPA002375, HPA027761","Approved",NA,NA,NA,"Endometrial cancer:3.03e-5 (favourable), Cervical cancer:2.76e-4 (favourable), Urothelial cancer:4.13e-4 (favourable)","Expressed in all","Mixed",NA,NA,"small intestine: 79.8","Cell line enhanced",NA,"A-431: 75.0;MCF7: 77.8;RT4: 107.6"
"STK24","MST-3, MST3, MST3B, STE20, STK3","ENSG00000102572","Serine/threonine kinase 24","13","98445185-98577940","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA026435, HPA026502","Enhanced",NA,"Supported","Nucleoli<br>Cytosol","Lung cancer:6.23e-6 (unfavourable), Renal cancer:6.91e-5 (favourable), Pancreatic cancer:5.81e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"esophagus: 169.5","Expressed in all",NA,NA
"STX2","EPIM, EPM, STX2A, STX2B, STX2C","ENSG00000111450","Syntaxin 2","12","130789600-130839266","Cancer-related genes, Predicted membrane proteins","Evidence at protein level","HPA038189, HPA069176, CAB079007","Uncertain","Supported","Approved","Nucleus<br>Cytosol","Renal cancer:5.15e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 35.2","Expressed in all",NA,NA
"SYNRG","AP1GBP1, MGC104959, SYNG","ENSG00000275066","Synergin gamma","17","37514797-37609496","Predicted intracellular proteins","Evidence at protein level","HPA023554, HPA023555","Approved",NA,"Approved","Cytosol","Urothelial cancer:3.96e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 20.4","Expressed in all",NA,NA
"TKT",NA,"ENSG00000163931","Transketolase","3","53224707-53256052","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA029480, HPA029481","Enhanced",NA,"Enhanced","Nucleoplasm","Liver cancer:7.21e-6 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"bone marrow: 431.3","Expressed in all",NA,NA
"TRIM2","CMT2R, KIAA0517, RNF86","ENSG00000109654","Tripartite motif containing 2","4","153152342-153339320","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA035853, HPA035854","Enhanced",NA,"Approved","Centrosome","Renal cancer:6.58e-14 (favourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 155.1","thyroid gland: 110.7","Cell line enhanced",NA,"AF22: 68.3"
"TSHZ2","C20orf17, OVC10-2, TSH2, ZABC2, ZNF218","ENSG00000182463","Teashirt zinc finger homeobox 2","20","52972407-53495330","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA038123","Uncertain",NA,"Approved","Nucleoplasm<br>Golgi apparatus",NA,"Mixed","Mixed",NA,NA,"ovary: 21.7","Cell line enhanced",NA,"AN3-CA: 24.7;HeLa: 15.8;SiHa: 16.3;U-2197: 12.7"
"UBTF","NOR-90, UBF, UBF1, UBF2","ENSG00000108312","Upstream binding transcription factor, RNA polymerase I","17","44205033-44221626","Plasma proteins, Predicted intracellular proteins, Transcription factors","Evidence at protein level","CAB004611, HPA006385","Enhanced","Supported","Enhanced","Nucleoli fibrillar center",NA,"Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 81.5","Expressed in all",NA,NA
"UBXN10","FLJ25429, UBXD3","ENSG00000162543","UBX domain protein 10","1","20186085-20196048","Predicted intracellular proteins","Evidence at protein level","HPA028555, HPA028564","Uncertain",NA,"Uncertain","Nucleoplasm<br>Plasma membrane<br>Cell Junctions","Glioma:1.64e-4 (unfavourable), Endometrial cancer:2.02e-4 (favourable)","Mixed","Tissue enhanced",NA,"fallopian tube: 79.1","testis: 25.5","Group enriched",6,"HEL: 2.5;HMC-1: 6.3;K-562: 7.6;SCLC-21H: 6.6"
"VPS50","CCDC132, DKFZp313I2429, FLJ20097, KIAA1861, VPS54L","ENSG00000004766","VPS50, EARP/GARPII complex subunit","7","93232340-93361121","Predicted intracellular proteins","Evidence at protein level","HPA026679","Approved",NA,"Uncertain","Plasma membrane<br>Cytosol","Renal cancer:1.35e-6 (favourable), Liver cancer:7.21e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 25.4","Expressed in all",NA,NA
"ZNF653","Zip67","ENSG00000161914","Zinc finger protein 653","19","11483427-11505923","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA023631, HPA023635","Uncertain",NA,"Supported","Nucleus","Endometrial cancer:4.15e-4 (favourable), Colorectal cancer:8.37e-4 (unfavourable), Urothelial cancer:8.74e-4 (favourable)","Expressed in all","Mixed",NA,NA,"testis: 19.0","Expressed in all",NA,NA
"APOL6","APOL-VI, APOLVI","ENSG00000221963","Apolipoprotein L6","22","35648395-35668409","Predicted membrane proteins","Evidence at protein level","CAB028574, HPA029165, HPA029167","Approved",NA,"Supported","Nucleoplasm<br>Nuclear bodies<br>Cytosol","Urothelial cancer:6.61e-4 (favourable)","Expressed in all","Mixed",NA,NA,"adipose tissue: 25.4","Mixed",NA,NA
"CYP11A1","CYP11A, P450SCC","ENSG00000140459","Cytochrome P450 family 11 subfamily A member 1","15","74337759-74367740","Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins","Evidence at protein level","HPA016436","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enriched",11,"adrenal gland: 748.5","testis: 68.5","Group enriched",25,"BEWO: 102.7;HEL: 79.0;SiHa: 23.2"
"CYP17A1","CPT7, CYP17, P450C17, S17AH","ENSG00000148795","Cytochrome P450 family 17 subfamily A member 1","10","102830531-102837533","Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA048533","Enhanced",NA,NA,NA,"Renal cancer:5.43e-7 (favourable)","Tissue enriched","Tissue enriched",25,"adrenal gland: 3751.4","testis: 152.4","Cell line enhanced",NA,"HMC-1: 2.6;SCLC-21H: 1.3"
"DECR1","DECR, SDR18C1","ENSG00000104325","2,4-dienoyl-CoA reductase 1","8","90001405-90052092","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA023160, HPA023162, HPA023238","Enhanced",NA,"Supported","Mitochondria<br>Cytosol","Renal cancer:1.79e-7 (favourable), Breast cancer:1.49e-4 (unfavourable), Urothelial cancer:6.06e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"liver: 262.9","Expressed in all",NA,NA
"GMFB","GMF","ENSG00000197045","Glia maturation factor beta","14","54474484-54489196","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA002954","Approved","Approved","Approved","Nucleoplasm<br>Nuclear bodies<br>Cytosol","Renal cancer:9.48e-5 (favourable), Liver cancer:2.21e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 108.7","Expressed in all",NA,NA
"GMFG",NA,"ENSG00000130755","Glia maturation factor gamma","19","39328353-39342372","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA002954","Uncertain","Approved","Approved","Nucleoplasm<br>Nuclear bodies<br>Cytosol","Renal cancer:9.11e-6 (unfavourable), Cervical cancer:7.35e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"spleen: 308.1","Cell line enhanced",NA,"HMC-1: 476.8;Karpas-707: 305.6;REH: 329.6;THP-1: 378.5;U-937: 301.7"
"MS4A1","B1, Bp35, CD20, MS4A2","ENSG00000156738","Membrane spanning 4-domains A1","11","60455752-60470760","CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters","Evidence at protein level","CAB000015, HPA014341, HPA014391","Enhanced",NA,"Supported","Plasma membrane","Breast cancer:4.34e-5 (favourable)","Mixed","Group enriched",15,"appendix: 240.0;lymph node: 770.3;spleen: 468.8;tonsil: 789.8","urinary bladder: 38.3","Group enriched",19,"Daudi: 534.8;U-698: 258.0"
"AAMDC","C11orf67, CK067, FLJ21035, PTD015","ENSG00000087884","Adipogenesis associated Mth938 domain containing","11","77821109-77918432","Predicted intracellular proteins","Evidence at protein level","HPA037918, HPA037919","Enhanced",NA,"Approved","Nucleoplasm<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"skeletal muscle: 231.6","Expressed in all",NA,NA
"AAR2","bA234K24.2, C20orf4","ENSG00000131043","AAR2 splicing factor homolog","20","36236459-36270918","Predicted intracellular proteins","Evidence at protein level","CAB034220, HPA048645","Uncertain",NA,"Approved","Cytosol","Liver cancer:1.83e-6 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"smooth muscle: 41.9","Expressed in all",NA,NA
"AATF","BFR2, CHE-1, CHE1, DED","ENSG00000275700","Apoptosis antagonizing transcription factor","17","36948875-37056871","Predicted intracellular proteins","Evidence at protein level","HPA004940","Uncertain",NA,NA,NA,"Renal cancer:4.14e-5 (unfavourable), Liver cancer:6.62e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"lymph node: 19.9","Expressed in all",NA,NA
"ABAT","GABAT","ENSG00000183044","4-aminobutyrate aminotransferase","16","8674565-8784575","Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA041528, HPA041690","Enhanced","Supported","Supported","Mitochondria","Renal cancer:5.44e-8 (favourable), Liver cancer:5.36e-5 (favourable), Lung cancer:5.93e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 164.5;kidney: 135.3;liver: 175.2","thyroid gland: 47.5","Cell line enhanced",NA,"Hep G2: 83.0;MCF7: 60.0;RH-30: 64.1;T-47d: 39.1"
"ABCC8","ABC36, HHF1, HI, HRINS, MRP8, PHHI, SUR, SUR1, TNDM2","ENSG00000006071","ATP binding cassette subfamily C member 8","11","17392885-17476845","Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters","Evidence at protein level","CAB011451, HPA042318","Approved",NA,"Approved","Nucleoli<br>Golgi apparatus<br>Cytosol",NA,"Tissue enriched","Tissue enhanced",NA,"cerebral cortex: 11.3","adrenal gland: 7.5","Cell line enhanced",NA,"A549: 1.7;AN3-CA: 1.8;SCLC-21H: 9.0"
"ABHD10","FLJ11342","ENSG00000144827","Abhydrolase domain containing 10","3","111979010-111993363","Enzymes, Predicted secreted proteins","Evidence at protein level","HPA036991, HPA036992, HPA066081","Supported",NA,"Approved","Mitochondria","Renal cancer:4.72e-9 (favourable), Cervical cancer:7.57e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"epididymis: 62.1","Expressed in all",NA,NA
"ABHD17A","C19orf27, FAM108A1, MGC5244","ENSG00000129968","Abhydrolase domain containing 17A","19","1876810-1885547","Predicted intracellular proteins","Evidence at protein level","HPA043270, HPA047226","Uncertain",NA,"Approved","Vesicles","Pancreatic cancer:1.76e-5 (favourable), Endometrial cancer:1.73e-4 (favourable), Head and neck cancer:6.46e-4 (favourable)","Expressed in all","Mixed",NA,NA,"cerebral cortex: 31.4","Mixed",NA,NA
"ABHD6",NA,"ENSG00000163686","Abhydrolase domain containing 6","3","58237506-58295693","Enzymes, Predicted membrane proteins","Evidence at protein level","HPA017283, HPA073225","Uncertain",NA,"Approved","Nucleoplasm<br>Vesicles","Renal cancer:1.11e-11 (favourable), Colorectal cancer:1.13e-4 (favourable)","Expressed in all","Mixed",NA,NA,"small intestine: 50.9","Mixed",NA,NA
"ABI1","ABI-1, E3B1, SSH3BP1","ENSG00000136754","Abl interactor 1","10","26746593-26861087","Cancer-related genes, Disease related genes, Predicted intracellular proteins","Evidence at protein level","CAB008375, HPA029973, HPA068407","Approved",NA,"Supported","Plasma membrane<br>Cell Junctions",NA,"Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 87.4","Expressed in all",NA,NA
"ABI2","ABI-2, ABI2B, AblBP3, AIP-1, argBPIA, SSH3BP2","ENSG00000138443","Abl interactor 2","2","203328219-203447723","Predicted intracellular proteins","Evidence at protein level","HPA062433, HPA070567","Enhanced",NA,"Approved","Nucleoplasm",NA,"Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 98.8","Mixed",NA,NA
"ABL2","ABLL, ARG","ENSG00000143322","ABL proto-oncogene 2, non-receptor tyrosine kinase","1","179099327-179229684","Cancer-related genes, Enzymes, Predicted intracellular proteins, RAS pathway related proteins","Evidence at protein level","HPA001866, CAB017106, HPA072754","Uncertain",NA,"Supported","Nucleoplasm","Renal cancer:1.78e-7 (unfavourable), Cervical cancer:3.50e-4 (unfavourable), Urothelial cancer:8.40e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"gallbladder: 20.3","Expressed in all",NA,NA
"ABLIM3","KIAA0843","ENSG00000173210","Actin binding LIM protein family member 3","5","149141483-149260542","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA003245","Approved",NA,"Approved","Nucleoplasm<br>Plasma membrane<br>Cell Junctions","Renal cancer:1.28e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"parathyroid gland: 79.4","adipose tissue: 63.7","Cell line enhanced",NA,"TIME: 84.5"
"ABR","MDB","ENSG00000159842","Active BCR-related","17","1003518-1229021","Predicted intracellular proteins","Evidence at protein level","HPA053618, HPA054824","Enhanced",NA,"Approved","Nucleoplasm<br>Cytosol","Renal cancer:2.21e-4 (favourable), Cervical cancer:4.03e-4 (favourable)","Expressed in all","Mixed",NA,NA,"smooth muscle: 12.6","Cell line enhanced",NA,"Daudi: 26.9;LHCN-M2: 20.5;TIME: 33.6;U-251 MG: 34.7;U-698: 21.1"
"ABTB2","ABTB2A, BTBD22, DKFZP586C1619","ENSG00000166016","Ankyrin repeat and BTB domain containing 2","11","34150988-34358008","Predicted intracellular proteins","Evidence at protein level","HPA020065, HPA030699","Approved",NA,"Supported","Nucleus","Renal cancer:3.51e-5 (favourable), Cervical cancer:5.70e-5 (unfavourable)","Expressed in all","Mixed",NA,NA,"adrenal gland: 13.0","Mixed",NA,NA
"AC138969.4",NA,"ENSG00000183889",NA,"16","16317444-16350590","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA053611","Approved",NA,"Approved","Nucleoplasm",NA,"Not detected","Expressed in all",NA,NA,"skin: 116.2","Expressed in all",NA,NA
"AC171558.1",NA,"ENSG00000274792",NA,"Unmapped","386278-387620","Predicted membrane proteins","Evidence at transcript level","HPA057442","Uncertain",NA,"Uncertain","Centrosome",NA,NA,"Tissue enriched",11,"testis: 4.3","cerebral cortex: 0.4","Cell line enriched",29,"U-2 OS: 3.3"
"ACAA1",NA,"ENSG00000060971","Acetyl-CoA acyltransferase 1","3","38103129-38137242","Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA006764, HPA007244","Enhanced",NA,"Enhanced","Peroxisomes","Renal cancer:6.99e-9 (favourable), Head and neck cancer:1.23e-4 (favourable), Breast cancer:3.00e-4 (favourable), Endometrial cancer:7.53e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"liver: 328.4","Expressed in all",NA,NA
"ACACB","ACC2, ACCB, HACC275","ENSG00000076555","Acetyl-CoA carboxylase beta","12","109116595-109268226","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA006554","Enhanced",NA,NA,NA,"Renal cancer:1.15e-5 (favourable), Pancreatic cancer:1.93e-4 (favourable)","Expressed in all","Tissue enriched",6,"adipose tissue: 194.8","parathyroid gland: 30.6","Cell line enriched",13,"ASC diff: 152.8"
"ACAD8",NA,"ENSG00000151498","Acyl-CoA dehydrogenase family member 8","11","134253495-134265855","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA040689, HPA043903","Enhanced",NA,NA,NA,"Renal cancer:6.42e-10 (favourable), Lung cancer:2.38e-4 (favourable), Head and neck cancer:6.19e-4 (favourable), Colorectal cancer:7.62e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 43.2","Expressed in all",NA,NA
"ACADL","ACAD4, LCAD","ENSG00000115361","Acyl-CoA dehydrogenase, long chain","2","210187939-210225491","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA011990","Enhanced","Supported",NA,NA,"Renal cancer:1.58e-11 (favourable)","Group enriched","Tissue enhanced",NA,"thyroid gland: 32.0","prostate: 27.0","Cell line enhanced",NA,"HAP1: 1.6;HeLa: 2.5;RPTEC TERT1: 2.5;U-2 OS: 1.9"
"ACAN","AGC1, CSPG1, CSPGCP, MSK16","ENSG00000157766","Aggrecan","15","88803443-88875354","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB016377, HPA038241, HPA038242","Enhanced",NA,NA,NA,"Renal cancer:1.47e-6 (unfavourable)","Mixed","Tissue enhanced",NA,"seminal vesicle: 5.0","testis: 3.3","Cell line enriched",5,"WM-115: 28.1"
"ACAT1","ACAT, THIL","ENSG00000075239","Acetyl-CoA acetyltransferase 1","11","108121516-108147776","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA004428, HPA007569","Enhanced",NA,"Enhanced","Mitochondria","Renal cancer:0.00e+0 (favourable), Liver cancer:1.43e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"kidney: 534.2","Expressed in all",NA,NA
"ACAT2",NA,"ENSG00000120437","Acetyl-CoA acetyltransferase 2","6","159760328-159779055","Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB021106, HPA025736, HPA025765, HPA025811","Enhanced",NA,"Supported","Nucleus<br>Cytosol","Colorectal cancer:1.12e-4 (favourable), Endometrial cancer:7.25e-4 (unfavourable), Renal cancer:7.38e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"liver: 45.8","Expressed in all",NA,NA
"ACE","ACE1, CD143, DCP1","ENSG00000159640","Angiotensin I converting enzyme","17","63477061-63498380","Candidate cardiovascular disease genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB002426, CAB002921, HPA029298, HPA069790","Enhanced",NA,"Approved","Vesicles",NA,"Expressed in all","Tissue enhanced",NA,"duodenum: 178.9;small intestine: 291.6","testis: 83.7","Cell line enhanced",NA,"ASC TERT1: 44.4;HUVEC TERT2: 28.2"
"ACOT6","C14orf42","ENSG00000205669","Acyl-CoA thioesterase 6","14","73610945-73619888","Predicted intracellular proteins","Evidence at protein level","HPA058258","Uncertain",NA,NA,NA,NA,"Not detected","Tissue enhanced",NA,"kidney: 3.8","adipose tissue: 1.7","Cell line enriched",7,"T-47d: 9.6"
"ACP5","HPAP, TRAP","ENSG00000102575","Acid phosphatase 5, tartrate resistant","19","11574660-11579008","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB002584, HPA057655, HPA059463","Enhanced",NA,"Approved","Cytosol",NA,"Expressed in all","Tissue enhanced",NA,"lung: 254.0","lymph node: 86.3","Cell line enhanced",NA,"BEWO: 36.2;SK-MEL-30: 85.3;U-138 MG: 97.5"
"ACP7","FLJ16165, PAPL, PAPL1","ENSG00000183760","Acid phosphatase 7, tartrate resistant (putative)","19","39083913-39111493","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA042005, HPA042613","Uncertain",NA,NA,NA,NA,"Group enriched","Group enriched",6,"cerebral cortex: 1.8;skin: 6.9;tonsil: 2.3","epididymis,prostate: 0.5","Cell line enhanced",NA,"hTEC/SVTERT24-B: 9.3;U-87 MG: 43.5"
"ACRV1","D11S4365, SP-10, SPACA2","ENSG00000134940","Acrosomal vesicle protein 1","11","125671522-125681123","Predicted secreted proteins","Evidence at protein level","HPA038718, HPA038719","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enriched",40,"testis: 153.6","epididymis: 3.8","Mixed",NA,NA
"ACSBG1","BG1, BGM, FLJ30320, hBG1, hsBG, KIAA0631, MGC14352","ENSG00000103740","Acyl-CoA synthetase bubblegum family member 1","15","78167468-78245688","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA041642, CAB045955, HPA058869","Approved",NA,"Approved","Vesicles",NA,"Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 25.6;skin: 13.3","adrenal gland: 8.1","Cell line enhanced",NA,"NTERA-2: 3.3"
"ACTL7B","Tact1","ENSG00000148156","Actin like 7B","9","108854589-108856967","Predicted intracellular proteins","Evidence at protein level","HPA021803, HPA024664","Enhanced",NA,NA,NA,NA,"Not detected","Tissue enriched",589,"testis: 58.9","all non-specific tissues: 0.0","Not detected",NA,NA
"ACTR3","ARP3","ENSG00000115091","ARP3 actin related protein 3 homolog","2","113889960-113962596","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB005085, HPA047016, HPA051683","Approved",NA,NA,NA,"Renal cancer:3.81e-5 (unfavourable), Cervical cancer:6.52e-5 (unfavourable), Liver cancer:7.76e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"lymph node: 335.6","Expressed in all",NA,NA
"ACTR3B","ARP11, ARP3beta","ENSG00000133627","ARP3 actin related protein 3 homolog B","7","152759749-152855378","Predicted intracellular proteins","Evidence at protein level","HPA047016, HPA051683","Uncertain",NA,NA,NA,"Renal cancer:1.66e-4 (favourable), Stomach cancer:4.53e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 50.9","Mixed",NA,NA
"ACTRT3","ARPM1","ENSG00000184378","Actin related protein T3","3","169766921-169769895","Predicted intracellular proteins","Evidence at protein level","HPA035817, HPA035818","Approved",NA,"Approved","Nucleoplasm","Endometrial cancer:4.11e-4 (unfavourable)","Mixed","Tissue enriched",22,"testis: 60.6","fallopian tube: 2.7","Cell line enhanced",NA,"ASC diff: 10.2"
"ACVRL1","ACVRLK1, ALK1, HHT, HHT2, ORW2","ENSG00000139567","Activin A receptor like type 1","12","51906908-51923361","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA007041","Approved",NA,NA,NA,NA,"Expressed in all","Tissue enhanced",NA,"placenta: 126.4","lung: 76.4","Cell line enhanced",NA,"ASC diff: 42.2;EFO-21: 52.0;HUVEC TERT2: 171.4;TIME: 130.8"
"ACY3","ACY-3, HCBP1, MGC9740","ENSG00000132744","Aminoacylase 3","11","67642555-67650659","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA039219, HPA048187","Enhanced",NA,NA,NA,"Endometrial cancer:4.80e-4 (favourable)","Mixed","Tissue enhanced",NA,"duodenum: 80.6;kidney: 53.3;small intestine: 78.6","cervix, uterine: 16.1","Cell line enhanced",NA,"CACO-2: 8.4;CAPAN-2: 13.6;Daudi: 41.2"
"ADAM11","MDC","ENSG00000073670","ADAM metallopeptidase domain 11","17","44759031-44781846","Predicted membrane proteins, Transporters","Evidence at protein level","HPA074550","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 19.8","heart muscle: 4.0","Cell line enhanced",NA,"HEK 293: 18.5"
"ADAM23","MDC3","ENSG00000114948","ADAM metallopeptidase domain 23","2","206443539-206621130","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA012130, CAB033276","Uncertain",NA,NA,NA,NA,"Mixed","Group enriched",6,"cerebral cortex: 55.4;parathyroid gland: 135.3","heart muscle: 16.5","Cell line enhanced",NA,"RH-30: 61.7;RPMI-8226: 120.2"
"ADAMTS18","ADAMTS21","ENSG00000140873","ADAM metallopeptidase with thrombospondin type 1 motif 18","16","77247813-77435114","Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA044326","Uncertain",NA,NA,NA,NA,"Mixed","Tissue enriched",16,"placenta: 29.1","cervix, uterine: 1.8","Group enriched",7,"HUVEC TERT2: 6.7;TIME: 2.0;U-87 MG: 4.7"
"ADAMTS4","ADAMTS-2, ADMP-1, KIAA0688","ENSG00000158859","ADAM metallopeptidase with thrombospondin type 1 motif 4","1","161184308-161199056","Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","CAB025876, HPA051296, HPA068374","Uncertain",NA,"Approved","Nuclear speckles","Renal cancer:7.27e-7 (unfavourable), Lung cancer:5.00e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"adipose tissue: 62.8","appendix: 22.9","Cell line enhanced",NA,"hTEC/SVTERT24-B: 11.8;HUVEC TERT2: 12.0;SH-SY5Y: 8.4;TIME: 9.9;U-251 MG: 9.0"
"ADCK5","FLJ35454","ENSG00000173137","AarF domain containing kinase 5","8","144373101-144393242","Enzymes, Predicted membrane proteins","Evidence at protein level","HPA025692, HPA028679","Approved",NA,"Approved","Plasma membrane<br>Cytosol",NA,"Expressed in all","Mixed",NA,NA,"duodenum: 9.6","Mixed",NA,NA
"ADD1",NA,"ENSG00000087274","Adducin 1","4","2843857-2930076","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB009794, HPA035873, HPA035874","Enhanced",NA,"Enhanced","Nucleoplasm<br>Plasma membrane","Renal cancer:1.29e-7 (favourable), Pancreatic cancer:3.94e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 201.1","Expressed in all",NA,NA
"ADGRE5","CD97, TM7LN1","ENSG00000123146","Adhesion G protein-coupled receptor E5","19","14380501-14408725","CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA013707","Enhanced",NA,"Approved","Cytosol","Renal cancer:1.87e-6 (unfavourable), Liver cancer:3.73e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"spleen: 140.3","Mixed",NA,NA
"ADGRF2","GPR111, hGPCR35, PGR20","ENSG00000164393","Adhesion G protein-coupled receptor F2","6","47656436-47697797","G-protein coupled receptors, Predicted membrane proteins","Evidence at transcript level","HPA035507","Uncertain",NA,NA,NA,NA,"Not detected","Tissue enhanced",NA,"fallopian tube: 1.5;skin: 1.4","esophagus: 0.3","Not detected",NA,NA
"ADIG","MGC39724, RP5-1100H13.2, SMAF1","ENSG00000182035","Adipogenin","20","38581195-38588463","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at transcript level","HPA041124","Uncertain",NA,NA,NA,NA,"Tissue enhanced","Group enriched",10,"epididymis: 5.1;testis: 16.1;thyroid gland: 3.4","seminal vesicle: 0.8","Not detected",NA,NA
"ADO","C10orf22, FLJ14547","ENSG00000181915","2-aminoethanethiol dioxygenase","10","62804857-62808483","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA039194, HPA040437","Approved",NA,NA,NA,"Liver cancer:8.01e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 70.7","Expressed in all",NA,NA
"AFM","ALB2, ALBA","ENSG00000079557","Afamin","4","73481683-73504001","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA017006, HPA052437","Enhanced",NA,NA,NA,"Liver cancer:1.80e-4 (favourable)","Tissue enriched","Tissue enriched",6,"liver: 468.3","kidney: 80.9","Cell line enriched",6,"CACO-2: 1.3"
"AGAP2","CENTG1","ENSG00000135439","ArfGAP with GTPase domain, ankyrin repeat and PH domain 2","12","57723761-57742157","Predicted intracellular proteins","Evidence at protein level","HPA023474","Approved",NA,"Supported","Nucleus<br>Nucleoli<br>Mitochondria",NA,"Tissue enriched","Tissue enriched",7,"cerebral cortex: 144.5","lymph node: 19.8","Cell line enhanced",NA,"RH-30: 95.5"
"AGPAT1","LPAAT-alpha","ENSG00000204310","1-acylglycerol-3-phosphate O-acyltransferase 1","6","32168212-32178096","Enzymes, Predicted membrane proteins","Evidence at protein level","HPA048478, HPA073355","Approved",NA,"Supported","Endoplasmic reticulum<br>Rods & Rings","Breast cancer:1.93e-4 (unfavourable), Endometrial cancer:5.21e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"epididymis: 52.2","Mixed",NA,NA
"AGRN","AGRIN","ENSG00000188157","Agrin","1","1020123-1056118","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA040090","Approved",NA,"Supported","Plasma membrane<br>Cytosol","Liver cancer:4.62e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 33.2","Cell line enhanced",NA,"EFO-21: 223.9"
"AGTR1","AG2S, AGTR1A, AGTR1B, AT1, AT1B, AT2R1, AT2R1A, AT2R1B, HAT1R","ENSG00000144891","Angiotensin II receptor type 1","3","148697784-148743008","Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters","Evidence at protein level","HPA003596","Enhanced",NA,"Uncertain","Vesicles",NA,"Group enriched","Tissue enhanced",NA,"placenta: 214.0","liver: 50.9","Cell line enhanced",NA,"ASC diff: 127.9;BJ hTERT+ SV40 Large T+: 33.9;HBF TERT88: 54.9;HSkMC: 24.7"
"AGXT","AGT, AGT1, AGXT1, PH1, SPAT, SPT","ENSG00000172482","Alanine-glyoxylate aminotransferase","2","240868479-240880502","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA035370, HPA035371","Enhanced",NA,"Supported","Vesicles","Liver cancer:5.92e-5 (favourable)","Tissue enriched","Tissue enriched",58,"liver: 611.6","kidney: 10.4","Cell line enhanced",NA,"Hep G2: 5.6;SK-BR-3: 1.1"
"AHSP","EDRF, ERAF","ENSG00000169877","Alpha hemoglobin stabilizing protein","16","31527864-31528803","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA040940","Enhanced",NA,NA,NA,NA,"Not detected","Tissue enriched",26,"bone marrow: 881.3","placenta: 34.3","Cell line enhanced",NA,"hTCEpi: 2.0;K-562: 1.1"
"AIFM1","AIF, CMTX4, NAMSD, PDCD8","ENSG00000156709","Apoptosis inducing factor mitochondria associated 1","X","130129362-130165887","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","CAB003764, HPA030611","Enhanced",NA,NA,NA,"Renal cancer:4.42e-10 (favourable)","Expressed in all","Expressed in all",NA,NA,"kidney: 158.1","Expressed in all",NA,NA
"AIMP1","EMAP-2, EMAPII, p43, SCYE1","ENSG00000164022","Aminoacyl tRNA synthetase complex interacting multifunctional protein 1","4","106315544-106349226","Disease related genes, Predicted intracellular proteins","Evidence at protein level","CAB017618, HPA018476","Supported",NA,"Enhanced","Cytosol","Head and neck cancer:1.54e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 63.2","Expressed in all",NA,NA
"AKAP8L","HAP95, NAKAP95","ENSG00000011243","A-kinase anchoring protein 8 like","19","15380048-15419141","Predicted intracellular proteins","Evidence at protein level","HPA042485, HPA042546","Enhanced",NA,"Supported","Nuclear speckles","Renal cancer:1.08e-7 (unfavourable), Colorectal cancer:3.49e-4 (unfavourable), Pancreatic cancer:8.04e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 41.6","Expressed in all",NA,NA
"AKT3","PKBG, PRKBG, RAC-gamma","ENSG00000117020","AKT serine/threonine kinase 3","1","243488233-243851079","Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins","Evidence at protein level","CAB013090, HPA026441","Approved",NA,"Supported","Cytosol","Urothelial cancer:9.27e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"cerebral cortex: 51.6","Mixed",NA,NA
"ALDH1L1","10-fTHF, FTHFD","ENSG00000144908","Aldehyde dehydrogenase 1 family member L1","3","126103562-126197994","Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA036900, HPA050139","Enhanced","Supported","Supported","Cytosol","Renal cancer:2.42e-8 (favourable)","Tissue enhanced","Tissue enhanced",NA,"kidney: 121.2;liver: 190.4","adipose tissue: 80.9","Cell line enhanced",NA,"Hep G2: 54.9;Karpas-707: 57.9;RT4: 174.8"
"ALDH6A1","MMSDH","ENSG00000119711","Aldehyde dehydrogenase 6 family member A1","14","74056850-74084493","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA029072, HPA029073, HPA029074, HPA029075","Enhanced",NA,"Enhanced","Mitochondria","Renal cancer:2.00e-15 (favourable), Lung cancer:4.22e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"kidney: 389.6","Expressed in all",NA,NA
"ALDH8A1","ALDH12","ENSG00000118514","Aldehyde dehydrogenase 8 family member A1","6","134917390-134950122","Predicted intracellular proteins","Evidence at protein level","HPA026292, HPA055414","Enhanced",NA,"Supported","Centrosome","Renal cancer:9.87e-4 (favourable)","Group enriched","Group enriched",29,"kidney: 74.3;liver: 127.7","cerebral cortex: 3.4","Mixed",NA,NA
"ALK","CD246","ENSG00000171094","Anaplastic lymphoma receptor tyrosine kinase","2","29192774-29921566","Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA010694","Approved",NA,"Supported","Plasma membrane",NA,"Group enriched","Tissue enhanced",NA,"cerebral cortex: 2.7;testis: 2.0","adrenal gland: 0.5","Cell line enriched",6,"SH-SY5Y: 28.3"
"ALOX12","12S-LOX","ENSG00000108839","Arachidonate 12-lipoxygenase, 12S type","17","6996065-7010736","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA010691, CAB019287","Approved",NA,"Supported","Nuclear speckles<br>Cytosol",NA,"Mixed","Group enriched",8,"esophagus: 50.3;skin: 25.9","gallbladder: 5.0","Group enriched",5,"A-431: 22.4;HEL: 36.7"
"AMPH",NA,"ENSG00000078053","Amphiphysin","7","38383704-38631567","Cancer-related genes, Predicted intracellular proteins","Evidence at protein level","CAB008559, HPA019828, HPA019829","Enhanced",NA,"Supported","Plasma membrane<br>Cytosol","Pancreatic cancer:9.96e-4 (favourable)","Tissue enhanced","Tissue enriched",9,"cerebral cortex: 83.7","cervix, uterine: 8.9","Cell line enhanced",NA,"ASC diff: 44.1;ASC TERT1: 26.4;BJ hTERT+ SV40 Large T+ RasG12V: 29.1;U-138 MG: 24.3"
"ANAPC7","APC7","ENSG00000196510","Anaphase promoting complex subunit 7","12","110372900-110403730","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB009567","Approved",NA,"Approved","Nucleoplasm<br>Cytosol","Renal cancer:4.36e-10 (unfavourable), Liver cancer:1.54e-6 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 48.9","Expressed in all",NA,NA
"ANK2","LQT4","ENSG00000145362","Ankyrin 2","4","112818109-113383740","Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters","Evidence at protein level","HPA008007, CAB015178, HPA035970","Enhanced",NA,"Supported","Plasma membrane","Renal cancer:2.41e-6 (unfavourable)","Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 184.4","kidney: 125.1","Cell line enhanced",NA,"RH-30: 60.5;SH-SY5Y: 33.1"
"ANKFY1","ANKHZN, BTBD23, KIAA1255, RANK-5, ZFYVE14","ENSG00000185722","Ankyrin repeat and FYVE domain containing 1","17","4163907-4263977","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA024513, HPA024522, HPA065849","Approved",NA,"Enhanced","Endosomes",NA,"Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 37.8","Expressed in all",NA,NA
"ANKHD1","FLJ10042, FLJ11979, FLJ14127, FLJ20288, KIAA1085, MASK, MASK1","ENSG00000131503","Ankyrin repeat and KH domain containing 1","5","140401814-140539856","Predicted intracellular proteins","Evidence at protein level","HPA008718","Approved",NA,NA,NA,NA,"Mixed","Expressed in all",NA,NA,"parathyroid gland: 74.5","Expressed in all",NA,NA
"ANKHD1-EIF4EBP3","MASK-BP3","ENSG00000254996","ANKHD1-EIF4EBP3 readthrough","5","140401908-140549569","Predicted intracellular proteins","Evidence at transcript level","HPA008718","Approved",NA,NA,NA,NA,"Mixed","Expressed in all",NA,NA,"parathyroid gland: 40.5","Expressed in all",NA,NA
"ANKRD6","KIAA0957","ENSG00000135299","Ankyrin repeat domain 6","6","89433170-89633834","Predicted intracellular proteins","Evidence at protein level","CAB020693, HPA035694, HPA064642","Enhanced",NA,"Supported","Vesicles",NA,"Mixed","Mixed",NA,NA,"cerebral cortex: 23.7","Cell line enhanced",NA,"AF22: 15.3;BEWO: 45.7;HAP1: 14.8"
"ANKS6","ANKRD14, FLJ36928, NPHP16, SAMD6","ENSG00000165138","Ankyrin repeat and sterile alpha motif domain containing 6","9","98731329-98796965","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA008355","Approved",NA,"Approved","Nucleus<br>Nucleoli<br>Cytosol","Renal cancer:3.44e-5 (favourable)","Expressed in all","Mixed",NA,NA,"thyroid gland: 15.3","Mixed",NA,NA
"ANO10","FLJ10375, MGC47890, SCAR10, TMEM16K","ENSG00000160746","Anoctamin 10","3","43354859-43691594","Disease related genes, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA051569","Approved",NA,NA,NA,"Renal cancer:6.41e-6 (favourable), Endometrial cancer:1.11e-4 (favourable), Liver cancer:3.19e-4 (unfavourable), Colorectal cancer:6.70e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"duodenum: 62.5","Mixed",NA,NA
"ANO3","C11orf25, DYT23, GENX-3947, TMEM16C","ENSG00000134343","Anoctamin 3","11","26309599-26663288","Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters","Evidence at protein level","HPA041629","Uncertain",NA,NA,NA,NA,"Not detected","Tissue enriched",6,"epididymis: 62.2","cerebral cortex: 10.5","Cell line enhanced",NA,"HDLM-2: 5.9;U-2 OS: 1.7;U-2197: 4.2"
"ANO5","GDD1, LGMD2L, TMEM16E","ENSG00000171714","Anoctamin 5","11","22193176-22283357","Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters","Evidence at protein level","HPA058857","Uncertain",NA,NA,NA,"Renal cancer:2.50e-7 (favourable)","Mixed","Tissue enhanced",NA,"parathyroid gland: 56.1","skeletal muscle: 23.6","Cell line enhanced",NA,"A549: 4.5;HAP1: 5.6;HEK 293: 6.2"
"ANPEP","CD13, gp150, LAP1, p150, PEPN","ENSG00000166825","Alanyl aminopeptidase, membrane","15","89784889-89815401","CD markers, Enzymes, Plasma proteins, Predicted membrane proteins","Evidence at protein level","CAB002417, HPA004625","Enhanced",NA,"Supported","Plasma membrane",NA,"Expressed in all","Group enriched",9,"duodenum: 2386.4;small intestine: 2133.7","kidney: 263.2","Cell line enhanced",NA,"BJ hTERT+: 958.3;HUVEC TERT2: 770.8;TIME: 760.6;U-2197: 926.0"
"ANXA1","ANX1, LPC1","ENSG00000135046","Annexin A1","9","73151757-73170393","Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transporters","Evidence at protein level","HPA011271, HPA011272, CAB013023, CAB035987, CAB058693","Enhanced",NA,"Enhanced","Nucleoplasm<br>Plasma membrane<br>Cytosol","Urothelial cancer:6.19e-6 (unfavourable), Thyroid cancer:4.57e-5 (favourable), Endometrial cancer:5.71e-5 (favourable)","Expressed in all","Tissue enriched",6,"esophagus: 7548.8","tonsil: 1217.6","Mixed",NA,NA
"AOX1","AO, AOH1","ENSG00000138356","Aldehyde oxidase 1","2","200585868-200677064","Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA040199, HPA040215","Enhanced",NA,NA,NA,"Renal cancer:6.05e-5 (favourable)","Tissue enriched","Group enriched",5,"adrenal gland: 368.8;kidney: 97.5;liver: 432.3","ovary: 56.8","Cell line enhanced",NA,"ASC diff: 241.4;ASC TERT1: 125.7;hTERT-HME1: 56.6"
"AP1B1","ADTB1, AP105A, BAM22, CLAPB2","ENSG00000100280","Adaptor related protein complex 1 beta 1 subunit","22","29327680-29423179","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA065226, HPA068520","Approved",NA,"Supported","Golgi apparatus<br>Vesicles","Renal cancer:7.24e-6 (favourable), Liver cancer:5.55e-5 (unfavourable), Cervical cancer:4.81e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 104.2","Expressed in all",NA,NA
"AP1G1","ADTG, CLAPG1","ENSG00000166747","Adaptor related protein complex 1 gamma 1 subunit","16","71729000-71809201","Predicted intracellular proteins","Evidence at protein level","CAB009049, HPA041224","Approved",NA,"Enhanced","Vesicles<br>Cytosol","Renal cancer:2.96e-8 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 88.8","Expressed in all",NA,NA
"AP2A2","ADTAB, CLAPA2, DKFZP564D1864, HIP9, HYPJ, KIAA0899","ENSG00000183020","Adaptor related protein complex 2 alpha 2 subunit","11","924894-1012245","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB017514, HPA043040","Enhanced",NA,"Supported","Nucleoplasm<br>Vesicles","Liver cancer:9.27e-5 (unfavourable), Pancreatic cancer:4.57e-4 (favourable)","Expressed in all","Mixed",NA,NA,"spleen: 16.0","Mixed",NA,NA
"AP2B1","ADTB2, CLAPB1","ENSG00000006125","Adaptor related protein complex 2 beta 1 subunit","17","35578046-35726409","Cancer-related genes, Predicted intracellular proteins","Evidence at protein level","CAB017631, HPA056733, HPA067983","Approved",NA,"Supported","Vesicles","Renal cancer:2.62e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 265.4","Expressed in all",NA,NA
"APBB1","Fe65, RIR","ENSG00000166313","Amyloid beta precursor protein binding family B member 1","11","6395124-6419414","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB022104, HPA038521, HPA038522","Approved",NA,"Enhanced","Plasma membrane","Renal cancer:7.44e-13 (favourable), Pancreatic cancer:1.86e-5 (favourable), Liver cancer:2.44e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 236.5","Cell line enhanced",NA,"SCLC-21H: 81.4"
"APC","DP2, DP2.5, DP3, PPP1R46","ENSG00000134982","APC, WNT signaling pathway regulator","5","112707498-112846239","Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA013349","Supported",NA,NA,NA,NA,"Expressed in all","Tissue enhanced",NA,"cerebral cortex: 60.1","parathyroid gland: 19.9","Expressed in all",NA,NA
"APLNR","AGTRL1, APJ, APJR, FLJ90771","ENSG00000134817","Apelin receptor","11","57233577-57237314","G-protein coupled receptors, Predicted membrane proteins, Transporters","Evidence at protein level","CAB025842","Approved",NA,NA,NA,NA,"Expressed in all","Group enriched",5,"cerebral cortex: 82.7;placenta: 146.8;spleen: 161.6","adipose tissue: 24.9","Group enriched",22,"AF22: 6.2;HEL: 5.0;K-562: 1.5;NTERA-2: 1.8"
"APMAP","BSCv, C20orf3","ENSG00000101474","Adipocyte plasma membrane associated protein","20","24962925-24992979","Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA012863, HPA064700","Uncertain",NA,"Approved","Plasma membrane",NA,"Expressed in all","Expressed in all",NA,NA,"thyroid gland: 323.5","Expressed in all",NA,NA
"APOC1",NA,"ENSG00000130208","Apolipoprotein C1","19","44914247-44919349","Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA051518","Supported",NA,NA,NA,"Liver cancer:1.15e-7 (favourable)","Tissue enriched","Tissue enriched",7,"liver: 7257.2","adrenal gland: 1113.0","Cell line enhanced",NA,"Hep G2: 389.1;HSkMC: 242.1;SK-MEL-30: 203.2"
"APOC4",NA,"ENSG00000267467","Apolipoprotein C4","19","44942238-44945496","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA062671","Approved",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",124,"liver: 347.3","testis: 2.8","Cell line enhanced",NA,"HEL: 1.5;SK-MEL-30: 2.0"
"APTX","AOA, AOA1, AXA1, EAOH, EOAHA, FLJ20157","ENSG00000137074","Aprataxin","9","32972606-33025168","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA064930","Supported",NA,"Enhanced","Nucleus<br>Nucleoli","Renal cancer:6.01e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 24.5","Expressed in all",NA,NA
"ARFGAP2","FLJ14576, IRZ, Zfp289, ZNF289","ENSG00000149182","ADP ribosylation factor GTPase activating protein 2","11","47164299-47177125","Predicted intracellular proteins","Evidence at protein level","HPA016649, HPA018152","Enhanced",NA,"Supported","Golgi apparatus","Renal cancer:7.65e-7 (favourable)","Expressed in all","Expressed in all",NA,NA,"skin: 90.1","Expressed in all",NA,NA
"ARGLU1","FLJ10154","ENSG00000134884","Arginine and glutamate rich 1","13","106541673-106568164","Predicted intracellular proteins","Evidence at protein level","HPA034962, HPA056792","Supported",NA,"Enhanced","Nucleoplasm<br>Mitochondria","Pancreatic cancer:3.92e-5 (favourable), Urothelial cancer:7.34e-5 (favourable), Renal cancer:1.09e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"endometrium: 328.3","Expressed in all",NA,NA
"ARHGAP25","KIAA0053","ENSG00000163219","Rho GTPase activating protein 25","2","68679601-68826833","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA035346, HPA061395","Enhanced",NA,"Approved","Nucleoplasm<br>Vesicles","Renal cancer:1.93e-4 (unfavourable), Cervical cancer:7.72e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"spleen: 89.6","lymph node: 81.2","Cell line enhanced",NA,"HEL: 59.7;HMC-1: 225.1"
"ARHGAP4","C1, KIAA0131, p115, RhoGAP4, SrGAP4","ENSG00000089820","Rho GTPase activating protein 4","X","153907367-153934999","Predicted intracellular proteins","Evidence at protein level","HPA001012, HPA001083","Enhanced",NA,"Approved","Nucleoplasm<br>Focal adhesion sites","Colorectal cancer:1.97e-5 (unfavourable), Cervical cancer:3.94e-5 (favourable), Renal cancer:2.49e-4 (unfavourable), Head and neck cancer:3.31e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"spleen: 95.1","lymph node: 87.2","Cell line enhanced",NA,"MOLT-4: 72.4;RPMI-8226: 121.4"
"ARHGAP44","KIAA0672, RICH-2, RICH2","ENSG00000006740","Rho GTPase activating protein 44","17","12789539-12991643","Predicted intracellular proteins","Evidence at protein level","HPA038814","Uncertain",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"parathyroid gland: 51.6","cerebral cortex: 33.4","Cell line enhanced",NA,"HEK 293: 9.0"
"ARHGAP45","HA-1, HMHA1, KIAA0223","ENSG00000180448","Rho GTPase activating protein 45","19","1065923-1086628","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA019816","Enhanced",NA,NA,NA,"Endometrial cancer:6.02e-4 (favourable), Head and neck cancer:7.82e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"appendix: 56.4;lymph node: 66.6;spleen: 77.8","bone marrow: 44.0","Cell line enhanced",NA,"Karpas-707: 72.0;U-266/70: 99.7"
"ARHGEF1","LBCL2, P115-RHOGEF, SUB1.5","ENSG00000076928","Rho guanine nucleotide exchange factor 1","19","41883161-41930150","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB009502, HPA012924, HPA060784","Enhanced",NA,"Enhanced","Plasma membrane<br>Cytosol","Renal cancer:3.36e-8 (unfavourable), Breast cancer:5.92e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"lymph node: 144.9","Expressed in all",NA,NA
"ARHGEF11","GTRAP48, KIAA0380, PDZ-RHOGEF","ENSG00000132694","Rho guanine nucleotide exchange factor 11","1","156934840-157045370","Predicted intracellular proteins","Evidence at protein level","HPA011026, HPA012037, HPA014658","Enhanced",NA,"Approved","Golgi apparatus<br>Plasma membrane","Pancreatic cancer:1.72e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 44.3","Mixed",NA,NA
"ARHGEF25","GEFT, p63RhoGEF","ENSG00000240771","Rho guanine nucleotide exchange factor 25","12","57610180-57619379","Predicted intracellular proteins","Evidence at protein level","HPA052016","Uncertain",NA,"Approved","Vesicles","Renal cancer:4.20e-7 (unfavourable)","Expressed in all","Mixed",NA,NA,"endometrium: 112.2","Cell line enhanced",NA,"RH-30: 125.8;SH-SY5Y: 62.5"
"ARHGEF33",NA,"ENSG00000214694","Rho guanine nucleotide exchange factor 33","2","38889880-38975449","Predicted intracellular proteins","Evidence at protein level","HPA034661, HPA041051","Enhanced",NA,"Supported","Vesicles",NA,"Mixed","Tissue enhanced",NA,"testis: 10.6","ovary: 4.3","Cell line enhanced",NA,"BEWO: 5.4;SiHa: 7.6"
"ARHGEF35","ARHGEF5L, CTAGE4, FLJ43692","ENSG00000213214","Rho guanine nucleotide exchange factor 35","7","144186083-144195655","Predicted intracellular proteins","Evidence at protein level","HPA044188, HPA045619, HPA045699","Supported",NA,NA,NA,"Renal cancer:4.57e-4 (favourable), Liver cancer:5.77e-4 (unfavourable)","Mixed","Mixed",NA,NA,"thyroid gland: 44.5","Cell line enhanced",NA,"A-431: 47.0;hTCEpi: 30.0;RPTEC TERT1: 41.9;WM-115: 28.8"
"ARHGEF4","ASEF, KIAA1112, STM6","ENSG00000136002","Rho guanine nucleotide exchange factor 4","2","130836916-131047263","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA018267","Approved",NA,NA,NA,"Testis cancer:7.00e-4 (favourable)","Mixed","Tissue enhanced",NA,"cerebral cortex: 61.6;skin: 44.1","esophagus: 14.5","Cell line enhanced",NA,"HaCaT: 31.5;hTCEpi: 52.8;SCLC-21H: 52.6"
"ARID5B","FLJ21150, MRF2","ENSG00000150347","AT-rich interaction domain 5B","10","61901300-62096944","Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA015037","Uncertain",NA,"Approved","Nucleoplasm<br>Endoplasmic reticulum<br>Plasma membrane<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"smooth muscle: 62.1","Cell line enhanced",NA,"BJ hTERT+: 91.0"
"ARL3","ARFL3","ENSG00000138175","ADP ribosylation factor like GTPase 3","10","102673731-102714407","Predicted intracellular proteins","Evidence at protein level","HPA036292, HPA063596","Approved",NA,"Supported","Nucleus<br>Centrosome","Renal cancer:1.71e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 35.8","Expressed in all",NA,NA
"ARL5C","ARL12","ENSG00000141748","ADP ribosylation factor like GTPase 5C","17","39156894-39167484","Predicted intracellular proteins","No evidence","HPA069849","Uncertain",NA,NA,NA,NA,"Not detected","Not detected",NA,NA,"lymph node: 0.4","Not detected",NA,NA
"ARPP19","ARPP-16, ARPP-19, ARPP16, ENSAL","ENSG00000128989","CAMP regulated phosphoprotein 19","15","52547045-52569883","Predicted intracellular proteins","Evidence at protein level","HPA056851","Approved",NA,NA,NA,"Renal cancer:1.72e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 510.5","Expressed in all",NA,NA
"ARRB1","ARR1","ENSG00000137486","Arrestin beta 1","11","75264182-75351705","Predicted intracellular proteins","Evidence at protein level","CAB003763, HPA049318, HPA070249","Approved",NA,"Supported","Nucleoplasm",NA,"Expressed in all","Expressed in all",NA,NA,"lung: 80.4","Cell line enhanced",NA,"HEL: 151.4;RH-30: 109.6"
"ARSB",NA,"ENSG00000113273","Arylsulfatase B","5","78777209-78986087","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins","Evidence at protein level","HPA037770, HPA037771","Enhanced",NA,"Approved","Golgi apparatus","Urothelial cancer:3.42e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"smooth muscle: 18.2","Expressed in all",NA,NA
"ARSI","FLJ16069, SPG66","ENSG00000183876","Arylsulfatase family member I","5","150296343-150339307","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA038386, HPA038398","Uncertain",NA,"Approved","Golgi apparatus","Urothelial cancer:1.19e-4 (unfavourable), Lung cancer:9.11e-4 (unfavourable)","Mixed","Mixed",NA,NA,"skin: 5.7","Cell line enhanced",NA,"HaCaT: 27.7;hTEC/SVTERT24-B: 30.9;U-87 MG: 38.4"
"ARSJ","FLJ23548","ENSG00000180801","Arylsulfatase family member J","4","113900284-113979727","Predicted intracellular proteins","Evidence at protein level","HPA036481, HPA036482","Uncertain",NA,"Supported","Nucleoli<br>Actin filaments","Renal cancer:2.97e-6 (favourable), Head and neck cancer:6.08e-4 (unfavourable)","Mixed","Mixed",NA,NA,"parathyroid gland: 12.7","Mixed",NA,NA
"ARV1",NA,"ENSG00000173409","ARV1 homolog, fatty acid homeostasis modulator","1","230978981-231000595","Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters","Evidence at protein level","HPA035709","Approved",NA,"Approved","Vesicles","Lung cancer:3.27e-5 (favourable), Colorectal cancer:1.33e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 61.9","Expressed in all",NA,NA
"ASAP1","CENTB4, DDEF1, KIAA1249, PAP, ZG14P","ENSG00000153317","ArfGAP with SH3 domain, ankyrin repeat and PH domain 1","8","130052104-130443660","Predicted intracellular proteins","Evidence at protein level","HPA011136, CAB037292, HPA048565","Approved",NA,"Approved","Plasma membrane<br>Centrosome<br>Cytosol","Liver cancer:5.63e-8 (unfavourable), Renal cancer:1.50e-7 (unfavourable), Lung cancer:3.56e-5 (unfavourable), Endometrial cancer:5.81e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 56.0","Expressed in all",NA,NA
"ASB9","DKFZP564L0862, FLJ20636, MGC4954","ENSG00000102048","Ankyrin repeat and SOCS box containing 9","X","15235288-15270467","Predicted intracellular proteins","Evidence at protein level","HPA003014, HPA003060, CAB004997","Enhanced",NA,NA,NA,"Prostate cancer:4.36e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"testis: 48.3","kidney: 16.9","Cell line enhanced",NA,"A549: 23.1;PC-3: 48.9"
"ASCC3","ASC1p200, dJ121G13.4, dJ467N11.1, HELIC1, RNAH","ENSG00000112249","Activating signal cointegrator 1 complex subunit 3","6","100508194-100881372","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA031608, HPA031609, HPA031610","Enhanced",NA,"Supported","Golgi apparatus<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 26.5","Expressed in all",NA,NA
"ASIC2","ACCN, ACCN1, ASIC2a, BNaC1, BNC1, hBNaC1, MDEG","ENSG00000108684","Acid sensing ion channel subunit 2","17","33013087-34174964","Plasma proteins, Predicted membrane proteins","Evidence at protein level","HPA052112","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Group enriched",6,"cerebral cortex: 8.6;cervix, uterine: 3.9;endometrium: 6.4;smooth muscle: 2.2","adrenal gland: 0.8","Cell line enhanced",NA,"NTERA-2: 1.1"
"ASIC3","ACCN3, DRASIC, TNaC1","ENSG00000213199","Acid sensing ion channel subunit 3","7","151048292-151052756","Predicted membrane proteins","Evidence at protein level","HPA049155, HPA054805","Enhanced",NA,"Approved","Nucleoplasm<br>Cytosol",NA,"Tissue enhanced","Tissue enhanced",NA,"testis: 8.1","cerebral cortex: 5.8","Cell line enhanced",NA,"U-266/70: 13.4"
"ASPH","BAH, CASQ2BP1, HAAH, JCTN","ENSG00000198363","Aspartate beta-hydroxylase","8","61500556-61714640","Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters","Evidence at protein level","HPA055161, HPA059303","Uncertain",NA,"Supported","Endoplasmic reticulum","Renal cancer:1.57e-5 (unfavourable), Cervical cancer:8.07e-5 (unfavourable), Pancreatic cancer:1.75e-4 (unfavourable), Lung cancer:3.61e-4 (unfavourable), Thyroid cancer:4.24e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"adipose tissue: 403.5","Mixed",NA,NA
"ASPRV1","FLJ25084, SASPase, Taps","ENSG00000244617","Aspartic peptidase, retroviral-like 1","2","69960089-69962265","Plasma proteins, Predicted membrane proteins","Evidence at protein level","HPA034809, HPA034810","Enhanced",NA,NA,NA,NA,"Group enriched","Tissue enriched",13,"skin: 286.1","breast: 22.6","Cell line enhanced",NA,"REH: 4.5"
"ATCAY","BNIP-H","ENSG00000167654","ATCAY, caytaxin","19","3879864-3928079","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA017755","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",12,"cerebral cortex: 108.9","adrenal gland: 8.8","Cell line enhanced",NA,"NTERA-2: 7.2;SCLC-21H: 15.5;SH-SY5Y: 9.8"
"ATF7IP","FLJ10688, p621","ENSG00000171681","Activating transcription factor 7 interacting protein","12","14365632-14502935","Predicted intracellular proteins","Evidence at protein level","HPA016578, HPA023505","Enhanced",NA,"Enhanced","Nucleoplasm<br>Nuclear bodies","Glioma:7.91e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 61.7","Expressed in all",NA,NA
"ATG4C","APG4C, AUTL1, AUTL3, FLJ14867","ENSG00000125703","Autophagy related 4C cysteine peptidase","1","62784135-62865513","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA007049","Approved",NA,"Approved","Nucleoplasm<br>Cytosol","Colorectal cancer:9.83e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 23.5","Expressed in all",NA,NA
"ATN1","B37, D12S755E, DRPLA","ENSG00000111676","Atrophin 1","12","6924463-6942321","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA031619","Enhanced",NA,"Enhanced","Nucleoplasm","Liver cancer:7.20e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"ovary: 139.5","Expressed in all",NA,NA
"ATP10B","ATPVB, FLJ21477, KIAA0715","ENSG00000118322","ATPase phospholipid transporting 10B (putative)","5","160563120-160852214","Enzymes, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA034574","Uncertain",NA,NA,NA,NA,"Group enriched","Tissue enhanced",NA,"colon: 36.0;rectum: 40.3","gallbladder: 21.4","Cell line enriched",23,"WM-115: 13.6"
"ATP11B","ATPIF, ATPIR, KIAA0956","ENSG00000058063","ATPase phospholipid transporting 11B (putative)","3","182793500-182921635","Enzymes, Predicted membrane proteins, Transporters","Evidence at protein level","HPA036237, HPA036238","Uncertain",NA,"Approved","Microtubule organizing center<br>Cytosol","Pancreatic cancer:1.09e-4 (unfavourable), Endometrial cancer:3.44e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 58.0","Expressed in all",NA,NA
"ATP13A2","CLN12, HSA9947, PARK9","ENSG00000159363","ATPase 13A2","1","16985958-17011928","Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters","Evidence at protein level","CAB037038, CAB037111, HPA050910, HPA054717","Approved",NA,NA,NA,"Liver cancer:3.33e-7 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 74.8","Expressed in all",NA,NA
"ATP1B2","AMOG","ENSG00000129244","ATPase Na+/K+ transporting subunit beta 2","17","7646627-7657768","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA010698","Enhanced",NA,NA,NA,"Pancreatic cancer:1.05e-4 (favourable), Renal cancer:4.17e-4 (unfavourable)","Tissue enriched","Tissue enriched",9,"cerebral cortex: 339.2","ovary: 36.7","Cell line enhanced",NA,"AF22: 9.7;HAP1: 3.1;K-562: 4.2"
"ATP2B2","PMCA2","ENSG00000157087","ATPase plasma membrane Ca2+ transporting 2","3","10324023-10708031","Enzymes, Plasma proteins, Predicted membrane proteins, Transporters","Evidence at protein level","CAB005606","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",7,"cerebral cortex: 64.7","salivary gland: 9.7","Group enriched",7,"EFO-21: 3.0;RPMI-8226: 5.4;SCLC-21H: 4.2;SH-SY5Y: 1.2"
"ATP2B3","CFAP39, CLA2, PMCA3, SCAX1","ENSG00000067842","ATPase plasma membrane Ca2+ transporting 3","X","153517676-153582939","Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins","Evidence at protein level","HPA001583","Enhanced",NA,"Uncertain","Golgi apparatus<br>Plasma membrane",NA,"Not detected","Group enriched",8,"adrenal gland: 12.1;cerebral cortex: 19.0","fallopian tube: 2.0","Cell line enhanced",NA,"SCLC-21H: 11.7;SH-SY5Y: 3.1;THP-1: 1.7;U-937: 1.9"
"ATP2C1","ATP2C1A, BCPM, KIAA1347, PMR1, SPCA1","ENSG00000017260","ATPase secretory pathway Ca2+ transporting 1","3","130850595-131016712","Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, Transporters","Evidence at protein level","CAB010207, HPA035116, HPA069684","Supported",NA,"Enhanced","Golgi apparatus","Liver cancer:5.06e-6 (unfavourable), Pancreatic cancer:1.52e-4 (unfavourable), Renal cancer:1.55e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"prostate: 138.3","Expressed in all",NA,NA
"ATP5B","ATPSB","ENSG00000110955","ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide","12","56638175-56646068","Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA001520, HPA001528, CAB017527","Enhanced",NA,"Enhanced","Mitochondria","Renal cancer:1.43e-9 (favourable), Breast cancer:7.17e-6 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 1254.0","Expressed in all",NA,NA
"ATP5D",NA,"ENSG00000099624","ATP synthase, H+ transporting, mitochondrial F1 complex, delta subunit","19","1241746-1244826","Predicted intracellular proteins","Evidence at protein level","HPA002865","Uncertain",NA,NA,NA,"Renal cancer:3.46e-5 (favourable), Endometrial cancer:1.23e-4 (favourable), Pancreatic cancer:4.60e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"skeletal muscle: 217.6","Expressed in all",NA,NA
"ATP5F1",NA,"ENSG00000116459","ATP synthase, H+ transporting, mitochondrial Fo complex subunit B1","1","111448864-111462773","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA046067, HPA057347","Enhanced",NA,"Supported","Mitochondria","Renal cancer:3.26e-9 (favourable), Stomach cancer:8.07e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"heart muscle: 50.4","Expressed in all",NA,NA
"ATP5H","ATP5JD, ATPQ","ENSG00000167863","ATP synthase, H+ transporting, mitochondrial Fo complex subunit D","17","75038863-75046985","Predicted intracellular proteins","Evidence at protein level","HPA042777, HPA048459","Enhanced",NA,"Supported","Nucleoplasm",NA,"Expressed in all","Expressed in all",NA,NA,"heart muscle: 616.6","Expressed in all",NA,NA
"ATP6V0A1","a1, ATP6N1, ATP6N1A, Stv1, Vph1, VPP1","ENSG00000033627","ATPase H+ transporting V0 subunit a1","17","42458844-42522611","Predicted intracellular proteins, Predicted membrane proteins, Transporters","Evidence at protein level","HPA022144","Enhanced",NA,"Approved","Nuclear speckles<br>Golgi apparatus<br>Vesicles<br>Cytosol","Renal cancer:1.28e-4 (favourable), Pancreatic cancer:2.05e-4 (favourable), Urothelial cancer:6.90e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 200.9","Mixed",NA,NA
"ATP6V0A4","a4, ATP6N1B, ATP6N2, RDRTA2, RTA1C, RTADR, Stv1, Vph1, VPP2","ENSG00000105929","ATPase H+ transporting V0 subunit a4","7","138706295-138799560","Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters","Evidence at protein level","HPA018029, HPA064555","Enhanced",NA,"Approved","Cytosol","Renal cancer:1.32e-6 (favourable)","Tissue enriched","Group enriched",9,"kidney: 69.6;salivary gland: 31.6","breast: 5.5","Cell line enriched",12,"SK-BR-3: 42.2"
"ATP6V0D2","ATP6D2, FLJ38708, VMA6","ENSG00000147614","ATPase H+ transporting V0 subunit d2","8","85987323-86154228","Predicted intracellular proteins","Evidence at protein level","HPA055327, HPA058496","Enhanced",NA,"Approved","Vesicles","Renal cancer:2.20e-6 (favourable)","Tissue enriched","Tissue enriched",15,"kidney: 59.4","rectum: 3.9","Cell line enhanced",NA,"SCLC-21H: 2.3;SK-MEL-30: 2.6;U-87 MG: 4.8"
"ATP6V1E1","ATP6E, ATP6E2, ATP6V1E, P31, Vma4","ENSG00000131100","ATPase H+ transporting V1 subunit E1","22","17592136-17628818","Plasma proteins, Predicted intracellular proteins, Transporters","Evidence at protein level","CAB009528, CAB018699, HPA029196","Enhanced",NA,"Approved","Nucleoplasm","Renal cancer:7.66e-8 (favourable), Liver cancer:1.56e-5 (unfavourable), Prostate cancer:4.18e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 301.3","Expressed in all",NA,NA
"ATP6V1F","ATP6S14, VATF, Vma7","ENSG00000128524","ATPase H+ transporting V1 subunit F","7","128862826-128865844","Predicted intracellular proteins, Transporters","Evidence at protein level","CAB009529, HPA048700, HPA062011","Enhanced",NA,NA,NA,"Renal cancer:2.49e-5 (favourable), Liver cancer:3.62e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 288.0","Expressed in all",NA,NA
"ATP6V1G2","ATP6G, ATP6G2, Em:AC004181.3, NG38, Vma10","ENSG00000213760","ATPase H+ transporting V1 subunit G2","6","31544462-31548427","Predicted intracellular proteins","Evidence at protein level","CAB004616","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",12,"cerebral cortex: 16.7","lymph node: 1.4","Cell line enhanced",NA,"HDLM-2: 3.0;Karpas-707: 2.5"
"ATP6V1H","CGI-11, SFD, SFDalpha, SFDbeta, VMA13","ENSG00000047249","ATPase H+ transporting V1 subunit H","8","53715557-53843558","Predicted intracellular proteins, Transporters","Evidence at protein level","CAB009532, HPA023421","Approved",NA,"Approved","Actin filaments<br>Cytosol","Renal cancer:1.46e-7 (favourable), Liver cancer:7.81e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 126.6","Expressed in all",NA,NA
"ATP8A1","ATPIA","ENSG00000124406","ATPase phospholipid transporting 8A1","4","42408373-42657105","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters","Evidence at protein level","HPA052935","Enhanced",NA,"Supported","Vesicles","Renal cancer:5.54e-10 (favourable)","Mixed","Tissue enhanced",NA,"parathyroid gland: 68.8;thyroid gland: 66.6","cerebral cortex: 58.2","Cell line enhanced",NA,"AN3-CA: 25.5;Daudi: 33.1"
"ATP8B1","ATPIC, BRIC, FIC1, PFIC, PFIC1","ENSG00000081923","ATPase phospholipid transporting 8B1","18","57646426-57803101","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters","Evidence at protein level","HPA018673, HPA018674","Enhanced",NA,NA,NA,"Colorectal cancer:2.60e-4 (favourable), Renal cancer:6.35e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"colon: 94.6","Cell line enhanced",NA,"RT4: 171.8"
"ATXN1","ATX1, D6S504E, SCA1","ENSG00000124788","Ataxin 1","6","16299112-16761491","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA008335, HPA070756","Approved",NA,"Supported","Nucleus<br>Nucleoli<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 17.5","Cell line enhanced",NA,"U-266/70: 22.6"
"ATXN10","E46L, FLJ37990, SCA10","ENSG00000130638","Ataxin 10","22","45671798-45845307","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA049531","Approved",NA,"Supported","Plasma membrane<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 133.9","Expressed in all",NA,NA
"AXIN2","DKFZp781B0869, MGC126582","ENSG00000168646","Axin 2","17","65528563-65561647","Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB012283, CAB017783","Approved",NA,"Uncertain","Nucleus<br>Plasma membrane<br>Cytosol","Pancreatic cancer:6.58e-4 (favourable)","Expressed in all","Mixed",NA,NA,"endometrium: 31.1","Cell line enhanced",NA,"AF22: 26.9;CACO-2: 43.2;Hep G2: 53.5"
"AZU1","AZAMP, AZU, CAP37, HBP, HUMAZUR, NAZC","ENSG00000172232","Azurocidin 1","19","825097-832018","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA055851","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enriched",525,"bone marrow: 1311.2","skin: 2.4","Cell line enriched",6,"THP-1: 722.4"
"B4GALT1","beta4Gal-T1, GGTB2","ENSG00000086062","Beta-1,4-galactosyltransferase 1","9","33104082-33167356","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins","Evidence at protein level","HPA010806, HPA010807","Enhanced",NA,"Enhanced","Golgi apparatus","Endometrial cancer:6.85e-7 (favourable), Lung cancer:1.25e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 140.5","Expressed in all",NA,NA
"BAALC",NA,"ENSG00000164929","Brain and acute leukemia, cytoplasmic","8","103140710-103230305","Predicted intracellular proteins","Evidence at protein level","HPA027132, HPA068307","Approved",NA,"Supported","Nucleus<br>Cytosol",NA,"Tissue enriched","Tissue enriched",16,"cerebral cortex: 247.7","adrenal gland: 15.6","Cell line enhanced",NA,"AF22: 50.6;SCLC-21H: 32.7;SH-SY5Y: 21.7;U-87 MG: 73.6"
"BACE2","AEPLC, ALP56, CEAP1, DRAP","ENSG00000182240","Beta-site APP-cleaving enzyme 2","21","41167801-41282518","Enzymes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA035416","Approved",NA,NA,NA,"Cervical cancer:1.11e-4 (unfavourable), Glioma:8.13e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"stomach: 30.5","Cell line enhanced",NA,"SK-BR-3: 43.8;WM-115: 41.2"
"BAG3",NA,"ENSG00000151929","BCL2 associated athanogene 3","10","119651370-119677819","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA018493, HPA020586","Enhanced",NA,"Enhanced","Plasma membrane<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"skeletal muscle: 98.2","Mixed",NA,NA
"BAIAP2","BAP2, IRSp53","ENSG00000175866","BAI1 associated protein 2","17","81035122-81117432","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA023310, HPA027421","Enhanced",NA,"Enhanced","Plasma membrane<br>Cytosol","Urothelial cancer:7.58e-6 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 124.7","Mixed",NA,NA
"BANK1","BANK, FLJ20706","ENSG00000153064","B-cell scaffold protein with ankyrin repeats 1","4","101411286-102074812","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA037002","Enhanced",NA,"Approved","Nucleoplasm<br>Plasma membrane<br>Cytosol",NA,"Mixed","Group enriched",5,"appendix: 45.9;lymph node: 96.8;spleen: 77.4;thyroid gland: 21.6;tonsil: 87.2","urinary bladder: 12.9","Cell line enhanced",NA,"Daudi: 9.7;HEL: 9.5;HL-60: 7.6;U-266/70: 23.8"
"BBX","HBP2, HSPC339, MDS001","ENSG00000114439","BBX, HMG-box containing","3","107522936-107811324","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA006049, HPA050646","Enhanced",NA,"Enhanced","Nucleoplasm<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"testis: 115.7","Expressed in all",NA,NA
"BCAP29","BAP29, DKFZp686M2086","ENSG00000075790","B-cell receptor associated protein 29","7","107579977-107629170","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA029215, HPA049694","Enhanced",NA,"Approved","Cytosol","Liver cancer:3.62e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 93.0","Expressed in all",NA,NA
"BCAS1","AIBC1, NABC1","ENSG00000064787","Breast carcinoma amplified sequence 1","20","53936777-54070594","Predicted intracellular proteins","Evidence at protein level","CAB033558, HPA051816, HPA054745","Enhanced",NA,"Approved","Vesicles",NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 108.7;stomach: 155.8","rectum: 80.7","Group enriched",6,"RT4: 143.2;SK-BR-3: 277.9"
"BCAS2","DAM1, Snt309, SPF27","ENSG00000116752","BCAS2, pre-mRNA processing factor","1","114567557-114581639","Predicted intracellular proteins","Evidence at protein level","HPA067881","Enhanced",NA,"Supported","Nuclear speckles<br>Centrosome","Liver cancer:8.23e-7 (unfavourable), Prostate cancer:4.27e-4 (unfavourable), Thyroid cancer:5.24e-4 (unfavourable), Renal cancer:6.49e-4 (favourable), Ovarian cancer:7.96e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 71.1","Expressed in all",NA,NA
"BCL2","Bcl-2, PPP1R50","ENSG00000171791","BCL2, apoptosis regulator","18","63123346-63320128","Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","CAB000003, HPA055295","Enhanced",NA,"Supported","Nucleoplasm<br>Nuclear membrane","Renal cancer:1.29e-8 (favourable), Cervical cancer:5.13e-5 (favourable), Thyroid cancer:2.47e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"thyroid gland: 69.3","parathyroid gland: 35.3","Cell line enhanced",NA,"Karpas-707: 59.5;U-266/70: 217.8"
"BDKRB1","B1BKR, BKR1, bradyb1","ENSG00000100739","Bradykinin receptor B1","14","96255824-96268967","G-protein coupled receptors, Predicted membrane proteins","Evidence at protein level","HPA002935","Approved",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"gallbladder: 18.2","urinary bladder: 9.9","Cell line enhanced",NA,"BJ hTERT+: 19.8;HHSteC: 20.3;hTEC/SVTERT24-B: 23.1;U-2197: 23.8;U-87 MG: 82.4"
"BDKRB2","BK-2","ENSG00000168398","Bradykinin receptor B2","14","96204679-96244166","FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins","Evidence at protein level","HPA050841","Approved",NA,NA,NA,NA,"Mixed","Mixed",NA,NA,"gallbladder: 32.5","Cell line enhanced",NA,"ASC TERT1: 34.0;BJ hTERT+: 75.7;U-87 MG: 38.4"
"BEGAIN","KIAA1446","ENSG00000183092","Brain enriched guanylate kinase associated","14","100537147-100587413","Predicted intracellular proteins","Evidence at protein level","HPA002899","Uncertain",NA,"Uncertain","Nucleus<br>Golgi apparatus<br>Cytosol",NA,"Mixed","Tissue enriched",5,"cerebral cortex: 20.0","adrenal gland: 3.8","Group enriched",8,"HeLa: 36.4;SH-SY5Y: 137.4"
"BEND2","CXorf20, MGC33653","ENSG00000177324","BEN domain containing 2","X","18162931-18220883","Predicted intracellular proteins","Evidence at protein level","HPA009420, HPA013142","Enhanced",NA,NA,NA,NA,"Not detected","Tissue enriched",30,"testis: 9.9","spleen: 0.3","Not detected",NA,NA
"BEND5","C1orf165, FLJ11588","ENSG00000162373","BEN domain containing 5","1","48727523-48776969","Predicted intracellular proteins","Evidence at protein level","HPA054347, HPA058007","Uncertain",NA,NA,NA,"Urothelial cancer:8.30e-6 (favourable), Breast cancer:2.50e-5 (favourable), Pancreatic cancer:1.29e-4 (favourable), Lung cancer:1.29e-4 (favourable)","Mixed","Mixed",NA,NA,"cerebral cortex: 6.0","Cell line enhanced",NA,"AF22: 3.2;HDLM-2: 10.2;MOLT-4: 3.6;REH: 5.7;SH-SY5Y: 3.1"
"BHMT","BHMT1","ENSG00000145692","Betaine--homocysteine S-methyltransferase","5","79111779-79132290","Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA038285, HPA058310","Enhanced",NA,"Supported","Cytosol","Liver cancer:7.32e-4 (favourable)","Tissue enhanced","Group enriched",225,"kidney: 788.8;liver: 563.6","urinary bladder: 3.0","Cell line enhanced",NA,"Hep G2: 2.4;NTERA-2: 1.4;SCLC-21H: 1.1"
"BIN1","AMPH2, AMPHL, SH3P9","ENSG00000136717","Bridging integrator 1","2","127048027-127107355","Disease related genes, Predicted intracellular proteins","Evidence at protein level","CAB001945, HPA003894, HPA005437","Enhanced",NA,"Supported","Cytosol",NA,"Expressed in all","Group enriched",7,"cerebral cortex: 156.4;skeletal muscle: 724.1","adrenal gland: 61.4","Mixed",NA,NA
"BIRC3","API2, c-IAP2, cIAP2, hiap-1, MALT2, MIHC, RNF49","ENSG00000023445","Baculoviral IAP repeat containing 3","11","102317450-102339403","Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA002317","Enhanced","Approved","Supported","Nucleoplasm<br>Cytosol","Renal cancer:6.66e-6 (unfavourable), Pancreatic cancer:3.03e-4 (unfavourable), Breast cancer:3.60e-4 (favourable), Colorectal cancer:9.35e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"lymph node: 138.1","appendix: 117.5","Cell line enhanced",NA,"CAPAN-2: 106.1;Daudi: 77.5;HDLM-2: 96.2;hTERT-HME1: 79.1"
"BLOC1S4","BCAS4L, CNO, FLJ11230","ENSG00000186222","Biogenesis of lysosomal organelles complex 1 subunit 4","4","6716055-6717671","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA043840","Approved",NA,"Approved","Vesicles<br>Cytosol","Liver cancer:1.06e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"ovary: 12.7","Expressed in all",NA,NA
"BPI","BPIFD1","ENSG00000101425","Bactericidal/permeability-increasing protein","20","38260149-38337505","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA061284","Enhanced",NA,NA,NA,NA,"Not detected","Tissue enriched",37,"bone marrow: 961.6","testis: 25.9","Group enriched",5,"AF22: 2.3;ASC diff: 1.1;ASC TERT1: 3.1;BJ: 2.1;BJ hTERT+: 2.1;HL-60: 1.1"
"BPIFB2","BPIL1, C20orf184, dJ726C3.2, LPLUNC2","ENSG00000078898","BPI fold containing family B member 2","20","33007600-33023709","Plasma proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA049491, HPA060121","Enhanced",NA,"Approved","Vesicles","Endometrial cancer:1.97e-5 (favourable)","Group enriched","Group enriched",23,"esophagus: 98.5;salivary gland: 90.5","cervix, uterine: 4.0","Cell line enriched",418,"Hep G2: 146.8"
"BRAF","BRAF1","ENSG00000157764","B-Raf proto-oncogene, serine/threonine kinase","7","140719327-140924764","Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins","Evidence at protein level","HPA001328, CAB004552, HPA071048","Approved",NA,"Approved","Vesicles<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"testis: 41.8","Expressed in all",NA,NA
"BRAP","BRAP2, IMP, RNF52","ENSG00000089234","BRCA1 associated protein","12","111642146-111685986","Enzymes, Predicted intracellular proteins, RAS pathway related proteins","Evidence at protein level","HPA040357, HPA058820","Approved",NA,"Supported","Nuclear membrane<br>Cytosol","Liver cancer:7.65e-6 (unfavourable)","Expressed in all","Tissue enriched",6,"testis: 120.9","bone marrow: 21.3","Expressed in all",NA,NA
"BRF2","BRFU, FLJ11052, TFIIIB50","ENSG00000104221","BRF2, RNA polymerase III transcription initiation factor subunit","8","37843268-37849904","Predicted intracellular proteins","Evidence at protein level","CAB019269, HPA023378","Enhanced",NA,"Approved","Nucleoli",NA,"Expressed in all","Expressed in all",NA,NA,"ovary: 16.1","Expressed in all",NA,NA
"BSCL2","GNG3LG, SPG17","ENSG00000168000","BSCL2, seipin lipid droplet biogenesis associated","11","62690275-62709845","Disease related genes, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA042394","Approved",NA,NA,NA,"Renal cancer:7.55e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 250.5","Expressed in all",NA,NA
"BTBD8",NA,"ENSG00000189195","BTB domain containing 8","1","92080305-92184725","Predicted intracellular proteins","Evidence at transcript level","HPA024216, HPA035311, HPA035312","Uncertain",NA,"Approved","Nucleoplasm",NA,"Not detected","Mixed",NA,NA,"parathyroid gland: 3.7","Cell line enhanced",NA,"ASC TERT1: 2.1;BEWO: 2.4"
"BTF3L4","MGC23908","ENSG00000134717","Basic transcription factor 3 like 4","1","52056125-52090716","Predicted intracellular proteins","Evidence at protein level","HPA067026","Approved",NA,"Approved","Nucleus<br>Cytosol","Liver cancer:6.73e-8 (unfavourable), Renal cancer:4.43e-6 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 72.6","Expressed in all",NA,NA
"BTK","AGMX1, ATK, IMD1, PSCTK1, XLA","ENSG00000010671","Bruton tyrosine kinase","X","101349447-101390796","Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA001198, HPA002028, CAB016689","Enhanced",NA,"Supported","Vesicles",NA,"Expressed in all","Tissue enhanced",NA,"lymph node: 65.2;tonsil: 70.8","spleen: 52.7","Cell line enhanced",NA,"Daudi: 147.2;HEL: 256.7;HMC-1: 868.2"
"BTLA","BTLA1, CD272","ENSG00000186265","B and T lymphocyte associated","3","112463968-112499561","CD markers, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA047211, HPA062029","Enhanced",NA,NA,NA,NA,"Mixed","Group enriched",7,"appendix: 14.1;lymph node: 29.3;spleen: 14.6;tonsil: 24.7","urinary bladder: 3.0","Cell line enhanced",NA,"U-698: 1.3"
"BUD13","Cwc26, fSAP71, MGC13125","ENSG00000137656","BUD13 homolog","11","116748170-116772988","Predicted intracellular proteins","Evidence at protein level","HPA038340, HPA038341","Enhanced",NA,"Enhanced","Nucleus","Liver cancer:5.07e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 39.5","Expressed in all",NA,NA
"C11orf53","MGC50104","ENSG00000150750","Chromosome 11 open reading frame 53","11","111245805-111286401","Predicted intracellular proteins","Evidence at transcript level","HPA056128","Uncertain",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"testis: 4.7","gallbladder: 2.2","Not detected",NA,NA
"C11orf87","LOC399947, LOH11CR1A, NEURIM1","ENSG00000185742","Chromosome 11 open reading frame 87","11","109422120-109429114","Predicted membrane proteins","Evidence at protein level","HPA034656","Approved",NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",20,"cerebral cortex: 30.8","endometrium: 1.5","Cell line enhanced",NA,"BJ hTERT+ SV40 Large T+: 2.7;fHDF/TERT166: 9.0;SCLC-21H: 3.4"
"C12orf76","FLJ40142","ENSG00000174456","Chromosome 12 open reading frame 76","12","110027028-110073686","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at transcript level","HPA039713, HPA042013","Uncertain",NA,"Approved","Plasma membrane<br>Actin filaments","Renal cancer:5.74e-5 (unfavourable), Lung cancer:6.44e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 105.7","Expressed in all",NA,NA
"C14orf37","UT2","ENSG00000139971","Chromosome 14 open reading frame 37","14","57999735-58298139","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA001580, HPA001789","Enhanced",NA,"Approved","Plasma membrane",NA,"Mixed","Mixed",NA,NA,"kidney: 8.8","Cell line enhanced",NA,"AF22: 9.6;fHDF/TERT166: 8.4"
"C15orf59","INSYN1, LOC388135, MGC131524","ENSG00000205363","Chromosome 15 open reading frame 59","15","73735431-73752747","Predicted intracellular proteins","Evidence at transcript level","HPA041563","Approved",NA,"Approved","Nucleoplasm<br>Cytosol","Renal cancer:5.38e-9 (favourable)","Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 55.9","seminal vesicle: 19.8","Cell line enhanced",NA,"ASC diff: 6.2;fHDF/TERT166: 4.8;HEK 293: 5.9;U-2 OS: 5.5"
"C17orf51","FLJ12977, FLJ31874, FLJ33618","ENSG00000212719","Chromosome 17 open reading frame 51","17","21524790-21574458","Predicted intracellular proteins","Evidence at protein level","HPA052106","Enhanced",NA,"Approved","Nucleoplasm<br>Nuclear bodies<br>Vesicles",NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 16.6","testis: 8.2","Mixed",NA,NA
"C17orf98","LOC388381","ENSG00000275489","Chromosome 17 open reading frame 98","17","38835088-38841455","Predicted intracellular proteins","Evidence at transcript level","HPA051696","Uncertain",NA,"Approved","Nucleoli<br>Intermediate filaments",NA,"Not detected","Tissue enriched",50,"testis: 9.5","adipose tissue,skin: 0.1","Cell line enriched",7,"hTCEpi: 1.9"
"C19orf35","FLJ45778","ENSG00000188305","Chromosome 19 open reading frame 35","19","2274622-2282176","Predicted intracellular proteins","Evidence at protein level","HPA057806","Uncertain",NA,NA,NA,NA,"Mixed","Mixed",NA,NA,"appendix: 1.8","Cell line enriched",13,"HMC-1: 10.7"
"C19orf71","LOC100128569","ENSG00000183397","Chromosome 19 open reading frame 71","19","3539154-3544030","Predicted intracellular proteins","Evidence at protein level","HPA048654","Uncertain",NA,"Approved","Endoplasmic reticulum<br>Plasma membrane<br>Cytosol","Renal cancer:2.02e-5 (favourable), Pancreatic cancer:2.03e-5 (favourable), Head and neck cancer:2.35e-4 (favourable)","Tissue enriched","Mixed",NA,NA,"testis: 29.5","Cell line enhanced",NA,"HeLa: 52.4;WM-115: 167.8"
"C1GALT1","C1GALT, T-synthase","ENSG00000106392","Core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1","7","7156934-7248651","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA011294, HPA012819","Enhanced",NA,"Approved","Nuclear bodies<br>Cytosol","Liver cancer:1.42e-5 (unfavourable), Cervical cancer:1.04e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 95.0","Expressed in all",NA,NA
"C1orf162","MGC24133","ENSG00000143110","Chromosome 1 open reading frame 162","1","111473792-111478512","Predicted membrane proteins","Evidence at protein level","HPA026988","Approved",NA,NA,NA,"Renal cancer:3.14e-6 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"spleen: 129.3","Cell line enhanced",NA,"HDLM-2: 121.3;HL-60: 50.8;THP-1: 33.7;U-937: 81.9"
"C1orf21","PIG13","ENSG00000116667","Chromosome 1 open reading frame 21","1","184387058-184629020","Predicted intracellular proteins","Evidence at protein level","HPA026831","Uncertain",NA,"Approved","Nucleoplasm<br>Cytosol","Renal cancer:3.35e-8 (unfavourable)","Expressed in all","Mixed",NA,NA,"skin: 30.1","Cell line enhanced",NA,"HDLM-2: 32.8"
"C1QTNF4","CTRP4, ZACRP4","ENSG00000172247","C1q and tumor necrosis factor related protein 4","11","47589664-47594659","Predicted secreted proteins","Evidence at protein level","HPA041032","Approved",NA,NA,NA,NA,"Mixed","Tissue enriched",5,"cerebral cortex: 28.2","parathyroid gland: 5.2","Cell line enriched",6,"REH: 10.4"
"C20orf194","DKFZp434N061","ENSG00000088854","Chromosome 20 open reading frame 194","20","3249305-3407625","Predicted intracellular proteins","Evidence at protein level","HPA052103, HPA067418","Approved",NA,"Approved","Nucleoli fibrillar center<br>Cytosol","Pancreatic cancer:1.68e-4 (favourable), Renal cancer:7.68e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 26.4","Mixed",NA,NA
"C2CD4C","FAM148C, KIAA1957, NLF3","ENSG00000183186","C2 calcium dependent domain containing 4C","19","405438-409170","Predicted intracellular proteins","Evidence at protein level","HPA055915","Uncertain",NA,"Approved","Vesicles",NA,"Tissue enhanced","Group enriched",6,"adipose tissue: 2.6;cerebral cortex: 10.6;gallbladder: 4.4","endometrium: 0.9","Cell line enhanced",NA,"HDLM-2: 5.9;NTERA-2: 6.2;SCLC-21H: 13.0;U-2 OS: 6.8"
"C2orf70","LOC339778","ENSG00000173557","Chromosome 2 open reading frame 70","2","26562582-26579532","Predicted intracellular proteins","Evidence at protein level","HPA062453","Enhanced",NA,"Approved","Nuclear membrane<br>Vesicles","Pancreatic cancer:6.49e-4 (favourable)","Mixed","Group enriched",6,"fallopian tube: 12.0;stomach: 4.9;testis: 17.5","thyroid gland: 1.9","Cell line enhanced",NA,"A-431: 3.6;CAPAN-2: 2.7;EFO-21: 1.8;RPTEC TERT1: 2.8"
"C2orf82","ASCL830, UNQ830","ENSG00000182600","Chromosome 2 open reading frame 82","2","232857270-232878708","Predicted intracellular proteins, Predicted membrane proteins","Evidence at transcript level","HPA052824","Uncertain",NA,"Approved","Nucleus<br>Nucleoli","Endometrial cancer:3.56e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"breast: 5.1;testis: 4.1","cerebral cortex: 2.6","Cell line enriched",13,"Hep G2: 40.1"
"C3","ARMD9, C3a, C3b, CPAMD1","ENSG00000125730","Complement C3","19","6677704-6730562","Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA003563, CAB004209, HPA020432","Enhanced",NA,NA,NA,"Renal cancer:1.09e-5 (unfavourable), Liver cancer:8.11e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"liver: 2486.8","Group enriched",6,"BJ hTERT+: 287.5;EFO-21: 689.2;Hep G2: 539.6;HSkMC: 386.3;SiHa: 220.2"
"C6orf1","LBH, MGC57858","ENSG00000186577","Chromosome 6 open reading frame 1","6","34246380-34249470","Predicted intracellular proteins, Predicted membrane proteins","Evidence at transcript level","HPA037659, HPA037660","Uncertain",NA,NA,NA,"Renal cancer:4.38e-4 (unfavourable), Pancreatic cancer:7.98e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 57.3","Expressed in all",NA,NA
"C6orf163",NA,"ENSG00000203872","Chromosome 6 open reading frame 163","6","87344849-87365463","Predicted intracellular proteins","Evidence at protein level","HPA044797, HPA052927","Uncertain",NA,"Uncertain","Nucleoplasm",NA,"Mixed","Tissue enriched",6,"testis: 14.0","fallopian tube: 2.4","Mixed",NA,NA
"C6orf58","LEG1","ENSG00000184530","Chromosome 6 open reading frame 58","6","127519455-127591817","Predicted secreted proteins","Evidence at protein level","HPA036263, HPA041449","Enhanced",NA,NA,NA,NA,"Group enriched","Group enriched",21,"duodenum: 603.5;salivary gland: 163.4;stomach: 314.9","esophagus: 17.1","Cell line enhanced",NA,"RPMI-8226: 1.8;WM-115: 1.8"
"C6orf89","BRAP, FLJ25357","ENSG00000198663","Chromosome 6 open reading frame 89","6","36871870-36928964","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA012548","Uncertain",NA,NA,NA,"Renal cancer:5.77e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 97.2","Expressed in all",NA,NA
"C7orf55-LUC7L2",NA,"ENSG00000269955","C7orf55-LUC7L2 readthrough","7","139341360-139422599","Predicted intracellular proteins","Evidence at protein level","HPA045663, HPA051631","Approved",NA,"Approved","Nucleus",NA,"Not detected","Expressed in all",NA,NA,"skeletal muscle: 21.1","Expressed in all",NA,NA
"C9orf135",NA,"ENSG00000204711","Chromosome 9 open reading frame 135","9","69820793-69906232","Predicted intracellular proteins","Evidence at protein level","HPA021261, HPA021325","Uncertain",NA,NA,NA,NA,"Tissue enriched","Group enriched",8,"fallopian tube: 55.2;testis: 24.3","parathyroid gland: 5.1","Group enriched",9,"HAP1: 11.5;NTERA-2: 29.5"
"C9orf24","bA573M23.4, CBE1, MGC32921, MGC33614, NYD-SP22, SMRP1","ENSG00000164972","Chromosome 9 open reading frame 24","9","34379019-34397832","Predicted intracellular proteins","Evidence at protein level","HPA053008","Enhanced",NA,NA,NA,"Endometrial cancer:3.23e-5 (favourable), Pancreatic cancer:1.75e-4 (favourable)","Tissue enhanced","Group enriched",11,"fallopian tube: 173.9;testis: 65.3","lung: 10.9","Not detected",NA,NA
"CAB39","CGI-66, MO25","ENSG00000135932","Calcium binding protein 39","2","230712845-230821075","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB037112","Supported",NA,"Approved","Nucleoli fibrillar center<br>Cytosol","Renal cancer:9.05e-6 (favourable), Pancreatic cancer:8.33e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 78.9","Expressed in all",NA,NA
"CACNA2D1","CACNA2, CACNL2A, LINC01112, lncRNA-N3, MHS3","ENSG00000153956","Calcium voltage-gated channel auxiliary subunit alpha2delta 1","7","81946444-82443798","FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA008213, HPA008621","Enhanced",NA,NA,NA,"Renal cancer:1.16e-4 (unfavourable)","Mixed","Mixed",NA,NA,"cerebral cortex: 35.4","Cell line enhanced",NA,"HUVEC TERT2: 45.6;SH-SY5Y: 66.1"
"CACNG8",NA,"ENSG00000142408","Calcium voltage-gated channel auxiliary subunit gamma 8","19","53963040-53990215","Predicted membrane proteins, Transporters","Evidence at protein level","HPA041351","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",34,"cerebral cortex: 23.7","testis: 0.6","Cell line enhanced",NA,"AF22: 7.2;HMC-1: 21.1;TIME: 12.3"
"CADPS","CAPS, CAPS1, KIAA1121, UNC-31","ENSG00000163618","Calcium dependent secretion activator","3","62398346-62875389","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA059328","Enhanced",NA,"Approved","Vesicles",NA,"Mixed","Group enriched",8,"adrenal gland: 21.6;cerebral cortex: 94.1","heart muscle: 7.5","Cell line enhanced",NA,"SCLC-21H: 23.2;SK-MEL-30: 7.0;U-698: 8.9;U-87 MG: 20.1"
"CALB2","CAL2","ENSG00000172137","Calbindin 2","16","71358713-71390438","Plasma proteins, Predicted intracellular proteins, Transporters","Evidence at protein level","CAB000106, HPA007305, HPA007306","Enhanced","Supported","Enhanced","Cytosol","Colorectal cancer:5.78e-5 (unfavourable)","Mixed","Tissue enhanced",NA,"adipose tissue: 54.6;testis: 24.9","adrenal gland: 12.7","Cell line enhanced",NA,"HEL: 57.0;HMC-1: 116.3;U-2 OS: 39.2"
"CALCR","CTR","ENSG00000004948","Calcitonin receptor","7","93424487-93574730","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA028962, HPA061428","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enhanced",NA,"kidney: 2.1;testis: 1.4","placenta: 1.0","Cell line enhanced",NA,"RPTEC TERT1: 1.5;T-47d: 3.6"
"CALD1","CDM, H-CAD, L-CAD","ENSG00000122786","Caldesmon 1","7","134744252-134970728","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB000006, HPA008066, HPA017330","Enhanced",NA,"Enhanced","Plasma membrane<br>Actin filaments","Renal cancer:1.84e-5 (unfavourable), Melanoma:3.73e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"seminal vesicle: 1289.8","smooth muscle: 1185.8","Cell line enhanced",NA,"fHDF/TERT166: 910.7"
"CALHM1","FAM26C","ENSG00000185933","Calcium homeostasis modulator 1","10","103453387-103458888","Predicted membrane proteins, Transporters","Evidence at protein level","HPA018317","Uncertain",NA,NA,NA,NA,"Not detected","Tissue enhanced",NA,"cerebral cortex: 1.8","kidney: 0.6","Cell line enhanced",NA,"U-266/70: 1.0;U-266/84: 1.2"
"CALN1",NA,"ENSG00000183166","Calneuron 1","7","71779491-72447151","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA036278, HPA036708","Approved",NA,"Uncertain","Vesicles<br>Plasma membrane",NA,"Mixed","Group enriched",5,"adrenal gland: 14.7;cerebral cortex: 46.4","testis: 6.0","Cell line enhanced",NA,"Karpas-707: 33.8;NTERA-2: 6.0;REH: 6.4;SCLC-21H: 7.8;U-2 OS: 7.6"
"CAMK2D","CAMKD","ENSG00000145349","Calcium/calmodulin dependent protein kinase II delta","4","113451032-113761927","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA026281, HPA051783, HPA051785, HPA053973","Approved",NA,"Supported","Plasma membrane<br>Cell Junctions<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"heart muscle: 110.3","Mixed",NA,NA
"CAMK2G","CAMKG","ENSG00000148660","Calcium/calmodulin dependent protein kinase II gamma","10","73812501-73874591","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA040656, HPA051783, HPA051785, HPA053973","Approved",NA,"Supported","Plasma membrane<br>Cell Junctions<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 119.0","Expressed in all",NA,NA
"CAMK4","CaMK-GR","ENSG00000152495","Calcium/calmodulin dependent protein kinase IV","5","111223653-111494886","Enzymes, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","CAB004347, HPA011753, HPA017206","Approved",NA,"Supported","Nucleoplasm<br>Nucleoli fibrillar center",NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 16.5;testis: 17.0","lymph node: 9.7","Cell line enhanced",NA,"HDLM-2: 83.9;SH-SY5Y: 35.7"
"CAMKK1","CAMKKA, DKFZp761M0423, MGC34095","ENSG00000004660","Calcium/calmodulin dependent protein kinase kinase 1","17","3860315-3894891","Enzymes, Predicted intracellular proteins","Evidence at protein level","CAB009111, HPA028062","Approved",NA,"Supported","Cytosol","Pancreatic cancer:2.65e-4 (favourable)","Mixed","Tissue enhanced",NA,"cerebral cortex: 51.5","seminal vesicle: 14.7","Cell line enhanced",NA,"U-87 MG: 27.3"
"CAMLG","CAML, GET2","ENSG00000164615","Calcium modulating ligand","5","134738501-134752160","FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters","Evidence at protein level","HPA052636, HPA056472","Approved",NA,"Approved","Nucleus<br>Nucleoli<br>Vesicles","Renal cancer:1.09e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 99.6","Expressed in all",NA,NA
"CAMP","CAP18, FALL-39, FALL39, LL37","ENSG00000164047","Cathelicidin antimicrobial peptide","3","48223347-48225491","Predicted secreted proteins","Evidence at protein level","CAB015949, CAB016522, HPA029874","Enhanced",NA,NA,NA,"Cervical cancer:5.73e-4 (favourable)","Tissue enhanced","Group enriched",101,"bone marrow: 1341.0;epididymis: 330.5","lymph node: 8.2","Group enriched",12,"Daudi: 18.4;hTCEpi: 12.5;U-698: 50.9"
"CAMSAP1","DKFZp434F195, FLJ31228","ENSG00000130559","Calmodulin regulated spectrin associated protein 1","9","135808487-135907228","Predicted intracellular proteins","Evidence at protein level","HPA020527, HPA024161","Approved",NA,"Supported","Mitotic spindle<br>Cytosol","Renal cancer:3.09e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 34.2","Expressed in all",NA,NA
"CANT1","SCAN-1, SHAPY","ENSG00000171302","Calcium activated nucleotidase 1","17","78991717-79009867","Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA019627, HPA019639, HPA022818","Enhanced",NA,NA,NA,"Liver cancer:1.41e-4 (unfavourable), Lung cancer:2.90e-4 (unfavourable), Renal cancer:6.21e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"prostate: 115.7","Expressed in all",NA,NA
"CANX","CNX, IP90, P90","ENSG00000127022","Calnexin","5","179678628-179730925","Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB004738, HPA009433, HPA009696","Enhanced",NA,"Enhanced","Endoplasmic reticulum","Colorectal cancer:1.38e-4 (favourable), Thyroid cancer:3.17e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 294.4","Expressed in all",NA,NA
"CAP2",NA,"ENSG00000112186","CAP, adenylate cyclase-associated protein, 2 (yeast)","6","17393216-17557792","Cancer-related genes, Predicted intracellular proteins","Evidence at protein level","HPA050530, HPA054147","Enhanced",NA,"Approved","Nucleoplasm<br>Plasma membrane<br>Cytosol",NA,"Expressed in all","Tissue enhanced",NA,"cerebral cortex: 125.1;skeletal muscle: 220.8","heart muscle: 70.1","Mixed",NA,NA
"CAPNS2","MGC12536, MGC14804","ENSG00000256812","Calpain small subunit 2","16","55566672-55567687","Predicted intracellular proteins","Evidence at protein level","HPA059749, HPA076768","Enhanced",NA,"Approved","Cytosol",NA,"Group enriched","Tissue enhanced",NA,"esophagus: 59.9;skin: 109.3","urinary bladder: 30.3","Cell line enriched",8,"hTCEpi: 158.7"
"CARD19","bA370F5.1, BinCARD, C9orf89, MGC11115","ENSG00000165233","Caspase recruitment domain family member 19","9","93096218-93113283","Predicted membrane proteins","Evidence at protein level","HPA010921, HPA010990, HPA038297","Approved",NA,"Supported","Mitochondria","Liver cancer:1.32e-5 (unfavourable), Glioma:6.41e-5 (unfavourable)","Expressed in all","Mixed",NA,NA,"testis: 11.1","Expressed in all",NA,NA
"CARD9",NA,"ENSG00000187796","Caspase recruitment domain family member 9","9","136361903-136373681","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA059502","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"bone marrow: 7.1;spleen: 8.2","appendix: 5.7","Cell line enhanced",NA,"HMC-1: 49.3;NB-4: 30.7;THP-1: 30.1"
"CARTPT","CART","ENSG00000164326","CART prepropeptide","5","71719163-71721048","FDA approved drug targets, Predicted secreted proteins","Evidence at protein level","CAB025515, HPA046278","Enhanced",NA,NA,NA,"Stomach cancer:4.36e-4 (unfavourable)","Tissue enriched","Tissue enriched",8,"adrenal gland: 132.5","cerebral cortex: 17.4","Not detected",NA,NA
"CBFA2T2","MTGR1, ZMYND3","ENSG00000078699","CBFA2/RUNX1 translocation partner 2","20","33490075-33650036","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA060523, HPA072433","Enhanced",NA,"Approved","Nuclear speckles","Pancreatic cancer:6.93e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"prostate: 24.2","Expressed in all",NA,NA
"CBLL1","FLJ23109, HAKAI, RNF188","ENSG00000105879","Cbl proto-oncogene like 1","7","107743697-107761667","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA021773, HPA026699","Enhanced",NA,"Supported","Nuclear speckles",NA,"Expressed in all","Expressed in all",NA,NA,"testis: 36.2","Expressed in all",NA,NA
"CBX7",NA,"ENSG00000100307","Chromobox 7","22","39120167-39152674","Predicted intracellular proteins","Evidence at protein level","CAB011574, HPA048677, HPA056480","Enhanced",NA,"Supported","Nucleoplasm<br>Cytosol","Renal cancer:2.45e-5 (favourable), Pancreatic cancer:1.04e-4 (favourable), Cervical cancer:3.63e-4 (favourable), Colorectal cancer:3.73e-4 (unfavourable), Breast cancer:6.18e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"seminal vesicle: 81.6","Cell line enhanced",NA,"HDLM-2: 34.6"
"CC2D1B","KIAA1836","ENSG00000154222","Coiled-coil and C2 domain containing 1B","1","52345723-52366193","Predicted intracellular proteins","Evidence at protein level","HPA027500, HPA031426","Uncertain",NA,"Supported","Nucleoplasm<br>Vesicles","Liver cancer:1.45e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"lung: 18.7","Expressed in all",NA,NA
"CCDC14","DKFZp434L1050, FLJ12892","ENSG00000175455","Coiled-coil domain containing 14","3","123897305-123961408","Predicted intracellular proteins","Evidence at protein level","HPA035278, HPA035279","Uncertain",NA,"Enhanced","Centrosome","Renal cancer:3.50e-8 (unfavourable), Urothelial cancer:2.72e-5 (favourable), Prostate cancer:4.76e-4 (unfavourable), Liver cancer:4.82e-4 (unfavourable), Head and neck cancer:5.27e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 46.5","Expressed in all",NA,NA
"CCDC181","C1orf114, FLJ25846","ENSG00000117477","Coiled-coil domain containing 181","1","169394870-169460669","Predicted intracellular proteins","Evidence at protein level","HPA027189, HPA027275, HPA027281, HPA027312","Enhanced",NA,"Approved","Nuclear speckles",NA,"Mixed","Tissue enhanced",NA,"parathyroid gland: 22.9;testis: 49.6","fallopian tube: 19.6","Cell line enhanced",NA,"NTERA-2: 13.8;SCLC-21H: 9.9;SH-SY5Y: 10.5"
"CCDC34","L15, NY-REN-41, RAMA3","ENSG00000109881","Coiled-coil domain containing 34","11","27330827-27363868","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA037574","Uncertain",NA,"Approved","Nuclear membrane<br>Nucleoli fibrillar center","Liver cancer:1.32e-7 (unfavourable), Renal cancer:1.82e-4 (unfavourable), Ovarian cancer:8.52e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"testis: 54.8","fallopian tube: 13.4","Expressed in all",NA,NA
"CCDC39","CILD14, DKFZp434A128, FAP59","ENSG00000145075","Coiled-coil domain containing 39","3","180602858-180871005","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA035363, HPA035364","Enhanced",NA,NA,NA,NA,"Mixed","Mixed",NA,NA,"lymph node: 23.7","Mixed",NA,NA
"CCL19","CKb11, ELC, exodus-3, MIP-3b, SCYA19","ENSG00000172724","C-C motif chemokine ligand 19","9","34689567-34691277","Cancer-related genes, Predicted secreted proteins","Evidence at protein level","HPA067758","Enhanced",NA,NA,NA,"Renal cancer:8.63e-7 (unfavourable), Cervical cancer:9.91e-6 (favourable), Breast cancer:2.88e-5 (favourable)","Expressed in all","Group enriched",5,"adipose tissue: 173.8;appendix: 771.8;lymph node: 703.2;tonsil: 556.0","gallbladder: 107.9","Cell line enhanced",NA,"HDLM-2: 2.9;TIME: 1.2"
"CCL21","6Ckine, CKb9, ECL, exodus-2, SCYA21, SLC, TCA4","ENSG00000137077","C-C motif chemokine ligand 21","9","34709005-34710124","Cancer-related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB005067, HPA051210","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"lymph node: 3155.9","tonsil: 946.7","Cell line enhanced",NA,"K-562: 1.0"
"CCNB2","HsT17299","ENSG00000157456","Cyclin B2","15","59105078-59125045","Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters","Evidence at protein level","HPA008873, CAB009575","Enhanced",NA,"Enhanced","Golgi apparatus<br>Cytosol","Renal cancer:0.00e+0 (unfavourable), Pancreatic cancer:1.74e-5 (unfavourable), Melanoma:3.21e-5 (unfavourable), Liver cancer:2.83e-4 (unfavourable), Lung cancer:4.63e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"testis: 122.6","bone marrow: 44.7","Expressed in all",NA,NA
"CCR7","BLR2, CD197, CDw197, CMKBR7, EBI1","ENSG00000126353","C-C motif chemokine receptor 7","17","40553769-40565472","Cancer-related genes, CD markers, G-protein coupled receptors, Predicted membrane proteins","Evidence at protein level","CAB003796, HPA031383, HPA074467","Enhanced",NA,"Supported","Mitochondria","Head and neck cancer:7.61e-7 (favourable), Cervical cancer:8.03e-6 (favourable), Breast cancer:3.84e-4 (favourable), Testis cancer:7.72e-4 (unfavourable)","Mixed","Group enriched",6,"appendix: 88.8;lymph node: 97.1;spleen: 39.3;tonsil: 77.2","urinary bladder: 12.4","Cell line enriched",79,"HDLM-2: 1284.5"
"CCT2","Cctb","ENSG00000166226","Chaperonin containing TCP1 subunit 2","12","69585334-69601570","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA003197, HPA003198","Enhanced",NA,"Supported","Cytosol","Liver cancer:3.61e-9 (unfavourable), Prostate cancer:3.67e-4 (unfavourable), Head and neck cancer:8.38e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 367.6","Expressed in all",NA,NA
"CCT5","KIAA0098","ENSG00000150753","Chaperonin containing TCP1 subunit 5","5","10249921-10266412","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA002238, HPA005958, CAB006271","Enhanced",NA,"Supported","Nucleoli<br>Cytosol","Liver cancer:6.57e-11 (unfavourable), Renal cancer:8.23e-6 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 190.8","Expressed in all",NA,NA
"CD14",NA,"ENSG00000170458","CD14 molecule","5","140631728-140633701","Cancer-related genes, CD markers, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA001887, HPA002127, CAB033631, CAB072865, CAB072866","Enhanced",NA,"Supported","Vesicles","Renal cancer:6.80e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"appendix: 267.3","Cell line enhanced",NA,"A549: 8.6;CACO-2: 12.0;SiHa: 18.3"
"CD163","M130, MM130, SCARI1","ENSG00000177575","CD163 molecule","12","7470813-7503893","CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","CAB002432, HPA046404, HPA051974","Enhanced",NA,"Approved","Plasma membrane","Ovarian cancer:7.27e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"appendix: 220.1","Cell line enhanced",NA,"HSkMC: 1.2"
"CD164","DFNA66, MGC-24, MUC-24","ENSG00000135535","CD164 molecule","6","109366514-109382457","CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA010636","Uncertain",NA,NA,NA,NA,"Expressed in all","Expressed in all",NA,NA,"thyroid gland: 613.1","Expressed in all",NA,NA
"CD177","HNA2A, NB1, PRV1","ENSG00000204936","CD177 molecule","19","43353659-43363172","Predicted secreted proteins","Evidence at protein level","HPA041820, HPA046601","Enhanced",NA,NA,NA,"Cervical cancer:3.66e-4 (favourable)","Tissue enhanced","Group enriched",16,"bone marrow: 193.1;colon: 155.7;prostate: 105.4;rectum: 181.9","appendix: 9.7","Cell line enriched",23,"RPMI-8226: 65.6"
"CD180","LY64, Ly78, RP105","ENSG00000134061","CD180 molecule","5","67179613-67196799","CD markers, Predicted membrane proteins","Evidence at protein level","HPA003740","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"lymph node: 27.4;tonsil: 21.3","spleen: 17.8","Group enriched",11,"Daudi: 32.2;Karpas-707: 29.5;U-266/70: 25.3;U-266/84: 34.5;U-698: 8.6"
"CD19",NA,"ENSG00000177455","CD19 molecule","16","28931939-28939346","CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins","Evidence at protein level","CAB016110","Enhanced",NA,NA,NA,NA,"Mixed","Group enriched",11,"appendix: 37.4;lymph node: 84.0;spleen: 47.4;tonsil: 68.3","urinary bladder: 5.5","Group enriched",40,"Daudi: 103.6;REH: 70.5;U-698: 22.6"
"CD2","SRBC","ENSG00000116824","CD2 molecule","1","116754385-116769228","CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB002430, HPA003883","Enhanced",NA,NA,NA,"Renal cancer:4.82e-6 (unfavourable), Endometrial cancer:1.69e-5 (favourable), Melanoma:3.97e-5 (favourable), Head and neck cancer:7.46e-5 (favourable), Cervical cancer:1.47e-4 (favourable), Breast cancer:4.36e-4 (favourable), Ovarian cancer:7.72e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"lymph node: 131.1","tonsil: 70.8","Group enriched",27,"HDLM-2: 201.2;MOLT-4: 129.2"
"CD200","MOX1, MOX2, MRC, OX-2","ENSG00000091972","CD200 molecule","3","112332347-112362812","CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA031149","Approved",NA,NA,NA,NA,"Expressed in all","Mixed",NA,NA,"cerebral cortex: 78.6","Cell line enhanced",NA,"AF22: 74.9;NTERA-2: 47.6;REH: 38.6;WM-115: 82.4"
"CD247","CD3H, CD3Q, CD3Z","ENSG00000198821","CD247 molecule","1","167430640-167518610","CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins","Evidence at protein level","CAB004651, HPA008750","Enhanced",NA,NA,NA,"Endometrial cancer:8.63e-6 (favourable), Renal cancer:9.94e-6 (unfavourable), Head and neck cancer:3.98e-4 (favourable), Breast cancer:9.12e-4 (favourable)","Mixed","Tissue enhanced",NA,"lymph node: 65.1;spleen: 48.6","tonsil: 33.6","Group enriched",34,"HDLM-2: 144.2;MOLT-4: 133.0"
"CD27","S152, TNFRSF7, Tp55","ENSG00000139193","CD27 molecule","12","6444867-6451718","Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins","Evidence at protein level","CAB002420, HPA038936","Enhanced",NA,NA,NA,"Head and neck cancer:6.65e-7 (favourable), Renal cancer:1.19e-6 (unfavourable), Cervical cancer:3.77e-5 (favourable), Endometrial cancer:2.90e-4 (favourable), Melanoma:5.50e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"lymph node: 140.5;tonsil: 85.8","spleen: 67.8","Group enriched",122,"Daudi: 153.8;U-698: 81.7"
"CD28",NA,"ENSG00000178562","CD28 molecule","2","203706475-203738912","CD markers, Predicted membrane proteins","Evidence at protein level","HPA070003","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"lymph node: 32.4;placenta: 20.9","appendix: 18.6","Group enriched",12,"Karpas-707: 257.5;RPMI-8226: 118.2;U-266/70: 222.7;U-266/84: 196.1"
"CD2AP","CMS","ENSG00000198087","CD2 associated protein","6","47477789-47627263","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA003267, HPA003326, CAB004352","Enhanced",NA,"Enhanced","Plasma membrane<br>Cytosol","Pancreatic cancer:5.53e-5 (unfavourable), Urothelial cancer:7.57e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 65.8","Expressed in all",NA,NA
"CD34",NA,"ENSG00000174059","CD34 molecule","1","207880972-207911402","CD markers, Predicted membrane proteins","Evidence at protein level","CAB000018, HPA036722, HPA036723","Enhanced",NA,"Approved","Nucleus<br>Plasma membrane<br>Cell Junctions","Head and neck cancer:5.93e-5 (favourable), Renal cancer:8.47e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 316.6","Group enriched",7,"HUVEC TERT2: 53.6;MOLT-4: 53.1"
"CD36","FAT, GP3B, GP4, GPIV, SCARB3","ENSG00000135218","CD36 molecule","7","80369575-80679277","Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters","Evidence at protein level","HPA002018, CAB025866, HPA071026","Enhanced",NA,"Enhanced","Golgi apparatus","Stomach cancer:4.47e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"adipose tissue: 1617.9","Cell line enhanced",NA,"ASC diff: 218.9;HEL: 144.7"
"CD37","TSPAN26","ENSG00000104894","CD37 molecule","19","49335171-49343335","CD markers, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","CAB002492, HPA032120, HPA032121","Enhanced",NA,NA,NA,"Endometrial cancer:4.51e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"lymph node: 241.4;spleen: 208.7","appendix: 129.0","Cell line enhanced",NA,"Daudi: 215.5;HMC-1: 252.2;RPMI-8226: 75.0;THP-1: 72.1"
"CD3D","T3D","ENSG00000167286","CD3d molecule","11","118338954-118342744","CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB013055","Enhanced",NA,NA,NA,"Endometrial cancer:1.73e-7 (favourable), Renal cancer:3.07e-5 (unfavourable), Cervical cancer:8.46e-5 (favourable), Head and neck cancer:1.70e-4 (favourable), Breast cancer:3.00e-4 (favourable), Urothelial cancer:6.16e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"lymph node: 199.3;tonsil: 119.1","appendix: 86.9","Cell line enriched",7,"MOLT-4: 903.0"
"CD3E",NA,"ENSG00000198851","CD3e molecule","11","118304545-118316175","CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins","Evidence at protein level","CAB000010, HPA040957, HPA043955, CAB072863, CAB072864","Enhanced",NA,NA,NA,"Endometrial cancer:2.30e-6 (favourable), Renal cancer:1.12e-5 (unfavourable), Melanoma:1.18e-4 (favourable), Head and neck cancer:1.32e-4 (favourable), Cervical cancer:1.62e-4 (favourable), Breast cancer:1.72e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"lymph node: 200.5;tonsil: 113.4","spleen: 95.0","Cell line enriched",92,"MOLT-4: 531.3"
"CD40","Bp50, p50, TNFRSF5","ENSG00000101017","CD40 molecule","20","46118272-46129863","Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB002495, HPA031567, HPA031568, CAB072868","Enhanced",NA,NA,NA,"Renal cancer:4.48e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"lymph node: 64.7","Cell line enhanced",NA,"CAPAN-2: 63.4;EFO-21: 116.6"
"CD40LG","CD154, CD40L, gp39, hCD40L, HIGM1, IMD3, TNFSF5, TRAP","ENSG00000102245","CD40 ligand","X","136648193-136660390","Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Predicted membrane proteins","Evidence at protein level","HPA045827","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"lymph node: 18.8;tonsil: 14.1","appendix: 10.5","Cell line enriched",65,"MOLT-4: 19.2"
"CD46","MCP, MGC26544, MIC10, TLX, TRA2.10","ENSG00000117335","CD46 molecule","1","207752057-207795513","Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins","Evidence at protein level","CAB010401, HPA016903","Enhanced",NA,"Approved","Plasma membrane","Cervical cancer:8.54e-5 (unfavourable), Stomach cancer:2.38e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 489.1","Expressed in all",NA,NA
"CD48","BCM1, BLAST, hCD48, mCD48, SLAMF2","ENSG00000117091","CD48 molecule","1","160678746-160711851","CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB002497, HPA055146","Enhanced",NA,"Supported","Nucleoli fibrillar center<br>Plasma membrane<br>Cytosol","Renal cancer:3.36e-4 (unfavourable), Breast cancer:3.91e-4 (favourable), Colorectal cancer:4.17e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"lymph node: 311.4;spleen: 213.1;tonsil: 226.0","appendix: 148.5","Cell line enhanced",NA,"Daudi: 153.4;HMC-1: 202.6;U-266/70: 372.1;U-266/84: 244.7"
"CD5","LEU1, T1","ENSG00000110448","CD5 molecule","11","61102395-61127852","CD markers, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB015392, CAB020308, HPA043416, HPA060839","Enhanced",NA,NA,NA,"Head and neck cancer:7.41e-6 (favourable), Renal cancer:8.94e-5 (unfavourable), Endometrial cancer:9.00e-5 (favourable), Cervical cancer:9.16e-5 (favourable), Melanoma:3.93e-4 (favourable), Breast cancer:4.05e-4 (favourable)","Mixed","Tissue enhanced",NA,"appendix: 29.8;lymph node: 43.0","tonsil: 20.2","Cell line enriched",71,"MOLT-4: 56.4"
"CD5L","API6, Spalpha","ENSG00000073754","CD5 molecule like","1","157830914-157898256","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA065686, HPA068384","Enhanced",NA,NA,NA,"Liver cancer:8.88e-5 (favourable)","Tissue enriched","Tissue enriched",14,"spleen: 787.1","liver: 54.4","Not detected",NA,NA
"CD6","Tp120","ENSG00000013725","CD6 molecule","11","60971680-61020377","CD markers, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB002489, CAB016252","Enhanced",NA,NA,NA,"Head and neck cancer:5.10e-6 (favourable), Cervical cancer:1.57e-5 (favourable), Renal cancer:1.82e-4 (unfavourable), Breast cancer:1.95e-4 (favourable), Endometrial cancer:2.41e-4 (favourable)","Mixed","Tissue enhanced",NA,"appendix: 28.5;lymph node: 49.2","tonsil: 26.8","Cell line enriched",17,"MOLT-4: 31.3"
"CD69","CLEC2C","ENSG00000110848","CD69 molecule","12","9752486-9760901","CD markers, Predicted membrane proteins","Evidence at protein level","CAB002503, HPA050525","Enhanced",NA,NA,NA,"Breast cancer:3.31e-5 (favourable), Renal cancer:7.87e-5 (unfavourable)","Mixed","Tissue enhanced",NA,"bone marrow: 105.9;lymph node: 109.1","appendix: 64.1","Cell line enhanced",NA,"HL-60: 23.7;K-562: 52.0;U-937: 76.0"
"CD7","GP40, LEU-9, Tp40, TP41","ENSG00000173762","CD7 molecule","17","82314868-82317602","CD markers, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB002594, HPA039079","Enhanced",NA,NA,NA,"Renal cancer:7.75e-11 (unfavourable), Endometrial cancer:2.03e-5 (favourable), Melanoma:2.69e-4 (favourable), Cervical cancer:5.51e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"appendix: 43.1;lymph node: 41.5;spleen: 43.1","small intestine: 17.0","Group enriched",5,"Hep G2: 35.2;MOLT-4: 95.7"
"CD72","CD72b, LYB2","ENSG00000137101","CD72 molecule","9","35609533-35646810","CD markers, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","CAB002505, HPA044658","Enhanced",NA,"Approved","Nucleus<br>Mitochondria","Renal cancer:2.49e-8 (unfavourable)","Expressed in all","Group enriched",8,"appendix: 25.1;lymph node: 71.1;spleen: 64.7;tonsil: 42.6","gallbladder: 6.2","Cell line enhanced",NA,"Daudi: 13.0;Karpas-707: 8.1;REH: 7.0;U-698: 27.7"
"CD74","DHLAG","ENSG00000019582","CD74 molecule","5","150401637-150412929","Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins","Evidence at protein level","CAB002506, HPA010592","Enhanced",NA,"Supported","Golgi apparatus","Endometrial cancer:6.53e-6 (favourable), Breast cancer:1.06e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"spleen: 6545.9","Cell line enhanced",NA,"CAPAN-2: 1796.9;Daudi: 2297.1;HDLM-2: 4315.9;REH: 2549.8"
"CD79A","IGA, MB-1","ENSG00000105369","CD79a molecule","19","41877120-41881372","Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB000019","Enhanced",NA,NA,NA,"Head and neck cancer:1.18e-5 (favourable), Renal cancer:2.15e-5 (unfavourable), Breast cancer:8.45e-5 (favourable)","Mixed","Group enriched",6,"appendix: 263.8;lymph node: 515.1;spleen: 317.9;tonsil: 423.1","stomach: 63.3","Group enriched",23,"Daudi: 1084.6;REH: 432.6;U-698: 905.8"
"CD79B","B29, IGB","ENSG00000007312","CD79b molecule","17","63928740-63932354","Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins","Evidence at protein level","HPA009178, CAB009751","Enhanced",NA,"Uncertain","Nucleoplasm<br>Plasma membrane<br>Cytosol","Head and neck cancer:2.35e-4 (favourable)","Expressed in all","Group enriched",5,"appendix: 91.1;lymph node: 311.5;spleen: 157.4;tonsil: 189.1","bone marrow: 36.1","Group enriched",17,"Daudi: 751.6;REH: 317.0;U-698: 986.5"
"CD8A","CD8","ENSG00000153563","CD8a molecule","2","86784610-86808396","CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB000012, HPA037756, CAB075722","Enhanced",NA,NA,NA,"Endometrial cancer:6.15e-6 (favourable), Renal cancer:1.91e-5 (unfavourable), Cervical cancer:4.54e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"spleen: 161.9","lymph node: 46.9","Cell line enriched",5,"MOLT-4: 11.7"
"CD99L2","CD99B, MIC2L1","ENSG00000102181","CD99 molecule like 2","X","150766337-150898816","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA038782, HPA038783, HPA061400","Enhanced",NA,"Supported","Plasma membrane","Pancreatic cancer:2.74e-5 (favourable), Lung cancer:4.96e-4 (favourable), Urothelial cancer:8.74e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 143.5","Expressed in all",NA,NA
"CDA","CDD","ENSG00000158825","Cytidine deaminase","1","20588948-20618908","Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA064202","Enhanced",NA,"Approved","Nucleoplasm","Pancreatic cancer:8.56e-5 (unfavourable), Cervical cancer:5.05e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"bone marrow: 104.6;esophagus: 56.7","liver: 33.3","Cell line enhanced",NA,"A-431: 142.3;CAPAN-2: 92.8;HeLa: 100.6;SiHa: 200.2"
"CDC42BPG","DMPK2, HSMDPKIN, kappa-200, MRCKgamma","ENSG00000171219","CDC42 binding protein kinase gamma","11","64823387-64844569","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA027382, HPA061836","Enhanced",NA,"Supported","Cytosol","Renal cancer:5.99e-13 (favourable)","Mixed","Tissue enhanced",NA,"skin: 35.6","parathyroid gland: 14.5","Cell line enhanced",NA,"BEWO: 30.1;HaCaT: 21.0;MCF7: 25.1;SCLC-21H: 19.6"
"CDC5L","CDC5, CEF1, hCDC5, PCDC5RP","ENSG00000096401","Cell division cycle 5 like","6","44387525-44450426","Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA006302, HPA011361, CAB012275","Supported",NA,"Supported","Nucleoplasm","Melanoma:7.02e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 36.0","Expressed in all",NA,NA
"CDH10",NA,"ENSG00000040731","Cadherin 10","5","24487100-24644978","Predicted membrane proteins","Evidence at protein level","HPA010651","Approved",NA,NA,NA,NA,"Group enriched","Group enriched",20,"cerebral cortex: 32.6;prostate: 7.5","adrenal gland: 1.0","Cell line enhanced",NA,"AF22: 7.0;HAP1: 4.8;U-138 MG: 1.5"
"CDH13","CDHH","ENSG00000140945","Cadherin 13","16","82626803-83800640","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA001380, CAB025863","Enhanced",NA,"Supported","Plasma membrane","Renal cancer:1.73e-6 (unfavourable)","Expressed in all","Tissue enhanced",NA,"endometrium: 70.0","cervix, uterine: 66.4","Cell line enhanced",NA,"LHCN-M2: 185.2;U-138 MG: 276.1;U-87 MG: 239.0"
"CDH18","CDH14, EY-CADHERIN","ENSG00000145526","Cadherin 18","5","19472951-20575873","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA014416","Uncertain",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"adrenal gland: 5.9;cerebral cortex: 19.0","testis: 3.2","Cell line enhanced",NA,"EFO-21: 4.1;U-2 OS: 7.1;U-2197: 5.6"
"CDH9",NA,"ENSG00000113100","Cadherin 9","5","26880600-27121150","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA007167","Approved",NA,NA,NA,NA,"Not detected","Tissue enhanced",NA,"cerebral cortex: 11.4;kidney: 6.5","testis: 4.3","Cell line enhanced",NA,"K-562: 6.6;NTERA-2: 10.2"
"CDIPT","PIS, PIS1","ENSG00000103502","CDP-diacylglycerol--inositol 3-phosphatidyltransferase","16","29858357-29863736","Enzymes, Predicted membrane proteins","Evidence at protein level","HPA056597","Approved",NA,"Approved","Nucleoplasm<br>Nuclear membrane<br>Plasma membrane","Cervical cancer:9.40e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 112.7","Expressed in all",NA,NA
"CDK14","PFTAIRE1, PFTK1","ENSG00000058091","Cyclin dependent kinase 14","7","90466424-91210590","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA015267","Approved",NA,"Supported","Nucleus<br>Cytosol","Breast cancer:5.86e-4 (favourable), Stomach cancer:7.79e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 56.7","Mixed",NA,NA
"CDK18","PCTAIRE3, PCTK3","ENSG00000117266","Cyclin dependent kinase 18","1","205504595-205532793","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA045429","Approved",NA,"Approved","Actin filaments","Renal cancer:5.07e-6 (unfavourable), Urothelial cancer:2.81e-5 (favourable)","Expressed in all","Mixed",NA,NA,"heart muscle: 62.0","Cell line enhanced",NA,"HBEC3-KT: 25.4"
"CDK19","bA346C16.3, CDC2L6, CDK11, KIAA1028","ENSG00000155111","Cyclin dependent kinase 19","6","110609978-110815958","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA007053","Approved",NA,"Approved","Nucleoplasm<br>Vesicles","Renal cancer:4.72e-5 (unfavourable), Liver cancer:3.56e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"prostate: 42.4","Expressed in all",NA,NA
"CDK7","CAK, CAK1, CDKN7, MO15, STK1","ENSG00000134058","Cyclin dependent kinase 7","5","69234795-69277430","Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB004364, HPA007932","Enhanced",NA,NA,NA,"Renal cancer:9.42e-7 (unfavourable), Pancreatic cancer:3.09e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"testis: 23.7","Mixed",NA,NA
"CDO1",NA,"ENSG00000129596","Cysteine dioxygenase type 1","5","115804733-115816954","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA036573, HPA057503","Enhanced",NA,"Uncertain","Nucleoplasm","Liver cancer:1.91e-5 (favourable)","Group enriched","Tissue enhanced",NA,"epididymis: 137.5;liver: 209.9","adipose tissue: 104.0","Cell line enhanced",NA,"AF22: 38.7;ASC diff: 32.4;HAP1: 14.4;NTERA-2: 14.5"
"CDR2","CDR62, Yo","ENSG00000140743","Cerebellar degeneration related protein 2","16","22345936-22437165","Predicted intracellular proteins","Evidence at protein level","HPA018151, HPA023870","Uncertain",NA,"Approved","Nucleoplasm",NA,"Expressed in all","Expressed in all",NA,NA,"testis: 108.5","Expressed in all",NA,NA
"CDSN","D6S586E","ENSG00000204539","Corneodesmosin","6","31115090-31120446","Predicted secreted proteins","Evidence at protein level","HPA044730, HPA054184","Enhanced",NA,NA,NA,NA,"Group enriched","Tissue enriched",20,"skin: 77.0","epididymis: 3.7","Cell line enriched",7,"A-431: 1.4"
"CDV3","H41","ENSG00000091527","CDV3 homolog","3","133573730-133590261","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA029761, HPA029762, HPA029763","Enhanced",NA,"Enhanced","Nucleoli<br>Plasma membrane<br>Cytosol","Liver cancer:5.21e-6 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"lymph node: 185.6","Expressed in all",NA,NA
"CEBPE","CRP1","ENSG00000092067","CCAAT/enhancer binding protein epsilon","14","23117304-23119616","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA002928, CAB005113","Enhanced",NA,"Enhanced","Nucleoplasm",NA,"Not detected","Tissue enriched",9,"bone marrow: 26.0","small intestine: 2.7","Cell line enhanced",NA,"HL-60: 143.2;HMC-1: 26.7;NB-4: 58.7"
"CECR2","KIAA1740","ENSG00000099954","CECR2, histone acetyl-lysine reader","22","17359949-17558149","Predicted intracellular proteins","Evidence at protein level","HPA002943","Approved",NA,"Approved","Nucleus<br>Vesicles",NA,"Tissue enriched","Tissue enhanced",NA,"cerebral cortex: 7.8","skeletal muscle: 7.5","Cell line enhanced",NA,"AF22: 15.3;HAP1: 14.9;NTERA-2: 22.8;SCLC-21H: 11.9"
"CEL","BSSL, MODY8","ENSG00000170835","Carboxyl ester lipase","9","133061978-133071861","Predicted secreted proteins","Evidence at protein level","HPA008023, HPA052701","Enhanced",NA,NA,NA,"Breast cancer:4.14e-4 (unfavourable)","Tissue enriched","Tissue enriched",95,"pancreas: 23233.0","epididymis: 244.0","Mixed",NA,NA
"CELF3","BRUNOL1, CAGH4, ERDA4, MGC57297, TNRC4","ENSG00000159409","CUGBP Elav-like family member 3","1","151702404-151716814","Predicted intracellular proteins","Evidence at protein level","HPA006292","Uncertain",NA,"Approved","Nucleoplasm",NA,"Group enriched","Group enriched",6,"adrenal gland: 15.2;cerebral cortex: 51.7","stomach: 5.5","Group enriched",10,"SCLC-21H: 50.0;SH-SY5Y: 31.5"
"CELF4","BRUNOL4","ENSG00000101489","CUGBP Elav-like family member 4","18","37243047-37566037","Predicted intracellular proteins","Evidence at protein level","HPA037986","Approved",NA,NA,NA,NA,"Mixed","Tissue enriched",9,"cerebral cortex: 126.9","adrenal gland: 14.7","Group enriched",15,"SCLC-21H: 51.8;SH-SY5Y: 11.4"
"CELSR2","ADGRC2, CDHF10, EGFL2, Flamingo1, KIAA0279, MEGF3","ENSG00000143126","Cadherin EGF LAG seven-pass G-type receptor 2","1","109250019-109275750","G-protein coupled receptors, Predicted membrane proteins","Evidence at protein level","HPA013952","Uncertain",NA,"Approved","Cytosol",NA,"Expressed in all","Tissue enhanced",NA,"cerebral cortex: 45.1","skin: 31.0","Cell line enhanced",NA,"AF22: 49.6;HaCaT: 44.6;MCF7: 45.4"
"CEND1","BM88, FLJ90066","ENSG00000184524","Cell cycle exit and neuronal differentiation 1","11","787104-790123","Predicted membrane proteins","Evidence at protein level","HPA042527","Enhanced",NA,"Approved","Mitochondria","Glioma:6.10e-5 (unfavourable)","Tissue enriched","Tissue enriched",16,"cerebral cortex: 113.9","adrenal gland: 7.0","Cell line enhanced",NA,"Karpas-707: 21.5;SCLC-21H: 62.8;SH-SY5Y: 21.2;U-266/70: 15.9;U-87 MG: 27.1"
"CENPA","CenH3, CENP-A","ENSG00000115163","Centromere protein A","2","26764289-26801067","Predicted intracellular proteins","Evidence at protein level","CAB008371, HPA073086","Enhanced",NA,"Supported","Nucleoplasm","Liver cancer:2.88e-8 (unfavourable), Pancreatic cancer:1.30e-4 (unfavourable), Endometrial cancer:2.38e-4 (unfavourable), Lung cancer:3.70e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"lymph node: 7.4","tonsil: 6.5","Mixed",NA,NA
"CENPT","C16orf56, CENP-T, FLJ13111","ENSG00000102901","Centromere protein T","16","67828157-67847811","Predicted intracellular proteins","Evidence at protein level","HPA041220, HPA058036","Approved",NA,"Enhanced","Nuclear bodies","Renal cancer:1.57e-7 (unfavourable), Pancreatic cancer:2.96e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"skin: 15.9","Mixed",NA,NA
"CEP350","CAP350, KIAA0480","ENSG00000135837","Centrosomal protein 350","1","179954738-180114880","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA028355, HPA028357, HPA030845","Enhanced",NA,"Supported","Centrosome","Renal cancer:1.02e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 44.7","Expressed in all",NA,NA
"CEP72","FLJ10565, KIAA1519","ENSG00000112877","Centrosomal protein 72","5","612272-667168","Predicted intracellular proteins","Evidence at protein level","HPA058235, HPA074879","Approved",NA,"Supported","Centrosome","Endometrial cancer:2.90e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"testis: 10.4","ovary: 3.3","Cell line enhanced",NA,"HDLM-2: 41.0"
"CES1","CEH, CES1A1, CES1A2, CES2, HMSE, HMSE1, SES1","ENSG00000198848","Carboxylesterase 1","16","55802851-55833337","Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA012023, HPA046717","Enhanced",NA,"Enhanced","Endoplasmic reticulum","Urothelial cancer:9.92e-4 (unfavourable)","Tissue enriched","Group enriched",7,"gallbladder: 399.2;liver: 1099.9;lung: 229.9","adipose tissue: 79.7","Group enriched",5,"Hep G2: 414.0;THP-1: 439.1;U-937: 102.6"
"CFAP70","FLJ25765, TTC18","ENSG00000156042","Cilia and flagella associated protein 70","10","73253759-73358859","Predicted intracellular proteins","Evidence at protein level","HPA037582, HPA070304","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"fallopian tube: 23.4;testis: 37.6","epididymis: 13.8","Mixed",NA,NA
"CFAP74","C1orf222, FLJ45476, KIAA1751","ENSG00000142609","Cilia and flagella associated protein 74","1","1921951-2003837","Predicted intracellular proteins","Evidence at protein level","HPA028521, HPA029274, HPA030240","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"fallopian tube: 9.6;testis: 8.5","skin: 4.0","Mixed",NA,NA
"CFTR","ABC35, ABCC7, CF, CFTR/MRP, dJ760C5.1, MRP7, TNR-CFTR","ENSG00000001626","Cystic fibrosis transmembrane conductance regulator","7","117465784-117715971","Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters","Evidence at protein level","CAB001951, HPA021939","Enhanced",NA,NA,NA,"Liver cancer:9.44e-4 (unfavourable)","Tissue enhanced","Tissue enhanced",NA,"gallbladder: 89.3","rectum: 49.0","Group enriched",19,"CACO-2: 26.2;MOLT-4: 97.6;U-266/70: 47.9"
"CGREF1","CGR11","ENSG00000138028","Cell growth regulator with EF-hand domain 1","2","27098889-27119115","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA008241","Uncertain",NA,NA,NA,"Endometrial cancer:3.18e-4 (unfavourable), Liver cancer:7.57e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"cerebral cortex: 44.7","stomach: 11.5","Cell line enhanced",NA,"SK-BR-3: 58.9"
"CHCHD4","FLJ31709, MIA40, TIMM40","ENSG00000163528","Coiled-coil-helix-coiled-coil-helix domain containing 4","3","14112077-14124870","Predicted intracellular proteins","Evidence at protein level","HPA034688, HPA063727","Uncertain",NA,"Supported","Mitochondria","Renal cancer:8.63e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 31.2","Expressed in all",NA,NA
"CHD1L","ALC1","ENSG00000131778","Chromodomain helicase DNA binding protein 1 like","1","147242641-147295766","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA027789, HPA028670","Enhanced",NA,"Supported","Nucleoplasm","Renal cancer:1.31e-9 (unfavourable), Liver cancer:3.07e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 48.4","Expressed in all",NA,NA
"CHD2","DKFZp547I1315, DKFZp686E01200, DKFZp781D1727, FLJ38614","ENSG00000173575","Chromodomain helicase DNA binding protein 2","15","92900189-93028005","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA060744, HPA060960","Enhanced",NA,"Enhanced","Nucleus",NA,"Expressed in all","Expressed in all",NA,NA,"bone marrow: 48.3","Mixed",NA,NA
"CHD3","Mi-2a, Mi2-ALPHA, ZFH","ENSG00000170004","Chromodomain helicase DNA binding protein 3","17","7884806-7912760","Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA043368, HPA076524","Supported",NA,"Approved","Nucleus<br>Nucleoli<br>Microtubule organizing center","Endometrial cancer:7.68e-5 (favourable), Colorectal cancer:2.43e-4 (unfavourable), Pancreatic cancer:8.36e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 85.1","Expressed in all",NA,NA
"CHEK2","bA444G7, CDS1, CHK2, HuCds1, PP1425, RAD53","ENSG00000183765","Checkpoint kinase 2","22","28687743-28742422","Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA001878, CAB002030","Enhanced",NA,"Supported","Nucleoplasm<br>Golgi apparatus","Renal cancer:7.80e-9 (unfavourable)","Expressed in all","Mixed",NA,NA,"testis: 13.4","Expressed in all",NA,NA
"CHERP","DAN16, ERPROT213-21","ENSG00000085872","Calcium homeostasis endoplasmic reticulum protein","19","16517889-16542530","Predicted intracellular proteins","Evidence at protein level","HPA050647","Uncertain",NA,NA,NA,NA,"Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 22.2","Expressed in all",NA,NA
"CHL1","CALL, FLJ44930, L1CAM2, MGC132578","ENSG00000134121","Cell adhesion molecule L1 like","3","196596-409417","Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA003345, CAB026120","Enhanced",NA,NA,NA,"Renal cancer:1.21e-6 (favourable)","Tissue enhanced","Tissue enriched",5,"cerebral cortex: 111.8","ovary: 20.9","Group enriched",6,"SK-MEL-30: 73.7;WM-115: 29.2"
"CHMP4B","C20orf178, dJ553F4.4, Shax1, SNF7-2, VPS32B","ENSG00000101421","Charged multivesicular body protein 4B","20","33811304-33854366","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA041401, HPA051751","Enhanced",NA,NA,NA,"Liver cancer:5.10e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 140.4","Expressed in all",NA,NA
"CHRM4",NA,"ENSG00000180720","Cholinergic receptor muscarinic 4","11","46385098-46386608","FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins","Evidence at protein level","CAB022444, HPA072083","Uncertain",NA,"Uncertain","Nucleus<br>Golgi apparatus",NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 8.1;small intestine: 7.8;spleen: 21.4","testis: 6.9","Cell line enhanced",NA,"RH-30: 3.3;SCLC-21H: 11.7;U-2 OS: 3.0"
"CHRNA5",NA,"ENSG00000169684","Cholinergic receptor nicotinic alpha 5 subunit","15","78565520-78595269","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA054381","Approved",NA,"Approved","Plasma membrane<br>Focal adhesion sites","Lung cancer:3.64e-5 (unfavourable)","Mixed","Mixed",NA,NA,"gallbladder: 6.9","Mixed",NA,NA
"CIITA","C2TA, MHC2TA, NLRA","ENSG00000179583","Class II major histocompatibility complex transactivator","16","10866222-10932281","Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","CAB016084","Enhanced",NA,"Approved","Nucleoplasm",NA,"Expressed in all","Mixed",NA,NA,"lymph node,spleen: 59.2","Cell line enhanced",NA,"HDLM-2: 44.9;REH: 81.4"
"CLC","Gal-10, LGALS10, MGC149659","ENSG00000105205","Charcot-Leyden crystal galectin","19","39731250-39738028","Predicted intracellular proteins","Evidence at protein level","HPA041751","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",5,"bone marrow: 285.9","urinary bladder: 55.3","Cell line enriched",14,"HMC-1: 6580.2"
"CLCC1","MCLC","ENSG00000121940","Chloride channel CLIC like 1","1","108929508-108963457","Predicted membrane proteins, Transporters","Evidence at protein level","HPA009087, HPA013210","Enhanced",NA,"Enhanced","Endoplasmic reticulum","Colorectal cancer:1.33e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 38.6","Expressed in all",NA,NA
"CLCN4","ClC-4, CLC4","ENSG00000073464","Chloride voltage-gated channel 4","X","10156945-10237660","Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters","Evidence at protein level","HPA031313, HPA063637","Enhanced",NA,"Approved","Vesicles","Endometrial cancer:2.13e-5 (unfavourable), Pancreatic cancer:9.55e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 49.1;epididymis: 28.1","skeletal muscle: 14.6","Cell line enhanced",NA,"HEL: 21.9;SCLC-21H: 28.6"
"CLDN11","OSP, OTM","ENSG00000013297","Claudin 11","3","170418865-170860380","Predicted membrane proteins","Evidence at protein level","CAB009789, HPA013166","Enhanced",NA,NA,NA,"Breast cancer:6.31e-4 (favourable)","Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 89.0;testis: 183.6","ovary: 61.7","Cell line enhanced",NA,"ASC diff: 254.1;ASC TERT1: 324.5;EFO-21: 266.5;HUVEC TERT2: 345.5;TIME: 539.4"
"CLEC12A","CD371, CLL-1, DCAL-2, MICL","ENSG00000172322","C-type lectin domain family 12 member A","12","9951316-9995694","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA048515","Enhanced",NA,NA,NA,"Urothelial cancer:9.33e-4 (favourable)","Mixed","Tissue enhanced",NA,"bone marrow: 51.3","spleen: 26.6","Group enriched",7,"HL-60: 17.3;U-937: 52.2"
"CLEC2L","FLJ32986","ENSG00000236279","C-type lectin domain family 2 member L","7","139523856-139544984","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA045050","Enhanced",NA,NA,NA,NA,"Mixed","Group enriched",9,"cerebral cortex: 21.0;parathyroid gland: 13.7","endometrium: 1.9","Cell line enhanced",NA,"NTERA-2: 1.3;U-266/70: 2.4;U-266/84: 8.8"
"CLEC3A","CLECSF1","ENSG00000166509","C-type lectin domain family 3 member A","16","78022515-78066761","Predicted secreted proteins","Evidence at protein level","HPA051511","Uncertain",NA,NA,NA,"Breast cancer:1.61e-4 (unfavourable)","Tissue enriched","Tissue enhanced",NA,"breast: 12.4;urinary bladder: 8.3","prostate: 3.3","Cell line enhanced",NA,"MCF7: 2.5;SK-BR-3: 5.5;T-47d: 19.7"
"CLIC3",NA,"ENSG00000169583","Chloride intracellular channel 3","9","136994635-136996803","Plasma proteins, Predicted intracellular proteins, Transporters","Evidence at protein level","HPA005963","Enhanced",NA,"Supported","Nuclear bodies","Renal cancer:1.12e-4 (unfavourable), Urothelial cancer:7.74e-4 (unfavourable)","Tissue enhanced","Tissue enhanced",NA,"esophagus: 86.8;thyroid gland: 85.7","skin: 43.5","Cell line enhanced",NA,"BEWO: 234.7;MCF7: 88.6;T-47d: 100.2;TIME: 70.2"
"CLIC4","CLIC4L, DKFZP566G223, H1, huH1, P64H1","ENSG00000169504","Chloride intracellular channel 4","1","24745357-24844324","Predicted intracellular proteins, Transporters","Evidence at protein level","HPA008019, HPA060804","Enhanced",NA,"Supported","Cytosol","Renal cancer:1.48e-5 (favourable), Cervical cancer:8.31e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"smooth muscle: 398.9","Expressed in all",NA,NA
"CLIP2","CLIP, CLIP-115, CYLN2, KIAA0291, WBSCR3, WBSCR4, WSCR3, WSCR4","ENSG00000106665","CAP-Gly domain containing linker protein 2","7","74289475-74405943","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA020430, CAB020767","Enhanced",NA,NA,NA,"Endometrial cancer:5.35e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 75.8","ovary: 21.0","Mixed",NA,NA
"CLSTN1","CDHR12, CSTN1, KIAA0911","ENSG00000171603","Calsyntenin 1","1","9729026-9824526","Cancer-related genes, Plasma proteins, Predicted membrane proteins","Evidence at protein level","HPA012412","Approved",NA,NA,NA,"Renal cancer:4.10e-7 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 381.7","Expressed in all",NA,NA
"CLVS2","bA160A10.4, C6orf212, C6orf213, RLBP1L2","ENSG00000146352","Clavesin 2","6","122995971-123072927","Predicted intracellular proteins","Evidence at protein level","HPA043764","Uncertain",NA,NA,NA,NA,"Tissue enhanced","Group enriched",6,"cerebral cortex: 15.4;prostate: 5.0","endometrium: 1.7","Group enriched",8,"HEL: 10.9;SCLC-21H: 10.7"
"CLYBL","CLB","ENSG00000125246","Citrate lyase beta like","13","99606669-99897134","Enzymes, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA039959, HPA040691","Enhanced",NA,"Approved","Cytosol","Renal cancer:6.66e-16 (favourable)","Expressed in all","Expressed in all",NA,NA,"kidney: 67.5","Cell line enhanced",NA,"SCLC-21H: 62.6"
"CMA1",NA,"ENSG00000092009","Chymase 1","14","24505353-24508265","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB000363, HPA052634","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"breast: 23.8","esophagus: 11.4","Not detected",NA,NA
"CNGA2","CNCA, CNCA1, CNG2, FLJ46312, OCNC1, OCNCa, OCNCALPHA","ENSG00000183862","Cyclic nucleotide gated channel alpha 2","X","151738451-151745304","Predicted membrane proteins, Voltage-gated ion channels","Evidence at protein level","HPA015065","Uncertain",NA,NA,NA,NA,"Not detected","Not detected",NA,NA,"testis: 0.4","Not detected",NA,NA
"CNGA3","ACHM2, CCNC1, CCNCa, CNCG3, CNG3","ENSG00000144191","Cyclic nucleotide gated channel alpha 3","2","98346155-98398601","Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels","Evidence at protein level","HPA049378, CAB079025","Approved","Approved",NA,NA,NA,"Tissue enriched","Mixed",NA,NA,"esophagus: 1.9","Cell line enriched",7,"U-87 MG: 6.9"
"CNOT3","KIAA0691, LENG2, NOT3, NOT3H","ENSG00000088038","CCR4-NOT transcription complex subunit 3","19","54137728-54155681","Cancer-related genes, Predicted intracellular proteins","Evidence at protein level","HPA006408","Approved",NA,"Approved","Cytosol","Liver cancer:2.22e-4 (unfavourable), Renal cancer:2.77e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 36.1","Expressed in all",NA,NA
"CNTF","HCNTF","ENSG00000242689","Ciliary neurotrophic factor","11","58622673-58625733","Cancer-related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA019654","Uncertain",NA,"Approved","Vesicles",NA,"Mixed","Tissue enhanced",NA,"fallopian tube: 7.7","bone marrow: 4.3","Mixed",NA,NA
"CNTN3","BIG-1, PANG","ENSG00000113805","Contactin 3","3","74262568-74521140","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA003341","Approved",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 12.4","fallopian tube: 12.0","Cell line enhanced",NA,"BJ: 6.0;fHDF/TERT166: 15.2"
"CNTNAP1","Caspr, CNTNAP, NRXN4, p190","ENSG00000108797","Contactin associated protein 1","17","42682613-42699814","Disease related genes, Predicted membrane proteins","Evidence at protein level","HPA011772","Approved",NA,"Approved","Nucleoplasm","Renal cancer:4.16e-14 (unfavourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 61.8;smooth muscle: 38.9","endometrium: 19.2","Cell line enhanced",NA,"TIME: 59.4;U-138 MG: 80.6"
"CNTNAP3","CASPR3, CNTNAP3A, FLJ14195, KIAA1714","ENSG00000106714","Contactin associated protein-like 3","9","39072767-39288315","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at transcript level","HPA047731","Uncertain",NA,NA,NA,NA,"Mixed","Mixed",NA,NA,"esophagus: 8.2","Cell line enhanced",NA,"A549: 17.0;AF22: 22.2;WM-115: 37.4"
"CNTNAP3B",NA,"ENSG00000154529","Contactin associated protein-like 3B","9","41890314-42129510","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at transcript level","HPA047731","Uncertain",NA,NA,NA,NA,"Not detected","Mixed",NA,NA,"esophagus,skin: 10.4","Cell line enhanced",NA,"A549: 27.0;AF22: 41.2;WM-115: 28.0"
"COBLL1","KIAA0977","ENSG00000082438","Cordon-bleu WH2 repeat protein like 1","2","164653624-164843679","Predicted intracellular proteins","Evidence at protein level","HPA044933, HPA053344","Enhanced",NA,"Approved","Cell Junctions","Renal cancer:5.27e-13 (favourable)","Expressed in all","Mixed",NA,NA,"placenta: 77.1","Mixed",NA,NA
"COL23A1","DKFZp434K0621","ENSG00000050767","Collagen type XXIII alpha 1 chain","5","178237618-178590555","Predicted intracellular proteins","Evidence at protein level","HPA067824","Uncertain",NA,NA,NA,"Endometrial cancer:6.46e-5 (unfavourable)","Tissue enhanced","Tissue enhanced",NA,"thyroid gland: 57.8","seminal vesicle: 16.2","Group enriched",8,"AF22: 5.7;K-562: 10.8;NB-4: 20.8;THP-1: 22.5"
"COL8A1","C3orf7, MGC9568","ENSG00000144810","Collagen type VIII alpha 1 chain","3","99638475-99799226","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA053107","Enhanced",NA,"Supported","Vesicles","Renal cancer:9.39e-8 (unfavourable)","Expressed in all","Tissue enhanced",NA,"parathyroid gland: 87.4","lung: 56.9","Cell line enhanced",NA,"fHDF/TERT166: 930.0;LHCN-M2: 289.1;TIME: 423.8"
"COPS8","COP9, CSN8, MGC1297, SGN8","ENSG00000198612","COP9 signalosome subunit 8","2","237085312-237100466","Predicted intracellular proteins","Evidence at protein level","HPA036485","Uncertain",NA,"Supported","Nucleoplasm<br>Cytosol","Liver cancer:4.70e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 116.1","Expressed in all",NA,NA
"COQ6","CGI-10","ENSG00000119723","Coenzyme Q6, monooxygenase","14","73949926-73963670","Disease related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA051371","Uncertain",NA,NA,NA,"Renal cancer:1.05e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 31.5","Expressed in all",NA,NA
"CORO2B","ClipinC, KIAA0925","ENSG00000103647","Coronin 2B","15","68578969-68727806","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA017960","Enhanced",NA,"Approved","Plasma membrane<br>Focal adhesion sites",NA,"Group enriched","Tissue enhanced",NA,"cerebral cortex: 73.3;fallopian tube: 36.7","ovary: 17.9","Cell line enhanced",NA,"ASC TERT1: 40.2;HSkMC: 30.2;hTEC/SVTERT24-B: 34.6;U-87 MG: 57.2"
"CPSF2","KIAA1367","ENSG00000165934","Cleavage and polyadenylation specific factor 2","14","92121937-92172145","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA024238","Supported",NA,"Approved","Nucleoplasm<br>Vesicles","Liver cancer:4.35e-7 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 47.7","Expressed in all",NA,NA
"CPT1C","CPT1P, CPTIC, FLJ23809","ENSG00000169169","Carnitine palmitoyltransferase 1C","19","49690898-49713731","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA014529, HPA063621","Approved",NA,"Approved","Centrosome","Pancreatic cancer:1.84e-4 (favourable)","Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 34.2","adrenal gland: 7.0","Cell line enhanced",NA,"AF22: 39.0;SH-SY5Y: 74.9"
"CR1","CD35, KN","ENSG00000203710","Complement C3b/C4b receptor 1 (Knops blood group)","1","207496147-207640647","Blood group antigen proteins, CD markers, Plasma proteins, Predicted membrane proteins","Evidence at protein level","CAB002491, CAB016271, HPA042455, HPA043579, HPA049348","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"appendix: 37.5;spleen: 33.6","lymph node: 23.4","Group enriched",8,"HL-60: 7.8;HMC-1: 19.1;NB-4: 5.8"
"CR2","C3DR, CD21","ENSG00000117322","Complement C3d receptor 2","1","207454230-207489895","CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","CAB002659, HPA052942, HPA060715","Enhanced",NA,NA,NA,"Breast cancer:6.90e-4 (favourable)","Mixed","Group enriched",21,"appendix: 68.3;lymph node: 206.0;spleen: 100.2;tonsil: 153.8","kidney: 6.2","Cell line enhanced",NA,"Daudi: 17.1;MOLT-4: 10.7;RPMI-8226: 3.2"
"CRACR2A","EFCAB4B, MGC4266","ENSG00000130038","Calcium release activated channel regulator 2A","12","3606633-3764819","Predicted intracellular proteins","Evidence at protein level","HPA038686","Enhanced",NA,NA,NA,"Prostate cancer:2.85e-6 (favourable)","Mixed","Mixed",NA,NA,"salivary gland: 15.1","Mixed",NA,NA
"CRADD","RAIDD","ENSG00000169372","CASP2 and RIPK1 domain containing adaptor with death domain","12","93677375-93894840","Cancer-related genes, Disease related genes, Predicted intracellular proteins","Evidence at protein level","CAB005337","Uncertain",NA,"Approved","Nucleus<br>Cytosol","Renal cancer:4.04e-9 (favourable), Cervical cancer:9.06e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 32.8","Expressed in all",NA,NA
"CRB3","MGC17303","ENSG00000130545","Crumbs 3, cell polarity complex component","19","6463777-6467221","Predicted membrane proteins","Evidence at protein level","HPA013835","Enhanced",NA,"Supported","Cell Junctions","Renal cancer:0.00e+0 (favourable), Urothelial cancer:8.06e-5 (favourable), Endometrial cancer:4.54e-4 (favourable)","Mixed","Mixed",NA,NA,"duodenum: 37.4","Cell line enhanced",NA,"A-431: 50.4;BEWO: 34.1;CACO-2: 31.7;HaCaT: 32.6"
"CRBN","MRT2, MRT2A","ENSG00000113851","Cereblon","3","3144628-3179727","Disease related genes, FDA approved drug targets, Predicted intracellular proteins","Evidence at protein level","HPA045910","Approved",NA,"Approved","Nucleoli",NA,"Expressed in all","Expressed in all",NA,NA,"testis: 87.7","Expressed in all",NA,NA
"CREM","hCREM-2","ENSG00000095794","CAMP responsive element modulator","10","35126791-35212958","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA001818, CAB018352","Enhanced",NA,"Supported","Nucleus<br>Vesicles","Renal cancer:1.23e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 339.8","Expressed in all",NA,NA
"CRISP1","AEGL1, ARP, CRISP-1, HSCRISP1D, HSCRISP1G, HUMARP","ENSG00000124812","Cysteine rich secretory protein 1","6","49834257-49877096","Predicted secreted proteins","Evidence at protein level","HPA028445, HPA030534","Enhanced",NA,NA,NA,NA,"Not detected","Tissue enriched",20,"epididymis: 1915.6","seminal vesicle: 96.7","Cell line enhanced",NA,"NB-4: 1.7"
"CRMP1","DPYSL1, DRP-1","ENSG00000072832","Collapsin response mediator protein 1","4","5748084-5893058","Predicted intracellular proteins","Evidence at protein level","HPA035640, CAB037313","Approved",NA,"Supported","Centrosome<br>Cytosol","Pancreatic cancer:4.54e-4 (favourable)","Expressed in all","Tissue enriched",5,"cerebral cortex: 133.7","endometrium: 24.5","Cell line enhanced",NA,"HAP1: 120.7;REH: 208.7;RH-30: 125.4;SCLC-21H: 196.8;SH-SY5Y: 112.2"
"CROCC","ROLT, rootletin","ENSG00000058453","Ciliary rootlet coiled-coil, rootletin","1","16740273-16972979","Predicted intracellular proteins","Evidence at protein level","HPA021191, HPA021762","Enhanced",NA,"Supported","Plasma membrane<br>Centrosome","Endometrial cancer:8.34e-5 (favourable), Lung cancer:7.92e-4 (favourable), Renal cancer:7.97e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"skin: 11.6","Mixed",NA,NA
"CRTC2","TORC2","ENSG00000160741","CREB regulated transcription coactivator 2","1","153947669-153958625","Predicted intracellular proteins","Evidence at protein level","HPA028454, HPA028465","Supported",NA,"Enhanced","Nucleoplasm","Renal cancer:1.35e-7 (unfavourable), Urothelial cancer:6.12e-5 (favourable), Colorectal cancer:5.75e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"spleen: 36.0","Expressed in all",NA,NA
"CRX","CORD2, CRD, LCA7, OTX3","ENSG00000105392","Cone-rod homeobox","19","47819779-47843330","Disease related genes, Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA036762, HPA036763","Enhanced",NA,NA,NA,NA,"Not detected","Not detected",NA,NA,"testis: 0.3","Not detected",NA,NA
"CRY1","PHLL1","ENSG00000008405","Cryptochrome circadian clock 1","12","106991364-107093829","Predicted intracellular proteins","Evidence at protein level","CAB018762","Approved",NA,"Supported","Nucleus<br>Nuclear membrane<br>Microtubules",NA,"Expressed in all","Expressed in all",NA,NA,"testis: 62.1","Mixed",NA,NA
"CRYAB","CRYA2, HSPB5","ENSG00000109846","Crystallin alpha B","11","111908565-111923722","Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","CAB002053, CAB040560, HPA057100","Enhanced",NA,"Enhanced","Plasma membrane<br>Cytosol","Urothelial cancer:1.70e-5 (unfavourable), Colorectal cancer:4.90e-5 (unfavourable)","Group enriched","Tissue enhanced",NA,"heart muscle: 3968.4","cerebral cortex: 1888.7","Cell line enhanced",NA,"ASC diff: 1679.2;fHDF/TERT166: 650.9;U-138 MG: 315.9"
"CS",NA,"ENSG00000062485","Citrate synthase","12","56271699-56300392","Citric acid cycle related proteins, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA038460, HPA038461, CAB075750, CAB075751, CAB075752, CAB075753, CAB075754","Enhanced",NA,"Enhanced","Mitochondria","Renal cancer:1.17e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"heart muscle: 190.9","Expressed in all",NA,NA
"CSE1L","CAS, CSE1, XPO2","ENSG00000124207","Chromosome segregation 1 like","20","49046246-49096960","Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters","Evidence at protein level","CAB002140, HPA038059, HPA038060","Enhanced",NA,"Enhanced","Nucleoplasm<br>Cytosol","Liver cancer:2.42e-8 (unfavourable), Endometrial cancer:2.91e-5 (unfavourable), Renal cancer:1.89e-4 (unfavourable), Urothelial cancer:6.91e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 159.7","Expressed in all",NA,NA
"CSF3R","CD114, GCSFR","ENSG00000119535","Colony stimulating factor 3 receptor","1","36466043-36483278","Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","CAB017116, HPA048086","Enhanced",NA,NA,NA,"Testis cancer:3.79e-4 (unfavourable), Renal cancer:5.72e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"appendix: 211.2;bone marrow: 243.4;placenta: 147.9","spleen: 96.5","Cell line enhanced",NA,"BEWO: 68.2;NB-4: 12.7;THP-1: 32.4;U-937: 36.3"
"CSN1S1","CASA, CSN1","ENSG00000126545","Casein alpha s1","4","69931081-69946574","Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA035659, HPA057031","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",85,"breast: 1600.9","adipose tissue: 18.9","Not detected",NA,NA
"CSRNP3","FAM130A2, FLJ32093, PPP1R73, TAIP-2","ENSG00000178662","Cysteine and serine rich nuclear protein 3","2","165469647-165689407","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA017905","Supported",NA,"Approved","Nucleus<br>Nucleoli",NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 16.1","endometrium: 4.6","Group enriched",5,"AF22: 9.7;PC-3: 2.2;SCLC-21H: 8.4;SH-SY5Y: 6.2"
"CST3",NA,"ENSG00000101439","Cystatin C","20","23626706-23638473","Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB000118, HPA013143","Enhanced",NA,"Supported","Golgi apparatus<br>Vesicles","Endometrial cancer:1.83e-4 (favourable), Urothelial cancer:8.77e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 1265.8","Cell line enhanced",NA,"ASC diff: 1105.8"
"CST7",NA,"ENSG00000077984","Cystatin F","20","24949230-24959928","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA040442","Enhanced",NA,NA,NA,"Renal cancer:4.37e-6 (unfavourable), Endometrial cancer:9.17e-6 (favourable), Head and neck cancer:5.85e-5 (favourable), Breast cancer:6.55e-4 (favourable), Cervical cancer:7.90e-4 (favourable)","Expressed in all","Tissue enriched",9,"bone marrow: 642.9","spleen: 74.1","Group enriched",19,"HL-60: 58.5;HMC-1: 170.9;NB-4: 126.6;U-937: 278.1"
"CSTF3","CstF-77","ENSG00000176102","Cleavage stimulation factor subunit 3","11","33077188-33162371","Predicted intracellular proteins","Evidence at protein level","HPA039743, HPA040168","Enhanced",NA,"Enhanced","Nucleoplasm","Liver cancer:8.20e-6 (unfavourable), Renal cancer:1.61e-5 (unfavourable), Colorectal cancer:1.63e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"epididymis: 76.3","Expressed in all",NA,NA
"CTAGE1","CT21.1, CT21.2, CTAGE, cTAGE-1, cTAGE-2","ENSG00000212710","Cutaneous T-cell lymphoma-associated antigen 1","18","22413601-22417915","Predicted membrane proteins","Evidence at protein level","HPA000387, HPA000922, CAB016204","Uncertain",NA,NA,NA,NA,"Not detected","Tissue enriched",50,"testis: 5.0","all non-specific tissues: 0.0","Not detected",NA,NA
"CTAGE15","CTAGE15P","ENSG00000271079","CTAGE family member 15","7","143571801-143574387","Predicted membrane proteins","Evidence at protein level","HPA000387, HPA000922","Uncertain",NA,NA,NA,NA,"Not detected","Tissue enhanced",NA,"testis: 7.3","thyroid gland: 1.6","Cell line enhanced",NA,"A-431: 2.8;RT4: 2.1;SiHa: 2.8;SK-BR-3: 1.8"
"CTAGE4","cTAGE-4, FLJ43692","ENSG00000225932","CTAGE family member 4","7","144183466-144186053","Predicted membrane proteins","Evidence at protein level","HPA000387, HPA000922","Uncertain",NA,NA,NA,NA,"Not detected","Tissue enhanced",NA,"thyroid gland: 16.4","testis: 13.6","Cell line enhanced",NA,"A-431: 16.9;hTCEpi: 10.1;RPTEC TERT1: 9.9;SiHa: 9.1"
"CTAGE5","cTAGE-5A, cTAGE-5B, cTAGE-5C, cTAGE-5D, MEA6, MGEA, MGEA11, MGEA6","ENSG00000150527","CTAGE family member 5, ER export factor","14","39265284-39388513","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA000387, HPA000922","Uncertain",NA,NA,NA,"Renal cancer:2.81e-4 (favourable)","Mixed","Expressed in all",NA,NA,"thyroid gland: 77.4","Expressed in all",NA,NA
"CTAGE6","CTAGE6P, MGC41943","ENSG00000271321","CTAGE family member 6","7","143755089-143757696","Predicted membrane proteins","Evidence at protein level","HPA000387, HPA000922","Uncertain",NA,NA,NA,NA,"Not detected","Tissue enriched",38,"testis: 9.9","skin: 0.2","Not detected",NA,NA
"CTAGE8",NA,"ENSG00000244693","CTAGE family member 8","7","144266701-144269288","Predicted membrane proteins","Evidence at protein level","HPA000387, HPA000922","Uncertain",NA,NA,NA,NA,"Not detected","Tissue enhanced",NA,"thyroid gland: 11.4","skin: 9.1","Cell line enhanced",NA,"A-431: 9.7;HaCaT: 5.8;RT4: 5.7;SiHa: 6.7"
"CTAGE9",NA,"ENSG00000236761","CTAGE family member 9","6","131708684-131711017","Predicted membrane proteins","Evidence at protein level","HPA000387, HPA000922","Uncertain",NA,NA,NA,NA,"Not detected","Tissue enriched",41,"testis: 7.6","duodenum,small intestine: 0.1","Not detected",NA,NA
"CTB-50L17.10",NA,"ENSG00000167674","Hepatoma-derived growth factor-related protein 2","19","4472287-4502211","Predicted intracellular proteins","Evidence at protein level","HPA042559, HPA044208","Enhanced",NA,"Supported","Nucleoplasm","Pancreatic cancer:6.57e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 62.2","Expressed in all",NA,NA
"CTSC","DPP1, PALS, PLS","ENSG00000109861","Cathepsin C","11","88293592-88337787","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB025364, HPA066610, HPA068434","Enhanced",NA,"Supported","Vesicles","Liver cancer:9.30e-5 (unfavourable), Renal cancer:4.80e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"lung: 390.4","Expressed in all",NA,NA
"CTSF","CATSF, CLN13","ENSG00000174080","Cathepsin F","11","66563463-66568841","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB002141, HPA031431, HPA055610","Approved",NA,"Approved","Vesicles<br>Plasma membrane<br>Cytosol","Renal cancer:8.92e-7 (favourable)","Expressed in all","Expressed in all",NA,NA,"ovary: 140.6","Cell line enhanced",NA,"SK-MEL-30: 123.6"
"CTSG","CG","ENSG00000100448","Cathepsin G","14","24573522-24576260","Enzymes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB000110, HPA047737","Enhanced",NA,NA,NA,"Head and neck cancer:1.57e-4 (favourable), Urothelial cancer:8.91e-4 (unfavourable)","Mixed","Tissue enriched",84,"bone marrow: 3457.0","gallbladder: 41.2","Cell line enriched",6,"THP-1: 6055.4"
"CTSW",NA,"ENSG00000172543","Cathepsin W","11","65879809-65883741","Enzymes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB016345","Enhanced",NA,NA,NA,"Endometrial cancer:8.36e-6 (favourable), Renal cancer:8.84e-6 (unfavourable), Breast cancer:3.06e-4 (favourable), Head and neck cancer:9.89e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"bone marrow: 70.6;spleen: 60.4","lung: 36.5","Group enriched",20,"HEL: 149.5;NB-4: 242.5"
"CTU2","C16orf84, NCS2","ENSG00000174177","Cytosolic thiouridylase subunit 2","16","88706463-88715386","Predicted intracellular proteins","Evidence at protein level","HPA041135, HPA041894","Uncertain",NA,"Supported","Mitochondria","Liver cancer:5.68e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 10.3","Expressed in all",NA,NA
"CUZD1","ERG-1, UO-44","ENSG00000138161","CUB and zona pellucida like domains 1","10","122832149-122850793","Predicted membrane proteins","Evidence at protein level","HPA068479, HPA068660, HPA074117","Enhanced",NA,"Approved","Nucleoli<br>Vesicles",NA,"Tissue enriched","Tissue enriched",173,"pancreas: 380.6","testis: 2.1","Mixed",NA,NA
"CXADR","CAR","ENSG00000154639","Coxsackie virus and adenovirus receptor","21","17512382-17593579","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA003342, CAB005103, HPA030411, HPA030412","Enhanced",NA,"Enhanced","Plasma membrane<br>Cell Junctions","Head and neck cancer:3.50e-4 (favourable)","Expressed in all","Mixed",NA,NA,"skin: 59.1","Cell line enhanced",NA,"CACO-2: 77.2;NTERA-2: 105.2;RT4: 82.7"
"CXCR2","CD182, CMKAR2, IL8RB","ENSG00000180871","C-X-C motif chemokine receptor 2","2","218125289-218137253","Cancer-related genes, CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","CAB016268, HPA031999, HPA032017","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"appendix: 55.7;spleen: 36.7","esophagus: 29.9","Group enriched",10,"BEWO: 13.6;HL-60: 6.5;HMC-1: 14.3;THP-1: 10.4;U-937: 11.8"
"CXCR3","CD183, CKR-L2, CMKAR3, GPR9, IP10-R, MigR","ENSG00000186810","C-X-C motif chemokine receptor 3","X","71615916-71618517","CD markers, G-protein coupled receptors, Predicted membrane proteins","Evidence at protein level","HPA045942","Enhanced",NA,NA,NA,"Renal cancer:1.67e-6 (unfavourable), Endometrial cancer:3.44e-6 (favourable), Melanoma:2.90e-4 (favourable), Head and neck cancer:3.35e-4 (favourable)","Mixed","Tissue enhanced",NA,"lymph node: 17.9","spleen: 8.7","Cell line enriched",13,"RPMI-8226: 32.7"
"CXCR5","BLR1, CD185, MDR15","ENSG00000160683","C-X-C motif chemokine receptor 5","11","118883766-118897799","CD markers, G-protein coupled receptors, Predicted membrane proteins","Evidence at protein level","CAB026149, HPA042432","Enhanced",NA,NA,NA,NA,"Not detected","Tissue enhanced",NA,"appendix: 14.5;lymph node: 32.5;spleen: 21.0;tonsil: 14.3","bone marrow: 6.4","Group enriched",8,"Daudi: 12.9;U-698: 43.3"
"CYB5R1","humb5R2, NQO3A2","ENSG00000159348","Cytochrome b5 reductase 1","1","202961869-202967280","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA010641, HPA014147","Enhanced",NA,"Uncertain","Nucleoli<br>Mitochondria<br>Cytosol","Endometrial cancer:1.14e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"skeletal muscle: 183.8","Expressed in all",NA,NA
"CYBA","p22-PHOX","ENSG00000051523","Cytochrome b-245 alpha chain","16","88643283-88651152","Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters","Evidence at protein level","CAB009492","Enhanced",NA,NA,NA,"Endometrial cancer:4.75e-5 (favourable), Renal cancer:1.83e-4 (unfavourable), Breast cancer:8.19e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"spleen: 466.1","Cell line enhanced",NA,"RPMI-8226: 1035.0"
"CYBB","CGD, GP91-PHOX, NOX2","ENSG00000165168","Cytochrome b-245 beta chain","X","37780011-37813461","Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters","Evidence at protein level","HPA051227","Enhanced",NA,NA,NA,NA,"Expressed in all","Tissue enhanced",NA,"appendix: 215.6","lung: 132.2","Group enriched",5,"Daudi: 37.3;NB-4: 40.0;REH: 49.1;RPMI-8226: 143.6"
"CYLD","CYLD1, KIAA0849, USPL2","ENSG00000083799","CYLD lysine 63 deubiquitinase","16","50742050-50801935","Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","CAB011713, HPA050095","Approved",NA,"Supported","Nucleoplasm<br>Microtubule organizing center",NA,"Expressed in all","Expressed in all",NA,NA,"testis: 70.2","Expressed in all",NA,NA
"CYP2C8","CPC8","ENSG00000138115","Cytochrome P450 family 2 subfamily C member 8","10","95036772-95069497","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA013547, HPA013970, HPA015066","Enhanced",NA,NA,NA,"Pancreatic cancer:9.82e-4 (favourable)","Tissue enriched","Tissue enriched",154,"liver: 1124.1","gallbladder: 7.3","Not detected",NA,NA
"CYP2D6","CPD6, CYP2D, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2, CYP2DL1, P450-DB1, P450C2D","ENSG00000100197","Cytochrome P450 family 2 subfamily D member 6","22","42126499-42130906","Enzymes, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA045223","Enhanced",NA,"Approved","Golgi apparatus",NA,"Tissue enriched","Group enriched",5,"duodenum: 3.7;liver: 10.0;small intestine: 13.0","testis: 1.7","Cell line enhanced",NA,"Hep G2: 1.2;HMC-1: 2.2;REH: 1.4;U-266/70: 1.3"
"CYP2E1","CYP2E","ENSG00000130649","Cytochrome P450 family 2 subfamily E member 1","10","133520406-133561220","Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA009128, HPA029564","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",177,"liver: 5332.2","tonsil: 30.1","Cell line enhanced",NA,"HaCaT: 9.7;NB-4: 15.1"
"CYP46A1","CYP46","ENSG00000036530","Cytochrome P450 family 46 subfamily A member 1","14","99684304-99727301","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA040702","Uncertain",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",21,"cerebral cortex: 64.1","heart muscle: 3.0","Group enriched",5,"AF22: 2.4;U-937: 5.4"
"DARS",NA,"ENSG00000115866","Aspartyl-tRNA synthetase","2","135906677-135986100","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA020451, HPA029804, HPA029805","Enhanced",NA,"Enhanced","Cytosol","Liver cancer:2.39e-6 (unfavourable), Renal cancer:1.24e-5 (unfavourable), Pancreatic cancer:6.54e-4 (unfavourable), Melanoma:7.57e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 91.0","Expressed in all",NA,NA
"DAZAP1","MGC19907","ENSG00000071626","DAZ associated protein 1","19","1407569-1435687","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA004201, HPA004631","Enhanced",NA,"Enhanced","Nucleoplasm<br>Cytosol","Liver cancer:5.86e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 102.8","Expressed in all",NA,NA
"DBH","DBM","ENSG00000123454","Dopamine beta-hydroxylase","9","133636360-133659344","Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA002130, HPA005960, HPA070789","Enhanced",NA,"Enhanced","Endoplasmic reticulum<br>Vesicles",NA,"Mixed","Tissue enriched",28,"adrenal gland: 356.8","liver: 12.6","Cell line enriched",370,"SH-SY5Y: 1924.2"
"DBNDD2","C20orf35, HSMNP1","ENSG00000244274","Dysbindin domain containing 2","20","45406057-45410610","Predicted intracellular proteins","Evidence at protein level","HPA043991","Enhanced",NA,"Approved","Nucleoplasm<br>Cytosol",NA,"Mixed","Expressed in all",NA,NA,"cerebral cortex: 460.2","Mixed",NA,NA
"DCAF1","KIAA0800, MGC102804, VPRBP","ENSG00000145041","DDB1 and CUL4 associated factor 1","3","51395867-51500002","Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA036142, HPA052445, HPA053203","Approved",NA,"Enhanced","Nucleus<br>Nucleoli fibrillar center","Renal cancer:7.45e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 96.8","Expressed in all",NA,NA
"DCAF10","FLJ23201, MGC10765, WDR32","ENSG00000122741","DDB1 and CUL4 associated factor 10","9","37800502-37867666","Predicted intracellular proteins","Evidence at protein level","HPA024160","Uncertain",NA,"Approved","Nucleoli fibrillar center","Renal cancer:1.02e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 36.0","Expressed in all",NA,NA
"DCAF7","HAN11, SWAN-1, WDR68","ENSG00000136485","DDB1 and CUL4 associated factor 7","17","63550461-63594266","Predicted intracellular proteins","Evidence at protein level","HPA022948, HPA022962","Enhanced",NA,"Supported","Nucleoplasm<br>Cytosol","Liver cancer:2.42e-4 (unfavourable), Renal cancer:3.49e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 61.4","Expressed in all",NA,NA
"DCDC2","DCDC2A, DFNB66, KIAA1154, NPHP19, RU2","ENSG00000146038","Doublecortin domain containing 2","6","24171756-24358052","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA031582, HPA031583, HPA031584","Enhanced",NA,"Enhanced","Microtubules<br>Mitotic spindle<br>Microtubule organizing center<br>Cytosol",NA,"Mixed","Tissue enhanced",NA,"kidney: 23.2","parathyroid gland: 15.3","Group enriched",8,"CACO-2: 59.2;EFO-21: 45.6;Hep G2: 55.9;RPTEC TERT1: 193.3"
"DCN","DSPG2, SLRR1B","ENSG00000011465","Decorin","12","91140484-91183123","Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA003315, CAB017118, HPA064736, CAB068930","Enhanced",NA,NA,NA,"Renal cancer:1.46e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"ovary: 3807.0","Cell line enhanced",NA,"ASC diff: 2514.0;ASC TERT1: 1962.9;BJ hTERT+: 2379.1;HSkMC: 1868.4"
"DCT","TYRP2","ENSG00000080166","Dopachrome tautomerase","13","94436808-94479682","Enzymes, Predicted membrane proteins","Evidence at protein level","HPA010743, HPA010800, CAB017634","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",31,"skin: 126.8","breast: 4.0","Cell line enriched",177,"SK-MEL-30: 202.8"
"DCTN2","DCTN-50, RBP50","ENSG00000175203","Dynactin subunit 2","12","57530102-57547331","Predicted intracellular proteins","Evidence at protein level","HPA039715, HPA040040","Enhanced",NA,"Enhanced","Centrosome","Liver cancer:1.38e-7 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 163.0","Expressed in all",NA,NA
"DDAH2","G6A","ENSG00000213722","Dimethylarginine dimethylaminohydrolase 2","6","31727038-31730617","Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA012509","Uncertain",NA,"Uncertain","Microtubule organizing center<br>Cytosol",NA,"Expressed in all","Mixed",NA,NA,"thyroid gland: 22.3","Cell line enhanced",NA,"EFO-21: 23.0;U-2 OS: 18.9"
"DDO",NA,"ENSG00000203797","D-aspartate oxidase","6","110391771-110415562","Enzymes, Predicted membrane proteins","Evidence at protein level","HPA037525, HPA037526","Enhanced",NA,"Supported","Cytosol","Renal cancer:8.69e-5 (favourable)","Mixed","Tissue enhanced",NA,"parathyroid gland: 24.3","heart muscle: 12.2","Cell line enhanced",NA,"RPMI-8226: 10.9;U-937: 13.6"
"DDX21","GURDB, RH-II/GU","ENSG00000165732","DExD-box helicase 21","10","68956128-68985073","Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA036592, HPA036593","Enhanced",NA,"Enhanced","Nucleus<br>Nucleoli","Pancreatic cancer:3.12e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"appendix: 71.2","Expressed in all",NA,NA
"DDX24",NA,"ENSG00000089737","DEAD-box helicase 24","14","94048291-94081245","Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA002554","Uncertain",NA,"Approved","Nucleoli<br>Cytosol","Renal cancer:3.06e-9 (favourable), Stomach cancer:2.89e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"epididymis: 45.3","testis: 26.5","Mixed",NA,NA
"DDX25","GRTH","ENSG00000109832","DEAD-box helicase 25","11","125903348-125943702","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA020137","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Group enriched",12,"cerebral cortex: 34.6;testis: 163.8","thyroid gland: 8.0","Cell line enhanced",NA,"NTERA-2: 10.8;SCLC-21H: 10.2"
"DDX41","ABS, MGC8828","ENSG00000183258","DEAD-box helicase 41","5","177511577-177517469","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA017911, HPA048803","Enhanced",NA,"Supported","Nucleus","Renal cancer:2.21e-6 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 52.6","Expressed in all",NA,NA
"DDX52","ROK1","ENSG00000278053","DExD-box helicase 52","17","37609739-37643464","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA056173","Uncertain",NA,"Supported","Nucleus<br>Nucleoli","Liver cancer:2.44e-6 (unfavourable), Colorectal cancer:9.41e-4 (favourable)","Expressed in all","Mixed",NA,NA,"epididymis: 4.6","Mixed",NA,NA
"DEFA4","DEF4, HP-4","ENSG00000164821","Defensin alpha 4","8","6935822-6938338","Predicted secreted proteins","Evidence at protein level","HPA051266","Enhanced",NA,NA,NA,NA,"Not detected","Tissue enriched",640,"bone marrow: 3105.2","spleen: 4.8","Cell line enriched",8,"THP-1: 8.6"
"DEFA6","DEF6, HD-6","ENSG00000164822","Defensin alpha 6","8","6924693-6926076","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA019462","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Group enriched",525,"duodenum: 5743.0;small intestine: 10524.2","colon: 15.4","Group enriched",9,"BEWO: 28.1;NB-4: 20.0;RPMI-8226: 25.8;SH-SY5Y: 26.0;U-2197: 10.6"
"DGCR14","DGCR13, DGS-H, DGSI, ES2, Es2el","ENSG00000100056","DiGeorge syndrome critical region gene 14","22","19130279-19144684","Predicted intracellular proteins","Evidence at protein level","HPA001221, HPA001222","Enhanced",NA,"Approved","Nucleoplasm",NA,"Expressed in all","Mixed",NA,NA,"testis: 1.9","Mixed",NA,NA
"DHX35","C20orf15, DDX35, FLJ22759, KAIA0875","ENSG00000101452","DEAH-box helicase 35","20","38962299-39039723","Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA054451, HPA062700","Uncertain",NA,"Approved","Nucleus<br>Nuclear bodies<br>Centrosome","Liver cancer:5.63e-6 (unfavourable), Endometrial cancer:4.25e-5 (unfavourable)","Expressed in all","Mixed",NA,NA,"endometrium: 14.9","Expressed in all",NA,NA
"DHX9","DDX9, LKP, RHA","ENSG00000135829","DExH-box helicase 9","1","182839369-182887751","Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB011819, HPA028050, HPA055684","Supported",NA,"Enhanced","Nucleus","Liver cancer:3.17e-4 (unfavourable), Melanoma:6.04e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 137.9","Expressed in all",NA,NA
"DIRAS2","Di-Ras2, DKFZp761C07121","ENSG00000165023","DIRAS family GTPase 2","9","90609832-90643105","Predicted intracellular proteins","Evidence at protein level","HPA043758","Uncertain",NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",9,"cerebral cortex: 128.3","cervix, uterine: 13.9","Cell line enhanced",NA,"AF22: 7.0;EFO-21: 1.9;SCLC-21H: 1.5"
"DKC1","Cbf5, DKC, dyskerin, NAP57, NOLA4, XAP101","ENSG00000130826","Dyskerin pseudouridine synthase 1","X","154762742-154777689","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA000166, HPA000447, HPA001022, CAB033086","Supported",NA,"Supported","Nucleus<br>Nucleoli fibrillar center","Renal cancer:1.46e-9 (unfavourable), Liver cancer:1.39e-5 (unfavourable), Endometrial cancer:2.66e-5 (unfavourable), Head and neck cancer:2.94e-4 (unfavourable), Melanoma:9.13e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 45.5","Expressed in all",NA,NA
"DLG3","KIAA1232, MRX90, NE-Dlg, NEDLG, PPP1R82, SAP-102, SAP102","ENSG00000082458","Discs large MAGUK scaffold protein 3","X","70444861-70505490","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA001733, HPA078130","Approved",NA,"Approved","Nucleus<br>Nucleoli","Renal cancer:1.72e-10 (favourable), Breast cancer:1.69e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"parathyroid gland: 36.6","Mixed",NA,NA
"DLG4","PSD-95, PSD95, SAP-90, SAP90","ENSG00000132535","Discs large MAGUK scaffold protein 4","17","7189890-7219702","Predicted intracellular proteins, Predicted secreted proteins, Transporters","Evidence at protein level","CAB001999, CAB002000, HPA010122","Enhanced",NA,"Approved","Vesicles","Pancreatic cancer:8.82e-6 (favourable), Renal cancer:1.70e-4 (unfavourable)","Expressed in all","Tissue enriched",6,"cerebral cortex: 178.6","endometrium: 28.9","Cell line enhanced",NA,"HMC-1: 57.4"
"DLGAP3","DAP3, SAPAP3","ENSG00000116544","DLG associated protein 3","1","34865436-34929585","Predicted intracellular proteins","Evidence at protein level","HPA026445","Enhanced",NA,NA,NA,NA,"Group enriched","Group enriched",12,"cerebral cortex: 21.9;testis: 5.7","spleen: 1.1","Cell line enhanced",NA,"Daudi: 5.7;NTERA-2: 4.2;SCLC-21H: 14.7"
"DMPK","DM, DM1, DM1PK, DMK, MDPK, MT-PK","ENSG00000104936","Dystrophia myotonica protein kinase","19","45769717-45782552","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA007164, HPA008905","Enhanced",NA,"Approved","Vesicles<br>Cytosol","Pancreatic cancer:9.39e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"smooth muscle: 97.3","Cell line enhanced",NA,"RH-30: 99.0"
"DMWD","D19S593E, DMR-N9, gene59","ENSG00000185800","Dystrophia myotonica, WD repeat containing","19","45782947-45792802","Predicted intracellular proteins","Evidence at protein level","HPA068172, HPA069843","Approved",NA,"Approved","Plasma membrane<br>Actin filaments","Liver cancer:1.47e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 39.7","Expressed in all",NA,NA
"DNAH10OS","FLJ45278","ENSG00000250091","Dynein axonemal heavy chain 10 opposite strand","12","123926424-123934984","Predicted intracellular proteins","Evidence at transcript level","HPA039786","Uncertain",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 4.0","kidney: 1.6","Mixed",NA,NA
"DNAH12","DHC3, DLP12, DNAH12L, DNAH7L, Dnahc3, DNHD2, FLJ40427, FLJ44290, hdhc3, HL-19","ENSG00000174844","Dynein axonemal heavy chain 12","3","57293699-57544344","Cancer-related genes, Predicted intracellular proteins","Evidence at protein level","HPA037493, HPA058203, HPA061365","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"fallopian tube: 16.3;testis: 11.1","lung: 2.7","Not detected",NA,NA
"DNAH5","CILD3, Dnahc5, HL1, KTGNR, PCD","ENSG00000039139","Dynein axonemal heavy chain 5","5","13690331-13944543","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA037469, HPA037470","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"fallopian tube: 6.2;lung: 2.6","breast: 2.0","Cell line enhanced",NA,"BJ hTERT+: 1.3;PC-3: 2.5;RPTEC TERT1: 1.1"
"DNAH9","DNAH17L, Dnahc9, DNAL1, DYH9, HL-20, HL20, KIAA0357","ENSG00000007174","Dynein axonemal heavy chain 9","17","11598431-11969748","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA052641","Enhanced",NA,NA,NA,"Endometrial cancer:6.79e-5 (favourable)","Tissue enhanced","Tissue enriched",5,"fallopian tube: 56.4","testis: 11.1","Cell line enhanced",NA,"HDLM-2: 2.8;WM-115: 1.7"
"DNAJB5","Hsc40","ENSG00000137094","DnaJ heat shock protein family (Hsp40) member B5","9","34989641-34998900","Predicted intracellular proteins","Evidence at protein level","HPA023818, HPA050794","Approved",NA,"Approved","Nucleus<br>Cytosol",NA,"Expressed in all","Mixed",NA,NA,"smooth muscle: 92.2","Mixed",NA,NA
"DNAJC1","DNAJL1, ERdj1, MTJ1","ENSG00000136770","DnaJ heat shock protein family (Hsp40) member C1","10","21756537-22003769","Predicted membrane proteins, Transcription factors","Evidence at protein level","HPA013432","Approved",NA,"Approved","Endoplasmic reticulum","Liver cancer:1.96e-5 (unfavourable), Renal cancer:2.33e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 57.8","Expressed in all",NA,NA
"DNM1L","DRP1, DVLP, DYMPLE, HDYNIV, VPS1","ENSG00000087470","Dynamin 1 like","12","32679200-32745650","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","CAB009952, HPA039324","Enhanced",NA,"Enhanced","Vesicles<br>Cytosol","Liver cancer:6.27e-6 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 88.1","Expressed in all",NA,NA
"DNPEP","ASPEP, DAP","ENSG00000123992","Aspartyl aminopeptidase","2","219373546-219400022","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA036398, HPA044860","Enhanced",NA,"Supported","Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"testis: 65.4","Expressed in all",NA,NA
"DOK3","FLJ22570","ENSG00000146094","Docking protein 3","5","177501907-177511274","Predicted intracellular proteins","Evidence at protein level","HPA077312","Enhanced",NA,NA,NA,"Renal cancer:3.82e-11 (unfavourable)","Expressed in all","Tissue enhanced",NA,"bone marrow: 92.0","spleen: 63.6","Cell line enhanced",NA,"Daudi: 120.7;HMC-1: 116.5;REH: 193.3;U-698: 118.3"
"DPEP3",NA,"ENSG00000141096","Dipeptidase 3","16","67975663-67980829","Enzymes, Predicted secreted proteins","Evidence at protein level","HPA031870, HPA058607","Enhanced",NA,NA,NA,NA,"Group enriched","Tissue enriched",25,"testis: 56.9","spleen: 2.3","Not detected",NA,NA
"DPF3","BAF45c, cer-d4, Cerd4, FLJ14079","ENSG00000205683","Double PHD fingers 3","14","72619296-72894116","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA066790, HPA070601","Enhanced",NA,"Enhanced","Nucleoplasm",NA,"Tissue enhanced","Tissue enhanced",NA,"ovary: 16.7","parathyroid gland: 10.0","Cell line enhanced",NA,"BEWO: 17.1;HEL: 28.2"
"DPP10","DPL2, DPPY, DPRP3","ENSG00000175497","Dipeptidyl peptidase like 10","2","114442299-115845752","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA048767","Uncertain",NA,"Approved","Nucleus<br>Vesicles<br>Cytosol",NA,"Mixed","Group enriched",7,"adrenal gland: 14.1;cerebral cortex: 34.7","pancreas: 3.6","Cell line enhanced",NA,"AF22: 4.1;HAP1: 6.4;HMC-1: 3.8;NTERA-2: 3.7;RT4: 5.3;SCLC-21H: 11.4;SH-SY5Y: 4.1"
"DPPA4","FLJ10713","ENSG00000121570","Developmental pluripotency associated 4","3","109326141-109337572","Predicted intracellular proteins","Evidence at protein level","CAB020678, HPA035249, HPA035250","Enhanced",NA,"Supported","Nucleus<br>Nucleoli",NA,"Tissue enriched","Group enriched",8,"bone marrow: 2.8;placenta: 3.0;testis: 7.7","lung,lymph node: 0.5","Cell line enhanced",NA,"AF22: 42.6;HAP1: 92.5;NTERA-2: 327.0"
"DPYSL5","CRAM, CRMP-5, CRMP5, Ulip6","ENSG00000157851","Dihydropyrimidinase like 5","2","26847747-26950351","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA034544, HPA072387","Enhanced",NA,"Approved","Nucleoplasm<br>Cytosol",NA,"Group enriched","Group enriched",8,"cerebral cortex: 31.3;testis: 10.0","adrenal gland: 2.5","Cell line enhanced",NA,"AF22: 139.1;HAP1: 122.4;SCLC-21H: 196.8;SH-SY5Y: 105.0"
"DR1","NC2-BETA, NC2B","ENSG00000117505","Down-regulator of transcription 1","1","93345888-93369498","Predicted intracellular proteins","Evidence at protein level","HPA050785, HPA055308","Enhanced",NA,"Supported","Nucleus","Liver cancer:9.95e-7 (unfavourable), Colorectal cancer:4.79e-4 (favourable), Renal cancer:7.23e-4 (unfavourable), Pancreatic cancer:9.11e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 102.1","Expressed in all",NA,NA
"DSP","DPI, DPII, KPPS2, PPKS2","ENSG00000096696","Desmoplakin","6","7541575-7586717","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB037324, HPA045840, HPA054950","Enhanced",NA,"Enhanced","Cell Junctions","Renal cancer:1.53e-9 (favourable), Urothelial cancer:1.82e-4 (unfavourable)","Tissue enhanced","Group enriched",8,"esophagus: 345.7;skin: 1016.4","placenta: 89.1","Cell line enhanced",NA,"BEWO: 263.2;HaCaT: 265.1;hTCEpi: 482.9"
"DUS2","DUS2L, FLJ20399, SMM1","ENSG00000167264","Dihydrouridine synthase 2","16","67987746-68079320","Predicted intracellular proteins","Evidence at protein level","HPA042560, HPA043528","Enhanced",NA,"Enhanced","Cytosol","Renal cancer:3.50e-5 (favourable)","Expressed in all","Mixed",NA,NA,"testis: 39.2","Expressed in all",NA,NA
"DUS3L","DUS3, FLJ13896","ENSG00000141994","Dihydrouridine synthase 3 like","19","5784832-5791238","Predicted intracellular proteins","Evidence at protein level","HPA041854, HPA041944, HPA062846","Uncertain",NA,"Approved","Nucleoplasm<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"testis: 26.7","Mixed",NA,NA
"DUSP8","C11orf81, FLJ42958, HB5, HVH-5","ENSG00000184545","Dual specificity phosphatase 8","11","1554044-1571920","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA020071","Approved",NA,"Approved","Cytosol","Renal cancer:2.75e-6 (favourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 5.1","smooth muscle: 2.3","Cell line enhanced",NA,"MCF7: 1.9;SH-SY5Y: 2.2"
"DYNC1H1","CMT2O, DHC1, DNCH1, Dnchc1, DNCL, DNECL, HL-3, p22","ENSG00000197102","Dynein cytoplasmic 1 heavy chain 1","14","101964528-102050792","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA003742, CAB010443","Enhanced",NA,"Supported","Centrosome<br>Cytosol","Liver cancer:3.03e-7 (unfavourable), Renal cancer:1.09e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 80.6","Expressed in all",NA,NA
"DYNC1I1","DNCI1, DNCIC1","ENSG00000158560","Dynein cytoplasmic 1 intermediate chain 1","7","95772506-96110322","Predicted intracellular proteins","Evidence at protein level","HPA061689","Enhanced",NA,NA,NA,"Endometrial cancer:3.79e-4 (favourable)","Mixed","Tissue enhanced",NA,"cerebral cortex: 83.9","adrenal gland: 16.8","Cell line enhanced",NA,"EFO-21: 13.2;SH-SY5Y: 11.0;WM-115: 9.0"
"DYNC1I2","DIC74, DNCI2","ENSG00000077380","Dynein cytoplasmic 1 intermediate chain 2","2","171687409-171748420","Predicted intracellular proteins","Evidence at protein level","CAB033836, HPA040619, HPA053987","Enhanced",NA,"Supported","Nucleoli<br>Endoplasmic reticulum<br>Microtubules<br>Cytosol","Renal cancer:8.04e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 146.6","Expressed in all",NA,NA
"DYNLT3","TCTE1L, TCTEX1L","ENSG00000165169","Dynein light chain Tctex-type 3","X","37836757-37847637","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA003938","Approved",NA,NA,NA,"Glioma:4.22e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"adrenal gland: 77.2","Mixed",NA,NA
"EBAG9","EB9, RCAS1","ENSG00000147654","Estrogen receptor binding site associated, antigen, 9","8","109539711-109565996","Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA021153, HPA021154, CAB072810, CAB072811, CAB072812","Enhanced",NA,"Enhanced","Golgi apparatus",NA,"Expressed in all","Expressed in all",NA,NA,"thyroid gland: 96.5","Expressed in all",NA,NA
"ECHDC3","FLJ20909","ENSG00000134463","Enoyl-CoA hydratase domain containing 3","10","11742366-11764070","Predicted intracellular proteins","Evidence at protein level","HPA038306","Enhanced",NA,"Approved","Nucleus<br>Nucleoli<br>Mitochondria","Renal cancer:3.43e-4 (favourable), Urothelial cancer:3.91e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"adipose tissue: 76.6","Cell line enhanced",NA,"A-431: 46.0;BEWO: 27.7"
"ECHS1","SCEH","ENSG00000127884","Enoyl-CoA hydratase, short chain 1","10","133362480-133373689","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","CAB003783, HPA021995, HPA022476","Enhanced",NA,"Enhanced","Mitochondria","Renal cancer:8.57e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"liver: 438.0","Expressed in all",NA,NA
"ECI1","DCI","ENSG00000167969","Enoyl-CoA delta isomerase 1","16","2239395-2252300","Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA041746, HPA043227","Enhanced",NA,NA,NA,"Renal cancer:8.99e-8 (favourable), Cervical cancer:3.04e-5 (favourable), Liver cancer:1.07e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"skeletal muscle: 69.3","Expressed in all",NA,NA
"EDEM3","C1orf22","ENSG00000116406","ER degradation enhancing alpha-mannosidase like protein 3","1","184690231-184754913","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA025754, HPA025755, HPA027297","Approved",NA,"Approved","Endoplasmic reticulum","Renal cancer:1.63e-6 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"stomach: 34.4","Expressed in all",NA,NA
"EEF1G","EF1G","ENSG00000254772","Eukaryotic translation elongation factor 1 gamma","11","62559601-62574086","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA040688, HPA055316","Enhanced",NA,"Approved","Mitochondria",NA,"Mixed","Expressed in all",NA,NA,"ovary: 2996.8","Expressed in all",NA,NA
"EFCAB12","C3orf25","ENSG00000172771","EF-hand calcium binding domain 12","3","129401321-129428651","Predicted intracellular proteins","Evidence at protein level","HPA037694","Uncertain","Supported",NA,NA,NA,"Mixed","Group enriched",5,"fallopian tube: 31.3;testis: 6.7","prostate: 3.7","Cell line enhanced",NA,"Hep G2: 1.0;SCLC-21H: 1.0"
"EFNA3","Ehk1-L, EPLG3, LERK3","ENSG00000143590","Ephrin A3","1","155078872-155087538","Predicted membrane proteins, RAS pathway related proteins","Evidence at protein level","CAB010494","Uncertain",NA,NA,NA,"Renal cancer:9.66e-10 (unfavourable), Liver cancer:2.46e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"skin: 51.3","cerebral cortex: 17.0","Cell line enhanced",NA,"HAP1: 19.5;SCLC-21H: 32.5;T-47d: 24.4"
"EFR3A","KIAA0143","ENSG00000132294","EFR3 homolog A","8","131904088-132013642","Predicted intracellular proteins","Evidence at protein level","HPA022859, HPA023092, HPA023402","Enhanced",NA,"Supported","Plasma membrane<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 70.4","Expressed in all",NA,NA
"EHBP1","KIAA0903, NACSIN","ENSG00000115504","EH domain binding protein 1","2","62673851-63046487","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA035468, HPA035469","Enhanced",NA,"Supported","Plasma membrane<br>Cytosol","Urothelial cancer:1.95e-8 (unfavourable), Lung cancer:9.03e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 68.0","Expressed in all",NA,NA
"EHHADH","ECHD","ENSG00000113790","Enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase","3","185190624-185281990","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA036401, HPA042021","Enhanced",NA,NA,NA,"Renal cancer:1.28e-5 (favourable)","Group enriched","Group enriched",7,"kidney: 148.6;liver: 173.1","duodenum: 21.4","Mixed",NA,NA
"EIF2AK4","GCN2, KIAA1338","ENSG00000128829","Eukaryotic translation initiation factor 2 alpha kinase 4","15","39934146-40035591","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA011811","Approved",NA,"Approved","Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"endometrium: 54.3","Expressed in all",NA,NA
"EIF2S1","EIF-2alpha, EIF2, EIF2A","ENSG00000134001","Eukaryotic translation initiation factor 2 subunit alpha","14","67359997-67386516","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB011663, HPA064885","Supported",NA,"Enhanced","Nucleoplasm<br>Cytosol","Liver cancer:4.73e-7 (unfavourable), Pancreatic cancer:4.97e-4 (unfavourable), Urothelial cancer:7.11e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 61.1","Expressed in all",NA,NA
"EIF2S3","EIF2, EIF2G, EIF2gamma","ENSG00000130741","Eukaryotic translation initiation factor 2 subunit gamma","X","24054716-24077971","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB012471","Approved",NA,NA,NA,"Renal cancer:5.44e-6 (unfavourable), Liver cancer:3.05e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"ovary: 179.5","Expressed in all",NA,NA
"EIF3A","EIF3, eIF3-p170, eIF3-theta, eIF3a, EIF3S10, KIAA0139, TIF32","ENSG00000107581","Eukaryotic translation initiation factor 3 subunit A","10","119033670-119080823","Predicted intracellular proteins","Evidence at protein level","HPA038315, HPA038316","Enhanced",NA,"Supported","Nucleus<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 135.7","Expressed in all",NA,NA
"EIF4A2","BM-010, DDX2B, EIF4A, EIF4F","ENSG00000156976","Eukaryotic translation initiation factor 4A2","3","186783205-186789900","Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB011690, HPA068286","Uncertain",NA,"Approved","Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"ovary: 726.0","Expressed in all",NA,NA
"EIF4E","EIF4E1, EIF4EL1, EIF4F","ENSG00000151247","Eukaryotic translation initiation factor 4E","4","98871684-98930637","Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB004077, CAB016316, HPA051311","Supported",NA,"Enhanced","Cytosol<br>Cytoplasmic bodies",NA,"Expressed in all","Expressed in all",NA,NA,"testis: 103.5","Expressed in all",NA,NA
"EIF4ENIF1","2610509L04Rik, 4E-T, Clast4, FLJ21601","ENSG00000184708","Eukaryotic translation initiation factor 4E nuclear import factor 1","22","31436977-31496108","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA001619, HPA002078","Enhanced",NA,"Enhanced","Vesicles","Renal cancer:1.57e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 65.0","Expressed in all",NA,NA
"EIF4G2","DAP5, NAT1, p97","ENSG00000110321","Eukaryotic translation initiation factor 4 gamma 2","11","10797050-10809110","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB005163, HPA006773, HPA016965","Approved",NA,"Enhanced","Cytosol","Liver cancer:6.18e-5 (unfavourable), Renal cancer:1.67e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 686.8","Expressed in all",NA,NA
"ELANE","ELA2, HLE, HNE, NE","ENSG00000197561","Elastase, neutrophil expressed","19","851014-856247","Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB015409, HPA066836","Enhanced",NA,NA,NA,NA,"Group enriched","Tissue enriched",320,"bone marrow: 1199.6","skin: 3.7","Cell line enriched",56,"THP-1: 1171.3"
"ELF4","ELFR, MEF","ENSG00000102034","E74 like ETS transcription factor 4","X","130064874-130110716","Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA058595, HPA060277","Enhanced",NA,"Supported","Nucleoplasm<br>Nuclear bodies","Renal cancer:6.49e-6 (unfavourable), Urothelial cancer:1.42e-4 (favourable)","Expressed in all","Mixed",NA,NA,"placenta: 34.9","Mixed",NA,NA
"ELFN2","dJ63G5.3, KIAA1904, LRRC62, PPP1R29","ENSG00000166897","Extracellular leucine rich repeat and fibronectin type III domain containing 2","22","37367960-37427470","Predicted membrane proteins","Evidence at protein level","HPA000781","Approved",NA,"Approved","Nucleoplasm<br>Vesicles","Renal cancer:7.21e-4 (unfavourable)","Mixed","Tissue enriched",7,"cerebral cortex: 24.3","testis: 3.4","Cell line enhanced",NA,"RPTEC TERT1: 16.3;U-2 OS: 25.4"
"ELOA2","HsT832, TCEB3B, TCEB3L","ENSG00000206181","Elongin A2","18","47032572-47035621","Predicted intracellular proteins","Evidence at protein level","HPA041009, HPA043501, HPA048971, HPA049178, HPA050086","Approved",NA,NA,NA,NA,"Not detected","Tissue enriched",44,"testis: 4.3","all non-specific tissues: 0.0","Not detected",NA,NA
"ELSPBP1","E12, EDDM12, HE12","ENSG00000169393","Epididymal sperm binding protein 1","19","47994651-48025153","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA044256, HPA050341","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",2038,"epididymis: 3638.2","testis: 1.7","Cell line enhanced",NA,"BEWO: 1.5;HMC-1: 9.1;NB-4: 3.7"
"EMC2","KIAA0103, TTC35","ENSG00000104412","ER membrane protein complex subunit 2","8","108443601-108486918","Predicted intracellular proteins","Evidence at protein level","HPA022838","Approved",NA,NA,NA,"Breast cancer:2.64e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 110.0","Expressed in all",NA,NA
"EMC4","FLJ90746, MGC24415, PIG17, TMEM85","ENSG00000128463","ER membrane protein complex subunit 4","15","34224999-34230156","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA026868, HPA053440","Approved",NA,"Approved","Cell Junctions<br>Focal adhesion sites",NA,"Expressed in all","Expressed in all",NA,NA,"epididymis: 122.1","Expressed in all",NA,NA
"EML1","ELP79, EMAP, EMAPL, HuEMAP","ENSG00000066629","Echinoderm microtubule associated protein like 1","14","99737693-99942060","Disease related genes, Predicted intracellular proteins","Evidence at protein level","CAB033137, HPA049105","Uncertain",NA,NA,NA,NA,"Expressed in all","Mixed",NA,NA,"parathyroid gland: 51.3","Cell line enhanced",NA,"HDLM-2: 84.2;U-2197: 100.9"
"EML4","C2orf2, ELP120, ROPP120","ENSG00000143924","Echinoderm microtubule associated protein like 4","2","42169350-42332548","Cancer-related genes, Predicted intracellular proteins","Evidence at protein level","HPA036687, HPA036688, HPA065337","Enhanced",NA,"Supported","Intermediate filaments<br>Microtubules<br>Cytosol",NA,"Expressed in all","Mixed",NA,NA,"placenta: 50.5","Expressed in all",NA,NA
"EMSY","C11orf30","ENSG00000158636","EMSY, BRCA2 interacting transcriptional repressor","11","76444923-76553025","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB012234, HPA050777","Supported",NA,"Enhanced","Nucleoplasm",NA,"Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 20.4","Expressed in all",NA,NA
"EN1",NA,"ENSG00000163064","Engrailed homeobox 1","2","118842171-118847678","Predicted intracellular proteins, Transcription factors","Evidence at protein level","CAB014884, HPA073141","Approved",NA,"Supported","Nucleus<br>Nucleoli",NA,"Tissue enhanced","Group enriched",13,"adipose tissue: 1.3;breast: 1.0;lymph node: 1.9;skeletal muscle: 4.7;skin: 2.2","testis: 0.1","Cell line enhanced",NA,"ASC diff: 10.8;fHDF/TERT166: 10.2;HSkMC: 9.7;PC-3: 7.1;U-138 MG: 9.6;U-2197: 10.2"
"ENAH","FLJ10773, MENA, NDPP1","ENSG00000154380","Enabled homolog (Drosophila)","1","225486835-225653142","Predicted intracellular proteins","Evidence at protein level","HPA028448, HPA028696","Enhanced",NA,"Enhanced","Plasma membrane<br>Focal adhesion sites<br>Cytosol",NA,"Expressed in all","Mixed",NA,NA,"smooth muscle: 81.3","Mixed",NA,NA
"ENDOD1","KIAA0830","ENSG00000149218","Endonuclease domain containing 1","11","95089810-95132645","Plasma proteins, Predicted membrane proteins","Evidence at protein level","HPA008932, HPA010517","Enhanced",NA,"Approved","Nuclear membrane","Renal cancer:6.64e-7 (favourable), Urothelial cancer:3.27e-4 (unfavourable), Pancreatic cancer:8.86e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 99.6","Cell line enhanced",NA,"ASC diff: 132.3"
"ENDOG",NA,"ENSG00000167136","Endonuclease G","9","128818474-128822677","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA021335, HPA021830","Approved",NA,NA,NA,"Renal cancer:1.06e-7 (favourable), Endometrial cancer:5.12e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"skeletal muscle: 45.8","Expressed in all",NA,NA
"ENO1","ENO1L1, MBP-1, MPB1, PPH","ENSG00000074800","Enolase 1","1","8861002-8879249","Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB018614, HPA068284, HPA068721, CAB069394","Enhanced",NA,"Enhanced","Plasma membrane<br>Cytosol","Liver cancer:1.30e-8 (unfavourable), Glioma:2.12e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"appendix: 768.2","Expressed in all",NA,NA
"ENOPH1","E1, MASA, mtnC","ENSG00000145293","Enolase-phosphatase 1","4","82430562-82461091","Enzymes, Predicted intracellular proteins","Evidence at protein level","CAB004985, HPA044607","Enhanced",NA,"Approved","Nucleoplasm<br>Nuclear bodies","Liver cancer:1.74e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 98.3","Expressed in all",NA,NA
"ENTPD8","NTPDase-8, UNQ2492","ENSG00000188833","Ectonucleoside triphosphate diphosphohydrolase 8","9","137434364-137441816","Enzymes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA021509","Enhanced",NA,"Approved","Nucleoplasm<br>Vesicles<br>Cytosol","Stomach cancer:7.17e-4 (favourable)","Mixed","Tissue enhanced",NA,"colon: 21.7;duodenum: 28.7;small intestine: 31.6","rectum: 12.5","Cell line enhanced",NA,"CAPAN-2: 4.8;RPMI-8226: 3.7;T-47d: 2.7"
"ENY2","DC6, FLJ20480, Sus1","ENSG00000120533","ENY2, transcription and export complex 2 subunit","8","109334324-109345953","Predicted intracellular proteins, Transporters","Evidence at protein level","HPA024648","Approved",NA,"Approved","Nucleoplasm<br>Mitochondria","Renal cancer:7.17e-6 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"kidney: 77.5","Expressed in all",NA,NA
"EPDR1","EPDR, MERP-1, MERP1, UCC1","ENSG00000086289","Ependymin related 1","7","37683843-37951941","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB026298","Approved",NA,NA,NA,"Urothelial cancer:1.00e-4 (unfavourable), Stomach cancer:3.43e-4 (unfavourable), Liver cancer:6.97e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 73.4","Cell line enhanced",NA,"WM-115: 112.2"
"EPOP","C17orf96, LOC100170841, PRR28","ENSG00000273604","Elongin BC and polycomb repressive complex 2 associated protein","17","38671703-38675421","Predicted intracellular proteins","Evidence at protein level","HPA055190, HPA056555","Enhanced",NA,"Supported","Nucleoplasm<br>Cytosol<br>Cytoplasmic bodies",NA,"Expressed in all","Tissue enhanced",NA,"cerebral cortex: 5.5;testis: 5.0","parathyroid gland: 2.1","Cell line enhanced",NA,"AN3-CA: 19.3"
"ERBB2","CD340, HER-2, HER2, NEU, NGL","ENSG00000141736","Erb-b2 receptor tyrosine kinase 2","17","39687914-39730426","Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","CAB000043, HPA001060, HPA001338, HPA001383, CAB020416, CAB062555","Enhanced",NA,"Supported","Plasma membrane<br>Cytosol","Renal cancer:2.41e-14 (favourable), Endometrial cancer:8.99e-8 (unfavourable), Pancreatic cancer:9.17e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 124.5","Cell line enriched",22,"SK-BR-3: 2343.7"
"ERCC2","EM9, MAG, MGC102762, MGC126218, MGC126219, TFIIH, XPD","ENSG00000104884","ERCC excision repair 2, TFIIH core complex helicase subunit","19","45349837-45370918","Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","CAB005375, HPA038057, HPA069266","Approved",NA,"Supported","Nucleoplasm","Pancreatic cancer:3.26e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 16.1","Expressed in all",NA,NA
"ERGIC3","C20orf47, CGI-54, Erv46, NY-BR-84, PRO0989, SDBCAG84","ENSG00000125991","ERGIC and golgi 3","20","35542021-35557634","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA015242, HPA015968","Approved",NA,"Supported","Nucleoplasm","Liver cancer:2.20e-7 (unfavourable), Renal cancer:9.81e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"epididymis: 530.3","Expressed in all",NA,NA
"ERICH5","C8orf47, FLJ39553","ENSG00000177459","Glutamate rich 5","8","98064311-98093610","Predicted intracellular proteins","Evidence at protein level","HPA025070, HPA025293, HPA027233","Enhanced",NA,"Approved","Nucleoplasm<br>Golgi apparatus<br>Cytosol","Renal cancer:3.76e-4 (favourable), Urothelial cancer:9.38e-4 (favourable)","Tissue enhanced","Tissue enhanced",NA,"fallopian tube: 13.8;gallbladder: 13.7","stomach: 9.2","Cell line enhanced",NA,"A549: 6.1;HAP1: 6.4;HEK 293: 8.2;RT4: 12.7"
"ERO1A","ERO1-alpha, Ero1alpha, ERO1L","ENSG00000197930","Endoplasmic reticulum oxidoreductase 1 alpha","14","52639916-52695900","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA026653, HPA030053, CAB034294","Enhanced",NA,NA,NA,"Renal cancer:6.54e-9 (unfavourable), Lung cancer:1.10e-5 (unfavourable), Pancreatic cancer:2.27e-4 (unfavourable), Liver cancer:7.59e-4 (unfavourable), Cervical cancer:8.47e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"esophagus: 181.5","Expressed in all",NA,NA
"ERP29","C12orf8, ERp28, ERp29, ERp31, PDI-DB, PDIA9","ENSG00000089248","Endoplasmic reticulum protein 29","12","112013316-112023451","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA039363, HPA039456","Enhanced",NA,"Uncertain","Nucleoplasm<br>Microtubules","Endometrial cancer:7.43e-5 (favourable), Liver cancer:2.02e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 150.9","Expressed in all",NA,NA
"ESR1","Era, ESR, NR3A1","ENSG00000091831","Estrogen receptor 1","6","151656691-152129619","Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors","Evidence at protein level","CAB000037, HPA000449, HPA000450, CAB055099, CAB072858","Enhanced",NA,"Approved","Nucleus<br>Vesicles","Endometrial cancer:5.47e-7 (favourable)","Group enriched","Group enriched",8,"breast: 37.6;cervix, uterine: 127.8;endometrium: 180.8;fallopian tube: 106.4;smooth muscle: 76.5","seminal vesicle: 13.5","Group enriched",11,"MCF7: 34.7;T-47d: 53.2"
"ESRP1","FLJ20171, RBM35A","ENSG00000104413","Epithelial splicing regulatory protein 1","8","94641074-94707466","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA023719, HPA023720, HPA067104","Enhanced",NA,"Enhanced","Nucleoplasm<br>Nuclear bodies","Renal cancer:1.96e-8 (favourable), Pancreatic cancer:2.05e-4 (unfavourable), Endometrial cancer:3.56e-4 (unfavourable), Breast cancer:9.28e-4 (unfavourable)","Mixed","Mixed",NA,NA,"skin: 72.8","Cell line enhanced",NA,"A-431: 122.3;BEWO: 98.9;CAPAN-2: 125.0;hTCEpi: 166.0;RT4: 84.1;T-47d: 103.3"
"ETAA1","ETAA16","ENSG00000143971","Ewing tumor associated antigen 1","2","67397319-67410545","Predicted intracellular proteins","Evidence at protein level","HPA035048, HPA035049","Uncertain",NA,"Approved","Nucleoplasm<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"parathyroid gland,thyroid gland: 15.7","Expressed in all",NA,NA
"ETNPPL","AGXT2L1","ENSG00000164089","Ethanolamine-phosphate phospho-lyase","4","108742040-108763054","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA044546, HPA072938","Approved",NA,"Approved","Nucleus","Glioma:1.31e-4 (favourable)","Group enriched","Group enriched",8,"cerebral cortex: 141.2;liver: 98.6","stomach: 15.2","Cell line enhanced",NA,"HeLa: 3.8;Hep G2: 1.5;NTERA-2: 1.1"
"ETV4","E1A-F, E1AF, PEA3","ENSG00000175832","ETS variant 4","17","43527844-43579620","Cancer-related genes, Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA005768","Approved",NA,"Supported","Nucleoli","Liver cancer:2.48e-4 (unfavourable), Thyroid cancer:7.60e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"parathyroid gland: 30.3","cerebral cortex: 13.6","Cell line enhanced",NA,"AN3-CA: 164.6;SK-MEL-30: 152.6"
"ETV5","ERM","ENSG00000244405","ETS variant 5","3","186046308-186110318","Cancer-related genes, Predicted intracellular proteins, Transcription factors","Evidence at protein level","CAB009590, HPA063065","Approved",NA,"Supported","Nucleoplasm","Liver cancer:7.85e-9 (unfavourable)","Expressed in all","Tissue enhanced",NA,"parathyroid gland: 114.5","cerebral cortex: 74.7","Cell line enhanced",NA,"SK-MEL-30: 141.2"
"EVA1B","C1orf78, FAM176B, FLJ10647","ENSG00000142694","Eva-1 homolog B","1","36322031-36324154","Predicted intracellular proteins","Evidence at protein level","HPA041928, HPA043537","Approved",NA,"Approved","Cytosol","Renal cancer:4.79e-5 (unfavourable), Breast cancer:4.58e-4 (favourable), Liver cancer:4.82e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"placenta: 14.6","Cell line enhanced",NA,"BJ: 28.4"
"EVI5","NB4S","ENSG00000067208","Ecotropic viral integration site 5","1","92508696-92792404","Disease related genes, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA027339, HPA053724","Approved",NA,"Supported","Golgi apparatus<br>Vesicles",NA,"Expressed in all","Mixed",NA,NA,"testis: 18.0","Mixed",NA,NA
"EVPLL",NA,"ENSG00000214860","Envoplakin like","17","18377662-18389647","Predicted intracellular proteins","Evidence at transcript level","HPA045728","Uncertain",NA,"Approved","Nucleoplasm<br>Nuclear bodies",NA,"Not detected","Tissue enhanced",NA,"esophagus: 1.7;skin: 3.0;testis: 1.5","lung: 0.8","Cell line enhanced",NA,"HeLa: 1.2;hTCEpi: 4.7;RT4: 1.8;SiHa: 1.3;T-47d: 1.9"
"EXOG","ENDOGL1, ENDOGL2, ENGL, ENGL-a, ENGL-b","ENSG00000157036","Exo/endonuclease G","3","38496127-38542161","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA012531","Enhanced",NA,NA,NA,"Pancreatic cancer:1.92e-5 (favourable), Prostate cancer:4.90e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"cerebral cortex: 7.4","Expressed in all",NA,NA
"EXTL1","EXTL, MGC70794","ENSG00000158008","Exostosin like glycosyltransferase 1","1","26019884-26036464","Enzymes, Predicted secreted proteins","Evidence at protein level","HPA037749","Approved",NA,NA,NA,NA,"Tissue enriched","Tissue enhanced",NA,"cerebral cortex: 11.2","skeletal muscle: 4.3","Cell line enriched",10,"WM-115: 148.7"
"EYS","bA166P24.2, bA307F22.3, bA74E24.1, C6orf178, C6orf179, C6orf180, dJ1018A4.2, dJ303F19.1, EGFL10, EGFL11, RP25, SPAM","ENSG00000188107","Eyes shut homolog (Drosophila)","6","63719980-65707225","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA027103","Uncertain",NA,NA,NA,NA,"Not detected","Tissue enhanced",NA,"testis: 1.4","adipose tissue: 0.8","Cell line enhanced",NA,"Karpas-707: 1.1;SCLC-21H: 1.3"
"FAM103A1","C15orf18, HsT19360, MGC2560, RAM","ENSG00000169612","Family with sequence similarity 103 member A1","15","82986207-82991057","Predicted intracellular proteins","Evidence at protein level","HPA041923, HPA041948","Enhanced",NA,"Supported","Nucleoplasm",NA,"Expressed in all","Expressed in all",NA,NA,"placenta: 37.0","Expressed in all",NA,NA
"FAM114A1","Noxp20","ENSG00000197712","Family with sequence similarity 114 member A1","4","38867677-38945739","Predicted intracellular proteins","Evidence at protein level","HPA067948, HPA069104, HPA069701","Uncertain",NA,"Enhanced","Nucleus<br>Golgi apparatus<br>Cytosol","Renal cancer:3.63e-6 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"smooth muscle: 88.5","Cell line enhanced",NA,"fHDF/TERT166: 212.1"
"FAM135A","FLJ20176, KIAA1411","ENSG00000082269","Family with sequence similarity 135 member A","6","70412941-70561174","Predicted intracellular proteins","Evidence at protein level","HPA031743, HPA031744","Approved",NA,"Approved","Nucleoplasm<br>Cytosol","Renal cancer:3.46e-4 (favourable), Colorectal cancer:8.00e-4 (favourable)","Expressed in all","Mixed",NA,NA,"esophagus: 33.3","Cell line enhanced",NA,"RH-30: 29.8"
"FAM160A1","FLJ43373","ENSG00000164142","Family with sequence similarity 160 member A1","4","151409216-151663632","Predicted intracellular proteins","Evidence at protein level","HPA046348","Enhanced",NA,"Approved","Cytosol",NA,"Mixed","Mixed",NA,NA,"parathyroid gland: 16.7","Cell line enhanced",NA,"SiHa: 9.2"
"FAM163B","C9orf166","ENSG00000196990","Family with sequence similarity 163 member B","9","133578415-133586197","Predicted membrane proteins","Evidence at transcript level","HPA067336","Approved",NA,"Approved","Nuclear bodies<br>Plasma membrane<br>Cytosol",NA,"Tissue enriched","Tissue enriched",6,"cerebral cortex: 103.5","adrenal gland: 16.4","Cell line enriched",19,"SH-SY5Y: 72.4"
"FAM167B","C1orf90, MGC10820","ENSG00000183615","Family with sequence similarity 167 member B","1","32247233-32248856","Predicted intracellular proteins","Evidence at protein level","HPA029398, HPA062074","Approved",NA,"Approved","Actin filaments","Colorectal cancer:1.11e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"thyroid gland: 9.4","Cell line enhanced",NA,"EFO-21: 11.4;SK-MEL-30: 23.7;U-2197: 28.2"
"FAM180A","HWKM1940, UNQ1940","ENSG00000189320","Family with sequence similarity 180 member A","7","135728348-135748846","Predicted secreted proteins","Evidence at protein level","HPA021224","Uncertain",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"gallbladder: 25.5","heart muscle: 10.4","Cell line enhanced",NA,"BJ hTERT+: 45.6;fHDF/TERT166: 44.5;U-138 MG: 55.9;U-2197: 239.9"
"FAM181B","LOC220382, MGC33846","ENSG00000182103","Family with sequence similarity 181 member B","11","82729941-82733864","Predicted intracellular proteins","Evidence at transcript level","HPA066861","Approved",NA,"Approved","Nuclear membrane<br>Mitochondria","Endometrial cancer:8.07e-4 (favourable)","Tissue enriched","Tissue enriched",20,"cerebral cortex: 17.5","adrenal gland,fallopian tube: 0.8","Cell line enhanced",NA,"RT4: 1.9;SH-SY5Y: 1.3;U-2 OS: 1.3"
"FAM199X","CXorf39","ENSG00000123575","Family with sequence similarity 199, X-linked","X","104166620-104195902","Predicted intracellular proteins","Evidence at protein level","HPA003093","Approved",NA,"Approved","Nucleus<br>Golgi apparatus<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"epididymis: 43.4","Expressed in all",NA,NA
"FAM19A1","TAFA-1, TAFA1","ENSG00000183662","Family with sequence similarity 19 member A1, C-C motif chemokine like","3","68004216-68545625","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA013407","Approved",NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",6,"cerebral cortex: 30.8","seminal vesicle: 5.3","Cell line enriched",9,"REH: 1.5"
"FAM19A5","TAFA-5","ENSG00000219438","Family with sequence similarity 19 member A5, C-C motif chemokine like","22","48489460-48850912","Predicted intracellular proteins, Predicted secreted proteins","Evidence at transcript level","CAB025629","Approved",NA,NA,NA,NA,"Expressed in all","Tissue enhanced",NA,"cerebral cortex: 49.9","cervix, uterine: 12.9","Cell line enhanced",NA,"fHDF/TERT166: 15.8;HEK 293: 12.4;Hep G2: 21.7;NTERA-2: 17.3;SCLC-21H: 10.2;U-2 OS: 24.8"
"FAM213A","Adrx, C10orf58, MGC4248, PAMM","ENSG00000122378","Family with sequence similarity 213 member A","10","80407829-80437115","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA009025, HPA024565","Approved",NA,NA,NA,"Urothelial cancer:6.11e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"adipose tissue: 425.0","Cell line enhanced",NA,"ASC diff: 650.7;HUVEC TERT2: 365.0"
"FAM221A","C7orf46, DKFZp686F0810, FLJ45875, MGC72075","ENSG00000188732","Family with sequence similarity 221 member A","7","23680130-23703249","Predicted intracellular proteins","Evidence at protein level","HPA019719, HPA026748, HPA026752","Enhanced",NA,"Approved","Cytosol",NA,"Mixed","Tissue enhanced",NA,"testis: 34.7","fallopian tube: 14.6","Cell line enhanced",NA,"MOLT-4: 20.7;SCLC-21H: 26.9;SH-SY5Y: 41.2"
"FAM234B","KIAA1467","ENSG00000084444","Family with sequence similarity 234 member B","12","13044284-13142521","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA010803, HPA010850","Approved",NA,"Approved","Endoplasmic reticulum",NA,"Expressed in all","Tissue enhanced",NA,"cerebral cortex: 32.4","breast: 20.8","Expressed in all",NA,NA
"FAM69A","FLJ23493","ENSG00000154511","Family with sequence similarity 69 member A","1","92832737-92961522","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA015718, HPA017281","Approved",NA,"Approved","Nucleus<br>Cytosol","Renal cancer:1.45e-7 (unfavourable), Breast cancer:8.96e-4 (favourable)","Expressed in all","Mixed",NA,NA,"cerebral cortex: 44.7","Mixed",NA,NA
"FAM69C","C18orf51","ENSG00000187773","Family with sequence similarity 69 member C","18","74434099-74457944","Predicted intracellular proteins","Evidence at protein level","HPA048928","Enhanced",NA,NA,NA,NA,"Group enriched","Tissue enhanced",NA,"cerebral cortex: 28.8;testis: 8.4","skin: 4.9","Cell line enriched",7,"SK-MEL-30: 4.2"
"FAM83B","C6orf143, FLJ30642","ENSG00000168143","Family with sequence similarity 83 member B","6","54846771-54942022","Predicted intracellular proteins","Evidence at protein level","HPA031464, HPA031465","Enhanced",NA,NA,NA,"Urothelial cancer:1.86e-5 (unfavourable), Lung cancer:1.48e-4 (unfavourable), Pancreatic cancer:7.60e-4 (unfavourable)","Tissue enhanced","Tissue enhanced",NA,"skin: 27.3","esophagus: 17.7","Cell line enhanced",NA,"A-431: 17.1;HaCaT: 18.9;hTCEpi: 15.2;hTERT-HME1: 21.2;RT4: 19.6"
"FARSB","FARSLB, FRSB, PheHB","ENSG00000116120","Phenylalanyl-tRNA synthetase beta subunit","2","222570536-222656337","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA036677, HPA036678, HPA061398","Enhanced",NA,"Supported","Nucleus<br>Cytosol","Liver cancer:6.45e-10 (unfavourable), Renal cancer:3.21e-5 (unfavourable), Urothelial cancer:1.25e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 34.4","Expressed in all",NA,NA
"FBP1","FBP","ENSG00000165140","Fructose-bisphosphatase 1","9","94603133-94640249","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA005857, HPA012513, CAB033869","Enhanced",NA,"Uncertain","Mitochondria","Renal cancer:6.86e-7 (favourable), Urothelial cancer:1.64e-5 (favourable), Liver cancer:1.79e-4 (favourable), Endometrial cancer:5.16e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"liver: 443.9","duodenum: 329.6","Cell line enhanced",NA,"HaCaT: 66.7;MCF7: 184.8;RT4: 124.5;U-698: 78.4"
"FBXO44","FBG3, FBX30, Fbx44, Fbxo6a, MGC14140","ENSG00000132879","F-box protein 44","1","11654375-11663327","Predicted intracellular proteins","Evidence at protein level","HPA003363","Approved",NA,"Approved","Nucleoplasm","Renal cancer:6.29e-5 (favourable), Pancreatic cancer:2.63e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 98.1","Mixed",NA,NA
"FCF1","Bka, C14orf111, CGI-35, UTP24","ENSG00000119616","FCF1 rRNA-processing protein","14","74713144-74738620","Predicted intracellular proteins","Evidence at protein level","HPA046681","Approved",NA,"Approved","Nucleoplasm","Liver cancer:5.54e-6 (unfavourable), Renal cancer:2.26e-4 (favourable), Pancreatic cancer:3.54e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 72.6","Expressed in all",NA,NA
"FCN1","FCNM","ENSG00000085265","Ficolin 1","9","134905890-134917963","Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA000685, HPA001295, CAB016760","Enhanced",NA,NA,NA,"Renal cancer:3.98e-4 (unfavourable)","Mixed","Group enriched",5,"appendix: 323.4;bone marrow: 634.5","spleen: 94.6","Group enriched",7,"NB-4: 12.4;U-937: 22.6"
"FCRL1","CD307a, FCRH1, IFGP1, IRTA5","ENSG00000163534","Fc receptor like 1","1","157794403-157820105","CD markers, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA013323","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"lymph node: 30.3;spleen: 23.5;tonsil: 20.0","appendix: 12.5","Group enriched",31,"Daudi: 3.7;U-698: 11.9"
"FCRL3","CD307c, FCRH3, IFGP3, IRTA3, SPAP2, SPAP2a, SPAP2b, SPAP2c, SPAP2d, SPAP2e","ENSG00000160856","Fc receptor like 3","1","157674321-157700857","CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA048022","Enhanced",NA,NA,NA,NA,"Mixed","Group enriched",13,"appendix: 18.1;lymph node: 55.9;spleen: 36.7;tonsil: 32.3","urinary bladder: 2.8","Cell line enriched",7,"Daudi: 6.9"
"FCRLA","FCRL, FCRLa, FCRLb, FCRLc1, FCRLc2, FCRLd, FCRLe, FCRLM1, FCRLX, FREB, MGC4595","ENSG00000132185","Fc receptor like A","1","161706972-161714352","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB016545","Enhanced",NA,NA,NA,NA,"Tissue enriched","Group enriched",10,"appendix: 31.2;lymph node: 80.5;spleen: 56.4;tonsil: 86.7","urinary bladder: 6.2","Cell line enhanced",NA,"Daudi: 338.0;SK-MEL-30: 150.5;U-698: 179.6"
"FDCSP","C4orf7, FDC-SP","ENSG00000181617","Follicular dendritic cell secreted protein","4","70226071-70235252","Predicted secreted proteins","Evidence at protein level","HPA014326, CAB014890","Enhanced",NA,NA,NA,"Lung cancer:1.32e-4 (favourable), Head and neck cancer:2.38e-4 (favourable)","Tissue enhanced","Tissue enhanced",NA,"lymph node: 1014.2;salivary gland: 1371.2;tonsil: 2458.1","appendix: 359.2","Cell line enhanced",NA,"HL-60: 1.0;K-562: 1.0;RH-30: 1.7;U-87 MG: 4.6"
"FERMT1","C20orf42, FLJ20116, KIND1, UNC112A, URP1","ENSG00000101311","Fermitin family member 1","20","6074845-6123544","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA039778, HPA041966","Approved",NA,NA,NA,"Pancreatic cancer:6.60e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"rectum: 30.8","Cell line enhanced",NA,"CAPAN-2: 58.4;HaCaT: 68.4;HBEC3-KT: 56.3"
"FGD2","ZFYVE4","ENSG00000146192","FYVE, RhoGEF and PH domain containing 2","6","37005646-37029070","Predicted intracellular proteins","Evidence at protein level","HPA029145, HPA049692","Approved",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"spleen: 42.4","lymph node: 25.0","Group enriched",6,"CAPAN-2: 2.4;Daudi: 8.2;HDLM-2: 10.5;U-698: 6.3"
"FGF2","FGFB","ENSG00000138685","Fibroblast growth factor 2","4","122826708-122898236","Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins","Evidence at protein level","CAB000125","Approved",NA,"Supported","Nucleoplasm<br>Nuclear bodies","Pancreatic cancer:9.85e-4 (unfavourable)","Mixed","Mixed",NA,NA,"adipose tissue: 26.1","Cell line enhanced",NA,"BJ: 206.0;fHDF/TERT166: 215.4"
"FGF4","HBGF-4, HST, HST-1, HSTF1, K-FGF, KFGF","ENSG00000075388","Fibroblast growth factor 4","11","69771016-69775403","Cancer-related genes, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","HPA011209","Uncertain",NA,NA,NA,NA,"Tissue enriched","Not detected",NA,NA,"testis: 0.4","Cell line enriched",90,"NTERA-2: 15.7"
"FGR","c-fgr, p55c-fgr, SRC2","ENSG00000000938","FGR proto-oncogene, Src family tyrosine kinase","1","27612064-27635277","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA002024","Enhanced",NA,"Approved","Plasma membrane<br>Aggresome",NA,"Expressed in all","Tissue enhanced",NA,"appendix: 85.6;bone marrow: 137.0;spleen: 90.6","lung: 56.3","Cell line enhanced",NA,"Daudi: 61.4;HMC-1: 25.8;U-266/70: 116.7"
"FHL2","DRAL, SLIM3","ENSG00000115641","Four and a half LIM domains 2","2","105357712-105438513","Predicted intracellular proteins","Evidence at protein level","HPA005922, HPA006028, CAB008368","Enhanced",NA,"Enhanced","Actin filaments<br>Focal adhesion sites","Renal cancer:6.42e-5 (unfavourable), Head and neck cancer:2.01e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"ovary: 659.3","Mixed",NA,NA
"FHOD3","FHOS2, FLJ22297, FLJ22717, KIAA1695","ENSG00000134775","Formin homology 2 domain containing 3","18","36297714-36780055","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA021827, HPA024696","Uncertain",NA,NA,NA,"Renal cancer:1.19e-5 (favourable)","Mixed","Tissue enhanced",NA,"heart muscle: 96.5;seminal vesicle: 88.0","epididymis: 51.4","Cell line enhanced",NA,"BJ hTERT+: 58.7;HDLM-2: 74.2"
"FKBP11","FKBP19","ENSG00000134285","FK506 binding protein 11","12","48921518-48926474","Enzymes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA041709","Enhanced",NA,"Approved","Centrosome","Renal cancer:0.00e+0 (unfavourable), Endometrial cancer:7.09e-4 (favourable)","Expressed in all","Mixed",NA,NA,"pancreas: 60.7","Mixed",NA,NA
"FKBP14","FKBP22, FLJ20731","ENSG00000106080","FK506 binding protein 14","7","30010587-30026684","Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins","Evidence at protein level","HPA013329, HPA026829","Uncertain",NA,"Approved","Nucleus<br>Golgi apparatus<br>Cytosol","Breast cancer:1.60e-4 (unfavourable), Urothelial cancer:4.25e-4 (unfavourable), Stomach cancer:4.57e-4 (unfavourable), Liver cancer:6.87e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"smooth muscle: 20.3","Mixed",NA,NA
"FKBP5","FKBP51, FKBP54, P54, PPIase, Ptg-10","ENSG00000096060","FK506 binding protein 5","6","35573585-35728583","Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB009315, HPA031092, HPA031093, HPA031095","Enhanced",NA,"Enhanced","Nucleoplasm",NA,"Expressed in all","Expressed in all",NA,NA,"adipose tissue: 415.3","Cell line enhanced",NA,"ASC diff: 517.9;HHSteC: 495.2;HSkMC: 518.9"
"FKBP8","FKBP38, FKBPr38","ENSG00000105701","FK506 binding protein 8","19","18531751-18544077","Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","CAB025346, HPA045177","Supported",NA,"Supported","Endoplasmic reticulum<br>Mitochondria<br>Cytosol","Colorectal cancer:1.24e-4 (unfavourable), Pancreatic cancer:7.76e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 354.7","Expressed in all",NA,NA
"FLAD1","FAD1, PP591","ENSG00000160688","Flavin adenine dinucleotide synthetase 1","1","154983338-154993111","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA028476, HPA028486, HPA028563","Approved",NA,"Supported","Plasma membrane<br>Cytosol","Renal cancer:2.55e-6 (unfavourable), Liver cancer:3.04e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"skin: 28.5","Expressed in all",NA,NA
"FLYWCH1","DKFZp761A132","ENSG00000059122","FLYWCH-type zinc finger 1","16","2911937-2951208","Predicted intracellular proteins","Evidence at protein level","HPA040753, HPA041001","Approved",NA,"Supported","Nucleoplasm<br>Nuclear bodies<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 30.3","Expressed in all",NA,NA
"FMNL2","FHOD2, KIAA1902","ENSG00000157827","Formin like 2","2","152335237-152649834","Predicted intracellular proteins","Evidence at protein level","HPA005464","Enhanced",NA,"Approved","Golgi apparatus<br>Plasma membrane<br>Cytosol","Liver cancer:9.04e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 137.8","placenta: 82.9","Cell line enhanced",NA,"BEWO: 184.8"
"FMO5",NA,"ENSG00000131781","Flavin containing monooxygenase 5","1","147175351-147243050","Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA012373","Enhanced",NA,"Supported","Endoplasmic reticulum<br>Cytosol","Renal cancer:1.34e-6 (favourable)","Tissue enriched","Tissue enhanced",NA,"liver: 324.7","small intestine: 75.4","Cell line enhanced",NA,"Hep G2: 26.6;HMC-1: 7.7;THP-1: 6.7"
"FNDC3B","DKFZp762K137, FAD104, FLJ23399, PRO4979, YVTM2421","ENSG00000075420","Fibronectin type III domain containing 3B","3","172039628-172401665","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA007859","Uncertain",NA,"Approved","Endoplasmic reticulum","Renal cancer:5.65e-7 (unfavourable), Cervical cancer:2.41e-5 (unfavourable), Pancreatic cancer:9.06e-5 (unfavourable), Liver cancer:9.85e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 77.5","Expressed in all",NA,NA
"FOXA3","HNF3G","ENSG00000170608","Forkhead box A3","19","45863989-45873797","Predicted intracellular proteins, Transcription factors","Evidence at protein level","CAB015154, HPA054034","Uncertain",NA,"Approved","Nucleoplasm",NA,"Mixed","Group enriched",5,"colon: 16.7;duodenum: 10.3;liver: 32.5;pancreas: 9.8;rectum: 17.9;small intestine: 13.9;stomach: 33.8","gallbladder: 3.6","Cell line enhanced",NA,"CACO-2: 8.4;HDLM-2: 11.2;Hep G2: 18.9;K-562: 20.1;NTERA-2: 10.8"
"FOXK1","IMAGE:5164497","ENSG00000164916","Forkhead box K1","7","4682309-4771443","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA017998, HPA018864","Enhanced",NA,"Supported","Nucleoplasm<br>Nucleoli fibrillar center","Liver cancer:2.54e-6 (unfavourable)","Expressed in all","Mixed",NA,NA,"cerebral cortex: 12.4","Expressed in all",NA,NA
"FOXR2","FOXN6, MGC21658","ENSG00000189299","Forkhead box R2","X","55623400-55625325","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA034487, HPA057358","Uncertain",NA,"Supported","Nucleoplasm",NA,"Tissue enhanced","Tissue enriched",15,"testis: 2.8","epididymis: 0.1","Group enriched",107,"NTERA-2: 12.2;SH-SY5Y: 11.3;U-266/70: 5.4;U-266/84: 13.9"
"FRA10AC1","C10orf4","ENSG00000148690","FRA10A associated CGG repeat 1","10","93667883-93702572","Predicted intracellular proteins","Evidence at protein level","HPA039204","Approved",NA,NA,NA,NA,"Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 21.3","Expressed in all",NA,NA
"FSCN1","FLJ38511, p55, SNL","ENSG00000075618","Fascin actin-bundling protein 1","7","5592823-5606655","Cancer-related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB000121, HPA005723, CAB035991, HPA050654","Enhanced",NA,"Supported","Plasma membrane<br>Cytosol","Renal cancer:8.15e-7 (unfavourable), Lung cancer:2.28e-4 (unfavourable), Head and neck cancer:5.76e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 85.5","spleen: 54.6","Cell line enhanced",NA,"BEWO: 579.4"
"FSD1","MGC3213, MIR1","ENSG00000105255","Fibronectin type III and SPRY domain containing 1","19","4304600-4323843","Predicted intracellular proteins","Evidence at protein level","HPA043141","Supported",NA,NA,NA,"Endometrial cancer:1.61e-4 (unfavourable)","Group enriched","Group enriched",12,"cerebral cortex: 25.4;testis: 9.1","lymph node: 1.4","Cell line enhanced",NA,"SCLC-21H: 65.0;SH-SY5Y: 60.9"
"FSHB",NA,"ENSG00000131808","Follicle stimulating hormone beta subunit","11","30231016-30235261","Cancer-related genes, Disease related genes, Predicted secreted proteins","Evidence at protein level","CAB023410, HPA069703","Supported",NA,NA,NA,NA,"Not detected","Not detected",NA,NA,"all non-specific tissues: 0.0","Not detected",NA,NA
"FTCD",NA,"ENSG00000160282","Formimidoyltransferase cyclodeaminase","21","46136262-46155567","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA020073, HPA030928, HPA030929, HPA036114","Enhanced",NA,"Approved","Plasma membrane<br>Cytosol","Pancreatic cancer:6.78e-5 (favourable), Liver cancer:1.70e-4 (favourable), Renal cancer:5.78e-4 (favourable)","Tissue enriched","Group enriched",18,"kidney: 100.2;liver: 184.7","testis: 7.7","Cell line enriched",24,"Hep G2: 62.7"
"FUCA2","dJ20N2.5, MGC1314","ENSG00000001036","Fucosidase, alpha-L- 2, plasma","6","143494811-143511690","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA031659, HPA031660, HPA031661","Uncertain",NA,NA,NA,"Liver cancer:2.70e-9 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 154.2","Mixed",NA,NA
"FUNDC2","DC44, HCBP6","ENSG00000165775","FUN14 domain containing 2","X","155025980-155060303","Predicted intracellular proteins","Evidence at protein level","HPA059129","Approved",NA,NA,NA,"Liver cancer:3.78e-5 (unfavourable), Endometrial cancer:7.26e-4 (unfavourable), Cervical cancer:9.20e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"ovary: 7.8","Expressed in all",NA,NA
"FUS","ALS6, FUS1, hnRNP-P2, HNRNPP2, TLS","ENSG00000089280","FUS RNA binding protein","16","31180110-31194871","Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA008784, CAB033036, CAB058691","Enhanced",NA,"Enhanced","Nucleoplasm","Liver cancer:4.38e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 145.8","Expressed in all",NA,NA
"FUT4","CD15, ELFT, FCT3A, FUC-TIV","ENSG00000196371","Fucosyltransferase 4","11","94543840-94549898","Predicted membrane proteins","Evidence at protein level","CAB000014, CAB016129","Enhanced",NA,"Enhanced","Vesicles","Lung cancer:3.64e-4 (unfavourable)","Expressed in all","Tissue enriched",5,"bone marrow: 62.9","duodenum: 12.4","Cell line enhanced",NA,"HL-60: 29.6;THP-1: 31.3;U-937: 25.8"
"FUT8",NA,"ENSG00000033170","Fucosyltransferase 8","14","65410592-65744121","Enzymes, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","CAB017129, HPA040863, HPA043410","Enhanced",NA,"Enhanced","Golgi apparatus<br>Cytosol",NA,"Expressed in all","Mixed",NA,NA,"cerebral cortex: 31.5","Expressed in all",NA,NA
"FXR2","FMR1L2","ENSG00000129245","FMR1 autosomal homolog 2","17","7591230-7614871","Predicted intracellular proteins","Evidence at protein level","CAB011205, HPA022997","Supported",NA,"Supported","Cytosol","Pancreatic cancer:3.49e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 44.4","Mixed",NA,NA
"FXYD6",NA,"ENSG00000137726","FXYD domain containing ion transport regulator 6","11","117836976-117877486","Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters","Evidence at protein level","HPA041334, HPA042284","Approved",NA,"Approved","Nucleoplasm<br>Cytosol","Endometrial cancer:1.05e-5 (unfavourable), Renal cancer:4.38e-5 (favourable), Urothelial cancer:1.60e-4 (unfavourable), Liver cancer:5.87e-4 (favourable), Pancreatic cancer:5.97e-4 (favourable)","Tissue enriched","Expressed in all",NA,NA,"cerebral cortex: 696.9","Cell line enhanced",NA,"AF22: 128.6;HAP1: 89.7;SCLC-21H: 231.1;SH-SY5Y: 118.8"
"FZD3",NA,"ENSG00000104290","Frizzled class receptor 3","8","28494205-28574268","G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","CAB024995","Approved",NA,NA,NA,"Colorectal cancer:1.17e-4 (favourable), Ovarian cancer:3.71e-4 (favourable)","Mixed","Mixed",NA,NA,"cerebral cortex: 16.4","Cell line enhanced",NA,"AF22: 53.7;SCLC-21H: 46.9"
"GAB1",NA,"ENSG00000109458","GRB2 associated binding protein 1","4","143336762-143474568","Predicted intracellular proteins, RAS pathway related proteins","Evidence at protein level","CAB034333, HPA049599","Enhanced",NA,"Approved","Vesicles","Renal cancer:3.91e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 32.2","Cell line enhanced",NA,"REH: 67.9"
"GABBR2","GABABR2, GPR51, GPRC3B, HG20","ENSG00000136928","Gamma-aminobutyric acid type B receptor subunit 2","9","98288082-98709197","FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters","Evidence at protein level","HPA013820, HPA031684, CAB079065","Enhanced","Approved",NA,NA,NA,"Group enriched","Tissue enriched",18,"cerebral cortex: 77.9","adrenal gland: 4.3","Cell line enhanced",NA,"BJ: 11.3;HUVEC TERT2: 22.8;U-138 MG: 10.3"
"GABRB1",NA,"ENSG00000163288","Gamma-aminobutyric acid type A receptor beta1 subunit","4","46993723-47426444","Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA051297","Uncertain",NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",12,"cerebral cortex: 19.7","heart muscle: 1.5","Cell line enhanced",NA,"REH: 1.4;U-87 MG: 2.4"
"GABRB2",NA,"ENSG00000145864","Gamma-aminobutyric acid type A receptor beta2 subunit","5","161288429-161549044","FDA approved drug targets, Predicted membrane proteins, Transporters","Evidence at protein level","CAB001964, HPA067632","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",12,"cerebral cortex: 62.8","epididymis: 5.2","Cell line enriched",17,"SCLC-21H: 27.6"
"GABRD",NA,"ENSG00000187730","Gamma-aminobutyric acid type A receptor delta subunit","1","2019298-2030758","Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA044371","Enhanced",NA,"Uncertain","Golgi apparatus<br>Vesicles","Renal cancer:4.12e-8 (unfavourable)","Expressed in all","Tissue enriched",12,"cerebral cortex: 34.0","testis: 2.7","Cell line enhanced",NA,"EFO-21: 1.3;MCF7: 3.1;NB-4: 1.6;SH-SY5Y: 1.6"
"GABRG1",NA,"ENSG00000163285","Gamma-aminobutyric acid type A receptor gamma1 subunit","4","46035769-46124081","FDA approved drug targets, Predicted membrane proteins","Evidence at transcript level","HPA035622","Approved",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",17,"cerebral cortex: 26.0","ovary: 1.5","Cell line enhanced",NA,"U-266/70: 1.1"
"GAD2","GAD65","ENSG00000136750","Glutamate decarboxylase 2","10","26216307-26304558","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA044637, CAB078177","Enhanced",NA,NA,NA,NA,"Group enriched","Tissue enriched",17,"cerebral cortex: 22.9","pancreas: 1.3","Group enriched",13,"MOLT-4: 2.4;SCLC-21H: 7.4"
"GAL","GAL-GMAP, GALN, GLNN, GMAP","ENSG00000069482","Galanin and GMAP prepropeptide","11","68683779-68691175","Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA049864","Enhanced","Supported","Approved","Golgi apparatus<br>Vesicles","Endometrial cancer:1.22e-4 (unfavourable), Lung cancer:8.17e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"appendix: 18.1;smooth muscle: 12.1","colon: 5.2","Cell line enhanced",NA,"CACO-2: 193.9;K-562: 111.4;NB-4: 277.5;SH-SY5Y: 179.1"
"GALM",NA,"ENSG00000143891","Galactose mutarotase","2","38665910-38741237","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA035472, HPA035473, HPA064835","Enhanced",NA,"Approved","Nucleoplasm","Renal cancer:9.06e-5 (favourable), Urothelial cancer:1.32e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"kidney: 118.1","Mixed",NA,NA
"GAREM1","C18orf11, FAM59A, FLJ21610, GAREM","ENSG00000141441","GRB2 associated regulator of MAPK1 subtype 1","18","32124877-32470484","Predicted intracellular proteins","Evidence at protein level","HPA040709, HPA042046","Approved",NA,"Approved","Nucleoplasm<br>Cytosol","Renal cancer:5.49e-6 (favourable), Pancreatic cancer:6.73e-5 (unfavourable)","Expressed in all","Mixed",NA,NA,"cerebral cortex: 13.7","Cell line enhanced",NA,"hTERT-HME1: 23.0;RT4: 21.0;SH-SY5Y: 22.6"
"GBE1",NA,"ENSG00000114480","1,4-alpha-glucan branching enzyme 1","3","81489699-81762161","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA038073, HPA038074, HPA038075","Enhanced",NA,"Approved","Nucleoplasm<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"adipose tissue: 79.6","Expressed in all",NA,NA
"GBP3","FLJ10961","ENSG00000117226","Guanylate binding protein 3","1","89006666-89022894","Predicted intracellular proteins","Evidence at protein level","HPA045657","Approved",NA,NA,NA,NA,"Expressed in all","Mixed",NA,NA,"duodenum: 77.0","Cell line enhanced",NA,"BJ hTERT+: 64.5;LHCN-M2: 58.7"
"GBP4","Mpa2","ENSG00000162654","Guanylate binding protein 4","1","89181148-89198932","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA030101, HPA062039","Enhanced",NA,"Approved","Plasma membrane","Renal cancer:1.30e-5 (unfavourable), Ovarian cancer:9.29e-5 (favourable)","Expressed in all","Mixed",NA,NA,"lung: 46.9","Cell line enhanced",NA,"CAPAN-2: 10.6;HEL: 11.8;REH: 10.2;RT4: 14.7;U-266/70: 12.3"
"GCA","GCL","ENSG00000115271","Grancalcin","2","162318840-162371595","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA035033, HPA035034","Enhanced",NA,"Supported","Plasma membrane<br>Cytosol",NA,"Expressed in all","Tissue enhanced",NA,"bone marrow: 214.5","appendix: 88.0","Mixed",NA,NA
"GCC2","GCC185, KIAA0336","ENSG00000135968","GRIP and coiled-coil domain containing 2","2","108448561-108509415","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA035849, HPA035850","Enhanced",NA,"Enhanced","Nucleoplasm<br>Golgi apparatus","Liver cancer:4.24e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"epididymis: 34.0","Expressed in all",NA,NA
"GCN1","GCN1L, GCN1L1, KIAA0219","ENSG00000089154","GCN1, eIF2 alpha kinase activator homolog","12","120127203-120194710","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA018799, HPA019648, HPA024367","Enhanced",NA,"Enhanced","Cytosol","Liver cancer:1.87e-8 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 37.5","Expressed in all",NA,NA
"GDA",NA,"ENSG00000119125","Guanine deaminase","9","72114595-72257193","Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA019352, HPA024099, HPA030387","Enhanced",NA,"Approved","Nucleus","Renal cancer:2.66e-5 (favourable)","Mixed","Tissue enhanced",NA,"cerebral cortex: 102.2;duodenum: 95.2;small intestine: 104.1","kidney: 43.6","Cell line enhanced",NA,"A-431: 31.0;EFO-21: 125.3;HeLa: 32.0;hTCEpi: 45.2"
"GDF11","BMP-11","ENSG00000135414","Growth differentiation factor 11","12","55743280-55757278","Predicted secreted proteins","Evidence at protein level","HPA060985, HPA069609","Enhanced",NA,"Approved","Vesicles","Pancreatic cancer:1.08e-4 (favourable)","Expressed in all","Mixed",NA,NA,"cerebral cortex,seminal vesicle: 13.3","Cell line enhanced",NA,"HMC-1: 112.3"
"GDI1","FLJ41411, GDIL, MRX41, MRX48, OPHN2, RABGDIA, XAP-4","ENSG00000203879","GDP dissociation inhibitor 1","X","154436913-154443467","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB012979, HPA049290, HPA057668","Enhanced",NA,"Approved","Vesicles","Colorectal cancer:3.83e-5 (unfavourable), Breast cancer:6.84e-4 (unfavourable)","Expressed in all","Tissue enriched",5,"cerebral cortex: 532.0","smooth muscle: 101.3","Expressed in all",NA,NA
"GDNF","ATF1, ATF2, HFB1-GDNF","ENSG00000168621","Glial cell derived neurotrophic factor","5","37812677-37839686","Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB005210, HPA070283","Supported",NA,"Approved","Nucleoplasm<br>Vesicles",NA,"Mixed","Mixed",NA,NA,"placenta: 7.0","Cell line enhanced",NA,"hTEC/SVTERT24-B: 41.1;U-87 MG: 12.1;WM-115: 45.1"
"GFI1","GFI-1, GFI1A, ZNF163","ENSG00000162676","Growth factor independent 1 transcriptional repressor","1","92474762-92486876","Disease related genes, Predicted intracellular proteins, Transcription factors","Evidence at protein level","CAB011197","Uncertain",NA,NA,NA,"Colorectal cancer:5.68e-5 (favourable)","Mixed","Tissue enhanced",NA,"bone marrow: 34.8","lymph node: 8.1","Cell line enhanced",NA,"HL-60: 49.8;HMC-1: 42.0;THP-1: 86.5;U-937: 207.4"
"GFI1B","ZNF163B","ENSG00000165702","Growth factor independent 1B transcriptional repressor","9","132944000-132991687","Disease related genes, Predicted intracellular proteins, Transcription factors","Evidence at protein level","CAB004420","Enhanced",NA,NA,NA,NA,"Not detected","Tissue enriched",15,"bone marrow: 23.8","testis: 1.5","Group enriched",6,"HEL: 151.4;HMC-1: 92.4;K-562: 47.5"
"GFPT2","GFAT2","ENSG00000131459","Glutamine-fructose-6-phosphate transaminase 2","5","180300690-180353387","Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA056892, HPA059910","Uncertain",NA,"Supported","Vesicles","Renal cancer:2.58e-14 (unfavourable), Lung cancer:2.95e-4 (unfavourable), Thyroid cancer:3.47e-4 (unfavourable), Cervical cancer:9.09e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"adipose tissue: 90.9","appendix: 25.7","Cell line enhanced",NA,"ASC TERT1: 138.7;hTEC/SVTERT24-B: 242.9;U-87 MG: 409.1"
"GIGYF1","GYF1, PERQ1","ENSG00000146830","GRB10 interacting GYF protein 1","7","100679507-100689448","Predicted intracellular proteins","Evidence at protein level","HPA020999, HPA023995","Enhanced",NA,"Approved","Vesicles<br>Microtubules","Pancreatic cancer:1.35e-5 (favourable), Liver cancer:2.30e-4 (unfavourable), Head and neck cancer:7.42e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"endometrium: 35.8","Expressed in all",NA,NA
"GIGYF2","GYF2, KIAA0642, PARK11, PERQ2, PERQ3, TNRC15","ENSG00000204120","GRB10 interacting GYF protein 2","2","232697299-232860575","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA050899, HPA054612, HPA059918, HPA065064","Approved",NA,"Enhanced","Cytosol","Renal cancer:6.97e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 85.1","Expressed in all",NA,NA
"GIMAP4","FLJ11110, HIMAP4, IAN1, IMAP4","ENSG00000133574","GTPase, IMAP family member 4","7","150567277-150573955","Predicted intracellular proteins","Evidence at protein level","HPA019135, HPA019137, HPA027198","Enhanced",NA,NA,NA,"Renal cancer:1.13e-4 (unfavourable), Endometrial cancer:7.63e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"spleen: 147.7","Cell line enriched",23,"HUVEC TERT2: 253.7"
"GJA10","CX62","ENSG00000135355","Gap junction protein alpha 10","6","89894469-89921760","Predicted membrane proteins","Evidence at protein level","HPA021145","Uncertain",NA,NA,NA,NA,"Tissue enriched","Not detected",NA,NA,"testis: 0.4","Not detected",NA,NA
"GJA8","CAE, CAE1, CX50, CZP1","ENSG00000121634","Gap junction protein alpha 8","1","147907956-147909257","Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters","Evidence at protein level","HPA014715, HPA062940","Enhanced",NA,NA,NA,NA,"Not detected","Tissue enriched",86,"testis: 11.4","kidney,smooth muscle: 0.1","Not detected",NA,NA
"GKAP1","FKSG21, GKAP42","ENSG00000165113","G kinase anchoring protein 1","9","83739421-83829516","Predicted intracellular proteins","Evidence at protein level","HPA035117, HPA035118, HPA066173","Enhanced","Approved","Approved","Microtubule organizing center<br>Cytosol","Renal cancer:1.05e-6 (favourable), Pancreatic cancer:6.96e-5 (favourable)","Mixed","Tissue enriched",21,"testis: 363.1","skeletal muscle: 17.6","Mixed",NA,NA
"GLB1L3","FLJ90231","ENSG00000166105","Galactosidase beta 1 like 3","11","134274245-134319564","Predicted intracellular proteins","Evidence at protein level","HPA039916","Uncertain",NA,NA,NA,"Lung cancer:1.97e-4 (favourable)","Tissue enhanced","Tissue enhanced",NA,"prostate: 14.5;seminal vesicle: 7.0","cerebral cortex: 4.0","Cell line enhanced",NA,"HEK 293: 5.2;NTERA-2: 3.5;PC-3: 4.3;SCLC-21H: 8.6"
"GLCE","HSEPI, KIAA0836","ENSG00000138604","Glucuronic acid epimerase","15","69160584-69272217","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA040481, HPA048216","Uncertain",NA,"Approved","Mitochondria",NA,"Expressed in all","Mixed",NA,NA,"placenta: 19.1","Cell line enhanced",NA,"HUVEC TERT2: 99.7"
"GLRA2","GLR","ENSG00000101958","Glycine receptor alpha 2","X","14529298-14731812","FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters","Evidence at protein level","CAB070422","Approved",NA,NA,NA,NA,"Mixed","Group enriched",10,"cerebral cortex: 6.1;colon: 1.4;rectum: 4.3","testis: 0.3","Cell line enriched",41,"AN3-CA: 16.1"
"GLTSCR1L","KIAA0240","ENSG00000112624","GLTSCR1 like","6","42746958-42868560","Predicted intracellular proteins","Evidence at protein level","HPA029390, HPA029391","Approved",NA,"Supported","Nucleoplasm","Head and neck cancer:5.47e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 21.9","Expressed in all",NA,NA
"GLUL","GLNS","ENSG00000135821","Glutamate-ammonia ligase","1","182381704-182392206","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA007316, HPA007571, CAB008636","Approved",NA,"Supported","Mitochondria<br>Cytosol","Breast cancer:4.81e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"adipose tissue: 851.0","Cell line enhanced",NA,"ASC diff: 791.8;ASC TERT1: 567.1;HSkMC: 512.4"
"GLYATL3","bA28H17.2, C6orf140","ENSG00000203972","Glycine-N-acyltransferase like 3","6","49499958-49527047","Predicted intracellular proteins","Evidence at transcript level","HPA044044","Uncertain",NA,NA,NA,NA,"Tissue enhanced","Not detected",NA,NA,"liver: 0.7","Cell line enriched",74,"T-47d: 13.7"
"GLYR1","BM045, HIBDL, N-PAC, NP60","ENSG00000140632","Glyoxylate reductase 1 homolog","16","4803203-4847342","Predicted intracellular proteins","Evidence at protein level","CAB017022, HPA048226, HPA050136","Enhanced",NA,"Enhanced","Nucleoplasm<br>Nuclear speckles","Renal cancer:8.74e-7 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 111.5","Expressed in all",NA,NA
"GNAI3","87U6","ENSG00000065135","G protein subunit alpha i3","1","109548611-109618321","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB022099, HPA042141","Approved",NA,"Supported","Nucleus<br>Nucleoli<br>Centrosome","Liver cancer:5.30e-6 (unfavourable), Colorectal cancer:1.62e-4 (favourable), Renal cancer:4.34e-4 (unfavourable), Ovarian cancer:4.59e-4 (favourable)","Expressed in all","Mixed",NA,NA,"esophagus: 7.9","Expressed in all",NA,NA
"GNAS","GNAS1, GNASXL, GPSA, NESP, NESP55, SCG6, SgVI","ENSG00000087460","GNAS complex locus","20","58839718-58911192","Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB010337, HPA018122, HPA027478, HPA028386","Uncertain",NA,"Supported","Nucleoplasm<br>Plasma membrane<br>Cytosol","Renal cancer:3.49e-4 (unfavourable), Ovarian cancer:8.76e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 1473.9","Expressed in all",NA,NA
"GNB1",NA,"ENSG00000078369","G protein subunit beta 1","1","1785285-1891117","Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins","Evidence at protein level","HPA040736","Supported",NA,"Approved","Golgi apparatus<br>Plasma membrane","Liver cancer:3.61e-6 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 447.4","Expressed in all",NA,NA
"GNB2",NA,"ENSG00000172354","G protein subunit beta 2","7","100673531-100679174","Predicted intracellular proteins, RAS pathway related proteins","Evidence at protein level","CAB010032, HPA040736","Approved",NA,"Enhanced","Plasma membrane",NA,"Expressed in all","Expressed in all",NA,NA,"esophagus: 235.4","Expressed in all",NA,NA
"GNB3",NA,"ENSG00000111664","G protein subunit beta 3","12","6839954-6847393","Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins","Evidence at protein level","HPA040736","Approved",NA,"Approved","Golgi apparatus<br>Plasma membrane",NA,"Tissue enhanced","Mixed",NA,NA,"smooth muscle: 3.8","Cell line enhanced",NA,"NTERA-2: 12.8;U-698: 22.7"
"GNB4",NA,"ENSG00000114450","G protein subunit beta 4","3","179396089-179451590","Disease related genes, Predicted intracellular proteins, RAS pathway related proteins","Evidence at protein level","CAB018383, CAB018737, HPA040736","Enhanced",NA,"Enhanced","Plasma membrane","Renal cancer:1.39e-6 (unfavourable)","Expressed in all","Mixed",NA,NA,"skin: 37.6","Mixed",NA,NA
"GNL3L","FLJ10613, GNL3B","ENSG00000130119","G protein nucleolar 3 like","X","54530211-54561071","Predicted intracellular proteins","Evidence at protein level","HPA036314, HPA036315","Supported",NA,"Supported","Nucleus<br>Nucleoli<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"thyroid gland: 16.4","Expressed in all",NA,NA
"GNLY","D2S69E, LAG-2, LAG2, NKG5, TLA519","ENSG00000115523","Granulysin","2","85685175-85698854","Predicted intracellular proteins, Predicted secreted proteins, Transporters","Evidence at protein level","CAB025186, HPA058021","Enhanced",NA,NA,NA,"Endometrial cancer:3.48e-5 (favourable), Melanoma:6.60e-5 (favourable), Renal cancer:1.50e-4 (unfavourable), Urothelial cancer:8.07e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"bone marrow: 152.4;endometrium: 113.5;spleen: 112.9","lung: 51.0","Not detected",NA,NA
"GOLGA2","GM130, golgin-95","ENSG00000167110","Golgin A2","9","128255829-128275995","Predicted intracellular proteins","Evidence at protein level","CAB015421, HPA021178, HPA021230, HPA021799","Enhanced",NA,"Enhanced","Golgi apparatus","Renal cancer:9.77e-5 (favourable), Colorectal cancer:1.64e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 161.0","Expressed in all",NA,NA
"GOLGA3","GCP170, golgin-160, MEA-2","ENSG00000090615","Golgin A3","12","132768909-132828858","Predicted intracellular proteins","Evidence at protein level","HPA039809, HPA040044","Enhanced",NA,"Supported","Nucleus<br>Golgi apparatus","Renal cancer:6.47e-5 (unfavourable), Liver cancer:2.73e-4 (unfavourable), Pancreatic cancer:3.87e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 18.5","Expressed in all",NA,NA
"GOLGB1","GCP, GCP372, giantin, GOLIM1","ENSG00000173230","Golgin B1","3","121663199-121749767","Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA011008, HPA011555","Enhanced",NA,"Enhanced","Golgi apparatus",NA,"Expressed in all","Expressed in all",NA,NA,"prostate: 41.9","Expressed in all",NA,NA
"GOLIM4","GIMPC, GOLPH4, GPP130, P138","ENSG00000173905","Golgi integral membrane protein 4","3","168008677-168095975","Predicted membrane proteins","Evidence at protein level","HPA001677, HPA002315","Enhanced",NA,"Enhanced","Golgi apparatus",NA,"Expressed in all","Expressed in all",NA,NA,"small intestine: 93.8","Mixed",NA,NA
"GP2","ZAP75","ENSG00000169347","Glycoprotein 2","16","20309572-20327808","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA015739, HPA016668","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",206,"pancreas: 7530.3","duodenum: 36.5","Not detected",NA,NA
"GP6","GPVI","ENSG00000088053","Glycoprotein VI platelet","19","55013705-55038264","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA066482","Approved",NA,"Approved","Nucleoplasm",NA,"Not detected","Tissue enhanced",NA,"testis: 1.2","skin: 0.7","Group enriched",12,"HEL: 8.5;K-562: 3.7;U-2 OS: 2.7"
"GP9","CD42a, GPIX","ENSG00000169704","Glycoprotein IX platelet","3","129060767-129062406","CD markers, Disease related genes, Predicted membrane proteins","Evidence at protein level","HPA063182","Enhanced",NA,NA,NA,NA,"Not detected","Tissue enhanced",NA,"bone marrow: 2.9;spleen: 2.7","testis: 1.2","Cell line enriched",19,"HEL: 75.1"
"GPKOW","GPATC5, GPATCH5, Spp2, T54","ENSG00000068394","G-patch domain and KOW motifs","X","49113389-49123801","Predicted intracellular proteins","Evidence at protein level","HPA000287, HPA001894","Enhanced",NA,"Enhanced","Nucleoplasm",NA,"Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 30.8","Expressed in all",NA,NA
"GPM6A","GPM6","ENSG00000150625","Glycoprotein M6A","4","175632934-176002664","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA017338","Supported",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",36,"cerebral cortex: 1104.1","lung: 30.7","Group enriched",9,"AF22: 49.3;Daudi: 30.7;HAP1: 18.0;U-251 MG: 42.1"
"GPR1",NA,"ENSG00000183671","G protein-coupled receptor 1","2","206175316-206218047","G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA010525","Uncertain",NA,"Supported","Nucleoplasm<br>Vesicles<br>Plasma membrane",NA,"Mixed","Tissue enhanced",NA,"placenta: 5.6","esophagus: 2.7","Cell line enhanced",NA,"HHSteC: 112.4;hTCEpi: 44.7"
"GPR137B","TM7SF1","ENSG00000077585","G protein-coupled receptor 137B","1","236142505-236221865","Predicted membrane proteins, Transporters","Evidence at protein level","HPA026422","Approved",NA,NA,NA,"Colorectal cancer:1.63e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"kidney: 70.7","Cell line enhanced",NA,"SK-MEL-30: 165.8"
"GPR137C","DKFZp762F0713, TM7SF1L2","ENSG00000180998","G protein-coupled receptor 137C","14","52553148-52637713","Predicted membrane proteins","Evidence at transcript level","HPA003640, HPA030763","Uncertain",NA,"Approved","Vesicles",NA,"Mixed","Group enriched",6,"cerebral cortex: 18.0;epididymis: 10.8;testis: 6.8","gallbladder: 2.1","Mixed",NA,NA
"GPR158","KIAA1136","ENSG00000151025","G protein-coupled receptor 158","10","25175062-25602226","G-protein coupled receptors, Predicted membrane proteins","Evidence at protein level","HPA013185","Uncertain",NA,"Approved","Cytosol",NA,"Mixed","Tissue enriched",17,"cerebral cortex: 17.9","testis: 1.0","Cell line enhanced",NA,"HEL: 18.7;T-47d: 5.2"
"GPR162","A-2, GRCA","ENSG00000250510","G protein-coupled receptor 162","12","6821545-6829972","G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA055135","Enhanced",NA,"Approved","Microtubule organizing center","Renal cancer:1.37e-6 (unfavourable), Pancreatic cancer:4.29e-5 (favourable)","Tissue enriched","Group enriched",6,"cerebral cortex: 84.3;fallopian tube: 29.4","lung: 9.5","Cell line enhanced",NA,"AF22: 17.4;AN3-CA: 19.5;NTERA-2: 19.7;SH-SY5Y: 14.2;U-2 OS: 17.2"
"GPR174","FKSG79","ENSG00000147138","G protein-coupled receptor 174","X","79170972-79172229","G-protein coupled receptors, Predicted membrane proteins","Evidence at protein level","HPA041025","Enhanced",NA,"Uncertain","Vesicles",NA,"Mixed","Tissue enhanced",NA,"lymph node: 29.8;spleen: 16.7;tonsil: 17.2","appendix: 12.6","Cell line enriched",8,"MOLT-4: 85.1"
"GPR18",NA,"ENSG00000125245","G protein-coupled receptor 18","13","99254714-99261744","G-protein coupled receptors, Predicted membrane proteins","Evidence at protein level","HPA013873","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"lymph node: 51.5;testis: 25.3;tonsil: 31.5","appendix: 16.4","Cell line enhanced",NA,"Daudi: 6.1;THP-1: 13.5;U-937: 2.6"
"GPR182","ADMR, AM-R, G10D, hrhAMR","ENSG00000166856","G protein-coupled receptor 182","12","56994446-56998441","G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA027037","Enhanced",NA,NA,NA,NA,"Not detected","Tissue enhanced",NA,"spleen: 12.2;testis: 6.7","liver: 2.0","Cell line enhanced",NA,"RH-30: 1.8"
"GPR3","ACCA","ENSG00000181773","G protein-coupled receptor 3","1","27392644-27395814","G-protein coupled receptors, Predicted membrane proteins","Evidence at protein level","CAB006254","Uncertain",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 5.2","thyroid gland: 1.3","Cell line enhanced",NA,"U-2197: 21.6"
"GPR34",NA,"ENSG00000171659","G protein-coupled receptor 34","X","41688973-41697277","G-protein coupled receptors, Predicted membrane proteins","Evidence at protein level","HPA010668, CAB025490","Uncertain",NA,"Uncertain","Nucleus<br>Cytosol",NA,"Expressed in all","Mixed",NA,NA,"placenta: 60.9","Cell line enhanced",NA,"HMC-1: 1.1"
"GPR37","EDNRBL, hET(B)R-LP, PAELR","ENSG00000170775","G protein-coupled receptor 37","7","124745997-124765627","G-protein coupled receptors, Predicted membrane proteins","Evidence at protein level","HPA042903, HPA068009","Approved",NA,"Approved","Nuclear membrane<br>Cytosol","Lung cancer:6.00e-5 (unfavourable), Ovarian cancer:7.26e-4 (favourable)","Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 78.7;testis: 27.6","placenta: 12.8","Cell line enhanced",NA,"AF22: 12.8;fHDF/TERT166: 24.0;TIME: 17.5"
"GPRASP2","FLJ37327, GASP2","ENSG00000158301","G protein-coupled receptor associated sorting protein 2","X","102712176-102717733","Predicted intracellular proteins","Evidence at protein level","HPA017438","Enhanced",NA,"Approved","Nucleoplasm<br>Cytosol","Renal cancer:4.60e-6 (favourable), Urothelial cancer:6.63e-5 (unfavourable), Pancreatic cancer:5.71e-4 (favourable)","Expressed in all","Mixed",NA,NA,"cerebral cortex: 41.6","Mixed",NA,NA
"GPRC5B","RAIG-2","ENSG00000167191","G protein-coupled receptor class C group 5 member B","16","19856691-19886167","G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA015247","Enhanced",NA,"Supported","Nucleus<br>Nucleoli<br>Vesicles","Colorectal cancer:9.27e-5 (unfavourable), Renal cancer:6.30e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 308.3","testis: 66.2","Cell line enhanced",NA,"EFO-21: 84.6;HHSteC: 50.7"
"GPRC5C","RAIG-3","ENSG00000170412","G protein-coupled receptor class C group 5 member C","17","74424851-74451653","G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters","Evidence at protein level","HPA029776","Enhanced",NA,"Uncertain","Nucleus<br>Microtubule organizing center<br>Cytosol","Renal cancer:1.58e-5 (favourable)","Expressed in all","Mixed",NA,NA,"thyroid gland: 104.0","Cell line enhanced",NA,"HMC-1: 144.5;RPTEC TERT1: 168.2;T-47d: 118.6"
"GPRIN1","GRIN1, KIAA1893","ENSG00000169258","G protein regulated inducer of neurite outgrowth 1","5","176595802-176610133","Predicted intracellular proteins","Evidence at protein level","HPA036478, HPA070892","Enhanced",NA,"Supported","Vesicles<br>Plasma membrane","Renal cancer:2.79e-7 (unfavourable), Lung cancer:6.83e-6 (unfavourable)","Expressed in all","Tissue enriched",7,"cerebral cortex: 27.8","duodenum: 3.8","Cell line enhanced",NA,"HDLM-2: 52.6;SCLC-21H: 70.4"
"GRAP2","GADS, GRBLG, GrbX, Grf40, Mona","ENSG00000100351","GRB2-related adaptor protein 2","22","39901082-39973721","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA005788, CAB022073","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"lymph node: 18.0","spleen: 12.8","Group enriched",8,"HDLM-2: 22.1;HEL: 40.9;K-562: 39.9;MOLT-4: 98.1"
"GRIK1","GluK1, GLUR5","ENSG00000171189","Glutamate ionotropic receptor kainate type subunit 1","21","29536933-29940033","FDA approved drug targets, Predicted membrane proteins","Evidence at protein level","HPA014623","Uncertain",NA,NA,NA,"Glioma:9.12e-4 (unfavourable)","Group enriched","Tissue enhanced",NA,"adrenal gland: 16.3;cerebral cortex: 9.0","prostate: 4.0","Not detected",NA,NA
"GRIK2","GluK2, GLUR6, MRT6","ENSG00000164418","Glutamate ionotropic receptor kainate type subunit 2","6","101398788-102070083","Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA014395, HPA014623, CAB022463","Approved",NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 22.5","thyroid gland: 6.3","Cell line enhanced",NA,"BJ: 14.3;BJ hTERT+: 22.6;fHDF/TERT166: 16.5;WM-115: 25.2"
"GRIK4","GluK4, GRIK, KA1","ENSG00000149403","Glutamate ionotropic receptor kainate type subunit 4","11","120511700-120988904","Predicted membrane proteins, Transporters","Evidence at protein level","HPA074453","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enhanced",NA,"cerebral cortex: 11.3","ovary,thyroid gland: 3.5","Group enriched",5,"HDLM-2: 5.7;HEL: 16.7;T-47d: 4.4"
"GRM4","GPRC1D, mGlu4, MGLUR4","ENSG00000124493","Glutamate metabotropic receptor 4","6","34018645-34155622","G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","CAB022096","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 2.9","testis: 0.7","Group enriched",11,"BEWO: 7.2;SCLC-21H: 35.0"
"GSDMA","FLJ39120, GSDM, GSDM1","ENSG00000167914","Gasdermin A","17","39953263-39977766","Predicted intracellular proteins, Transporters","Evidence at protein level","HPA023313, HPA064826","Enhanced",NA,"Supported","Nucleoplasm<br>Nuclear bodies<br>Plasma membrane<br>Cytosol",NA,"Tissue enhanced","Tissue enriched",7,"skin: 58.4","epididymis: 7.9","Cell line enhanced",NA,"HBEC3-KT: 2.9;hTCEpi: 2.0;hTERT-HME1: 4.1"
"GSK3A",NA,"ENSG00000105723","Glycogen synthase kinase 3 alpha","19","42230186-42242625","Cancer-related genes, Enzymes, Predicted intracellular proteins","Evidence at protein level","CAB004422, HPA028423","Approved",NA,"Approved","Cytosol","Liver cancer:1.13e-4 (unfavourable), Endometrial cancer:4.02e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 74.5","Expressed in all",NA,NA
"GSS",NA,"ENSG00000100983","Glutathione synthetase","20","34928430-34955817","Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA054508, HPA059315","Enhanced",NA,"Supported","Nucleus","Renal cancer:7.31e-6 (favourable), Liver cancer:7.21e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"epididymis: 105.8","Expressed in all",NA,NA
"GTF3A","AP2, TFIIIA","ENSG00000122034","General transcription factor IIIA","13","27424544-27435823","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA007990","Supported",NA,"Supported","Nucleus","Renal cancer:3.43e-6 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"lymph node: 122.3","Expressed in all",NA,NA
"GTPBP8","HSPC135","ENSG00000163607","GTP binding protein 8 (putative)","3","112990918-113015060","Predicted intracellular proteins","Evidence at protein level","HPA034831, HPA058631","Approved",NA,"Enhanced","Mitochondria","Renal cancer:3.07e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 33.0","Expressed in all",NA,NA
"GUCY1B3","GC-S-beta-1, GC-SB3, GUC1B3","ENSG00000061918","Guanylate cyclase 1 soluble subunit beta","4","155758992-155807591","Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB010890, HPA020870","Approved",NA,"Approved","Cytosol","Renal cancer:2.42e-4 (unfavourable), Testis cancer:3.23e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 177.3","Cell line enhanced",NA,"HEL: 42.7;MOLT-4: 24.5;RPTEC TERT1: 35.1"
"GUK1",NA,"ENSG00000143774","Guanylate kinase 1","1","228139962-228148984","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA028118, HPA048587","Approved",NA,"Uncertain","Nucleoplasm<br>Cytosol","Renal cancer:8.85e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 264.8","Expressed in all",NA,NA
"GYG2","GN-2","ENSG00000056998","Glycogenin 2","X","2828788-2882820","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA005495, HPA064686","Enhanced",NA,"Approved","Nucleus<br>Nucleoli<br>Cytosol","Pancreatic cancer:3.01e-5 (favourable)","Expressed in all","Tissue enriched",13,"adipose tissue: 173.1","breast: 13.2","Cell line enhanced",NA,"AF22: 39.5;NTERA-2: 39.5;SK-MEL-30: 68.1"
"GYPA","CD235a, GPA, MN, MNS","ENSG00000170180","Glycophorin A (MNS blood group)","4","144109303-144140751","Blood group antigen proteins, CD markers, Predicted membrane proteins","Evidence at protein level","CAB002658, HPA014811","Enhanced",NA,NA,NA,NA,"Not detected","Tissue enriched",16,"bone marrow: 84.6","placenta: 5.4","Group enriched",264,"HEL: 127.3;K-562: 31.3"
"GZMB","CCPI, CGL-1, CGL1, CSP-B, CSPB, CTLA1, CTSGL1, HLP, SECT","ENSG00000100453","Granzyme B","14","24630954-24634267","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB000376, HPA003418","Enhanced",NA,NA,NA,"Renal cancer:1.10e-7 (unfavourable), Endometrial cancer:1.58e-5 (favourable), Breast cancer:7.27e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"lymph node: 40.1","bone marrow,spleen: 36.2","Cell line enriched",6,"HMC-1: 17.4"
"GZMK","PRSS, TRYP2","ENSG00000113088","Granzyme K","5","55024253-55034570","Enzymes, Predicted secreted proteins","Evidence at protein level","HPA063181","Enhanced",NA,NA,NA,"Renal cancer:1.06e-4 (unfavourable), Breast cancer:8.68e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"lymph node: 103.9","spleen: 41.9","Not detected",NA,NA
"GZMM","LMET1, MET1","ENSG00000197540","Granzyme M","19","544034-549924","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA015624","Enhanced",NA,NA,NA,"Head and neck cancer:1.87e-7 (favourable), Renal cancer:1.21e-4 (unfavourable), Endometrial cancer:1.89e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"lymph node: 20.9;spleen: 19.7","appendix: 13.0","Cell line enhanced",NA,"EFO-21: 1.9;HDLM-2: 1.6;HMC-1: 1.8;MOLT-4: 1.1"
"H1FX","H1X, MGC15959, MGC8350","ENSG00000184897","H1 histone family member X","3","129314771-129316277","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB012235, HPA040099","Supported",NA,"Enhanced","Nucleus<br>Nucleoli",NA,"Expressed in all","Tissue enriched",7,"bone marrow: 670.4","spleen: 95.9","Expressed in all",NA,NA
"HACD3","B-ind1, HSPC121, PTPLAD1","ENSG00000074696","3-hydroxyacyl-CoA dehydratase 3","15","65530418-65578352","Enzymes, Predicted membrane proteins","Evidence at protein level","HPA014837, HPA060347","Enhanced",NA,"Enhanced","Nuclear membrane<br>Endoplasmic reticulum<br>Mitochondria<br>Cytosol","Renal cancer:3.09e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 138.9","Expressed in all",NA,NA
"HAGHL","MGC2605","ENSG00000103253","Hydroxyacylglutathione hydrolase-like","16","726936-735525","Predicted intracellular proteins","Evidence at transcript level","HPA074402","Approved",NA,NA,NA,"Renal cancer:1.18e-5 (favourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 9.1","spleen: 4.4","Cell line enhanced",NA,"RPMI-8226: 44.3;U-266/70: 49.9"
"HAL","HIS","ENSG00000084110","Histidine ammonia-lyase","12","95972662-95996365","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA038547, HPA038548","Enhanced",NA,"Uncertain","Cytosol",NA,"Tissue enriched","Group enriched",8,"liver: 51.2;skin: 72.5","bone marrow: 7.4","Cell line enhanced",NA,"BEWO: 2.1;THP-1: 7.4"
"HAND1","bHLHa27, eHand, Hxt, Thing1","ENSG00000113196","Heart and neural crest derivatives expressed 1","5","154474972-154478264","Predicted intracellular proteins, Transcription factors","Evidence at transcript level","HPA040925","Approved",NA,"Uncertain","Nucleus<br>Nuclear membrane",NA,"Group enriched","Tissue enhanced",NA,"smooth muscle: 16.8","adrenal gland: 6.2","Cell line enriched",8,"SH-SY5Y: 123.7"
"HAPLN1","CRTL1","ENSG00000145681","Hyaluronan and proteoglycan link protein 1","5","83637805-83721613","Predicted secreted proteins","Evidence at protein level","HPA019105, HPA019482, HPA025238","Enhanced","Approved","Supported","Vesicles","Renal cancer:4.81e-9 (unfavourable)","Mixed","Tissue enriched",8,"placenta: 103.4","cerebral cortex: 12.8","Group enriched",35,"PC-3: 130.7;TIME: 73.5;U-2 OS: 149.3"
"HAPLN2","BRAL1","ENSG00000132702","Hyaluronan and proteoglycan link protein 2","1","156619294-156625725","Predicted secreted proteins","Evidence at protein level","HPA045765","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",47,"cerebral cortex: 42.1","duodenum: 0.8","Not detected",NA,NA
"HAUS3","C4orf15, dgt3, IT1, MGC4701","ENSG00000214367","HAUS augmin like complex subunit 3","4","2227464-2242164","Predicted intracellular proteins","Evidence at protein level","HPA040649, HPA048190","Approved",NA,"Approved","Microtubules<br>Cytokinetic bridge<br>Mitotic spindle<br>Mitochondria","Urothelial cancer:4.78e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"bone marrow: 31.8","Expressed in all",NA,NA
"HBA1","HBA-T3","ENSG00000206172","Hemoglobin subunit alpha 1","16","176680-177522","Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transporters","Evidence at protein level","CAB032534, HPA043780","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Group enriched",34,"bone marrow: 17119.3;placenta: 3433.6","spleen: 303.5","Group enriched",51,"HEL: 3255.0;K-562: 2173.8"
"HBA2","HBA-T2","ENSG00000188536","Hemoglobin subunit alpha 2","16","172847-173710","Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transporters","Evidence at protein level","CAB038417, HPA043780","Enhanced",NA,NA,NA,NA,"Expressed in all","Group enriched",27,"bone marrow: 18369.0;placenta: 4302.7","spleen: 427.2","Group enriched",18,"HEL: 802.0;K-562: 265.1"
"HBB","beta-globin, CD113t-C, HBD","ENSG00000244734","Hemoglobin subunit beta","11","5225464-5229395","Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transporters","Evidence at protein level","CAB009526, HPA043234","Enhanced",NA,"Approved","Vesicles",NA,"Expressed in all","Tissue enriched",9,"bone marrow: 78046.6","placenta: 9082.6","Cell line enhanced",NA,"HEL: 5.3;SCLC-21H: 5.9;SH-SY5Y: 6.7;U-266/70: 17.4"
"HDAC2","RPD3, YAF1","ENSG00000196591","Histone deacetylase 2","6","113933028-114011308","Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB005054, HPA011727","Supported",NA,"Enhanced","Nucleus","Liver cancer:5.39e-10 (unfavourable), Breast cancer:7.07e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 141.1","Expressed in all",NA,NA
"HDAC3","HD3, RPD3, RPD3-2","ENSG00000171720","Histone deacetylase 3","5","141620876-141636870","Enzymes, FDA approved drug targets, Predicted intracellular proteins","Evidence at protein level","CAB005583, HPA052052","Supported",NA,"Supported","Nucleoplasm<br>Golgi apparatus","Renal cancer:2.65e-6 (unfavourable), Colorectal cancer:3.39e-4 (favourable), Pancreatic cancer:3.95e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 52.1","Expressed in all",NA,NA
"HECTD1","KIAA1131","ENSG00000092148","HECT domain E3 ubiquitin protein ligase 1","14","31100112-31207804","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA002929, HPA054461","Approved",NA,"Supported","Nucleus<br>Nucleoli","Renal cancer:1.20e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 109.5","Expressed in all",NA,NA
"HECW1","KIAA0322, NEDL1","ENSG00000002746","HECT, C2 and WW domain containing E3 ubiquitin protein ligase 1","7","43112599-43566001","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA007203, HPA007593, HPA007609","Approved",NA,"Supported","Cytosol",NA,"Not detected","Tissue enhanced",NA,"cerebral cortex: 10.9;kidney: 8.2","testis: 3.4","Cell line enhanced",NA,"A549: 3.9;U-266/70: 9.1"
"HEMGN","CT155, EDAG, NDR","ENSG00000136929","Hemogen","9","97926791-97944856","Predicted intracellular proteins","Evidence at protein level","HPA019572, HPA019604, HPA019606","Enhanced",NA,NA,NA,NA,"Not detected","Group enriched",14,"bone marrow: 141.7;testis: 88.2","placenta: 8.1","Group enriched",7,"HEL: 54.8;K-562: 247.2"
"HEY1","bHLHb31, CHF-2, CHF2, HERP2, HESR-1, HESR1, HRT-1","ENSG00000164683","Hes related family bHLH transcription factor with YRPW motif 1","8","79764010-79767863","Cancer-related genes, Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA055599, HPA063472","Uncertain",NA,"Approved","Nucleoplasm<br>Nuclear membrane<br>Cytosol",NA,"Expressed in all","Tissue enhanced",NA,"cerebral cortex: 96.4","placenta: 28.8","Cell line enhanced",NA,"HEK 293: 120.1;SK-MEL-30: 70.9"
"HIPK4","FLJ32818","ENSG00000160396","Homeodomain interacting protein kinase 4","19","40379271-40390187","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA027733","Uncertain",NA,NA,NA,NA,"Not detected","Group enriched",29,"cerebral cortex: 4.7;testis: 14.6","endometrium: 0.3","Not detected",NA,NA
"HIST1H1T","H1FT, H1t","ENSG00000187475","Histone cluster 1 H1 family member t","6","26107419-26108136","Predicted intracellular proteins","Evidence at protein level","HPA065718, HPA068266","Enhanced",NA,NA,NA,NA,"Not detected","Tissue enriched",8,"testis: 1.4","appendix,breast,prostate: 0.1","Not detected",NA,NA
"HK1",NA,"ENSG00000156515","Hexokinase 1","10","69269984-69401882","Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA007043, HPA007044, CAB010052, HPA011956","Supported",NA,"Enhanced","Mitochondria","Head and neck cancer:3.39e-6 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 153.6","Cell line enhanced",NA,"K-562: 491.8"
"HK3",NA,"ENSG00000160883","Hexokinase 3","5","176880869-176899332","Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA056743","Enhanced",NA,NA,NA,"Renal cancer:3.84e-8 (unfavourable)","Mixed","Tissue enhanced",NA,"bone marrow: 87.9","spleen: 27.9","Cell line enhanced",NA,"SCLC-21H: 5.3;THP-1: 2.5;U-937: 16.3"
"HKDC1","FLJ22761, FLJ37767","ENSG00000156510","Hexokinase domain containing 1","10","69220303-69267559","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA011956, HPA064198, HPA064230","Approved",NA,"Enhanced","Mitochondria",NA,"Mixed","Tissue enhanced",NA,"duodenum: 53.1;small intestine: 52.3","thyroid gland: 15.2","Group enriched",6,"A549: 35.7;CACO-2: 46.7;CAPAN-2: 96.8;EFO-21: 31.5;Hep G2: 22.5;RPTEC TERT1: 61.4"
"HLA-DMA","D6S222E, RING6","ENSG00000204257","Major histocompatibility complex, class II, DM alpha","6","32948613-32969094","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA012750, HPA017295","Enhanced",NA,"Approved","Vesicles","Endometrial cancer:4.64e-5 (favourable), Lung cancer:4.59e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"lung: 65.0","fallopian tube: 41.9","Cell line enhanced",NA,"U-266/70: 22.0;U-266/84: 9.5;U-698: 52.4"
"HLA-DOB",NA,"ENSG00000241106","Major histocompatibility complex, class II, DO beta","6","32812763-32817048","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA013846","Enhanced",NA,NA,NA,"Renal cancer:3.15e-5 (unfavourable), Ovarian cancer:4.17e-5 (favourable), Breast cancer:4.29e-4 (favourable)","Expressed in all","Group enriched",5,"lymph node: 19.6;spleen: 18.6;tonsil: 30.7;urinary bladder: 8.3","colon: 3.5","Cell line enhanced",NA,"Daudi: 37.8;U-698: 12.8;U-937: 6.1"
"HLA-DPA1","HLA-DP1A","ENSG00000231389","Major histocompatibility complex, class II, DP alpha 1","6","33064569-33080775","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA017967","Enhanced",NA,"Supported","Vesicles",NA,"Expressed in all","Expressed in all",NA,NA,"lung: 120.6","Cell line enhanced",NA,"Daudi: 26.7;HDLM-2: 107.3;REH: 26.8"
"HLA-DRA","HLA-DRA1","ENSG00000204287","Major histocompatibility complex, class II, DR alpha","6","32439842-32445046","Plasma proteins, Predicted membrane proteins","Evidence at protein level","CAB002798, CAB015402, HPA050162, HPA053176","Enhanced",NA,NA,NA,"Colorectal cancer:5.30e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"lung: 731.8;lymph node: 894.1","tonsil: 476.7","Cell line enhanced",NA,"Daudi: 254.2;HDLM-2: 588.3;REH: 234.5;U-698: 247.8;U-87 MG: 236.0"
"HLA-DRB1","HLA-DR1B","ENSG00000196126","Major histocompatibility complex, class II, DR beta 1","6","32578769-32589848","Disease related genes, Plasma proteins, Predicted membrane proteins","Evidence at protein level","CAB015400, CAB034021, HPA043151","Enhanced",NA,NA,NA,NA,"Expressed in all","Tissue enhanced",NA,"lung: 868.4","lymph node: 619.6","Cell line enhanced",NA,"HDLM-2: 1095.2;U-87 MG: 302.0"
"HMBOX1","FLJ21616, HNF1LA, HOT1, PBHNF","ENSG00000147421","Homeobox containing 1","8","28890394-29064764","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA055855, HPA058586, CAB070418","Enhanced",NA,"Enhanced","Nucleoplasm<br>Nuclear bodies<br>Cytosol",NA,"Expressed in all","Mixed",NA,NA,"testis: 13.9","Expressed in all",NA,NA
"HMBS","PBGD, PORC, UPS","ENSG00000256269","Hydroxymethylbilane synthase","11","119084866-119093549","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA006114, HPA050659","Enhanced",NA,"Approved","Lipid droplets",NA,"Expressed in all","Tissue enriched",5,"bone marrow: 52.8","parathyroid gland: 9.8","Expressed in all",NA,NA
"HMGCS2",NA,"ENSG00000134240","3-hydroxy-3-methylglutaryl-CoA synthase 2","1","119747996-119768905","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA027423, HPA027442, CAB032906","Enhanced",NA,"Supported","Mitochondria","Liver cancer:2.43e-7 (favourable), Renal cancer:3.43e-5 (favourable), Ovarian cancer:2.17e-4 (favourable)","Tissue enhanced","Tissue enhanced",NA,"liver: 1270.5","colon: 363.4","Cell line enriched",15,"RT4: 161.6"
"HMP19",NA,"ENSG00000170091","HMP19 protein","5","174045604-174243501","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA046531, HPA056191","Enhanced",NA,"Supported","Golgi apparatus",NA,"Tissue enriched","Tissue enriched",7,"cerebral cortex: 288.5","adrenal gland: 42.0","Group enriched",84,"SCLC-21H: 45.2;SH-SY5Y: 65.3"
"HN1","ARM2, HN1A","ENSG00000189159","Hematological and neurological expressed 1","17","75135248-75168281","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA059729","Approved",NA,"Supported","Nucleus<br>Nuclear membrane<br>Nucleoli","Liver cancer:1.58e-7 (unfavourable), Renal cancer:1.77e-7 (unfavourable), Ovarian cancer:4.91e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 422.3","Expressed in all",NA,NA
"HNRNPU","C1orf199, FLJ30202, FLJ37978, hnRNPU, HNRNPU-AS1, HNRPU, NCRNA00201, SAF-A","ENSG00000153187","Heterogeneous nuclear ribonucleoprotein U","1","244840638-244864560","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB011532, HPA041057, HPA058707","Supported",NA,"Supported","Nucleoplasm","Liver cancer:8.88e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 225.2","Expressed in all",NA,NA
"HNRNPUL2","DKFZp762N1910, HNRPUL2","ENSG00000214753","Heterogeneous nuclear ribonucleoprotein U like 2","11","62712630-62727349","Predicted intracellular proteins","Evidence at protein level","HPA041632, HPA056696, HPA067699","Enhanced",NA,"Enhanced","Nucleoplasm",NA,"Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 59.2","Expressed in all",NA,NA
"HOOK3","HK3","ENSG00000168172","Hook microtubule tethering protein 3","8","42896932-43030539","Cancer-related genes, Predicted intracellular proteins","Evidence at protein level","HPA024756","Approved",NA,"Supported","Golgi apparatus<br>Microtubule organizing center<br>Cytosol","Renal cancer:1.32e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"thyroid gland: 36.6","Expressed in all",NA,NA
"HOXA9","HOX1, HOX1G","ENSG00000078399","Homeobox A9","7","27162435-27175180","Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA061982","Uncertain",NA,"Supported","Nucleus",NA,"Mixed","Mixed",NA,NA,"kidney: 12.6","Cell line enhanced",NA,"HEK 293: 113.8;SCLC-21H: 133.7"
"HOXC13","HOX3, HOX3G","ENSG00000123364","Homeobox C13","12","53938765-53946544","Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA051634","Supported",NA,NA,NA,NA,"Mixed","Tissue enriched",8,"skin: 4.6","breast,testis: 0.5","Cell line enhanced",NA,"AN3-CA: 28.1;HaCaT: 56.8;SK-BR-3: 26.3;T-47d: 25.6"
"HP",NA,"ENSG00000257017","Haptoglobin","16","72054592-72061055","Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB003787, HPA047750","Enhanced",NA,"Approved","Vesicles","Renal cancer:6.94e-13 (unfavourable)","Tissue enriched","Tissue enriched",182,"liver: 28407.0","bone marrow: 155.8","Cell line enhanced",NA,"Hep G2: 153.5;HSkMC: 88.2"
"HRK","DP5","ENSG00000135116","Harakiri, BCL2 interacting protein","12","116856144-116881441","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","CAB025973","Uncertain",NA,NA,NA,NA,"Mixed","Group enriched",9,"cerebral cortex: 13.3;thyroid gland: 6.4","testis: 1.1","Cell line enhanced",NA,"Daudi: 7.9;SCLC-21H: 10.7;SH-SY5Y: 8.3;SK-MEL-30: 16.7;U-698: 25.7"
"HS2ST1","KIAA0448","ENSG00000153936","Heparan sulfate 2-O-sulfotransferase 1","1","86914648-87109998","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA043069, HPA043603, HPA075001","Supported",NA,"Approved","Mitochondria","Liver cancer:6.88e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"adrenal gland: 34.0","Expressed in all",NA,NA
"HS6ST2",NA,"ENSG00000171004","Heparan sulfate 6-O-sulfotransferase 2","X","132626016-132961395","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA034625, HPA034626","Uncertain",NA,"Supported","Nucleoplasm","Urothelial cancer:6.03e-4 (favourable)","Mixed","Tissue enhanced",NA,"kidney: 15.0;ovary: 17.6","placenta: 11.9","Cell line enhanced",NA,"HEK 293: 42.3;RH-30: 63.9;SH-SY5Y: 87.0"
"HSD17B1","EDH17B2, EDHB17, HSD17, MGC138140, SDR28C1","ENSG00000108786","Hydroxysteroid 17-beta dehydrogenase 1","17","42549214-42555213","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA021032, HPA065296","Enhanced",NA,"Supported","Cytosol",NA,"Mixed","Tissue enriched",14,"placenta: 98.3","cerebral cortex: 7.1","Cell line enriched",8,"BEWO: 331.8"
"HSD17B2","HSD17, SDR9C2","ENSG00000086696","Hydroxysteroid 17-beta dehydrogenase 2","16","82035004-82098534","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA021826, HPA050235","Enhanced",NA,"Approved","Endoplasmic reticulum","Urothelial cancer:3.83e-4 (favourable)","Tissue enhanced","Tissue enhanced",NA,"duodenum: 430.9;placenta: 552.6","small intestine: 199.4","Cell line enhanced",NA,"BJ hTERT+: 47.0;Hep G2: 32.2;RT4: 77.0;TIME: 44.0"
"HSPA9","GRP75, HSPA9B, mot-2, mthsp75, PBP74","ENSG00000113013","Heat shock protein family A (Hsp70) member 9","5","138554882-138575444","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA000898, CAB005219","Enhanced",NA,"Enhanced","Mitochondria","Breast cancer:2.93e-4 (unfavourable), Colorectal cancer:4.53e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 263.5","Expressed in all",NA,NA
"HTR1E","5-HT1E","ENSG00000168830","5-hydroxytryptamine receptor 1E","6","86937306-87016683","FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins","Evidence at protein level","HPA004931","Approved",NA,NA,NA,NA,"Not detected","Tissue enhanced",NA,"endometrium: 2.4;ovary: 4.9","cerebral cortex: 1.8","Group enriched",19,"PC-3: 1.4;SH-SY5Y: 6.2"
"HTR2A","5-HT2A, HTR2","ENSG00000102468","5-hydroxytryptamine receptor 2A","13","46831550-46897076","FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins","Evidence at protein level","HPA014011","Enhanced",NA,NA,NA,NA,"Not detected","Tissue enriched",8,"cerebral cortex: 32.2","smooth muscle: 3.9","Cell line enhanced",NA,"ASC diff: 1.3;ASC TERT1: 3.2;BEWO: 1.4;HEL: 1.3;U-138 MG: 2.3;U-2 OS: 1.6"
"HYLS1","FLJ32915","ENSG00000198331","HYLS1, centriolar and ciliogenesis associated","11","125883614-125900648","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA041210","Uncertain",NA,"Supported","Plasma membrane<br>Cytosol","Liver cancer:1.92e-4 (unfavourable)","Expressed in all","Tissue enriched",6,"testis: 37.5","smooth muscle: 6.6","Mixed",NA,NA
"HYPK","C15orf63, FLJ20431, HSPC136","ENSG00000242028","Huntingtin interacting protein K","15","43796142-43803043","Predicted intracellular proteins","Evidence at protein level","HPA055252","Uncertain",NA,"Supported","Nucleoplasm<br>Microtubules",NA,"Mixed","Mixed",NA,NA,"testis: 6.3","Mixed",NA,NA
"IARS","IARS1, ILRS","ENSG00000196305","Isoleucyl-tRNA synthetase","9","92210207-92293756","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA029806","Approved",NA,"Supported","Cytosol","Liver cancer:4.98e-7 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 141.8","Expressed in all",NA,NA
"IARS2","FLJ10326","ENSG00000067704","Isoleucyl-tRNA synthetase 2, mitochondrial","1","220094102-220148041","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA024212, HPA024594, HPA024596","Enhanced",NA,"Enhanced","Mitochondria","Pancreatic cancer:9.24e-5 (unfavourable), Cervical cancer:1.04e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 144.3","Expressed in all",NA,NA
"IBTK","BTBD26, BTKI, DKFZP564B116","ENSG00000005700","Inhibitor of Bruton tyrosine kinase","6","82169983-82247754","Predicted intracellular proteins","Evidence at protein level","HPA023826, HPA048438","Uncertain",NA,"Supported","Nucleoplasm","Cervical cancer:3.86e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 21.4","Expressed in all",NA,NA
"ICAM3","CD50, CDW50, ICAM-R","ENSG00000076662","Intercellular adhesion molecule 3","19","10333776-10339823","CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","CAB002498, HPA049820","Enhanced",NA,"Approved","Nucleus<br>Nuclear membrane<br>Mitochondria",NA,"Mixed","Expressed in all",NA,NA,"bone marrow: 111.9","Cell line enhanced",NA,"Karpas-707: 205.5;NB-4: 121.3;RPMI-8226: 154.3;U-937: 121.2"
"IDH3G",NA,"ENSG00000067829","Isocitrate dehydrogenase 3 (NAD(+)) gamma","X","153785766-153794523","Citric acid cycle related proteins, Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA000425, HPA002017","Enhanced",NA,"Enhanced","Mitochondria","Renal cancer:5.73e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 64.9","Expressed in all",NA,NA
"IFT27","BBS19, RABL4, RAYL","ENSG00000100360","Intraflagellar transport 27","22","36758202-36776256","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA018418","Uncertain",NA,"Approved","Nucleoplasm<br>Mitochondria","Endometrial cancer:1.91e-4 (favourable), Urothelial cancer:5.55e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"fallopian tube: 57.4","Cell line enhanced",NA,"U-138 MG: 156.6"
"IGLL1","14.1, CD179B, IGL5, IGLL, IGVPB","ENSG00000128322","Immunoglobulin lambda like polypeptide 1","22","23573125-23580308","CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA051134, HPA071406","Enhanced",NA,"Approved","Endoplasmic reticulum",NA,"Tissue enhanced","Group enriched",18,"bone marrow: 44.2;testis: 15.8","tonsil: 1.6","Cell line enriched",39,"REH: 687.9"
"IGSF21","MGC15730, RP11-121A23.1","ENSG00000117154","Immunoglobin superfamily member 21","1","18107746-18378483","Predicted secreted proteins","Evidence at protein level","HPA044535","Approved",NA,NA,NA,NA,"Group enriched","Tissue enhanced",NA,"cerebral cortex: 28.9;spleen: 13.2","adrenal gland: 5.9","Cell line enriched",6,"SCLC-21H: 21.2"
"IGSF9B","KIAA1030","ENSG00000080854","Immunoglobulin superfamily member 9B","11","133908564-133956985","Predicted intracellular proteins, Predicted membrane proteins","Evidence at transcript level","HPA010744, HPA010802","Uncertain",NA,"Approved","Cytosol",NA,"Mixed","Mixed",NA,NA,"cerebral cortex: 9.0","Cell line enhanced",NA,"SCLC-21H: 19.6;SH-SY5Y: 9.0"
"IKZF1","hIk-1, Hs.54452, IKAROS, LyF-1, PPP1R92, ZNFN1A1","ENSG00000185811","IKAROS family zinc finger 1","7","50304124-50405101","Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors","Evidence at protein level","CAB009247, HPA035221, HPA035222","Enhanced",NA,"Supported","Nucleoplasm","Cervical cancer:2.02e-4 (favourable), Breast cancer:4.28e-4 (favourable), Head and neck cancer:8.63e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"lymph node: 83.0","tonsil: 55.9","Cell line enhanced",NA,"HDLM-2: 172.0;HMC-1: 152.5;MOLT-4: 116.9;REH: 122.5;U-698: 108.4"
"IKZF3","Aiolos, ZNFN1A3","ENSG00000161405","IKAROS family zinc finger 3","17","39757715-39864188","Predicted intracellular proteins, Transcription factors","Evidence at protein level","CAB017105, HPA024377","Enhanced",NA,"Uncertain","Plasma membrane<br>Cytosol","Cervical cancer:6.85e-6 (favourable), Head and neck cancer:4.16e-4 (favourable), Melanoma:5.42e-4 (favourable), Renal cancer:7.38e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"lymph node: 44.7;spleen: 31.7;tonsil: 39.2","appendix: 25.5","Cell line enhanced",NA,"Daudi: 50.3;Karpas-707: 25.9;U-266/70: 32.8;U-266/84: 35.9;U-698: 78.2"
"IL10","CSIF, IL-10, IL10A, TGIF","ENSG00000136634","Interleukin 10","1","206767602-206772494","Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB013120","Uncertain",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"appendix: 8.7","adipose tissue: 7.4","Group enriched",7,"HMC-1: 5.2;U-266/70: 6.5"
"IL12RB2",NA,"ENSG00000081985","Interleukin 12 receptor subunit beta 2","1","67307364-67396900","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA024168","Uncertain",NA,"Uncertain","Plasma membrane<br>Cytosol",NA,"Tissue enhanced","Tissue enhanced",NA,"placenta: 11.8","cerebral cortex: 4.4","Cell line enhanced",NA,"HMC-1: 4.6;SCLC-21H: 12.2;SK-MEL-30: 21.0;THP-1: 10.6"
"IL16","FLJ16806, FLJ42735, HsT19289, IL-16, LCF, prIL-16","ENSG00000172349","Interleukin 16","15","81159575-81314058","Cancer-related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB005247, HPA018467","Enhanced",NA,"Approved","Nuclear speckles<br>Plasma membrane<br>Cytosol",NA,"Expressed in all","Tissue enhanced",NA,"lymph node: 154.4;tonsil: 124.0","spleen: 118.2","Cell line enhanced",NA,"HEL: 26.3;HMC-1: 44.5;RPMI-8226: 34.9;U-266/70: 45.9;U-937: 27.4"
"IL18RAP","AcPL, CD218b","ENSG00000115607","Interleukin 18 receptor accessory protein","2","102418689-102452565","CD markers, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB025270","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"bone marrow: 70.9","appendix: 16.9","Cell line enriched",10,"U-937: 42.2"
"IL1RL1","DER4, FIT-1, IL33R, ST2, ST2L, ST2V, T1","ENSG00000115602","Interleukin 1 receptor like 1","2","102311502-102352037","Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA007406, HPA007917","Uncertain",NA,"Approved","Vesicles",NA,"Tissue enhanced","Tissue enriched",12,"placenta: 289.6","gallbladder: 23.7","Group enriched",6,"HHSteC: 206.0;HMC-1: 327.3;HUVEC TERT2: 154.2"
"IL1RL2","IL1R-rp2, IL1RRP2","ENSG00000115598","Interleukin 1 receptor like 2","2","102186973-102240002","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA015485","Uncertain",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"skin: 15.5","parathyroid gland: 8.5","Cell line enhanced",NA,"A-431: 7.2;ASC TERT1: 3.6;HaCaT: 3.3;HSkMC: 3.1"
"IL2RA","CD25, IDDM10, IL2R","ENSG00000134460","Interleukin 2 receptor subunit alpha","10","6010689-6062325","Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","CAB002419, HPA054622","Enhanced",NA,NA,NA,"Renal cancer:2.08e-9 (unfavourable)","Mixed","Tissue enhanced",NA,"adipose tissue: 24.2;appendix: 19.8;lymph node: 20.4","tonsil: 12.0","Cell line enriched",80,"HDLM-2: 1041.6"
"IL2RB","CD122, IL15RB","ENSG00000100385","Interleukin 2 receptor subunit beta","22","37125838-37175054","Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA062657","Enhanced",NA,NA,NA,"Renal cancer:3.50e-7 (unfavourable), Endometrial cancer:3.18e-5 (favourable), Colorectal cancer:6.76e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"placenta: 52.7;spleen: 67.1","lymph node: 39.8","Cell line enriched",10,"HDLM-2: 476.9"
"IL4R","CD124","ENSG00000077238","Interleukin 4 receptor","16","27313668-27364778","Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB004451, HPA050124","Enhanced",NA,NA,NA,"Renal cancer:1.23e-5 (unfavourable), Endometrial cancer:6.43e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"lymph node: 137.6","Mixed",NA,NA
"IMPG1","GP147, IPM150, SPACR","ENSG00000112706","Interphotoreceptor matrix proteoglycan 1","6","75921115-76072678","Disease related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA027142, HPA030332, HPA030333","Enhanced",NA,NA,NA,NA,"Not detected","Tissue enhanced",NA,"cerebral cortex: 1.5;skin: 1.6","duodenum,small intestine: 0.9","Cell line enhanced",NA,"HaCaT: 1.0"
"IMPG2","IPM200, RP56","ENSG00000081148","Interphotoreceptor matrix proteoglycan 2","3","101222546-101320560","Disease related genes, Predicted membrane proteins","Evidence at protein level","HPA008779, HPA015907","Supported",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",45,"fallopian tube: 15.7","appendix,lymph node,spleen: 0.3","Not detected",NA,NA
"INA","NEF5, NF-66","ENSG00000148798","Internexin neuronal intermediate filament protein alpha","10","103277163-103290351","Predicted intracellular proteins","Evidence at protein level","CAB002059, HPA008057","Enhanced","Supported","Supported","Nucleoplasm<br>Nuclear membrane<br>Intermediate filaments",NA,"Tissue enhanced","Tissue enriched",6,"cerebral cortex: 89.0","adrenal gland: 16.0","Cell line enhanced",NA,"NTERA-2: 53.4;SCLC-21H: 122.4;SH-SY5Y: 62.7;SiHa: 76.3"
"INO80D","FLJ20309","ENSG00000114933","INO80 complex subunit D","2","205993721-206086303","Predicted intracellular proteins","Evidence at protein level","HPA043976","Approved",NA,NA,NA,"Head and neck cancer:5.53e-4 (favourable)","Expressed in all","Mixed",NA,NA,"bone marrow: 11.3","Mixed",NA,NA
"INSM2","IA-6, Mlt1","ENSG00000168348","INSM transcriptional repressor 2","14","35534042-35537054","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA044885, HPA051925","Uncertain",NA,"Approved","Nucleoplasm",NA,"Not detected","Tissue enhanced",NA,"cerebral cortex: 1.3","testis: 0.7","Cell line enriched",121,"SH-SY5Y: 115.7"
"INTS8","C8orf52, FLJ20530, INT8, MGC131633","ENSG00000164941","Integrator complex subunit 8","8","94813311-94881746","Predicted intracellular proteins","Evidence at protein level","HPA057299","Approved",NA,"Approved","Nucleoplasm","Renal cancer:0.00e+0 (unfavourable), Liver cancer:2.54e-6 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 57.3","Expressed in all",NA,NA
"IPO11","RanBP11","ENSG00000086200","Importin 11","5","62403972-62628582","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA067097","Approved",NA,"Enhanced","Nucleus<br>Nucleoli fibrillar center","Liver cancer:4.28e-5 (unfavourable), Colorectal cancer:1.70e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 40.6","Expressed in all",NA,NA
"IPO7","Imp7, RANBP7","ENSG00000205339","Importin 7","11","9384622-9448126","Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters","Evidence at protein level","HPA019002, HPA056590","Approved","Approved","Enhanced","Nucleoplasm<br>Cytosol","Pancreatic cancer:8.38e-6 (unfavourable), Cervical cancer:4.98e-4 (unfavourable), Liver cancer:6.57e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 89.8","Expressed in all",NA,NA
"IRF4","LSIRF, MUM1","ENSG00000137265","Interferon regulatory factor 4","6","391739-411447","Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA002038, HPA002698, CAB013508","Enhanced",NA,"Supported","Nucleoplasm","Head and neck cancer:1.64e-6 (favourable), Breast cancer:6.44e-4 (favourable)","Tissue enriched","Tissue enhanced",NA,"lymph node: 27.1","tonsil: 24.1","Group enriched",5,"HDLM-2: 204.2;Karpas-707: 141.1;RPMI-8226: 136.6;U-266/70: 134.4;U-266/84: 98.3;U-698: 40.9;WM-115: 106.9"
"IRGQ","FKSG27, IRGQ1","ENSG00000167378","Immunity related GTPase Q","19","43584369-43596135","Predicted intracellular proteins","Evidence at protein level","HPA043254, HPA050338","Enhanced",NA,"Supported","Vesicles","Pancreatic cancer:3.57e-5 (favourable), Renal cancer:3.92e-4 (favourable), Cervical cancer:5.17e-4 (favourable), Liver cancer:9.60e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"cerebral cortex: 7.2","Mixed",NA,NA
"ISCU","hnifU, IscU, ISU2, NIFUN","ENSG00000136003","Iron-sulfur cluster assembly enzyme","12","108562582-108569384","Disease related genes, Predicted intracellular proteins","Evidence at protein level","CAB006329, HPA038602, HPA057592","Approved",NA,"Supported","Cytosol","Renal cancer:2.73e-7 (favourable), Cervical cancer:4.90e-7 (favourable), Urothelial cancer:6.12e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"adrenal gland: 399.3","Expressed in all",NA,NA
"ISLR2","KIAA1465","ENSG00000167178","Immunoglobulin superfamily containing leucine rich repeat 2","15","74100311-74138540","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA012930, HPA067333","Uncertain",NA,NA,NA,NA,"Mixed","Group enriched",5,"cerebral cortex: 31.1;testis: 14.8","endometrium: 4.5","Group enriched",13,"SCLC-21H: 68.2;SH-SY5Y: 91.6"
"ITGAL","CD11A, LFA-1","ENSG00000005844","Integrin subunit alpha L","16","30472658-30523185","CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB025011","Enhanced",NA,NA,NA,"Renal cancer:2.69e-5 (unfavourable), Endometrial cancer:5.63e-5 (favourable), Head and neck cancer:3.34e-4 (favourable), Melanoma:5.57e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"lymph node: 79.0;spleen: 80.9","appendix: 52.5","Cell line enriched",5,"HMC-1: 570.1"
"ITGAM","CD11B, CR3A, MAC-1","ENSG00000169896","Integrin subunit alpha M","16","31259990-31332892","Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA002274, CAB025091, CAB072870","Enhanced",NA,NA,NA,"Renal cancer:6.93e-5 (unfavourable), Liver cancer:3.43e-4 (unfavourable), Testis cancer:6.93e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"bone marrow: 130.2","appendix: 36.3","Cell line enhanced",NA,"HMC-1: 47.6;NB-4: 12.7;U-937: 18.8"
"ITGAX","CD11C","ENSG00000140678","Integrin subunit alpha X","16","31355134-31382997","CD markers, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB004458, HPA004723, CAB072871","Enhanced",NA,NA,NA,"Renal cancer:1.37e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"appendix: 58.3;spleen: 59.0","bone marrow: 30.4","Cell line enriched",5,"HMC-1: 92.2"
"ITPKA","IP3-3KA, IP3KA","ENSG00000137825","Inositol-trisphosphate 3-kinase A","15","41493393-41503551","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA040454","Enhanced","Approved","Approved","Vesicles","Renal cancer:3.76e-9 (unfavourable), Glioma:5.08e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"cerebral cortex: 25.7;duodenum: 17.7;small intestine: 19.8","stomach: 8.9","Cell line enhanced",NA,"Hep G2: 22.6"
"ITPKB","IP3-3KB, IP3KB","ENSG00000143772","Inositol-trisphosphate 3-kinase B","1","226631690-226739323","Cancer-related genes, Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA030273, HPA072923","Uncertain",NA,"Approved","Nucleus","Head and neck cancer:1.72e-5 (favourable), Lung cancer:6.65e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 61.6","Cell line enhanced",NA,"SK-MEL-30: 36.3"
"IYD","C6orf71, DEHAL1, dJ422F24.1","ENSG00000009765","Iodotyrosine deiodinase","6","150368892-150405969","Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins","Evidence at protein level","HPA059627","Enhanced",NA,"Supported","Plasma membrane","Liver cancer:6.22e-4 (favourable)","Tissue enriched","Tissue enriched",28,"thyroid gland: 794.5","kidney: 27.9","Cell line enhanced",NA,"CACO-2: 1.1;SK-BR-3: 2.4"
"JADE3","JADE-3, KIAA0215, PHF16","ENSG00000102221","Jade family PHD finger 3","X","46912276-47061242","Predicted intracellular proteins","Evidence at protein level","HPA006007, HPA064697","Uncertain",NA,"Approved","Nucleus<br>Nucleoli",NA,"Expressed in all","Mixed",NA,NA,"testis: 22.6","Cell line enhanced",NA,"BEWO: 63.4"
"JAKMIP2","JAMIP2, KIAA0555","ENSG00000176049","Janus kinase and microtubule interacting protein 2","5","147585439-147782848","Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA046929, HPA065023","Approved",NA,"Supported","Golgi apparatus",NA,"Tissue enriched","Tissue enriched",6,"cerebral cortex: 32.7","testis: 5.3","Cell line enhanced",NA,"AF22: 19.7;Karpas-707: 34.1;RH-30: 46.3;SCLC-21H: 26.3"
"JAZF1","DKFZp761K2222, TIP27, ZNF802","ENSG00000153814","JAZF zinc finger 1","7","27830573-28180743","Cancer-related genes, Disease related genes, Predicted intracellular proteins","Evidence at protein level","CAB019271, HPA066967","Approved",NA,"Supported","Nucleus<br>Nucleoli fibrillar center",NA,"Expressed in all","Expressed in all",NA,NA,"adrenal gland: 112.8","Mixed",NA,NA
"JPH1","JP-1","ENSG00000104369","Junctophilin 1","8","74234700-74321328","Predicted membrane proteins","Evidence at protein level","HPA008996, HPA009413, CAB013461","Enhanced",NA,"Supported","Nucleus","Lung cancer:5.77e-5 (favourable)","Mixed","Tissue enriched",10,"skeletal muscle: 88.0","cerebral cortex: 8.6","Cell line enhanced",NA,"SK-BR-3: 27.1;T-47d: 24.2"
"KALRN","ARHGEF24, DUET, duo, HAPIP, Hs.8004, Kalirin, TRAD","ENSG00000160145","Kalirin, RhoGEF kinase","3","124080023-124726325","Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA011913, CAB026456","Approved",NA,"Supported","Nucleoplasm<br>Cytosol",NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 51.3","spleen: 11.8","Cell line enhanced",NA,"CACO-2: 47.6;HEL: 31.9;SH-SY5Y: 16.9"
"KANK2","ANKRD25, KIAA1518, MXRA3","ENSG00000197256","KN motif and ankyrin repeat domains 2","19","11164267-11197791","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA015643","Approved",NA,NA,NA,"Renal cancer:8.73e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"endometrium: 439.0","Expressed in all",NA,NA
"KANSL1","CENP-36, DKFZP727C091, KIAA1267, MSL1v1, NSL1","ENSG00000120071","KAT8 regulatory NSL complex subunit 1","17","46029916-46225389","Predicted intracellular proteins","Evidence at protein level","HPA006874, HPA007208","Approved",NA,"Supported","Nucleoplasm","Liver cancer:3.74e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 32.4","Mixed",NA,NA
"KARS","DFNB89, KARS1, KARS2","ENSG00000065427","Lysyl-tRNA synthetase","16","75627474-75648643","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA041345, HPA041550","Enhanced",NA,"Supported","Cytosol","Head and neck cancer:8.84e-6 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 178.6","Expressed in all",NA,NA
"KAT14","ATAC2, CRP2BP, CSRP2BP, dJ717M23.1, PRO1194","ENSG00000149474","Lysine acetyltransferase 14","20","18138118-18188387","Predicted intracellular proteins","Evidence at protein level","CAB034224, HPA068443","Uncertain",NA,"Approved","Vesicles","Renal cancer:4.64e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 21.4","Expressed in all",NA,NA
"KAT5","cPLA2, ESA1, HTATIP, HTATIP1, PLIP, TIP60, ZC2HC5","ENSG00000172977","Lysine acetyltransferase 5","11","65711996-65719604","Enzymes, Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA016953","Approved",NA,"Supported","Nucleoplasm","Renal cancer:1.10e-13 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 84.4","Expressed in all",NA,NA
"KAZN","FLJ43806, KAZRIN, KIAA1026","ENSG00000189337","Kazrin, periplakin interacting protein","1","13892792-15118043","Predicted intracellular proteins","Evidence at protein level","HPA032095, HPA032096","Approved",NA,"Supported","Nucleoplasm<br>Nuclear speckles<br>Cytosol","Renal cancer:1.20e-6 (favourable)","Mixed","Tissue enhanced",NA,"spleen: 118.3","parathyroid gland: 42.3","Cell line enhanced",NA,"AN3-CA: 79.3"
"KCMF1","DEBT91, DKFZP434L1021, PCMF, ZZZ1","ENSG00000176407","Potassium channel modulatory factor 1","2","84971093-85059472","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA030383, HPA030384","Enhanced",NA,"Enhanced","Nucleoplasm<br>Cytosol","Liver cancer:2.33e-7 (unfavourable), Renal cancer:4.18e-6 (unfavourable), Pancreatic cancer:6.10e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 124.6","Expressed in all",NA,NA
"KCNA3","HLK3, HPCN3, Kv1.3, MK3","ENSG00000177272","Potassium voltage-gated channel subfamily A member 3","1","110672465-110675033","FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels","Evidence at protein level","HPA016625","Approved",NA,NA,NA,NA,"Mixed","Mixed",NA,NA,"lymph node: 10.5","Cell line enhanced",NA,"HDLM-2: 20.5;Karpas-707: 31.5;U-266/70: 23.9;U-266/84: 21.1"
"KCNAB2","AKR6A5, HKvbeta2.1, HKvbeta2.2, KCNA2B","ENSG00000069424","Potassium voltage-gated channel subfamily A regulatory beta subunit 2","1","5991466-6101193","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB001975","Enhanced",NA,NA,NA,"Renal cancer:3.50e-5 (unfavourable)","Tissue enriched","Tissue enhanced",NA,"cerebral cortex: 145.9","bone marrow: 74.8","Cell line enhanced",NA,"HL-60: 277.8;U-937: 287.1"
"KCNE2","LQT6, MiRP1","ENSG00000159197","Potassium voltage-gated channel subfamily E regulatory subunit 2","21","34364024-34371389","Disease related genes, Predicted membrane proteins","Evidence at protein level","HPA029706, HPA051553","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",25,"stomach: 175.3","duodenum: 7.0","Cell line enhanced",NA,"SCLC-21H: 2.3"
"KCNE5","KCNE1L","ENSG00000176076","Potassium voltage-gated channel subfamily E regulatory subunit 5","X","109623700-109625172","Disease related genes, Predicted membrane proteins","Evidence at protein level","HPA042316","Uncertain",NA,"Uncertain","Cytosol",NA,"Group enriched","Tissue enhanced",NA,"cerebral cortex: 2.1","adipose tissue: 1.1","Cell line enhanced",NA,"hTEC/SVTERT24-B: 2.0"
"KCNG1","K13, KCNG, kH2, Kv6.1","ENSG00000026559","Potassium voltage-gated channel modifier subfamily G member 1","20","51003656-51023129","Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels","Evidence at protein level","HPA039530, HPA040024","Approved",NA,"Approved","Vesicles",NA,"Tissue enhanced","Tissue enhanced",NA,"endometrium: 23.4;seminal vesicle: 18.1","placenta: 10.1","Cell line enhanced",NA,"hTCEpi: 38.3;U-138 MG: 39.5"
"KCNH1","eag, eag1, h-eag, Kv10.1","ENSG00000143473","Potassium voltage-gated channel subfamily H member 1","1","210676823-211134180","Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels","Evidence at protein level","HPA014551, HPA019445","Enhanced",NA,"Approved","Vesicles",NA,"Not detected","Tissue enriched",6,"cerebral cortex: 6.2","testis: 1.0","Cell line enhanced",NA,"RH-30: 4.9;SH-SY5Y: 6.8;SK-MEL-30: 4.8;T-47d: 4.3"
"KCNIP3","CSEN, DREAM, KCHIP3","ENSG00000115041","Potassium voltage-gated channel interacting protein 3","2","95297304-95386083","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA069797","Approved",NA,NA,NA,"Endometrial cancer:1.58e-5 (unfavourable)","Mixed","Tissue enhanced",NA,"cerebral cortex: 40.6;parathyroid gland: 44.0","thyroid gland: 28.0","Cell line enhanced",NA,"BJ hTERT+: 14.6;RPTEC TERT1: 26.5;U-138 MG: 16.1"
"KCNJ5","CIR, GIRK4, KATP1, Kir3.4, LQT13","ENSG00000120457","Potassium voltage-gated channel subfamily J member 5","11","128891356-128921035","Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels","Evidence at protein level","HPA014722, HPA017353, CAB022569","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"adrenal gland: 84.8","spleen: 18.8","Cell line enriched",12,"HBEC3-KT: 9.5"
"KCNMB4",NA,"ENSG00000135643","Potassium calcium-activated channel subfamily M regulatory beta subunit 4","12","70366276-70434292","Predicted membrane proteins","Evidence at protein level","HPA072287","Enhanced",NA,"Approved","Cytosol",NA,"Mixed","Group enriched",8,"adrenal gland: 19.5;cerebral cortex: 38.1","placenta: 3.7","Cell line enhanced",NA,"NTERA-2: 7.7;RH-30: 8.0;RT4: 7.4"
"KCNN3","hSK3, KCa2.3, SKCA3","ENSG00000143603","Potassium calcium-activated channel subfamily N member 3","1","154697455-154870280","Predicted membrane proteins, Voltage-gated ion channels","Evidence at protein level","HPA017990, HPA057127","Uncertain",NA,"Approved","Nucleoplasm","Renal cancer:1.97e-4 (unfavourable)","Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 25.4","fallopian tube: 9.4","Cell line enhanced",NA,"Daudi: 28.1;HMC-1: 23.0;Karpas-707: 46.9;U-266/70: 47.5"
"KCNQ2","BFNC, EBN, EBN1, ENB1, HNSPC, KCNA11, Kv7.2","ENSG00000075043","Potassium voltage-gated channel subfamily Q member 2","20","63400210-63472677","Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels","Evidence at protein level","HPA016642, HPA057112","Enhanced",NA,"Approved","Endoplasmic reticulum",NA,"Tissue enriched","Tissue enriched",7,"cerebral cortex: 57.2","testis: 8.2","Cell line enhanced",NA,"AN3-CA: 32.4;SCLC-21H: 79.6;SH-SY5Y: 126.1"
"KCNQ5","Kv7.5","ENSG00000185760","Potassium voltage-gated channel subfamily Q member 5","6","72621792-73198851","Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels","Evidence at protein level","HPA016655","Enhanced",NA,"Approved","Vesicles",NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 22.3","thyroid gland: 7.9","Cell line enhanced",NA,"BJ: 29.6"
"KCTD10","BTBD28, MSTP028","ENSG00000110906","Potassium channel tetramerization domain containing 10","12","109448656-109477544","Predicted intracellular proteins","Evidence at protein level","HPA014273","Approved",NA,"Supported","Nucleoplasm<br>Cytosol","Liver cancer:5.32e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"smooth muscle: 79.7","Expressed in all",NA,NA
"KCTD8",NA,"ENSG00000183783","Potassium channel tetramerization domain containing 8","4","44173909-44448807","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA031562","Enhanced",NA,"Approved","Vesicles",NA,"Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 11.5;thyroid gland: 5.2","testis: 2.4","Cell line enhanced",NA,"HAP1: 2.2;NTERA-2: 1.5;SCLC-21H: 6.8;U-2 OS: 1.8"
"KDELR2","ELP-1, ERD2.2","ENSG00000136240","KDEL endoplasmic reticulum protein retention receptor 2","7","6445953-6484242","Predicted membrane proteins","Evidence at protein level","HPA016459","Approved",NA,NA,NA,"Renal cancer:6.79e-8 (unfavourable), Head and neck cancer:1.03e-5 (unfavourable), Glioma:8.16e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 204.0","Expressed in all",NA,NA
"KDM6B","JMJD3, KIAA0346","ENSG00000132510","Lysine demethylase 6B","17","7839904-7854796","Predicted intracellular proteins","Evidence at protein level","HPA037988","Enhanced",NA,"Approved","Nuclear speckles","Thyroid cancer:3.37e-4 (unfavourable), Renal cancer:6.07e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"appendix: 28.8","Mixed",NA,NA
"KDM7A","JHDM1D, KIAA1718","ENSG00000006459","Lysine demethylase 7A","7","140084746-140177035","Predicted secreted proteins","Evidence at protein level","HPA012114","Uncertain",NA,"Approved","Nucleoplasm<br>Nucleoli",NA,"Expressed in all","Mixed",NA,NA,"cervix, uterine: 14.2","Mixed",NA,NA
"KHDRBS2","MGC26664, SLM-1, SLM1","ENSG00000112232","KH RNA binding domain containing, signal transduction associated 2","6","61679960-62286227","Predicted intracellular proteins","Evidence at protein level","HPA000500, HPA029392","Supported",NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 6.6;lung: 5.6;thyroid gland: 11.0","spleen: 1.8","Cell line enhanced",NA,"AF22: 7.2;NTERA-2: 1.9;THP-1: 1.0"
"KHSRP","FBP2, FUBP2, KSRP","ENSG00000088247","KH-type splicing regulatory protein","19","6413348-6424794","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA034739, HPA056518","Enhanced",NA,"Enhanced","Nucleoplasm","Renal cancer:2.56e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 179.1","Expressed in all",NA,NA
"KIAA0753","MNR, OFIP","ENSG00000198920","KIAA0753","17","6578148-6640927","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA023057, HPA023494","Enhanced",NA,"Enhanced","Centrosome<br>Cytosol",NA,"Expressed in all","Mixed",NA,NA,"parathyroid gland: 33.2","Mixed",NA,NA
"KIAA0895",NA,"ENSG00000164542","KIAA0895","7","36324221-36390125","Predicted intracellular proteins","Evidence at transcript level","HPA021036, HPA061066","Uncertain",NA,"Approved","Nucleus<br>Plasma membrane<br>Cell Junctions<br>Cytosol",NA,"Expressed in all","Tissue enhanced",NA,"testis: 44.5","parathyroid gland: 23.9","Cell line enhanced",NA,"SCLC-21H: 51.4"
"KIAA0930","bK268H5.C22.1, C22orf9","ENSG00000100364","KIAA0930","22","45190338-45240769","Predicted intracellular proteins","Evidence at protein level","HPA038091","Uncertain",NA,"Approved","Nuclear membrane<br>Mitochondria","Liver cancer:6.90e-8 (unfavourable), Renal cancer:8.95e-7 (unfavourable), Endometrial cancer:9.22e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 76.2","Cell line enhanced",NA,"THP-1: 220.8"
"KIAA1107",NA,"ENSG00000069712","KIAA1107","1","92166985-92184723","Predicted intracellular proteins","Evidence at protein level","HPA024216","Supported",NA,NA,NA,NA,"Mixed","Group enriched",9,"cerebral cortex: 45.9;testis: 10.7","adrenal gland,epididymis: 3.2","Mixed",NA,NA
"KIAA1161","NET37","ENSG00000164976","KIAA1161","9","34366670-34376853","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA060533, HPA067487","Approved",NA,"Approved","Mitochondria","Renal cancer:1.20e-13 (favourable), Endometrial cancer:6.96e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"skeletal muscle: 29.4","Cell line enhanced",NA,"SK-BR-3: 43.1;T-47d: 50.4"
"KIAA1324","EIG121, maba1","ENSG00000116299","KIAA1324","1","109113679-109206781","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA029869, HPA070749","Enhanced",NA,"Supported","Plasma membrane","Endometrial cancer:2.14e-7 (favourable), Lung cancer:5.69e-5 (favourable), Ovarian cancer:2.16e-4 (favourable)","Mixed","Mixed",NA,NA,"cervix, uterine: 129.0","Cell line enhanced",NA,"MCF7: 21.5;SCLC-21H: 20.3;SK-BR-3: 15.8;T-47d: 68.2;U-87 MG: 13.3"
"KIAA2022","KIDLIA, MRX98, XPN","ENSG00000050030","KIAA2022","X","74732849-74925485","Disease related genes, Predicted intracellular proteins","Evidence at transcript level","HPA000407","Uncertain",NA,"Uncertain","Nucleoplasm<br>Midbody",NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 5.4;parathyroid gland: 5.3","prostate: 1.9","Group enriched",6,"HAP1: 5.0;Karpas-707: 5.9;SiHa: 6.2"
"KIF26B","FLJ10157","ENSG00000162849","Kinesin family member 26B","1","245154985-245709431","Predicted intracellular proteins","Evidence at protein level","HPA027709, HPA028478, HPA028561, HPA028562","Enhanced",NA,"Approved","Plasma membrane<br>Microtubules","Ovarian cancer:1.24e-4 (unfavourable)","Mixed","Mixed",NA,NA,"cerebral cortex: 2.3","Cell line enhanced",NA,"HSkMC: 8.1;REH: 19.4;SH-SY5Y: 11.8;U-937: 8.1"
"KLC1","hKLC1B, hKLC1G, hKLC1J, hKLC1N, hKLC1P, hKLC1R, hKLC1S, KLC, KNS2, KNS2A","ENSG00000126214","Kinesin light chain 1","14","103561896-103714249","Predicted intracellular proteins","Evidence at protein level","CAB009798, HPA044617, HPA052450","Uncertain",NA,"Uncertain","Nucleoplasm<br>Plasma membrane<br>Cytosol","Pancreatic cancer:6.75e-4 (favourable), Renal cancer:7.17e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 467.9","Expressed in all",NA,NA
"KLC2","FLJ12387","ENSG00000174996","Kinesin light chain 2","11","66257294-66267860","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA040416, HPA040434","Enhanced",NA,"Supported","Nucleoplasm<br>Plasma membrane<br>Cytosol","Head and neck cancer:3.16e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 63.8","Expressed in all",NA,NA
"KLF1","EKLF","ENSG00000105610","Kruppel like factor 1","19","12884423-12887181","Disease related genes, Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA051850","Enhanced",NA,"Supported","Nucleoplasm",NA,"Not detected","Tissue enriched",24,"bone marrow: 25.7","placenta: 1.0","Group enriched",33,"HEL: 56.0;K-562: 136.3"
"KLF2","LKLF","ENSG00000127528","Kruppel like factor 2","19","16324817-16327874","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA055964","Approved",NA,"Approved","Nucleoplasm","Liver cancer:8.55e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"adipose tissue: 115.9","Cell line enhanced",NA,"TIME: 57.5;U-266/70: 36.1;U-266/84: 34.1"
"KLHDC7B","MGC16635","ENSG00000130487","Kelch domain containing 7B","22","50548033-50551023","Predicted intracellular proteins","Evidence at protein level","HPA000518","Uncertain",NA,NA,NA,"Breast cancer:1.30e-4 (favourable)","Tissue enhanced","Tissue enhanced",NA,"parathyroid gland: 12.7","thyroid gland: 3.4","Group enriched",6,"HHSteC: 18.6;HMC-1: 87.0"
"KLHDC8B","MGC35097","ENSG00000185909","Kelch domain containing 8B","3","49171611-49176486","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA008463, HPA014467","Supported",NA,"Enhanced","Cytosol","Lung cancer:1.47e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"adrenal gland: 70.0","Mixed",NA,NA
"KLHL11","FLJ10572","ENSG00000178502","Kelch like family member 11","17","41853545-41865431","Predicted secreted proteins","Evidence at protein level","HPA023021, HPA054269","Uncertain",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"testis: 22.4","cerebral cortex: 10.7","Mixed",NA,NA
"KLHL41","KBTBD10, Krp1, SARCOSIN","ENSG00000239474","Kelch like family member 41","2","169509702-169526262","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA021165, HPA021753, HPA021760","Enhanced",NA,"Supported","Nucleus<br>Plasma membrane<br>Cytosol",NA,"Group enriched","Tissue enriched",22,"skeletal muscle: 1750.6","esophagus: 79.6","Group enriched",8,"HSkMC: 15.5;LHCN-M2: 29.3;RH-30: 53.9"
"KLRK1","CD314, D12S2489E, KLR, NKG2-D, NKG2D","ENSG00000213809","Killer cell lectin like receptor K1","12","10372353-10391874","Cancer-related genes, CD markers, Predicted membrane proteins","Evidence at protein level","CAB021896, HPA068877","Enhanced",NA,"Supported","Plasma membrane",NA,"Not detected","Tissue enhanced",NA,"lymph node: 35.1;spleen: 52.8","tonsil: 16.2","Cell line enriched",8,"U-698: 41.6"
"KMT2D","ALR, CAGL114, MLL2, MLL4, TNRC21","ENSG00000167548","Lysine methyltransferase 2D","12","49018975-49059774","Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA035977","Approved",NA,"Approved","Nucleus<br>Plasma membrane<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 46.6","Expressed in all",NA,NA
"KRI1","FLJ12949","ENSG00000129347","KRI1 homolog","19","10553078-10566037","Predicted intracellular proteins","Evidence at protein level","HPA043110, HPA043574","Approved",NA,"Enhanced","Nucleoli","Renal cancer:4.89e-10 (unfavourable), Liver cancer:1.21e-4 (unfavourable), Colorectal cancer:9.37e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"appendix: 26.6","Expressed in all",NA,NA
"KRT25","KRT25A","ENSG00000204897","Keratin 25","17","40748021-40755332","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA053977, HPA058943","Enhanced",NA,"Approved","Vesicles",NA,"Not detected","Group enriched",15,"breast: 3.6;testis: 1.6","smooth muscle: 0.1","Cell line enriched",5,"RPTEC TERT1: 1.0"
"KRT7","CK7, K2C7, K7, SCL","ENSG00000135480","Keratin 7","12","52232520-52252186","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB000028, HPA007272","Enhanced",NA,NA,NA,"Renal cancer:2.77e-9 (favourable), Pancreatic cancer:7.78e-5 (unfavourable), Ovarian cancer:9.42e-5 (unfavourable), Endometrial cancer:1.99e-4 (unfavourable)","Tissue enhanced","Tissue enhanced",NA,"thyroid gland: 984.0","urinary bladder: 454.0","Cell line enhanced",NA,"HBEC3-KT: 4461.4;RT4: 5973.0;SiHa: 6200.7"
"KRT73","K6IRS3, KRT6IRS3","ENSG00000186049","Keratin 73","12","52607570-52618559","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA044031","Enhanced",NA,NA,NA,NA,"Not detected","Group enriched",7,"lymph node: 2.5;skin: 12.1","appendix: 1.0","Not detected",NA,NA
"KRTAP3-2","KAP3.2","ENSG00000212900","Keratin associated protein 3-2","17","40999193-40999894","Predicted intracellular proteins","Evidence at protein level","HPA042992","Approved",NA,NA,NA,NA,"Not detected","Tissue enriched",7,"esophagus: 3.3","skin: 0.5","Not detected",NA,NA
"KRTAP3-3","KAP3.3","ENSG00000212899","Keratin associated protein 3-3","17","40993430-40994133","Predicted intracellular proteins","Evidence at protein level","HPA042992","Approved",NA,NA,NA,NA,"Tissue enhanced","Not detected",NA,NA,"breast,skin: 0.1","Not detected",NA,NA
"KSR2","FLJ25965","ENSG00000171435","Kinase suppressor of ras 2","12","117453012-117968983","Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins","Evidence at protein level","HPA035536","Approved",NA,NA,NA,NA,"Not detected","Tissue enhanced",NA,"cerebral cortex: 4.1","adrenal gland: 1.2","Group enriched",6,"HUVEC TERT2: 3.8;SCLC-21H: 3.8;TIME: 5.6"
"KTN1","CG1, KIAA0004, KNT","ENSG00000126777","Kinectin 1","14","55559072-55701526","Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA003178, CAB015331, HPA017876","Enhanced",NA,"Enhanced","Endoplasmic reticulum","Renal cancer:1.01e-6 (favourable), Head and neck cancer:6.83e-5 (unfavourable), Liver cancer:3.76e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 268.4","Expressed in all",NA,NA
"LAG3","CD223","ENSG00000089692","Lymphocyte activating 3","12","6772512-6778455","CD markers, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB002301, HPA013967","Enhanced",NA,NA,NA,"Renal cancer:4.62e-11 (unfavourable), Cervical cancer:3.89e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"spleen: 32.0","lymph node: 17.6","Cell line enriched",140,"HDLM-2: 136.0"
"LAMC1","LAMB2","ENSG00000135862","Laminin subunit gamma 1","1","183023460-183145592","Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA001908, HPA001909, CAB004486, CAB078163","Enhanced",NA,"Approved","Endoplasmic reticulum<br>Plasma membrane","Urothelial cancer:8.85e-5 (unfavourable)","Expressed in all","Tissue enhanced",NA,"placenta: 332.9","smooth muscle: 147.5","Cell line enhanced",NA,"ASC diff: 1091.5;HSkMC: 716.3"
"LANCL1","GPR69A, p40","ENSG00000115365","LanC like 1","2","210431249-210477652","Predicted intracellular proteins","Evidence at protein level","HPA034994","Approved",NA,"Approved","Microtubules",NA,"Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 153.3","Expressed in all",NA,NA
"LANCL2","GPR69B, TASP","ENSG00000132434","LanC like 2","7","55365448-55433742","Predicted intracellular proteins","Evidence at protein level","HPA019711, HPA029535","Uncertain",NA,"Supported","Nucleus<br>Cytosol","Renal cancer:1.03e-6 (favourable), Ovarian cancer:1.89e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 41.2","parathyroid gland: 16.5","Cell line enriched",6,"A-431: 130.0"
"LAT","LAT1","ENSG00000213658","Linker for activation of T-cells","16","28984826-28990783","Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","CAB002223, HPA011157, CAB012978","Enhanced",NA,"Supported","Golgi apparatus<br>Plasma membrane",NA,"Not detected","Tissue enhanced",NA,"lymph node: 75.3","appendix: 31.8","Group enriched",8,"HEL: 173.8;HMC-1: 690.0;MOLT-4: 227.5"
"LAX1","FLJ20340, LAX","ENSG00000122188","Lymphocyte transmembrane adaptor 1","1","203765176-203776233","Predicted membrane proteins","Evidence at protein level","HPA002461, HPA003887, CAB025358","Enhanced",NA,"Enhanced","Golgi apparatus<br>Plasma membrane<br>Cytosol",NA,"Mixed","Tissue enhanced",NA,"tonsil: 15.3","lymph node: 10.3","Cell line enhanced",NA,"Karpas-707: 14.1;U-266/70: 18.2;U-266/84: 40.4;U-698: 14.6"
"LCK",NA,"ENSG00000182866","LCK proto-oncogene, Src family tyrosine kinase","1","32251239-32286165","Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins","Evidence at protein level","HPA003494, CAB003816","Enhanced",NA,"Approved","Golgi apparatus","Endometrial cancer:2.96e-6 (favourable), Renal cancer:2.60e-5 (unfavourable), Melanoma:5.65e-5 (favourable), Head and neck cancer:2.91e-4 (favourable)","Mixed","Tissue enhanced",NA,"lymph node: 125.9;tonsil: 72.4","appendix: 66.3","Group enriched",7,"MOLT-4: 429.5;U-698: 207.6"
"LCN2","24p3, NGAL","ENSG00000148346","Lipocalin 2","9","128149071-128153455","Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA002695, CAB016549, CAB016550","Enhanced",NA,"Supported","Endoplasmic reticulum","Breast cancer:9.61e-4 (favourable)","Mixed","Tissue enhanced",NA,"bone marrow: 1852.1;gallbladder: 3419.4","cervix, uterine: 1163.5","Group enriched",11,"CAPAN-2: 3169.5;EFO-21: 1362.3"
"LCP2","SLP-76, SLP76","ENSG00000043462","Lymphocyte cytosolic protein 2","5","170246237-170298227","Predicted intracellular proteins","Evidence at protein level","CAB004574, HPA036396, HPA036397","Enhanced",NA,NA,NA,"Renal cancer:6.22e-5 (unfavourable), Endometrial cancer:5.08e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"spleen: 125.5","Cell line enhanced",NA,"HEL: 149.4;HL-60: 137.8;HMC-1: 372.4;MOLT-4: 84.0;U-937: 87.8"
"LDB2","CLIM1, LDB1","ENSG00000169744","LIM domain binding 2","4","16501541-16898809","Predicted intracellular proteins","Evidence at protein level","CAB017544, HPA068634","Supported",NA,"Supported","Nucleus<br>Nucleoli<br>Plasma membrane",NA,"Expressed in all","Mixed",NA,NA,"endometrium: 108.3","Cell line enhanced",NA,"HAP1: 35.5;HUVEC TERT2: 54.3;U-138 MG: 25.3"
"LDLRAP1","ARH, ARH2, DKFZp586D0624, FHCB1, FHCB2, MGC34705","ENSG00000157978","Low density lipoprotein receptor adaptor protein 1","1","25543580-25568886","Disease related genes, Predicted intracellular proteins","Evidence at protein level","CAB003705, HPA050358","Approved",NA,"Approved","Microtubules",NA,"Expressed in all","Expressed in all",NA,NA,"spleen: 50.9","Mixed",NA,NA
"LEF1","TCF10, TCF1ALPHA, TCF7L3","ENSG00000138795","Lymphoid enhancer binding factor 1","4","108047545-108168956","Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA002087, CAB019405","Enhanced",NA,"Approved","Nucleoplasm","Renal cancer:2.47e-6 (unfavourable), Endometrial cancer:1.37e-5 (favourable)","Expressed in all","Tissue enhanced",NA,"lymph node: 41.7","tonsil: 28.3","Group enriched",6,"MOLT-4: 512.4;REH: 443.8"
"LGALS3","GALIG, LGALS2, MAC-2","ENSG00000131981","Galectin 3","14","55124110-55145413","Cancer-related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA003162, CAB005191","Enhanced",NA,"Supported","Nucleoplasm<br>Plasma membrane<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"colon: 871.1","Cell line enhanced",NA,"SK-MEL-30: 1368.8"
"LHX9",NA,"ENSG00000143355","LIM homeobox 9","1","197911902-197935478","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA009695","Uncertain",NA,"Approved","Nucleus",NA,"Mixed","Tissue enhanced",NA,"ovary: 11.5;testis: 4.5","lung: 2.2","Cell line enriched",9,"fHDF/TERT166: 213.5"
"LIMK1","LIMK","ENSG00000106683","LIM domain kinase 1","7","74082933-74122525","Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA028064, HPA028516","Approved",NA,"Supported","Nuclear speckles<br>Cytosol","Renal cancer:6.63e-8 (unfavourable), Liver cancer:7.79e-6 (unfavourable), Colorectal cancer:4.95e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 39.5","Expressed in all",NA,NA
"LIPG","EDL","ENSG00000101670","Lipase G, endothelial type","18","49560699-49599182","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA016966","Uncertain",NA,NA,NA,NA,"Tissue enriched","Group enriched",11,"placenta: 214.4;thyroid gland: 403.2","seminal vesicle: 29.1","Cell line enhanced",NA,"AN3-CA: 113.7;HaCaT: 167.5;RPTEC TERT1: 93.8;TIME: 201.4"
"LLGL1","DLG4, HUGL, HUGL-1, Lgl1, LLGL, Mgl1","ENSG00000131899","LLGL1, scribble cell polarity complex component","17","18225587-18244875","Predicted intracellular proteins","Evidence at protein level","HPA022924, HPA023569","Enhanced",NA,NA,NA,"Liver cancer:2.72e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 21.1","endometrium: 7.0","Expressed in all",NA,NA
"LNPK","KIAA1715, LNP, LNP1, Ul","ENSG00000144320","Lunapark, ER junction formation factor","2","175923892-176002839","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA014205","Approved",NA,"Supported","Nucleoplasm<br>Endoplasmic reticulum",NA,"Expressed in all","Expressed in all",NA,NA,"testis: 44.7","Expressed in all",NA,NA
"LOR",NA,"ENSG00000203782","Loricrin","1","153259700-153262122","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA076123, HPA077266","Enhanced",NA,NA,NA,"Head and neck cancer:8.53e-4 (favourable)","Tissue enriched","Tissue enriched",16,"skin: 532.0","breast: 32.9","Cell line enriched",83,"HDLM-2: 33.1"
"LPCAT1","AGPAT10, AGPAT9, AYTL2, FLJ12443","ENSG00000153395","Lysophosphatidylcholine acyltransferase 1","5","1456480-1523977","Enzymes, Predicted membrane proteins","Evidence at protein level","HPA012501, HPA022268","Enhanced",NA,"Supported","Endoplasmic reticulum<br>Lipid droplets","Liver cancer:1.88e-8 (unfavourable), Renal cancer:2.64e-7 (unfavourable), Pancreatic cancer:4.90e-5 (favourable), Cervical cancer:7.11e-5 (unfavourable), Endometrial cancer:3.67e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"lung: 19.0;spleen: 14.7","cerebral cortex: 4.4","Cell line enhanced",NA,"BEWO: 80.0;EFO-21: 74.7;PC-3: 52.0"
"LRG1","LRG","ENSG00000171236","Leucine rich alpha-2-glycoprotein 1","19","4536409-4540474","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA001888, HPA001889","Enhanced",NA,"Approved","Vesicles","Renal cancer:3.66e-6 (unfavourable), Thyroid cancer:3.49e-4 (favourable)","Tissue enriched","Tissue enriched",8,"liver: 173.8","appendix,esophagus: 21.1","Cell line enhanced",NA,"THP-1: 15.8;U-937: 34.0"
"LRRC23","B7, LRPB7","ENSG00000010626","Leucine rich repeat containing 23","12","6873569-6914243","Predicted intracellular proteins","Evidence at protein level","HPA037766, HPA057533","Enhanced",NA,"Supported","Nucleoli","Breast cancer:6.02e-4 (favourable)","Expressed in all","Group enriched",7,"fallopian tube: 165.3;testis: 43.3","epididymis: 15.2","Mixed",NA,NA
"LRRC3B","LRP15","ENSG00000179796","Leucine rich repeat containing 3B","3","26622806-26710776","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA015568","Approved",NA,NA,NA,NA,"Group enriched","Group enriched",7,"cerebral cortex: 19.2;skeletal muscle: 3.9;testis: 13.0","endometrium,ovary: 1.6","Cell line enhanced",NA,"NTERA-2: 1.6"
"LRRC47","KIAA1185, RP1-286D6.3","ENSG00000130764","Leucine rich repeat containing 47","1","3778558-3796504","Predicted intracellular proteins","Evidence at protein level","HPA008512, HPA012018","Enhanced",NA,"Supported","Nucleoli fibrillar center","Renal cancer:2.75e-4 (favourable), Liver cancer:3.25e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 19.7","Expressed in all",NA,NA
"LRRC49","FLJ20156","ENSG00000137821","Leucine rich repeat containing 49","15","70853239-71053657","Predicted intracellular proteins","Evidence at protein level","HPA015596","Uncertain",NA,NA,NA,NA,"Mixed","Mixed",NA,NA,"heart muscle: 36.4","Cell line enhanced",NA,"HHSteC: 28.0"
"LRRC4C","KIAA1580, NGL-1","ENSG00000148948","Leucine rich repeat containing 4C","11","40114203-41459773","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA051335, HPA054800","Approved",NA,"Approved","Cytosol",NA,"Tissue enhanced","Tissue enriched",7,"cerebral cortex: 34.4","cervix, uterine: 4.7","Group enriched",9,"AF22: 18.9;U-2 OS: 21.7"
"LRRC55","FLJ45686","ENSG00000183908","Leucine rich repeat containing 55","11","57181747-57191717","Predicted membrane proteins, Transporters","Evidence at protein level","HPA014053","Uncertain",NA,NA,NA,NA,"Group enriched","Tissue enhanced",NA,"cerebral cortex: 6.6","lymph node: 2.4","Group enriched",33,"AF22: 19.1;NTERA-2: 4.6"
"LRRC59","FLJ21675, PRO1855","ENSG00000108829","Leucine rich repeat containing 59","17","50375059-50397553","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA030827, HPA030829","Enhanced",NA,"Enhanced","Endoplasmic reticulum","Renal cancer:1.19e-6 (unfavourable), Liver cancer:3.12e-6 (unfavourable), Head and neck cancer:1.00e-5 (unfavourable), Urothelial cancer:1.90e-5 (unfavourable), Colorectal cancer:2.60e-4 (favourable), Pancreatic cancer:6.87e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cervix, uterine: 92.0","Expressed in all",NA,NA
"LRRC8E","FLJ23420","ENSG00000171017","Leucine rich repeat containing 8 family member E","19","7888505-7902021","Predicted intracellular proteins, Predicted membrane proteins, Transporters","Evidence at protein level","HPA020466","Uncertain",NA,NA,NA,NA,"Mixed","Mixed",NA,NA,"skin: 11.0","Cell line enhanced",NA,"U-87 MG: 35.6"
"LRRCC1","CLERC, KIAA1764, VFL1","ENSG00000133739","Leucine rich repeat and coiled-coil centrosomal protein 1","8","85107147-85146076","Predicted intracellular proteins","Evidence at protein level","HPA012893","Uncertain",NA,NA,NA,NA,"Expressed in all","Tissue enhanced",NA,"testis: 57.8","thyroid gland: 14.2","Cell line enhanced",NA,"HDLM-2: 38.0"
"LRRK1","FLJ23119, KIAA1790, RIPK6, Roco1","ENSG00000154237","Leucine rich repeat kinase 1","15","100919215-101078254","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA010537","Uncertain",NA,"Supported","Mitochondria<br>Cytosol","Renal cancer:5.71e-5 (unfavourable)","Mixed","Mixed",NA,NA,"lymph node: 12.6","Cell line enhanced",NA,"Daudi: 27.9"
"LRRN1","FIGLER3","ENSG00000175928","Leucine rich repeat neuronal 1","3","3799437-3847703","Predicted membrane proteins","Evidence at protein level","HPA011071","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 44.3","parathyroid gland: 18.3","Cell line enhanced",NA,"AF22: 159.4;CAPAN-2: 50.8;HAP1: 50.2;NTERA-2: 96.1"
"LRRTM1","FLJ32082","ENSG00000162951","Leucine rich repeat transmembrane neuronal 1","2","80288351-80304749","Predicted membrane proteins, Predicted secreted proteins","Evidence at transcript level","HPA062660","Approved",NA,NA,NA,NA,"Group enriched","Tissue enhanced",NA,"cerebral cortex: 13.3;salivary gland: 4.9","thyroid gland: 2.2","Cell line enhanced",NA,"SH-SY5Y: 1.4"
"LRTM2",NA,"ENSG00000166159","Leucine rich repeats and transmembrane domains 2","12","1820267-1836752","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA055094","Uncertain",NA,NA,NA,NA,"Not detected","Tissue enriched",47,"cerebral cortex: 8.3","testis: 0.1","Group enriched",12,"HEL: 7.7;SCLC-21H: 5.2"
"LSP1","WP34","ENSG00000130592","Lymphocyte-specific protein 1","11","1852970-1892267","Predicted intracellular proteins","Evidence at protein level","CAB017781, HPA019693, HPA071843","Enhanced",NA,"Supported","Plasma membrane","Endometrial cancer:2.54e-4 (favourable), Cervical cancer:3.56e-4 (favourable), Glioma:9.00e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"spleen: 279.2","Cell line enhanced",NA,"Daudi: 229.4;HDLM-2: 1037.0;RPMI-8226: 322.1"
"LTF","HLF2","ENSG00000012223","Lactotransferrin","3","46435645-46485234","Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB008646, CAB016201, HPA057177, HPA059976","Enhanced",NA,NA,NA,"Renal cancer:6.30e-5 (favourable)","Expressed in all","Tissue enhanced",NA,"bone marrow: 2804.3;cervix, uterine: 1030.7","seminal vesicle: 532.6","Group enriched",10,"RPMI-8226: 28.9;TIME: 11.6"
"LTN1","C21orf10, C21orf98, FLJ11053, KIAA0714, LISTERIN, RNF160, ZNF294","ENSG00000198862","Listerin E3 ubiquitin protein ligase 1","21","28928144-28992956","Enzymes, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA029143, CAB034164, HPA055604","Uncertain",NA,"Enhanced","Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"placenta: 26.6","Expressed in all",NA,NA
"LUC7L2","CGI-59, CGI-74, FLJ10657, H_NH0792N18.3, hLuc7B2, LUC7B2","ENSG00000146963","LUC7 like 2, pre-mRNA splicing factor","7","139340359-139423457","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA051631","Approved",NA,"Approved","Nucleus","Renal cancer:4.92e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 100.7","Expressed in all",NA,NA
"LUC7L3","CRA, CREAP-1, CROP, FLJ11063, hLuc7A, LUC7A, OA48-18","ENSG00000108848","LUC7 like 3 pre-mRNA splicing factor","17","50719544-50756213","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA018475, HPA018484, HPA020017","Enhanced",NA,"Enhanced","Nuclear speckles","Renal cancer:8.41e-7 (unfavourable), Liver cancer:1.05e-5 (unfavourable), Urothelial cancer:5.35e-5 (favourable), Pancreatic cancer:6.07e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"endometrium: 236.1","Expressed in all",NA,NA
"LURAP1","C1orf190, FLJ25163, LRAP35a","ENSG00000171357","Leucine rich adaptor protein 1","1","46203334-46221261","Predicted intracellular proteins","Evidence at protein level","HPA030060, HPA030061","Uncertain",NA,"Approved","Vesicles","Renal cancer:8.81e-8 (favourable)","Mixed","Tissue enhanced",NA,"parathyroid gland: 18.1;thyroid gland: 17.6","testis: 9.2","Mixed",NA,NA
"LUZP1","LUZP","ENSG00000169641","Leucine zipper protein 1","1","23084023-23177808","Predicted intracellular proteins","Evidence at protein level","HPA028506, HPA028542","Enhanced",NA,"Uncertain","Vesicles<br>Actin filaments<br>Cytosol","Renal cancer:1.46e-7 (favourable), Cervical cancer:5.57e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 47.1","Mixed",NA,NA
"LUZP4","CT-8, CT28, HOM-TES-85","ENSG00000102021","Leucine zipper protein 4","X","115289727-115307556","Predicted intracellular proteins","Evidence at protein level","HPA046436, HPA051999","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",157,"testis: 15.7","all non-specific tissues: 0.0","Not detected",NA,NA
"LY86","dJ80N2.1, MD-1","ENSG00000112799","Lymphocyte antigen 86","6","6588108-6654983","Predicted secreted proteins","Evidence at protein level","CAB025000, HPA044895","Approved",NA,NA,NA,"Testis cancer:5.61e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"lymph node: 82.3","spleen: 66.3","Cell line enhanced",NA,"Daudi: 51.2;RPMI-8226: 162.0;THP-1: 62.7;U-937: 34.1"
"LYN","JTK8","ENSG00000254087","LYN proto-oncogene, Src family tyrosine kinase","8","55879813-56014168","Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA001231, CAB004492","Enhanced",NA,"Supported","Golgi apparatus<br>Vesicles<br>Plasma membrane","Renal cancer:3.43e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"spleen: 161.1","appendix: 130.6","Cell line enhanced",NA,"HEL: 215.0;HMC-1: 205.1"
"MACROD2","C20orf133, dJ631M13.5","ENSG00000172264","MACRO domain containing 2","20","13995369-16053197","Predicted intracellular proteins","Evidence at protein level","HPA049076","Enhanced",NA,"Supported","Nucleus<br>Nucleoli<br>Centrosome",NA,"Mixed","Mixed",NA,NA,"lung: 16.2","Cell line enhanced",NA,"EFO-21: 14.4;Karpas-707: 13.4;SCLC-21H: 12.6"
"MADCAM1","MACAM1","ENSG00000099866","Mucosal vascular addressin cell adhesion molecule 1","19","489176-505342","Predicted membrane proteins","Evidence at protein level","CAB075699","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"appendix: 17.8;spleen: 11.4","gallbladder: 3.3","Mixed",NA,NA
"MADD","DENN, KIAA0358, RAB3GEP","ENSG00000110514","MAP kinase activating death domain","11","47269161-47330031","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA038568","Uncertain",NA,"Supported","Plasma membrane<br>Cytosol","Pancreatic cancer:5.69e-5 (favourable), Endometrial cancer:6.62e-5 (favourable), Urothelial cancer:8.25e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 103.9","Expressed in all",NA,NA
"MAFG","MGC13090, MGC20149","ENSG00000197063","MAF bZIP transcription factor G","17","81918270-81927714","Predicted intracellular proteins, Transcription factors","Evidence at protein level","CAB025573","Approved",NA,NA,NA,"Liver cancer:1.90e-6 (unfavourable), Endometrial cancer:5.82e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 28.6","Expressed in all",NA,NA
"MAGEB3","CT3.5","ENSG00000198798","MAGE family member B3","X","30230436-30237492","Predicted intracellular proteins","Evidence at protein level","HPA072203","Approved",NA,NA,NA,NA,"Not detected","Group enriched",156,"epididymis: 21.5;testis: 9.5","all non-specific tissues: 0.0","Cell line enriched",10,"U-266/70: 1.6"
"MAGEE1","DAMAGE, KIAA1587","ENSG00000198934","MAGE family member E1","X","76427724-76431353","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA003047","Approved",NA,"Approved","Cytokinetic bridge<br>Cytosol","Renal cancer:6.86e-6 (favourable), Pancreatic cancer:3.95e-4 (favourable)","Mixed","Tissue enhanced",NA,"cerebral cortex: 29.8","parathyroid gland: 14.3","Mixed",NA,NA
"MAGI2","ACVRIP1, AIP1, ARIP1, KIAA0705, MAGI-2","ENSG00000187391","Membrane associated guanylate kinase, WW and PDZ domain containing 2","7","78017057-79453574","Predicted intracellular proteins","Evidence at protein level","HPA013650","Approved",NA,NA,NA,"Renal cancer:1.08e-4 (favourable)","Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 46.2;parathyroid gland: 38.6","prostate: 14.0","Group enriched",5,"AF22: 19.3;Karpas-707: 58.7"
"MAGOH","MAGOH1, MAGOHA","ENSG00000162385","Mago homolog, exon junction complex core component","1","53226892-53238610","Predicted intracellular proteins, Transporters","Evidence at protein level","CAB015425, HPA043036, HPA047754","Approved",NA,"Supported","Nucleus","Renal cancer:1.45e-5 (unfavourable), Breast cancer:1.85e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"lymph node: 82.2","Expressed in all",NA,NA
"MAGOHB","FLJ10292, MGN2","ENSG00000111196","Mago homolog B, exon junction complex core component","12","10604190-10613623","Predicted intracellular proteins","Evidence at protein level","HPA043036, HPA047754","Uncertain",NA,NA,NA,"Renal cancer:5.04e-8 (unfavourable), Ovarian cancer:5.56e-6 (favourable), Stomach cancer:6.50e-4 (favourable)","Expressed in all","Mixed",NA,NA,"epididymis: 14.3","Expressed in all",NA,NA
"MAOB",NA,"ENSG00000069535","Monoamine oxidase B","X","43766611-43882447","Enzymes, FDA approved drug targets, Predicted membrane proteins","Evidence at protein level","HPA002328, CAB037200","Enhanced",NA,"Approved","Nucleoli<br>Mitochondria",NA,"Expressed in all","Mixed",NA,NA,"seminal vesicle: 215.4","Group enriched",9,"Hep G2: 28.1;SiHa: 82.8"
"MAP1LC3B","ATG8F","ENSG00000140941","Microtubule associated protein 1 light chain 3 beta","16","87383995-87404779","Predicted intracellular proteins","Evidence at protein level","CAB037216, HPA052474, HPA052484, HPA053767","Uncertain",NA,NA,NA,"Renal cancer:2.77e-7 (favourable), Stomach cancer:8.97e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"bone marrow: 122.4","Expressed in all",NA,NA
"MAP1LC3B2","ATG8G","ENSG00000258102","Microtubule associated protein 1 light chain 3 beta 2","12","116548105-116576448","Predicted intracellular proteins","Evidence at transcript level","HPA052474, HPA052484, HPA053767","Uncertain",NA,NA,NA,NA,"Mixed","Mixed",NA,NA,"adrenal gland: 2.7","Cell line enhanced",NA,"SK-MEL-30: 5.6"
"MAP4K1","HPK1","ENSG00000104814","Mitogen-activated protein kinase kinase kinase kinase 1","19","38587641-38618882","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA007419, CAB007754","Enhanced",NA,"Uncertain","Nucleoplasm<br>Plasma membrane","Renal cancer:7.99e-10 (unfavourable), Cervical cancer:6.17e-5 (favourable), Head and neck cancer:3.26e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"lymph node: 37.3;spleen: 23.8;tonsil: 27.2","appendix: 19.2","Cell line enhanced",NA,"Daudi: 34.0;HDLM-2: 44.1;Karpas-707: 34.0;U-266/70: 28.3;U-266/84: 27.3;U-698: 41.0"
"MAP6","FLJ41346, KIAA1878, MAP6-N, STOP","ENSG00000171533","Microtubule associated protein 6","11","75586918-75669120","Predicted intracellular proteins","Evidence at protein level","CAB015442, CAB022600, HPA039061, HPA039062","Enhanced",NA,"Uncertain","Plasma membrane","Pancreatic cancer:3.41e-4 (favourable), Prostate cancer:9.15e-4 (favourable)","Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 68.1;fallopian tube: 65.5","parathyroid gland: 52.6","Group enriched",6,"AF22: 37.3;CACO-2: 31.4;HDLM-2: 19.9;SCLC-21H: 73.4;SH-SY5Y: 33.6"
"MAP6D1","FLJ12748, SL21","ENSG00000180834","MAP6 domain containing 1","3","183815876-183825594","Predicted intracellular proteins","Evidence at protein level","HPA037991","Supported",NA,"Approved","Cytosol","Prostate cancer:3.37e-4 (unfavourable)","Mixed","Group enriched",7,"cerebral cortex: 39.7;skeletal muscle: 10.3","skin: 3.6","Cell line enhanced",NA,"T-47d: 66.1"
"MAP7","E-MAP-115","ENSG00000135525","Microtubule associated protein 7","6","136342281-136550819","Predicted intracellular proteins","Evidence at protein level","HPA029712, HPA029713","Enhanced",NA,"Supported","Microtubules<br>Cytosol","Renal cancer:5.07e-7 (favourable), Cervical cancer:9.70e-5 (unfavourable), Liver cancer:9.22e-4 (favourable)","Expressed in all","Mixed",NA,NA,"cerebral cortex: 52.9","Cell line enhanced",NA,"MCF7: 67.4"
"MAPK9","JNK2, p54a, PRKM9, SAPK","ENSG00000050748","Mitogen-activated protein kinase 9","5","180233143-180292099","Enzymes, Predicted intracellular proteins, RAS pathway related proteins","Evidence at protein level","CAB008910","Approved",NA,NA,NA,"Colorectal cancer:1.11e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 83.9","Expressed in all",NA,NA
"MAPRE3","EB3, RP3","ENSG00000084764","Microtubule associated protein RP/EB family member 3","2","26970612-27027196","Predicted intracellular proteins","Evidence at protein level","HPA009263","Uncertain",NA,"Supported","Cytosol",NA,"Expressed in all","Tissue enhanced",NA,"cerebral cortex: 177.3","testis: 70.2","Mixed",NA,NA
"MAPT","DDPAC, FLJ31424, FTDP-17, MAPTL, MGC138549, MSTD, MTBT1, MTBT2, PPND, PPP1R103, tau","ENSG00000186868","Microtubule associated protein tau","17","45894382-46028334","Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB000151, HPA048895, HPA069524, HPA069570, CAB072344","Enhanced",NA,"Supported","Nuclear speckles<br>Plasma membrane",NA,"Group enriched","Tissue enriched",8,"cerebral cortex: 116.2","skeletal muscle: 13.7","Cell line enhanced",NA,"HDLM-2: 37.4;SCLC-21H: 16.3;T-47d: 16.5"
"MARC2","FLJ20605, MOSC2","ENSG00000117791","Mitochondrial amidoxime reducing component 2","1","220748225-220784815","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA015085, HPA017572","Enhanced",NA,NA,NA,"Liver cancer:1.40e-10 (favourable), Renal cancer:3.09e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"parathyroid gland: 338.5","kidney: 139.5","Cell line enhanced",NA,"T-47d: 33.9"
"MB21D1","C6orf150, cGAS","ENSG00000164430","Mab-21 domain containing 1","6","73413515-73452276","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA031700, HPA031702","Enhanced",NA,"Approved","Microtubule organizing center<br>Cytosol","Renal cancer:2.27e-7 (unfavourable)","Expressed in all","Mixed",NA,NA,"bone marrow: 8.7","Cell line enhanced",NA,"RH-30: 40.2"
"MBD3",NA,"ENSG00000071655","Methyl-CpG binding domain protein 3","19","1573596-1592801","Predicted intracellular proteins","Evidence at protein level","CAB013265","Supported",NA,"Supported","Nucleoplasm","Pancreatic cancer:1.76e-5 (favourable), Liver cancer:2.99e-4 (unfavourable), Endometrial cancer:5.08e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 45.8","Expressed in all",NA,NA
"MCCC1","MCCA","ENSG00000078070","Methylcrotonoyl-CoA carboxylase 1","3","183015218-183116075","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA008310","Approved",NA,"Enhanced","Mitochondria","Renal cancer:3.68e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"kidney: 57.9","Expressed in all",NA,NA
"MCCD1",NA,"ENSG00000204511","Mitochondrial coiled-coil domain 1","6","31528717-31530232","Predicted secreted proteins","Evidence at transcript level","HPA046948","Uncertain",NA,NA,NA,"Renal cancer:1.73e-4 (favourable)","Tissue enhanced","Tissue enriched",36,"kidney: 3.5","all non-specific tissues: 0.0","Not detected",NA,NA
"MCF2L2","ARHGEF22, KIAA0861","ENSG00000053524","MCF.2 cell line derived transforming sequence-like 2","3","183178043-183428778","Disease related genes, Predicted intracellular proteins","Evidence at transcript level","HPA038946, HPA038947","Uncertain",NA,"Approved","Plasma membrane<br>Cytosol",NA,"Not detected","Group enriched",8,"adrenal gland: 10.2;cerebral cortex: 17.2;parathyroid gland: 7.7;spleen: 3.5;testis: 4.7","prostate: 1.0","Cell line enhanced",NA,"HDLM-2: 5.5;Karpas-707: 3.6;REH: 3.1"
"ME2",NA,"ENSG00000082212","Malic enzyme 2","18","50878734-50954257","Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA008247, HPA008880","Enhanced",NA,"Enhanced","Mitochondria","Liver cancer:8.29e-8 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 39.2","Expressed in all",NA,NA
"MECR","CGI-63, ETR1, FASN2B, NRBF1","ENSG00000116353","Mitochondrial trans-2-enoyl-CoA reductase","1","29192873-29230942","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA022018, HPA022030, HPA028740","Enhanced",NA,"Supported","Mitochondria","Renal cancer:5.81e-6 (favourable), Urothelial cancer:5.29e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 18.4","Expressed in all",NA,NA
"MED12","CAGH45, FGS1, HOPA, KIAA0192, OKS, OPA1, TNRC11, TRAP230","ENSG00000184634","Mediator complex subunit 12","X","71118556-71142454","Cancer-related genes, Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA003184, HPA003185","Enhanced",NA,"Approved","Nucleoplasm",NA,"Expressed in all","Expressed in all",NA,NA,"ovary: 26.8","Expressed in all",NA,NA
"MED12L","KIAA1635, TNRC11L, TRALP, TRALPUSH","ENSG00000144893","Mediator complex subunit 12 like","3","151085697-151437072","Predicted intracellular proteins","Evidence at protein level","HPA036807","Uncertain",NA,"Approved","Nucleoli",NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 26.6","testis: 8.5","Cell line enhanced",NA,"BEWO: 17.8;HEL: 18.7"
"MED19","LCMR1","ENSG00000156603","Mediator complex subunit 19","11","57703714-57712323","Predicted intracellular proteins","Evidence at protein level","HPA039912, HPA040860","Uncertain",NA,"Supported","Nucleus<br>Nuclear bodies","Liver cancer:1.34e-6 (unfavourable), Ovarian cancer:1.76e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 28.6","Expressed in all",NA,NA
"MEGF8","C19orf49, EGFL4, FLJ22365, SBP1","ENSG00000105429","Multiple EGF like domains 8","19","42325609-42378769","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA049248","Approved",NA,NA,NA,"Renal cancer:2.17e-7 (favourable), Pancreatic cancer:6.03e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 38.0","Expressed in all",NA,NA
"MEN1",NA,"ENSG00000133895","Menin 1","11","64803510-64811294","Cancer-related genes, Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA030342","Uncertain",NA,"Supported","Nucleoplasm<br>Cytosol","Stomach cancer:6.31e-5 (favourable), Liver cancer:1.08e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 22.3","Expressed in all",NA,NA
"MET","DFNB97, HGFR, RCCP2","ENSG00000105976","MET proto-oncogene, receptor tyrosine kinase","7","116672390-116798386","Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","CAB005282, CAB018577, HPA055607","Uncertain",NA,"Supported","Plasma membrane<br>Cytosol","Pancreatic cancer:1.21e-7 (unfavourable), Head and neck cancer:6.75e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 39.0","Mixed",NA,NA
"METTL13","CGI-01, KIAA0859","ENSG00000010165","Methyltransferase like 13","1","171781664-171814023","Predicted intracellular proteins","Evidence at protein level","HPA044498, HPA053705","Approved",NA,"Approved","Cytosol","Liver cancer:5.68e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 24.7","Expressed in all",NA,NA
"MFAP3",NA,"ENSG00000037749","Microfibrillar associated protein 3","5","154038906-154220478","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA015883, HPA049198","Approved",NA,"Approved","Nucleoplasm<br>Golgi apparatus","Cervical cancer:4.28e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 74.8","Expressed in all",NA,NA
"MFAP5","MAGP2, MP25","ENSG00000197614","Microfibrillar associated protein 5","12","8637346-8662888","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA010553","Enhanced",NA,NA,NA,"Urothelial cancer:5.81e-4 (unfavourable), Stomach cancer:6.87e-4 (unfavourable)","Mixed","Expressed in all",NA,NA,"smooth muscle: 207.1","Cell line enhanced",NA,"BEWO: 166.7;EFO-21: 142.4"
"MFHAS1","LRRC65, MASL1","ENSG00000147324","Malignant fibrous histiocytoma amplified sequence 1","8","8783354-8893645","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA051213, HPA054471","Uncertain",NA,"Approved","Nucleoplasm<br>Cytosol",NA,"Expressed in all","Mixed",NA,NA,"spleen: 16.6","Cell line enhanced",NA,"MOLT-4: 111.7"
"MFSD2B",NA,"ENSG00000205639","Major facilitator superfamily domain containing 2B","2","24010081-24063321","Predicted membrane proteins","Evidence at protein level","HPA044145","Enhanced",NA,NA,NA,NA,"Not detected","Tissue enriched",9,"bone marrow: 7.2","placenta: 0.7","Group enriched",16,"HEL: 7.5;K-562: 3.3"
"MGARP","C4orf49, CESP-1, HUMMR, OSAP","ENSG00000137463","Mitochondria localized glutamic acid rich protein","4","139266163-139280338","Predicted membrane proteins","Evidence at protein level","HPA015994","Enhanced",NA,"Supported","Mitochondria",NA,"Tissue enhanced","Tissue enriched",10,"adrenal gland: 267.2","ovary: 27.1","Cell line enhanced",NA,"BJ: 15.5;fHDF/TERT166: 21.3;HHSteC: 17.8;HUVEC TERT2: 46.0"
"MGLL","HU-K5, MGL","ENSG00000074416","Monoglyceride lipase","3","127689062-127823250","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA011348, HPA011993, HPA011994","Enhanced",NA,"Supported","Nucleoplasm","Pancreatic cancer:6.41e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"adipose tissue: 188.3","Cell line enhanced",NA,"BJ hTERT+: 193.8"
"MIA3","FLJ39207, KIAA0268, TANGO, TANGO1, UNQ6077","ENSG00000154305","MIA family member 3, ER export factor","1","222618086-222668012","Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA055922, HPA056816","Enhanced",NA,"Enhanced","Vesicles","Renal cancer:3.73e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 81.5","Expressed in all",NA,NA
"MIB1","DIP-1, KIAA1323, MIB, ZZANK2, ZZZ6","ENSG00000101752","Mindbomb E3 ubiquitin protein ligase 1","18","21704957-21870957","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA019100, CAB037044","Approved",NA,"Approved","Nuclear membrane<br>Vesicles<br>Plasma membrane",NA,"Expressed in all","Expressed in all",NA,NA,"thyroid gland: 24.2","Expressed in all",NA,NA
"MIER3","DKFZp686L09111, DKFZp781I1119, FLJ35954","ENSG00000155545","MIER family member 3","5","56919602-56971675","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA058349, HPA065946","Uncertain",NA,"Enhanced","Nucleoplasm",NA,"Expressed in all","Expressed in all",NA,NA,"colon: 30.2","Expressed in all",NA,NA
"MIIP","FLJ12438, IIp45","ENSG00000116691","Migration and invasion inhibitory protein","1","12019466-12032045","Predicted intracellular proteins","Evidence at protein level","HPA044948","Uncertain",NA,"Approved","Nucleoplasm<br>Cytosol","Renal cancer:8.26e-7 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"bone marrow: 27.4","Cell line enriched",8,"HDLM-2: 334.7"
"MKI67","MIB-, PPP1R105","ENSG00000148773","Marker of proliferation Ki-67","10","128096659-128126385","Cancer-related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB000058, HPA000451, HPA001164, CAB068198","Enhanced",NA,"Enhanced","Nucleus<br>Nucleoli<br>Nuclear bodies","Renal cancer:0.00e+0 (unfavourable), Liver cancer:3.61e-6 (unfavourable), Pancreatic cancer:9.47e-5 (unfavourable)","Expressed in all","Tissue enhanced",NA,"bone marrow: 28.8","lymph node: 17.9","Mixed",NA,NA
"MKRN2","HSPC070, RNF62","ENSG00000075975","Makorin ring finger protein 2","3","12557014-12583713","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA037559, HPA037560","Enhanced",NA,"Approved","Nucleoplasm<br>Cytosol","Liver cancer:1.58e-4 (unfavourable), Renal cancer:6.04e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 100.1","Expressed in all",NA,NA
"MKS1","BBS13, FLJ20345, MKS, POC12","ENSG00000011143","Meckel syndrome, type 1","17","58205437-58219605","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA021372, HPA021812","Enhanced",NA,NA,NA,"Pancreatic cancer:1.25e-4 (favourable), Renal cancer:1.33e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"fallopian tube: 32.0","Expressed in all",NA,NA
"MLH1","COCA2, FCC2, HNPCC, HNPCC2","ENSG00000076242","MutL homolog 1","3","36993332-37050918","Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB013294, HPA052707, HPA060714, CAB070868","Supported",NA,"Enhanced","Nucleoplasm","Liver cancer:8.24e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 60.0","Mixed",NA,NA
"MLLT11","AF1Q","ENSG00000213190","Myeloid/lymphoid or mixed-lineage leukemia; translocated to, 11","1","151057758-151068497","Cancer-related genes, Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA000540","Uncertain",NA,"Supported","Nucleoplasm<br>Cytosol","Renal cancer:4.25e-12 (unfavourable), Endometrial cancer:4.26e-5 (unfavourable)","Expressed in all","Tissue enriched",5,"cerebral cortex: 122.5","parathyroid gland: 24.0","Cell line enhanced",NA,"AF22: 129.2;SH-SY5Y: 151.4"
"MME","CALLA, CD10, NEP","ENSG00000196549","Membrane metalloendopeptidase","3","155024124-155183729","Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","CAB000013, HPA052583, HPA056072","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"duodenum: 428.2;kidney: 384.2;small intestine: 401.5","prostate: 162.5","Cell line enhanced",NA,"ASC TERT1: 595.9;BJ hTERT+: 1084.7;HSkMC: 604.7"
"MMP9","CLG4B","ENSG00000100985","Matrix metallopeptidase 9","20","46008908-46016561","Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB000348, HPA001238, HPA063909, CAB068199, CAB068200, CAB068201","Enhanced",NA,"Approved","Cytosol","Renal cancer:4.05e-5 (unfavourable), Endometrial cancer:2.55e-4 (favourable), Liver cancer:7.19e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"bone marrow: 252.6;lymph node: 117.7","appendix: 82.8","Cell line enriched",8,"NB-4: 227.3"
"MNDA","PYHIN3","ENSG00000163563","Myeloid cell nuclear differentiation antigen","1","158831317-158849506","Predicted intracellular proteins","Evidence at protein level","HPA034532, HPA073215","Enhanced",NA,"Supported","Nucleoplasm<br>Nucleoli",NA,"Expressed in all","Tissue enhanced",NA,"bone marrow: 194.8;spleen: 144.9","appendix: 111.3","Group enriched",13,"NB-4: 93.3;THP-1: 185.6;U-937: 141.2"
"MOAP1","MAP-1, PNMA4","ENSG00000165943","Modulator of apoptosis 1","14","93182196-93184928","Predicted intracellular proteins","Evidence at protein level","HPA000939","Uncertain",NA,"Approved","Nucleus<br>Cell Junctions","Lung cancer:7.37e-9 (favourable), Renal cancer:3.15e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 86.1","Expressed in all",NA,NA
"MORC4","FLJ11565, ZCW4, ZCWCC2","ENSG00000133131","MORC family CW-type zinc finger 4","X","106813871-107000244","Cancer-related genes, Predicted intracellular proteins","Evidence at protein level","HPA000395, HPA015547, HPA050250","Enhanced",NA,"Enhanced","Nucleoplasm","Breast cancer:3.56e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 114.4","Expressed in all",NA,NA
"MPDZ","MUPP1","ENSG00000107186","Multiple PDZ domain crumbs cell polarity complex component","9","13105704-13279590","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB013512, HPA020255, HPA026686","Uncertain",NA,NA,NA,"Pancreatic cancer:7.40e-4 (favourable), Liver cancer:8.68e-4 (favourable)","Expressed in all","Mixed",NA,NA,"liver: 44.3","Cell line enhanced",NA,"AF22: 57.0"
"MPG","MDG","ENSG00000103152","N-methylpurine DNA glycosylase","16","77007-85853","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA006531","Approved",NA,"Approved","Nucleoplasm<br>Cytosol","Endometrial cancer:2.82e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 49.0","Expressed in all",NA,NA
"MPHOSPH8","HSMPP8, mpp8","ENSG00000196199","M-phase phosphoprotein 8","13","19633681-19673459","Predicted intracellular proteins","Evidence at protein level","HPA039701, HPA040035","Enhanced",NA,"Supported","Nucleus<br>Plasma membrane<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"ovary: 63.5","Expressed in all",NA,NA
"MPO",NA,"ENSG00000005381","Myeloperoxidase","17","58269856-58280935","Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB000059, HPA021147, HPA061464","Enhanced",NA,"Supported","Nucleus<br>Vesicles",NA,"Tissue enhanced","Tissue enriched",82,"bone marrow: 2499.6","salivary gland: 30.6","Group enriched",98,"HL-60: 2786.8;NB-4: 2892.7"
"MPRIP","M-RIP, p116Rip, RHOIP3","ENSG00000133030","Myosin phosphatase Rho interacting protein","17","17042545-17217679","Predicted intracellular proteins","Evidence at protein level","HPA022034, HPA022901","Enhanced",NA,"Supported","Actin filaments<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"smooth muscle: 197.8","Expressed in all",NA,NA
"MRFAP1","PAM14, PGR1","ENSG00000179010","Morf4 family associated protein 1","4","6640091-6642745","Predicted intracellular proteins","Evidence at protein level","CAB042447, HPA056367","Approved",NA,"Approved","Nucleus","Renal cancer:2.90e-7 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 505.0","Expressed in all",NA,NA
"MROH1","HEATR7A, KIAA1833","ENSG00000179832","Maestro heat like repeat family member 1","8","144148016-144261940","Predicted intracellular proteins","Evidence at protein level","HPA044465","Approved","Supported",NA,NA,"Renal cancer:3.65e-6 (favourable), Endometrial cancer:6.74e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 14.9","Mixed",NA,NA
"MRPL48","CGI-118","ENSG00000175581","Mitochondrial ribosomal protein L48","11","73787316-73865133","Predicted intracellular proteins, Ribosomal proteins","Evidence at protein level","HPA040241, HPA040864","Approved",NA,NA,NA,"Liver cancer:3.30e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 24.1","Expressed in all",NA,NA
"MRPS22","C3orf5, GIBT, GK002, MRP-S22","ENSG00000175110","Mitochondrial ribosomal protein S22","3","139005806-139357223","Disease related genes, Predicted intracellular proteins, Predicted secreted proteins, Ribosomal proteins","Evidence at protein level","HPA006083, HPA007830","Enhanced",NA,"Supported","Mitochondria","Endometrial cancer:1.35e-5 (unfavourable), Pancreatic cancer:1.55e-5 (unfavourable), Prostate cancer:1.85e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"adrenal gland: 69.5","Expressed in all",NA,NA
"MRPS33","CGI-139","ENSG00000090263","Mitochondrial ribosomal protein S33","7","141002610-141015228","Predicted intracellular proteins, Ribosomal proteins","Evidence at protein level","HPA030425","Uncertain",NA,NA,NA,NA,"Expressed in all","Expressed in all",NA,NA,"epididymis: 96.2","Expressed in all",NA,NA
"MSANTD4","KIAA1826","ENSG00000170903","Myb/SANT DNA binding domain containing 4 with coiled-coils","11","105995623-106022403","Predicted intracellular proteins","Evidence at protein level","HPA014411","Approved",NA,"Approved","Nucleus","Renal cancer:1.26e-5 (favourable), Breast cancer:4.95e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 27.4","Mixed",NA,NA
"MTA1",NA,"ENSG00000182979","Metastasis associated 1","14","105419820-105470729","Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors","Evidence at protein level","CAB004508, HPA005544","Supported",NA,"Enhanced","Nucleoplasm<br>Cytosol","Pancreatic cancer:9.48e-5 (favourable), Liver cancer:4.62e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 35.8","Expressed in all",NA,NA
"MTDH","3D3, AEG-1, LYRIC","ENSG00000147649","Metadherin","8","97644179-97728770","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA010932, HPA015104, CAB068204, CAB068205","Supported",NA,"Enhanced","Endoplasmic reticulum","Renal cancer:3.82e-4 (unfavourable), Pancreatic cancer:5.36e-4 (unfavourable), Lung cancer:7.76e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 104.4","Expressed in all",NA,NA
"MTERF4","MGC61716, MTERFD2","ENSG00000122085","Mitochondrial transcription termination factor 4","2","241072169-241102332","Predicted intracellular proteins","Evidence at protein level","HPA027097","Uncertain",NA,"Supported","Mitochondria<br>Cytosol","Pancreatic cancer:3.48e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 58.3","Expressed in all",NA,NA
"MTFR1","CHPPR, FAM54A2, KIAA0009","ENSG00000066855","Mitochondrial fission regulator 1","8","65644734-65771261","Predicted intracellular proteins","Evidence at protein level","HPA023152, HPA056120","Uncertain",NA,"Supported","Mitochondria<br>Cytosol","Breast cancer:4.06e-4 (unfavourable), Thyroid cancer:5.21e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 35.2","Expressed in all",NA,NA
"MTX1","MTX, MTXN","ENSG00000173171","Metaxin 1","1","155208699-155213824","Predicted membrane proteins","Evidence at protein level","HPA011543","Uncertain",NA,"Supported","Mitochondria","Renal cancer:3.39e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 71.8","Expressed in all",NA,NA
"MURC","cavin-4, CAVIN4","ENSG00000170681","Muscle related coiled-coil protein","9","100578079-100587906","Predicted intracellular proteins","Evidence at protein level","HPA020973, HPA020987, HPA021021","Enhanced",NA,"Supported","Nucleoplasm<br>Golgi apparatus<br>Plasma membrane",NA,"Tissue enhanced","Group enriched",9,"heart muscle: 34.8;skeletal muscle: 103.8","prostate: 7.4","Cell line enhanced",NA,"NTERA-2: 9.6;SCLC-21H: 17.1"
"MYEF2","FLJ11213, HsT18564, KIAA1341, MEF-2","ENSG00000104177","Myelin expression factor 2","15","48134631-48178517","Predicted intracellular proteins","Evidence at protein level","HPA004883","Supported",NA,"Supported","Nucleoplasm",NA,"Mixed","Tissue enhanced",NA,"testis: 51.3","cerebral cortex: 47.2","Cell line enhanced",NA,"AF22: 100.6;SCLC-21H: 106.7"
"MYEOV","OCIM","ENSG00000172927","Myeloma overexpressed","11","69294138-69367726","Predicted membrane proteins","Evidence at transcript level","HPA012949","Uncertain",NA,"Approved","Nucleus<br>Vesicles","Pancreatic cancer:1.54e-7 (unfavourable), Renal cancer:1.48e-5 (unfavourable), Lung cancer:2.00e-4 (unfavourable)","Mixed","Group enriched",5,"adipose tissue: 4.0;breast: 5.8;esophagus: 9.2;skin: 1.8;stomach: 6.8","appendix: 1.0","Cell line enhanced",NA,"A-431: 154.1;A549: 74.9;U-2 OS: 38.7"
"MYO18A","KIAA0216, MysPDZ","ENSG00000196535","Myosin XVIIIA","17","29071124-29180412","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA019646, HPA021121","Enhanced",NA,NA,NA,"Renal cancer:3.18e-4 (favourable), Ovarian cancer:3.28e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"skeletal muscle: 133.5","Expressed in all",NA,NA
"MYO1F",NA,"ENSG00000142347","Myosin IF","19","8520790-8577577","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA055242","Enhanced",NA,NA,NA,"Renal cancer:3.27e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"appendix: 50.4;bone marrow: 59.7;spleen: 63.3","lung: 23.4","Cell line enhanced",NA,"HDLM-2: 45.8;HMC-1: 73.1;NB-4: 127.9;THP-1: 99.8;U-937: 61.8"
"MYO1G","HA-2","ENSG00000136286","Myosin IG","7","44962662-44979098","Predicted intracellular proteins","Evidence at protein level","HPA021252","Enhanced",NA,NA,NA,"Renal cancer:8.71e-8 (unfavourable), Cervical cancer:8.26e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"bone marrow: 27.7;lymph node: 27.7;spleen: 24.6","appendix: 21.9","Cell line enhanced",NA,"HDLM-2: 53.6;HEL: 62.4;HL-60: 31.8;MOLT-4: 71.7;THP-1: 52.2;U-937: 44.7"
"MYOM1",NA,"ENSG00000101605","Myomesin 1","18","3066807-3220108","Predicted intracellular proteins","Evidence at protein level","HPA014305, HPA049193","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Group enriched",13,"heart muscle: 278.1;skeletal muscle: 299.1","gallbladder: 22.9","Group enriched",12,"HAP1: 13.8;HMC-1: 3.1;HSkMC: 4.5"
"MYOT","LGMD1, LGMD1A, TTID","ENSG00000120729","Myotilin","5","137867791-137887851","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA037733, HPA037734","Enhanced",NA,NA,NA,"Head and neck cancer:8.85e-4 (unfavourable)","Tissue enhanced","Tissue enriched",21,"skeletal muscle: 766.9","esophagus: 36.1","Not detected",NA,NA
"MYOZ1","CS-2, FATZ, MYOZ","ENSG00000177791","Myozenin 1","10","73631654-73641757","Predicted intracellular proteins","Evidence at protein level","HPA037848, HPA038437","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",38,"skeletal muscle: 2058.9","esophagus: 54.7","Cell line enriched",25,"BEWO: 38.7"
"MYPN","MYOP","ENSG00000138347","Myopalladin","10","68106117-68212017","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA036299, HPA061494","Enhanced",NA,"Approved","Nucleus<br>Vesicles<br>Cytosol",NA,"Tissue enriched","Group enriched",27,"heart muscle: 41.6;skeletal muscle: 99.9","prostate: 2.6","Cell line enhanced",NA,"BJ: 33.6;fHDF/TERT166: 87.0;HBF TERT88: 24.6;LHCN-M2: 39.6"
"MZF1","MZF-1, MZF1B, Zfp98, ZNF42, ZSCAN6","ENSG00000099326","Myeloid zinc finger 1","19","58561931-58573575","Plasma proteins, Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA001757","Approved",NA,"Supported","Nucleus","Renal cancer:2.83e-8 (unfavourable), Urothelial cancer:4.09e-5 (favourable), Pancreatic cancer:7.97e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 14.6","Cell line enhanced",NA,"HEK 293: 39.4"
"NAE1","APP-BP1, APPBP1, ula-1","ENSG00000159593","NEDD8 activating enzyme E1 subunit 1","16","66802875-66873256","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA041178, HPA042041","Enhanced",NA,"Approved","Nucleus<br>Microtubules<br>Centrosome","Liver cancer:3.92e-8 (unfavourable), Thyroid cancer:9.44e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 86.4","Expressed in all",NA,NA
"NAGA","D22S674","ENSG00000198951","Alpha-N-acetylgalactosaminidase","22","42058354-42070842","Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins","Evidence at protein level","HPA000649","Enhanced",NA,NA,NA,NA,"Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 63.7","Expressed in all",NA,NA
"NALCN","bA430M15.1, CanIon, VGCNL1","ENSG00000102452","Sodium leak channel, non-selective","13","101053776-101416492","Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters","Evidence at protein level","HPA031889, HPA031890, HPA031958","Approved",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 28.1","adrenal gland: 6.0","Cell line enhanced",NA,"HaCaT: 12.6;HHSteC: 12.3;TIME: 15.4;U-87 MG: 11.1"
"NAP1L5","DRLM","ENSG00000177432","Nucleosome assembly protein 1 like 5","4","88695915-88698235","Predicted intracellular proteins","Evidence at protein level","HPA058227","Approved",NA,"Approved","Nucleoplasm<br>Cytosol",NA,"Expressed in all","Tissue enhanced",NA,"cerebral cortex: 91.1","adrenal gland: 29.5","Cell line enhanced",NA,"SH-SY5Y: 42.7"
"NAT10","FLJ10774, FLJ12179, hALP, KIAA1709, NET43","ENSG00000135372","N-acetyltransferase 10","11","34105602-34147670","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB035546, HPA057576, HPA071628","Enhanced",NA,"Enhanced","Nucleoli<br>Midbody","Liver cancer:9.61e-8 (unfavourable), Renal cancer:8.83e-5 (unfavourable), Head and neck cancer:1.07e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 35.7","Expressed in all",NA,NA
"NAV1","DKFZp781D0314, FLJ12560, FLJ14203, KIAA1151, MGC14961, POMFIL3, steerin-1","ENSG00000134369","Neuron navigator 1","1","201622885-201826969","Predicted intracellular proteins","Evidence at protein level","CAB012302, HPA018127, HPA027887","Enhanced",NA,"Approved","Microtubules","Renal cancer:3.10e-6 (unfavourable)","Mixed","Mixed",NA,NA,"cerebral cortex: 31.8","Cell line enhanced",NA,"TIME: 153.0"
"NAV3","KIAA0938, POMFIL1","ENSG00000067798","Neuron navigator 3","12","77324641-78213008","Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA032111, HPA032112, CAB037063","Uncertain",NA,"Approved","Nuclear membrane<br>Cytosol",NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 27.2;ovary: 24.6","spleen: 12.3","Cell line enhanced",NA,"hTEC/SVTERT24-B: 46.2;WM-115: 38.6"
"NAXE","AIBP, APOA1BP, MGC119143, MGC119144, MGC119145, YJEFN1","ENSG00000163382","NAD(P)HX epimerase","1","156591762-156594299","Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins","Evidence at protein level","HPA043766, HPA048164","Enhanced",NA,"Enhanced","Nucleoplasm<br>Cytosol","Endometrial cancer:4.94e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"epididymis: 112.2","Expressed in all",NA,NA
"NCAM2","MGC51008, NCAM21","ENSG00000154654","Neural cell adhesion molecule 2","21","20998315-21543329","Plasma proteins, Predicted membrane proteins","Evidence at protein level","HPA030900, HPA030901","Supported",NA,"Supported","Nuclear bodies<br>Plasma membrane",NA,"Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 68.8","adrenal gland: 15.8","Cell line enhanced",NA,"T-47d: 86.4;WM-115: 22.5"
"NCAPG2","CAP-G2, FLJ20311, hCAP-G2, LUZP5, MTB","ENSG00000146918","Non-SMC condensin II complex subunit G2","7","158631311-158704829","Predicted intracellular proteins","Evidence at protein level","HPA026631","Approved",NA,"Supported","Nuclear speckles","Liver cancer:3.00e-5 (unfavourable), Renal cancer:4.06e-5 (unfavourable), Head and neck cancer:1.91e-4 (favourable), Melanoma:3.21e-4 (unfavourable), Endometrial cancer:7.94e-4 (unfavourable), Pancreatic cancer:8.50e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"testis: 27.7","Expressed in all",NA,NA
"NCAPH","BRRN1, CAP-H, hCAP-H","ENSG00000121152","Non-SMC condensin I complex subunit H","2","96335787-96373845","Predicted intracellular proteins","Evidence at protein level","HPA002647, HPA003008","Enhanced",NA,"Supported","Nucleus<br>Cytosol","Liver cancer:9.53e-6 (unfavourable), Pancreatic cancer:1.02e-4 (unfavourable), Lung cancer:6.73e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"testis: 55.4","lymph node: 21.3","Mixed",NA,NA
"NCF1","NCF1A, NOXO2, p47phox, SH3PXD1A","ENSG00000158517","Neutrophil cytosolic factor 1","7","74773962-74789315","Disease related genes, Predicted intracellular proteins","Evidence at protein level","CAB004524, HPA047836, HPA052095","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"lymph node: 71.2;spleen: 74.1","bone marrow: 60.9","Group enriched",6,"Daudi: 72.6;HMC-1: 122.5"
"NCF4","p40phox, SH3PXD4","ENSG00000100365","Neutrophil cytosolic factor 4","22","36860988-36878015","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB010146, HPA036156, HPA057975","Enhanced",NA,"Supported","Cytosol","Renal cancer:7.06e-8 (unfavourable)","Expressed in all","Tissue enhanced",NA,"bone marrow: 119.9","appendix: 59.4","Cell line enhanced",NA,"HEL: 78.2;HMC-1: 349.8;NB-4: 93.8;RPMI-8226: 102.1;THP-1: 92.9"
"NCKAP1","HEM2, Nap1, NAP125","ENSG00000061676","NCK associated protein 1","2","182909115-183038858","Predicted membrane proteins","Evidence at protein level","HPA020449","Enhanced",NA,"Approved","Cytosol","Pancreatic cancer:3.81e-4 (unfavourable), Lung cancer:9.71e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"cerebral cortex: 145.1","Mixed",NA,NA
"NCOR1","hCIT529I10, hN-CoR, KIAA1047, MGC104216, N-CoR, PPP1R109, TRAC1","ENSG00000141027","Nuclear receptor corepressor 1","17","16029157-16218185","Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA043246, HPA050288, HPA051168, CAB072830","Enhanced",NA,"Enhanced","Nucleoplasm<br>Cytosol","Renal cancer:7.92e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 84.7","Expressed in all",NA,NA
"NDRG2","KIAA1248, SYLD","ENSG00000165795","NDRG family member 2","14","21016763-21070872","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA002896, HPA003590, CAB017491","Enhanced",NA,"Approved","Nucleoplasm<br>Microtubule organizing center<br>Cytosol","Renal cancer:1.43e-12 (favourable), Liver cancer:6.71e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 1029.5","Cell line enhanced",NA,"Hep G2: 38.7"
"NDRG4","KIAA1180, SMAP-8","ENSG00000103034","NDRG family member 4","16","58462846-58513628","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA015313, HPA017587","Enhanced",NA,"Uncertain","Nucleus<br>Cytosol",NA,"Tissue enriched","Tissue enhanced",NA,"adrenal gland: 146.6;cerebral cortex: 420.0;heart muscle: 150.6","testis: 72.0","Cell line enhanced",NA,"EFO-21: 30.7;SCLC-21H: 58.1"
"NDUFA2","B8","ENSG00000131495","NADH:ubiquinone oxidoreductase subunit A2","5","140638740-140647785","Predicted intracellular proteins","Evidence at protein level","HPA035933","Uncertain",NA,NA,NA,"Cervical cancer:6.53e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"adrenal gland: 117.4","Expressed in all",NA,NA
"NDUFA8","MGC793, PGIV","ENSG00000119421","NADH:ubiquinone oxidoreductase subunit A8","9","122144058-122159819","Predicted intracellular proteins","Evidence at protein level","HPA041510, HPA041600","Enhanced",NA,"Enhanced","Mitochondria","Renal cancer:4.17e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"heart muscle: 226.5","Expressed in all",NA,NA
"NDUFV3","CI-10k","ENSG00000160194","NADH:ubiquinone oxidoreductase subunit V3","21","42879644-42913304","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA019791, HPA020463, HPA030427, CAB034142","Enhanced",NA,"Enhanced","Mitochondria",NA,"Expressed in all","Expressed in all",NA,NA,"skeletal muscle: 29.0","Expressed in all",NA,NA
"NECAB3","APBA2BP, dJ63M2.4, dJ63M2.5, EFCBP3, NIP1, SYTIP2, XB51","ENSG00000125967","N-terminal EF-hand calcium binding protein 3","20","33657087-33674463","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA044785, HPA070595, HPA071786","Supported",NA,"Supported","Golgi apparatus","Pancreatic cancer:3.19e-5 (favourable), Renal cancer:7.81e-4 (unfavourable), Endometrial cancer:9.57e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"prostate: 34.6","Expressed in all",NA,NA
"NECTIN2","CD112, HVEB, PRR2, PVRL2, PVRR2","ENSG00000130202","Nectin cell adhesion molecule 2","19","44846175-44889228","CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA012759, CAB026138, HPA073459","Enhanced",NA,"Approved","Nucleoli fibrillar center<br>Cell Junctions",NA,"Expressed in all","Expressed in all",NA,NA,"placenta: 111.4","Mixed",NA,NA
"NEDD8","Nedd-8","ENSG00000129559","Neural precursor cell expressed, developmentally down-regulated 8","14","24216852-24232454","Cancer-related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB004082, HPA027583, HPA060254","Uncertain",NA,"Enhanced","Nucleoplasm<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 559.0","Expressed in all",NA,NA
"NEFM","NEF3, NF-M, NFM","ENSG00000104722","Neurofilament medium","8","24913012-24919098","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB010900, CAB012976, HPA022845, HPA023138","Enhanced",NA,"Enhanced","Intermediate filaments",NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 171.7;seminal vesicle: 42.2","adrenal gland: 28.2","Cell line enriched",22,"HEK 293: 3411.6"
"NEK3","HSPK36, MGC29949","ENSG00000136098","NIMA related kinase 3","13","52132639-52159861","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA019062, HPA043230","Enhanced",NA,"Approved","Microtubules",NA,"Expressed in all","Expressed in all",NA,NA,"testis: 29.6","Mixed",NA,NA
"NELFE","D6S45, NELF-E, RD, RDBP, RDP","ENSG00000204356","Negative elongation factor complex member E","6","31952087-31959110","Predicted intracellular proteins","Evidence at protein level","HPA007187, HPA007594, HPA046502","Enhanced",NA,"Enhanced","Nucleoplasm<br>Nuclear bodies","Renal cancer:2.70e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 49.4","Expressed in all",NA,NA
"NEMF","FLJ10051, NY-CO-1, SDCCAG1","ENSG00000165525","Nuclear export mediator factor","14","49782083-49853203","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA004160","Uncertain",NA,"Approved","Nucleoplasm<br>Nuclear bodies<br>Cytosol","Renal cancer:2.85e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 46.3","Expressed in all",NA,NA
"NEO1","HsT17534, IGDCC2, NGN, NTN1R2","ENSG00000067141","Neogenin 1","15","73051710-73305206","Cancer-related genes, Plasma proteins, Predicted membrane proteins","Evidence at protein level","CAB009320, HPA027804, HPA027805, HPA027806","Uncertain",NA,"Approved","Nucleoplasm<br>Golgi apparatus<br>Plasma membrane","Renal cancer:4.39e-4 (favourable)","Expressed in all","Mixed",NA,NA,"parathyroid gland: 102.7","Mixed",NA,NA
"NEUROD1","BETA2, BHF-1, bHLHa3, MODY6, NEUROD","ENSG00000162992","Neuronal differentiation 1","2","181673088-181680876","Disease related genes, Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA003278, CAB022450","Approved",NA,NA,NA,"Glioma:6.83e-5 (favourable)","Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 5.9;duodenum: 6.0;small intestine: 4.4;stomach: 4.9","pancreas: 1.8","Cell line enriched",79,"SCLC-21H: 331.4"
"NEUROD6","Atoh2, bHLHa2, Math-2, Nex1, NEX1M","ENSG00000164600","Neuronal differentiation 6","7","31337461-31340894","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA027046, HPA074530","Enhanced","Approved",NA,NA,NA,"Not detected","Tissue enriched",180,"cerebral cortex: 18.0","all non-specific tissues: 0.0","Cell line enriched",71,"SCLC-21H: 7.0"
"NEUROG2","Atoh4, bHLHa8, Math4A, ngn-2, NGN2","ENSG00000178403","Neurogenin 2","4","112513516-112516172","Predicted intracellular proteins, Transcription factors","Evidence at transcript level","CAB012342","Uncertain",NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"testis: 1.5","cerebral cortex: 0.4","Cell line enriched",8,"SH-SY5Y: 216.2"
"NF2","ACN, BANF, merlin, SCH","ENSG00000186575","Neurofibromin 2","22","29603556-29698598","Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA003097, CAB005385","Supported",NA,"Enhanced","Nucleus<br>Plasma membrane<br>Cytosol","Renal cancer:2.89e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 58.7","Expressed in all",NA,NA
"NFASC","FLJ46866, KIAA0756, NF, NRCAML","ENSG00000163531","Neurofascin","1","204828651-205022822","Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA008832","Enhanced",NA,NA,NA,"Renal cancer:2.93e-5 (unfavourable), Pancreatic cancer:3.21e-5 (favourable)","Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 55.7","seminal vesicle: 22.4","Cell line enhanced",NA,"BJ: 23.3;fHDF/TERT166: 39.1;SCLC-21H: 26.9;U-138 MG: 62.0;U-87 MG: 30.5"
"NFATC2","NF-ATP, NFAT1, NFATp","ENSG00000101096","Nuclear factor of activated T-cells 2","20","51386957-51562831","Cancer-related genes, Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA008789, CAB018567, HPA024369","Enhanced",NA,"Supported","Nucleoplasm<br>Cytosol","Renal cancer:1.57e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"gallbladder: 26.8","Cell line enhanced",NA,"HDLM-2: 22.7;HMC-1: 23.5;WM-115: 40.4"
"NFIA","KIAA1439, NFI-L","ENSG00000162599","Nuclear factor I A","1","60865259-61462793","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA006111, HPA008884","Enhanced",NA,"Enhanced","Nucleoplasm","Urothelial cancer:2.03e-4 (unfavourable), Renal cancer:7.01e-4 (favourable), Head and neck cancer:7.30e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 53.8","Cell line enhanced",NA,"AN3-CA: 77.5"
"NFKB2","LYT-10, NF-kB2, p105, p49/p100, p52","ENSG00000077150","Nuclear factor kappa B subunit 2","10","102394110-102402529","Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA008422, CAB022098, HPA023900","Enhanced",NA,"Approved","Nucleoplasm<br>Cytosol","Renal cancer:6.69e-12 (unfavourable), Melanoma:8.45e-5 (favourable), Colorectal cancer:3.86e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"appendix: 70.7","Expressed in all",NA,NA
"NFKBIZ","FLJ34463, INAP, MAIL","ENSG00000144802","NFKB inhibitor zeta","3","101827991-101861022","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA010547, HPA075363","Enhanced",NA,"Supported","Nuclear speckles<br>Cytoplasmic bodies","Renal cancer:4.30e-8 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"bone marrow: 268.5","Cell line enhanced",NA,"BJ hTERT+: 58.3"
"NINJ1","NIN1","ENSG00000131669","Ninjurin 1","9","93121489-93134288","Predicted membrane proteins","Evidence at protein level","HPA045063","Uncertain",NA,NA,NA,NA,"Expressed in all","Expressed in all",NA,NA,"bone marrow: 158.2","Mixed",NA,NA
"NIT1",NA,"ENSG00000158793","Nitrilase 1","1","161118086-161125445","Predicted intracellular proteins","Evidence at protein level","HPA006657","Approved",NA,NA,NA,"Renal cancer:4.21e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 49.9","Expressed in all",NA,NA
"NLGN1","KIAA1070","ENSG00000169760","Neuroligin 1","3","173396284-174286644","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA006572, HPA006680","Approved",NA,"Uncertain","Nuclear bodies<br>Plasma membrane",NA,"Group enriched","Tissue enhanced",NA,"cerebral cortex: 25.4","testis: 12.5","Cell line enhanced",NA,"fHDF/TERT166: 20.1;HUVEC TERT2: 20.7;RH-30: 25.4;WM-115: 26.7"
"NLGN3","ASPGX1, AUTSX1, HNL3, KIAA1480","ENSG00000196338","Neuroligin 3","X","71144831-71171201","Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA003183, HPA004066","Enhanced",NA,"Supported","Golgi apparatus<br>Cell Junctions",NA,"Tissue enriched","Tissue enhanced",NA,"cerebral cortex: 62.2","seminal vesicle: 17.3","Cell line enhanced",NA,"AF22: 6.8;NTERA-2: 5.0;SH-SY5Y: 2.9"
"NLGN4X","HLNX, KIAA1260, NLGN, NLGN4","ENSG00000146938","Neuroligin 4, X-linked","X","5840637-6228863","Disease related genes, Predicted membrane proteins","Evidence at protein level","HPA001651","Approved",NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 20.1","ovary: 12.9","Group enriched",5,"AF22: 51.1;NTERA-2: 42.7"
"NLGN4Y","KIAA0951","ENSG00000165246","Neuroligin 4, Y-linked","Y","14522638-14845650","Predicted membrane proteins, Predicted secreted proteins","Evidence at transcript level","HPA001651","Approved",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"prostate: 11.4;seminal vesicle: 12.5","cerebral cortex: 7.5","Cell line enhanced",NA,"BJ hTERT+: 28.5;fHDF/TERT166: 21.5;HDLM-2: 30.2;hTCEpi: 16.2;U-138 MG: 23.0"
"NLK",NA,"ENSG00000087095","Nemo like kinase","17","28041737-28196381","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA018192, HPA056511","Approved",NA,"Supported","Nucleus<br>Nucleoli<br>Cell Junctions",NA,"Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 52.4","Expressed in all",NA,NA
"NMB","MGC17211, MGC2277, MGC3936","ENSG00000197696","Neuromedin B","15","84655129-84658563","Predicted secreted proteins","Evidence at protein level","CAB019302","Approved",NA,"Approved","Nucleus<br>Vesicles<br>Plasma membrane","Renal cancer:2.25e-4 (unfavourable), Glioma:5.07e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"adipose tissue: 46.2;cerebral cortex: 47.2","thyroid gland: 14.8","Cell line enhanced",NA,"A-431: 46.7"
"NME8","CILD6, NM23-H8, SPTRX2, TXNDC3","ENSG00000086288","NME/NM23 family member 8","7","37848597-37900401","Disease related genes, Predicted intracellular proteins","Evidence at protein level","CAB016416, HPA019259","Supported",NA,NA,NA,NA,"Mixed","Group enriched",14,"bone marrow: 8.2;testis: 18.4","appendix,spleen: 0.9","Cell line enhanced",NA,"HMC-1: 1.1;NB-4: 1.2;NTERA-2: 1.7;THP-1: 1.1;U-937: 4.1"
"NME9","NM23-H9, TXL-2, TXNDC6","ENSG00000181322","NME/NM23 family member 9","3","138261437-138329886","Predicted intracellular proteins","Evidence at protein level","HPA040000, HPA043881","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"fallopian tube: 30.0","testis: 6.7","Mixed",NA,NA
"NMT1","NMT","ENSG00000136448","N-myristoyltransferase 1","17","45051610-45109016","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA022949, HPA022963","Enhanced",NA,"Supported","Plasma membrane<br>Cytosol","Liver cancer:4.94e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 58.6","Expressed in all",NA,NA
"NOL4L","C20orf112, C20orf113, dJ1184F4.2, dJ1184F4.4, DKFZP566G1424","ENSG00000197183","Nucleolar protein 4 like","20","32443059-32585074","Predicted intracellular proteins","Evidence at protein level","HPA041768, HPA043600","Enhanced",NA,"Enhanced","Nucleoplasm","Endometrial cancer:1.01e-4 (unfavourable), Urothelial cancer:2.63e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"testis: 60.2","small intestine: 21.8","Cell line enhanced",NA,"CACO-2: 60.7"
"NOLC1","KIAA0035, NOPP130, NOPP140, P130","ENSG00000166197","Nucleolar and coiled-body phosphoprotein 1","10","102152176-102163871","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB032654, HPA037366, HPA050388","Supported",NA,"Enhanced","Nucleoli","Thyroid cancer:8.25e-5 (unfavourable), Renal cancer:9.19e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 69.2","Expressed in all",NA,NA
"NOMO2","NOMO, PM5","ENSG00000185164","NODAL modulator 2","16","18417325-18562211","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA046697, HPA061174","Approved",NA,NA,NA,NA,"Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 157.3","Expressed in all",NA,NA
"NOMO3",NA,"ENSG00000103226","NODAL modulator 3","16","16232495-16294814","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA046697, HPA061174","Approved",NA,NA,NA,NA,"Mixed","Mixed",NA,NA,"skin: 1.9","Mixed",NA,NA
"NONO","NMT55, NRB54, P54, P54NRB, PPP1R114","ENSG00000147140","Non-POU domain containing, octamer-binding","X","71283192-71301168","Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors","Evidence at protein level","CAB022069, HPA054094, HPA054559","Enhanced",NA,"Enhanced","Nucleoplasm","Endometrial cancer:9.29e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"ovary: 245.9","Expressed in all",NA,NA
"NOP56","NOL5A, SCA36","ENSG00000101361","NOP56 ribonucleoprotein","20","2652145-2658393","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA049918, CAB075757","Enhanced",NA,"Enhanced","Nucleoli fibrillar center","Renal cancer:2.22e-16 (unfavourable), Liver cancer:1.59e-7 (unfavourable), Endometrial cancer:1.24e-4 (unfavourable), Melanoma:6.77e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"fallopian tube: 60.3","Expressed in all",NA,NA
"NOS3","ECNOS, eNOS","ENSG00000164867","Nitric oxide synthase 3","7","150990995-151014588","Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB002168","Enhanced",NA,NA,NA,"Renal cancer:3.63e-4 (unfavourable)","Expressed in all","Tissue enriched",7,"spleen: 71.8","adipose tissue: 10.6","Cell line enhanced",NA,"BEWO: 22.3;HUVEC TERT2: 37.6;TIME: 67.7"
"NOV","CCN3, IGFBP9","ENSG00000136999","Nephroblastoma overexpressed","8","119416306-119424353","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA018449, HPA019684, CAB034423","Enhanced",NA,"Supported","Vesicles",NA,"Expressed in all","Tissue enriched",39,"adrenal gland: 1392.1","prostate: 35.4","Cell line enhanced",NA,"BJ hTERT+: 99.0;U-2197: 116.0"
"NOVA1",NA,"ENSG00000139910","NOVA alternative splicing regulator 1","14","26443093-26597754","Predicted intracellular proteins","Evidence at protein level","HPA004155","Uncertain",NA,"Supported","Nucleus<br>Nucleoli",NA,"Tissue enriched","Tissue enhanced",NA,"cerebral cortex: 62.2","breast: 31.8","Cell line enhanced",NA,"AF22: 40.2;HAP1: 20.8"
"NOXRED1","C14orf148, FLJ32809","ENSG00000165555","NADP dependent oxidoreductase domain containing 1","14","77394021-77423517","Predicted intracellular proteins","Evidence at transcript level","HPA055658","Approved",NA,NA,NA,NA,"Mixed","Tissue enriched",7,"testis: 11.7","thyroid gland: 1.6","Not detected",NA,NA
"NPAS3","bHLHe12, MOP6, PASD6","ENSG00000151322","Neuronal PAS domain protein 3","14","32934933-33804176","Disease related genes, Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA002892","Enhanced",NA,"Approved","Nucleoplasm",NA,"Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 24.9","cervix, uterine: 10.1","Group enriched",8,"AF22: 9.3;U-266/70: 17.8;U-266/84: 5.0"
"NPAS4","bHLHe79, Le-PAS, NXF, PASD10","ENSG00000174576","Neuronal PAS domain protein 4","11","66421004-66426707","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA039255","Uncertain",NA,NA,NA,NA,"Not detected","Tissue enhanced",NA,"cerebral cortex: 4.1;endometrium: 1.9","smooth muscle: 1.6","Not detected",NA,NA
"NPHP4","KIAA0673, POC10, SLSN4","ENSG00000131697","Nephrocystin 4","1","5862811-5992473","Disease related genes, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA065526","Approved",NA,NA,NA,NA,"Mixed","Mixed",NA,NA,"fallopian tube: 12.5","Mixed",NA,NA
"NPIPA1","morpheus, NPIP","ENSG00000183426","Nuclear pore complex interacting protein family member A1","16","14922802-14952060","Predicted intracellular proteins, Predicted membrane proteins, Transporters","Evidence at protein level","HPA053611","Supported",NA,"Approved","Nucleoplasm",NA,"Mixed","Mixed",NA,NA,"ovary: 68.6","Mixed",NA,NA
"NPIPA2",NA,"ENSG00000254852","Nuclear pore complex interacting protein family member A2","16","14748066-14765413","Predicted membrane proteins","Evidence at protein level","HPA053611","Approved",NA,"Approved","Nucleoplasm",NA,"Not detected","Tissue enhanced",NA,"testis: 3.6","cerebral cortex: 1.8","Cell line enhanced",NA,"BEWO: 6.5"
"NPIPA3",NA,"ENSG00000224712","Nuclear pore complex interacting protein family member A3","16","14708944-14726338","Predicted membrane proteins","Evidence at protein level","HPA053611","Approved",NA,"Approved","Nucleoplasm",NA,"Mixed","Mixed",NA,NA,"parathyroid gland: 4.3","Cell line enhanced",NA,"NB-4: 6.7;SK-MEL-30: 11.7"
"NPIPA5",NA,"ENSG00000183793","Nuclear pore complex interacting protein family member A5","16","15363624-15381047","Predicted membrane proteins","Evidence at protein level","HPA053611","Approved",NA,"Approved","Nucleoplasm",NA,"Mixed","Mixed",NA,NA,"testis: 17.2","Mixed",NA,NA
"NPIPA7",NA,"ENSG00000214967","Nuclear pore complex interacting protein family member A7","16","16379055-16393954","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA053611","Approved",NA,"Approved","Nucleoplasm",NA,"Not detected","Expressed in all",NA,NA,"parathyroid gland: 48.8","Expressed in all",NA,NA
"NPIPA8","LCR16a9","ENSG00000214940","Nuclear pore complex interacting protein family member A8","16","18317942-18336736","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA053611","Approved",NA,"Approved","Nucleoplasm",NA,"Not detected","Mixed",NA,NA,"cerebral cortex: 21.8","Cell line enhanced",NA,"EFO-21: 55.7;HMC-1: 196.9;SCLC-21H: 63.6"
"NPIPB11",NA,"ENSG00000254206","Nuclear pore complex interacting protein family member B11","16","29381354-29404029","Predicted membrane proteins","Evidence at protein level","HPA053611","Approved",NA,"Approved","Nucleoplasm",NA,"Mixed","Mixed",NA,NA,"skin: 8.1","Mixed",NA,NA
"NPIPB12",NA,"ENSG00000169203","Nuclear pore complex interacting protein family, member B12","16","29483642-29505999","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA053611","Approved",NA,"Approved","Nucleoplasm",NA,"Not detected","Expressed in all",NA,NA,"skin: 133.9","Expressed in all",NA,NA
"NPIPB13",NA,"ENSG00000198064","Nuclear pore complex interacting protein family, member B13","16","30222937-30254510","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA053611","Approved",NA,"Approved","Nucleoplasm",NA,"Not detected","Mixed",NA,NA,"skin: 9.1","Mixed",NA,NA
"NPIPB15","LOC440348, NPIPL2","ENSG00000196436","Nuclear pore complex interacting protein family member B15","16","74377878-74392080","Predicted membrane proteins","Evidence at protein level","HPA011188, HPA053611","Supported",NA,"Approved","Nucleoplasm",NA,"Expressed in all","Tissue enhanced",NA,"testis: 39.2","rectum: 13.2","Cell line enhanced",NA,"T-47d: 11.2"
"NPIPB2",NA,"ENSG00000234719","Nuclear pore complex interacting protein family, member B2","16","11927373-11976643","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA053611","Supported",NA,"Approved","Nucleoplasm",NA,"Mixed","Tissue enhanced",NA,"testis: 14.8","parathyroid gland: 8.8","Cell line enhanced",NA,"RPMI-8226: 10.3;U-266/70: 19.3"
"NPIPB3","KIAA0220, NPIPL3","ENSG00000169246","Nuclear pore complex interacting protein family member B3","16","21402237-21448567","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA053611","Approved",NA,"Approved","Nucleoplasm",NA,"Mixed","Expressed in all",NA,NA,"skin: 189.3","Expressed in all",NA,NA
"NPIPB4",NA,"ENSG00000185864","Nuclear pore complex interacting protein family member B4","16","21834569-21880827","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA053611","Approved",NA,"Approved","Nucleoplasm",NA,"Mixed","Expressed in all",NA,NA,"skin: 124.6","Expressed in all",NA,NA
"NPIPB5",NA,"ENSG00000243716","Nuclear pore complex interacting protein family member B5","16","22479121-22536521","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA053611","Approved",NA,"Approved","Nucleoplasm",NA,"Mixed","Expressed in all",NA,NA,"skin: 261.4","Expressed in all",NA,NA
"NPIPB6",NA,"ENSG00000198156","Nuclear pore complex interacting protein family member B6","16","28342555-28363508","Predicted membrane proteins","Evidence at protein level","HPA011188, HPA053611","Approved",NA,"Approved","Nucleoplasm",NA,"Not detected","Tissue enriched",24,"testis: 54.8","skin: 2.3","Mixed",NA,NA
"NPIPB7","LOC440350, NPIPL1","ENSG00000233232","Nuclear pore complex interacting protein family member B7","16","28456372-28471175","Predicted membrane proteins","Evidence at protein level","HPA011188, HPA053611","Approved",NA,"Approved","Nucleoplasm",NA,"Not detected","Tissue enriched",32,"testis: 15.3","skin: 0.4","Cell line enhanced",NA,"BEWO: 1.7"
"NPIPB8",NA,"ENSG00000255524","Nuclear pore complex interacting protein family member B8","16","28637654-28658682","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA011188, HPA053611","Uncertain",NA,"Approved","Nucleoplasm",NA,"Not detected","Tissue enriched",12,"testis: 12.8","small intestine: 1.1","Cell line enriched",23,"hTCEpi: 15.2"
"NPIPB9",NA,"ENSG00000196993","Nuclear pore complex interacting protein family member B9","16","28751787-28772807","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA011188, HPA053611","Approved",NA,"Approved","Nucleoplasm",NA,"Not detected","Tissue enriched",8,"testis: 14.5","skin: 1.9","Cell line enhanced",NA,"hTCEpi: 3.1"
"NR4A2","HZF-3, NOT, NURR1, RNR1, TINUR","ENSG00000153234","Nuclear receptor subfamily 4 group A member 2","2","156324432-156342348","Cancer-related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA000543, CAB010481","Uncertain",NA,"Supported","Nuclear speckles",NA,"Expressed in all","Tissue enhanced",NA,"adrenal gland: 174.3","ovary: 95.8","Cell line enhanced",NA,"HeLa: 10.1;HMC-1: 9.6;U-266/70: 11.3"
"NRCAM","Bravo, KIAA0343","ENSG00000091129","Neuronal cell adhesion molecule","7","108147623-108456717","Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA012606","Approved",NA,NA,NA,NA,"Tissue enriched","Tissue enhanced",NA,"cerebral cortex: 180.4","adrenal gland: 49.5","Cell line enhanced",NA,"A549: 90.2;AF22: 93.7;EFO-21: 165.3;HMC-1: 165.2;SH-SY5Y: 122.8"
"NRXN3","C14orf60, KIAA0743","ENSG00000021645","Neurexin 3","14","78170373-79868290","Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA002727","Approved",NA,NA,NA,"Renal cancer:1.83e-7 (favourable)","Mixed","Tissue enhanced",NA,"cerebral cortex: 43.0;smooth muscle: 28.9","seminal vesicle: 15.3","Cell line enhanced",NA,"BJ hTERT+ SV40 Large T+: 8.7;RT4: 19.0"
"NSD3","FLJ20353, KMT3F, WHISTLE, WHSC1L1","ENSG00000147548","Nuclear receptor binding SET domain protein 3","8","38269697-38382272","Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA005659, CAB013721, HPA018893","Uncertain",NA,"Approved","Nucleoplasm<br>Mitochondria","Pancreatic cancer:7.48e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 47.8","Expressed in all",NA,NA
"NSDHL","H105e3, SDR31E1, XAP104","ENSG00000147383","NAD(P) dependent steroid dehydrogenase-like","X","152830967-152869729","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA000248, HPA000571","Enhanced",NA,"Enhanced","Endoplasmic reticulum<br>Lipid droplets","Renal cancer:6.09e-5 (favourable), Liver cancer:5.04e-4 (unfavourable), Cervical cancer:5.65e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"epididymis: 54.1","Expressed in all",NA,NA
"NSF","SKD2","ENSG00000073969","N-ethylmaleimide sensitive factor, vesicle fusing ATPase","17","46590669-46757464","Enzymes, Predicted intracellular proteins, Transporters","Evidence at protein level","HPA003154, CAB009324, CAB013645, HPA071089","Enhanced",NA,"Supported","Cytosol",NA,"Expressed in all","Tissue enriched",5,"cerebral cortex: 134.3","parathyroid gland: 25.6","Mixed",NA,NA
"NSFL1C","dJ776F14.1, p47, UBX1, UBXD10, UBXN2C","ENSG00000088833","NSFL1 cofactor","20","1442162-1473842","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA047108, HPA050628","Enhanced",NA,"Enhanced","Nucleoplasm<br>Plasma membrane<br>Cytosol","Liver cancer:1.29e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"fallopian tube: 35.4","Expressed in all",NA,NA
"NTHL1","NTH1, OCTS3","ENSG00000065057","Nth like DNA glycosylase 1","16","2039815-2047866","Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","CAB025152","Supported",NA,NA,NA,NA,"Expressed in all","Expressed in all",NA,NA,"fallopian tube: 21.3","Expressed in all",NA,NA
"NTM","HNT, IGLON2, NTRI","ENSG00000182667","Neurotrimin","11","131370478-132336822","Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB024875","Enhanced",NA,NA,NA,"Renal cancer:1.10e-8 (unfavourable)","Mixed","Tissue enhanced",NA,"cerebral cortex: 116.0","lung: 39.1","Cell line enhanced",NA,"LHCN-M2: 102.1;U-2 OS: 86.6;WM-115: 164.5"
"NTN1","NTN1L","ENSG00000065320","Netrin 1","17","9021542-9244000","Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA056419","Approved",NA,NA,NA,NA,"Mixed","Mixed",NA,NA,"esophagus: 21.2","Cell line enhanced",NA,"BEWO: 26.7;T-47d: 15.6;U-2 OS: 15.2;U-251 MG: 18.3;WM-115: 12.7"
"NTRK1","MTC, TRK, TRKA","ENSG00000198400","Neurotrophic receptor tyrosine kinase 1","1","156815640-156881850","Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins","Evidence at protein level","CAB004606, HPA035799, HPA076570","Approved",NA,"Uncertain","Vesicles<br>Cytosol",NA,"Tissue enhanced","Tissue enriched",6,"adrenal gland: 9.5","testis: 1.6","Cell line enhanced",NA,"HDLM-2: 10.4;HEL: 11.9;HMC-1: 69.1;SH-SY5Y: 19.1"
"NUDC","NudC","ENSG00000090273","Nuclear distribution C, dynein complex regulator","1","26900238-26946862","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA027183, HPA028105","Enhanced",NA,"Enhanced","Cytosol","Liver cancer:1.21e-6 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"fallopian tube: 150.6","Expressed in all",NA,NA
"NUP153","HNUP153","ENSG00000124789","Nucleoporin 153","6","17615035-17706834","Predicted intracellular proteins, Transporters","Evidence at protein level","HPA027896, HPA027897, HPA027898","Enhanced",NA,"Enhanced","Nuclear membrane",NA,"Expressed in all","Expressed in all",NA,NA,"testis: 53.6","Expressed in all",NA,NA
"NUP62","DKFZp547L134, FLJ20822, FLJ43869, IBSN, MGC841, p62, SNDI","ENSG00000213024","Nucleoporin 62","19","49906825-49929763","Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters","Evidence at protein level","HPA005435, CAB020724","Enhanced",NA,"Supported","Nucleus<br>Nuclear membrane","Renal cancer:5.71e-12 (unfavourable), Liver cancer:2.50e-7 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 76.9","Expressed in all",NA,NA
"NUP88","MGC8530","ENSG00000108559","Nucleoporin 88","17","5360963-5420160","Plasma proteins, Predicted intracellular proteins, Transporters","Evidence at protein level","CAB002209, HPA021816","Approved",NA,"Supported","Nucleoplasm",NA,"Expressed in all","Expressed in all",NA,NA,"testis: 94.6","Expressed in all",NA,NA
"NUSAP1","ANKT, BM037, FLJ13421, LNP, NuSAP1, PRO0310p1, Q0310, SAPL","ENSG00000137804","Nucleolar and spindle associated protein 1","15","41332694-41381050","Predicted intracellular proteins","Evidence at protein level","HPA042904, HPA074847","Enhanced",NA,"Enhanced","Nucleus<br>Nucleoli fibrillar center","Renal cancer:6.82e-14 (unfavourable), Pancreatic cancer:6.27e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"bone marrow: 75.3","lymph node: 57.2","Expressed in all",NA,NA
"NXF2","CT39, TAPL-2","ENSG00000269405","Nuclear RNA export factor 2","X","102247161-102326719","Predicted intracellular proteins","Evidence at protein level","HPA002079","Uncertain",NA,NA,NA,NA,"Not detected","Group enriched",21,"epididymis: 18.6;testis: 23.3","fallopian tube: 0.9","Cell line enriched",38,"U-266/84: 24.8"
"NXF2B","bA353J17.1","ENSG00000269437","Nuclear RNA export factor 2B","X","102360395-102463274","Predicted intracellular proteins","Evidence at protein level","HPA002079","Uncertain",NA,NA,NA,NA,"Not detected","Group enriched",6,"epididymis: 19.1;testis: 4.9","fallopian tube: 2.1","Cell line enriched",30,"U-266/84: 25.0"
"NXF5",NA,"ENSG00000126952","Nuclear RNA export factor 5","X","101832112-101857577","Disease related genes, Predicted intracellular proteins","Evidence at transcript level","HPA002079","Uncertain",NA,NA,NA,NA,"Not detected","Not detected",NA,NA,"cerebral cortex,epididymis,spleen: 0.1","Not detected",NA,NA
"NXPH1",NA,"ENSG00000122584","Neurexophilin 1","7","8433955-8752963","Predicted intracellular proteins, Predicted secreted proteins","Evidence at transcript level","HPA020062","Uncertain",NA,NA,NA,NA,"Group enriched","Group enriched",81,"adrenal gland: 52.1;cerebral cortex: 47.2","breast: 0.6","Cell line enhanced",NA,"Karpas-707: 7.7;SCLC-21H: 1.3;WM-115: 3.3"
"OAS2",NA,"ENSG00000111335","2'-5'-oligoadenylate synthetase 2","12","112978395-113011723","Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB024984, HPA045947","Approved",NA,"Approved","Nucleoplasm<br>Cytosol","Renal cancer:4.31e-6 (unfavourable), Pancreatic cancer:4.63e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"spleen: 59.7","Cell line enhanced",NA,"BJ hTERT+ SV40 Large T+: 292.1;BJ hTERT+ SV40 Large T+ RasG12V: 247.3;SK-MEL-30: 98.7"
"ODF3","CT135, hSHIPPO, SHIPPO1","ENSG00000177947","Outer dense fiber of sperm tails 3","11","196738-200261","Predicted intracellular proteins","Evidence at protein level","HPA038919, HPA039241","Enhanced",NA,NA,NA,NA,"Not detected","Tissue enriched",94,"testis: 9.4","all non-specific tissues: 0.0","Not detected",NA,NA
"OLAH","FLJ11106, SAST, THEDC1","ENSG00000152463","Oleoyl-ACP hydrolase","10","15032227-15073852","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA037947, HPA037948","Enhanced",NA,NA,NA,NA,"Group enriched","Tissue enriched",7,"testis: 46.0","breast: 6.2","Cell line enhanced",NA,"hTCEpi: 3.3;LHCN-M2: 3.0;SK-BR-3: 4.2"
"OPA1","FLJ12460, KIAA0567, MGM1, NPG, NTG","ENSG00000198836","OPA1, mitochondrial dynamin like GTPase","3","193593144-193697823","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters","Evidence at protein level","HPA036926, HPA036927","Enhanced",NA,"Supported","Nucleoplasm<br>Mitochondria","Pancreatic cancer:8.44e-5 (unfavourable), Renal cancer:1.84e-4 (favourable), Endometrial cancer:8.61e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 56.2","Expressed in all",NA,NA
"OPN1SW","BCP, BOP, CBT","ENSG00000128617","Opsin 1, short wave sensitive","7","128772491-128775790","Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins","Evidence at protein level","HPA013562, HPA014083","Enhanced",NA,NA,NA,"Renal cancer:2.26e-8 (unfavourable), Stomach cancer:5.98e-8 (unfavourable), Liver cancer:8.50e-5 (unfavourable), Urothelial cancer:9.33e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"heart muscle: 6.7","Cell line enhanced",NA,"U-87 MG: 64.7"
"OPRD1",NA,"ENSG00000116329","Opioid receptor delta 1","1","28812142-28871267","FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins","Evidence at protein level","HPA070831","Approved",NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 2.6","adrenal gland: 0.8","Group enriched",12,"RH-30: 15.8;SCLC-21H: 7.6;SH-SY5Y: 6.9;WM-115: 21.7"
"OR2K2","HSHTPCRH06, HTPCRH06, OR2AR1P","ENSG00000171133","Olfactory receptor family 2 subfamily K member 2","9","111327483-111328520","G-protein coupled receptors, Predicted membrane proteins","Evidence at transcript level","HPA024261","Uncertain",NA,NA,NA,NA,"Not detected","Not detected",NA,NA,"testis: 0.3","Not detected",NA,NA
"OR4N4",NA,"ENSG00000183706","Olfactory receptor family 4 subfamily N member 4","15","22094431-22095556","G-protein coupled receptors, Predicted membrane proteins","Evidence at transcript level","HPA057442","Uncertain",NA,"Uncertain","Centrosome",NA,"Not detected","Tissue enriched",103,"testis: 10.4","cervix, uterine: 0.1","Not detected",NA,NA
"OR51D1","OR51D1Q","ENSG00000197428","Olfactory receptor family 51 subfamily D member 1","11","4639715-4640838","G-protein coupled receptors, Predicted membrane proteins","Evidence at transcript level","HPA061240","Uncertain",NA,NA,NA,NA,"Not detected","Not detected",NA,NA,"all non-specific tissues: 0.0","Not detected",NA,NA
"OR8D1","OR8D3, OST004","ENSG00000196341","Olfactory receptor family 8 subfamily D member 1","11","124309812-124310837","G-protein coupled receptors, Predicted membrane proteins","Evidence at transcript level","HPA059510","Uncertain",NA,NA,NA,NA,"Not detected","Tissue enriched",13,"testis: 1.3","all non-specific tissues: 0.0","Not detected",NA,NA
"ORC1","HSORC1, ORC1L, PARC1","ENSG00000085840","Origin recognition complex subunit 1","1","52372829-52404459","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA027450","Approved",NA,"Approved","Nucleus<br>Plasma membrane<br>Cytosol","Colorectal cancer:1.74e-5 (favourable), Liver cancer:3.22e-5 (unfavourable), Melanoma:3.69e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"bone marrow: 17.9","lymph node: 7.9","Mixed",NA,NA
"ORC4","HsORC4, ORC4L, Orc4p","ENSG00000115947","Origin recognition complex subunit 4","2","147930397-148021604","Disease related genes, Predicted intracellular proteins","Evidence at protein level","CAB015124, HPA064562","Approved",NA,"Supported","Nucleus<br>Nucleoli","Liver cancer:4.98e-8 (unfavourable), Renal cancer:4.10e-6 (favourable), Endometrial cancer:7.27e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 28.5","Expressed in all",NA,NA
"OTC",NA,"ENSG00000036473","Ornithine carbamoyltransferase","X","38352545-38421450","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA000243, HPA000570","Enhanced",NA,"Supported","Mitochondria",NA,"Tissue enriched","Group enriched",26,"duodenum: 114.4;liver: 195.4;small intestine: 96.9","colon: 5.3","Not detected",NA,NA
"OTX1",NA,"ENSG00000115507","Orthodenticle homeobox 1","2","63050057-63057836","Predicted intracellular proteins, Transcription factors","Evidence at protein level","CAB012341, HPA052122","Approved",NA,"Uncertain","Nuclear speckles<br>Cytosol",NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 1.7;skin: 6.1","prostate: 1.0","Cell line enriched",6,"THP-1: 35.9"
"OVOL2","bA504H3.3, CHED, CHED1, HOVO2, ZNF339","ENSG00000125850","Ovo like zinc finger 2","20","17956979-18059188","Disease related genes, Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA038531","Uncertain",NA,"Approved","Nucleoplasm<br>Cytosol",NA,"Mixed","Tissue enhanced",NA,"stomach: 8.0","colon: 3.5","Cell line enhanced",NA,"A-431: 5.2;CAPAN-2: 6.7;HaCaT: 5.0;SCLC-21H: 10.2;SK-BR-3: 4.4"
"OXSM","CEM1, FASN2D, FLJ20604, KS","ENSG00000151093","3-oxoacyl-ACP synthase, mitochondrial","3","25782917-25794534","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA021293, HPA021300, HPA021337","Enhanced",NA,"Approved","Mitochondria<br>Cytosol","Renal cancer:4.18e-9 (favourable), Colorectal cancer:1.35e-4 (favourable), Endometrial cancer:5.51e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 17.4","Mixed",NA,NA
"P2RY10","P2Y10","ENSG00000078589","Purinergic receptor P2Y10","X","78945332-78961954","G-protein coupled receptors, Predicted membrane proteins","Evidence at protein level","HPA036757, HPA065766","Enhanced",NA,NA,NA,"Renal cancer:3.63e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"lymph node: 33.1;spleen: 22.6;tonsil: 24.0","appendix: 19.4","Group enriched",5,"Karpas-707: 90.1;U-266/70: 20.1"
"P2RY13","FKSG77, GPR86, GPR94, P2Y13","ENSG00000181631","Purinergic receptor P2Y13","3","151326312-151329548","G-protein coupled receptors, Predicted membrane proteins","Evidence at protein level","HPA049047","Enhanced",NA,NA,NA,NA,"Expressed in all","Tissue enhanced",NA,"spleen: 51.2","appendix: 27.9","Not detected",NA,NA
"P2RY8","P2Y8","ENSG00000182162","Purinergic receptor P2Y8","X","1462572-1537107","Cancer-related genes, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA003631","Enhanced",NA,NA,NA,"Head and neck cancer:7.80e-5 (favourable), Liver cancer:1.73e-4 (favourable), Pancreatic cancer:6.54e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"lymph node: 47.6","tonsil: 31.3","Cell line enhanced",NA,"Daudi: 87.1;U-266/70: 75.0;U-698: 136.4"
"P4HA2","C-P4Halpha(II)","ENSG00000072682","Prolyl 4-hydroxylase subunit alpha 2","5","132191838-132295315","Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins","Evidence at protein level","HPA016997, HPA027824, CAB062557","Enhanced",NA,"Enhanced","Endoplasmic reticulum<br>Vesicles","Renal cancer:2.77e-7 (unfavourable), Cervical cancer:1.24e-5 (unfavourable), Urothelial cancer:3.12e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"epididymis: 95.3","Mixed",NA,NA
"P4HTM","EGLN4, FLJ20262, HIFPH4, P4H-TM, PH-4, PH4, PHD4","ENSG00000178467","Prolyl 4-hydroxylase, transmembrane","3","48989886-49007154","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA007199","Supported",NA,"Uncertain","Vesicles<br>Cytosol","Renal cancer:3.28e-5 (favourable), Endometrial cancer:8.18e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"fallopian tube: 50.0","Mixed",NA,NA
"PABPC1L2B","RBM32B","ENSG00000184388","Poly(A) binding protein cytoplasmic 1 like 2B","X","73003517-73005713","Predicted intracellular proteins","Evidence at transcript level","HPA041573","Approved",NA,NA,NA,NA,"Tissue enriched","Group enriched",5,"cerebral cortex: 8.7;prostate: 4.6","testis: 1.2","Cell line enhanced",NA,"NTERA-2: 1.6"
"PABPC5","PABP5","ENSG00000174740","Poly(A) binding protein cytoplasmic 5","X","91434595-91438584","Predicted intracellular proteins","Evidence at transcript level","HPA000164, HPA000165","Approved",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"ovary: 13.4","adrenal gland: 9.6","Cell line enhanced",NA,"AF22: 6.8;RH-30: 8.1"
"PACSIN2","SDPII","ENSG00000100266","Protein kinase C and casein kinase substrate in neurons 2","22","42835412-43015145","Predicted intracellular proteins","Evidence at protein level","HPA049854, HPA056520","Enhanced",NA,"Supported","Nuclear speckles<br>Vesicles<br>Plasma membrane<br>Cytosol","Renal cancer:1.09e-13 (favourable), Liver cancer:7.33e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"adrenal gland: 95.3","Expressed in all",NA,NA
"PACSIN3","SDPIII","ENSG00000165912","Protein kinase C and casein kinase substrate in neurons 3","11","47177525-47186443","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA039480, HPA043904","Approved","Approved","Supported","Plasma membrane<br>Cytosol","Ovarian cancer:2.09e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"skeletal muscle: 164.2","heart muscle: 93.6","Mixed",NA,NA
"PAEP","GD, GdA, GdF, GdS, MGC138509, MGC142288, PAEG, PEP, PP14","ENSG00000122133","Progestagen associated endometrial protein","9","135561756-135566955","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB016762, HPA020108, HPA029473","Enhanced",NA,NA,NA,"Renal cancer:0.00e+0 (unfavourable), Liver cancer:6.61e-6 (unfavourable), Stomach cancer:5.46e-4 (unfavourable)","Tissue enriched","Tissue enriched",7,"endometrium: 437.0","seminal vesicle: 61.5","Cell line enriched",6,"SK-MEL-30: 16.7"
"PAFAH2","HSD-PLA2","ENSG00000158006","Platelet activating factor acetylhydrolase 2","1","25959767-25998157","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA018157","Approved",NA,NA,NA,"Renal cancer:0.00e+0 (favourable), Endometrial cancer:3.28e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 29.1","Expressed in all",NA,NA
"PAH","PH","ENSG00000171759","Phenylalanine hydroxylase","12","102836885-102958410","Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins","Evidence at protein level","HPA028407, HPA031642","Enhanced",NA,"Approved","Endoplasmic reticulum<br>Vesicles","Liver cancer:4.30e-4 (favourable)","Tissue enriched","Tissue enhanced",NA,"kidney: 504.6;liver: 722.4","gallbladder: 125.9","Cell line enriched",26,"Hep G2: 161.3"
"PAICS","ADE2H1, AIRC, PAIS","ENSG00000128050","Phosphoribosylaminoimidazole carboxylase and phosphoribosylaminoimidazolesuccinocarboxamide synthase","4","56435741-56464579","Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA035895, HPA041538","Uncertain",NA,"Approved","Cytosol","Renal cancer:5.85e-5 (unfavourable), Liver cancer:1.50e-4 (unfavourable), Thyroid cancer:2.41e-4 (unfavourable), Ovarian cancer:8.44e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 74.0","Expressed in all",NA,NA
"PAK5","KIAA1264, PAK7","ENSG00000101349","P21 (RAC1) activated kinase 5","20","9537389-9839041","Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins","Evidence at protein level","HPA020444","Approved",NA,"Approved","Nucleoplasm",NA,"Mixed","Tissue enriched",5,"cerebral cortex: 13.4","adrenal gland: 2.6","Group enriched",10,"SCLC-21H: 5.6;SH-SY5Y: 1.8"
"PALD1","KIAA1274, PALD","ENSG00000107719","Phosphatase domain containing, paladin 1","10","70478821-70568449","Predicted membrane proteins","Evidence at protein level","HPA015696, HPA017343","Uncertain",NA,NA,NA,NA,"Expressed in all","Mixed",NA,NA,"lung: 15.0","Cell line enhanced",NA,"AN3-CA: 20.7;Daudi: 19.8;RPMI-8226: 23.0"
"PAPD7","LAK-1, POLK, POLS, TRF4, TRF4-1","ENSG00000112941","Poly(A) RNA polymerase D7, non-canonical","5","6713007-6757048","Enzymes, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA045487, HPA046742","Enhanced",NA,"Supported","Nucleoplasm<br>Nuclear membrane<br>Golgi apparatus","Renal cancer:7.99e-5 (unfavourable), Urothelial cancer:8.55e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 19.1","Expressed in all",NA,NA
"PARK2","AR-JP, parkin, PDJ","ENSG00000185345","Parkin RBR E3 ubiquitin protein ligase","6","161347420-162727771","Disease related genes, Predicted intracellular proteins","Evidence at protein level","CAB016257, HPA036012","Enhanced",NA,"Supported","Nuclear speckles<br>Cytosol","Renal cancer:6.75e-12 (favourable)","Mixed","Mixed",NA,NA,"cerebral cortex: 13.8","Cell line enhanced",NA,"HEL: 4.7;Karpas-707: 2.3;RPMI-8226: 2.3"
"PARN","DAN","ENSG00000140694","Poly(A)-specific ribonuclease","16","14435701-14632728","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA006314, CAB011673, HPA012010","Enhanced",NA,"Approved","Nucleoli<br>Nuclear speckles","Head and neck cancer:4.64e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 28.0","Expressed in all",NA,NA
"PASD1","CT63","ENSG00000166049","PAS domain containing repressor 1","X","151563622-151676739","Predicted intracellular proteins","Evidence at protein level","HPA011122, HPA011152","Enhanced",NA,"Supported","Nuclear speckles",NA,"Mixed","Tissue enriched",298,"testis: 29.8","all non-specific tissues: 0.0","Group enriched",7,"BEWO: 33.0;HMC-1: 47.7;U-266/84: 19.0"
"PAX8",NA,"ENSG00000125618","Paired box 8","2","113215997-113278950","Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA030062, CAB055097, CAB061888, HPA064554","Enhanced",NA,"Enhanced","Nucleoplasm","Endometrial cancer:1.75e-5 (unfavourable)","Group enriched","Tissue enriched",10,"thyroid gland: 644.0","kidney: 65.2","Group enriched",8,"EFO-21: 76.3;RPTEC TERT1: 144.9"
"PBRM1","BAF180, PB1","ENSG00000163939","Polybromo 1","3","52545352-52685917","Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA015629, HPA059373","Uncertain",NA,"Supported","Nucleoplasm",NA,"Expressed in all","Expressed in all",NA,NA,"thyroid gland: 44.7","Expressed in all",NA,NA
"PCDH10","KIAA1400, OL-PCDH","ENSG00000138650","Protocadherin 10","4","133149315-133208606","Predicted membrane proteins","Evidence at protein level","HPA011220, HPA073462","Approved",NA,"Approved","Nucleus<br>Golgi apparatus<br>Vesicles",NA,"Tissue enhanced","Group enriched",5,"cerebral cortex: 62.0;placenta: 36.7;prostate: 17.6;seminal vesicle: 24.5","adrenal gland: 6.8","Cell line enhanced",NA,"HUVEC TERT2: 23.1;MOLT-4: 19.4;TIME: 45.4;U-138 MG: 14.3"
"PCDH19","EFMR, EIEE9, KIAA1313","ENSG00000165194","Protocadherin 19","X","100291644-100410273","Disease related genes, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA027533","Approved",NA,"Approved","Cytosol",NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 11.3","cervix, uterine: 2.6","Cell line enriched",7,"AF22: 17.7"
"PCDHA4","CNR1, CNRN1, CRNR1, PCDH-ALPHA4","ENSG00000204967","Protocadherin alpha 4","5","140806929-141012344","Predicted membrane proteins","Evidence at protein level","HPA043180, HPA073478","Approved",NA,"Approved","Nucleoplasm<br>Plasma membrane<br>Cytosol",NA,"Not detected","Tissue enhanced",NA,"cerebral cortex: 4.4","gallbladder: 2.5","Cell line enhanced",NA,"A549: 5.9;AF22: 6.1;EFO-21: 5.0;T-47d: 5.1"
"PCDHA5","CNR6, CNRN6, CNRS6, CRNR6, PCDH-ALPHA5","ENSG00000204965","Protocadherin alpha 5","5","140821604-141012344","Predicted membrane proteins","Evidence at transcript level","HPA044557","Approved",NA,NA,NA,NA,"Not detected","Tissue enriched",10,"cerebral cortex: 4.1","endometrium: 0.4","Cell line enhanced",NA,"A549: 1.2;EFO-21: 3.4;T-47d: 3.5;WM-115: 1.4"
"PCDHA6","CNR2, CNRS2, CRNR2, PCDH-ALPHA6","ENSG00000081842","Protocadherin alpha 6","5","140827958-141012344","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA059326, HPA078110","Enhanced",NA,"Approved","Vesicles",NA,"Not detected","Tissue enhanced",NA,"cerebral cortex: 4.8","parathyroid gland: 1.9","Cell line enhanced",NA,"AF22: 2.0;EFO-21: 8.1;U-2 OS: 3.7;WM-115: 5.1"
"PCDHB15","PCDH-BETA15","ENSG00000113248","Protocadherin beta 15","5","141245349-141249365","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA007172, CAB026471, HPA074676","Uncertain",NA,"Approved","Mitochondria",NA,"Mixed","Mixed",NA,NA,"cerebral cortex: 12.7","Cell line enhanced",NA,"AF22: 5.7;LHCN-M2: 4.0;WM-115: 4.7"
"PCDHB2","PCDH-BETA2","ENSG00000112852","Protocadherin beta 2","5","141094578-141098703","Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA007548","Enhanced",NA,"Approved","Nucleoplasm","Urothelial cancer:4.84e-4 (unfavourable), Renal cancer:6.99e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"cerebral cortex: 7.7","testis: 7.5","Cell line enhanced",NA,"AF22: 23.3;AN3-CA: 47.2;EFO-21: 26.8"
"PCDHGA1","PCDH-GAMMA-A1","ENSG00000204956","Protocadherin gamma subfamily A, 1","5","141330571-141512981","Predicted membrane proteins","Evidence at protein level","HPA008755, HPA010580, HPA036547","Uncertain",NA,"Approved","Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol",NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 3.2","testis: 1.3","Cell line enhanced",NA,"LHCN-M2: 3.7;T-47d: 6.9"
"PCDHGA10","PCDH-GAMMA-A10","ENSG00000253846","Protocadherin gamma subfamily A, 10","5","141412987-141512979","Predicted membrane proteins","Evidence at protein level","HPA008755, HPA010580","Uncertain",NA,"Approved","Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol",NA,"Mixed","Tissue enriched",5,"cerebral cortex: 28.0","placenta: 5.1","Cell line enhanced",NA,"AF22: 14.4;T-47d: 18.5"
"PCDHGA11","PCDH-GAMMA-A11","ENSG00000253873","Protocadherin gamma subfamily A, 11","5","141421047-141512979","Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA008755, HPA010580","Uncertain",NA,"Approved","Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol",NA,"Mixed","Mixed",NA,NA,"cerebral cortex,placenta: 3.2","Cell line enhanced",NA,"ASC diff: 16.8;ASC TERT1: 18.5;SK-MEL-30: 16.7;WM-115: 43.4"
"PCDHGA12","CDH21, FIB3, KIAA0588, PCDH-GAMMA-A12","ENSG00000253159","Protocadherin gamma subfamily A, 12","5","141430589-141512979","Plasma proteins, Predicted membrane proteins","Evidence at protein level","HPA008755, HPA010580","Uncertain",NA,"Approved","Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol",NA,"Tissue enhanced","Mixed",NA,NA,"cerebral cortex: 8.1","Cell line enhanced",NA,"BJ: 8.3;BJ hTERT+: 13.2;fHDF/TERT166: 18.9;HSkMC: 12.6"
"PCDHGA2","PCDH-GAMMA-A2","ENSG00000081853","Protocadherin gamma subfamily A, 2","5","141338760-141512979","Plasma proteins, Predicted membrane proteins","Evidence at protein level","HPA008755, HPA010580, HPA038625","Approved",NA,"Approved","Nucleus<br>Nucleoli<br>Vesicles<br>Plasma membrane<br>Cytosol",NA,"Mixed","Mixed",NA,NA,"cerebral cortex: 8.4","Cell line enhanced",NA,"ASC TERT1: 4.3;BJ: 3.0;fHDF/TERT166: 3.3"
"PCDHGA3","PCDH-GAMMA-A3","ENSG00000254245","Protocadherin gamma subfamily A, 3","5","141343829-141512979","Predicted membrane proteins","Evidence at protein level","HPA008755, HPA010580","Uncertain",NA,"Approved","Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol",NA,"Not detected","Tissue enhanced",NA,"cerebral cortex: 6.5","ovary: 3.1","Group enriched",7,"AF22: 7.0;BJ: 2.0;EFO-21: 5.4"
"PCDHGA4","PCDH-GAMMA-A4","ENSG00000262576","Protocadherin gamma subfamily A, 4","5","141355025-141512979","Predicted membrane proteins","Evidence at protein level","HPA008755, HPA010580","Uncertain",NA,"Approved","Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol",NA,"Mixed","Mixed",NA,NA,"cerebral cortex: 5.7","Cell line enhanced",NA,"ASC TERT1: 5.2;U-87 MG: 5.9"
"PCDHGA5","CDH-GAMMA-A5, ME3, PCDH-GAMMA-A5","ENSG00000253485","Protocadherin gamma subfamily A, 5","5","141364232-141512979","Plasma proteins, Predicted membrane proteins","Evidence at protein level","HPA008755, HPA010580","Uncertain",NA,"Approved","Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol",NA,"Tissue enhanced","Mixed",NA,NA,"cerebral cortex: 3.8","Group enriched",6,"ASC diff: 10.8;ASC TERT1: 4.3"
"PCDHGA6","PCDH-GAMMA-A6","ENSG00000253731","Protocadherin gamma subfamily A, 6","5","141373914-141512979","Predicted membrane proteins","Evidence at protein level","HPA008755, HPA010580","Uncertain",NA,"Approved","Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol",NA,"Mixed","Mixed",NA,NA,"endometrium,ovary: 3.8","Cell line enhanced",NA,"SCLC-21H: 11.4;WM-115: 12.0"
"PCDHGA7","PCDH-GAMMA-A7","ENSG00000253537","Protocadherin gamma subfamily A, 7","5","141382739-141512979","Predicted membrane proteins","Evidence at protein level","HPA008755, HPA010580","Uncertain",NA,"Approved","Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol",NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 7.4","thyroid gland: 3.3","Cell line enhanced",NA,"BJ hTERT+: 17.1;SH-SY5Y: 19.7"
"PCDHGA8","KIAA0327, PCDH-GAMMA-A8","ENSG00000253767","Protocadherin gamma subfamily A, 8","5","141390157-141512979","Predicted membrane proteins","Evidence at protein level","HPA008755, HPA010580","Uncertain",NA,"Approved","Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol",NA,"Not detected","Not detected",NA,NA,"thyroid gland: 0.7","Not detected",NA,NA
"PCDHGA9","PCDH-GAMMA-A9","ENSG00000261934","Protocadherin gamma subfamily A, 9","5","141402932-141512979","Predicted membrane proteins","Evidence at protein level","HPA008755, HPA010580","Uncertain",NA,"Approved","Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol",NA,"Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 9.6","endometrium: 4.1","Cell line enhanced",NA,"EFO-21: 3.4;TIME: 3.7;U-87 MG: 5.0"
"PCDHGB1","PCDH-GAMMA-B1","ENSG00000254221","Protocadherin gamma subfamily B, 1","5","141350102-141512979","Predicted membrane proteins","Evidence at protein level","HPA008755, HPA010580, HPA076182","Uncertain",NA,"Approved","Nucleus<br>Vesicles<br>Plasma membrane<br>Focal adhesion sites<br>Midbody<br>Cytosol",NA,"Mixed","Tissue enriched",11,"cerebral cortex: 23.8","endometrium: 2.0","Cell line enhanced",NA,"ASC diff: 8.8;T-47d: 8.1"
"PCDHGB2","PCDH-GAMMA-B2","ENSG00000253910","Protocadherin gamma subfamily B, 2","5","141360042-141512979","Predicted membrane proteins","Evidence at protein level","HPA008755, HPA010580, HPA077526","Uncertain",NA,"Approved","Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol",NA,"Tissue enriched","Mixed",NA,NA,"cerebral cortex: 6.5","Cell line enhanced",NA,"ASC diff: 9.2"
"PCDHGB3","PCDH-GAMMA-B3","ENSG00000262209","Protocadherin gamma subfamily B, 3","5","141370264-141512979","Plasma proteins, Predicted membrane proteins","Evidence at protein level","HPA008755, HPA010580, HPA035823","Uncertain",NA,"Approved","Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol",NA,"Mixed","Mixed",NA,NA,"endometrium: 1.5","Cell line enhanced",NA,"ASC diff: 7.2;ASC TERT1: 5.9;TIME: 4.5"
"PCDHGB4","CDH20, FIB2, PCDH-GAMMA-B4","ENSG00000253953","Protocadherin gamma subfamily B, 4","5","141387698-141512979","Predicted membrane proteins","Evidence at protein level","HPA008755, HPA010580","Uncertain",NA,"Approved","Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol",NA,"Mixed","Mixed",NA,NA,"placenta: 4.3","Cell line enhanced",NA,"BJ hTERT+: 35.5;TIME: 18.0"
"PCDHGB5","PCDH-GAMMA-B5","ENSG00000276547","Protocadherin gamma subfamily B, 5","5","141397987-141512979","Predicted membrane proteins","Evidence at protein level","HPA008755, HPA010580","Uncertain",NA,"Approved","Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol",NA,"Mixed","Tissue enhanced",NA,"parathyroid gland: 19.8","thyroid gland: 7.6","Cell line enhanced",NA,"ASC diff: 45.6;ASC TERT1: 34.8;BJ hTERT+ SV40 Large T+: 27.3;BJ hTERT+ SV40 Large T+ RasG12V: 31.8"
"PCDHGB6","PCDH-GAMMA-B6","ENSG00000253305","Protocadherin gamma subfamily B, 6","5","141408021-141512979","Predicted membrane proteins","Evidence at protein level","HPA008755, HPA010580","Uncertain",NA,"Approved","Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol",NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 20.8","parathyroid gland: 11.9","Cell line enhanced",NA,"AF22: 15.8;EFO-21: 5.1"
"PCDHGB7","ME6, PCDH-GAMMA-B7","ENSG00000254122","Protocadherin gamma subfamily B, 7","5","141417645-141512979","Predicted membrane proteins","Evidence at protein level","HPA008755, HPA010580","Uncertain",NA,"Approved","Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol",NA,"Tissue enhanced","Mixed",NA,NA,"ovary: 10.2","Cell line enhanced",NA,"AN3-CA: 80.7;HSkMC: 19.4"
"PCDHGC3","PC-43, PC43, PCDH-GAMMA-C3, PCDH2","ENSG00000240184","Protocadherin gamma subfamily C, 3","5","141475947-141512979","Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA008755, HPA010580, HPA077289","Approved",NA,"Approved","Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol","Urothelial cancer:6.00e-4 (unfavourable), Ovarian cancer:6.19e-4 (unfavourable), Renal cancer:8.18e-4 (unfavourable)","Group enriched","Tissue enhanced",NA,"cerebral cortex: 376.0","cervix, uterine: 93.8","Cell line enhanced",NA,"U-138 MG: 264.5;WM-115: 404.1"
"PCDHGC4","PCDH-GAMMA-C4","ENSG00000242419","Protocadherin gamma subfamily C, 4","5","141484997-141512979","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA008755, HPA010580","Uncertain",NA,"Approved","Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol",NA,"Tissue enriched","Tissue enriched",11,"cerebral cortex: 16.3","adrenal gland: 1.4","Cell line enhanced",NA,"REH: 8.3;SCLC-21H: 8.7;SH-SY5Y: 15.1"
"PCDHGC5","PCDH-GAMMA-C5","ENSG00000240764","Protocadherin gamma subfamily C, 5","5","141489121-141512979","Predicted membrane proteins","Evidence at protein level","HPA008755, HPA010580, HPA051540","Uncertain",NA,"Approved","Nucleus<br>Nucleoplasm<br>Vesicles<br>Plasma membrane<br>Cytosol",NA,"Group enriched","Tissue enriched",43,"cerebral cortex: 50.6","smooth muscle: 1.1","Cell line enhanced",NA,"U-138 MG: 14.5;U-251 MG: 5.4;U-87 MG: 8.8"
"PCK2","PEPCK, PEPCK2","ENSG00000100889","Phosphoenolpyruvate carboxykinase 2, mitochondrial","14","24094053-24110598","Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","CAB018734, HPA051162, HPA053502","Enhanced",NA,"Enhanced","Mitochondria","Liver cancer:2.81e-4 (favourable)","Expressed in all","Group enriched",6,"duodenum: 367.6;kidney: 192.2;liver: 258.6;small intestine: 276.5","colon: 47.0","Expressed in all",NA,NA
"PCLO","ACZ, DKFZp779G1236, KIAA0559","ENSG00000186472","Piccolo presynaptic cytomatrix protein","7","82754013-83162930","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA015858, HPA029579, CAB079012","Approved","Approved","Approved","Nuclear speckles<br>Plasma membrane",NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 17.4","parathyroid gland: 9.8","Group enriched",36,"REH: 239.6;U-2 OS: 298.6"
"PCNX2","FLJ11383, KIAA0435, PCNXL2","ENSG00000135749","Pecanex homolog 2 (Drosophila)","1","232983435-233295713","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA013815, HPA014427","Uncertain",NA,"Approved","Endoplasmic reticulum","Renal cancer:2.27e-5 (unfavourable)","Mixed","Mixed",NA,NA,"cerebral cortex: 14.0","Mixed",NA,NA
"PCSK1N","BigLEN, PEN, proSAAS, SAAS, SCG8, SgVIII","ENSG00000102109","Proprotein convertase subtilisin/kexin type 1 inhibitor","X","48831094-48835633","Predicted secreted proteins","Evidence at protein level","HPA003925, HPA064734","Enhanced",NA,"Approved","Vesicles","Endometrial cancer:1.15e-4 (unfavourable), Renal cancer:1.36e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 93.6;kidney: 65.7","adrenal gland: 28.5","Cell line enhanced",NA,"HEK 293: 52.2;PC-3: 133.3;SCLC-21H: 66.4;SH-SY5Y: 55.2;SiHa: 53.6;U-266/84: 49.2"
"PCYOX1L","MGC3265","ENSG00000145882","Prenylcysteine oxidase 1 like","5","149358007-149369653","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA037463, HPA038402","Approved",NA,"Approved","Nucleoplasm<br>Mitochondria",NA,"Expressed in all","Tissue enhanced",NA,"parathyroid gland: 21.4","cerebral cortex: 12.5","Mixed",NA,NA
"PCYT1B","CCT-beta, CTB","ENSG00000102230","Phosphate cytidylyltransferase 1, choline, beta","X","24558087-24672677","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA006367","Uncertain",NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 21.9;testis: 17.4","fallopian tube,smooth muscle: 4.7","Cell line enhanced",NA,"AF22: 11.6;CACO-2: 21.4;HEL: 28.7;NTERA-2: 13.3;SCLC-21H: 10.7"
"PDCD1","CD279, hSLE1, PD-1, PD1, SLEB2","ENSG00000188389","Programmed cell death 1","2","241849881-241858908","CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA035981, CAB038418, CAB076386","Enhanced",NA,NA,NA,"Renal cancer:3.48e-7 (unfavourable), Endometrial cancer:9.44e-5 (favourable)","Mixed","Tissue enhanced",NA,"lymph node: 12.0","appendix: 3.3","Group enriched",13,"MOLT-4: 4.6;RPMI-8226: 4.0"
"PDDC1","FLJ34283","ENSG00000177225","Parkinson disease 7 domain containing 1","11","767220-777488","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA008812","Uncertain",NA,"Supported","Nucleoplasm","Renal cancer:3.79e-5 (favourable), Liver cancer:3.98e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 31.7","Expressed in all",NA,NA
"PDE1C","Hcam3","ENSG00000154678","Phosphodiesterase 1C","7","31751179-32299329","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA021751, HPA052375","Uncertain",NA,"Approved","Nucleus",NA,"Tissue enhanced","Tissue enhanced",NA,"heart muscle: 37.2","cerebral cortex: 20.8","Cell line enhanced",NA,"fHDF/TERT166: 114.5;U-251 MG: 66.4;WM-115: 102.6"
"PDE6A","PDEA, RP43","ENSG00000132915","Phosphodiesterase 6A","5","149857955-149944793","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA016970, HPA074677","Enhanced",NA,NA,NA,NA,"Not detected","Tissue enriched",8,"epididymis: 20.2","testis: 2.4","Cell line enhanced",NA,"CACO-2: 2.1"
"PDE8A","HsT19550","ENSG00000073417","Phosphodiesterase 8A","15","84980440-85139145","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA007722","Approved",NA,"Approved","Golgi apparatus",NA,"Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 30.2","Expressed in all",NA,NA
"PDIA3","ERp57, ERp60, ERp61, GRP57, GRP58, HsT17083, P58, PI-PLC","ENSG00000167004","Protein disulfide isomerase family A member 3","15","43746392-43773279","Enzymes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA002645, HPA003230, CAB011199, CAB075744","Enhanced",NA,"Enhanced","Endoplasmic reticulum","Renal cancer:2.11e-8 (unfavourable), Head and neck cancer:8.95e-5 (unfavourable), Endometrial cancer:2.05e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 91.5","Expressed in all",NA,NA
"PDIA5","FLJ30401, PDIR","ENSG00000065485","Protein disulfide isomerase family A member 5","3","123067062-123225227","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA030353, HPA030355","Enhanced",NA,"Supported","Nucleoplasm<br>Nucleoli fibrillar center<br>Golgi apparatus","Renal cancer:8.09e-11 (unfavourable), Endometrial cancer:4.55e-4 (favourable)","Expressed in all","Mixed",NA,NA,"placenta: 70.8","Mixed",NA,NA
"PDIA6","ERp5, P5, TXNDC7","ENSG00000143870","Protein disulfide isomerase family A member 6","2","10783391-10837977","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB034347, HPA034652, HPA034653","Enhanced",NA,"Supported","Endoplasmic reticulum<br>Cytosol","Renal cancer:2.51e-6 (unfavourable), Liver cancer:3.63e-5 (unfavourable), Head and neck cancer:1.20e-4 (unfavourable), Cervical cancer:1.80e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 591.9","Expressed in all",NA,NA
"PDLIM3","ALP","ENSG00000154553","PDZ and LIM domain 3","4","185500660-185535612","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA004749","Enhanced",NA,NA,NA,"Renal cancer:4.97e-7 (unfavourable), Thyroid cancer:2.13e-6 (unfavourable), Liver cancer:7.22e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"skeletal muscle: 1097.6","seminal vesicle: 292.1","Cell line enhanced",NA,"LHCN-M2: 125.9;RH-30: 35.3;U-266/70: 91.6"
"PDS5A","KIAA0648, PIG54, SCC-112","ENSG00000121892","PDS5 cohesin associated factor A","4","39822863-39977956","Predicted intracellular proteins","Evidence at protein level","HPA036661, HPA036662","Enhanced",NA,"Enhanced","Nucleoplasm",NA,"Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 57.4","Expressed in all",NA,NA
"PDS5B","APRIN, AS3, CG008, FLJ23236, KIAA0979","ENSG00000083642","PDS5 cohesin associated factor B","13","32586427-32778019","Predicted intracellular proteins","Evidence at protein level","HPA039513, HPA040015","Supported",NA,"Enhanced","Nucleoplasm",NA,"Expressed in all","Expressed in all",NA,NA,"endometrium: 31.3","Expressed in all",NA,NA
"PEA15","HMAT1, HUMMAT1H, MAT1, MAT1H, PEA-15, PED","ENSG00000162734","Phosphoprotein enriched in astrocytes 15","1","160205337-160215376","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA028356, HPA070820","Enhanced",NA,"Approved","Nucleus<br>Cytosol","Renal cancer:6.53e-7 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 1087.0","Expressed in all",NA,NA
"PEG3","KIAA0287, ZKSCAN22, ZNF904, ZSCAN24","ENSG00000198300","Paternally expressed 3","19","56810083-56840728","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA026070","Approved",NA,"Supported","Nucleoplasm","Thyroid cancer:1.56e-4 (unfavourable)","Tissue enhanced","Tissue enhanced",NA,"ovary: 340.4;placenta: 197.8","adrenal gland: 102.0","Cell line enhanced",NA,"BEWO: 100.6;Hep G2: 150.6;RH-30: 70.4"
"PENK",NA,"ENSG00000181195","Proenkephalin","8","56436674-56446734","Plasma proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA013138, CAB016390","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Group enriched",9,"adrenal gland: 566.0;testis: 208.0","prostate: 41.3","Cell line enhanced",NA,"ASC diff: 10.8;ASC TERT1: 6.5;BJ: 7.7;THP-1: 5.8"
"PER2","KIAA0347","ENSG00000132326","Period circadian clock 2","2","238244038-238290102","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA060510","Enhanced",NA,NA,NA,"Head and neck cancer:2.29e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 22.2","Mixed",NA,NA
"PERM1","C1orf170, MGC13275, Perm1, RP11-54O7.8","ENSG00000187642","PPARGC1 and ESRR induced regulator, muscle 1","1","975204-982093","Predicted intracellular proteins","Evidence at protein level","HPA031711, HPA031712","Enhanced",NA,NA,NA,"Renal cancer:1.95e-4 (unfavourable)","Mixed","Group enriched",15,"heart muscle: 20.7;skeletal muscle: 68.1","esophagus: 3.0","Cell line enhanced",NA,"HaCaT: 1.3;SK-BR-3: 1.2"
"PEX10","RNF69","ENSG00000157911","Peroxisomal biogenesis factor 10","1","2403964-2413797","Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters","Evidence at protein level","HPA049458, HPA049755","Approved",NA,"Approved","Nucleoplasm","Renal cancer:4.16e-6 (favourable), Breast cancer:4.50e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 19.2","Expressed in all",NA,NA
"PEX5L","PEX5R, PXR2, TRIP8b","ENSG00000114757","Peroxisomal biogenesis factor 5 like","3","179794958-180037053","Predicted intracellular proteins","Evidence at protein level","HPA058026","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Group enriched",9,"cerebral cortex: 67.5;parathyroid gland: 94.8","testis: 8.6","Group enriched",5,"HDLM-2: 7.2;MOLT-4: 22.2;RPMI-8226: 15.1;SCLC-21H: 15.0;U-266/70: 12.8"
"PF4","CXCL4, SCYB4","ENSG00000163737","Platelet factor 4","4","73981077-73982124","Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB026008, HPA052485","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Group enriched",5,"bone marrow: 53.7;spleen: 13.4","placenta: 6.5","Cell line enriched",13,"HEL: 37.2"
"PFDN1","PFD1","ENSG00000113068","Prefoldin subunit 1","5","140245039-140303121","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA006499","Approved",NA,"Approved","Nucleoli<br>Plasma membrane<br>Cytosol","Liver cancer:8.81e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 106.3","Expressed in all",NA,NA
"PFKFB2",NA,"ENSG00000123836","6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2","1","207034366-207081024","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA049975, HPA063575","Uncertain",NA,"Enhanced","Nucleus","Renal cancer:3.23e-7 (favourable), Thyroid cancer:8.63e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 86.2","Mixed",NA,NA
"PGLYRP1","PGLYRP, PGRP, PGRP-S, PGRPS, TAG7, TNFSF3L","ENSG00000008438","Peptidoglycan recognition protein 1","19","46019153-46023065","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA045702","Enhanced",NA,NA,NA,NA,"Not detected","Tissue enriched",57,"bone marrow: 421.1","spleen: 7.4","Cell line enhanced",NA,"A549: 2.9"
"PHACTR1","dJ257A7.2, KIAA1733, RPEL1","ENSG00000112137","Phosphatase and actin regulator 1","6","12716805-13290484","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA029755, HPA029756, HPA029757","Enhanced",NA,"Uncertain","Plasma membrane","Renal cancer:5.48e-6 (unfavourable)","Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 26.6","bone marrow: 15.6","Cell line enhanced",NA,"HMC-1: 33.9;U-266/70: 72.3;U-266/84: 46.3"
"PIEZO1","FAM38A, KIAA0233","ENSG00000103335","Piezo type mechanosensitive ion channel component 1","16","88715343-88785211","Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters","Evidence at protein level","HPA047185","Uncertain",NA,NA,NA,"Renal cancer:8.89e-7 (unfavourable), Lung cancer:2.36e-5 (unfavourable), Cervical cancer:2.37e-4 (unfavourable), Ovarian cancer:3.78e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"adipose tissue: 42.0","Expressed in all",NA,NA
"PIGQ","GPI1, hGPI1","ENSG00000007541","Phosphatidylinositol glycan anchor biosynthesis class Q","16","566995-584136","Enzymes, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA039105, HPA039828, HPA061414","Approved",NA,"Approved","Nucleoplasm<br>Golgi apparatus<br>Vesicles","Renal cancer:2.53e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"bone marrow: 17.5","Expressed in all",NA,NA
"PIK3AP1","BCAP, FLJ35564","ENSG00000155629","Phosphoinositide-3-kinase adaptor protein 1","10","96593312-96720514","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB026136, HPA038452","Enhanced",NA,"Approved","Nucleus<br>Plasma membrane<br>Cytosol",NA,"Expressed in all","Tissue enhanced",NA,"spleen: 85.6","lymph node: 72.0","Cell line enhanced",NA,"Daudi: 60.8;REH: 166.9;THP-1: 62.4;U-698: 79.5;U-937: 74.4"
"PIK3CD","p110D","ENSG00000171608","Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta","1","9651732-9729114","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins","Evidence at protein level","CAB015420, HPA044953","Enhanced",NA,"Approved","Vesicles<br>Cytokinetic bridge",NA,"Expressed in all","Tissue enhanced",NA,"lymph node: 56.4","spleen: 51.2","Cell line enhanced",NA,"HDLM-2: 146.7;REH: 64.7;U-937: 63.7"
"PIK3R3","p55","ENSG00000117461","Phosphoinositide-3-kinase regulatory subunit 3","1","46040140-46133036","Cancer-related genes, Predicted intracellular proteins, RAS pathway related proteins","Evidence at protein level","HPA005751, HPA071988","Approved",NA,"Approved","Nucleoplasm<br>Vesicles","Endometrial cancer:1.93e-4 (favourable), Head and neck cancer:3.62e-4 (favourable)","Expressed in all","Mixed",NA,NA,"testis: 46.2","Expressed in all",NA,NA
"PINK1","PARK6","ENSG00000158828","PTEN induced putative kinase 1","1","20633455-20651511","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA001931, CAB026191","Uncertain",NA,NA,NA,"Renal cancer:1.11e-16 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 145.5","Expressed in all",NA,NA
"PINX1","FLJ20565, LPTL, LPTS, MGC8850, PinX1","ENSG00000254093","PIN2/TERF1 interacting, telomerase inhibitor 1","8","10764963-10839884","Predicted intracellular proteins","Evidence at protein level","HPA023139","Uncertain",NA,NA,NA,"Cervical cancer:2.45e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 16.1","Expressed in all",NA,NA
"PIP4K2A","PIP5K2A, PIP5KIIA, PIP5KIIalpha","ENSG00000150867","Phosphatidylinositol-5-phosphate 4-kinase type 2 alpha","10","22534849-22714555","Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA065440, HPA068771","Supported",NA,"Approved","Golgi apparatus<br>Plasma membrane<br>Cytosol","Renal cancer:1.46e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 144.3","Expressed in all",NA,NA
"PIP4K2B","PIP5K2B, PIP5KIIB, PIP5KIIbeta","ENSG00000276293","Phosphatidylinositol-5-phosphate 4-kinase type 2 beta","17","38765689-38800126","Cancer-related genes, Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA047875, HPA062220","Approved",NA,"Supported","Nucleoplasm","Thyroid cancer:1.36e-4 (favourable), Liver cancer:4.54e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 51.6","Expressed in all",NA,NA
"PIRT",NA,"ENSG00000233670","Phosphoinositide interacting regulator of transient receptor potential channels","17","10822475-10838445","Predicted membrane proteins, Transporters","Evidence at transcript level","HPA042337","Uncertain",NA,"Uncertain","Plasma membrane<br>Cytosol",NA,"Tissue enriched","Tissue enhanced",NA,"adrenal gland: 3.1;cerebral cortex: 2.6;rectum: 2.7","colon: 2.1","Not detected",NA,NA
"PITPNC1","RDGB-BETA, RDGBB, RDGBB1","ENSG00000154217","Phosphatidylinositol transfer protein, cytoplasmic 1","17","67377281-67697261","Predicted intracellular proteins","Evidence at protein level","HPA026563, HPA031250","Uncertain",NA,"Approved","Nucleoplasm<br>Cytosol","Head and neck cancer:4.85e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 46.6","Mixed",NA,NA
"PITPNM3","ACKR6, CORD5, NIR1, RDGBA3","ENSG00000091622","PITPNM family member 3","17","6451264-6556494","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA022432, HPA059005","Enhanced",NA,"Approved","Plasma membrane","Head and neck cancer:3.67e-6 (favourable)","Mixed","Tissue enhanced",NA,"spleen: 76.8","ovary: 33.7","Cell line enhanced",NA,"HaCaT: 15.7;hTCEpi: 36.7"
"PITRM1","hMP1, KIAA1104, MP1, PreP","ENSG00000107959","Pitrilysin metallopeptidase 1","10","3137728-3172841","Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA006753, HPA006754","Enhanced",NA,"Supported","Mitochondria",NA,"Expressed in all","Expressed in all",NA,NA,"testis: 86.6","Expressed in all",NA,NA
"PJA1","FLJ11830, RNF70","ENSG00000181191","Praja ring finger ubiquitin ligase 1","X","69160851-69165793","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA000595","Enhanced",NA,"Approved","Nucleus<br>Nucleoli","Renal cancer:7.44e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"epididymis: 181.5","Cell line enhanced",NA,"HAP1: 88.6"
"PKP3",NA,"ENSG00000184363","Plakophilin 3","11","392614-404908","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB012993, HPA062937","Enhanced",NA,"Enhanced","Nucleoplasm<br>Cell Junctions<br>Cytosol","Lung cancer:2.89e-5 (unfavourable), Renal cancer:1.08e-4 (unfavourable), Pancreatic cancer:3.93e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"esophagus: 98.2;skin: 148.2","duodenum: 31.4","Cell line enhanced",NA,"A-431: 131.6;HaCaT: 174.9;SK-BR-3: 111.1"
"PLA2G2E",NA,"ENSG00000188784","Phospholipase A2 group IIE","1","19920009-19923617","Enzymes, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","HPA064085","Uncertain",NA,NA,NA,NA,"Not detected","Tissue enriched",11,"tonsil: 2.3","small intestine: 0.2","Not detected",NA,NA
"PLA2G4E","FLJ45651","ENSG00000188089","Phospholipase A2 group IVE","15","41981582-42051190","Enzymes, Predicted intracellular proteins, RAS pathway related proteins","Evidence at protein level","HPA041105","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",10,"skin: 20.4","esophagus,tonsil: 2.0","Not detected",NA,NA
"PLCB3",NA,"ENSG00000149782","Phospholipase C beta 3","11","64251523-64269150","Enzymes, Predicted intracellular proteins","Evidence at protein level","CAB009257, HPA039279, HPA043907","Enhanced",NA,"Enhanced","Nucleoplasm","Renal cancer:4.31e-5 (unfavourable), Liver cancer:1.39e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"duodenum: 114.9","Expressed in all",NA,NA
"PLCH1","DKFZp434C1372, KIAA1069, MGC117152, PLCeta1, PLCL3","ENSG00000114805","Phospholipase C eta 1","3","155375580-155745067","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA036176, HPA057978","Uncertain",NA,"Enhanced","Vesicles","Renal cancer:3.03e-5 (favourable)","Mixed","Tissue enhanced",NA,"testis: 20.6","fallopian tube: 13.0","Cell line enhanced",NA,"AF22: 38.5;NTERA-2: 20.8"
"PLEKHG3","ARHGEF43, KIAA0599","ENSG00000126822","Pleckstrin homology and RhoGEF domain containing G3","14","64704102-64750247","Predicted intracellular proteins","Evidence at protein level","HPA063455, HPA065323, HPA073702, HPA074734","Enhanced",NA,"Supported","Nucleoplasm<br>Plasma membrane<br>Cytokinetic bridge<br>Centrosome<br>Cytosol","Renal cancer:7.39e-8 (favourable)","Expressed in all","Expressed in all",NA,NA,"seminal vesicle: 53.5","Mixed",NA,NA
"PLEKHG5","GEF720, KIAA0720, Syx, Tech","ENSG00000171680","Pleckstrin homology and RhoGEF domain containing G5","1","6466092-6520061","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA049570","Uncertain",NA,"Approved","Nucleus","Glioma:8.72e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"skin: 110.9","spleen: 34.6","Mixed",NA,NA
"PLIN4","KIAA1881, S3-12","ENSG00000167676","Perilipin 4","19","4502180-4518465","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA044682, HPA054657","Enhanced",NA,"Supported","Vesicles<br>Lipid droplets<br>Plasma membrane<br>Cytosol","Endometrial cancer:2.31e-4 (unfavourable), Colorectal cancer:8.31e-4 (unfavourable)","Mixed","Tissue enriched",14,"adipose tissue: 812.2","skeletal muscle: 59.1","Cell line enriched",7,"ASC diff: 171.0"
"PLLP","PMLP, TM4SF11","ENSG00000102934","Plasmolipin","16","57248547-57284687","Predicted membrane proteins","Evidence at protein level","HPA041862","Enhanced",NA,NA,NA,"Renal cancer:6.21e-9 (favourable), Endometrial cancer:2.80e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 118.0","Cell line enhanced",NA,"EFO-21: 25.9;Hep G2: 54.1;RPTEC TERT1: 24.7"
"PLPP4","DPPL2, PPAPDC1, PPAPDC1A","ENSG00000203805","Phospholipid phosphatase 4","10","120456954-120589855","Enzymes, Predicted membrane proteins","Evidence at protein level","HPA045188","Approved",NA,"Approved","Nucleus<br>Nucleoli",NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 17.1;gallbladder: 10.4;testis: 12.7","kidney: 7.8","Cell line enhanced",NA,"BJ: 30.3;U-251 MG: 92.6"
"PLSCR4",NA,"ENSG00000114698","Phospholipid scramblase 4","3","146192339-146251179","Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters","Evidence at protein level","HPA002276","Uncertain",NA,"Approved","Nucleoplasm<br>Nuclear bodies","Endometrial cancer:3.90e-4 (unfavourable), Renal cancer:4.13e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 80.2","Cell line enhanced",NA,"ASC diff: 41.7;HUVEC TERT2: 42.5;TIME: 86.2"
"PLXNB3","PLEXB3, PLEXR, PLXN6","ENSG00000198753","Plexin B3","X","153764196-153779346","Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA048046","Enhanced",NA,NA,NA,"Breast cancer:6.13e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"cerebral cortex: 67.3","adrenal gland: 19.7","Cell line enhanced",NA,"WM-115: 69.8"
"PNMAL1","FLJ10781, KIAA1183L","ENSG00000182013","Paraneoplastic Ma antigen family like 1","19","46466491-46471563","Predicted intracellular proteins","Evidence at protein level","HPA012956","Approved",NA,"Approved","Nucleoplasm<br>Nuclear bodies<br>Cytosol",NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 133.9","testis: 42.5","Cell line enhanced",NA,"HAP1: 33.8;K-562: 32.4;LHCN-M2: 29.9;SH-SY5Y: 33.2"
"PODXL","Gp200, PC, PCLP","ENSG00000128567","Podocalyxin like","7","131500262-131558217","Plasma proteins, Predicted membrane proteins","Evidence at protein level","HPA002110, CAB016169, HPA045507, CAB062558, CAB068219, CAB068220","Enhanced",NA,"Approved","Vesicles<br>Plasma membrane<br>Microtubule organizing center","Renal cancer:2.89e-4 (favourable)","Expressed in all","Mixed",NA,NA,"fallopian tube: 29.6","Cell line enhanced",NA,"fHDF/TERT166: 106.7;NTERA-2: 181.6;TIME: 168.8"
"POM121","DKFZP586G1822, DKFZP586P2220, KIAA0618, POM121A","ENSG00000196313","POM121 transmembrane nucleoporin","7","72879365-72951440","Predicted intracellular proteins, Transporters","Evidence at protein level","CAB003710, HPA043809, HPA049817","Approved",NA,"Enhanced","Nucleoplasm<br>Nuclear membrane",NA,"Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 30.2","Expressed in all",NA,NA
"POMC","ACTH, CLIP, LPH, MSH, NPP, POC","ENSG00000115138","Proopiomelanocortin","2","25160853-25168903","Cancer-related genes, Disease related genes, Predicted secreted proteins","Evidence at protein level","CAB002762, HPA046135, HPA063644","Enhanced",NA,NA,NA,"Pancreatic cancer:5.70e-4 (favourable)","Tissue enriched","Tissue enhanced",NA,"testis: 6.8","pancreas: 5.3","Cell line enhanced",NA,"HMC-1: 1.2;THP-1: 1.2"
"POMGNT2","AGO61, C3orf39, FLJ14566, GTDC2","ENSG00000144647","Protein O-linked mannose N-acetylglucosaminyltransferase 2 (beta 1,4-)","3","43079232-43106076","Disease related genes, Predicted secreted proteins","Evidence at protein level","HPA034870, HPA040989","Uncertain",NA,NA,NA,"Renal cancer:4.00e-7 (favourable), Liver cancer:1.26e-5 (unfavourable), Colorectal cancer:8.13e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"endometrium: 35.7","Mixed",NA,NA
"POU1F1","GHF-1, PIT1, POU1F1a","ENSG00000064835","POU class 1 homeobox 1","3","87259404-87276587","Disease related genes, Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA041646, HPA050624","Enhanced",NA,NA,NA,NA,"Not detected","Not detected",NA,NA,"adrenal gland,cerebral cortex,gallbladder,skeletal muscle,spleen,thyroid gland: 0.1","Not detected",NA,NA
"POU2F2","OCT2, OTF2","ENSG00000028277","POU class 2 homeobox 2","19","42086110-42196585","Cancer-related genes, Predicted intracellular proteins, Transcription factors","Evidence at protein level","CAB002513, HPA049056, HPA062096, HPA064404","Enhanced",NA,"Enhanced","Nucleoplasm<br>Vesicles","Renal cancer:7.57e-11 (unfavourable)","Mixed","Tissue enhanced",NA,"lymph node: 62.3;tonsil: 44.4","appendix,spleen: 37.6","Cell line enhanced",NA,"BJ hTERT+: 42.5;Daudi: 81.0;hTEC/SVTERT24-B: 42.8;U-266/70: 57.7;U-266/84: 54.8;U-698: 61.5"
"POU2F3","Epoc-1, OCT11, PLA-1, Skn-1a","ENSG00000137709","POU class 2 homeobox 3","11","120236640-120319944","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA019652","Enhanced",NA,NA,NA,"Thyroid cancer:8.14e-4 (favourable)","Mixed","Group enriched",11,"parathyroid gland: 15.5;skin: 72.3","seminal vesicle: 3.8","Cell line enhanced",NA,"CAPAN-2: 3.7;SK-BR-3: 2.2;T-47d: 5.2"
"POU4F3","BRN3C, DFNA15, DFNA42, DFNA52","ENSG00000091010","POU class 4 homeobox 3","5","146339024-146340520","Disease related genes, Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA038215","Uncertain",NA,"Supported","Nucleoplasm",NA,"Tissue enhanced","Not detected",NA,NA,"all non-specific tissues: 0.0","Not detected",NA,NA
"POU5F1","MGC22487, OCT3, Oct4, OTF3","ENSG00000204531","POU class 5 homeobox 1","6","31164337-31180731","Cancer-related genes, Predicted intracellular proteins, Transcription factors","Evidence at protein level","CAB025600, CAB026380, HPA058267","Approved",NA,"Supported","Nucleoplasm<br>Cytosol","Urothelial cancer:2.04e-5 (favourable)","Tissue enriched","Mixed",NA,NA,"fallopian tube: 6.4","Group enriched",12,"HAP1: 366.6;NTERA-2: 938.2"
"PPARA","hPPAR, NR1C1, PPAR","ENSG00000186951","Peroxisome proliferator activated receptor alpha","22","46150521-46243756","FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA058901, HPA067049, CAB075701","Supported",NA,"Enhanced","Nucleus","Renal cancer:4.39e-9 (favourable)","Expressed in all","Expressed in all",NA,NA,"kidney: 24.2","Mixed",NA,NA
"PPFIA1","LIP.1, LIPRIN","ENSG00000131626","PTPRF interacting protein alpha 1","11","70270700-70384403","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA008272, CAB017032, HPA042271","Uncertain",NA,"Enhanced","Focal adhesion sites<br>Cytosol","Renal cancer:3.76e-4 (favourable), Head and neck cancer:5.58e-4 (unfavourable), Pancreatic cancer:8.26e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 57.2","Expressed in all",NA,NA
"PPIG","CARS-Cyp, SCAF10, SRCyp","ENSG00000138398","Peptidylprolyl isomerase G","2","169584340-169641406","Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA021788, HPA057469","Supported",NA,"Supported","Nuclear speckles<br>Cytosol","Renal cancer:4.56e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 84.6","Expressed in all",NA,NA
"PPM1G","PP2CG, PP2Cgamma","ENSG00000115241","Protein phosphatase, Mg2+/Mn2+ dependent 1G","2","27381194-27409687","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA035530, HPA035531","Enhanced",NA,"Enhanced","Nucleoplasm","Liver cancer:3.14e-7 (unfavourable), Ovarian cancer:6.08e-5 (favourable)","Expressed in all","Tissue enriched",5,"testis: 337.3","lymph node: 65.2","Expressed in all",NA,NA
"PPP1CB","PP-1B, PP1B, PP1beta","ENSG00000213639","Protein phosphatase 1 catalytic subunit beta","2","28751640-28802940","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","CAB022558, HPA065425, CAB069426","Supported",NA,"Enhanced","Nucleus<br>Plasma membrane","Liver cancer:6.52e-6 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"esophagus: 273.8","Expressed in all",NA,NA
"PPP1R13L","IASPP, RAI","ENSG00000104881","Protein phosphatase 1 regulatory subunit 13 like","19","45379634-45406349","Predicted intracellular proteins, Transcription factors","Evidence at protein level","CAB005016, HPA041231, HPA059883","Approved",NA,"Enhanced","Cytosol","Lung cancer:3.39e-5 (unfavourable), Ovarian cancer:5.40e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"skin: 191.4","esophagus: 53.8","Cell line enhanced",NA,"hTCEpi: 138.6"
"PPP1R18","KIAA1949, phostensin","ENSG00000146112","Protein phosphatase 1 regulatory subunit 18","6","30676389-30687895","Predicted intracellular proteins","Evidence at protein level","HPA044745, HPA051000","Enhanced",NA,"Approved","Nucleoplasm<br>Plasma membrane","Renal cancer:1.11e-16 (unfavourable), Colorectal cancer:4.71e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"lymph node: 53.3","spleen: 35.1","Mixed",NA,NA
"PPP1R37","LRRC68","ENSG00000104866","Protein phosphatase 1 regulatory subunit 37","19","45091396-45148077","Predicted intracellular proteins","Evidence at protein level","HPA041500","Approved",NA,"Approved","Cytosol","Urothelial cancer:2.04e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 22.3","Expressed in all",NA,NA
"PPP1R8","ard-1, ARD1, NIPP-1, NIPP1, PRO2047","ENSG00000117751","Protein phosphatase 1 regulatory subunit 8","1","27830778-27851676","Predicted intracellular proteins","Evidence at protein level","HPA027406, HPA027417, HPA027452","Enhanced",NA,"Enhanced","Nucleoplasm<br>Nuclear speckles","Liver cancer:2.19e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"endometrium: 46.5","Expressed in all",NA,NA
"PPP1R9A","FLJ20068, KIAA1222, Neurabin-I","ENSG00000158528","Protein phosphatase 1 regulatory subunit 9A","7","94907202-95296415","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA027726, HPA075591","Uncertain",NA,"Approved","Plasma membrane","Renal cancer:8.63e-6 (favourable), Ovarian cancer:7.17e-4 (favourable)","Mixed","Mixed",NA,NA,"cerebral cortex: 20.6","Mixed",NA,NA
"PPP2R2A","B55A, PR52A, PR55A","ENSG00000221914","Protein phosphatase 2 regulatory subunit Balpha","8","26291491-26372680","Predicted intracellular proteins","Evidence at protein level","HPA042122, HPA042770, CAB079289","Approved",NA,"Approved","Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"placenta: 72.2","Expressed in all",NA,NA
"PPP2R2B","PR52B, PR55-BETA, SCA12","ENSG00000156475","Protein phosphatase 2 regulatory subunit Bbeta","5","146581146-147084784","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA038118, HPA042122, HPA042770","Approved",NA,"Approved","Cytosol",NA,"Tissue enriched","Tissue enhanced",NA,"cerebral cortex: 135.2","testis: 33.9","Cell line enhanced",NA,"HaCaT: 19.5;HDLM-2: 97.5;RT4: 19.0"
"PPP2R2C","IMYPNO, MGC33570, PR52, PR55G","ENSG00000074211","Protein phosphatase 2 regulatory subunit Bgamma","4","6320578-6563600","Predicted intracellular proteins","Evidence at protein level","HPA042122, HPA042770","Approved",NA,NA,NA,"Lung cancer:4.94e-4 (unfavourable)","Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 164.4","endometrium: 53.2","Cell line enhanced",NA,"A-431: 30.5;A549: 45.5;MCF7: 32.3;PC-3: 43.7;SCLC-21H: 53.0"
"PPP2R2D","MDS026","ENSG00000175470","Protein phosphatase 2 regulatory subunit Bdelta","10","131900644-131959834","Predicted intracellular proteins","Evidence at protein level","HPA042122, HPA042770","Approved",NA,"Approved","Cytosol","Colorectal cancer:3.14e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"cerebral cortex: 6.7","Mixed",NA,NA
"PPP3CA","CALN, CALNA, CNA1, PPP2B","ENSG00000138814","Protein phosphatase 3 catalytic subunit alpha","4","101023409-101348278","Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA012778, CAB018581","Enhanced",NA,"Enhanced","Nucleoplasm<br>Cytosol","Pancreatic cancer:3.82e-4 (unfavourable)","Tissue enriched","Expressed in all",NA,NA,"cerebral cortex: 164.3","Expressed in all",NA,NA
"PPP3CB","CALNA2, CALNB, CNA2, PP2Bbeta","ENSG00000107758","Protein phosphatase 3 catalytic subunit beta","10","73436428-73496024","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA008233, HPA008823","Uncertain",NA,"Approved","Mitochondria","Pancreatic cancer:6.96e-5 (favourable), Liver cancer:9.59e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 153.2","Expressed in all",NA,NA
"PPP4R3B","FLFL2, FLJ31474, KIAA1387, PSY2, SMEK2","ENSG00000275052","Protein phosphatase 4 regulatory subunit 3B","2","55547292-55618880","Predicted intracellular proteins","Evidence at protein level","HPA001233, CAB017185","Approved",NA,"Supported","Nucleoplasm<br>Nuclear speckles<br>Centrosome","Renal cancer:6.03e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 58.0","Expressed in all",NA,NA
"PPP5D1",NA,"ENSG00000230510","PPP5 tetratricopeptide repeat domain containing 1","19","46480796-46601200","Predicted intracellular proteins","Evidence at transcript level","HPA073186","Uncertain",NA,"Uncertain","Cytosol",NA,"Not detected","Mixed",NA,NA,"cerebral cortex: 4.8","Mixed",NA,NA
"PPP6R2","dJ579N16.1, KIAA0685, SAP190, SAPS2","ENSG00000100239","Protein phosphatase 6 regulatory subunit 2","22","50343304-50445090","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA030656, CAB034919","Uncertain",NA,"Supported","Vesicles<br>Cytosol","Endometrial cancer:1.70e-5 (favourable), Pancreatic cancer:7.51e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 65.3","Expressed in all",NA,NA
"PPWD1","KIAA0073","ENSG00000113593","Peptidylprolyl isomerase domain and WD repeat containing 1","5","65563236-65587549","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA019353, HPA019360","Enhanced",NA,"Supported","Nuclear bodies","Liver cancer:2.19e-4 (unfavourable), Renal cancer:6.72e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"lymph node: 31.6","Expressed in all",NA,NA
"PRAMEF12",NA,"ENSG00000116726","PRAME family member 12","1","12774841-12777906","Plasma proteins, Predicted intracellular proteins","No evidence","HPA045286, HPA051704","Uncertain",NA,"Uncertain","Nucleoplasm",NA,"Not detected","Not detected",NA,NA,"all non-specific tissues: 0.0","Not detected",NA,NA
"PREB","SEC12","ENSG00000138073","Prolactin regulatory element binding","2","27130756-27134675","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA013582, HPA014133","Uncertain",NA,"Approved","Endoplasmic reticulum",NA,"Expressed in all","Expressed in all",NA,NA,"epididymis: 107.6","Expressed in all",NA,NA
"PRELID2","FLJ38376, MGC21644","ENSG00000186314","PRELI domain containing 2","5","145471799-145835369","Predicted intracellular proteins","Evidence at transcript level","HPA042486","Uncertain",NA,"Approved","Nucleoplasm","Renal cancer:9.65e-6 (unfavourable), Pancreatic cancer:3.78e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"small intestine: 28.7","rectum: 19.2","Mixed",NA,NA
"PREPL","KIAA0436","ENSG00000138078","Prolyl endopeptidase-like","2","44316281-44361862","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA063238","Approved",NA,NA,NA,NA,"Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 257.4","Expressed in all",NA,NA
"PRG3","MBP2, MBPH","ENSG00000156575","Proteoglycan 3, pro eosinophil major basic protein 2","11","57376769-57381150","Predicted secreted proteins","Evidence at protein level","HPA064183","Enhanced",NA,NA,NA,NA,"Not detected","Tissue enriched",45,"bone marrow: 29.3","liver,spleen: 0.6","Cell line enriched",64,"HMC-1: 174.6"
"PRICKLE1","EPM1B, FLJ31937, RILP","ENSG00000139174","Prickle planar cell polarity protein 1","12","42456757-42590355","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA001379, HPA050037","Enhanced",NA,"Approved","Nucleoplasm","Glioma:5.56e-4 (unfavourable)","Mixed","Mixed",NA,NA,"cerebral cortex: 21.2","Cell line enriched",13,"HBEC3-KT: 727.1"
"PRKAA1","AMPKa1","ENSG00000132356","Protein kinase AMP-activated catalytic subunit alpha 1","5","40759379-40798374","Enzymes, FDA approved drug targets, Predicted intracellular proteins","Evidence at protein level","CAB005050, HPA035409, HPA064946","Supported",NA,"Supported","Nuclear speckles",NA,"Expressed in all","Expressed in all",NA,NA,"testis: 74.4","Expressed in all",NA,NA
"PRKAR1B",NA,"ENSG00000188191","Protein kinase cAMP-dependent type I regulatory subunit beta","7","549197-727650","Predicted intracellular proteins","Evidence at protein level","HPA026719","Approved",NA,NA,NA,NA,"Expressed in all","Tissue enriched",9,"cerebral cortex: 239.1","ovary: 26.3","Expressed in all",NA,NA
"PRKD2","DKFZP586E0820, HSPC187, PKD2","ENSG00000105287","Protein kinase D2","19","46674275-46717127","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA021490, HPA056727","Enhanced",NA,"Supported","Nucleoplasm<br>Cytosol","Urothelial cancer:9.15e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"spleen: 60.3","Expressed in all",NA,NA
"PRKG2","cGKII, PRKGR2","ENSG00000138669","Protein kinase, cGMP-dependent, type II","4","81087370-81215117","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA007386, CAB018739","Approved",NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"prostate: 15.3;small intestine: 14.4","duodenum: 9.7","Cell line enhanced",NA,"HEL: 18.8;SCLC-21H: 7.3"
"PRKRA","DYT16, HSD14, PACT, RAX","ENSG00000180228","Protein activator of interferon induced protein kinase EIF2AK2","2","178431414-178451512","Disease related genes, Predicted intracellular proteins","Evidence at protein level","CAB004648, HPA034996, HPA034997","Approved",NA,"Supported","Nucleoplasm<br>Cytosol","Liver cancer:8.33e-5 (unfavourable), Testis cancer:5.45e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 56.2","Expressed in all",NA,NA
"PRL",NA,"ENSG00000172179","Prolactin","6","22287244-22297501","Cancer-related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB023353, HPA042416, HPA062017","Enhanced",NA,"Uncertain","Cytosol",NA,"Not detected","Group enriched",9,"endometrium: 10.7;placenta: 27.2","testis: 2.2","Cell line enhanced",NA,"Daudi: 11.1;SCLC-21H: 6.5;U-937: 2.1"
"PRMT1","ANM1, HCP1, HRMT1L2","ENSG00000126457","Protein arginine methyltransferase 1","19","49675786-49689029","Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB022550, HPA069769, HPA072136","Enhanced",NA,"Supported","Nucleoplasm","Liver cancer:8.04e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"fallopian tube: 181.1","Expressed in all",NA,NA
"PRNP","AltPrP, CD230, CJD, GSS, PRIP, PRP","ENSG00000171867","Prion protein","20","4686236-4701590","CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA042754, HPA043398","Enhanced",NA,"Approved","Nuclear membrane<br>Vesicles<br>Cytosol","Liver cancer:7.41e-5 (unfavourable), Glioma:1.99e-4 (unfavourable), Colorectal cancer:2.96e-4 (unfavourable), Endometrial cancer:4.64e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 619.4","Cell line enhanced",NA,"WM-115: 985.1"
"PRPF4","HPRP4, HPRP4P, PRP4, Prp4p, SNRNP60","ENSG00000136875","Pre-mRNA processing factor 4","9","113275343-113292905","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA021794, HPA022248","Enhanced",NA,"Enhanced","Nuclear speckles","Liver cancer:9.35e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"epididymis: 24.3","Expressed in all",NA,NA
"PRPH","NEF4, PRPH1","ENSG00000135406","Peripherin","12","49293252-49298686","Predicted intracellular proteins","Evidence at protein level","CAB002437, HPA039277, HPA063887","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"adrenal gland: 20.5","testis: 11.6","Group enriched",93,"AN3-CA: 342.0;SCLC-21H: 92.7"
"PRR14L","C22orf30, MGC50372","ENSG00000183530","Proline rich 14 like","22","31676256-31750140","Predicted intracellular proteins","Evidence at protein level","HPA062645","Uncertain",NA,"Approved","Nucleoplasm","Renal cancer:3.00e-4 (favourable)","Expressed in all","Mixed",NA,NA,"parathyroid gland: 15.2","Expressed in all",NA,NA
"PRR18","MGC35308","ENSG00000176381","Proline rich 18","6","166305300-166308448","Predicted intracellular proteins","Evidence at protein level","HPA077250","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",9,"cerebral cortex: 32.6","fallopian tube: 3.4","Group enriched",11,"SCLC-21H: 5.0;SH-SY5Y: 2.7"
"PRRC2C","BAT2D1, BAT2L2, KIAA1096, XTP2","ENSG00000117523","Proline rich coiled-coil 2C","1","171485551-171593511","Predicted intracellular proteins","Evidence at protein level","HPA025766, HPA028659","Approved",NA,"Enhanced","Cytosol","Renal cancer:7.76e-6 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 59.3","Expressed in all",NA,NA
"PRRT2","DKFZp547J199, DSPB3, DYT10, EKD1, FICCA, FLJ25513, ICCA, IFITMD1, PKC","ENSG00000167371","Proline rich transmembrane protein 2","16","29811382-29815892","Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters","Evidence at protein level","HPA014447, HPA019203","Enhanced",NA,"Supported","Plasma membrane",NA,"Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 98.1","ovary: 54.6","Cell line enhanced",NA,"AF22: 26.4;REH: 19.4;U-138 MG: 18.0"
"PRRT4",NA,"ENSG00000224940","Proline rich transmembrane protein 4","7","128350325-128361685","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA046373, HPA052681","Uncertain",NA,"Approved","Nucleoplasm<br>Peroxisomes<br>Plasma membrane",NA,"Mixed","Group enriched",12,"adipose tissue: 15.7;bone marrow: 41.2","cerebral cortex: 2.2","Cell line enriched",8,"SH-SY5Y: 239.1"
"PRTN3","ACPA, AGP7, C-ANCA, MBT, P29, PR-3","ENSG00000196415","Proteinase 3","19","840960-848175","Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA005938, CAB017558","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",724,"bone marrow: 616.4","spleen: 0.8","Cell line enriched",6,"THP-1: 696.6"
"PSAP","GLBA, SAP1","ENSG00000197746","Prosaposin","10","71816298-71851375","Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA004426, CAB004647","Enhanced",NA,"Supported","Vesicles",NA,"Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 1912.4","Expressed in all",NA,NA
"PSMB10","beta2i, LMP10, MECL1, MGC1665","ENSG00000205220","Proteasome subunit beta 10","16","67934502-67937087","Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA030224, HPA030225, CAB034384","Enhanced",NA,"Enhanced","Cytosol","Urothelial cancer:5.44e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"lymph node: 91.2","Mixed",NA,NA
"PSMC3","TBP-1, TBP1","ENSG00000165916","Proteasome 26S subunit, ATPase 3","11","47418769-47426473","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA006065","Approved",NA,"Supported","Nucleus<br>Cytosol","Renal cancer:4.24e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 119.6","Expressed in all",NA,NA
"PSMD4","AF, AF-1, Rpn10, S5A","ENSG00000159352","Proteasome 26S subunit, non-ATPase 4","1","151254703-151267479","Cancer-related genes, Predicted intracellular proteins","Evidence at protein level","HPA038807, HPA039252, CAB047300","Enhanced",NA,"Enhanced","Nucleoplasm<br>Cytosol","Renal cancer:6.66e-10 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 174.0","Expressed in all",NA,NA
"PSMD7","MOV34, P40, Rpn8, S12","ENSG00000103035","Proteasome 26S subunit, non-ATPase 7","16","74296775-74306288","Enzymes, Predicted intracellular proteins","Evidence at protein level","CAB019379, HPA049824, HPA056069","Enhanced",NA,"Enhanced","Nucleoplasm","Liver cancer:7.71e-6 (unfavourable), Head and neck cancer:6.64e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"prostate: 107.1","Expressed in all",NA,NA
"PSMD8","HIP6, HYPF, Nin1p, p31, Rpn12, S14","ENSG00000099341","Proteasome 26S subunit, non-ATPase 8","19","38374536-38383824","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA006702, CAB021101","Enhanced",NA,"Approved","Nuclear speckles<br>Cytosol","Endometrial cancer:3.84e-4 (unfavourable), Renal cancer:4.66e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 195.0","Expressed in all",NA,NA
"PSTPIP1","CD2BP1, CD2BP1L, CD2BP1S, H-PIP, PAPAS, PSTPIP","ENSG00000140368","Proline-serine-threonine phosphatase interacting protein 1","15","76993359-77037332","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA010600","Enhanced",NA,NA,NA,"Renal cancer:7.36e-9 (unfavourable), Endometrial cancer:4.74e-5 (favourable)","Expressed in all","Tissue enhanced",NA,"bone marrow: 37.6","appendix: 16.2","Cell line enhanced",NA,"HDLM-2: 55.7;NB-4: 15.1;U-937: 50.2"
"PSTPIP2",NA,"ENSG00000152229","Proline-serine-threonine phosphatase interacting protein 2","18","45983536-46072272","Predicted intracellular proteins","Evidence at protein level","HPA040923, HPA040944","Enhanced",NA,"Approved","Nucleus<br>Plasma membrane<br>Mitochondria","Renal cancer:2.39e-7 (unfavourable)","Expressed in all","Tissue enhanced",NA,"bone marrow: 47.2;spleen: 69.7","placenta: 17.3","Cell line enhanced",NA,"HEL: 91.3;HMC-1: 95.2"
"PTOV1",NA,"ENSG00000104960","Prostate tumor overexpressed 1","19","49850735-49860744","Predicted intracellular proteins","Evidence at protein level","HPA051812, HPA075125","Approved",NA,"Supported","Nucleus","Colorectal cancer:6.64e-4 (unfavourable), Pancreatic cancer:9.20e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"adrenal gland: 59.4","Expressed in all",NA,NA
"PTPN13","PTP-BAS, PTP-BL, PTP1E, PTPL1","ENSG00000163629","Protein tyrosine phosphatase, non-receptor type 13","4","86594315-86815171","Cancer-related genes, Enzymes, Predicted intracellular proteins","Evidence at protein level","CAB002213, HPA048888, HPA065290","Approved",NA,"Approved","Plasma membrane<br>Cytosol",NA,"Mixed","Mixed",NA,NA,"skin: 65.9","Cell line enhanced",NA,"AF22: 114.7"
"PTPRCAP","CD45-AP, LPAP","ENSG00000213402","Protein tyrosine phosphatase, receptor type C associated protein","11","67435510-67438067","Predicted secreted proteins","Evidence at protein level","HPA043734","Enhanced",NA,NA,NA,NA,"Not detected","Tissue enhanced",NA,"appendix: 64.0;lymph node: 91.4;spleen: 84.9","tonsil: 29.0","Cell line enhanced",NA,"Daudi: 161.8;HDLM-2: 148.3;MOLT-4: 110.0;NB-4: 409.0;U-698: 109.1"
"PTPRU","FMI, hPTP-J, PCP-2, PTP, PTPRO","ENSG00000060656","Protein tyrosine phosphatase, receptor type U","1","29236516-29326813","Enzymes, Plasma proteins, Predicted membrane proteins","Evidence at protein level","CAB011476, HPA039832","Approved",NA,NA,NA,"Head and neck cancer:8.32e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"cervix, uterine: 28.0","Cell line enhanced",NA,"BEWO: 92.2"
"PUF60","FIR, RoBPI, SIAHBP1","ENSG00000179950","Poly(U) binding splicing factor 60","8","143816344-143829859","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA045733, HPA052096, HPA059714","Enhanced",NA,"Enhanced","Nucleoplasm",NA,"Expressed in all","Expressed in all",NA,NA,"testis: 26.1","Expressed in all",NA,NA
"PYCARD","ASC, CARD5, TMS-1","ENSG00000103490","PYD and CARD domain containing","16","31201485-31203450","Predicted intracellular proteins","Evidence at protein level","CAB006853, CAB015948, HPA049074, HPA054496","Enhanced",NA,"Supported","Nucleus<br>Nucleoli<br>Cytosol","Renal cancer:6.09e-7 (unfavourable)","Expressed in all","Mixed",NA,NA,"duodenum: 51.4","Cell line enhanced",NA,"MCF7: 97.4;NB-4: 127.0;THP-1: 98.8"
"PYCR1","P5C","ENSG00000183010","Pyrroline-5-carboxylate reductase 1","17","81932384-81942412","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA047660","Approved",NA,NA,NA,"Renal cancer:7.33e-12 (unfavourable), Liver cancer:2.33e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"salivary gland: 52.3","Mixed",NA,NA
"PYGL",NA,"ENSG00000100504","Glycogen phosphorylase L","14","50857891-50944736","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA000962, HPA004119","Enhanced",NA,"Supported","Plasma membrane<br>Cytosol","Pancreatic cancer:2.63e-4 (unfavourable), Head and neck cancer:5.97e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"adipose tissue: 116.5","Mixed",NA,NA
"PZP","CPAMD6","ENSG00000126838","PZP, alpha-2-macroglobulin like","12","9148840-9208370","Cancer-related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA041403, HPA041471","Supported",NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",12,"liver: 45.9","testis: 3.8","Group enriched",7,"HeLa: 3.2;SiHa: 2.6"
"QARS",NA,"ENSG00000172053","Glutaminyl-tRNA synthetase","3","49095932-49105135","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA036986, HPA036987","Enhanced",NA,"Enhanced","Cytosol","Renal cancer:5.60e-6 (favourable), Breast cancer:1.43e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"rectum: 117.0","Expressed in all",NA,NA
"QDPR","DHPR, PKU2, SDR33C1","ENSG00000151552","Quinoid dihydropteridine reductase","4","17460261-17512234","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA058951, HPA065649","Enhanced",NA,"Approved","Mitochondria","Renal cancer:7.84e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 226.3","Expressed in all",NA,NA
"RAB11FIP5","GAF1, KIAA0857, pp75, RIP11","ENSG00000135631","RAB11 family interacting protein 5","2","73073382-73156721","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA036406, HPA036407","Enhanced",NA,"Enhanced","Vesicles<br>Microtubule organizing center","Renal cancer:2.26e-5 (favourable), Ovarian cancer:3.87e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"testis: 73.1","parathyroid gland: 26.9","Mixed",NA,NA
"RAB12",NA,"ENSG00000206418","RAB12, member RAS oncogene family","18","8609445-8639381","Predicted intracellular proteins","Evidence at protein level","HPA040727","Approved",NA,"Approved","Vesicles",NA,"Expressed in all","Expressed in all",NA,NA,"skeletal muscle: 67.4","Expressed in all",NA,NA
"RAB7A","RAB7","ENSG00000075785","RAB7A, member RAS oncogene family","3","128726122-128814796","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA006964, CAB037131","Supported",NA,"Supported","Lysosomes","Liver cancer:9.89e-6 (unfavourable), Endometrial cancer:1.52e-4 (unfavourable), Pancreatic cancer:4.63e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 270.2","Expressed in all",NA,NA
"RABAC1","PRA1, PRAF1, YIP3","ENSG00000105404","Rab acceptor 1","19","41956681-41959390","Predicted membrane proteins, Transporters","Evidence at protein level","CAB019320, HPA029171","Enhanced",NA,"Approved","Nuclear membrane<br>Nucleoli fibrillar center",NA,"Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 107.2","Expressed in all",NA,NA
"RABEPK","bA65N13.1, RAB9P40","ENSG00000136933","Rab9 effector protein with kelch motifs","9","125200542-125234158","Predicted intracellular proteins","Evidence at protein level","HPA023920, HPA067106","Enhanced",NA,"Uncertain","Plasma membrane",NA,"Expressed in all","Expressed in all",NA,NA,"liver: 30.6","Expressed in all",NA,NA
"RAI2",NA,"ENSG00000131831","Retinoic acid induced 2","X","17800049-17861337","Predicted intracellular proteins","Evidence at protein level","HPA051054","Uncertain",NA,"Approved","Plasma membrane","Renal cancer:3.39e-14 (favourable), Pancreatic cancer:2.77e-4 (favourable)","Expressed in all","Mixed",NA,NA,"fallopian tube: 79.1","Cell line enriched",9,"ASC diff: 71.0"
"RANBP2","ADANE, ANE1, NUP358","ENSG00000153201","RAN binding protein 2","2","108719481-108785811","Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters","Evidence at protein level","HPA018437, HPA023960, CAB034063, HPA049497, HPA051675, HPA067564","Supported",NA,NA,NA,NA,"Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 74.9","Expressed in all",NA,NA
"RANBP3",NA,"ENSG00000031823","RAN binding protein 3","19","5916139-5978142","Cancer-related genes, Predicted intracellular proteins","Evidence at protein level","HPA043375, HPA043389","Enhanced",NA,"Enhanced","Nucleoplasm","Endometrial cancer:1.22e-5 (favourable), Pancreatic cancer:4.14e-4 (favourable), Thyroid cancer:8.14e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 60.1","Expressed in all",NA,NA
"RAP1GAP","KIAA0474, RAP1GA1, RAP1GAP1, RAP1GAPII","ENSG00000076864","RAP1 GTPase activating protein","1","21596215-21669363","Predicted intracellular proteins","Evidence at protein level","HPA001922, CAB003851","Enhanced","Supported","Approved","Cytosol","Renal cancer:1.12e-6 (favourable), Liver cancer:5.85e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 122.1;thyroid gland: 232.8","adrenal gland: 93.2","Cell line enhanced",NA,"A549: 41.8;K-562: 26.3;SCLC-21H: 61.3"
"RAP1GDS1","SmgGDS","ENSG00000138698","Rap1 GTPase-GDP dissociation stimulator 1","4","98261384-98443861","Cancer-related genes, Predicted intracellular proteins","Evidence at protein level","HPA019060","Approved",NA,"Supported","Cytosol","Renal cancer:2.00e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 93.9","Expressed in all",NA,NA
"RASA1","CM-AVM, GAP, p120, p120GAP, p120RASGAP, RASA","ENSG00000145715","RAS p21 protein activator 1","5","87267888-87391931","Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins","Evidence at protein level","CAB007789, HPA036393, HPA064556","Enhanced",NA,NA,NA,NA,"Expressed in all","Expressed in all",NA,NA,"placenta: 136.4","Expressed in all",NA,NA
"RASA2","GAP1M","ENSG00000155903","RAS p21 protein activator 2","3","141487047-141615342","Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","HPA035374, HPA035375","Approved",NA,"Approved","Vesicles","Renal cancer:7.62e-7 (unfavourable), Urothelial cancer:4.34e-5 (favourable)","Expressed in all","Mixed",NA,NA,"lymph node: 25.0","Expressed in all",NA,NA
"RASAL2","nGAP","ENSG00000075391","RAS protein activator like 2","1","178094141-178484147","Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins","Evidence at protein level","HPA018805, HPA020453","Enhanced",NA,"Approved","Plasma membrane<br>Focal adhesion sites","Urothelial cancer:2.05e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"esophagus: 19.4","Mixed",NA,NA
"RAVER2","FLJ10770, KIAA1579","ENSG00000162437","Ribonucleoprotein, PTB binding 2","1","64745095-64833232","Predicted intracellular proteins","Evidence at protein level","HPA045785","Approved",NA,"Approved","Nucleoplasm","Renal cancer:5.14e-6 (favourable)","Expressed in all","Mixed",NA,NA,"rectum: 29.4","Mixed",NA,NA
"RBKS","DKFZp686G13268, RBSK","ENSG00000171174","Ribokinase","2","27781364-27891098","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA019725, HPA028285","Enhanced",NA,"Approved","Cytosol",NA,"Expressed in all","Tissue enhanced",NA,"adrenal gland: 34.7","kidney: 19.5","Cell line enhanced",NA,"EFO-21: 10.8;RPTEC TERT1: 18.4"
"RBL1","cp107, p107, PRB1","ENSG00000080839","RB transcriptional corepressor like 1","20","36996349-37095995","Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA054962, HPA056525","Enhanced",NA,"Enhanced","Nucleoplasm","Renal cancer:2.52e-6 (unfavourable)","Expressed in all","Mixed",NA,NA,"bone marrow: 9.2","Expressed in all",NA,NA
"RBM14","COAA, DKFZp779J0927, SIP, SYTIP1","ENSG00000239306","RNA binding motif protein 14","11","66616582-66627347","Predicted intracellular proteins","Evidence at protein level","HPA006628","Supported",NA,"Supported","Nuclear speckles","Liver cancer:2.02e-7 (unfavourable), Pancreatic cancer:1.04e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 50.0","Expressed in all",NA,NA
"RBM22","Cwc2, FLJ10290, fSAP47, ZC3H16","ENSG00000086589","RNA binding motif protein 22","5","150690794-150701107","Predicted intracellular proteins","Evidence at protein level","HPA001634","Supported",NA,"Enhanced","Nucleus","Liver cancer:5.50e-6 (unfavourable), Renal cancer:3.58e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"fallopian tube: 40.5","Expressed in all",NA,NA
"RBM28","FLJ10377","ENSG00000106344","RNA binding motif protein 28","7","128297685-128343908","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA019058, HPA026672, HPA031519","Enhanced",NA,"Enhanced","Nucleoli","Liver cancer:2.72e-11 (unfavourable), Endometrial cancer:2.94e-4 (unfavourable), Melanoma:6.44e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 26.9","Expressed in all",NA,NA
"RBM4","LARK, RBM4A, ZCCHC21, ZCRB3A","ENSG00000173933","RNA binding motif protein 4","11","66638617-66666682","Predicted intracellular proteins","Evidence at protein level","HPA042174, HPA047849","Approved",NA,"Approved","Nucleoplasm<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 133.6","Expressed in all",NA,NA
"RBM48","C7orf64, DKFZp564O0523, HSPC304","ENSG00000127993","RNA binding motif protein 48","7","92528773-92538005","Predicted intracellular proteins","Evidence at protein level","HPA021777, HPA025306","Uncertain",NA,"Enhanced","Nucleoplasm","Liver cancer:3.17e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 19.8","Expressed in all",NA,NA
"RBM4B","MGC10871, RBM30, RBM4L, ZCCHC15, ZCCHC21B, ZCRB3B","ENSG00000173914","RNA binding motif protein 4B","11","66664998-66677921","Predicted intracellular proteins","Evidence at protein level","HPA042174, HPA047849","Uncertain",NA,"Approved","Nucleoplasm<br>Cytosol","Renal cancer:1.02e-4 (unfavourable), Pancreatic cancer:2.10e-4 (favourable), Liver cancer:2.94e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"ovary: 36.2","Expressed in all",NA,NA
"RBM6","3G2, DEF-3, DEF3, g16, NY-LU-12","ENSG00000004534","RNA binding motif protein 6","3","49940007-50100045","Cancer-related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA026272, HPA027164","Enhanced",NA,"Approved","Nuclear speckles<br>Cytoplasmic bodies","Urothelial cancer:5.13e-5 (favourable), Pancreatic cancer:1.41e-4 (favourable), Renal cancer:8.83e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 83.7","Expressed in all",NA,NA
"RCN3","RLP49","ENSG00000142552","Reticulocalbin 3","19","49527618-49546962","Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA043134, HPA050402","Uncertain",NA,"Approved","Endoplasmic reticulum<br>Vesicles","Renal cancer:5.80e-12 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"small intestine: 45.0","Cell line enhanced",NA,"ASC diff: 170.1;BJ: 238.6;fHDF/TERT166: 192.6"
"RCOR2",NA,"ENSG00000167771","REST corepressor 2","11","63911221-63916844","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA021638","Uncertain",NA,"Approved","Nucleus<br>Vesicles<br>Midbody",NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 13.2","testis: 3.7","Cell line enhanced",NA,"AF22: 39.9;NTERA-2: 52.3;SCLC-21H: 95.8;SH-SY5Y: 57.5"
"RCOR3","FLJ10876","ENSG00000117625","REST corepressor 3","1","211258377-211316385","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA007413, HPA071997","Enhanced",NA,"Approved","Nucleus<br>Nucleoli","Glioma:1.92e-5 (favourable), Lung cancer:5.75e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 66.3","Expressed in all",NA,NA
"REEP2","C5orf19, SGC32445, SPG72, Yip2d","ENSG00000132563","Receptor accessory protein 2","5","138439017-138446969","Disease related genes, Predicted membrane proteins","Evidence at protein level","HPA031813","Enhanced",NA,NA,NA,"Breast cancer:7.83e-5 (favourable), Glioma:3.43e-4 (unfavourable), Melanoma:9.31e-4 (favourable)","Tissue enriched","Tissue enhanced",NA,"cerebral cortex: 90.1","smooth muscle: 18.0","Cell line enhanced",NA,"AN3-CA: 89.1;SCLC-21H: 46.8;SH-SY5Y: 47.6"
"RENBP","RBP, RNBP","ENSG00000102032","Renin binding protein","X","153935263-153944691","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA000428, HPA000522","Enhanced",NA,NA,NA,"Renal cancer:3.08e-5 (favourable), Cervical cancer:3.95e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"spleen: 58.5","kidney: 37.8","Cell line enhanced",NA,"EFO-21: 31.9;HMC-1: 101.6;SK-MEL-30: 61.5;U-266/84: 49.9"
"RFT1","CDG1N","ENSG00000163933","RFT1 homolog","3","53088483-53130462","Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters","Evidence at protein level","HPA060327, HPA069022","Approved",NA,"Approved","Vesicles","Liver cancer:1.69e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 25.8","Expressed in all",NA,NA
"RFX1","EF-C","ENSG00000132005","Regulatory factor X1","19","13961538-14007039","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA048722","Approved",NA,"Supported","Nucleoplasm","Head and neck cancer:2.42e-4 (favourable), Pancreatic cancer:4.92e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 16.8","Expressed in all",NA,NA
"RGMA","RGM, RGMa","ENSG00000182175","Repulsive guidance molecule family member a","15","93035273-93089204","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB012343, HPA039880, HPA044222","Approved",NA,"Supported","Nucleoplasm<br>Cytosol","Lung cancer:2.78e-4 (favourable)","Tissue enriched","Tissue enhanced",NA,"cerebral cortex: 116.6;smooth muscle: 84.8","skeletal muscle: 42.6","Cell line enhanced",NA,"AF22: 49.7;NTERA-2: 22.5"
"RGPD1","RGP1","ENSG00000187627","RANBP2-like and GRIP domain containing 1","2","86907953-87013981","Predicted intracellular proteins","Evidence at transcript level","HPA049497, HPA051675, HPA067564","Uncertain",NA,"Approved","Nuclear membrane<br>Vesicles",NA,"Not detected","Group enriched",12,"cervix, uterine: 11.8;placenta: 9.0;testis: 24.5","parathyroid gland: 1.2","Cell line enhanced",NA,"BEWO: 6.0;MOLT-4: 8.6;NTERA-2: 3.1"
"RGPD2","RANBP2L2, RGP2","ENSG00000185304","RANBP2-like and GRIP domain containing 2","2","87755955-87825952","Predicted intracellular proteins","Evidence at transcript level","HPA049497, HPA051675, HPA067564","Uncertain",NA,"Approved","Nuclear membrane<br>Vesicles",NA,"Not detected","Tissue enhanced",NA,"placenta: 14.3;testis: 33.3","bone marrow: 6.3","Cell line enhanced",NA,"BEWO: 10.9;MOLT-4: 10.5;NTERA-2: 5.4;SiHa: 4.7"
"RGPD3","RGP3","ENSG00000153165","RANBP2-like and GRIP domain containing 3","2","106391290-106468376","Predicted intracellular proteins","Evidence at transcript level","HPA049497, HPA051675, HPA067564","Uncertain",NA,"Approved","Nuclear membrane<br>Vesicles",NA,"Not detected","Tissue enriched",13,"testis: 11.7","cerebral cortex,kidney: 0.8","Cell line enhanced",NA,"HEL: 1.4;MOLT-4: 4.1"
"RGPD4","DKFZp686P0288, RGP4","ENSG00000196862","RANBP2-like and GRIP domain containing 4","2","107826937-107890841","Predicted intracellular proteins","Evidence at transcript level","HPA049497, HPA051675, HPA067564","Uncertain",NA,"Uncertain","Nuclear membrane<br>Vesicles",NA,"Not detected","Tissue enriched",57,"testis: 5.7","all non-specific tissues: 0.0","Not detected",NA,NA
"RGPD5","BS-63, DKFZp686I1842, RGP5","ENSG00000015568","RANBP2-like and GRIP domain containing 5","2","109792758-109857695","Predicted intracellular proteins","Evidence at protein level","HPA045704, HPA049497, HPA051675, HPA067564","Uncertain",NA,"Uncertain","Nuclear membrane<br>Vesicles",NA,"Not detected","Tissue enhanced",NA,"testis: 6.6","duodenum: 3.2","Mixed",NA,NA
"RGPD6","RGP6","ENSG00000183054","RANBP2-like and GRIP domain containing 6","2","110513812-110577185","Predicted intracellular proteins","Evidence at protein level","HPA045704, HPA049497, HPA051675, HPA067564","Uncertain",NA,"Uncertain","Nuclear membrane<br>Vesicles",NA,"Not detected","Expressed in all",NA,NA,"testis: 83.3","Mixed",NA,NA
"RGPD8","RanBP2alpha, RANBP2L1","ENSG00000169629","RANBP2-like and GRIP domain containing 8","2","112370092-112434488","Predicted intracellular proteins","Evidence at protein level","HPA045704, HPA049497, HPA051675, HPA067564","Uncertain",NA,"Uncertain","Nuclear membrane<br>Vesicles",NA,"Not detected","Tissue enriched",5,"testis: 31.7","cerebral cortex: 5.8","Cell line enhanced",NA,"HEL: 14.4"
"RGS11",NA,"ENSG00000076344","Regulator of G-protein signaling 11","16","268301-275980","Predicted intracellular proteins","Evidence at protein level","HPA041692, HPA043039","Uncertain",NA,NA,NA,"Pancreatic cancer:1.24e-4 (favourable)","Mixed","Tissue enhanced",NA,"cerebral cortex: 20.3","adipose tissue: 8.1","Cell line enhanced",NA,"HHSteC: 2.6;SCLC-21H: 3.6;SH-SY5Y: 2.5;T-47d: 2.4"
"RGS19","GAIP, RGSGAIP","ENSG00000171700","Regulator of G-protein signaling 19","20","64073181-64079988","Predicted intracellular proteins","Evidence at protein level","HPA056384, HPA069984","Enhanced",NA,"Supported","Nucleoli fibrillar center<br>Cell Junctions","Renal cancer:2.06e-9 (unfavourable), Liver cancer:2.75e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"spleen: 53.7","lymph node: 39.8","Expressed in all",NA,NA
"RGS5",NA,"ENSG00000143248","Regulator of G-protein signaling 5","1","163111121-163321791","Predicted intracellular proteins","Evidence at protein level","HPA001821",NA,"Approved","Supported","Cytosol","Renal cancer:9.17e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"adrenal gland: 406.2","Group enriched",45,"HUVEC TERT2: 1084.9;SH-SY5Y: 4496.0"
"RGS6",NA,"ENSG00000182732","Regulator of G-protein signaling 6","14","71932439-72566529","Predicted intracellular proteins","Evidence at protein level","HPA003067","Uncertain",NA,NA,NA,NA,"Group enriched","Tissue enhanced",NA,"cerebral cortex: 17.5;testis: 18.7","thyroid gland: 8.8","Group enriched",8,"HEL: 10.1;Karpas-707: 24.7"
"RHBDL3","RHBDL4, VRHO","ENSG00000141314","Rhomboid like 3","17","32266176-32324661","Enzymes, Predicted membrane proteins","Evidence at transcript level","HPA059607","Uncertain",NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 20.7","adrenal gland: 5.5","Cell line enhanced",NA,"A549: 4.0;AF22: 4.3;HDLM-2: 5.7;NTERA-2: 6.4;U-2 OS: 4.6"
"RHO","CSNBAD1, OPN2, RP4","ENSG00000163914","Rhodopsin","3","129528640-129535169","Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins, Transporters","Evidence at protein level","HPA013440, CAB022486, CAB034887, CAB034888","Supported",NA,NA,NA,NA,"Not detected","Not detected",NA,NA,"cerebral cortex: 0.3","Not detected",NA,NA
"RIOK1","AD034, bA288G3.1, FLJ30006, RRP10","ENSG00000124784","RIO kinase 1","6","7389496-7418037","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA017866, HPA051446","Enhanced",NA,"Approved","Nucleoli<br>Nuclear speckles<br>Cytosol","Liver cancer:3.41e-5 (unfavourable), Renal cancer:5.85e-5 (unfavourable), Melanoma:4.43e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 29.6","Expressed in all",NA,NA
"RIPPLY1",NA,"ENSG00000147223","Ripply transcriptional repressor 1","X","106900063-106903335","Predicted secreted proteins","Evidence at protein level","HPA052284","Uncertain",NA,NA,NA,NA,"Group enriched","Tissue enhanced",NA,"kidney: 2.3;liver: 3.0","seminal vesicle: 1.2","Cell line enriched",11,"RH-30: 6.3"
"RIPPLY3","DSCR6","ENSG00000183145","Ripply transcriptional repressor 3","21","37006150-37019659","Predicted intracellular proteins","Evidence at transcript level","HPA055541","Uncertain",NA,NA,NA,NA,"Mixed","Not detected",NA,NA,"prostate: 0.2","Cell line enhanced",NA,"SCLC-21H: 3.2;T-47d: 1.5"
"RNASE2","EDN, RAF3, RNS2","ENSG00000169385","Ribonuclease A family member 2","14","20955452-20956436","Enzymes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA044983","Enhanced",NA,NA,NA,"Renal cancer:3.28e-13 (unfavourable)","Tissue enriched","Tissue enriched",73,"bone marrow: 995.8","smooth muscle: 13.6","Group enriched",286,"HL-60: 411.9;NB-4: 325.9;THP-1: 920.7;U-937: 968.9"
"RNASE3","ECP, RAF1, RNS3","ENSG00000169397","Ribonuclease A family member 3","14","20891399-20892348","Predicted secreted proteins","Evidence at protein level","HPA056183","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",300,"bone marrow: 572.3","skin: 1.9","Cell line enhanced",NA,"HL-60: 114.0;THP-1: 41.0;U-937: 225.8"
"RNF13","RZF","ENSG00000082996","Ring finger protein 13","3","149812708-149962139","Enzymes, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA064784","Approved",NA,"Approved","Nucleoplasm<br>Vesicles<br>Cytosol","Renal cancer:2.00e-8 (favourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 94.4","Expressed in all",NA,NA
"RNF141","ZFP26, ZNF230","ENSG00000110315","Ring finger protein 141","11","10511678-10541230","Predicted intracellular proteins","Evidence at protein level","HPA018133","Approved",NA,"Approved","Nucleoplasm<br>Microtubules","Pancreatic cancer:1.14e-4 (unfavourable), Renal cancer:2.60e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 130.2","Expressed in all",NA,NA
"RNF213","C17orf27, KIAA1554, KIAA1618, MYMY2, NET57","ENSG00000173821","Ring finger protein 213","17","80260866-80398786","Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA003347, HPA026790","Approved",NA,"Supported","Cytosol","Endometrial cancer:4.65e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 65.3","Expressed in all",NA,NA
"RNF219","C13orf7, FLJ13449","ENSG00000152193","Ring finger protein 219","13","78614291-78659179","Predicted intracellular proteins","Evidence at protein level","HPA034785, HPA034786","Enhanced",NA,"Approved","Nucleoplasm<br>Nuclear bodies<br>Cytosol","Renal cancer:4.99e-6 (unfavourable)","Expressed in all","Mixed",NA,NA,"testis: 27.3","Mixed",NA,NA
"RNF26","MGC2642","ENSG00000173456","Ring finger protein 26","11","119334527-119337313","Predicted membrane proteins","Evidence at transcript level","HPA027620","Uncertain",NA,"Approved","Nucleoplasm<br>Vesicles<br>Cytosol","Renal cancer:3.45e-6 (favourable), Liver cancer:3.19e-4 (unfavourable), Urothelial cancer:7.73e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 33.9","Mixed",NA,NA
"RNF38",NA,"ENSG00000137075","Ring finger protein 38","9","36336396-36487548","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA015853","Approved",NA,"Supported","Nucleoplasm","Renal cancer:2.90e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 116.8","Expressed in all",NA,NA
"RNFT2","FLJ14627, TMEM118","ENSG00000135119","Ring finger protein, transmembrane 2","12","116738178-116853631","Predicted membrane proteins","Evidence at protein level","HPA064161","Enhanced",NA,"Approved","Nucleoplasm<br>Cytosol",NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 15.3","testis: 6.0","Mixed",NA,NA
"RNMT","RG7MT1","ENSG00000101654","RNA guanine-7 methyltransferase","18","13726660-13764558","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA039409","Approved",NA,"Enhanced","Nucleoplasm",NA,"Expressed in all","Expressed in all",NA,NA,"testis: 31.0","Expressed in all",NA,NA
"ROPN1L","ASP, FLJ25776, RSPH11","ENSG00000145491","Rhophilin associated tail protein 1 like","5","10441524-10472029","Predicted intracellular proteins","Evidence at protein level","HPA039193, HPA041830","Enhanced",NA,NA,NA,NA,"Group enriched","Tissue enriched",7,"testis: 298.1","fallopian tube: 43.4","Cell line enhanced",NA,"HMC-1: 2.3;NB-4: 8.4"
"RORB","NR1F2, ROR-BETA, RZRB","ENSG00000198963","RAR related orphan receptor B","9","74497365-74693177","Nuclear receptors, Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA008393","Uncertain",NA,"Approved","Nucleus",NA,"Group enriched","Tissue enhanced",NA,"cerebral cortex: 12.6;cervix, uterine: 14.1","prostate: 7.4","Cell line enhanced",NA,"HHSteC: 18.9;HSkMC: 9.0;MOLT-4: 5.5;SH-SY5Y: 14.3"
"RP11-1212A22.4",NA,"ENSG00000233024",NA,"16","18358086-18379331","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA053611","Approved",NA,"Uncertain","Nucleoplasm",NA,"Not detected","Expressed in all",NA,NA,"parathyroid gland: 131.8","Expressed in all",NA,NA
"RP11-294C11.3",NA,"ENSG00000279408",NA,"15","21651844-21653039","Predicted membrane proteins","Evidence at transcript level","HPA057442","Uncertain",NA,"Uncertain","Centrosome",NA,"Not detected","Tissue enriched",17,"testis: 14.6","cerebral cortex: 0.8","Cell line enriched",42,"U-2 OS: 6.9"
"RP11-407N17.3",NA,"ENSG00000258941","CTAGE family member 5 isoform 8 precursor","14","39233902-39350423","Predicted membrane proteins","Evidence at protein level","HPA000387, HPA000922, HPA054066, HPA055459","Uncertain",NA,"Approved","Endoplasmic reticulum",NA,"Not detected","Tissue enhanced",NA,"duodenum: 23.9;liver: 22.8;parathyroid gland: 44.1;small intestine: 29.5","kidney: 19.0","Cell line enhanced",NA,"CAPAN-2: 17.3;EFO-21: 5.5;Hep G2: 8.5;RPTEC TERT1: 7.0"
"RP11-435I10.4",NA,"ENSG00000261832",NA,"16","28456371-28492098","Predicted membrane proteins","Evidence at protein level","HPA053611","Uncertain",NA,"Approved","Nucleoplasm",NA,"Not detected","Not detected",NA,NA,"smooth muscle: 0.1","Not detected",NA,NA
"RP11-507K12.1",NA,"ENSG00000283321",NA,"7","17299295-17467234","Predicted intracellular proteins","Evidence at transcript level","HPA029722","Uncertain",NA,NA,NA,NA,NA,"Group enriched",5,"cervix, uterine: 12.8;urinary bladder: 23.3","fallopian tube: 3.3","Cell line enriched",5,"RT4: 44.0"
"RP11-566K11.2",NA,"ENSG00000198211",NA,"16","89919165-89936092","Predicted membrane proteins","Evidence at protein level","CAB011512, HPA043640, HPA046280","Uncertain",NA,NA,NA,NA,"Not detected","Tissue enhanced",NA,"skin: 1.0","testis: 0.6","Cell line enriched",7,"SK-MEL-30: 12.4"
"RP11-73M18.2",NA,"ENSG00000256500",NA,"14","103562962-103685924","Predicted intracellular proteins","Evidence at protein level","HPA044617, HPA052450","Uncertain",NA,"Uncertain","Nucleoplasm<br>Plasma membrane<br>Cytosol",NA,"Not detected","Tissue enhanced",NA,"cerebral cortex: 21.5;testis: 21.6","skeletal muscle: 9.0","Expressed in all",NA,NA
"RP1L1","DCDC4B","ENSG00000183638","RP1 like 1","8","10606349-10712187","Predicted intracellular proteins","Evidence at protein level","HPA024686, HPA024744","Enhanced",NA,NA,NA,NA,"Not detected","Not detected",NA,NA,"skin: 0.2","Not detected",NA,NA
"RP4-533D7.6",NA,"ENSG00000278139",NA,"1","46043661-46176488","Predicted intracellular proteins, RAS pathway related proteins","Evidence at transcript level","HPA005751","Uncertain",NA,NA,NA,NA,"Not detected","Tissue enriched",30,"testis: 41.3","gallbladder: 1.3","Cell line enhanced",NA,"HeLa: 2.1;RT4: 8.4"
"RP5-1052I5.2",NA,"ENSG00000267561",NA,"1","86993009-87169204","Predicted intracellular proteins","Evidence at protein level","HPA043069, HPA043603","Approved",NA,"Uncertain","Mitochondria",NA,"Not detected","Tissue enhanced",NA,"adipose tissue: 22.0","breast: 8.9","Cell line enhanced",NA,"ASC TERT1: 6.6;HEL: 13.2;HMC-1: 15.7;THP-1: 8.5"
"RPA3","REPA3","ENSG00000106399","Replication protein A3","7","7636518-7718607","Predicted intracellular proteins","Evidence at protein level","HPA005708","Approved",NA,NA,NA,"Liver cancer:5.16e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 50.7","Expressed in all",NA,NA
"RPAP3","FLJ21908, spag","ENSG00000005175","RNA polymerase II associated protein 3","12","47661249-47706061","Predicted intracellular proteins","Evidence at protein level","HPA038311, HPA038312","Enhanced",NA,"Approved","Cytosol","Liver cancer:2.01e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"lymph node: 34.4","Expressed in all",NA,NA
"RPF2","bA397G5.4, BXDC1, FLJ21087","ENSG00000197498","Ribosome production factor 2 homolog","6","110982015-111028263","Predicted intracellular proteins","Evidence at protein level","HPA035475","Supported",NA,"Supported","Nucleus<br>Nucleoli","Renal cancer:2.07e-6 (unfavourable), Head and neck cancer:2.04e-4 (unfavourable), Liver cancer:2.25e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 28.2","Expressed in all",NA,NA
"RPH3A","exophilin-1, KIAA0985, rabphilin","ENSG00000089169","Rabphilin 3A","12","112570380-112898881","Predicted intracellular proteins","Evidence at protein level","HPA002475","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",7,"cerebral cortex: 95.2","bone marrow: 13.8","Cell line enhanced",NA,"SH-SY5Y: 17.7"
"RPL29","HIP, HUMRPL29, L29, RPL29P10","ENSG00000162244","Ribosomal protein L29","3","51993600-51995942","Predicted intracellular proteins, Ribosomal proteins","Evidence at protein level","HPA069064","Approved",NA,"Enhanced","Nucleoli<br>Endoplasmic reticulum<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"ovary: 2738.5","Expressed in all",NA,NA
"RPL3","L3","ENSG00000100316","Ribosomal protein L3","22","39312882-39320389","FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Ribosomal proteins","Evidence at protein level","HPA003365, HPA055361","Uncertain",NA,"Supported","Nucleoli<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"ovary: 5675.2","Expressed in all",NA,NA
"RPL32","L32","ENSG00000144713","Ribosomal protein L32","3","12834485-12841588","Plasma proteins, Predicted intracellular proteins, Ribosomal proteins","Evidence at protein level","HPA047501, HPA051994","Enhanced",NA,"Approved","Endoplasmic reticulum<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"ovary: 4513.7","Expressed in all",NA,NA
"RPL38","L38","ENSG00000172809","Ribosomal protein L38","17","74203582-74210655","Predicted intracellular proteins, Ribosomal proteins","Evidence at protein level","HPA052543","Approved",NA,"Supported","Endoplasmic reticulum<br>Cytosol","Renal cancer:6.17e-8 (unfavourable), Head and neck cancer:2.51e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"ovary: 2584.8","Expressed in all",NA,NA
"RPL8","L8","ENSG00000161016","Ribosomal protein L8","8","144789765-144792587","Plasma proteins, Predicted intracellular proteins, Ribosomal proteins","Evidence at protein level","HPA045095, HPA050165","Enhanced",NA,"Enhanced","Nucleoli<br>Endoplasmic reticulum<br>Cytosol","Liver cancer:7.22e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"ovary: 954.7","Expressed in all",NA,NA
"RPN1","OST1","ENSG00000163902","Ribophorin I","3","128619970-128681075","Cancer-related genes, Plasma proteins, Predicted membrane proteins","Evidence at protein level","CAB009748, HPA026828, HPA051520","Enhanced",NA,"Enhanced","Endoplasmic reticulum","Liver cancer:4.80e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"epididymis: 422.3","Expressed in all",NA,NA
"RPS15","MGC111130, RIG, S15","ENSG00000115268","Ribosomal protein S15","19","1438358-1440494","Cancer-related genes, Predicted intracellular proteins, Ribosomal proteins","Evidence at protein level","HPA054510, HPA057793","Enhanced",NA,"Approved","Endoplasmic reticulum<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"ovary: 1335.2","Expressed in all",NA,NA
"RPS16","S16","ENSG00000105193","Ribosomal protein S16","19","39433207-39435948","Plasma proteins, Predicted intracellular proteins, Ribosomal proteins","Evidence at protein level","HPA064222","Approved",NA,"Enhanced","Endoplasmic reticulum<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"ovary: 3703.7","Expressed in all",NA,NA
"RPS17","MGC72007, RPS17L, RPS17L1, RPS17L2, S17","ENSG00000182774","Ribosomal protein S17","15","82536753-82540564","Disease related genes, Predicted intracellular proteins, Ribosomal proteins","Evidence at protein level","HPA055060","Approved",NA,"Supported","Nucleoli<br>Endoplasmic reticulum<br>Cytosol","Renal cancer:1.78e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"ovary: 1572.3","Expressed in all",NA,NA
"RPS21","S21","ENSG00000171858","Ribosomal protein S21","20","62387116-62388520","Plasma proteins, Predicted intracellular proteins, Ribosomal proteins","Evidence at protein level","HPA003371","Approved",NA,"Enhanced","Endoplasmic reticulum<br>Cytosol","Liver cancer:8.46e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"ovary: 2356.2","Expressed in all",NA,NA
"RPS5","S5","ENSG00000083845","Ribosomal protein S5","19","58386400-58394806","Plasma proteins, Predicted intracellular proteins, Ribosomal proteins","Evidence at protein level","HPA055878, HPA061979","Enhanced",NA,"Supported","Endoplasmic reticulum<br>Cytosol","Liver cancer:1.12e-5 (unfavourable), Renal cancer:4.75e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"ovary: 2648.9","Expressed in all",NA,NA
"RPS6","S6","ENSG00000137154","Ribosomal protein S6","9","19375715-19380254","Predicted intracellular proteins, Ribosomal proteins","Evidence at protein level","CAB004027, HPA031153","Supported",NA,"Enhanced","Endoplasmic reticulum<br>Cytosol","Endometrial cancer:4.12e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"ovary: 4805.4","Expressed in all",NA,NA
"RPS6KA5","MSK1, RLPK","ENSG00000100784","Ribosomal protein S6 kinase A5","14","90847862-91060636","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA001274, HPA001780, CAB025458","Approved",NA,"Enhanced","Nucleoplasm",NA,"Mixed","Mixed",NA,NA,"breast: 12.1","Cell line enhanced",NA,"HMC-1: 40.2"
"RPSA","37LRP, LAMR1, LRP, p40, SA","ENSG00000168028","Ribosomal protein SA","3","39406689-39412542","Disease related genes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins","Evidence at protein level","CAB009561","Approved",NA,"Supported","Plasma membrane<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"ovary: 2084.6","Expressed in all",NA,NA
"RPTN","FLJ39117","ENSG00000215853","Repetin","1","152153595-152159228","Predicted intracellular proteins","Evidence at protein level","HPA030483, HPA030485","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Group enriched",34,"skin: 35.1;tonsil: 47.4","esophagus: 1.2","Not detected",NA,NA
"RRAGA","FIP-1, RAGA","ENSG00000155876","Ras related GTP binding A","9","19049395-19050983","Predicted intracellular proteins","Evidence at protein level","HPA003734","Supported",NA,"Approved","Golgi apparatus<br>Vesicles","Head and neck cancer:7.43e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 128.1","Expressed in all",NA,NA
"RRAGB",NA,"ENSG00000083750","Ras related GTP binding B","X","55717739-55758774","Predicted intracellular proteins","Evidence at protein level","HPA003734","Approved",NA,"Approved","Golgi apparatus<br>Vesicles","Lung cancer:3.64e-6 (favourable), Glioma:5.36e-5 (favourable), Colorectal cancer:7.60e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"epididymis: 42.3","Expressed in all",NA,NA
"RRAGD","bA11D8.2.1, DKFZP761H171","ENSG00000025039","Ras related GTP binding D","6","89364636-89412270","Predicted intracellular proteins","Evidence at protein level","HPA068664","Approved",NA,"Approved","Nucleoplasm<br>Centrosome","Renal cancer:8.47e-8 (favourable), Liver cancer:7.80e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 46.8","Cell line enhanced",NA,"Karpas-707: 45.9;SCLC-21H: 39.1;U-266/70: 61.2"
"RRP1","D21S2056E, NNP-1, Nop52, RRP1A","ENSG00000160214","Ribosomal RNA processing 1","21","43789513-43805293","Predicted intracellular proteins","Evidence at protein level","HPA016818, HPA018166","Approved",NA,"Enhanced","Nucleoli","Renal cancer:6.29e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 12.1","Expressed in all",NA,NA
"RRP15","CGI-115, KIAA0507","ENSG00000067533","Ribosomal RNA processing 15 homolog","1","218285287-218337983","Predicted intracellular proteins","Evidence at protein level","HPA024639","Approved",NA,"Approved","Nucleus<br>Nucleoli<br>Mitochondria","Liver cancer:4.26e-5 (unfavourable)","Expressed in all","Mixed",NA,NA,"parathyroid gland: 7.7","Expressed in all",NA,NA
"RSBN1L","FLJ42526, FLJ45813, MGC71764","ENSG00000187257","Round spermatid basic protein 1 like","7","77696443-77783022","Cancer-related genes, Predicted intracellular proteins","Evidence at protein level","HPA020406, HPA020413","Approved",NA,"Supported","Nuclear speckles<br>Plasma membrane","Lung cancer:3.74e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 46.7","Expressed in all",NA,NA
"RSPH1","CILD24, FLJ32753, RSP44, RSPH10A, TSGA2","ENSG00000160188","Radial spoke head 1 homolog","21","42472486-42496354","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA016816, HPA017382","Enhanced",NA,"Approved","Nucleoplasm",NA,"Tissue enhanced","Tissue enriched",6,"fallopian tube: 251.8","testis: 42.3","Cell line enhanced",NA,"HEL: 4.8;MCF7: 8.1;RPTEC TERT1: 11.5"
"RSRC1","BM-011, MGC12197, SFRS21, SRrp53","ENSG00000174891","Arginine and serine rich coiled-coil 1","3","158105855-158545730","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA044792","Enhanced",NA,"Approved","Nuclear speckles","Endometrial cancer:7.40e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 39.0","Expressed in all",NA,NA
"RTFDC1","C20orf43, CDAO5, HSPC164","ENSG00000022277","Replication termination factor 2 domain containing 1","20","56468585-56519449","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA053986","Approved",NA,"Approved","Nucleus<br>Nucleoli","Liver cancer:1.31e-4 (unfavourable), Endometrial cancer:6.35e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 140.4","Expressed in all",NA,NA
"RTN1","NSP","ENSG00000139970","Reticulon 1","14","59595976-59870966","Plasma proteins, Predicted membrane proteins","Evidence at protein level","CAB002745, HPA040945, HPA044249","Enhanced",NA,"Enhanced","Endoplasmic reticulum","Pancreatic cancer:3.69e-4 (favourable)","Tissue enhanced","Tissue enriched",8,"cerebral cortex: 411.6","parathyroid gland: 49.6","Cell line enhanced",NA,"HEL: 54.3;SCLC-21H: 84.4;SH-SY5Y: 121.8"
"RUNDC1","DKFZp761H0421","ENSG00000198863","RUN domain containing 1","17","42980565-42993690","Predicted intracellular proteins","Evidence at protein level","HPA023726","Uncertain",NA,"Approved","Nuclear speckles<br>Cytosol","Endometrial cancer:6.93e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"fallopian tube: 23.5","Expressed in all",NA,NA
"RUNDC3A","RAP2IP, RPIP8","ENSG00000108309","RUN domain containing 3A","17","44308413-44318671","Predicted intracellular proteins","Evidence at protein level","HPA023548, HPA070733","Enhanced","Supported","Approved","Vesicles",NA,"Tissue enhanced","Tissue enriched",10,"cerebral cortex: 178.0","adrenal gland: 18.2","Group enriched",8,"SCLC-21H: 72.5;SH-SY5Y: 41.7"
"RUNX1T1","AML1T1, CBFA2T1, CDR, ETO, MTG8, ZMYND2","ENSG00000079102","RUNX1 translocation partner 1","8","91954967-92103286","Cancer-related genes, Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA049852, HPA070951","Approved",NA,"Supported","Nucleoplasm",NA,"Mixed","Mixed",NA,NA,"cervix, uterine: 12.8","Cell line enhanced",NA,"Daudi: 14.0;HEL: 32.2"
"RUNX3","AML2, CBFA3, PEBP2A3","ENSG00000020633","Runt related transcription factor 3","1","24899511-24965121","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA004195, CAB025416, HPA059006","Enhanced",NA,"Supported","Nucleus<br>Cytosol","Renal cancer:5.59e-5 (unfavourable), Colorectal cancer:8.71e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"spleen: 50.5","bone marrow: 45.2","Cell line enhanced",NA,"HDLM-2: 125.1;Karpas-707: 125.3;SK-MEL-30: 77.0"
"RXRB","H-2RIIBP, NR2B2, RCoR-1","ENSG00000204231","Retinoid X receptor beta","6","33193588-33200688","Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors","Evidence at protein level","CAB002003, HPA063653","Supported",NA,"Supported","Nucleus",NA,"Expressed in all","Mixed",NA,NA,"epididymis: 15.7","Cell line enhanced",NA,"RH-30: 8.5;T-47d: 8.2"
"RYR2","ARVC2, ARVD2, VTSIP","ENSG00000198626","Ryanodine receptor 2","1","237042205-237833988","Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters","Evidence at protein level","HPA020028","Approved",NA,"Approved","Nucleoplasm<br>Plasma membrane<br>Cytosol",NA,"Mixed","Tissue enriched",8,"heart muscle: 65.9","cerebral cortex: 7.9","Cell line enhanced",NA,"HDLM-2: 4.8;HEK 293: 6.3;K-562: 2.0;NTERA-2: 2.5;U-937: 2.5"
"S100A11","S100C","ENSG00000163191","S100 calcium binding protein A11","1","152032506-152047907","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB034320, HPA042745","Enhanced",NA,NA,NA,"Renal cancer:3.24e-6 (unfavourable), Liver cancer:3.64e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"esophagus: 2721.4","Expressed in all",NA,NA
"S100A12","CAAF1, CAGC, CGRP, ENRAGE, MRP6, p6","ENSG00000163221","S100 calcium binding protein A12","1","153373706-153375649","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA002881, CAB025872","Enhanced",NA,NA,NA,"Renal cancer:5.03e-4 (unfavourable)","Tissue enhanced","Tissue enriched",19,"bone marrow: 2045.4","spleen: 107.1","Cell line enhanced",NA,"hTCEpi: 1.6;THP-1: 1.0"
"S100A7","PSOR1, S100A7c","ENSG00000143556","S100 calcium binding protein A7","1","153457744-153460701","Cancer-related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB001453, HPA006997, CAB033766","Enhanced",NA,NA,NA,NA,"Group enriched","Group enriched",6,"skin: 326.2;tonsil: 885.9","esophagus: 95.9","Cell line enhanced",NA,"HaCaT: 5.4;SK-BR-3: 10.6"
"SAFB2","KIAA0138","ENSG00000130254","Scaffold attachment factor B2","19","5586999-5624046","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA050894","Approved",NA,"Supported","Nucleoplasm<br>Nuclear bodies<br>Vesicles","Urothelial cancer:2.12e-4 (favourable), Pancreatic cancer:2.53e-4 (favourable), Endometrial cancer:7.10e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"ovary: 40.0","Expressed in all",NA,NA
"SAMD14","FLJ36890","ENSG00000167100","Sterile alpha motif domain containing 14","17","50110040-50129882","Predicted intracellular proteins","Evidence at protein level","HPA051916","Uncertain",NA,"Approved","Nucleus<br>Nucleoli fibrillar center",NA,"Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 6.2","testis: 1.8","Cell line enhanced",NA,"HDLM-2: 12.8;HEL: 7.8;HMC-1: 24.7;SH-SY5Y: 14.0"
"SAMD15","C14orf174, FAM15A, FLJ35963","ENSG00000100583","Sterile alpha motif domain containing 15","14","77376689-77391497","Predicted intracellular proteins","Evidence at protein level","HPA030673, HPA030677","Enhanced",NA,"Approved","Nucleus<br>Nuclear membrane<br>Nucleoli",NA,"Mixed","Tissue enhanced",NA,"testis: 32.0","fallopian tube: 7.3","Mixed",NA,NA
"SAT1","SAT, SSAT","ENSG00000130066","Spermidine/spermine N1-acetyltransferase 1","X","23783173-23786226","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","CAB047343, HPA055312, CAB069914","Supported",NA,NA,NA,"Endometrial cancer:2.87e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 1269.5","Expressed in all",NA,NA
"SAYSD1","C6orf64, FLJ11101","ENSG00000112167","SAYSVFN motif domain containing 1","6","39104064-39115189","Predicted membrane proteins","Evidence at protein level","HPA007959",NA,"Approved","Enhanced","Vesicles",NA,"Expressed in all","Tissue enriched",6,"testis: 85.8","prostate: 14.6","Mixed",NA,NA
"SBSN","HLAR698, UNQ698","ENSG00000189001","Suprabasin","19","35523367-35528351","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA062568, HPA067734","Enhanced",NA,"Approved","Vesicles",NA,"Group enriched","Group enriched",12,"esophagus: 1055.9;skin: 2690.8","tonsil: 151.8","Cell line enhanced",NA,"ASC diff: 42.6;ASC TERT1: 75.3;HSkMC: 106.4;U-2197: 48.0;U-87 MG: 117.4"
"SCAF4","DKFZp434E098, KIAA1172, SFRS15, SRA4","ENSG00000156304","SR-related CTD associated factor 4","21","31671033-31732075","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA018319, HPA018668, HPA021504, HPA028807","Enhanced",NA,"Enhanced","Nucleoplasm",NA,"Expressed in all","Expressed in all",NA,NA,"testis: 28.4","Expressed in all",NA,NA
"SCAF8","KIAA1116, RBM16","ENSG00000213079","SR-related CTD associated factor 8","6","154733325-154834244","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA035601, HPA035602","Enhanced",NA,"Enhanced","Nucleoplasm","Ovarian cancer:6.61e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 45.1","Expressed in all",NA,NA
"SCAMP5","MGC24969","ENSG00000198794","Secretory carrier membrane protein 5","15","74957219-75021496","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA046645","Enhanced",NA,NA,NA,"Renal cancer:1.34e-6 (favourable), Pancreatic cancer:5.67e-5 (favourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 275.5","parathyroid gland: 81.7","Cell line enhanced",NA,"SCLC-21H: 103.1;SH-SY5Y: 51.9"
"SCG3","FLJ90833, SgIII","ENSG00000104112","Secretogranin III","15","51681353-51721031","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA006880, CAB033274, HPA053715","Enhanced","Approved","Enhanced","Vesicles",NA,"Group enriched","Tissue enriched",13,"cerebral cortex: 278.4","adrenal gland: 21.9","Group enriched",8,"NTERA-2: 50.4;SCLC-21H: 140.8;SH-SY5Y: 60.1"
"SCRG1","SCRG-1","ENSG00000164106","Stimulator of chondrogenesis 1","4","173384701-173406380","Predicted secreted proteins","Evidence at protein level","HPA012882","Approved",NA,NA,NA,NA,"Tissue enriched","Tissue enhanced",NA,"cerebral cortex: 24.4;testis: 15.5","smooth muscle: 11.0","Group enriched",13,"HSkMC: 4.3;WM-115: 17.6"
"SEC31A","ABP125, ABP130, KIAA0905, SEC31L1","ENSG00000138674","SEC31 homolog A, COPII coat complex component","4","82818661-82901166","Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA005457","Approved",NA,"Supported","Vesicles<br>Cytosol","Urothelial cancer:2.69e-4 (unfavourable), Liver cancer:3.32e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 281.0","Expressed in all",NA,NA
"SEC62","Dtrp1, HTP1, TLOC1","ENSG00000008952","SEC62 homolog, preprotein translocation factor","3","169966635-169998373","Predicted membrane proteins","Evidence at protein level","HPA014059, HPA061450","Approved",NA,"Approved","Endoplasmic reticulum<br>Intermediate filaments",NA,"Expressed in all","Expressed in all",NA,NA,"thyroid gland: 203.0","Expressed in all",NA,NA
"SELL","CD62L, hLHRc, LAM-1, LAM1, Leu-8, LNHR, LSEL, Lyam-1, LYAM1, PLNHR","ENSG00000188404","Selectin L","1","169690667-169711698","Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted membrane proteins","Evidence at protein level","CAB002144, HPA051972","Enhanced",NA,"Approved","Cytosol","Renal cancer:4.96e-5 (unfavourable), Cervical cancer:2.25e-4 (favourable), Ovarian cancer:3.14e-4 (favourable), Breast cancer:3.76e-4 (favourable), Head and neck cancer:6.43e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"lymph node: 254.9;spleen: 219.3;tonsil: 179.1","appendix: 152.7","Cell line enhanced",NA,"EFO-21: 9.7;MOLT-4: 16.7;U-266/70: 28.0;U-698: 12.2"
"SEPT3","SEP3","ENSG00000100167","Septin 3","22","41976272-41998221","Predicted intracellular proteins","Evidence at protein level","HPA003548, CAB017633","Enhanced",NA,"Approved","Nucleoplasm<br>Plasma membrane<br>Actin filaments","Endometrial cancer:1.78e-4 (unfavourable)","Tissue enhanced","Tissue enriched",11,"cerebral cortex: 234.8","parathyroid gland: 21.5","Cell line enhanced",NA,"AF22: 26.2;SCLC-21H: 84.0"
"SEPT4","ARTS, CE5B3, H5, hCDCREL-2, hucep-7, MART, PNUTL2","ENSG00000108387","Septin 4","17","58520250-58540818","Predicted intracellular proteins","Evidence at protein level","CAB006855, HPA021587, HPA022905","Enhanced",NA,"Supported","Nucleoplasm","Renal cancer:3.28e-7 (unfavourable)","Expressed in all","Tissue enhanced",NA,"adrenal gland: 217.2;cerebral cortex: 287.9","spleen: 56.8","Cell line enhanced",NA,"HHSteC: 11.8;SK-MEL-30: 25.2"
"SEPT7","CDC10, CDC3, SEPT7A","ENSG00000122545","Septin 7","7","35800932-35907105","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA023309, HPA029524","Enhanced",NA,"Enhanced","Nucleoli<br>Actin filaments<br>Midbody","Liver cancer:2.37e-4 (unfavourable), Renal cancer:2.78e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 430.4","Expressed in all",NA,NA
"SERAC1","FLJ14917","ENSG00000122335","Serine active site containing 1","6","158109515-158168270","Disease related genes, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA025715, HPA025716","Enhanced",NA,NA,NA,NA,"Expressed in all","Expressed in all",NA,NA,"testis: 16.5","Expressed in all",NA,NA
"SERINC1","KIAA1253, TDE1L, TDE2, TMS-2","ENSG00000111897","Serine incorporator 1","6","122443354-122471822","Plasma proteins, Predicted membrane proteins","Evidence at protein level","HPA035738, HPA035739","Uncertain",NA,"Approved","Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 615.4","Expressed in all",NA,NA
"SERINC2","FKSG84, PRO0899, TDE2, TDE2L","ENSG00000168528","Serine incorporator 2","1","31409565-31434680","Predicted membrane proteins","Evidence at protein level","HPA005974","Enhanced",NA,NA,NA,"Endometrial cancer:1.69e-7 (favourable), Liver cancer:2.11e-4 (unfavourable), Lung cancer:5.70e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"urinary bladder: 133.9","Cell line enhanced",NA,"HaCaT: 290.8;HBEC3-KT: 373.3;RT4: 285.7"
"SERPINA1","A1A, A1AT, AAT, alpha-1-antitrypsin, alpha1AT, PI, PI1","ENSG00000197249","Serpin family A member 1","14","94376747-94390693","Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA000927, HPA001292, CAB013211, CAB016648, CAB073396","Enhanced",NA,"Enhanced","Vesicles","Breast cancer:1.61e-5 (favourable), Colorectal cancer:5.86e-4 (favourable)","Tissue enriched","Tissue enriched",20,"liver: 17144.0","small intestine: 857.0","Cell line enriched",6,"Hep G2: 3254.2"
"SERPINA3","AACT, ACT","ENSG00000196136","Serpin family A member 3","14","94612377-94624055","Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA000893, HPA002560, CAB016647","Enhanced",NA,NA,NA,"Breast cancer:8.92e-4 (favourable)","Mixed","Group enriched",6,"cervix, uterine: 515.4;liver: 2304.3","gallbladder: 228.3","Cell line enriched",6,"Hep G2: 302.6"
"SERPINB1","anti-elastase, EI, ELANH2, PI2","ENSG00000021355","Serpin family B member 1","6","2832332-2842006","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA018871, HPA018882, HPA052642","Enhanced",NA,"Supported","Cytoplasmic bodies",NA,"Expressed in all","Expressed in all",NA,NA,"esophagus: 464.5","Cell line enhanced",NA,"U-937: 105.0"
"SERPINB5","maspin, PI5","ENSG00000206075","Serpin family B member 5","18","63476761-63505085","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB009570, HPA019025, HPA019132, HPA020136","Enhanced",NA,"Supported","Vesicles","Pancreatic cancer:5.71e-6 (unfavourable), Lung cancer:1.54e-4 (unfavourable)","Tissue enhanced","Group enriched",5,"esophagus: 220.2;skin: 261.8","breast: 44.2","Cell line enhanced",NA,"HaCaT: 1048.4;HBEC3-KT: 281.3;hTCEpi: 583.7"
"SERPINB6","CAP, DFNB91, PI6, PTI","ENSG00000124570","Serpin family B member 6","6","2948159-2972165","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA009668, HPA012736","Enhanced",NA,"Approved","Centrosome","Renal cancer:2.21e-4 (unfavourable), Ovarian cancer:4.81e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 255.6","Mixed",NA,NA
"SERTAD2","KIAA0127, Sei-2, TRIP-Br2","ENSG00000179833","SERTA domain containing 2","2","64631621-64751005","Predicted intracellular proteins","Evidence at protein level","HPA019021, HPA020904","Enhanced",NA,"Supported","Nucleoplasm<br>Cytosol","Renal cancer:1.70e-4 (unfavourable), Endometrial cancer:4.03e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"bone marrow: 54.0","Expressed in all",NA,NA
"SETD1A","KIAA0339, KMT2F, Set1","ENSG00000099381","SET domain containing 1A","16","30957294-30984664","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA020646, HPA058376","Enhanced",NA,"Supported","Nuclear speckles","Liver cancer:8.47e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 24.5","Expressed in all",NA,NA
"SEZ6",NA,"ENSG00000063015","Seizure related 6 homolog","17","28954901-29006440","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA011777","Enhanced",NA,"Uncertain","Intermediate filaments",NA,"Tissue enriched","Tissue enriched",53,"cerebral cortex: 54.3","duodenum: 1.0","Cell line enriched",6,"SCLC-21H: 69.9"
"SF3A1","Prp21, PRPF21, SAP114, SF3a120","ENSG00000099995","Splicing factor 3a subunit 1","22","30331988-30356947","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA000690, HPA030083","Enhanced",NA,"Enhanced","Nuclear speckles","Renal cancer:1.16e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 88.7","Expressed in all",NA,NA
"SF3A2","Prp11, PRPF11, SAP62, SF3a66","ENSG00000104897","Splicing factor 3a subunit 2","19","2236504-2248679","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA042843, HPA049439","Enhanced",NA,"Approved","Nucleoplasm","Liver cancer:3.23e-5 (unfavourable), Renal cancer:2.07e-4 (unfavourable), Cervical cancer:7.16e-4 (favourable), Colorectal cancer:8.64e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 50.3","Expressed in all",NA,NA
"SF3B6","CGI-110, Ht006, P14, SAP14a, SF3B14a","ENSG00000115128","Splicing factor 3b subunit 6","2","24067584-24076443","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA034829, HPA034830","Enhanced",NA,"Supported","Nucleoplasm","Liver cancer:5.57e-5 (unfavourable), Renal cancer:1.74e-4 (unfavourable), Pancreatic cancer:8.92e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 153.3","Expressed in all",NA,NA
"SFRP4","FRP-4, frpHE","ENSG00000106483","Secreted frizzled related protein 4","7","37905932-38025695","Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA009712, HPA050585","Enhanced",NA,NA,NA,"Renal cancer:1.36e-5 (unfavourable)","Expressed in all","Group enriched",5,"cervix, uterine: 935.5;endometrium: 776.1;fallopian tube: 338.6","smooth muscle: 130.5","Cell line enhanced",NA,"ASC diff: 6.5;HSkMC: 2.7;U-937: 2.9"
"SFTPD","COLEC7, SFTP4, SP-D","ENSG00000133661","Surfactant protein D","10","79937740-79982614","Predicted secreted proteins","Evidence at protein level","CAB004578, HPA044582, HPA056768","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",56,"lung: 782.5","bone marrow: 13.8","Cell line enhanced",NA,"BEWO: 1.3;hTCEpi: 2.3;MCF7: 1.1"
"SGIP1","DKFZp761D221","ENSG00000118473","SH3 domain GRB2 like endophilin interacting protein 1","1","66533383-66748299","Predicted intracellular proteins","Evidence at protein level","HPA017963","Approved",NA,"Approved","Mitochondria",NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 36.2","endometrium: 16.9","Cell line enhanced",NA,"BJ: 24.8;BJ hTERT+: 30.5;fHDF/TERT166: 18.7;RPTEC TERT1: 20.7;SH-SY5Y: 15.7;U-138 MG: 26.6"
"SGK1","SGK","ENSG00000118515","Serum/glucocorticoid regulated kinase 1","6","134169246-134318112","Cancer-related genes, Enzymes, Predicted intracellular proteins","Evidence at protein level","CAB022085, CAB025148, HPA051251","Approved",NA,"Enhanced","Nuclear speckles","Cervical cancer:5.26e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 793.4","Cell line enhanced",NA,"RPTEC TERT1: 354.6;TIME: 304.3"
"SH2D4A","FLJ20967, PPP1R38, SH2A","ENSG00000104611","SH2 domain containing 4A","8","19313617-19396218","Predicted intracellular proteins","Evidence at protein level","HPA001871, HPA001919","Enhanced",NA,"Enhanced","Cytosol","Renal cancer:6.02e-8 (favourable)","Expressed in all","Mixed",NA,NA,"ovary: 44.9","Cell line enhanced",NA,"fHDF/TERT166: 140.4;U-2197: 121.2"
"SH3BGRL2",NA,"ENSG00000198478","SH3 domain binding glutamate rich protein like 2","6","79631283-79703659","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA047486","Approved",NA,"Supported","Nucleoplasm","Renal cancer:2.24e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 98.4","Cell line enhanced",NA,"CACO-2: 66.4;HEL: 37.0"
"SHANK2","CORTBP1, CTTNBP1, ProSAP1, SHANK, SPANK-3","ENSG00000162105","SH3 and multiple ankyrin repeat domains 2","11","70467856-71252577","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA008174","Approved",NA,NA,NA,"Renal cancer:1.94e-6 (favourable)","Mixed","Tissue enhanced",NA,"cerebral cortex: 20.9","thyroid gland: 11.6","Cell line enhanced",NA,"Karpas-707: 16.4;RT4: 16.7;T-47d: 15.1"
"SHANK3","KIAA1650, prosap2, PSAP2, SPANK-2","ENSG00000251322","SH3 and multiple ankyrin repeat domains 3","22","50674415-50733298","Predicted intracellular proteins","Evidence at protein level","HPA003446, CAB079070","Enhanced","Approved",NA,NA,"Colorectal cancer:7.40e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"cerebral cortex: 2.7","Cell line enhanced",NA,"HEL: 3.8;TIME: 4.6"
"SHC3","N-Shc, NSHC, SHCC","ENSG00000148082","SHC adaptor protein 3","9","89005771-89178767","Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins","Evidence at protein level","HPA031427, HPA046656, HPA072448","Uncertain",NA,"Enhanced","Nucleoplasm<br>Cytosol",NA,"Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 45.3","parathyroid gland: 12.6","Cell line enhanced",NA,"AF22: 20.5;SH-SY5Y: 8.1;U-87 MG: 11.2"
"SHCBP1L","C1orf14","ENSG00000157060","SHC binding and spindle associated 1 like","1","182899865-182953525","Predicted intracellular proteins","Evidence at protein level","HPA036124, HPA036125, HPA064821","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",989,"testis: 98.9","all non-specific tissues: 0.0","Not detected",NA,NA
"SHISA2","bA398O19.2, C13orf13, hShisa, PRO28631, TMEM46, WGAR9166","ENSG00000180730","Shisa family member 2","13","26044597-26051031","Predicted membrane proteins","Evidence at protein level","HPA049752, HPA050172","Uncertain",NA,"Approved","Nucleoplasm<br>Nuclear bodies<br>Vesicles","Renal cancer:2.43e-4 (favourable), Lung cancer:3.30e-4 (favourable)","Mixed","Tissue enhanced",NA,"breast: 22.3;thyroid gland: 48.3","epididymis: 13.1","Cell line enhanced",NA,"LHCN-M2: 21.2;NTERA-2: 18.4;RH-30: 56.6;U-2197: 34.1"
"SHISA7",NA,"ENSG00000187902","Shisa family member 7","19","55428740-55442863","Predicted membrane proteins","Evidence at protein level","HPA058935","Uncertain",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",13,"cerebral cortex: 18.2","testis: 1.4","Cell line enhanced",NA,"HEL: 2.7;HMC-1: 2.7;THP-1: 1.1"
"SHROOM4","KIAA1202","ENSG00000158352","Shroom family member 4","X","50591647-50814302","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA010565","Uncertain",NA,NA,NA,"Renal cancer:4.66e-4 (unfavourable), Endometrial cancer:8.37e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"lung: 19.2","placenta: 13.1","Cell line enhanced",NA,"EFO-21: 6.5;HUVEC TERT2: 22.2;TIME: 8.3"
"SHTN1","KIAA1598, shootin-1, shootin1","ENSG00000187164","Shootin 1","10","116881482-117126586","Cancer-related genes, Predicted intracellular proteins","Evidence at protein level","HPA037942, HPA037943","Enhanced","Approved","Approved","Nucleus<br>Plasma membrane<br>Cytosol","Urothelial cancer:5.08e-6 (unfavourable), Prostate cancer:5.07e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 36.1","parathyroid gland: 18.7","Mixed",NA,NA
"SIAE","CSE-C, LSE, MGC87009, YSG2","ENSG00000110013","Sialic acid acetylesterase","11","124633113-124695707","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA038052, HPA038053","Approved",NA,NA,NA,"Renal cancer:4.42e-11 (favourable), Endometrial cancer:4.66e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"rectum: 114.5","Mixed",NA,NA
"SIGLEC9","CD329","ENSG00000129450","Sialic acid binding Ig like lectin 9","19","51124908-51136651","Predicted membrane proteins","Evidence at protein level","HPA010682","Uncertain",NA,NA,NA,"Renal cancer:6.17e-5 (unfavourable)","Mixed","Tissue enhanced",NA,"appendix: 24.7;spleen: 23.5","lung: 12.2","Group enriched",7,"Karpas-707: 16.8;RPMI-8226: 11.4"
"SIPA1L1","E6TP1, KIAA0440","ENSG00000197555","Signal induced proliferation associated 1 like 1","14","71320449-71741229","Predicted intracellular proteins","Evidence at protein level","HPA002875","Approved",NA,"Approved","Plasma membrane<br>Actin filaments","Renal cancer:6.80e-8 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 47.0","Mixed",NA,NA
"SIPA1L3","KIAA0545","ENSG00000105738","Signal induced proliferation associated 1 like 3","19","37907228-38208372","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA042072, HPA045480","Uncertain",NA,"Approved","Nuclear membrane<br>Nuclear speckles",NA,"Expressed in all","Mixed",NA,NA,"small intestine: 19.8","Expressed in all",NA,NA
"SIT1","SIT","ENSG00000137078","Signaling threshold regulating transmembrane adaptor 1","9","35649295-35650950","Predicted membrane proteins","Evidence at protein level","HPA018506","Enhanced",NA,NA,NA,"Endometrial cancer:1.94e-6 (favourable), Renal cancer:1.75e-5 (unfavourable), Head and neck cancer:1.14e-4 (favourable), Cervical cancer:6.56e-4 (favourable), Melanoma:8.17e-4 (favourable)","Mixed","Group enriched",5,"appendix: 24.6;lymph node: 56.1;spleen: 21.9;tonsil: 29.6","urinary bladder: 6.0","Cell line enhanced",NA,"Daudi: 80.3;HDLM-2: 65.0;U-698: 70.1"
"SKAP2","RA70, SAPS, SCAP2, SKAP-HOM, SKAP55R","ENSG00000005020","Src kinase associated phosphoprotein 2","7","26667062-26995239","Predicted intracellular proteins","Evidence at protein level","HPA005560, HPA024045","Enhanced",NA,"Supported","Nucleoplasm<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 54.6","Cell line enhanced",NA,"CAPAN-2: 125.0"
"SKIV2L","170A, DDX13, HLP, SKI2W, SKIV2, SKIV2L1","ENSG00000204351","Ski2 like RNA helicase","6","31959080-31969755","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA051959, HPA054419","Uncertain",NA,"Approved","Nucleoplasm","Renal cancer:3.02e-7 (unfavourable), Liver cancer:6.58e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"epididymis: 10.5","Mixed",NA,NA
"SLAMF7","19A, CD319, CRACC, CS1","ENSG00000026751","SLAM family member 7","1","160739057-160754821","CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB015445, HPA055945, HPA061654","Enhanced",NA,"Approved","Vesicles","Renal cancer:8.57e-5 (unfavourable), Ovarian cancer:3.93e-4 (favourable)","Mixed","Mixed",NA,NA,"spleen: 58.3","Group enriched",7,"SK-MEL-30: 45.6;U-266/70: 216.2"
"SLAMF8","BLAME, CD353, SBBI42","ENSG00000158714","SLAM family member 8","1","159826750-159837249","CD markers, Predicted membrane proteins","Evidence at protein level","HPA067601","Enhanced",NA,NA,NA,"Renal cancer:5.42e-5 (unfavourable)","Expressed in all","Tissue enhanced",NA,"appendix: 39.3","lymph node: 36.1","Cell line enhanced",NA,"ASC TERT1: 1.1;HL-60: 1.0;U-138 MG: 2.0;U-87 MG: 1.3"
"SLC11A2","DCT1, DMT1, NRAMP2","ENSG00000110911","Solute carrier family 11 member 2","12","50979401-51028566","Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters","Evidence at protein level","HPA032139, HPA032140","Uncertain",NA,"Supported","Mitochondria","Lung cancer:3.07e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 75.1","Expressed in all",NA,NA
"SLC12A1","NKCC2","ENSG00000074803","Solute carrier family 12 member 1","15","48191664-48304078","Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters","Evidence at protein level","HPA014967, HPA018107","Enhanced",NA,"Approved","Nucleus<br>Vesicles",NA,"Tissue enhanced","Tissue enriched",477,"kidney: 780.2","testis: 1.6","Cell line enriched",19,"RPTEC TERT1: 19.2"
"SLC12A5","KCC2, KIAA1176","ENSG00000124140","Solute carrier family 12 member 5","20","46021690-46060152","Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters","Evidence at protein level","HPA072058","Enhanced",NA,NA,NA,"Glioma:8.45e-4 (unfavourable)","Mixed","Tissue enriched",8,"cerebral cortex: 94.2","adrenal gland: 11.9","Cell line enhanced",NA,"NB-4: 32.3;U-2 OS: 29.1"
"SLC12A7","DKFZP434F076, KCC4","ENSG00000113504","Solute carrier family 12 member 7","5","1050376-1112035","Plasma proteins, Predicted membrane proteins, Transporters","Evidence at protein level","HPA041652","Approved",NA,"Uncertain","Cytosol","Liver cancer:2.12e-6 (unfavourable), Urothelial cancer:3.16e-5 (favourable)","Expressed in all","Mixed",NA,NA,"duodenum: 24.3","Cell line enhanced",NA,"REH: 40.1"
"SLC16A7","MCT2","ENSG00000118596","Solute carrier family 16 member 7","12","59596067-59789855","Predicted membrane proteins, Transporters","Evidence at protein level","HPA005911","Approved",NA,"Approved","Nucleoplasm<br>Plasma membrane","Renal cancer:8.85e-5 (favourable)","Mixed","Mixed",NA,NA,"adipose tissue,heart muscle: 24.9","Mixed",NA,NA
"SLC18A1","CGAT, VAT1, VMAT1","ENSG00000036565","Solute carrier family 18 member A1","8","20144855-20183206","FDA approved drug targets, Predicted membrane proteins, Transporters","Evidence at protein level","HPA006877, HPA063797","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",11,"adrenal gland: 32.6","rectum: 3.0","Cell line enriched",9,"SH-SY5Y: 70.0"
"SLC1A2","EAAT2, GLT-1","ENSG00000110436","Solute carrier family 1 member 2","11","35251206-35420063","Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters","Evidence at protein level","CAB002574, HPA009172","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",30,"cerebral cortex: 365.8","liver: 12.2","Cell line enhanced",NA,"fHDF/TERT166: 1.5;NTERA-2: 2.4;SCLC-21H: 1.5"
"SLC1A6","EAAT4","ENSG00000105143","Solute carrier family 1 member 6","19","14950034-15022990","Predicted intracellular proteins, Predicted membrane proteins, Transporters","Evidence at protein level","HPA041505, HPA044066","Enhanced",NA,"Uncertain","Intermediate filaments","Urothelial cancer:6.88e-6 (unfavourable)","Tissue enriched","Group enriched",5,"cerebral cortex: 16.2;skin: 8.9;testis: 36.9","epididymis: 3.7","Group enriched",5,"HAP1: 7.6;NTERA-2: 6.0;U-698: 19.3"
"SLC22A15","FLIPT1","ENSG00000163393","Solute carrier family 22 member 15","1","115976498-116070054","Predicted membrane proteins, Transporters","Evidence at protein level","HPA019785","Approved",NA,NA,NA,NA,"Expressed in all","Tissue enhanced",NA,"bone marrow: 20.5","skin: 11.1","Cell line enhanced",NA,"hTCEpi: 26.0;hTERT-HME1: 36.4"
"SLC22A4","DFNB60, MGC34546, OCTN1","ENSG00000197208","Solute carrier family 22 member 4","5","132294443-132344206","Disease related genes, Predicted membrane proteins","Evidence at protein level","CAB015468, HPA036974","Approved",NA,"Approved","Mitochondria",NA,"Mixed","Tissue enhanced",NA,"fallopian tube: 18.4","bone marrow: 13.2","Cell line enhanced",NA,"BJ hTERT+: 48.5;U-138 MG: 24.5"
"SLC25A20","CAC, CACT","ENSG00000178537","Solute carrier family 25 member 20","3","48856931-48898993","Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters","Evidence at protein level","HPA016862, HPA029863","Approved",NA,"Supported","Mitochondria<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"liver: 70.9","Cell line enhanced",NA,"RPMI-8226: 88.8"
"SLC27A4","ACSVL4, FATP4","ENSG00000167114","Solute carrier family 27 member 4","9","128340646-128361470","Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters","Evidence at protein level","HPA007293, CAB009771","Approved",NA,"Supported","Vesicles","Renal cancer:2.61e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"duodenum: 72.1","Expressed in all",NA,NA
"SLC2A13","HMIT","ENSG00000151229","Solute carrier family 2 member 13","12","39755021-40106089","Predicted membrane proteins, Transporters","Evidence at protein level","HPA006584","Approved",NA,"Approved","Nuclear membrane",NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 49.3;parathyroid gland: 74.7","cervix, uterine: 20.4","Mixed",NA,NA
"SLC33A1","ACATN, AT-1, AT1, SPG42","ENSG00000169359","Solute carrier family 33 member 1","3","155821024-155854429","Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters","Evidence at protein level","HPA042430, HPA060345","Uncertain",NA,"Approved","Nucleus",NA,"Expressed in all","Expressed in all",NA,NA,"thyroid gland: 67.3","Expressed in all",NA,NA
"SLC35E3","BLOV1","ENSG00000175782","Solute carrier family 35 member E3","12","68746106-68793964","Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at transcript level","HPA049403","Uncertain",NA,NA,NA,"Endometrial cancer:1.78e-4 (favourable)","Expressed in all","Mixed",NA,NA,"skin: 6.1","Mixed",NA,NA
"SLC35F3","FLJ37712","ENSG00000183780","Solute carrier family 35 member F3","1","233904933-234324516","Predicted membrane proteins, Transporters","Evidence at protein level","HPA051327, HPA061582","Uncertain",NA,"Approved","Nucleoli<br>Golgi apparatus",NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 10.1","breast: 3.0","Cell line enriched",7,"HDLM-2: 103.6"
"SLC35F6","ANT2BP, C2orf18, FLJ20555, TANGO9","ENSG00000213699","Solute carrier family 35 member F6","2","26764284-26781231","Predicted membrane proteins, Transporters","Evidence at protein level","HPA034655","Approved",NA,"Approved","Nucleoplasm<br>Vesicles<br>Cytosol","Liver cancer:1.11e-4 (unfavourable), Lung cancer:3.71e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 26.2","Expressed in all",NA,NA
"SLC36A2","PAT2, TRAMD1, tramdorin","ENSG00000186335","Solute carrier family 36 member 2","5","151314978-151347590","Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters","Evidence at protein level","HPA044002, HPA062229","Enhanced",NA,NA,NA,NA,"Tissue enriched","Group enriched",27,"kidney: 67.7;skeletal muscle: 28.0","testis: 1.7","Not detected",NA,NA
"SLC36A4","FLJ38932, PAT4","ENSG00000180773","Solute carrier family 36 member 4","11","93144171-93197964","Predicted membrane proteins, Transporters","Evidence at protein level","HPA017887","Enhanced",NA,"Approved","Golgi apparatus<br>Plasma membrane<br>Cytosol",NA,"Expressed in all","Mixed",NA,NA,"thyroid gland: 14.8","Mixed",NA,NA
"SLC38A7","FLJ10815","ENSG00000103042","Solute carrier family 38 member 7","16","58665109-58685104","Predicted membrane proteins, Transporters","Evidence at protein level","HPA041777","Uncertain",NA,"Approved","Nucleoplasm<br>Plasma membrane<br>Cytosol","Renal cancer:2.87e-4 (favourable), Endometrial cancer:6.87e-4 (favourable)","Expressed in all","Mixed",NA,NA,"testis: 34.7","Expressed in all",NA,NA
"SLC41A3","FLJ20473","ENSG00000114544","Solute carrier family 41 member 3","3","126006355-126101561","Predicted membrane proteins, Transporters","Evidence at protein level","HPA045847","Approved",NA,"Supported","Plasma membrane","Liver cancer:1.49e-7 (unfavourable), Renal cancer:6.04e-7 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 77.4","Expressed in all",NA,NA
"SLC4A1","AE1, CD233, DI, EPB3, FR, RTA1A, SW, WD, WR","ENSG00000004939","Solute carrier family 4 member 1 (Diego blood group)","17","44248385-44268141","Blood group antigen proteins, CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters","Evidence at protein level","HPA015584, CAB034438, HPA063911","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",8,"bone marrow: 238.0","kidney: 30.0","Mixed",NA,NA
"SLC4A10","NBCn2, NCBE","ENSG00000144290","Solute carrier family 4 member 10","2","161424332-161985282","Predicted membrane proteins, Transporters","Evidence at protein level","HPA034755","Supported",NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",22,"cerebral cortex: 57.5","adrenal gland: 2.6","Cell line enriched",10,"Karpas-707: 6.1"
"SLC5A1","D22S675, NAGT, SGLT1","ENSG00000100170","Solute carrier family 5 member 1","22","32043032-32113029","Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters","Evidence at protein level","CAB015467, HPA051805, HPA055106","Enhanced",NA,"Approved","Nucleoplasm<br>Vesicles","Renal cancer:6.97e-7 (favourable), Endometrial cancer:2.59e-4 (favourable)","Mixed","Group enriched",10,"duodenum: 505.0;small intestine: 313.4","gallbladder: 40.2","Cell line enhanced",NA,"CACO-2: 2.1;RPMI-8226: 1.3;SH-SY5Y: 1.0"
"SLC6A1","GABATHG, GABATR, GAT1","ENSG00000157103","Solute carrier family 6 member 1","3","10992724-11039247","Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters","Evidence at protein level","HPA013341, CAB022293","Enhanced",NA,"Uncertain","Mitochondria","Renal cancer:5.05e-6 (unfavourable), Liver cancer:3.20e-4 (favourable)","Group enriched","Group enriched",5,"cerebral cortex: 119.4;liver: 50.4","parathyroid gland: 16.0","Not detected",NA,NA
"SLC6A15","FLJ10316, hv7-3, NTT73, SBAT1, V7-3","ENSG00000072041","Solute carrier family 6 member 15","12","84859488-84913615","Predicted intracellular proteins, Predicted membrane proteins, Transporters","Evidence at protein level","HPA008609","Uncertain",NA,"Approved","Nucleoli<br>Vesicles",NA,"Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 23.0","placenta: 5.5","Cell line enhanced",NA,"ASC diff: 62.0;hTERT-HME1: 99.4;SCLC-21H: 104.6"
"SLC8A2","KIAA1087, NCX2","ENSG00000118160","Solute carrier family 8 member A2","19","47428017-47472168","Plasma proteins, Predicted membrane proteins, Transporters","Evidence at protein level","HPA050818, HPA054671","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enriched",11,"cerebral cortex: 68.2","endometrium: 6.3","Group enriched",8,"NTERA-2: 3.2;SCLC-21H: 10.8;SH-SY5Y: 5.2;SiHa: 4.1;U-2 OS: 6.2"
"SLC9A1","APNH, NHE1, PPP1R143","ENSG00000090020","Solute carrier family 9 member A1","1","27098815-27166981","Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters","Evidence at protein level","CAB022371, HPA048532, HPA052891","Enhanced",NA,"Supported","Plasma membrane","Glioma:6.32e-4 (unfavourable), Ovarian cancer:7.10e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"stomach: 65.5","Expressed in all",NA,NA
"SLC9A3","NHE3","ENSG00000066230","Solute carrier family 9 member A3","5","473310-524332","Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters","Evidence at protein level","HPA036493, HPA036669","Enhanced",NA,"Supported","Plasma membrane","Melanoma:8.49e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"colon: 80.9;gallbladder: 66.1;small intestine: 72.6","kidney: 57.3","Cell line enhanced",NA,"HDLM-2: 30.4"
"SLFN14",NA,"ENSG00000236320","Schlafen family member 14","17","35548125-35558098","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA022994, HPA023065","Uncertain",NA,NA,NA,NA,"Not detected","Tissue enhanced",NA,"bone marrow: 2.5","lymph node: 0.6","Cell line enriched",7,"HEL: 19.4"
"SLIT2","SLIL3, Slit-2","ENSG00000145147","Slit guidance ligand 2","4","20253260-20620561","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB007590, HPA019511, HPA023088","Uncertain",NA,NA,NA,"Renal cancer:6.51e-4 (favourable)","Mixed","Mixed",NA,NA,"lung: 49.5","Cell line enhanced",NA,"BJ hTERT+: 175.8;BJ hTERT+ SV40 Large T+: 96.6;fHDF/TERT166: 96.4;HBF TERT88: 115.2"
"SLITRK1","KIAA1910, LRRC12","ENSG00000178235","SLIT and NTRK like family member 1","13","83877205-83882393","Disease related genes, Plasma proteins, Predicted membrane proteins","Evidence at protein level","HPA012414","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",81,"cerebral cortex: 23.8","adrenal gland,cervix, uterine,pancreas,seminal vesicle: 0.2","Cell line enhanced",NA,"A-431: 2.6;AF22: 1.1"
"SLITRK5","bA364G4.2, KIAA0918, LRRC11","ENSG00000165300","SLIT and NTRK like family member 5","13","87672615-87696272","Predicted membrane proteins","Evidence at protein level","HPA013843","Uncertain",NA,"Supported","Nucleoplasm<br>Golgi apparatus",NA,"Not detected","Tissue enhanced",NA,"cerebral cortex: 4.9;fallopian tube: 4.7","seminal vesicle: 1.8","Cell line enhanced",NA,"AF22: 6.9"
"SLTM","FLJ13213, Met","ENSG00000137776","SAFB like transcription modulator","15","58879045-58933653","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA040256, HPA040381","Enhanced",NA,"Enhanced","Nucleoplasm<br>Nuclear bodies",NA,"Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 66.5","Expressed in all",NA,NA
"SMAD2","JV18-1, MADH2, MADR2","ENSG00000175387","SMAD family member 2","18","47808957-47931146","Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors","Evidence at protein level","CAB025507, HPA067203, CAB073546","Approved",NA,"Supported","Nucleus<br>Nucleoli<br>Cytosol","Liver cancer:9.44e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 126.7","Expressed in all",NA,NA
"SMARCA5","hISWI, hSNF2H, ISWI","ENSG00000153147","SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 5","4","143513463-143557486","Predicted intracellular proteins, Transcription factors","Evidence at protein level","CAB005227, HPA008751","Supported",NA,"Supported","Nucleus<br>Nucleoli fibrillar center","Liver cancer:1.61e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 59.1","Expressed in all",NA,NA
"SMC5","KIAA0594, SMC5L1","ENSG00000198887","Structural maintenance of chromosomes 5","9","70258962-70354888","Predicted intracellular proteins","Evidence at protein level","HPA054900","Enhanced",NA,"Supported","Nuclear speckles",NA,"Expressed in all","Expressed in all",NA,NA,"ovary: 30.8","Expressed in all",NA,NA
"SMG1","ATX, KIAA0421, LIP","ENSG00000157106","SMG1, nonsense mediated mRNA decay associated PI3K related kinase","16","18804853-18926454","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA006870, HPA031623, HPA073972","Approved",NA,"Supported","Nucleoplasm",NA,"Expressed in all","Expressed in all",NA,NA,"skin: 50.1","Expressed in all",NA,NA
"SMU1","BWD, FLJ10805, fSAP57, SMU-1","ENSG00000122692","DNA replication regulator and spliceosomal factor","9","33041764-33076659","Predicted intracellular proteins","Evidence at protein level","HPA019228, HPA019708","Supported",NA,"Approved","Vesicles","Renal cancer:1.67e-5 (favourable), Ovarian cancer:1.25e-4 (favourable), Cervical cancer:2.66e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 27.4","Expressed in all",NA,NA
"SMYD3","KMT3E, ZMYND1, ZNFN3A1","ENSG00000185420","SET and MYND domain containing 3","1","245749342-246507312","Cancer-related genes, Enzymes, Predicted intracellular proteins","Evidence at protein level","CAB012229, HPA045821, HPA054352","Approved",NA,"Approved","Nucleoplasm<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"epididymis,thyroid gland: 27.0","Expressed in all",NA,NA
"SNCAIP","SYPH1","ENSG00000064692","Synuclein alpha interacting protein","5","122311354-122464219","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA064687","Uncertain",NA,"Supported","Nucleoplasm<br>Cytoplasmic bodies",NA,"Mixed","Tissue enhanced",NA,"endometrium: 29.8;ovary: 43.3","cervix, uterine: 25.8","Cell line enhanced",NA,"AF22: 4.9;BJ hTERT+: 3.9;RPMI-8226: 3.7"
"SNCB",NA,"ENSG00000074317","Synuclein beta","5","176620084-176630556","Predicted intracellular proteins","Evidence at protein level","CAB002681, HPA035876","Enhanced","Supported",NA,NA,NA,"Tissue enriched","Tissue enriched",71,"cerebral cortex: 329.2","adrenal gland: 4.6","Cell line enriched",15,"SCLC-21H: 68.9"
"SNCG","BCSG1, persyn, SR","ENSG00000173267","Synuclein gamma","10","86958618-86963260","Predicted intracellular proteins","Evidence at protein level","CAB001452, HPA014404, CAB040581","Enhanced","Approved",NA,NA,"Renal cancer:2.29e-8 (unfavourable), Stomach cancer:7.15e-4 (unfavourable)","Group enriched","Tissue enhanced",NA,"adipose tissue: 174.6;adrenal gland: 198.1;urinary bladder: 183.2","seminal vesicle: 114.9","Cell line enhanced",NA,"CAPAN-2: 463.6;RT4: 350.3;T-47d: 106.9"
"SND1","p100, TDRD11","ENSG00000197157","Staphylococcal nuclease and tudor domain containing 1","7","127652180-128092609","Cancer-related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA002529, HPA002632, CAB019323","Enhanced",NA,"Enhanced","Cytosol","Endometrial cancer:1.95e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 122.3","Expressed in all",NA,NA
"SNIP1",NA,"ENSG00000163877","Smad nuclear interacting protein 1","1","37534449-37554344","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA036896","Enhanced",NA,"Supported","Nucleoplasm<br>Cytosol",NA,"Expressed in all","Mixed",NA,NA,"testis: 7.6","Expressed in all",NA,NA
"SNN",NA,"ENSG00000184602","Stannin","16","11668414-11679159","Predicted membrane proteins","Evidence at protein level","HPA011055","Approved",NA,"Approved","Cytosol","Liver cancer:1.85e-6 (unfavourable), Renal cancer:1.83e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 150.6","Expressed in all",NA,NA
"SNRPB","COD, Sm-B/B', SmB/SmB', snRNP-B, SNRPB1","ENSG00000125835","Small nuclear ribonucleoprotein polypeptides B and B1","20","2461634-2470853","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA003482, CAB009610, HPA067842","Approved",NA,"Supported","Nucleoplasm","Liver cancer:1.07e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"bone marrow: 202.0","Expressed in all",NA,NA
"SNTN","FLJ44379, S100AL","ENSG00000188817","Sentan, cilia apical structure protein","3","63652668-63679020","Predicted intracellular proteins","Evidence at protein level","HPA043322, HPA058399","Enhanced",NA,NA,NA,NA,"Group enriched","Tissue enriched",12,"fallopian tube: 349.6","thyroid gland: 29.2","Not detected",NA,NA
"SNW1","Bx42, NCoA-62, Prp45, PRPF45, SKIIP, SKIP","ENSG00000100603","SNW domain containing 1","14","77717599-77761207","Predicted intracellular proteins","Evidence at protein level","HPA002457, CAB009931, HPA017370","Supported",NA,"Enhanced","Nucleoplasm","Liver cancer:1.96e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 85.0","Expressed in all",NA,NA
"SNX31","MGC39715","ENSG00000174226","Sorting nexin 31","8","100572882-100663415","Predicted intracellular proteins, Transporters","Evidence at protein level","HPA024284, HPA053466","Uncertain",NA,"Approved","Nucleoplasm<br>Golgi apparatus<br>Cytosol","Testis cancer:1.47e-4 (favourable)","Tissue enriched","Tissue enhanced",NA,"urinary bladder: 32.4","esophagus: 7.3","Cell line enriched",51,"RT4: 64.7"
"SNX32","FLJ30934, SNX6B","ENSG00000172803","Sorting nexin 32","11","65833641-65856896","Predicted intracellular proteins","Evidence at protein level","HPA041775","Uncertain",NA,"Uncertain","Cell Junctions<br>Focal adhesion sites",NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 7.7","testis: 1.8","Cell line enhanced",NA,"HHSteC: 3.0;HSkMC: 3.4;SH-SY5Y: 1.9;U-266/70: 4.3"
"SNX4","ATG24B","ENSG00000114520","Sorting nexin 4","3","125446644-125520197","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA005709","Uncertain",NA,NA,NA,"Renal cancer:5.01e-5 (favourable), Endometrial cancer:6.10e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 75.4","Expressed in all",NA,NA
"SOD1","ALS, ALS1, IPOA","ENSG00000142168","Superoxide dismutase 1","21","31659622-31668931","Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA001401, CAB008670","Enhanced",NA,"Supported","Nucleus<br>Plasma membrane<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"liver: 768.9","Expressed in all",NA,NA
"SORBS1","CAP, FLJ12406, KIAA1296, ponsin, SH3D5, sh3p12","ENSG00000095637","Sorbin and SH3 domain containing 1","10","95311771-95561414","Predicted intracellular proteins","Evidence at protein level","HPA027559, HPA043084","Enhanced",NA,"Supported","Plasma membrane<br>Focal adhesion sites<br>Centrosome","Breast cancer:2.84e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"adipose tissue: 320.1","Cell line enhanced",NA,"CACO-2: 21.9;HMC-1: 39.4;SK-MEL-30: 30.9"
"SORT1","Gp95, NT3","ENSG00000134243","Sortilin 1","1","109309568-109397951","Disease related genes, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA006889, CAB011498","Approved",NA,"Approved","Golgi apparatus<br>Plasma membrane<br>Cytosol","Colorectal cancer:7.74e-6 (favourable), Liver cancer:1.23e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"epididymis: 169.5","Mixed",NA,NA
"SOS1","GF1, GINGF, HGF","ENSG00000115904","SOS Ras/Rac guanine nucleotide exchange factor 1","2","38981396-39124345","Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins","Evidence at protein level","CAB005396, HPA012613","Uncertain",NA,"Uncertain","Nucleus<br>Nucleoli<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 41.0","Expressed in all",NA,NA
"SOST","DAND6, VBCH","ENSG00000167941","Sclerostin","17","43753731-43758788","Disease related genes, Predicted secreted proteins","Evidence at protein level","CAB025660","Approved",NA,NA,NA,NA,"Group enriched","Tissue enriched",16,"kidney: 10.3","lung: 0.6","Cell line enriched",37,"HaCaT: 4.6"
"SOX10","DOM, WS2E, WS4","ENSG00000100146","SRY-box 10","22","37970686-37987422","Disease related genes, Predicted intracellular proteins, Transcription factors","Evidence at protein level","CAB003171, HPA068898","Enhanced",NA,"Supported","Nucleoplasm",NA,"Not detected","Tissue enhanced",NA,"cerebral cortex: 56.6;salivary gland: 50.5","breast: 24.0","Group enriched",686,"SK-MEL-30: 236.8;WM-115: 425.1"
"SP1",NA,"ENSG00000185591","Sp1 transcription factor","12","53380176-53416446","Cancer-related genes, Predicted intracellular proteins, Transcription factors","Evidence at protein level","CAB000330, HPA001853, HPA012292","Supported",NA,"Enhanced","Nucleoplasm","Pancreatic cancer:1.43e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"endometrium: 54.3","Expressed in all",NA,NA
"SP140","LYSP100-A, LYSP100-B","ENSG00000079263","SP140 nuclear body protein","2","230203110-230313215","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA006162, HPA067493","Enhanced",NA,"Approved","Nucleoli fibrillar center<br>Mitochondria",NA,"Mixed","Group enriched",6,"appendix: 32.8;lymph node: 64.4;spleen: 38.3;tonsil: 50.7","urinary bladder: 7.6","Cell line enhanced",NA,"Daudi: 22.1;HDLM-2: 48.5;Karpas-707: 18.0;RPMI-8226: 11.2"
"SP9","ZNF990","ENSG00000217236","Sp9 transcription factor","2","174334946-174338492","Predicted intracellular proteins, Transcription factors","Evidence at transcript level","HPA062616","Uncertain",NA,"Approved","Mitochondria",NA,"Mixed","Tissue enhanced",NA,"fallopian tube: 1.4","skin: 0.9","Cell line enhanced",NA,"A549: 6.5;fHDF/TERT166: 4.2;THP-1: 7.8"
"SPACA1","SAMP32","ENSG00000118434","Sperm acrosome associated 1","6","88047789-88066832","Predicted membrane proteins","Evidence at protein level","HPA026744, HPA043297","Enhanced",NA,NA,NA,NA,"Not detected","Tissue enriched",512,"testis: 51.2","all non-specific tissues: 0.0","Not detected",NA,NA
"SPACA4","SAMP14","ENSG00000177202","Sperm acrosome associated 4","19","48606743-48607714","Predicted secreted proteins","Evidence at protein level","HPA041927, HPA061302","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enriched",18,"testis: 64.9","stomach: 3.5","Not detected",NA,NA
"SPARCL1","MAST9","ENSG00000152583","SPARC like 1","4","87473335-87531061","Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB026225","Enhanced",NA,NA,NA,"Urothelial cancer:3.33e-4 (unfavourable), Colorectal cancer:4.06e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"cerebral cortex: 2035.8","Cell line enhanced",NA,"AF22: 23.6;U-266/70: 7.1"
"SPATA18","FLJ32906","ENSG00000163071","Spermatogenesis associated 18","4","52051331-52097292","Predicted intracellular proteins","Evidence at protein level","HPA036854, HPA036855","Enhanced",NA,NA,NA,"Renal cancer:3.73e-9 (favourable), Endometrial cancer:1.32e-5 (favourable)","Expressed in all","Tissue enhanced",NA,"fallopian tube: 109.4;testis: 42.6","cervix, uterine: 16.2","Cell line enhanced",NA,"ASC TERT1: 22.1;BEWO: 23.6;HSkMC: 21.4;hTCEpi: 20.9"
"SPATA20","FLJ21347, SSP411, Tisp78","ENSG00000006282","Spermatogenesis associated 20","17","50543058-50555852","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA022023, HPA027144, HPA031442","Enhanced",NA,"Approved","Nucleoplasm","Urothelial cancer:9.69e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 97.7","Mixed",NA,NA
"SPESP1","SP-ESP","ENSG00000258484","Sperm equatorial segment protein 1","15","68818221-68946811","Predicted secreted proteins","Evidence at protein level","HPA045936, HPA051040","Enhanced",NA,NA,NA,NA,"Expressed in all","Tissue enriched",7,"testis: 128.4","placenta: 18.0","Cell line enhanced",NA,"BJ hTERT+ SV40 Large T+: 16.1;BJ hTERT+ SV40 Large T+ RasG12V: 17.7;HBF TERT88: 20.5;RPTEC TERT1: 19.6;SCLC-21H: 23.0;WM-115: 30.5"
"SPHKAP","SKIP","ENSG00000153820","SPHK1 interactor, AKAP domain containing","2","227979950-228181645","Predicted intracellular proteins","Evidence at protein level","HPA042499, HPA048168","Enhanced",NA,NA,NA,NA,"Not detected","Group enriched",7,"cerebral cortex: 19.4;heart muscle: 19.0","ovary: 2.7","Cell line enriched",17,"BJ hTERT+: 37.3"
"SPINT3","HKIB9","ENSG00000101446","Serine peptidase inhibitor, Kunitz type 3","20","45512461-45515624","Predicted secreted proteins","Evidence at protein level","HPA026852","Enhanced",NA,NA,NA,NA,"Not detected","Group enriched",32,"epididymis: 5.8;seminal vesicle: 15.4","skin: 0.3","Not detected",NA,NA
"SPN","CD43, GPL115, LSN","ENSG00000197471","Sialophorin","16","29662979-29670876","CD markers, Predicted membrane proteins","Evidence at protein level","CAB002666, HPA055244","Enhanced",NA,"Uncertain","Golgi apparatus<br>Plasma membrane<br>Cell Junctions","Endometrial cancer:3.08e-5 (favourable), Breast cancer:1.40e-4 (favourable), Melanoma:1.88e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"bone marrow: 38.6;lung: 33.3","lymph node: 25.4","Cell line enhanced",NA,"HEL: 209.9;HL-60: 167.0;HMC-1: 98.8;U-937: 115.3"
"SPRED2","FLJ21897, FLJ31917, Spred-2","ENSG00000198369","Sprouty related EVH1 domain containing 2","2","65310851-65432637","Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA038256, HPA064394","Approved",NA,"Uncertain","Nucleoplasm<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 44.0","Expressed in all",NA,NA
"SREK1","DKFZp564B176, SFRS12, SRrp508, SRrp86","ENSG00000153914","Splicing regulatory glutamic acid and lysine rich protein 1","5","66139971-66183615","Predicted intracellular proteins","Evidence at protein level","HPA037673, HPA037674, HPA059332","Enhanced",NA,"Enhanced","Nucleoplasm<br>Nuclear speckles","Head and neck cancer:2.54e-4 (favourable), Renal cancer:5.77e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"parathyroid gland: 15.0","Expressed in all",NA,NA
"SRGAP2","ARHGAP34, FNBP2, KIAA0456, SRGAP2A","ENSG00000266028","SLIT-ROBO Rho GTPase activating protein 2","1","206203345-206464443","Predicted intracellular proteins","Evidence at protein level","HPA028191, HPA028196","Approved",NA,"Supported","Nucleoplasm<br>Cytosol","Renal cancer:4.61e-7 (unfavourable), Liver cancer:9.61e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 55.9","Expressed in all",NA,NA
"SRI",NA,"ENSG00000075142","Sorcin","7","88205118-88226993","Predicted intracellular proteins","Evidence at protein level","HPA019004, HPA073666","Enhanced",NA,"Supported","Nucleoplasm<br>Cytosol","Lung cancer:3.08e-4 (favourable), Pancreatic cancer:9.03e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"colon: 562.9","Mixed",NA,NA
"SRRM3","FLJ37078","ENSG00000177679","Serine/arginine repetitive matrix 3","7","76201900-76287288","Predicted intracellular proteins","Evidence at protein level","HPA019337","Uncertain",NA,"Approved","Plasma membrane<br>Intermediate filaments<br>Microtubules",NA,"Mixed","Group enriched",10,"adrenal gland: 2.7;cerebral cortex: 8.5;testis: 1.8","stomach: 0.4","Group enriched",12,"SCLC-21H: 12.8;SH-SY5Y: 8.5"
"SRRM4","KIAA1853, nSR100","ENSG00000139767","Serine/arginine repetitive matrix 4","12","118981495-119163051","Predicted intracellular proteins","Evidence at protein level","HPA052783","Uncertain",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",9,"cerebral cortex: 13.5","adrenal gland: 1.5","Group enriched",5,"HeLa: 2.3;SCLC-21H: 4.6;SH-SY5Y: 3.3"
"SS18L1","CREST, KIAA0693","ENSG00000184402","SS18L1, nBAF chromatin remodeling complex subunit","20","62143795-62182484","Cancer-related genes, Predicted intracellular proteins","Evidence at protein level","CAB011827, HPA059046","Approved",NA,"Supported","Nucleoplasm<br>Cytosol","Head and neck cancer:8.00e-5 (favourable), Lung cancer:3.74e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"skin: 23.7","Expressed in all",NA,NA
"SSBP2","HSPC116","ENSG00000145687","Single stranded DNA binding protein 2","5","81413021-81751797","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","CAB020834, HPA068605","Approved",NA,"Supported","Nucleoplasm",NA,"Mixed","Expressed in all",NA,NA,"parathyroid gland: 76.2","Cell line enhanced",NA,"REH: 178.5"
"SSC4D","S4D-SRCRB, SRCRB-S4D, SRCRB4D","ENSG00000146700","Scavenger receptor cysteine rich family member with 4 domains","7","76389334-76409695","Predicted secreted proteins","Evidence at transcript level","HPA062611","Uncertain",NA,NA,NA,"Endometrial cancer:2.83e-6 (unfavourable), Renal cancer:4.71e-4 (unfavourable), Glioma:6.31e-4 (unfavourable)","Mixed","Group enriched",5,"kidney: 1.4;parathyroid gland: 4.2;thyroid gland: 2.0","cervix, uterine: 0.5","Group enriched",12,"EFO-21: 6.3;Hep G2: 6.5;U-2 OS: 27.2"
"SSR1","TRAPA","ENSG00000124783","Signal sequence receptor subunit 1","6","7268306-7347446","Predicted membrane proteins","Evidence at protein level","HPA011276, HPA017062","Enhanced",NA,"Supported","Endoplasmic reticulum","Renal cancer:5.79e-6 (unfavourable), Liver cancer:4.92e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 141.0","Expressed in all",NA,NA
"SSTR2",NA,"ENSG00000180616","Somatostatin receptor 2","17","73165012-73176633","FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins","Evidence at protein level","HPA007264","Uncertain",NA,"Supported","Cytosol","Renal cancer:9.04e-7 (unfavourable), Pancreatic cancer:6.63e-4 (favourable)","Mixed","Tissue enhanced",NA,"cerebral cortex: 22.9","spleen: 5.8","Cell line enriched",9,"SCLC-21H: 14.9"
"ST18","KIAA0535, NZF3, ZC2H2C3, ZC2HC10, ZNF387","ENSG00000147488","ST18, C2H2C-type zinc finger","8","52110839-52460959","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA044919","Uncertain",NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",7,"cerebral cortex: 11.6","stomach: 1.5","Cell line enhanced",NA,"HAP1: 2.8;SCLC-21H: 11.3;U-87 MG: 1.5"
"ST5","DENND2B, HTS1, p126","ENSG00000166444","Suppression of tumorigenicity 5","11","8693351-8910951","Predicted intracellular proteins","Evidence at protein level","HPA046796","Approved",NA,"Approved","Nucleoplasm",NA,"Expressed in all","Expressed in all",NA,NA,"endometrium: 194.5","Mixed",NA,NA
"ST6GALNAC5","MGC3184, SIAT7E, ST6GalNAcV","ENSG00000117069","ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 5","1","76867441-77065711","Predicted secreted proteins","Evidence at protein level","HPA065593, HPA070354","Uncertain",NA,"Approved","Vesicles",NA,"Tissue enhanced","Mixed",NA,NA,"lung: 8.8","Cell line enhanced",NA,"AF22: 7.6;fHDF/TERT166: 7.3;SH-SY5Y: 7.0;U-2 OS: 7.8"
"ST8SIA5","SIAT8E","ENSG00000101638","ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 5","18","46667821-46759257","Predicted membrane proteins","Evidence at protein level","HPA043813, HPA046771","Approved",NA,"Approved","Plasma membrane<br>Midbody",NA,"Tissue enriched","Tissue enhanced",NA,"adrenal gland: 5.5;cerebral cortex: 11.4","parathyroid gland: 3.4","Cell line enriched",7,"WM-115: 121.0"
"STAB2","DKFZP434E0321, FEEL-2, FELL, HARE, SCARH1, STAB-2","ENSG00000136011","Stabilin 2","12","103587273-103766727","Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA026871","Enhanced",NA,"Uncertain","Cytosol",NA,"Not detected","Tissue enriched",6,"spleen: 48.3","liver: 7.8","Cell line enhanced",NA,"BEWO: 11.1;HaCaT: 2.8"
"STAG3",NA,"ENSG00000066923","Stromal antigen 3","7","100177563-100221488","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA049106, HPA058330","Enhanced",NA,NA,NA,"Cervical cancer:8.45e-4 (favourable)","Mixed","Tissue enriched",5,"testis: 130.2","fallopian tube: 23.9","Group enriched",6,"BEWO: 49.1;HMC-1: 56.4;U-698: 13.2"
"STAP1","BRDG1, STAP-1","ENSG00000035720","Signal transducing adaptor family member 1","4","67558728-67607337","Predicted intracellular proteins","Evidence at protein level","HPA038529","Enhanced",NA,"Uncertain","Nucleoplasm<br>Vesicles",NA,"Tissue enriched","Group enriched",6,"appendix: 23.8;kidney: 13.2;lymph node: 59.6;spleen: 26.6;tonsil: 56.3","testis: 6.1","Cell line enhanced",NA,"Daudi: 141.5;U-698: 60.7;U-937: 22.3"
"STAU2","39K2","ENSG00000040341","Staufen double-stranded RNA binding protein 2","8","73420369-73747708","Predicted intracellular proteins","Evidence at protein level","HPA019155, CAB020836","Approved",NA,"Supported","Nucleoplasm<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 74.0","Expressed in all",NA,NA
"STIM1","D11S4896E, GOK","ENSG00000167323","Stromal interaction molecule 1","11","3854527-4093210","Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters","Evidence at protein level","HPA011088, HPA012123, CAB037128, CAB037288","Enhanced",NA,"Enhanced","Endoplasmic reticulum",NA,"Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 86.8","Expressed in all",NA,NA
"STIM2",NA,"ENSG00000109689","Stromal interaction molecule 2","4","26857678-27025381","Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters","Evidence at protein level","HPA036933, CAB037196, HPA057511","Supported",NA,NA,NA,"Liver cancer:3.97e-5 (unfavourable), Pancreatic cancer:5.01e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"gallbladder: 45.8","Expressed in all",NA,NA
"STIP1","HOP, STI1","ENSG00000168439","Stress induced phosphoprotein 1","11","64185272-64204543","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB017448, HPA039291, HPA044062","Enhanced",NA,"Supported","Nucleoplasm<br>Plasma membrane<br>Cytosol","Liver cancer:6.18e-8 (unfavourable), Head and neck cancer:1.23e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 220.4","Expressed in all",NA,NA
"STK39","DCHT, SPAK","ENSG00000198648","Serine/threonine kinase 39","2","167954020-168248141","Enzymes, Predicted intracellular proteins","Evidence at protein level","CAB046022, HPA061803, HPA062802","Enhanced",NA,"Supported","Nucleoplasm<br>Vesicles<br>Cytosol","Liver cancer:5.67e-5 (unfavourable), Breast cancer:3.96e-4 (favourable)","Expressed in all","Mixed",NA,NA,"testis: 71.4","Mixed",NA,NA
"STMN1","C1orf215, FLJ32206, Lag, LAP18, OP18, PP17, PP19, PR22, SMN","ENSG00000117632","Stathmin 1","1","25884181-25906991","Cancer-related genes, Predicted intracellular proteins","Evidence at protein level","CAB010107","Approved",NA,"Supported","Cytosol","Liver cancer:9.90e-7 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 1039.4","Expressed in all",NA,NA
"STMN3","SCLIP","ENSG00000197457","Stathmin 3","20","63639705-63657682","Predicted intracellular proteins","Evidence at protein level","HPA012947","Enhanced",NA,NA,NA,NA,"Expressed in all","Tissue enhanced",NA,"cerebral cortex: 225.7","thyroid gland: 52.6","Cell line enhanced",NA,"SCLC-21H: 225.8;SH-SY5Y: 155.0"
"STON2","STN2, STNB2","ENSG00000140022","Stonin 2","14","81260656-81436465","Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA003086","Enhanced",NA,"Supported","Nucleoli<br>Cytosol","Endometrial cancer:4.96e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"cerebral cortex: 34.2","Cell line enhanced",NA,"HEL: 130.5;HMC-1: 63.9"
"STX17","FLJ20651","ENSG00000136874","Syntaxin 17","9","99906633-99970341","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA001204","Approved",NA,"Uncertain","Nucleoli<br>Cytosol","Renal cancer:1.62e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 35.7","Expressed in all",NA,NA
"STX1B","STX1B1, STX1B2","ENSG00000099365","Syntaxin 1B","16","30989256-31010661","Disease related genes, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA069176, CAB079008","Supported","Supported",NA,NA,NA,"Tissue enriched","Tissue enriched",22,"cerebral cortex: 108.6","testis: 4.8","Cell line enhanced",NA,"hTEC/SVTERT24-B: 11.1"
"STX3","STX3A","ENSG00000166900","Syntaxin 3","11","59755059-59805882","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA002191, HPA069176","Approved",NA,"Approved","Nucleus<br>Nuclear bodies<br>Golgi apparatus<br>Cytosol","Liver cancer:8.41e-7 (unfavourable), Renal cancer:1.14e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 72.4","Mixed",NA,NA
"STX6",NA,"ENSG00000135823","Syntaxin 6","1","180972712-181023121","Plasma proteins, Predicted membrane proteins","Evidence at protein level","HPA038557, HPA038558","Approved",NA,"Enhanced","Nucleoplasm<br>Golgi apparatus","Renal cancer:1.93e-8 (unfavourable), Liver cancer:6.24e-5 (unfavourable)","Expressed in all","Mixed",NA,NA,"cerebral cortex: 30.2","Expressed in all",NA,NA
"STX7",NA,"ENSG00000079950","Syntaxin 7","6","132445867-132513198","Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA001467, CAB062564","Enhanced",NA,"Enhanced","Lysosomes","Liver cancer:1.60e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"lymph node: 91.4","Expressed in all",NA,NA
"SUCLA2",NA,"ENSG00000136143","Succinate-CoA ligase ADP-forming beta subunit","13","47936491-48001354","Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA039435, HPA039536, HPA061528","Enhanced","Supported","Enhanced","Mitochondria","Renal cancer:7.59e-14 (favourable), Urothelial cancer:1.22e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"skeletal muscle: 78.7","Expressed in all",NA,NA
"SUCLG1",NA,"ENSG00000163541","Succinate-CoA ligase alpha subunit","2","84423523-84460045","Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins","Evidence at protein level","HPA036683, HPA036684","Enhanced",NA,"Supported","Plasma membrane<br>Mitochondria","Renal cancer:2.21e-8 (favourable), Endometrial cancer:5.23e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"kidney: 471.2","Expressed in all",NA,NA
"SUGP1","DKFZp434E2216, F23858, RBP, SF4","ENSG00000105705","SURP and G-patch domain containing 1","19","19276018-19320844","Predicted intracellular proteins","Evidence at protein level","HPA004890","Approved",NA,"Enhanced","Nucleoplasm",NA,"Expressed in all","Mixed",NA,NA,"testis: 17.0","Expressed in all",NA,NA
"SUGP2","KIAA0365, SFRS14","ENSG00000064607","SURP and G-patch domain containing 2","19","18990888-19034023","Predicted intracellular proteins","Evidence at protein level","HPA041557, HPA061111","Enhanced",NA,"Enhanced","Nucleoplasm<br>Nuclear bodies","Liver cancer:3.21e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 161.7","Expressed in all",NA,NA
"SUSD6","KIAA0247","ENSG00000100647","Sushi domain containing 6","14","69611596-69715142","Predicted membrane proteins","Evidence at protein level","HPA030464","Uncertain",NA,"Approved","Nucleoplasm<br>Intermediate filaments","Renal cancer:2.16e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"epididymis: 52.4","Expressed in all",NA,NA
"SV2B","HsT19680, KIAA0735","ENSG00000185518","Synaptic vesicle glycoprotein 2B","15","91099950-91301309","Predicted membrane proteins","Evidence at protein level","HPA046247","Approved",NA,NA,NA,NA,"Mixed","Tissue enriched",23,"cerebral cortex: 47.9","adipose tissue: 2.1","Group enriched",6,"RPMI-8226: 1.4;SCLC-21H: 4.6"
"SWT1","C1orf26, FLJ20121, HsSwt1","ENSG00000116668","SWT1, RNA endoribonuclease homolog","1","185157080-185291765","Predicted intracellular proteins","Evidence at protein level","HPA024214, HPA027334","Enhanced",NA,"Approved","Cytosol","Renal cancer:5.63e-4 (favourable)","Expressed in all","Tissue enriched",8,"testis: 69.4","thyroid gland: 8.7","Mixed",NA,NA
"SYCE2","CESC1","ENSG00000161860","Synaptonemal complex central element protein 2","19","12898786-12919276","Predicted intracellular proteins","Evidence at protein level","HPA042080, HPA062919","Enhanced",NA,"Supported","Nucleus","Cervical cancer:3.85e-5 (favourable), Endometrial cancer:9.91e-4 (unfavourable)","Mixed","Tissue enriched",15,"testis: 38.9","cerebral cortex: 2.5","Cell line enhanced",NA,"EFO-21: 11.1;SiHa: 12.6"
"SYN1",NA,"ENSG00000008056","Synapsin I","X","47571898-47619943","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA000397, CAB021929","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",26,"cerebral cortex: 378.9","adrenal gland: 14.5","Cell line enhanced",NA,"NTERA-2: 17.4;SCLC-21H: 35.6;SH-SY5Y: 8.3"
"SYN3",NA,"ENSG00000185666","Synapsin III","22","32512552-33058372","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA034566","Uncertain",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 9.5;testis: 7.9","placenta: 4.2","Cell line enhanced",NA,"HAP1: 5.8;NTERA-2: 3.7;SCLC-21H: 8.6"
"SYNGAP1","KIAA1938, RASA5, SYNGAP","ENSG00000197283","Synaptic Ras GTPase activating protein 1","6","33419661-33457541","Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins","Evidence at protein level","HPA038373","Enhanced",NA,"Approved","Nucleus","Renal cancer:1.34e-6 (unfavourable), Head and neck cancer:2.80e-4 (favourable)","Mixed","Tissue enhanced",NA,"cerebral cortex: 26.3","endometrium: 12.5","Cell line enhanced",NA,"AF22: 28.5"
"SYNGR1",NA,"ENSG00000100321","Synaptogyrin 1","22","39349925-39385588","Predicted membrane proteins","Evidence at protein level","HPA029673, CAB034277","Enhanced",NA,"Supported","Cytosol","Renal cancer:4.98e-7 (favourable), Pancreatic cancer:2.41e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 175.4","Mixed",NA,NA
"SYNGR3",NA,"ENSG00000127561","Synaptogyrin 3","16","1989660-1994275","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","CAB034278, HPA042842","Enhanced",NA,"Approved","Plasma membrane","Renal cancer:7.12e-7 (favourable), Cervical cancer:6.92e-4 (favourable)","Mixed","Tissue enriched",7,"cerebral cortex: 82.6","parathyroid gland: 12.6","Cell line enhanced",NA,"HDLM-2: 45.7;HMC-1: 26.7;U-266/70: 30.7"
"SYNPO","KIAA1029","ENSG00000171992","Synaptopodin","5","150601080-150659220","Predicted intracellular proteins","Evidence at protein level","CAB033265, HPA034631, CAB037325, HPA071347","Enhanced",NA,"Approved","Nucleoplasm<br>Actin filaments<br>Cytosol","Renal cancer:1.53e-6 (unfavourable)","Expressed in all","Tissue enhanced",NA,"skeletal muscle: 446.6","heart muscle: 226.3","Cell line enhanced",NA,"BEWO: 85.1;TIME: 144.5;U-87 MG: 148.8"
"SYT13","KIAA1427","ENSG00000019505","Synaptotagmin 13","11","45240301-45286319","Predicted intracellular proteins","Evidence at protein level","HPA046224, HPA056602","Uncertain",NA,"Supported","Vesicles","Endometrial cancer:7.79e-5 (unfavourable)","Mixed","Tissue enhanced",NA,"cerebral cortex: 69.9;gallbladder: 32.9","small intestine: 14.4","Group enriched",9,"A549: 17.3;NTERA-2: 8.8;RPTEC TERT1: 43.3;SCLC-21H: 17.8"
"SYT5",NA,"ENSG00000129990","Synaptotagmin 5","19","55171199-55180441","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA078390","Enhanced",NA,NA,NA,"Pancreatic cancer:5.54e-4 (favourable), Glioma:8.26e-4 (unfavourable)","Mixed","Tissue enriched",10,"cerebral cortex: 131.4","adrenal gland: 12.7","Cell line enhanced",NA,"EFO-21: 25.6;HMC-1: 53.1;K-562: 20.2;SCLC-21H: 18.7"
"SYVN1","DER3, HRD1","ENSG00000162298","Synoviolin 1","11","65121780-65134533","Enzymes, Predicted membrane proteins","Evidence at protein level","HPA005480, HPA024300, CAB037030","Enhanced",NA,"Supported","Nucleoplasm<br>Endoplasmic reticulum<br>Plasma membrane","Head and neck cancer:6.88e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"tonsil: 73.8","Expressed in all",NA,NA
"TAB2","KIAA0733, MAP3K7IP2","ENSG00000055208","TGF-beta activated kinase 1/MAP3K7 binding protein 2","6","149218641-149411613","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA065436, HPA070137, HPA071215","Approved",NA,"Supported","Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 70.3","Expressed in all",NA,NA
"TAF13","TAF2K, TAFII18","ENSG00000197780","TATA-box binding protein associated factor 13","1","109062486-109076002","Predicted intracellular proteins","Evidence at protein level","HPA044492","Approved",NA,"Enhanced","Nucleus<br>Nucleoli","Liver cancer:8.74e-6 (unfavourable), Ovarian cancer:2.42e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"smooth muscle: 50.5","Expressed in all",NA,NA
"TAF5","TAF2D, TAFII100","ENSG00000148835","TATA-box binding protein associated factor 5","10","103367967-103389065","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA006195, HPA006474","Supported",NA,"Supported","Nucleoplasm","Renal cancer:1.36e-9 (unfavourable), Stomach cancer:7.39e-5 (favourable)","Expressed in all","Tissue enhanced",NA,"testis: 20.7","lymph node,placenta: 5.1","Expressed in all",NA,NA
"TAF7","TAF2F, TAFII55","ENSG00000178913","TATA-box binding protein associated factor 7","5","141260225-141320821","Predicted intracellular proteins","Evidence at protein level","HPA006429","Approved",NA,"Supported","Nucleoplasm<br>Golgi apparatus",NA,"Expressed in all","Expressed in all",NA,NA,"testis: 138.7","Expressed in all",NA,NA
"TAGLN3","NP22, NP25","ENSG00000144834","Transgelin 3","3","111998664-112013887","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA062620","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",8,"cerebral cortex: 356.0","adrenal gland: 42.3","Group enriched",6,"AF22: 98.0;RPTEC TERT1: 30.7;SCLC-21H: 63.4;SH-SY5Y: 96.4"
"TAL1","bHLHa17, SCL, TCL5","ENSG00000162367","TAL bHLH transcription factor 1, erythroid differentiation factor","1","47216290-47232220","Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors","Evidence at protein level","CAB017805, HPA047866, HPA073983","Approved",NA,"Supported","Nucleus",NA,"Mixed","Tissue enhanced",NA,"bone marrow: 17.7","placenta: 10.0","Cell line enhanced",NA,"HEL: 137.6;HMC-1: 62.0;K-562: 43.6;TIME: 28.0"
"TAOK2","KIAA0881, MAP3K17, PSK, PSK1, TAO1, TAO2","ENSG00000149930","TAO kinase 2","16","29973641-29992261","Enzymes, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA010650","Approved",NA,"Supported","Nucleus<br>Nucleoli<br>Cytosol","Endometrial cancer:3.87e-5 (favourable), Colorectal cancer:2.51e-4 (unfavourable), Renal cancer:3.66e-4 (favourable), Pancreatic cancer:4.78e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 36.9","Expressed in all",NA,NA
"TAPT1","FLJ90013","ENSG00000169762","Transmembrane anterior posterior transformation 1","4","16160505-16227410","Disease related genes, Predicted membrane proteins","Evidence at protein level","HPA042567, HPA048658","Approved",NA,"Approved","Vesicles","Urothelial cancer:4.18e-4 (favourable), Pancreatic cancer:5.34e-4 (favourable), Renal cancer:8.52e-4 (favourable), Endometrial cancer:9.75e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 21.5","Expressed in all",NA,NA
"TARBP2","Trbp","ENSG00000139546","TARBP2, RISC loading complex RNA binding subunit","12","53500921-53506431","Predicted intracellular proteins","Evidence at protein level","HPA051181, HPA061454, CAB069406","Approved",NA,"Supported","Nucleoplasm<br>Nuclear bodies","Renal cancer:4.75e-6 (unfavourable), Liver cancer:3.09e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 18.9","Expressed in all",NA,NA
"TARSL2","FLJ25005","ENSG00000185418","Threonyl-tRNA synthetase like 2","15","101653598-101724604","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA066697","Approved",NA,"Approved","Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 15.7","Expressed in all",NA,NA
"TAS2R38","PTC, T2R61","ENSG00000257138","Taste 2 receptor member 38","7","141972631-141973773","G-protein coupled receptors, Predicted membrane proteins, Transporters","Evidence at transcript level","HPA043862, HPA054366","Uncertain",NA,NA,NA,NA,"Not detected","Not detected",NA,NA,"rectum,small intestine: 0.3","Not detected",NA,NA
"TBC1D10C","Carabin, EPI64C, FLJ00332","ENSG00000175463","TBC1 domain family member 10C","11","67403915-67410089","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA069743","Enhanced",NA,"Approved","Nuclear bodies","Renal cancer:4.35e-7 (unfavourable), Head and neck cancer:1.86e-5 (favourable), Breast cancer:3.83e-4 (favourable), Cervical cancer:4.20e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"lymph node: 45.6;spleen: 37.9","appendix: 22.0","Cell line enhanced",NA,"MOLT-4: 34.1;NB-4: 32.0;U-937: 16.2"
"TBX15","TBX14","ENSG00000092607","T-box 15","1","118883046-118989556","Disease related genes, Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA052245, HPA053713","Uncertain",NA,"Approved","Nucleoplasm<br>Centrosome","Renal cancer:5.57e-8 (unfavourable)","Mixed","Group enriched",7,"adipose tissue: 17.0;breast: 8.9;liver: 24.1;skeletal muscle: 42.2","lymph node: 3.1","Cell line enhanced",NA,"ASC diff: 36.8;BJ hTERT+ SV40 Large T+ RasG12V: 20.9;fHDF/TERT166: 22.5;HSkMC: 28.3;RH-30: 29.4;U-2197: 26.3"
"TCF21","bHLHa23, POD1","ENSG00000118526","Transcription factor 21","6","133889138-133895553","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA013189","Uncertain",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"placenta: 62.4;spleen: 46.9","ovary: 32.1","Cell line enriched",10,"HHSteC: 13.5"
"TCF7","TCF-1","ENSG00000081059","Transcription factor 7 (T-cell specific, HMG-box)","5","134114711-134151865","Cancer-related genes, Predicted intracellular proteins, Transcription factors","Evidence at protein level","CAB019403, HPA058863, HPA070505","Enhanced",NA,"Enhanced","Nucleoplasm",NA,"Expressed in all","Tissue enhanced",NA,"lymph node: 110.1","appendix: 71.7","Cell line enriched",13,"MOLT-4: 1060.4"
"TCHHL1","S100A17, THHL1","ENSG00000182898","Trichohyalin like 1","1","152084144-152089064","Predicted intracellular proteins","Evidence at protein level","HPA042579, HPA063483","Enhanced",NA,"Approved","Nuclear membrane<br>Nucleoli",NA,"Not detected","Not detected",NA,NA,"epididymis: 0.1","Cell line enriched",37,"SK-BR-3: 3.7"
"TCL1A","TCL1","ENSG00000100721","T-cell leukemia/lymphoma 1A","14","95709967-95714196","Cancer-related genes, Disease related genes, Predicted intracellular proteins","Evidence at protein level","CAB004045, HPA016604","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enhanced",NA,"lymph node: 324.7;tonsil: 196.7","spleen: 77.8","Group enriched",147,"Daudi: 334.2;REH: 557.7;U-698: 425.7"
"TCOF1","TCS, treacle","ENSG00000070814","Treacle ribosome biogenesis factor 1","5","150357639-150400308","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB033199, HPA038237, HPA038238","Enhanced",NA,"Enhanced","Nucleoli fibrillar center","Liver cancer:2.26e-8 (unfavourable), Renal cancer:2.62e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"lymph node: 22.0","Expressed in all",NA,NA
"TDRD15",NA,"ENSG00000218819","Tudor domain containing 15","2","21123917-21143272","Predicted intracellular proteins","Evidence at transcript level","HPA051770, HPA054675","Uncertain",NA,NA,NA,NA,"Not detected","Tissue enriched",77,"testis: 10.0","liver: 0.1","Cell line enhanced",NA,"U-266/70: 5.9;U-266/84: 2.1"
"TEKT1",NA,"ENSG00000167858","Tektin 1","17","6789133-6831761","Predicted intracellular proteins","Evidence at protein level","HPA044444, HPA062285","Approved",NA,NA,NA,"Endometrial cancer:6.08e-4 (favourable)","Group enriched","Group enriched",7,"fallopian tube: 79.5;testis: 16.7","lung: 6.9","Not detected",NA,NA
"TENM1","ODZ1, ODZ3, TEN-M1, TNM","ENSG00000009694","Teneurin transmembrane protein 1","X","124375903-124963817","Predicted membrane proteins","Evidence at protein level","HPA002848","Uncertain",NA,NA,NA,NA,"Group enriched","Mixed",NA,NA,"prostate: 4.0","Cell line enhanced",NA,"MOLT-4: 4.7;RPTEC TERT1: 1.5;SCLC-21H: 2.3;U-138 MG: 3.2"
"TERF2","TRBF2, TRF2","ENSG00000132604","Telomeric repeat binding factor 2","16","69355561-69408571","Predicted intracellular proteins","Evidence at protein level","HPA001907, HPA002735, CAB010451","Enhanced",NA,"Supported","Nuclear bodies",NA,"Expressed in all","Expressed in all",NA,NA,"lymph node: 42.2","Expressed in all",NA,NA
"TESPA1","KIAA0748","ENSG00000135426","Thymocyte expressed, positive selection associated 1","12","54948018-54984746","Predicted intracellular proteins","Evidence at protein level","HPA058823","Approved",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"lymph node: 46.7","cerebral cortex: 34.7","Group enriched",6,"HEL: 238.5;HMC-1: 184.2"
"TEX101","CT131, MGC4766, SGRG, SPATA44","ENSG00000131126","Testis expressed 101","19","43401496-43418597","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA041915, HPA042513","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enriched",108,"testis: 173.9","skin: 1.6","Not detected",NA,NA
"TEX15","CT42","ENSG00000133863","Testis expressed 15, meiosis and synapsis associated","8","30831544-30890606","Predicted intracellular proteins","Evidence at protein level","HPA036799, HPA036800","Enhanced",NA,"Approved","Nuclear speckles",NA,"Not detected","Group enriched",32,"endometrium: 11.0;smooth muscle: 8.3;testis: 22.3","cerebral cortex,gallbladder: 0.4","Cell line enhanced",NA,"HAP1: 8.7;HEL: 17.3;K-562: 4.9;SCLC-21H: 4.9"
"TEX44","C2orf57, MGC35154","ENSG00000177673","Testis expressed 44","2","231592901-231594283","Predicted intracellular proteins","Evidence at protein level","HPA049917, HPA056433","Enhanced",NA,NA,NA,NA,"Not detected","Tissue enriched",1204,"testis: 120.3","all non-specific tissues: 0.0","Not detected",NA,NA
"TFAP2D","TFAP2BL1","ENSG00000008197","Transcription factor AP-2 delta","6","50713828-50772988","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA048962","Uncertain",NA,NA,NA,NA,"Tissue enriched","Not detected",NA,NA,"cerebral cortex: 0.1","Cell line enhanced",NA,"HAP1: 1.3"
"TGFBI","BIGH3, CDB1, CDGG1, CSD1, CSD2, CSD3, LCD1","ENSG00000120708","Transforming growth factor beta induced","5","136028895-136063818","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA008612, HPA017019","Enhanced",NA,NA,NA,"Renal cancer:7.82e-10 (unfavourable), Cervical cancer:1.03e-5 (unfavourable), Ovarian cancer:1.14e-5 (unfavourable), Endometrial cancer:1.17e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 607.8","Cell line enhanced",NA,"fHDF/TERT166: 2100.5;HSkMC: 1955.4;U-87 MG: 3543.6"
"TGM1","ICR2, LI, LI1, TGASE, TGK","ENSG00000092295","Transglutaminase 1","14","24249114-24264432","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","CAB015159, HPA040171","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",12,"esophagus: 831.8","tonsil: 72.2","Cell line enhanced",NA,"BEWO: 33.0;HaCaT: 42.3;MCF7: 27.0;SK-BR-3: 31.6"
"TGOLN2","TGN38, TGN46, TGN48, TGN51, TTGN2","ENSG00000152291","Trans-golgi network protein 2","2","85318020-85328425","Plasma proteins, Predicted membrane proteins","Evidence at protein level","CAB011489, HPA012609, HPA012723","Enhanced",NA,"Enhanced","Nucleoplasm<br>Golgi apparatus",NA,"Expressed in all","Expressed in all",NA,NA,"thyroid gland: 146.3","Expressed in all",NA,NA
"THEMIS2","C1orf38, ICB-1","ENSG00000130775","Thymocyte selection associated family member 2","1","27872543-27886685","Predicted intracellular proteins","Evidence at protein level","HPA031096, HPA031097","Uncertain",NA,"Approved","Golgi apparatus",NA,"Expressed in all","Tissue enhanced",NA,"bone marrow: 137.5","spleen: 117.3","Cell line enhanced",NA,"Karpas-707: 98.1;U-266/70: 80.2"
"THOC7","FLJ23445, fSAP24, NIF3L1BP1","ENSG00000163634","THO complex 7","3","63833870-63863903","Predicted intracellular proteins","Evidence at protein level","HPA044143","Approved",NA,"Supported","Nuclear speckles<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"breast: 84.4","Expressed in all",NA,NA
"THOP1",NA,"ENSG00000172009","Thimet oligopeptidase 1","19","2785460-2815807","Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB025497, HPA035262","Uncertain",NA,"Supported","Cytosol","Endometrial cancer:2.35e-4 (favourable), Stomach cancer:5.90e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 36.1","Mixed",NA,NA
"THRA","AR7, EAR-7.1/EAR-7.2, ERBA, ERBA1, NR1A1, THRA1, THRA2, THRA3","ENSG00000126351","Thyroid hormone receptor, alpha","17","40058290-40093867","Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA009654, CAB023349","Uncertain",NA,"Supported","Cytosol","Renal cancer:6.05e-8 (favourable), Lung cancer:1.84e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 238.9","Expressed in all",NA,NA
"THRSP","Lpgp, LPGP1, S14, SPOT14, THRP","ENSG00000151365","Thyroid hormone responsive","11","78063861-78068351","Predicted intracellular proteins","Evidence at protein level","HPA040642","Approved",NA,"Approved","Nucleoplasm","Renal cancer:1.16e-4 (unfavourable), Thyroid cancer:3.28e-4 (favourable)","Tissue enhanced","Tissue enhanced",NA,"adipose tissue: 231.2;liver: 182.9","breast: 43.6","Cell line enriched",12,"ASC diff: 52.2"
"THY1","CD90","ENSG00000154096","Thy-1 cell surface antigen","11","119417378-119424985","CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA003733, CAB068243, CAB068244","Enhanced",NA,"Approved","Nucleus<br>Plasma membrane","Renal cancer:2.40e-6 (unfavourable), Glioma:9.64e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 421.8;smooth muscle: 434.2","gallbladder: 161.0","Cell line enhanced",NA,"BJ: 643.3;BJ hTERT+: 686.4;fHDF/TERT166: 1040.5"
"TIAM2","STEF","ENSG00000146426","T-cell lymphoma invasion and metastasis 2","6","154832697-155257723","Predicted intracellular proteins","Evidence at protein level","HPA011134, HPA013903","Approved",NA,"Supported","Nucleoplasm<br>Nucleoli fibrillar center<br>Cytosol",NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 18.0;testis: 24.4","thyroid gland: 10.2","Cell line enhanced",NA,"AF22: 62.0;HDLM-2: 27.3;RH-30: 39.8"
"TIFAB",NA,"ENSG00000255833","TIFA inhibitor","5","135444218-135452399","Predicted intracellular proteins","Evidence at protein level","HPA049372","Uncertain",NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"appendix: 4.9;lymph node: 6.3","tonsil: 4.5","Group enriched",14,"THP-1: 6.0;U-937: 1.5"
"TIMMDC1","C3orf1, FLJ22597","ENSG00000113845","Translocase of inner mitochondrial membrane domain containing 1","3","119498532-119525090","Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA053214, HPA055846","Uncertain",NA,"Enhanced","Nucleus<br>Mitochondria","Liver cancer:1.12e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 31.5","Expressed in all",NA,NA
"TJP1","DKFZp686M05161, MGC133289, ZO-1","ENSG00000104067","Tight junction protein 1","15","29699367-29968865","Predicted intracellular proteins","Evidence at protein level","HPA001636, HPA001637, CAB010822","Enhanced",NA,"Enhanced","Cell Junctions","Renal cancer:1.72e-4 (favourable)","Expressed in all","Mixed",NA,NA,"cerebral cortex: 49.6","Mixed",NA,NA
"TLE2","ESG, ESG2, FLJ41188, GRG2","ENSG00000065717","Transducin like enhancer of split 2","19","2997638-3047635","Predicted intracellular proteins","Evidence at protein level","HPA049103","Approved",NA,"Supported","Nuclear bodies<br>Focal adhesion sites","Pancreatic cancer:2.39e-6 (favourable), Renal cancer:9.49e-6 (favourable), Endometrial cancer:2.51e-4 (favourable), Urothelial cancer:8.88e-4 (favourable)","Expressed in all","Mixed",NA,NA,"seminal vesicle: 39.6","Cell line enhanced",NA,"AN3-CA: 39.6;RT4: 27.6"
"TM4SF20","FLJ22800, TCCE518","ENSG00000168955","Transmembrane 4 L six family member 20","2","227362156-227381995","Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters","Evidence at protein level","HPA051838, HPA063184, HPA065531","Uncertain",NA,"Supported","Plasma membrane<br>Focal adhesion sites",NA,"Group enriched","Group enriched",35,"duodenum: 277.2;small intestine: 163.8","testis: 6.3","Cell line enhanced",NA,"A549: 2.5;RPMI-8226: 1.2"
"TMC5","FLJ13593","ENSG00000103534","Transmembrane channel like 5","16","19410496-19499113","Predicted membrane proteins","Evidence at protein level","HPA040810, HPA042037","Enhanced",NA,"Approved","Nucleus<br>Plasma membrane","Liver cancer:7.96e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"small intestine: 59.1","duodenum: 45.4","Cell line enriched",6,"CAPAN-2: 61.8"
"TMED2","P24A, p24b1, p24beta1, RNP24","ENSG00000086598","Transmembrane p24 trafficking protein 2","12","123584531-123598577","Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA014060","Approved",NA,"Supported","Vesicles","Renal cancer:2.35e-7 (unfavourable), Head and neck cancer:3.36e-6 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 328.1","Expressed in all",NA,NA
"TMEM132B","KIAA1786, KIAA1906","ENSG00000139364","Transmembrane protein 132B","12","125186836-125662377","Predicted membrane proteins","Evidence at protein level","HPA035661, HPA035662","Uncertain",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",7,"cerebral cortex: 21.8","thyroid gland: 3.1","Cell line enhanced",NA,"HSkMC: 4.8;NTERA-2: 7.7;U-138 MG: 11.6"
"TMEM155","FLJ30834","ENSG00000164112","Transmembrane protein 155","4","121758933-121765427","Predicted secreted proteins","Evidence at transcript level","HPA077585","Approved",NA,NA,NA,NA,"Mixed","Group enriched",6,"cerebral cortex: 27.6;placenta: 5.7","lymph node: 3.0","Cell line enhanced",NA,"fHDF/TERT166: 4.0;HAP1: 2.2;LHCN-M2: 5.5;MOLT-4: 5.1"
"TMEM192","FLJ38482","ENSG00000170088","Transmembrane protein 192","4","165070608-165208549","Predicted membrane proteins, Transporters","Evidence at protein level","HPA014717, HPA024110","Enhanced",NA,"Enhanced","Nucleoplasm<br>Endosomes<br>Lysosomes","Renal cancer:2.33e-14 (favourable), Breast cancer:9.52e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"kidney: 51.0","Expressed in all",NA,NA
"TMEM229B","C14orf83, FLJ33387","ENSG00000198133","Transmembrane protein 229B","14","67447084-67533739","Predicted intracellular proteins, Predicted membrane proteins","Evidence at transcript level","HPA046562","Approved",NA,NA,NA,"Endometrial cancer:1.21e-5 (favourable), Urothelial cancer:1.79e-5 (favourable), Breast cancer:5.38e-4 (favourable)","Expressed in all","Mixed",NA,NA,"cervix, uterine: 16.0","Cell line enhanced",NA,"U-937: 26.9"
"TMEM234","C1orf91, dJ622L5.7, FLJ90779, RP4-622L5","ENSG00000160055","Transmembrane protein 234","1","32214472-32222359","Predicted membrane proteins, Transporters","Evidence at protein level","HPA015049","Uncertain",NA,"Approved","Vesicles","Liver cancer:2.35e-5 (unfavourable), Renal cancer:4.12e-5 (unfavourable)","Expressed in all","Mixed",NA,NA,"epididymis: 12.8","Expressed in all",NA,NA
"TMEM235",NA,"ENSG00000204278","Transmembrane protein 235","17","78231310-78240987","Predicted membrane proteins","Evidence at transcript level","HPA053939","Uncertain",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",100,"cerebral cortex: 15.6","placenta,testis: 0.1","Not detected",NA,NA
"TMEM242","BM033, C6orf35","ENSG00000215712","Transmembrane protein 242","6","157289386-157323601","Predicted membrane proteins","Evidence at protein level","HPA025764","Approved",NA,NA,NA,NA,"Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 16.9","Expressed in all",NA,NA
"TMEM266","C15orf27, FLJ38190","ENSG00000169758","Transmembrane protein 266","15","76059837-76229121","Predicted membrane proteins","Evidence at protein level","HPA041921, HPA049425","Enhanced",NA,"Supported","Plasma membrane<br>Cytosol",NA,"Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 1.9;skeletal muscle: 1.5","placenta: 1.2","Cell line enhanced",NA,"NTERA-2: 1.0"
"TMEM55A","DKFZp762O076","ENSG00000155099","Transmembrane protein 55A","8","90993796-91041064","Enzymes, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA014591","Approved",NA,NA,NA,"Liver cancer:3.76e-5 (unfavourable), Cervical cancer:1.01e-4 (unfavourable), Head and neck cancer:1.54e-4 (unfavourable), Stomach cancer:8.01e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"cerebral cortex: 21.7","Mixed",NA,NA
"TMEM59L","BSMAP, C19orf4","ENSG00000105696","Transmembrane protein 59 like","19","18607430-18621039","Predicted intracellular proteins, Predicted membrane proteins, Transporters","Evidence at transcript level","HPA010661, HPA070701","Approved",NA,"Approved","Nucleoplasm<br>Actin filaments","Endometrial cancer:1.62e-4 (unfavourable), Pancreatic cancer:8.80e-4 (favourable)","Tissue enriched","Tissue enriched",16,"cerebral cortex: 366.3","adrenal gland: 22.2","Cell line enhanced",NA,"AN3-CA: 33.4;ASC diff: 29.2;EFO-21: 24.0;Hep G2: 18.4;SH-SY5Y: 22.4"
"TMEM72","bA285G1.3, C10orf127, KSP37","ENSG00000187783","Transmembrane protein 72","10","44911200-44937002","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA039894, HPA062907","Enhanced",NA,NA,NA,"Renal cancer:1.01e-4 (favourable)","Tissue enriched","Tissue enriched",7,"kidney: 54.3","rectum: 7.8","Group enriched",105,"RPMI-8226: 24.8;U-937: 17.4"
"TMEM87A","DKFZP564G2022","ENSG00000103978","Transmembrane protein 87A","15","42210452-42273663","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA018104, HPA018189","Enhanced",NA,"Supported","Golgi apparatus",NA,"Expressed in all","Expressed in all",NA,NA,"prostate: 124.3","Expressed in all",NA,NA
"TMEM88B",NA,"ENSG00000205116","Transmembrane protein 88B","1","1426128-1427787","Predicted membrane proteins","Evidence at protein level","HPA065743","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",14,"cerebral cortex: 11.8","testis: 0.8","Cell line enhanced",NA,"Hep G2: 2.8;SCLC-21H: 1.9"
"TMEM8C","TMEM226","ENSG00000187616","Transmembrane protein 8C","9","133514586-133528612","Predicted membrane proteins, Transporters","Evidence at transcript level","HPA051846, HPA055785","Uncertain",NA,NA,NA,NA,"Not detected","Not detected",NA,NA,"cerebral cortex,epididymis: 0.5","Group enriched",29,"HSkMC: 11.3;RH-30: 6.9"
"TMOD2","NTMOD","ENSG00000128872","Tropomodulin 2","15","51751561-51816368","Predicted intracellular proteins","Evidence at protein level","HPA041365","Enhanced",NA,"Approved","Nucleus<br>Nucleoli fibrillar center","Pancreatic cancer:4.53e-4 (favourable)","Tissue enhanced","Tissue enriched",9,"cerebral cortex: 111.0","seminal vesicle: 11.7","Cell line enhanced",NA,"SCLC-21H: 43.4"
"TMPRSS9",NA,"ENSG00000178297","Transmembrane protease, serine 9","19","2389771-2426239","Enzymes, Predicted membrane proteins","Evidence at protein level","HPA051483","Uncertain",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"spleen: 2.3;testis: 1.7","skin: 0.8","Cell line enhanced",NA,"Karpas-707: 1.8;U-266/70: 1.7"
"TNFRSF11A","CD265, FEO, LOH18CR1, PDB2, RANK","ENSG00000141655","TNF receptor superfamily member 11a","18","62325287-62391292","CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB010391, HPA027728, HPA047976","Uncertain",NA,"Supported","Plasma membrane<br>Cytosol",NA,"Mixed","Tissue enhanced",NA,"duodenum: 30.6","small intestine: 20.5","Cell line enhanced",NA,"HDLM-2: 116.8;PC-3: 18.0;SCLC-21H: 24.0"
"TNFRSF13C","BAFFR, CD268","ENSG00000159958","TNF receptor superfamily member 13C","22","41922023-41926818","CD markers, Disease related genes, Predicted membrane proteins","Evidence at protein level","HPA003246, CAB008380","Enhanced",NA,"Uncertain","Nucleus","Cervical cancer:4.44e-7 (favourable)","Mixed","Group enriched",10,"appendix: 22.9;lymph node: 46.1;spleen: 43.5;tonsil: 49.9","bone marrow: 4.0","Cell line enhanced",NA,"REH: 19.1;U-698: 7.7"
"TNFRSF21","CD358, DR6","ENSG00000146072","TNF receptor superfamily member 21","6","47231532-47309905","CD markers, Plasma proteins, Predicted membrane proteins","Evidence at protein level","HPA006746, CAB009805","Approved",NA,NA,NA,"Renal cancer:7.23e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 105.2","Cell line enhanced",NA,"RT4: 416.8"
"TNFRSF4","ACT35, CD134, OX40, TXGP1L","ENSG00000186827","TNF receptor superfamily member 4","1","1211326-1214138","Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins","Evidence at protein level","CAB016128","Enhanced",NA,NA,NA,"Head and neck cancer:3.50e-6 (favourable), Renal cancer:4.52e-6 (unfavourable), Liver cancer:6.03e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"adipose tissue: 9.7;appendix: 8.3","lymph node: 7.1","Group enriched",8,"MOLT-4: 5.0;NB-4: 7.6"
"TNFSF11","CD254, ODF, OPGL, RANKL, TRANCE","ENSG00000120659","Tumor necrosis factor superfamily member 11","13","42562736-42608013","Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB009193, HPA045142","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"lymph node: 17.3","appendix: 6.3","Cell line enhanced",NA,"HSkMC: 1.5;NTERA-2: 3.0"
"TNMD","BRICD4, ChM1L, myodulin, TEM, tendin","ENSG00000000005","Tenomodulin","X","100584802-100599885","Predicted membrane proteins","Evidence at protein level","HPA034961, HPA055634","Uncertain",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"adipose tissue: 10.1;seminal vesicle: 33.2","breast: 4.3","Group enriched",19,"HAP1: 6.2;NTERA-2: 14.2"
"TOM1L2",NA,"ENSG00000175662","Target of myb1 like 2 membrane trafficking protein","17","17843511-17972422","Predicted intracellular proteins","Evidence at protein level","HPA022541, HPA023304","Enhanced",NA,"Supported","Golgi apparatus<br>Intermediate filaments","Renal cancer:6.21e-9 (favourable), Head and neck cancer:1.24e-4 (favourable), Pancreatic cancer:1.92e-4 (favourable), Ovarian cancer:2.58e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 110.6","Expressed in all",NA,NA
"TOMM70","KIAA0719, Tom70, TOMM70A","ENSG00000154174","Translocase of outer mitochondrial membrane 70","3","100363431-100401398","Predicted membrane proteins","Evidence at protein level","HPA014589, CAB017156, HPA048020","Enhanced",NA,"Enhanced","Mitochondria",NA,"Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 52.8","Expressed in all",NA,NA
"TOP1",NA,"ENSG00000198900","Topoisomerase (DNA) I","20","41028818-41124487","Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins","Evidence at protein level","CAB009058, HPA019039","Enhanced",NA,"Supported","Nucleus<br>Nucleoli fibrillar center","Liver cancer:6.42e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 71.7","Expressed in all",NA,NA
"TOP1MT",NA,"ENSG00000184428","Topoisomerase (DNA) I, mitochondrial","8","143304384-143359979","Enzymes, FDA approved drug targets, Predicted intracellular proteins","Evidence at protein level","HPA001915, HPA021542","Approved",NA,"Supported","Mitochondria","Renal cancer:1.52e-7 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 41.2","Expressed in all",NA,NA
"TOR1AIP1","FLJ13142, LAP1B","ENSG00000143337","Torsin 1A interacting protein 1","1","179882042-179925000","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA047151, HPA050546","Enhanced",NA,"Enhanced","Nuclear membrane",NA,"Expressed in all","Expressed in all",NA,NA,"thyroid gland: 79.3","Expressed in all",NA,NA
"TP53INP1","DKFZp434M1317, FLJ22139, P53DINP1, SIP, Teap, TP53INP1A, TP53INP1B","ENSG00000164938","Tumor protein p53 inducible nuclear protein 1","8","94925972-94949411","Predicted intracellular proteins","Evidence at protein level","HPA005856","Uncertain",NA,"Supported","Cytosol","Urothelial cancer:5.45e-5 (favourable), Head and neck cancer:1.11e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 52.8","Cell line enhanced",NA,"Karpas-707: 57.1;U-266/70: 65.0"
"TPD52","D52, hD52, N8L","ENSG00000076554","Tumor protein D52","8","80034745-80231232","Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA028427, HPA062167","Enhanced",NA,"Approved","Golgi apparatus<br>Cytosol","Renal cancer:4.77e-6 (unfavourable), Breast cancer:1.11e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"prostate: 168.9","Cell line enhanced",NA,"SK-BR-3: 428.2"
"TPO","TPX","ENSG00000115705","Thyroid peroxidase","2","1374223-1543711","Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA007987, CAB009587","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",103,"thyroid gland: 1817.4","spleen: 17.6","Cell line enhanced",NA,"Karpas-707: 6.9;RPMI-8226: 2.9"
"TRABD","PP2447","ENSG00000170638","TraB domain containing","22","50185915-50199598","Plasma proteins, Predicted membrane proteins","Evidence at protein level","HPA000822","Approved",NA,"Approved","Nucleus<br>Mitochondria","Endometrial cancer:1.19e-5 (favourable), Renal cancer:1.85e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"bone marrow: 38.5","Expressed in all",NA,NA
"TRAF4","CART1, MLN62, RNF83","ENSG00000076604","TNF receptor associated factor 4","17","28743984-28750958","Cancer-related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA052377","Enhanced",NA,NA,NA,NA,"Expressed in all","Mixed",NA,NA,"duodenum: 47.2","Expressed in all",NA,NA
"TRAIP","RNF206, TRIP","ENSG00000183763","TRAF interacting protein","3","49828599-49856574","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA036261, HPA036262","Enhanced",NA,"Supported","Plasma membrane<br>Cytosol","Liver cancer:8.77e-5 (unfavourable)","Expressed in all","Mixed",NA,NA,"testis: 11.3","Mixed",NA,NA
"TRAK1","KIAA1042, MILT1, OIP106","ENSG00000182606","Trafficking kinesin protein 1","3","42013802-42225889","Predicted intracellular proteins","Evidence at protein level","HPA005853, HPA011367","Approved",NA,"Approved","Nucleoplasm<br>Endoplasmic reticulum","Renal cancer:4.84e-8 (favourable)","Expressed in all","Expressed in all",NA,NA,"heart muscle: 110.1","Expressed in all",NA,NA
"TRAP1","HSP75, HSP90L","ENSG00000126602","TNF receptor associated protein 1","16","3651639-3717597","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA041082, HPA044227","Enhanced",NA,"Enhanced","Mitochondria","Colorectal cancer:1.80e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"fallopian tube: 95.4","Expressed in all",NA,NA
"TRAT1","HSPC062, TCRIM, TRIM","ENSG00000163519","T-cell receptor associated transmembrane adaptor 1","3","108822698-108855005","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA002356, CAB026130","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"appendix: 14.0;lymph node: 26.4","spleen: 11.5","Cell line enriched",39,"MOLT-4: 58.7"
"TRDMT1","DNMT2, RNMT1","ENSG00000107614","TRNA aspartic acid methyltransferase 1","10","17142254-17202054","Enzymes, Predicted intracellular proteins","Evidence at protein level","CAB009468, HPA036945, HPA036946","Approved",NA,"Approved","Nucleus<br>Nucleoli<br>Centrosome",NA,"Mixed","Mixed",NA,NA,"parathyroid gland: 8.7","Mixed",NA,NA
"TREH","MGC129621, TRE, TREA","ENSG00000118094","Trehalase","11","118657316-118679690","Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins","Evidence at protein level","HPA039913, HPA042045","Enhanced",NA,NA,NA,"Renal cancer:2.33e-6 (favourable), Liver cancer:3.76e-4 (favourable)","Mixed","Tissue enhanced",NA,"duodenum: 60.6;small intestine: 72.6","kidney: 13.5","Cell line enhanced",NA,"BEWO: 1.5"
"TRIM13","DLEU5, Leu5, RFP2, RNF77","ENSG00000204977","Tripartite motif containing 13","13","49995888-50020481","Enzymes, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA000367","Enhanced",NA,NA,NA,NA,"Expressed in all","Expressed in all",NA,NA,"testis: 141.2","Expressed in all",NA,NA
"TRIM14","KIAA0129","ENSG00000106785","Tripartite motif containing 14","9","98069275-98119212","Predicted intracellular proteins","Evidence at protein level","HPA053217","Uncertain",NA,"Approved","Nucleoplasm<br>Cytosol",NA,"Expressed in all","Mixed",NA,NA,"parathyroid gland: 37.6","Mixed",NA,NA
"TRIO","ARHGEF23","ENSG00000038382","Trio Rho guanine nucleotide exchange factor","5","14143702-14532128","Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA008157, HPA064664","Supported",NA,"Approved","Vesicles<br>Cytosol","Renal cancer:3.11e-5 (unfavourable), Endometrial cancer:1.90e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 47.2","Cell line enhanced",NA,"hTEC/SVTERT24-B: 190.1;U-87 MG: 248.3"
"TRIOBP","DFNB28, HRIHFB2122, KIAA1662, TAP68, Tara","ENSG00000100106","TRIO and F-actin binding protein","22","37697004-37776556","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA003747, HPA019769","Enhanced",NA,NA,NA,"Cervical cancer:4.29e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"spleen: 65.9","Expressed in all",NA,NA
"TRMT61B","FLJ20628","ENSG00000171103","TRNA methyltransferase 61B","2","28849821-28870301","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA026747, HPA026751","Enhanced",NA,"Uncertain","Cytosol","Renal cancer:9.61e-5 (favourable), Liver cancer:3.61e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 23.5","Expressed in all",NA,NA
"TRPC1","HTRP-1","ENSG00000144935","Transient receptor potential cation channel subfamily C member 1","3","142724074-142807888","Predicted membrane proteins, Transporters, Voltage-gated ion channels","Evidence at protein level","CAB009387, HPA021130","Supported",NA,"Approved","Vesicles","Renal cancer:2.72e-5 (unfavourable)","Mixed","Mixed",NA,NA,"endometrium: 18.6","Mixed",NA,NA
"TSC2","LAM, PPP1R160, TSC4, tuberin","ENSG00000103197","Tuberous sclerosis 2","16","2047465-2088720","Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","CAB002225, HPA030409, HPA049679","Approved",NA,"Enhanced","Cytosol","Pancreatic cancer:5.06e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"seminal vesicle: 36.7","Expressed in all",NA,NA
"TSPAN7","A15, CD231, DXS1692E, MRX58, MXS1, TALLA-1, TM4SF2","ENSG00000156298","Tetraspanin 7","X","38561370-38688920","CD markers, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters","Evidence at protein level","HPA003140, CAB062566, CAB068245","Enhanced",NA,NA,NA,"Renal cancer:5.48e-7 (favourable), Pancreatic cancer:1.70e-4 (favourable), Endometrial cancer:3.40e-4 (unfavourable)","Expressed in all","Tissue enriched",6,"cerebral cortex: 574.4","adrenal gland: 99.2","Cell line enhanced",NA,"HDLM-2: 39.2;MOLT-4: 141.6;SCLC-21H: 109.6;U-266/70: 47.0"
"TSPEAR","C21orf29, DFNB98, MGC11251, TSP-EAR","ENSG00000175894","Thrombospondin type laminin G domain and EAR repeats","21","44497892-44711580","Disease related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB034203, CAB034204, HPA052995","Approved",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"parathyroid gland: 2.7;testis: 2.6","spleen: 1.9","Cell line enhanced",NA,"Karpas-707: 8.0;RPMI-8226: 4.6;SH-SY5Y: 4.0;U-266/70: 4.9;U-266/84: 5.1"
"TSPOAP1","BZRAP1, KIAA0612, PRAX-1, RIM-BP1, RIMBP1","ENSG00000005379","TSPO associated protein 1","17","58301228-58328760","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA024662, HPA025244","Enhanced",NA,NA,NA,"Pancreatic cancer:9.15e-7 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 69.1","Cell line enhanced",NA,"HDLM-2: 164.7;HL-60: 51.5;REH: 119.1"
"TSPYL1","TSPYL","ENSG00000189241","TSPY like 1","6","116276578-116279903","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA031970, HPA031971","Approved",NA,"Supported","Nucleus<br>Nucleoli","Renal cancer:1.48e-13 (favourable), Pancreatic cancer:5.40e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 191.9","Expressed in all",NA,NA
"TTC1","TPR1","ENSG00000113312","Tetratricopeptide repeat domain 1","5","160009113-160065543","Predicted intracellular proteins","Evidence at protein level","HPA036557, HPA057502","Approved",NA,"Enhanced","Cytosol","Liver cancer:1.71e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 80.4","Expressed in all",NA,NA
"TTC13","FLJ22584","ENSG00000143643","Tetratricopeptide repeat domain 13","1","230906243-230978875","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA018022, HPA051558","Uncertain",NA,"Approved","Nucleoplasm","Renal cancer:1.60e-11 (unfavourable), Pancreatic cancer:4.59e-5 (favourable), Head and neck cancer:7.66e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"lymph node: 23.0","Expressed in all",NA,NA
"TTC19","FLJ20343, MGC19520","ENSG00000011295","Tetratricopeptide repeat domain 19","17","15999380-16045015","Disease related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA023010, HPA052380","Enhanced",NA,"Enhanced","Mitochondria","Renal cancer:5.67e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 18.6","Expressed in all",NA,NA
"TTC34",NA,"ENSG00000215912","Tetratricopeptide repeat domain 34","1","2635976-2801717","Predicted intracellular proteins","Evidence at transcript level","HPA066832","Uncertain",NA,NA,NA,NA,"Not detected","Tissue enhanced",NA,"fallopian tube: 1.6;testis: 2.6","thyroid gland: 0.8","Not detected",NA,NA
"TTYH3","KIAA1691","ENSG00000136295","Tweety family member 3","7","2631951-2664802","Predicted membrane proteins","Evidence at protein level","HPA053520","Uncertain",NA,NA,NA,"Liver cancer:2.53e-5 (unfavourable), Renal cancer:2.58e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 62.2","Expressed in all",NA,NA
"TUBA1B","K-ALPHA-1","ENSG00000123416","Tubulin alpha 1b","12","49127782-49131397","Predicted intracellular proteins","Evidence at protein level","CAB011513, HPA039247, HPA043684, HPA063394","Enhanced",NA,"Supported","Microtubules","Renal cancer:2.85e-12 (unfavourable), Liver cancer:1.68e-7 (unfavourable), Breast cancer:5.49e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"smooth muscle: 1433.9","Expressed in all",NA,NA
"TUBA8","TUBAL2","ENSG00000183785","Tubulin alpha 8","22","18110331-18146554","Disease related genes, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA043684, CAB046031, HPA063394","Approved",NA,"Supported","Microtubules",NA,"Not detected","Group enriched",6,"cerebral cortex: 28.6;heart muscle: 83.0;skeletal muscle: 121.7;testis: 47.4","thyroid gland: 11.2","Group enriched",5,"NB-4: 19.8;SCLC-21H: 17.4;TIME: 31.1"
"TUBB","M40, MGC16435, OK/SW-cl.56, Tubb5","ENSG00000196230","Tubulin beta class I","6","30720201-30725426","Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB005417, CAB012406, HPA043640, HPA046280","Enhanced",NA,"Supported","Microtubules","Renal cancer:2.62e-8 (unfavourable), Liver cancer:5.97e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"ovary: 72.3","Mixed",NA,NA
"TUBB1","dJ543J19.4","ENSG00000101162","Tubulin beta 1 class VI","20","59019254-59026654","Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB004286, HPA043640, HPA046280","Approved",NA,NA,NA,NA,"Not detected","Group enriched",5,"bone marrow: 4.8;lung: 2.1;placenta: 1.5;spleen: 5.6;testis: 1.5","gallbladder: 0.5","Cell line enriched",20,"HEL: 24.9"
"TUBB2A","dJ40E16.7, TUBB, TUBB2","ENSG00000137267","Tubulin beta 2A class IIa","6","3153669-3157526","Disease related genes, Predicted intracellular proteins","Evidence at protein level","CAB015339, HPA043640, HPA046280","Supported",NA,"Supported","Microtubules","Urothelial cancer:1.61e-4 (unfavourable), Renal cancer:4.65e-4 (favourable)","Expressed in all","Tissue enriched",9,"cerebral cortex: 622.8","skin: 72.0","Expressed in all",NA,NA
"TUBB2B","bA506K6.1, DKFZp566F223, MGC8685","ENSG00000137285","Tubulin beta 2B class IIb","6","3224261-3231730","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA043640, HPA046280","Supported",NA,NA,NA,"Endometrial cancer:1.94e-4 (unfavourable)","Tissue enriched","Tissue enriched",6,"cerebral cortex: 308.7","epididymis: 51.8","Cell line enhanced",NA,"AF22: 504.0;CACO-2: 319.1;SCLC-21H: 896.6;SH-SY5Y: 392.2"
"TUBB3","beta-4, CFEOM3, CFEOM3A, FEOM3","ENSG00000258947","Tubulin beta 3 class III","16","89921392-89938761","Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA043640, HPA046280","Approved",NA,NA,NA,NA,"Mixed","Tissue enriched",6,"cerebral cortex: 195.6","adrenal gland: 34.5","Cell line enhanced",NA,"SCLC-21H: 490.8"
"TUBB4A","beta-5, DYT4, TUBB4","ENSG00000104833","Tubulin beta 4A class IVa","19","6494319-6502848","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB010768, HPA043640, HPA046280","Approved",NA,"Supported","Microtubules","Endometrial cancer:8.42e-7 (unfavourable)","Group enriched","Tissue enhanced",NA,"adrenal gland: 137.6;cerebral cortex: 554.4","testis: 102.4","Cell line enhanced",NA,"AN3-CA: 82.5;HAP1: 52.9;HEL: 69.1"
"TUBB4B","Beta2, TUBB2C","ENSG00000188229","Tubulin beta 4B class IVb","9","137241213-137243707","FDA approved drug targets, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB010880, HPA043640, HPA046280","Enhanced",NA,"Supported","Microtubules","Thyroid cancer:6.36e-6 (favourable), Endometrial cancer:4.91e-4 (favourable), Liver cancer:9.98e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 786.8","Expressed in all",NA,NA
"TUBB6","HsT1601, MGC4083","ENSG00000176014","Tubulin beta 6 class V","18","12307669-12344320","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA043640, HPA046280","Approved",NA,NA,NA,"Renal cancer:1.22e-7 (unfavourable), Urothelial cancer:9.69e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"esophagus: 214.3","Mixed",NA,NA
"TUBB8","bA631M21.2","ENSG00000261456","Tubulin beta 8 class VIII","10","46892-74163","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA043640, HPA046280","Uncertain",NA,NA,NA,NA,"Tissue enriched","Tissue enhanced",NA,"testis: 1.0","parathyroid gland: 0.8","Cell line enhanced",NA,"MCF7: 1.1"
"TUFM","EF-TuMT, EFTu","ENSG00000178952","Tu translation elongation factor, mitochondrial","16","28842411-28846408","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA018991, HPA024087, CAB075730, CAB075731","Enhanced",NA,"Enhanced","Mitochondria","Renal cancer:2.69e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 162.7","Expressed in all",NA,NA
"TXLNB","C6orf198, dJ522B19.2, DKFZp451A175, MDP77","ENSG00000164440","Taxilin beta","6","139240061-139292139","Predicted intracellular proteins","Evidence at protein level","HPA030401, HPA030402, HPA030403","Enhanced",NA,NA,NA,NA,"Mixed","Group enriched",6,"heart muscle: 52.2;skeletal muscle: 102.3","ovary: 13.7","Cell line enhanced",NA,"Daudi: 3.4;RPMI-8226: 2.5;U-698: 4.7"
"TXNDC5","EndoPDI, ERp46, FLJ21353, FLJ90810, Hcc-2, MGC3178, PDIA15","ENSG00000239264","Thioredoxin domain containing 5","6","7881517-7910814","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA034677, HPA034678","Enhanced",NA,"Approved","Endoplasmic reticulum","Renal cancer:1.16e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"urinary bladder: 312.7","Expressed in all",NA,NA
"U2AF1","RN, RNU2AF1, U2AF35, U2AFBP","ENSG00000160201","U2 small nuclear RNA auxiliary factor 1","21","43092956-43107587","Cancer-related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA044833, HPA052083","Supported",NA,"Enhanced","Nucleoplasm",NA,"Not detected","Expressed in all",NA,NA,"thyroid gland: 70.1","Expressed in all",NA,NA
"U2AF1L4","MGC33901, U2AF1L3, U2af26","ENSG00000161265","U2 small nuclear RNA auxiliary factor 1 like 4","19","35742464-35745445","Predicted intracellular proteins","Evidence at protein level","HPA052083, HPA061644","Supported",NA,"Approved","Nucleoplasm","Head and neck cancer:2.58e-5 (favourable), Pancreatic cancer:8.58e-5 (favourable), Renal cancer:9.73e-5 (unfavourable), Breast cancer:2.44e-4 (favourable), Urothelial cancer:7.05e-4 (favourable)","Expressed in all","Mixed",NA,NA,"testis: 7.7","Mixed",NA,NA
"U2AF1L5",NA,"ENSG00000275895","U2 small nuclear RNA auxiliary factor 1 like 5","21","6484623-6499261","Predicted intracellular proteins","Evidence at protein level","HPA044833, HPA052083","Supported",NA,"Uncertain","Nucleoplasm",NA,"Not detected","Expressed in all",NA,NA,"tonsil: 100.1","Expressed in all",NA,NA
"UBA1","A1S9T, CFAP124, GXP1, POC20, UBE1, UBE1X","ENSG00000130985","Ubiquitin like modifier activating enzyme 1","X","47190861-47215128","Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA000289, HPA001506, CAB019435, CAB073410","Approved",NA,"Enhanced","Nucleoplasm","Liver cancer:6.10e-5 (unfavourable), Thyroid cancer:1.78e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 239.4","Expressed in all",NA,NA
"UBAC1","GBDR1, KPC2, UBADC1","ENSG00000130560","UBA domain containing 1","9","135932969-135961380","Predicted intracellular proteins","Evidence at protein level","HPA005651","Approved",NA,"Supported","Golgi apparatus<br>Plasma membrane<br>Cytosol","Renal cancer:3.58e-7 (favourable), Cervical cancer:4.34e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"skeletal muscle: 88.7","Expressed in all",NA,NA
"UBAP2L","KIAA0144, NICE-4","ENSG00000143569","Ubiquitin associated protein 2 like","1","154220179-154271510","Predicted intracellular proteins","Evidence at protein level","HPA035068","Approved",NA,"Approved","Nuclear speckles<br>Cytosol","Renal cancer:2.89e-5 (unfavourable), Liver cancer:4.65e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 122.8","Expressed in all",NA,NA
"UBQLN2","Chap1, CHAP1/DSK2, Dsk2, LIC-2, N4BP4, PLIC-2, PLIC2, RIHFB2157","ENSG00000188021","Ubiquilin 2","X","56563639-56567868","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA006431, CAB013481","Enhanced",NA,"Enhanced","Plasma membrane<br>Cytosol","Liver cancer:2.29e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 53.7","Expressed in all",NA,NA
"UCHL5","CGI-70, INO80R, UCH37","ENSG00000116750","Ubiquitin C-terminal hydrolase L5","1","193012250-193060080","Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA005908, HPA006069, HPA075383","Approved","Approved","Approved","Nucleoplasm<br>Mitochondria","Thyroid cancer:7.10e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 43.0","Expressed in all",NA,NA
"UGGT2","FLJ10873, FLJ11485, HUGT2, MGC117360, MGC150689, MGC87276, UGCGL2","ENSG00000102595","UDP-glucose glycoprotein glucosyltransferase 2","13","95801580-96053482","Predicted secreted proteins","Evidence at protein level","HPA047955","Uncertain",NA,NA,NA,"Lung cancer:5.47e-4 (unfavourable), Liver cancer:9.99e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"testis: 22.7","Mixed",NA,NA
"UGT8","CGT","ENSG00000174607","UDP glycosyltransferase 8","4","114598455-114678224","Enzymes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA014405, HPA065785","Approved",NA,"Approved","Mitochondria","Renal cancer:8.55e-5 (favourable)","Mixed","Tissue enhanced",NA,"cerebral cortex: 101.0","kidney: 29.8","Cell line enhanced",NA,"CAPAN-2: 44.4;RPTEC TERT1: 37.0;SCLC-21H: 32.8"
"UHRF1","FLJ21925, ICBP90, Np95, RNF106, TDRD22","ENSG00000276043","Ubiquitin like with PHD and ring finger domains 1","19","4903080-4962154","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA049408, HPA055446","Enhanced",NA,"Supported","Nucleoplasm","Pancreatic cancer:4.52e-5 (unfavourable), Liver cancer:1.63e-4 (unfavourable), Melanoma:6.81e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"lymph node: 18.8","bone marrow: 17.5","Expressed in all",NA,NA
"UIMC1","RAP80","ENSG00000087206","Ubiquitin interaction motif containing 1","5","176905005-177022633","Predicted intracellular proteins","Evidence at protein level","HPA037503, HPA037504","Enhanced",NA,"Enhanced","Nuclear bodies","Liver cancer:7.67e-6 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 109.5","Expressed in all",NA,NA
"UMOD",NA,"ENSG00000169344","Uromodulin","16","20333052-20356301","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB009446, HPA043420, HPA054721","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",726,"kidney: 2392.4","cerebral cortex: 3.2","Not detected",NA,NA
"UNC80","C2orf21, FLJ33496, KIAA1843, UNC-80","ENSG00000144406","Unc-80 homolog, NALCN activator","2","209771993-209999300","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA042472","Enhanced",NA,"Approved","Vesicles",NA,"Tissue enhanced","Tissue enhanced",NA,"adrenal gland: 5.1;cerebral cortex: 15.8;testis: 5.2","gallbladder: 1.9","Cell line enhanced",NA,"AF22: 2.4;SCLC-21H: 4.7;SH-SY5Y: 2.4"
"UPF1","HUPF1, KIAA0221, NORF1, pNORF1, RENT1, smg-2","ENSG00000005007","UPF1, RNA helicase and ATPase","19","18831938-18868236","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA019587, HPA020857","Approved",NA,"Supported","Nucleoplasm","Renal cancer:2.97e-6 (favourable), Melanoma:2.72e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 56.7","Expressed in all",NA,NA
"UPK2","MGC138598, UP2, UPII","ENSG00000110375","Uroplakin 2","11","118925164-118958559","Predicted membrane proteins, Transporters","Evidence at protein level","HPA043312, HPA061106","Enhanced",NA,NA,NA,"Renal cancer:7.30e-7 (unfavourable), Lung cancer:9.57e-4 (unfavourable)","Tissue enriched","Tissue enriched",44,"urinary bladder: 68.5","adipose tissue: 1.5","Cell line enhanced",NA,"BEWO: 25.9;MCF7: 113.9;RT4: 131.8"
"UQCRC2","QCR2, UQCR2","ENSG00000140740","Ubiquinol-cytochrome c reductase core protein II","16","21952660-21983660","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA007998, HPA019146","Enhanced",NA,"Enhanced","Mitochondria","Renal cancer:6.58e-9 (favourable)","Expressed in all","Expressed in all",NA,NA,"heart muscle: 151.1","Expressed in all",NA,NA
"USF1","bHLHb11, MLTFI, UEF","ENSG00000158773","Upstream transcription factor 1","1","161039251-161045977","Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors","Evidence at protein level","CAB001480, HPA036233, HPA036535","Supported",NA,"Enhanced","Nucleoplasm","Renal cancer:6.01e-12 (unfavourable), Urothelial cancer:1.95e-5 (favourable), Head and neck cancer:8.70e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"spleen: 34.8","Expressed in all",NA,NA
"USP10","KIAA0190, UBPO","ENSG00000103194","Ubiquitin specific peptidase 10","16","84699978-84779922","Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA006731, HPA006749","Enhanced",NA,"Enhanced","Nucleoplasm<br>Cytosol","Renal cancer:1.00e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 63.1","Expressed in all",NA,NA
"USP11","UHX1","ENSG00000102226","Ubiquitin specific peptidase 11","X","47232690-47248328","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA003103, HPA037536","Enhanced","Approved","Supported","Nucleoplasm","Renal cancer:4.13e-5 (favourable), Endometrial cancer:2.95e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 212.7","Expressed in all",NA,NA
"USP22","KIAA1063, USP3L","ENSG00000124422","Ubiquitin specific peptidase 22","17","20999593-21043760","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA044980","Supported",NA,"Supported","Nuclear speckles","Renal cancer:1.53e-7 (favourable), Liver cancer:9.66e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 154.1","Expressed in all",NA,NA
"USP5","IsoT","ENSG00000111667","Ubiquitin specific peptidase 5","12","6852128-6866632","Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA006756","Uncertain",NA,"Approved","Nucleoplasm<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 87.5","Expressed in all",NA,NA
"USP51",NA,"ENSG00000247746","Ubiquitin specific peptidase 51","X","55484616-55489202","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA001942","Uncertain",NA,"Approved","Nucleoli fibrillar center<br>Cytosol","Renal cancer:2.63e-5 (favourable), Ovarian cancer:5.70e-4 (favourable)","Mixed","Tissue enriched",7,"epididymis: 62.9","parathyroid gland: 9.3","Mixed",NA,NA
"UTP18","CGI-48, WDR50","ENSG00000011260","UTP18, small subunit processome component","17","51260528-51297936","Predicted intracellular proteins","Evidence at protein level","HPA052378","Approved",NA,"Supported","Nucleus<br>Nuclear membrane<br>Nucleoli","Liver cancer:1.99e-4 (unfavourable), Colorectal cancer:3.33e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 106.1","Expressed in all",NA,NA
"VAMP8","EDB","ENSG00000118640","Vesicle associated membrane protein 8","2","85561562-85582031","Predicted intracellular proteins, Predicted membrane proteins, Transporters","Evidence at protein level","HPA006882, CAB037132, CAB037147","Enhanced",NA,NA,NA,"Thyroid cancer:8.07e-9 (favourable), Urothelial cancer:1.59e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"lung: 327.6","Cell line enhanced",NA,"HL-60: 584.2;NB-4: 722.5;U-937: 587.5"
"VARS","VARS2","ENSG00000204394","Valyl-tRNA synthetase","6","31777518-31795953","Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA046710","Approved",NA,"Enhanced","Cytosol","Liver cancer:1.86e-4 (unfavourable), Lung cancer:6.90e-4 (unfavourable), Cervical cancer:7.25e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"testis: 5.5","Mixed",NA,NA
"VAT1L","KIAA1576","ENSG00000171724","Vesicle amine transport 1 like","16","77788530-77980107","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA044061, CAB046032","Enhanced",NA,"Approved","Cytosol","Renal cancer:3.01e-6 (unfavourable)","Tissue enhanced","Group enriched",6,"adrenal gland: 90.6;cerebral cortex: 38.8","heart muscle: 10.3","Cell line enhanced",NA,"BJ hTERT+: 55.2;fHDF/TERT166: 29.2;NTERA-2: 79.1;U-87 MG: 80.3"
"VBP1","PFD3, PFDN3","ENSG00000155959","VHL binding protein 1","X","155197007-155239817","Predicted intracellular proteins","Evidence at protein level","CAB006260, HPA023230","Approved",NA,"Supported","Vesicles<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 85.3","Expressed in all",NA,NA
"VCAM1","CD106","ENSG00000162692","Vascular cell adhesion molecule 1","1","100719742-100739045","Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins","Evidence at protein level","CAB000154, HPA034796, HPA069867","Enhanced",NA,"Approved","Cell Junctions","Head and neck cancer:7.19e-5 (favourable), Cervical cancer:3.82e-4 (favourable)","Tissue enriched","Tissue enriched",5,"spleen: 549.1","lymph node: 109.7","Cell line enhanced",NA,"HHSteC: 144.7;HSkMC: 83.9;hTEC/SVTERT24-B: 31.1;U-138 MG: 25.9"
"VCAN","CSPG2, PG-M","ENSG00000038427","Versican","5","83471465-83582303","Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA004726, CAB008979","Enhanced",NA,"Supported","Vesicles","Stomach cancer:1.41e-4 (unfavourable), Renal cancer:5.17e-4 (unfavourable), Melanoma:7.59e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"appendix: 105.5;placenta: 104.6","smooth muscle: 67.1","Cell line enhanced",NA,"AF22: 296.8;RPTEC TERT1: 288.7;U-2197: 156.9"
"VCL",NA,"ENSG00000035403","Vinculin","10","73995193-74121363","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA002131, CAB002453, HPA063777","Enhanced",NA,"Enhanced","Focal adhesion sites","Pancreatic cancer:2.75e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"smooth muscle: 326.5","Expressed in all",NA,NA
"VGLL4","KIAA0121","ENSG00000144560","Vestigial like family member 4","3","11556070-11771350","Predicted intracellular proteins","Evidence at protein level","HPA038225, HPA038614","Approved",NA,"Approved","Nucleus<br>Nucleoli fibrillar center","Renal cancer:1.32e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"ovary: 111.1","Expressed in all",NA,NA
"VPS25","DERP9, EAP20, MGC10540","ENSG00000131475","Vacuolar protein sorting 25 homolog","17","42773436-42779599","Predicted intracellular proteins","Evidence at protein level","CAB004978, HPA052217, HPA057284","Uncertain",NA,"Approved","Centrosome","Colorectal cancer:3.18e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"fallopian tube: 93.3","Expressed in all",NA,NA
"VPS33B","FLJ14848","ENSG00000184056","VPS33B, late endosome and lysosome associated","15","90998416-91022603","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA040415","Approved",NA,NA,NA,NA,"Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 16.1","Expressed in all",NA,NA
"VPS37B","FLJ12750","ENSG00000139722","VPS37B, ESCRT-I subunit","12","122865328-122896444","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA038217, HPA038218","Enhanced",NA,NA,NA,"Renal cancer:1.35e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"esophagus: 34.8","Mixed",NA,NA
"VPS53","FLJ10979, HCCS1","ENSG00000141252","VPS53, GARP complex subunit","17","508668-721717","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA022988, HPA024446","Enhanced",NA,"Approved","Golgi apparatus<br>Cytosol","Endometrial cancer:1.08e-5 (favourable), Pancreatic cancer:1.56e-5 (favourable)","Expressed in all","Mixed",NA,NA,"cerebral cortex: 9.3","Expressed in all",NA,NA
"VTI1B","VTI2","ENSG00000100568","Vesicle transport through interaction with t-SNAREs 1B","14","67647075-67674831","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA044121, HPA048150, HPA060118","Approved",NA,"Enhanced","Golgi apparatus<br>Vesicles","Renal cancer:3.53e-12 (favourable)","Expressed in all","Expressed in all",NA,NA,"epididymis: 64.9","Expressed in all",NA,NA
"WAS","IMD2, THC, WASP, WASPA","ENSG00000015285","Wiskott-Aldrich syndrome","X","48676596-48691427","Cancer-related genes, Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA002022, CAB004290","Enhanced",NA,NA,NA,"Renal cancer:5.58e-6 (unfavourable), Head and neck cancer:3.78e-4 (favourable), Endometrial cancer:4.95e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"appendix: 69.0;lymph node: 60.8;spleen: 68.8","bone marrow: 37.5","Cell line enhanced",NA,"HMC-1: 135.1;U-937: 66.6"
"WASF1","KIAA0269, SCAR1, WAVE, WAVE1","ENSG00000112290","WAS protein family member 1","6","110099819-110180004","Predicted intracellular proteins","Evidence at protein level","HPA004105, CAB022161","Approved","Approved",NA,NA,"Liver cancer:2.82e-8 (unfavourable), Renal cancer:2.79e-5 (unfavourable)","Expressed in all","Group enriched",5,"cerebral cortex: 138.9;testis: 149.9","ovary: 27.8","Mixed",NA,NA
"WASF3","KIAA0900, SCAR3, WAVE3","ENSG00000132970","WAS protein family member 3","13","26557703-26688948","Cancer-related genes, Predicted intracellular proteins","Evidence at protein level","CAB037086","Approved",NA,NA,NA,"Pancreatic cancer:2.21e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 86.4","thyroid gland: 28.1","Cell line enhanced",NA,"ASC diff: 56.8"
"WDR13",NA,"ENSG00000101940","WD repeat domain 13","X","48590042-48608867","Predicted intracellular proteins","Evidence at protein level","HPA000913","Enhanced",NA,"Supported","Nucleoplasm<br>Plasma membrane<br>Microtubule organizing center",NA,"Expressed in all","Expressed in all",NA,NA,"fallopian tube: 91.9","Expressed in all",NA,NA
"WDR17",NA,"ENSG00000150627","WD repeat domain 17","4","176065834-176182818","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA042766, HPA054501","Approved",NA,"Approved","Nuclear speckles",NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 25.2;parathyroid gland: 19.3","thyroid gland: 11.0","Cell line enhanced",NA,"AF22: 7.7;SCLC-21H: 10.5"
"WDR37","KIAA0982","ENSG00000047056","WD repeat domain 37","10","1049538-1132297","Predicted intracellular proteins","Evidence at protein level","HPA037376, HPA037565","Enhanced",NA,"Uncertain","Intermediate filaments<br>Centrosome<br>Cytosol","Pancreatic cancer:1.46e-6 (favourable), Thyroid cancer:1.34e-5 (unfavourable), Head and neck cancer:1.75e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 36.4","Expressed in all",NA,NA
"WDR54","FLJ12953","ENSG00000005448","WD repeat domain 54","2","74421678-74425755","Predicted intracellular proteins","Evidence at protein level","HPA043257, HPA053558","Enhanced",NA,"Approved","Vesicles<br>Cytosol",NA,"Expressed in all","Tissue enhanced",NA,"fallopian tube: 113.2","testis: 48.2","Expressed in all",NA,NA
"WDR61","REC14","ENSG00000140395","WD repeat domain 61","15","78277835-78299794","Predicted intracellular proteins","Evidence at protein level","HPA039932, HPA040065","Enhanced",NA,"Enhanced","Nucleoplasm<br>Cytosol","Renal cancer:2.03e-10 (favourable)","Expressed in all","Expressed in all",NA,NA,"epididymis: 126.8","Expressed in all",NA,NA
"WDR97","KIAA1875","ENSG00000179698","WD repeat domain 97","8","144107726-144118315","Predicted intracellular proteins","Evidence at transcript level","HPA059409","Uncertain",NA,NA,NA,NA,"Mixed","Tissue enriched",9,"testis: 1.1","adrenal gland: 0.1","Not detected",NA,NA
"WFDC8","C20orf170, dJ461P17.1, WAP8","ENSG00000158901","WAP four-disulfide core domain 8","20","45551153-45579326","Predicted secreted proteins","Evidence at protein level","HPA042710, HPA071119","Enhanced",NA,NA,NA,NA,"Not detected","Tissue enriched",436,"epididymis: 487.6","seminal vesicle: 1.1","Cell line enriched",6,"U-87 MG: 2.6"
"WNK2","KIAA1760, NY-CO-43, PRKWNK2, SDCCAG43","ENSG00000165238","WNK lysine deficient protein kinase 2","9","93184916-93320572","Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA015555, HPA016519, CAB017813","Enhanced",NA,"Approved","Cytosol",NA,"Mixed","Mixed",NA,NA,"heart muscle: 29.1","Cell line enhanced",NA,"Hep G2: 21.0;SCLC-21H: 44.2"
"WRNIP1","bA420G6.2, FLJ22526, WHIP","ENSG00000124535","Werner helicase interacting protein 1","6","2765414-2786952","Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA031752, HPA031753","Enhanced",NA,"Approved","Nucleoplasm",NA,"Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 78.7","Expressed in all",NA,NA
"XRCC6","D22S671, D22S731, G22P1, KU70, ML8","ENSG00000196419","X-ray repair cross complementing 6","22","41621119-41664048","Cancer-related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB004254, HPA047549, HPA062226","Enhanced",NA,"Enhanced","Nucleoplasm",NA,"Expressed in all","Expressed in all",NA,NA,"testis: 396.5","Expressed in all",NA,NA
"YAE1D1","C7orf36, GK003","ENSG00000241127","Yae1 domain containing 1","7","39566376-39610320","Predicted intracellular proteins","Evidence at protein level","HPA019226, HPA031249","Uncertain",NA,"Approved","Cytosol","Liver cancer:1.64e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 34.5","Expressed in all",NA,NA
"YAF2",NA,"ENSG00000015153","YY1 associated factor 2","12","42157104-42238349","Predicted intracellular proteins","Evidence at protein level","HPA026867","Enhanced",NA,"Supported","Nucleoplasm",NA,"Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 29.5","Expressed in all",NA,NA
"YARS","tyrRS, YRS, YTS","ENSG00000134684","Tyrosyl-tRNA synthetase","1","32775237-32818153","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA017936, HPA018950, HPA018954","Enhanced",NA,"Enhanced","Cytosol","Renal cancer:1.02e-11 (unfavourable), Liver cancer:6.97e-11 (unfavourable), Urothelial cancer:6.57e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 81.5","Expressed in all",NA,NA
"YLPM1","C14orf170, PPP1R169, ZAP","ENSG00000119596","YLP motif containing 1","14","74763366-74859435","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA048070, HPA061123","Uncertain",NA,"Supported","Nucleoplasm<br>Nuclear speckles","Renal cancer:6.08e-7 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 39.1","Expressed in all",NA,NA
"YWHAG","PPP1R170","ENSG00000170027","Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein gamma","7","76326794-76359031","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB013274, CAB018389, HPA026918","Approved","Supported",NA,NA,"Renal cancer:4.01e-4 (unfavourable), Cervical cancer:4.53e-4 (unfavourable), Lung cancer:5.34e-4 (unfavourable), Pancreatic cancer:7.44e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 611.5","Expressed in all",NA,NA
"ZAP70","SRK, STD, ZAP-70","ENSG00000115085","Zeta chain of T-cell receptor associated protein kinase 70","2","97713560-97739862","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins","Evidence at protein level","CAB002625, HPA003134","Enhanced",NA,NA,NA,"Renal cancer:3.02e-8 (unfavourable), Endometrial cancer:9.66e-8 (favourable), Head and neck cancer:3.93e-6 (favourable), Cervical cancer:6.89e-5 (favourable)","Mixed","Tissue enhanced",NA,"appendix: 36.2;lymph node: 64.3;spleen: 37.7","tonsil: 16.2","Cell line enriched",16,"MOLT-4: 144.9"
"ZBBX","FLJ23049","ENSG00000169064","Zinc finger B-box domain containing","3","167240287-167381346","Predicted intracellular proteins","Evidence at protein level","HPA036327, HPA036328","Enhanced",NA,NA,NA,NA,"Tissue enhanced","Group enriched",10,"fallopian tube: 38.1;testis: 67.6","lung: 5.5","Not detected",NA,NA
"ZBTB11","ZNF-U69274, ZNF913","ENSG00000066422","Zinc finger and BTB domain containing 11","3","101648889-101677495","Predicted intracellular proteins, Predicted membrane proteins, Transcription factors","Evidence at protein level","HPA015328, HPA024138","Approved",NA,"Enhanced","Nucleoplasm","Endometrial cancer:7.49e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"bone marrow: 23.4","Expressed in all",NA,NA
"ZBTB4","KAISO-L1, KIAA1538, ZNF903","ENSG00000174282","Zinc finger and BTB domain containing 4","17","7459366-7484263","Predicted intracellular proteins, Transcription factors","Evidence at protein level","CAB008980, HPA064763","Supported",NA,"Supported","Nucleoplasm<br>Nuclear bodies<br>Cytosol","Renal cancer:1.65e-9 (favourable), Pancreatic cancer:2.53e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 84.8","Mixed",NA,NA
"ZBTB46","BTBD4, BZEL, FLJ13502, RINZF, ZNF340","ENSG00000130584","Zinc finger and BTB domain containing 46","20","63743666-63831244","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA013997","Uncertain",NA,"Approved","Nucleus","Pancreatic cancer:2.17e-4 (favourable)","Expressed in all","Mixed",NA,NA,"spleen: 13.3","Mixed",NA,NA
"ZBTB49","FLJ38559, ZNF509","ENSG00000168826","Zinc finger and BTB domain containing 49","4","4290251-4321786","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA024450","Approved",NA,"Approved","Nucleoplasm<br>Microtubules<br>Cytosol","Urothelial cancer:2.88e-5 (favourable), Pancreatic cancer:1.76e-4 (favourable), Head and neck cancer:5.24e-4 (favourable)","Expressed in all","Mixed",NA,NA,"testis: 7.4","Expressed in all",NA,NA
"ZBTB7A","DKFZp547O146, FBI-1, LRF, pokemon, ZBTB7, ZNF857A","ENSG00000178951","Zinc finger and BTB domain containing 7A","19","4044364-4066945","Predicted intracellular proteins, Transcription factors","Evidence at protein level","CAB037214, CAB037285, HPA046387","Enhanced",NA,"Approved","Nucleoplasm","Renal cancer:1.34e-6 (favourable), Endometrial cancer:6.50e-6 (favourable), Stomach cancer:1.79e-4 (favourable), Pancreatic cancer:2.99e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 23.9","Expressed in all",NA,NA
"ZBTB7B","c-Krox, hcKrox, ZBTB15, ZFP67, ZNF857B","ENSG00000160685","Zinc finger and BTB domain containing 7B","1","155002630-155018522","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA006811, HPA025820","Enhanced",NA,"Enhanced","Nucleoplasm",NA,"Expressed in all","Expressed in all",NA,NA,"skin: 89.4","Mixed",NA,NA
"ZBTB8A","BOZF1, FLJ90065, ZBTB8, ZNF916A","ENSG00000160062","Zinc finger and BTB domain containing 8A","1","32539427-32605939","Predicted intracellular proteins","Evidence at protein level","HPA031768, HPA031769, HPA031770","Approved",NA,"Approved","Nuclear speckles<br>Focal adhesion sites",NA,"Expressed in all","Mixed",NA,NA,"endometrium: 10.3","Mixed",NA,NA
"ZC2HC1A","C8orf70, CGI-62, FAM164A","ENSG00000104427","Zinc finger C2HC-type containing 1A","8","78666047-78719765","Predicted intracellular proteins","Evidence at protein level","HPA024726","Approved",NA,"Approved","Actin filaments<br>Cytosol","Stomach cancer:5.85e-4 (unfavourable), Ovarian cancer:9.00e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"skin: 52.9","Cell line enhanced",NA,"SK-BR-3: 58.7"
"ZC3H12C","KIAA1726, MCPIP3","ENSG00000149289","Zinc finger CCCH-type containing 12C","11","110093361-110171841","Predicted intracellular proteins","Evidence at protein level","HPA038836, HPA038837","Approved",NA,"Approved","Nuclear membrane<br>Golgi apparatus","Renal cancer:9.90e-6 (favourable)","Expressed in all","Mixed",NA,NA,"thyroid gland: 13.6","Mixed",NA,NA
"ZC3H15","LEREPO4","ENSG00000065548","Zinc finger CCCH-type containing 15","2","186486156-186509363","Predicted intracellular proteins","Evidence at protein level","HPA031099, HPA031100, HPA031101","Enhanced",NA,"Enhanced","Cytosol","Liver cancer:1.48e-7 (unfavourable), Cervical cancer:6.45e-5 (unfavourable), Ovarian cancer:3.98e-4 (favourable), Pancreatic cancer:9.75e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 78.5","Expressed in all",NA,NA
"ZC3H18","NHN1","ENSG00000158545","Zinc finger CCCH-type containing 18","16","88570381-88631966","Predicted intracellular proteins","Evidence at protein level","HPA040847, HPA041327","Enhanced",NA,"Enhanced","Nuclear speckles","Renal cancer:3.68e-4 (favourable), Liver cancer:4.06e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 30.8","Expressed in all",NA,NA
"ZC3H7B","DKFZp434K0920, FLJ13787, KIAA1031, RoXaN","ENSG00000100403","Zinc finger CCCH-type containing 7B","22","41301522-41360147","Predicted intracellular proteins","Evidence at protein level","HPA001784","Uncertain",NA,"Uncertain","Cytosol","Renal cancer:5.43e-7 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 81.6","Expressed in all",NA,NA
"ZC3H8","Fliz1, ZC3HDC8","ENSG00000144161","Zinc finger CCCH-type containing 8","2","112211525-112255136","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA034803, HPA034804","Approved",NA,"Supported","Nucleoplasm<br>Nuclear bodies","Endometrial cancer:1.12e-6 (unfavourable), Renal cancer:1.89e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 16.2","Expressed in all",NA,NA
"ZC3HC1","NIPA","ENSG00000091732","Zinc finger C3HC-type containing 1","7","130018286-130051451","Predicted intracellular proteins","Evidence at protein level","HPA019089, HPA024023","Enhanced",NA,"Supported","Nucleus<br>Nuclear membrane","Liver cancer:1.02e-6 (unfavourable), Endometrial cancer:3.36e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 26.5","Expressed in all",NA,NA
"ZEB1","AREB6, BZP, FECD6, NIL-2-A, PPCD3, TCF8, ZEB, Zfhep, Zfhx1a","ENSG00000148516","Zinc finger E-box binding homeobox 1","10","31318495-31529814","Disease related genes, Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA027524, CAB058686","Enhanced",NA,"Supported","Nucleoplasm","Renal cancer:7.34e-6 (unfavourable)","Expressed in all","Mixed",NA,NA,"smooth muscle: 79.9","Cell line enhanced",NA,"ASC TERT1: 102.9"
"ZFAND2A","AIRAP","ENSG00000178381","Zinc finger AN1-type containing 2A","7","1152071-1160759","Predicted intracellular proteins","Evidence at transcript level","HPA019469","Approved",NA,NA,NA,"Renal cancer:5.47e-7 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"bone marrow: 50.0","Expressed in all",NA,NA
"ZFP92","ZNF897","ENSG00000189420","ZFP92 zinc finger protein","X","153418322-153426481","Predicted intracellular proteins, Transcription factors","Evidence at transcript level","HPA003030","Uncertain",NA,NA,NA,NA,"Tissue enhanced","Mixed",NA,NA,"fallopian tube: 5.3","Cell line enhanced",NA,"HDLM-2: 3.5;HMC-1: 3.1;U-937: 4.8"
"ZFPL1","D11S750, MCG4","ENSG00000162300","Zinc finger protein like 1","11","65084223-65088400","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA014909, HPA017347","Enhanced",NA,"Enhanced","Golgi apparatus","Liver cancer:9.12e-6 (unfavourable), Renal cancer:2.73e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"fallopian tube: 31.7","Expressed in all",NA,NA
"ZFYVE26","KIAA0321, SPG15","ENSG00000072121","Zinc finger FYVE-type containing 26","14","67727374-67816590","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA055500","Approved",NA,NA,NA,"Renal cancer:1.54e-6 (favourable), Liver cancer:2.84e-6 (unfavourable)","Expressed in all","Mixed",NA,NA,"parathyroid gland: 14.7","Expressed in all",NA,NA
"ZFYVE9","MADHIP, PPP1R173, SARA, SMADIP","ENSG00000157077","Zinc finger FYVE-type containing 9","1","52142094-52346686","Predicted intracellular proteins","Evidence at protein level","CAB017702, HPA065852, HPA065862","Approved",NA,"Enhanced","Vesicles<br>Cytosol",NA,"Expressed in all","Mixed",NA,NA,"parathyroid gland: 45.2","Mixed",NA,NA
"ZIC1","ZIC, ZNF201","ENSG00000152977","Zic family member 1","3","147393422-147510293","Disease related genes, Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA004098","Supported",NA,"Supported","Nucleoplasm",NA,"Tissue enhanced","Tissue enriched",9,"cerebral cortex: 23.8","skin: 2.5","Cell line enriched",5,"AF22: 171.9"
"ZIC4",NA,"ENSG00000174963","Zic family member 4","3","147386046-147406860","Predicted intracellular proteins, Predicted secreted proteins, Transcription factors","Evidence at transcript level","HPA030194","Uncertain",NA,"Approved","Nucleus<br>Cytosol",NA,"Mixed","Group enriched",6,"cerebral cortex: 4.3;skin: 1.4","skeletal muscle: 0.5","Cell line enhanced",NA,"AF22: 17.0;SH-SY5Y: 5.5"
"ZKSCAN1","KOX18, PHZ-37, ZNF139, ZNF36, ZSCAN33","ENSG00000106261","Zinc finger with KRAB and SCAN domains 1","7","100015572-100041689","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA006672","Uncertain",NA,"Approved","Nucleus<br>Nuclear bodies<br>Mitochondria",NA,"Expressed in all","Expressed in all",NA,NA,"skin: 38.9","Expressed in all",NA,NA
"ZMYND8","PRKCBP1, RACK7","ENSG00000101040","Zinc finger MYND-type containing 8","20","47209214-47356889","Predicted intracellular proteins","Evidence at protein level","HPA020949","Approved",NA,"Approved","Nucleoplasm<br>Golgi apparatus","Renal cancer:7.06e-5 (unfavourable), Breast cancer:2.56e-4 (unfavourable), Liver cancer:2.62e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"epididymis: 40.5","Expressed in all",NA,NA
"ZNF189",NA,"ENSG00000136870","Zinc finger protein 189","9","101398873-101410660","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA034814","Uncertain",NA,"Approved","Intermediate filaments","Renal cancer:5.32e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"epididymis: 104.7","Expressed in all",NA,NA
"ZNF248","bA162G10.3","ENSG00000198105","Zinc finger protein 248","10","37776526-37858106","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA018237, HPA018287, HPA018455","Uncertain",NA,"Approved","Nucleoplasm","Lung cancer:1.04e-4 (favourable), Pancreatic cancer:1.22e-4 (favourable), Renal cancer:2.25e-4 (unfavourable), Prostate cancer:6.71e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"parathyroid gland: 25.9","Expressed in all",NA,NA
"ZNF280B","5'OY11.1, SUHW2, ZNF279, ZNF632","ENSG00000275004","Zinc finger protein 280B","22","22484421-22509154","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA059519","Uncertain",NA,"Approved","Nucleoplasm",NA,"Mixed","Tissue enriched",7,"testis: 12.6","cerebral cortex: 1.8","Cell line enhanced",NA,"K-562: 8.3;U-2 OS: 4.7"
"ZNF280D","FLJ20086, SUHW4, ZNF634","ENSG00000137871","Zinc finger protein 280D","15","56630181-56918571","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA030233","Approved",NA,"Approved","Nucleoplasm<br>Golgi apparatus<br>Centrosome<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"endometrium: 31.8","Mixed",NA,NA
"ZNF292","bA393I2.3, KIAA0530, ZFP292, Zn-15, Zn-16","ENSG00000188994","Zinc finger protein 292","6","87152833-87264196","Plasma proteins, Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA032154, HPA050618","Uncertain",NA,"Approved","Nucleus<br>Nuclear membrane",NA,"Expressed in all","Expressed in all",NA,NA,"endometrium: 17.1","Expressed in all",NA,NA
"ZNF326","FLJ20403, ZAN75, Zfp326, ZIRD","ENSG00000162664","Zinc finger protein 326","1","89995112-90035531","Predicted intracellular proteins","Evidence at protein level","HPA028450, HPA028461, HPA028466","Supported",NA,"Enhanced","Nucleoplasm<br>Golgi apparatus<br>Vesicles","Urothelial cancer:2.84e-4 (favourable), Breast cancer:9.46e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"bone marrow: 29.5","Expressed in all",NA,NA
"ZNF346","JAZ, Zfp346","ENSG00000113761","Zinc finger protein 346","5","177022696-177081189","Predicted intracellular proteins","Evidence at protein level","HPA018485","Approved",NA,"Enhanced","Nucleus","Liver cancer:1.88e-7 (unfavourable), Endometrial cancer:9.54e-5 (unfavourable), Pancreatic cancer:1.20e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 18.0","Expressed in all",NA,NA
"ZNF41","MGC8941, MRX89","ENSG00000147124","Zinc finger protein 41","X","47445879-47482946","Disease related genes, Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA069102","Enhanced",NA,"Approved","Nucleoplasm","Renal cancer:6.95e-4 (favourable), Head and neck cancer:8.32e-4 (favourable)","Expressed in all","Mixed",NA,NA,"parathyroid gland: 19.4","Expressed in all",NA,NA
"ZNF415",NA,"ENSG00000170954","Zinc finger protein 415","19","53107879-53133077","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA005553","Approved",NA,"Approved","Nucleoli fibrillar center<br>Microtubules",NA,"Mixed","Mixed",NA,NA,"testis: 39.6","Cell line enhanced",NA,"RT4: 17.7"
"ZNF423","Ebfaz, JBTS19, KIAA0760, NPHP14, OAZ, Roaz, Zfp104","ENSG00000102935","Zinc finger protein 423","16","49487524-49857919","Disease related genes, Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA015258, HPA065820","Uncertain",NA,"Enhanced","Nucleus",NA,"Mixed","Mixed",NA,NA,"fallopian tube: 15.4","Cell line enhanced",NA,"AF22: 53.5;NTERA-2: 27.7;REH: 22.3;SCLC-21H: 34.3;SH-SY5Y: 92.6"
"ZNF436","KIAA1710, Zfp46","ENSG00000125945","Zinc finger protein 436","1","23359448-23369442","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA043817","Enhanced",NA,"Supported","Nucleoplasm<br>Cytosol",NA,"Expressed in all","Mixed",NA,NA,"ovary: 12.4","Cell line enhanced",NA,"HSkMC: 26.4"
"ZNF518B","KIAA1729","ENSG00000178163","Zinc finger protein 518B","4","10439874-10457410","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA031215, HPA031216","Approved",NA,"Approved","Nucleus",NA,"Mixed","Mixed",NA,NA,"testis: 16.9","Mixed",NA,NA
"ZNF572","FLJ38002","ENSG00000180938","Zinc finger protein 572","8","124973298-124979389","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA066838","Enhanced",NA,"Approved","Nuclear speckles",NA,"Expressed in all","Mixed",NA,NA,"testis: 6.7","Mixed",NA,NA
"ZNF579","FLJ35453","ENSG00000218891","Zinc finger protein 579","19","55576770-55580845","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA062812","Approved",NA,"Approved","Nucleus","Renal cancer:1.00e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"gallbladder: 13.0","Expressed in all",NA,NA
"ZNF610","FLJ36040","ENSG00000167554","Zinc finger protein 610","19","52336245-52367778","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA055771, HPA078134","Enhanced",NA,"Approved","Nucleus","Renal cancer:1.05e-7 (favourable), Ovarian cancer:3.38e-4 (favourable)","Mixed","Tissue enhanced",NA,"testis: 22.0","ovary: 10.4","Mixed",NA,NA
"ZNF670","MGC12466","ENSG00000277462","Zinc finger protein 670","1","247036784-247078755","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA003142","Uncertain",NA,"Approved","Nucleus<br>Cytosol",NA,"Expressed in all","Mixed",NA,NA,"testis: 6.1","Expressed in all",NA,NA
"ZNF672","FLJ22301","ENSG00000171161","Zinc finger protein 672","1","248838210-248849517","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA055779, HPA062506","Approved",NA,"Enhanced","Nucleoplasm","Urothelial cancer:1.79e-5 (favourable), Pancreatic cancer:7.51e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 24.8","Expressed in all",NA,NA
"ZNF683","Hobit, MGC33414","ENSG00000176083","Zinc finger protein 683","1","26361634-26374522","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA023865","Uncertain",NA,NA,NA,"Endometrial cancer:2.90e-5 (favourable), Urothelial cancer:3.45e-5 (favourable)","Mixed","Tissue enriched",11,"testis: 78.7","lung: 7.1","Cell line enhanced",NA,"NB-4: 1.4"
"ZNF727","ZNF727P","ENSG00000214652","Zinc finger protein 727","7","64045443-64078549","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA051027, HPA061215","Uncertain",NA,"Uncertain","Nucleoplasm",NA,"Tissue enhanced","Mixed",NA,NA,"thyroid gland: 5.8","Cell line enriched",7,"T-47d: 7.1"
"ZNF736",NA,"ENSG00000234444","Zinc finger protein 736","7","64307459-64354860","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA051027, HPA061215","Uncertain",NA,"Uncertain","Nucleoplasm","Endometrial cancer:3.03e-4 (unfavourable), Prostate cancer:5.01e-4 (unfavourable), Urothelial cancer:8.65e-4 (favourable)","Mixed","Mixed",NA,NA,"testis: 15.1","Mixed",NA,NA
"ZNF770","FLJ20582, PRO1914","ENSG00000198146","Zinc finger protein 770","15","34978341-34988287","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA024518","Approved",NA,NA,NA,NA,"Expressed in all","Expressed in all",NA,NA,"thyroid gland: 73.6","Expressed in all",NA,NA
"ZNF777","KIAA1285","ENSG00000196453","Zinc finger protein 777","7","149431363-149461123","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA003252","Approved",NA,"Approved","Nucleus",NA,"Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 10.4","Mixed",NA,NA
"ZNF830","CCDC16, MGC20398, OMCG1","ENSG00000198783","Zinc finger protein 830","17","34961530-34963775","Predicted intracellular proteins","Evidence at protein level","HPA024754, HPA027211","Enhanced",NA,"Enhanced","Nucleoplasm","Prostate cancer:2.01e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"spleen: 16.6","Expressed in all",NA,NA
"ZNF853","DKFZp434J1015","ENSG00000236609","Zinc finger protein 853","7","6615617-6624290","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA067690","Approved",NA,"Approved","Nucleoli","Renal cancer:2.30e-6 (favourable)","Mixed","Mixed",NA,NA,"cerebral cortex: 17.4","Cell line enhanced",NA,"AN3-CA: 18.6;SH-SY5Y: 31.3;U-2 OS: 20.5"
"ZNF860",NA,"ENSG00000197385","Zinc finger protein 860","3","31981771-31991628","Predicted intracellular proteins, Transcription factors","Evidence at transcript level","HPA063386","Uncertain",NA,"Approved","Nucleus<br>Nucleoli",NA,"Mixed","Mixed",NA,NA,"prostate: 4.7","Cell line enriched",6,"BEWO: 44.1"
"ZSCAN1","FLJ33779, ZNF915","ENSG00000152467","Zinc finger and SCAN domain containing 1","19","58034032-58054631","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA007938","Uncertain",NA,"Approved","Nucleoli","Ovarian cancer:7.36e-4 (favourable)","Mixed","Tissue enhanced",NA,"epididymis: 7.4","cerebral cortex: 5.3","Cell line enhanced",NA,"EFO-21: 2.8;HMC-1: 1.8;NTERA-2: 2.1;T-47d: 2.9"
"ZSCAN12","dJ29K1.2, KIAA0426, ZFP96, ZNF29K1, ZNF305, ZNF96","ENSG00000158691","Zinc finger and SCAN domain containing 12","6","28378955-28399734","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA006637","Approved",NA,"Approved","Microtubules<br>Cytosol",NA,"Expressed in all","Mixed",NA,NA,"thyroid gland: 8.7","Mixed",NA,NA
"ZSCAN16","dJ265C24.3, FLJ22191, ZNF392, ZNF435","ENSG00000196812","Zinc finger and SCAN domain containing 16","6","28124560-28130082","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA007290","Supported",NA,"Approved","Nucleus","Ovarian cancer:1.14e-5 (favourable), Urothelial cancer:3.41e-5 (favourable), Lung cancer:3.19e-4 (favourable), Cervical cancer:5.73e-4 (favourable)","Expressed in all","Mixed",NA,NA,"parathyroid gland: 12.6","Mixed",NA,NA
"ZSCAN18","FLJ12895, ZNF447","ENSG00000121413","Zinc finger and SCAN domain containing 18","19","58083838-58118427","Predicted intracellular proteins","Evidence at protein level","HPA024318","Supported",NA,"Approved","Nucleoplasm","Renal cancer:3.95e-7 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 78.8","Cell line enhanced",NA,"HEK 293: 121.2;SCLC-21H: 73.3"
"ZZEF1","FLJ10821, KIAA0399, ZZZ4","ENSG00000074755","Zinc finger ZZ-type and EF-hand domain containing 1","17","4004445-4143020","Predicted membrane proteins","Evidence at protein level","HPA031778, HPA031790","Uncertain",NA,"Approved","Nucleoplasm<br>Mitochondria","Head and neck cancer:1.02e-4 (favourable), Pancreatic cancer:6.08e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"small intestine: 25.8","Expressed in all",NA,NA
"ABC7-42404400C24.1",NA,"ENSG00000277758",NA,"10","47750864-47763592","Predicted intracellular proteins, Predicted membrane proteins","Evidence at transcript level","HPA036971, HPA036972, HPA064559","Approved",NA,"Approved","Golgi apparatus",NA,"Not detected","Tissue enhanced",NA,"cerebral cortex: 13.8;lung: 19.3","skin: 5.7","Cell line enriched",7,"SK-BR-3: 45.1"
"ADGRL1","CIRL1, KIAA0821, LEC2, LPHN1","ENSG00000072071","Adhesion G protein-coupled receptor L1","19","14147743-14206187","G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA037974","Uncertain",NA,NA,NA,"Pancreatic cancer:1.14e-4 (favourable), Renal cancer:4.45e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 60.1","parathyroid gland: 24.2","Cell line enhanced",NA,"AN3-CA: 66.4;SCLC-21H: 64.6"
"AKAP6","ADAP6, AKAP100, KIAA0311, mAKAP, PRKA6","ENSG00000151320","A-kinase anchoring protein 6","14","32329273-32837681","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","CAB001983, HPA048741","Enhanced",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 49.0;heart muscle: 36.0","skeletal muscle: 16.6","Cell line enhanced",NA,"fHDF/TERT166: 12.2"
"ANGPTL4","ARP4, FIAF, HFARP, NL2, PGAR, pp1158","ENSG00000167772","Angiopoietin like 4","19","8363289-8374373","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA007879, CAB033770","Approved",NA,"Approved","Nucleoplasm<br>Vesicles","Renal cancer:1.34e-5 (unfavourable), Colorectal cancer:7.53e-4 (unfavourable), Lung cancer:9.50e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"adipose tissue: 78.7","liver: 43.2","Cell line enhanced",NA,"HBEC3-KT: 161.5;TIME: 92.8;U-138 MG: 64.0"
"B3GNT4","B3GN-T4, beta3Gn-T4","ENSG00000176383","UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 4","12","122203543-122208952","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA055261","Uncertain",NA,"Approved","Nucleoli<br>Mitochondria","Renal cancer:3.52e-6 (unfavourable)","Mixed","Tissue enhanced",NA,"cerebral cortex: 4.3;skin: 2.9","kidney: 1.9","Cell line enhanced",NA,"HDLM-2: 4.5;hTCEpi: 4.9;T-47d: 5.0"
"BCL11B","CTIP-2, CTIP2, hRIT1-alpha, ZNF856B","ENSG00000127152","B-cell CLL/lymphoma 11B","14","99169287-99271524","Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA049117","Enhanced","Supported","Approved","Nucleus<br>Nucleoli fibrillar center","Urothelial cancer:7.48e-4 (favourable)","Mixed","Tissue enhanced",NA,"lymph node: 12.2;skin: 18.7","tonsil: 7.4","Cell line enriched",6,"MOLT-4: 41.1"
"BCL9",NA,"ENSG00000116128","B-cell CLL/lymphoma 9","1","147541412-147626216","Cancer-related genes, Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA020274","Enhanced",NA,"Approved","Nucleoplasm<br>Nuclear bodies","Liver cancer:6.74e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"fallopian tube: 26.5","Cell line enhanced",NA,"NTERA-2: 42.4"
"BEST3","MGC13168, MGC40411, VMD2L3","ENSG00000127325","Bestrophin 3","12","69643360-69699476","Predicted intracellular proteins, Predicted membrane proteins","Evidence at transcript level","HPA054582","Approved",NA,NA,NA,NA,"Tissue enriched","Tissue enhanced",NA,"cerebral cortex: 16.3;skeletal muscle: 12.2","testis: 5.6","Group enriched",13,"REH: 32.4;RPMI-8226: 26.4;U-698: 43.2"
"BPIFC","BPIL2, dJ149A16.7","ENSG00000184459","BPI fold containing family C","22","32413847-32464484","Predicted intracellular proteins, Predicted secreted proteins","Evidence at transcript level","HPA037665, HPA043306","Uncertain",NA,NA,NA,NA,"Group enriched","Tissue enriched",18,"skin: 75.6","breast: 4.1","Cell line enhanced",NA,"SCLC-21H: 1.5"
"CD163L1","CD163B, M160, SCARI2","ENSG00000177675","CD163 molecule like 1","12","7346685-7479897","CD markers, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA015663","Enhanced",NA,"Approved","Nucleoplasm<br>Centrosome<br>Cytosol",NA,"Mixed","Tissue enhanced",NA,"spleen: 43.2","rectum: 24.1","Cell line enhanced",NA,"U-87 MG: 22.1"
"CDHR2","FLJ20124, FLJ20383, PC-LKC, PCDH24, PCLKC","ENSG00000074276","Cadherin related family member 2","5","176542511-176595974","Plasma proteins, Predicted membrane proteins","Evidence at protein level","HPA012569, HPA017053","Enhanced",NA,NA,NA,"Renal cancer:9.29e-4 (favourable)","Group enriched","Group enriched",12,"duodenum: 276.5;small intestine: 260.3","colon: 22.6","Cell line enriched",12,"Hep G2: 15.0"
"CPED1","C7orf58, FLJ21986","ENSG00000106034","Cadherin like and PC-esterase domain containing 1","7","120988677-121297444","Predicted intracellular proteins","Evidence at transcript level","HPA012058","Uncertain",NA,"Approved","Nucleus","Lung cancer:3.00e-4 (favourable), Renal cancer:4.87e-4 (unfavourable)","Mixed","Mixed",NA,NA,"ovary: 96.6","Cell line enhanced",NA,"BJ hTERT+: 70.8;K-562: 158.4"
"CTD-2006C1.13",NA,"ENSG00000267179",NA,"19","11925075-11979290","Predicted intracellular proteins","No evidence","HPA047845","Uncertain",NA,"Uncertain","Nucleus",NA,"Not detected","Not detected",NA,NA,"testis: 0.5","Not detected",NA,NA
"CX3CR1","CCRL1, CMKBRL1, CMKDR1, GPR13, V28","ENSG00000168329","C-X3-C motif chemokine receptor 1","3","39263494-39281735","Disease related genes, G-protein coupled receptors, Plasma proteins, Potential drug targets, Predicted membrane proteins","Evidence at protein level","HPA030311, CAB032478, HPA046587, HPA077743","Approved",NA,"Approved","Nucleus",NA,"Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 59.2","spleen: 16.6","Cell line enriched",18,"RPMI-8226: 409.2"
"CYP4F11",NA,"ENSG00000171903","Cytochrome P450 family 4 subfamily F member 11","19","15912367-15934867","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA017265, CAB033648, HPA058960","Enhanced",NA,NA,NA,"Breast cancer:4.05e-4 (favourable), Pancreatic cancer:9.28e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"gallbladder: 29.5;liver: 32.7;small intestine: 26.3","epididymis: 20.0","Cell line enhanced",NA,"A-431: 11.4;CAPAN-2: 44.2;EFO-21: 17.4;Hep G2: 17.0;RT4: 12.1"
"EMID1","EMI5, EMU1, hEmu1","ENSG00000186998","EMI domain containing 1","22","29205851-29259597","Predicted intracellular proteins, Predicted secreted proteins","Evidence at transcript level","HPA000592","Uncertain",NA,NA,NA,NA,"Expressed in all","Mixed",NA,NA,"spleen: 30.6","Cell line enhanced",NA,"HEL: 25.7;NB-4: 63.2"
"EPHX4","ABHD7, EPHXRP, FLJ90341","ENSG00000172031","Epoxide hydrolase 4","1","92029982-92063536","Predicted intracellular proteins","Evidence at protein level","HPA035067","Uncertain",NA,"Approved","Vesicles","Pancreatic cancer:2.00e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"cerebral cortex: 14.6","thyroid gland: 3.0","Cell line enhanced",NA,"A-431: 13.4;CAPAN-2: 11.4;EFO-21: 24.3;RPTEC TERT1: 27.3"
"GABRG2",NA,"ENSG00000113327","Gamma-aminobutyric acid type A receptor gamma2 subunit","5","162000057-162162977","Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters","Evidence at protein level","CAB079060",NA,"Supported",NA,NA,NA,"Tissue enhanced","Tissue enriched",12,"cerebral cortex: 66.5","adrenal gland: 5.3","Cell line enhanced",NA,"CACO-2: 11.6;U-266/70: 17.2;U-266/84: 13.6"
"GUCY1A3","GC-SA3, GUC1A3","ENSG00000164116","Guanylate cyclase 1 soluble subunit alpha","4","155666711-155732349","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","CAB010887, HPA056004, HPA058617","Uncertain",NA,"Supported","Nucleus","Lung cancer:2.38e-4 (favourable), Testis cancer:3.59e-4 (unfavourable), Renal cancer:7.59e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"parathyroid gland: 136.7","smooth muscle: 43.8","Cell line enhanced",NA,"HAP1: 7.2;Karpas-707: 7.1;MOLT-4: 15.2;RPTEC TERT1: 9.3;RT4: 11.7;SH-SY5Y: 9.5"
"KCNJ3","GIRK1, KGA, Kir3.1","ENSG00000162989","Potassium voltage-gated channel subfamily J member 3","2","154698299-154858352","Plasma proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels","Evidence at protein level","HPA024231","Uncertain",NA,NA,NA,NA,"Group enriched","Tissue enhanced",NA,"cerebral cortex: 25.4;parathyroid gland: 39.8","seminal vesicle: 14.1","Cell line enhanced",NA,"BJ: 1.2"
"KRT84","Hb-4, KRTHB4","ENSG00000161849","Keratin 84","12","52377812-52385652","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA039714","Supported",NA,NA,NA,NA,"Tissue enhanced","Not detected",NA,NA,"tonsil: 0.5","Not detected",NA,NA
"LPCAT2","AGPAT11, AYTL1, FLJ20481, LysoPAFAT","ENSG00000087253","Lysophosphatidylcholine acyltransferase 2","16","55508998-55586670","Enzymes, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA007891, HPA008433","Enhanced","Supported","Enhanced","Endoplasmic reticulum<br>Lipid droplets","Endometrial cancer:8.03e-6 (favourable), Colorectal cancer:3.43e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"thyroid gland: 142.6","bone marrow: 56.4","Cell line enhanced",NA,"CAPAN-2: 100.9;HMC-1: 141.4;WM-115: 114.8"
"MEIS1",NA,"ENSG00000143995","Meis homeobox 1","2","66433452-66573869","Disease related genes, Predicted intracellular proteins, Predicted secreted proteins, Transcription factors","Evidence at protein level","CAB011521, HPA056000, HPA058641","Approved",NA,"Supported","Nucleoplasm","Head and neck cancer:2.70e-5 (favourable), Renal cancer:1.69e-4 (unfavourable)","Tissue enhanced","Expressed in all",NA,NA,"endometrium: 92.6","Cell line enhanced",NA,"BJ hTERT+: 37.0;SH-SY5Y: 30.4"
"MKNK2","GPRK7, MNK2","ENSG00000099875","MAP kinase interacting serine/threonine kinase 2","19","2037465-2051244","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA021875, CAB037253, HPA070499","Enhanced",NA,"Supported","Nuclear bodies","Endometrial cancer:4.86e-5 (favourable), Stomach cancer:4.01e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"skeletal muscle: 174.3","Expressed in all",NA,NA
"RAB39B","MRX72","ENSG00000155961","RAB39B, member RAS oncogene family","X","155258241-155264589","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA001114, HPA042505","Approved",NA,NA,NA,"Breast cancer:8.95e-4 (favourable)","Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 19.4","epididymis: 7.5","Cell line enhanced",NA,"Daudi: 19.2;Karpas-707: 24.8;SCLC-21H: 15.4;U-266/70: 26.3;U-266/84: 17.9"
"RALGPS2","FLJ10244, FLJ25604, KIAA0351","ENSG00000116191","Ral GEF with PH domain and SH3 binding motif 2","1","178725147-178921841","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA027143, HPA028328","Enhanced",NA,"Uncertain","Nucleoplasm<br>Cytosol",NA,"Expressed in all","Tissue enhanced",NA,"testis: 138.2","lymph node: 62.7","Cell line enhanced",NA,"U-266/84: 172.2;U-698: 134.0"
"RFPL4B","RNF211","ENSG00000251258","Ret finger protein like 4B","6","112347330-112351296","Predicted intracellular proteins","Evidence at transcript level","HPA059324, HPA066464","Uncertain",NA,NA,NA,NA,"Group enriched","Tissue enriched",5,"testis: 2.9","placenta: 0.5","Cell line enhanced",NA,"K-562: 1.7;RPTEC TERT1: 1.8;U-266/84: 5.6"
"RP11-506B6.7",NA,"ENSG00000281613",NA,"6","112236806-112350094","Predicted intracellular proteins","Evidence at transcript level","HPA059324","Uncertain",NA,NA,NA,NA,"Not detected","Tissue enriched",14,"testis: 8.2","placenta: 0.6","Cell line enriched",12,"RPTEC TERT1: 2.7"
"SDK1","FLJ31425","ENSG00000146555","Sidekick cell adhesion molecule 1","7","3301448-4269000","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA011392","Approved",NA,"Approved","Cytosol","Pancreatic cancer:4.08e-4 (favourable)","Mixed","Tissue enhanced",NA,"cervix, uterine: 15.0","spleen: 6.0","Cell line enhanced",NA,"BEWO: 10.1;RT4: 8.9;U-2 OS: 13.6"
"SEMA3E","coll-5, KIAA0331, M-SemaK, SEMAH","ENSG00000170381","Semaphorin 3E","7","83363906-83649010","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA029419, HPA063804","Uncertain","Supported","Approved","Nucleoplasm<br>Vesicles",NA,"Mixed","Mixed",NA,NA,"prostate: 8.7","Cell line enhanced",NA,"SK-BR-3: 29.4;U-2 OS: 21.3"
"SLC22A17","BOCT, BOIT, NGALR","ENSG00000092096","Solute carrier family 22 member 17","14","23346306-23352912","Predicted membrane proteins, Transporters","Evidence at protein level","HPA002728","Uncertain",NA,NA,NA,"Pancreatic cancer:1.73e-4 (favourable), Stomach cancer:5.95e-4 (unfavourable)","Expressed in all","Tissue enriched",5,"cerebral cortex: 275.0","prostate: 52.6","Cell line enhanced",NA,"AN3-CA: 35.6;SH-SY5Y: 46.8"
"SLC26A1","EDM4, SAT-1","ENSG00000145217","Solute carrier family 26 member 1","4","979073-993440","Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters","Evidence at protein level","HPA041654","Uncertain",NA,"Approved","Microtubules","Renal cancer:1.19e-4 (favourable)","Mixed","Mixed",NA,NA,"adrenal gland,kidney: 6.0","Mixed",NA,NA
"SPATA16","NYD-SP12","ENSG00000144962","Spermatogenesis associated 16","3","172889358-173141268","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA037884","Enhanced",NA,NA,NA,NA,"Not detected","Tissue enriched",606,"testis: 105.7","kidney: 0.1","Not detected",NA,NA
"STXBP5","LLGL3, tomosyn","ENSG00000164506","Syntaxin binding protein 5","6","147204425-147390476","Predicted intracellular proteins","Evidence at protein level","HPA039991, HPA049727, CAB079016","Enhanced","Supported","Enhanced","Cytosol","Renal cancer:2.74e-7 (unfavourable), Breast cancer:4.48e-4 (unfavourable)","Expressed in all","Tissue enriched",7,"parathyroid gland: 278.8","testis: 40.2","Cell line enhanced",NA,"HEL: 188.3;HMC-1: 193.3"
"TANGO2","C22orf25, DKFZp761P1121","ENSG00000183597","Transport and golgi organization 2 homolog","22","20017014-20065926","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA003080","Approved","Approved",NA,NA,"Pancreatic cancer:3.01e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"heart muscle: 47.5","Expressed in all",NA,NA
"TFAP2C","AP2-GAMMA, ERF1, hAP-2g, TFAP2G","ENSG00000087510","Transcription factor AP-2 gamma","20","56629302-56639283","Predicted intracellular proteins, Transcription factors","Evidence at protein level","CAB016061, CAB016079, HPA055179, HPA057076","Enhanced",NA,"Supported","Nucleoplasm","Cervical cancer:6.90e-4 (favourable)","Tissue enhanced","Tissue enhanced",NA,"skin: 63.0","breast: 31.6","Cell line enhanced",NA,"BEWO: 183.4;MCF7: 128.7;SK-BR-3: 231.1;WM-115: 112.9"
"TST","RDS","ENSG00000128311","Thiosulfate sulfurtransferase","22","37010859-37020183","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA003044, HPA003643, CAB009546","Enhanced",NA,"Supported","Mitochondria","Renal cancer:7.59e-6 (favourable), Urothelial cancer:1.04e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"colon: 143.5","Mixed",NA,NA
"TYSND1","MGC34695, NET41","ENSG00000156521","Trypsin domain containing 1","10","70137981-70146676","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA030304","Uncertain",NA,"Uncertain","Nucleoplasm<br>Centrosome<br>Cytosol",NA,"Expressed in all","Mixed",NA,NA,"adipose tissue: 5.8","Cell line enhanced",NA,"HaCaT: 24.4;PC-3: 39.1"
"ZNF439","DKFZp571K0837","ENSG00000171291","Zinc finger protein 439","19","11848726-11883750","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA047845","Uncertain",NA,"Uncertain","Nucleus",NA,"Mixed","Mixed",NA,NA,"parathyroid gland: 25.5","Cell line enhanced",NA,"U-138 MG: 15.4"
"ZNF440","FLJ37933","ENSG00000171295","Zinc finger protein 440","19","11814284-11835201","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA047845","Uncertain",NA,"Uncertain","Nucleus","Renal cancer:1.18e-4 (favourable), Prostate cancer:3.57e-4 (unfavourable), Urothelial cancer:9.88e-4 (favourable)","Expressed in all","Mixed",NA,NA,"fallopian tube: 23.2","Mixed",NA,NA
"ZNF69","Cos5","ENSG00000198429","Zinc finger protein 69","19","11887784-11914329","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA047845","Uncertain",NA,"Uncertain","Nucleus","Endometrial cancer:1.55e-4 (favourable)","Mixed","Tissue enhanced",NA,"parathyroid gland: 24.9","kidney: 10.3","Cell line enhanced",NA,"AF22: 13.8"
"ZNF700","DKFZp434I1610","ENSG00000196757","Zinc finger protein 700","19","11925068-11950773","Predicted intracellular proteins, Transcription factors","Evidence at transcript level","HPA047845","Uncertain",NA,"Uncertain","Nucleus","Renal cancer:2.01e-5 (unfavourable), Urothelial cancer:2.53e-5 (favourable), Head and neck cancer:1.27e-4 (favourable), Prostate cancer:1.75e-4 (unfavourable), Melanoma:2.58e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"skin: 19.1","Mixed",NA,NA
"ZNF763","ZNF440L","ENSG00000197054","Zinc finger protein 763","19","11965037-11980381","Predicted intracellular proteins, Transcription factors","Evidence at transcript level","HPA047845","Uncertain",NA,"Uncertain","Nucleus",NA,"Mixed","Mixed",NA,NA,"parathyroid gland: 11.5","Cell line enhanced",NA,"BEWO: 5.9"
"ABHD5","CGI-58, NCIE2","ENSG00000011198","Abhydrolase domain containing 5","3","43690113-43734371","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","CAB020685, HPA035851, HPA035852","Approved",NA,"Approved","Vesicles","Renal cancer:9.17e-5 (favourable), Colorectal cancer:8.89e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"adipose tissue: 50.6","Expressed in all",NA,NA
"ABTB1","BPOZ, Btb3, BTBD21, EF1ABP","ENSG00000114626","Ankyrin repeat and BTB domain containing 1","3","127672935-127680920","Predicted intracellular proteins","Evidence at protein level","HPA035022, HPA035023","Uncertain",NA,"Supported","Nucleoli<br>Cytosol","Renal cancer:1.13e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"spleen: 50.2","Mixed",NA,NA
"AC004381.6",NA,"ENSG00000005189","Putative RNA exonuclease NEF-sp","16","20806429-20849668","Predicted intracellular proteins","Evidence at protein level","HPA040755, HPA040868","Enhanced",NA,"Approved","Nuclear membrane<br>Nucleoli<br>Endoplasmic reticulum",NA,"Expressed in all","Tissue enriched",33,"testis: 618.5","parathyroid gland: 18.9","Mixed",NA,NA
"ACO2","ACONM","ENSG00000100412","Aconitase 2","22","41469125-41528989","Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA001097","Enhanced","Supported","Supported","Mitochondria","Renal cancer:0.00e+0 (favourable)","Expressed in all","Expressed in all",NA,NA,"heart muscle: 308.9","Expressed in all",NA,NA
"ACRBP","CT23, OY-TES-1, SP32","ENSG00000111644","Acrosin binding protein","12","6638075-6647460","Predicted secreted proteins","Evidence at protein level","HPA039081, HPA039082","Enhanced",NA,"Approved","Nucleoplasm<br>Vesicles",NA,"Mixed","Tissue enriched",19,"testis: 432.5","thyroid gland: 22.6","Cell line enhanced",NA,"HMC-1: 5.8;U-266/70: 11.3;U-266/84: 7.3"
"ADCY2","AC2, HBAC2, KIAA1060","ENSG00000078295","Adenylate cyclase 2","5","7396208-7830081","Enzymes, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","CAB031482, HPA038015, HPA038483","Approved",NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 57.2;skeletal muscle: 23.6","prostate: 8.4","Group enriched",7,"AF22: 5.6;NTERA-2: 4.3;SK-MEL-30: 3.8"
"ADRA1A","ADRA1C, ADRA1L1","ENSG00000120907","Adrenoceptor alpha 1A","8","26748150-26867273","FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins","Evidence at protein level","HPA029678, HPA029679","Approved",NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"adipose tissue: 22.6;liver: 31.6;prostate: 20.8","seminal vesicle: 19.1","Not detected",NA,NA
"ADRA1D","ADRA1, ADRA1A, ADRA1R","ENSG00000171873","Adrenoceptor alpha 1D","20","4220631-4249074","FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins","Evidence at protein level","HPA038789","Uncertain",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"cervix, uterine: 4.3;prostate: 4.5","seminal vesicle: 2.6","Cell line enhanced",NA,"BJ: 6.7;CAPAN-2: 3.1;fHDF/TERT166: 3.7"
"AFP","FETA, HPAFP","ENSG00000081051","Alpha fetoprotein","4","73431138-73456174","Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA010607, HPA023600, CAB024283, CAB025339","Approved",NA,"Uncertain","Cytosol",NA,"Group enriched","Tissue enhanced",NA,"liver: 1.9","breast: 0.5","Cell line enriched",158,"Hep G2: 1466.5"
"AGA","ASRG","ENSG00000038002","Aspartylglucosaminidase","4","177430770-177442503","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA031415, HPA031417","Enhanced",NA,NA,NA,"Liver cancer:1.99e-4 (unfavourable), Head and neck cancer:8.61e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"epididymis: 35.3","Expressed in all",NA,NA
"AHCY","SAHH","ENSG00000101444","Adenosylhomocysteinase","20","34280268-34311802","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA041225, HPA044675","Approved",NA,"Supported","Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"kidney: 159.4","Expressed in all",NA,NA
"AKNAD1","C1orf62, MGC26989","ENSG00000162641","AKNA domain containing 1","1","108815898-108858228","Predicted intracellular proteins","Evidence at transcript level","HPA030270, HPA030271, HPA030272","Uncertain",NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",63,"testis: 6.4","skin: 0.1","Not detected",NA,NA
"ALG2","CDG1I, CDGIi, FLJ14511, hALPG2, NET38","ENSG00000119523","ALG2, alpha-1,3/1,6-mannosyltransferase","9","99216426-99221956","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA041512, HPA041601","Approved",NA,"Enhanced","Actin filaments<br>Cytosol","Renal cancer:2.28e-7 (favourable), Endometrial cancer:8.44e-5 (favourable), Head and neck cancer:1.56e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"epididymis: 77.1","Expressed in all",NA,NA
"AMD1","SAMDC","ENSG00000123505","Adenosylmethionine decarboxylase 1","6","110874770-110895713","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA029281, HPA029282","Approved",NA,"Approved","Nucleoplasm","Liver cancer:1.91e-6 (unfavourable), Breast cancer:3.87e-4 (unfavourable), Renal cancer:4.28e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"prostate: 323.8","Expressed in all",NA,NA
"ANAPC11","APC11, Apc11p, HSPC214, MGC882","ENSG00000141552","Anaphase promoting complex subunit 11","17","81890790-81900991","Predicted intracellular proteins","Evidence at protein level","HPA021989, HPA027838","Approved",NA,"Enhanced","Nucleoplasm<br>Nucleoli",NA,"Expressed in all","Expressed in all",NA,NA,"testis: 109.9","Expressed in all",NA,NA
"ANAPC15","APC15, C11orf51, DKFZP564M082, HSPC020","ENSG00000110200","Anaphase promoting complex subunit 15","11","72106378-72112780","Predicted intracellular proteins","Evidence at protein level","HPA036596","Approved",NA,"Approved","Nucleoplasm<br>Vesicles","Ovarian cancer:2.55e-4 (favourable), Liver cancer:4.37e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 77.6","Expressed in all",NA,NA
"ANGPTL3","ANGPT5","ENSG00000132855","Angiopoietin like 3","1","62597487-62606159","Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA038097","Approved",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",6,"liver: 356.4","kidney: 55.7","Not detected",NA,NA
"ANKRD23","DARP, FLJ32449, MARP3","ENSG00000163126","Ankyrin repeat domain 23","2","96824526-96857934","Predicted intracellular proteins","Evidence at protein level","HPA036201","Approved",NA,"Supported","Nucleoplasm<br>Actin filaments",NA,"Not detected","Tissue enriched",64,"skeletal muscle: 495.5","prostate: 7.7","Cell line enriched",8,"Karpas-707: 27.1"
"ANKRD42","FLJ37874, PPP1R79, SARP","ENSG00000137494","Ankyrin repeat domain 42","11","83193739-83260694","Predicted intracellular proteins","Evidence at protein level","HPA039917","Approved",NA,"Approved","Nucleoplasm<br>Plasma membrane<br>Cytosol",NA,"Expressed in all","Tissue enhanced",NA,"testis: 71.5","fallopian tube: 26.2","Expressed in all",NA,NA
"ANKS3","FLJ32345, FLJ32767, KIAA1977","ENSG00000168096","Ankyrin repeat and sterile alpha motif domain containing 3","16","4696510-4734378","Predicted intracellular proteins","Evidence at protein level","HPA041409, HPA041482","Uncertain",NA,"Supported","Nucleoplasm<br>Cytosol",NA,"Expressed in all","Mixed",NA,NA,"ovary: 8.1","Expressed in all",NA,NA
"AOC1","ABP1, DAO","ENSG00000002726","Amine oxidase, copper containing 1","7","150824627-150861504","Enzymes, Predicted secreted proteins","Evidence at protein level","HPA031032, HPA031033","Approved",NA,NA,NA,"Prostate cancer:1.71e-4 (favourable)","Group enriched","Tissue enhanced",NA,"placenta: 716.9;small intestine: 247.6","duodenum: 183.2","Cell line enhanced",NA,"CAPAN-2: 17.4;HaCaT: 5.4;THP-1: 17.8"
"AOC3","HPAO, VAP-1, VAP1","ENSG00000131471","Amine oxidase, copper containing 3","17","42851184-42858130","Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA000980, CAB025797","Enhanced",NA,"Approved","Golgi apparatus<br>Cytosol","Renal cancer:1.79e-5 (unfavourable), Colorectal cancer:3.68e-4 (unfavourable), Urothelial cancer:6.98e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"adipose tissue: 450.1","smooth muscle: 205.7","Cell line enriched",17,"ASC diff: 210.1"
"AP000322.53",NA,"ENSG00000243627",NA,"21","34418715-34423966","Predicted membrane proteins","Evidence at transcript level","HPA029085","Uncertain",NA,NA,NA,NA,"Not detected","Group enriched",7,"breast: 1.5;fallopian tube: 1.4;kidney: 4.3","skin: 0.3","Not detected",NA,NA
"APIP","APIP2, CGI-29, Mmrp19","ENSG00000149089","APAF1 interacting protein","11","34853094-34916499","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA021188, HPA024131","Approved",NA,"Approved","Nucleoplasm<br>Cytosol","Liver cancer:1.99e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 33.2","Expressed in all",NA,NA
"APOM","ApoM, G3a, NG20","ENSG00000204444","Apolipoprotein M","6","31652416-31658210","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB034086, HPA051006","Approved",NA,"Approved","Golgi apparatus",NA,"Tissue enriched","Mixed",NA,NA,"testis: 5.6","Mixed",NA,NA
"ARHGAP18","bA307O14.2, MacGAP","ENSG00000146376","Rho GTPase activating protein 18","6","129576132-129710225","Predicted intracellular proteins","Evidence at protein level","HPA031595","Approved",NA,"Approved","Nuclear speckles<br>Plasma membrane<br>Cytosol","Pancreatic cancer:2.54e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"adrenal gland: 48.0","Cell line enhanced",NA,"HMC-1: 344.1"
"ARHGAP30","FLJ00267","ENSG00000186517","Rho GTPase activating protein 30","1","161046946-161069970","Predicted intracellular proteins","Evidence at protein level","HPA036300","Uncertain",NA,"Supported","Vesicles","Renal cancer:9.78e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"lymph node: 86.1;spleen: 80.6","appendix: 73.2","Cell line enhanced",NA,"Daudi: 82.8;HL-60: 72.0;HMC-1: 106.5;U-266/70: 103.3"
"ARHGEF18","KIAA0521, MGC15913, P114-RhoGEF","ENSG00000104880","Rho/Rac guanine nucleotide exchange factor 18","19","7395113-7472477","Predicted intracellular proteins","Evidence at protein level","HPA042689, HPA071867","Approved",NA,"Enhanced","Cytosol","Renal cancer:3.11e-5 (favourable), Head and neck cancer:4.21e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"spleen: 30.5","Expressed in all",NA,NA
"ARMCX1","ALEX1, GASP7","ENSG00000126947","Armadillo repeat containing, X-linked 1","X","101550531-101554700","Predicted membrane proteins","Evidence at protein level","HPA005685, CAB020695","Supported",NA,"Approved","Nucleus<br>Mitochondria<br>Cytosol","Pancreatic cancer:7.32e-5 (favourable), Cervical cancer:3.62e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"ovary: 59.0","Cell line enhanced",NA,"BJ hTERT+ SV40 Large T+ RasG12V: 75.6;RH-30: 84.3"
"ARSG","KIAA1001","ENSG00000141337","Arylsulfatase G","17","68259182-68422731","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA023245, HPA023285","Enhanced",NA,NA,NA,"Renal cancer:7.04e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"epididymis: 48.6","thyroid gland: 18.9","Mixed",NA,NA
"ATF5",NA,"ENSG00000169136","Activating transcription factor 5","19","49928702-49933935","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA030187","Uncertain",NA,"Supported","Nucleoplasm<br>Cytosol","Renal cancer:3.39e-7 (unfavourable), Cervical cancer:1.14e-4 (favourable), Endometrial cancer:1.16e-4 (unfavourable)","Tissue enriched","Group enriched",7,"liver: 387.6;thyroid gland: 190.2","appendix: 42.4","Expressed in all",NA,NA
"ATP8B4","ATPIM, KIAA1939","ENSG00000104043","ATPase phospholipid transporting 8B4 (putative)","15","49858238-50182817","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA040254","Approved",NA,"Approved","Nucleoplasm<br>Vesicles",NA,"Mixed","Tissue enhanced",NA,"bone marrow: 23.0","endometrium: 9.3","Cell line enhanced",NA,"HMC-1: 32.2;THP-1: 16.5;U-937: 60.0"
"BCKDHB",NA,"ENSG00000083123","Branched chain keto acid dehydrogenase E1 subunit beta","6","80106647-80346270","Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins","Evidence at protein level","HPA031580","Approved",NA,NA,NA,"Renal cancer:5.54e-9 (favourable)","Expressed in all","Expressed in all",NA,NA,"liver: 39.9","Expressed in all",NA,NA
"BCL2L15","Bfk, C1orf178, FLJ22588","ENSG00000188761","BCL2 like 15","1","113878168-113887547","Predicted intracellular proteins","Evidence at protein level","HPA029732, HPA029733","Enhanced",NA,NA,NA,"Endometrial cancer:5.63e-4 (favourable)","Tissue enhanced","Tissue enhanced",NA,"colon: 47.4;duodenum: 66.5;rectum: 52.2;small intestine: 64.3","stomach: 24.0","Cell line enhanced",NA,"CAPAN-2: 22.4;EFO-21: 8.1;RPTEC TERT1: 5.6"
"BCORL1","CXorf10, FLJ11362","ENSG00000085185","BCL6 corepressor-like 1","X","129981107-130058083","Cancer-related genes, Predicted intracellular proteins","Evidence at protein level","HPA031775, HPA031777, HPA068568","Uncertain",NA,"Approved","Nucleoplasm<br>Plasma membrane","Endometrial cancer:2.20e-5 (unfavourable), Renal cancer:5.00e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 18.3","Cell line enhanced",NA,"HAP1: 51.8"
"BMI1","PCGF4, RNF51","ENSG00000168283","BMI1 proto-oncogene, polycomb ring finger","10","22321211-22331484","Cancer-related genes, Predicted intracellular proteins","Evidence at protein level","CAB011120, HPA030471, HPA030472","Supported",NA,"Approved","Nucleus<br>Nucleoli<br>Nuclear bodies<br>Cytosol","Liver cancer:2.60e-8 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 86.3","Expressed in all",NA,NA
"BMPER","CRIM3, Cv2","ENSG00000164619","BMP binding endothelial regulator","7","33904911-34155872","Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA018083",NA,"Supported",NA,NA,NA,"Tissue enhanced","Mixed",NA,NA,"placenta: 9.5","Cell line enhanced",NA,"fHDF/TERT166: 17.5;HBF TERT88: 23.1;hTEC/SVTERT24-B: 16.0;U-138 MG: 24.5"
"BORCS5","LOH12CR1, LOH1CR12","ENSG00000165714","BLOC-1 related complex subunit 5","12","12357079-12469694","Predicted intracellular proteins","Evidence at protein level","HPA039509, HPA043627","Approved",NA,"Supported","Cytosol","Liver cancer:3.47e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"cerebral cortex,epididymis: 7.4","Expressed in all",NA,NA
"BTBD16","C10orf87, Em:AC061711.1, FLJ25359","ENSG00000138152","BTB domain containing 16","10","122271306-122338162","Predicted intracellular proteins","Evidence at protein level","HPA040529, HPA057638","Uncertain",NA,"Uncertain","Nucleoli<br>Cytosol","Renal cancer:1.50e-4 (unfavourable)","Tissue enriched","Group enriched",7,"skin: 9.9;testis: 14.2;urinary bladder: 19.0","liver: 2.1","Cell line enriched",9,"RT4: 26.9"
"C10orf88","Em:AC073585.5, FLJ13490","ENSG00000119965","Chromosome 10 open reading frame 88","10","122930903-122954403","Predicted intracellular proteins","Evidence at protein level","HPA039681, HPA040991","Enhanced",NA,NA,NA,"Liver cancer:2.05e-5 (unfavourable)","Expressed in all","Mixed",NA,NA,"testis: 14.3","Expressed in all",NA,NA
"C11orf57","FLJ10726","ENSG00000150776","Chromosome 11 open reading frame 57","11","112074086-112085150","Predicted intracellular proteins","Evidence at protein level","HPA039493, HPA039892","Approved",NA,"Supported","Cytosol","Liver cancer:2.70e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 26.7","Expressed in all",NA,NA
"C11orf58","SMAP","ENSG00000110696","Chromosome 11 open reading frame 58","11","16613132-16756881","Predicted intracellular proteins","Evidence at protein level","HPA036591, HPA076406","Uncertain",NA,"Approved","Nucleoplasm<br>Endoplasmic reticulum","Liver cancer:5.84e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 217.7","Expressed in all",NA,NA
"C17orf67",NA,"ENSG00000214226","Chromosome 17 open reading frame 67","17","56791913-56838773","Predicted secreted proteins","Evidence at protein level","HPA043479","Uncertain","Approved",NA,NA,NA,"Mixed","Mixed",NA,NA,"spleen: 3.7","Cell line enhanced",NA,"MOLT-4: 11.9"
"C19orf66","FLJ11286, RyDEN","ENSG00000130813","Chromosome 19 open reading frame 66","19","10086122-10093252","Predicted intracellular proteins","Evidence at protein level","HPA042001","Approved",NA,"Supported","Nucleoplasm<br>Cytosol","Renal cancer:8.96e-11 (unfavourable), Urothelial cancer:1.35e-4 (favourable), Breast cancer:4.04e-4 (favourable)","Expressed in all","Mixed",NA,NA,"fallopian tube: 20.5","Cell line enhanced",NA,"BJ hTERT+ SV40 Large T+: 44.2;BJ hTERT+ SV40 Large T+ RasG12V: 48.5"
"C22orf42",NA,"ENSG00000205856","Chromosome 22 open reading frame 42","22","32149006-32159322","Predicted intracellular proteins","Evidence at protein level","HPA019531","Enhanced",NA,NA,NA,NA,"Group enriched","Tissue enriched",8,"testis: 10.8","prostate: 1.3","Not detected",NA,NA
"C4BPA","C4BP","ENSG00000123838","Complement component 4 binding protein alpha","1","207104262-207144972","Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA000926, HPA001578","Enhanced",NA,NA,NA,"Endometrial cancer:6.37e-5 (favourable), Liver cancer:2.24e-4 (favourable)","Tissue enriched","Group enriched",65,"liver: 997.5;lung: 262.3","cervix, uterine: 9.6","Cell line enriched",6,"Hep G2: 25.8"
"C6orf62","DKFZP564G182, FLJ12619, XTP12","ENSG00000112308","Chromosome 6 open reading frame 62","6","24704861-24720836","Predicted intracellular proteins","Evidence at protein level","HPA030564, HPA030566","Enhanced",NA,"Approved","Cytosol","Urothelial cancer:3.62e-6 (favourable), Liver cancer:5.77e-5 (unfavourable), Ovarian cancer:4.04e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 174.4","Expressed in all",NA,NA
"C7orf43","FLJ10925","ENSG00000146826","Chromosome 7 open reading frame 43","7","100154420-100158715","Predicted intracellular proteins","Evidence at protein level","HPA019359, HPA029463, HPA029464","Approved",NA,"Enhanced","Vesicles<br>Plasma membrane<br>Microtubule organizing center","Pancreatic cancer:6.19e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 33.1","Expressed in all",NA,NA
"CA3","CAIII, Car3","ENSG00000164879","Carbonic anhydrase 3","8","85373436-85449040","Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB004967, HPA021775, HPA026700","Enhanced",NA,NA,NA,"Breast cancer:4.24e-6 (favourable)","Group enriched","Tissue enriched",13,"skeletal muscle: 1838.7","prostate: 138.3","Group enriched",34,"HEL: 44.2;RH-30: 77.2"
"CACNB4","EJM4","ENSG00000182389","Calcium voltage-gated channel auxiliary subunit beta 4","2","151832768-152099475","Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters","Evidence at protein level","HPA015601","Approved",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 25.9","skin: 8.0","Cell line enhanced",NA,"HMC-1: 17.7"
"CACTIN","C19orf29, cactin, fSAPc, NY-REN-24","ENSG00000105298","Cactin, spliceosome C complex subunit","19","3610641-3626815","Predicted intracellular proteins","Evidence at protein level","HPA042504, HPA042548","Approved",NA,"Supported","Nucleoplasm<br>Nuclear speckles<br>Cytosol","Endometrial cancer:3.69e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"spleen: 14.4","Expressed in all",NA,NA
"CALCOCO1","calphoglin, Cocoa, KIAA1536","ENSG00000012822","Calcium binding and coiled-coil domain 1","12","53708517-53727745","Predicted intracellular proteins","Evidence at protein level","HPA038313, HPA038314","Approved",NA,"Enhanced","Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"skin: 160.7","Expressed in all",NA,NA
"CARS2","FLJ12118","ENSG00000134905","Cysteinyl-tRNA synthetase 2, mitochondrial (putative)","13","110641412-110713603","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA041776","Uncertain",NA,"Approved","Nucleoplasm<br>Mitochondria","Renal cancer:2.49e-5 (unfavourable), Liver cancer:1.21e-4 (unfavourable), Endometrial cancer:1.84e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"cervix, uterine: 28.4","Expressed in all",NA,NA
"CASK","CAGH39, FGS4, LIN2, TNRC8","ENSG00000147044","Calcium/calmodulin dependent serine protein kinase","X","41514934-41923463","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","CAB001949, HPA023857","Enhanced",NA,"Approved","Nucleoplasm<br>Cytosol","Pancreatic cancer:6.11e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"small intestine: 34.5","Mixed",NA,NA
"CCDC102A","MGC10992","ENSG00000135736","Coiled-coil domain containing 102A","16","57512178-57536599","Predicted intracellular proteins","Evidence at protein level","HPA040598, HPA040958","Supported",NA,"Approved","Nucleoplasm<br>Nuclear bodies",NA,"Expressed in all","Mixed",NA,NA,"prostate: 5.5","Mixed",NA,NA
"CCDC18","NY-SAR-41","ENSG00000122483","Coiled-coil domain containing 18","1","93179919-93278730","Predicted intracellular proteins","Evidence at protein level","HPA028035","Uncertain",NA,"Approved","Nucleoplasm<br>Cytosol",NA,"Mixed","Tissue enhanced",NA,"testis: 17.2","lymph node: 10.7","Mixed",NA,NA
"CCDC183","bA216L13.7, KIAA1984, MGC15438","ENSG00000213213","Coiled-coil domain containing 183","9","136796350-136807741","Predicted intracellular proteins","Evidence at transcript level","HPA043812","Uncertain",NA,NA,NA,NA,"Mixed","Tissue enriched",51,"testis: 11.8","prostate: 0.2","Not detected",NA,NA
"CCDC65","CFAP250, CILD27, DRC2, FAP250, FLJ35732, NYD-SP28","ENSG00000139537","Coiled-coil domain containing 65","12","48904110-48931840","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA038520, HPA057573","Uncertain",NA,"Approved","Vesicles<br>Microtubule organizing center",NA,"Mixed","Group enriched",12,"fallopian tube: 42.8;testis: 67.9","lung: 4.4","Mixed",NA,NA
"CCSER2","FAM190B, KIAA1128","ENSG00000107771","Coiled-coil serine rich protein 2","10","84328586-84518521","Predicted intracellular proteins","Evidence at protein level","HPA037481, HPA037482","Approved",NA,"Approved","Nucleoplasm<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 39.5","Expressed in all",NA,NA
"CCT4","Cctd","ENSG00000115484","Chaperonin containing TCP1 subunit 4","2","61868089-61888804","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA029349","Enhanced",NA,"Supported","Nucleoplasm<br>Cytosol","Liver cancer:9.37e-12 (unfavourable), Breast cancer:2.03e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 133.6","Expressed in all",NA,NA
"CD8B","CD8B1","ENSG00000172116","CD8b molecule","2","86815339-86861924","CD markers, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB004353, HPA029164","Enhanced",NA,"Supported","Plasma membrane","Endometrial cancer:7.88e-7 (favourable), Renal cancer:7.11e-6 (unfavourable)","Mixed","Tissue enhanced",NA,"cervix, uterine: 60.8;lymph node: 39.6","parathyroid gland: 22.7","Cell line enriched",50,"RPMI-8226: 837.8"
"CDC23","ANAPC8, APC8, CUT23","ENSG00000094880","Cell division cycle 23","5","138187648-138213343","Predicted secreted proteins","Evidence at protein level","HPA039593","Approved",NA,NA,NA,"Liver cancer:1.50e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 37.3","Expressed in all",NA,NA
"CENPL","C1orf155, dJ383J4.3, FLJ31044","ENSG00000120334","Centromere protein L","1","173799550-173824720","Predicted intracellular proteins","Evidence at protein level","HPA044520","Uncertain",NA,NA,NA,"Melanoma:2.51e-4 (unfavourable), Ovarian cancer:3.60e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"testis: 18.2","lymph node: 7.8","Expressed in all",NA,NA
"CENPP","CENP-P, RP11-19J3.3","ENSG00000188312","Centromere protein P","9","92325484-92620533","Predicted intracellular proteins","Evidence at protein level","HPA021787, HPA058945","Uncertain",NA,"Supported","Nucleus<br>Nucleoli","Head and neck cancer:3.65e-4 (favourable), Cervical cancer:3.91e-4 (favourable)","Mixed","Tissue enhanced",NA,"skin: 25.2","parathyroid gland: 8.0","Expressed in all",NA,NA
"CFAP44","FLJ11142, WDR52","ENSG00000206530","Cilia and flagella associated protein 44","3","113286947-113441610","Predicted intracellular proteins","Evidence at protein level","HPA067258","Uncertain",NA,NA,NA,"Urothelial cancer:7.09e-6 (favourable)","Mixed","Tissue enhanced",NA,"testis: 14.4","fallopian tube: 13.7","Mixed",NA,NA
"CH507-396I9.3",NA,"ENSG00000278961",NA,"21","7788703-7793954","Predicted membrane proteins","Evidence at transcript level","HPA029085","Uncertain",NA,NA,NA,NA,"Not detected","Group enriched",7,"breast: 1.5;fallopian tube: 1.4;kidney: 4.3","skin: 0.3","Not detected",NA,NA
"CHST12","C4S-2, C4ST2","ENSG00000136213","Carbohydrate sulfotransferase 12","7","2403560-2448483","Enzymes, Predicted membrane proteins","Evidence at protein level","HPA041680","Approved",NA,"Approved","Golgi apparatus","Pancreatic cancer:1.32e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"spleen: 16.1","Cell line enhanced",NA,"U-266/70: 68.5"
"CISH","CIS, CIS-1, G18, SOCS","ENSG00000114737","Cytokine inducible SH2 containing protein","3","50606490-50611831","Predicted intracellular proteins","Evidence at protein level","CAB034039, HPA040812","Approved",NA,"Approved","Microtubules<br>Cytokinetic bridge","Renal cancer:3.53e-12 (favourable), Endometrial cancer:1.13e-5 (favourable), Liver cancer:6.98e-4 (favourable), Pancreatic cancer:9.65e-4 (favourable)","Expressed in all","Mixed",NA,NA,"thyroid gland: 42.9","Group enriched",6,"HDLM-2: 287.3;K-562: 65.9"
"CLEC16A","Gop-1, KIAA0350","ENSG00000038532","C-type lectin domain family 16 member A","16","10944488-11182189","Disease related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA035814, HPA035815, HPA061385","Approved",NA,"Approved","Nucleus<br>Vesicles","Renal cancer:2.92e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 60.3","Expressed in all",NA,NA
"CNNM1","ACDP1","ENSG00000119946","Cyclin and CBS domain divalent metal cation transport mediator 1","10","99329099-99394330","Predicted membrane proteins","Evidence at protein level","HPA040408","Approved",NA,"Uncertain","Plasma membrane<br>Cytosol",NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 10.2;testis: 16.8","ovary: 3.0","Cell line enhanced",NA,"A549: 16.9;BJ hTERT+ SV40 Large T+ RasG12V: 10.6;HAP1: 8.6"
"COMMD1","C2orf5, MGC27155, MURR1","ENSG00000173163","Copper metabolism domain containing 1","2","61888724-62147247","Predicted intracellular proteins","Evidence at protein level","HPA034633, HPA049223","Approved",NA,"Supported","Nucleoplasm<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"thyroid gland: 47.8","Expressed in all",NA,NA
"COPS2","ALIEN, CSN2, TRIP15","ENSG00000166200","COP9 signalosome subunit 2","15","49106068-49155661","Predicted intracellular proteins","Evidence at protein level","HPA016867, HPA018271, HPA061071","Approved",NA,"Enhanced","Vesicles<br>Cytokinetic bridge",NA,"Expressed in all","Expressed in all",NA,NA,"thyroid gland: 103.5","Expressed in all",NA,NA
"CPPED1","CSTP1, FLJ11151","ENSG00000103381","Calcineurin like phosphoesterase domain containing 1","16","12659799-12804017","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA040938, HPA041970","Uncertain",NA,"Supported","Plasma membrane<br>Cytosol","Renal cancer:1.62e-9 (favourable), Breast cancer:9.72e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"spleen: 41.0","Cell line enhanced",NA,"Hep G2: 97.8;HMC-1: 114.2"
"CRLF1","CISS, CISS1, CLF, CLF-1","ENSG00000006016","Cytokine receptor like factor 1","19","18572220-18607741","Disease related genes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA041493, HPA041793","Approved",NA,NA,NA,"Renal cancer:3.96e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"cerebral cortex: 17.2;placenta: 16.8","adipose tissue: 10.1","Group enriched",8,"ASC diff: 706.3;Hep G2: 309.6"
"CRYGS","CRYG8","ENSG00000213139","Crystallin gamma S","3","186538441-186546702","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA035103","Uncertain",NA,"Uncertain","Cytosol","Renal cancer:3.72e-9 (unfavourable), Urothelial cancer:2.73e-4 (favourable)","Expressed in all","Mixed",NA,NA,"lymph node,spleen: 4.1","Mixed",NA,NA
"CT45A1","CT45-1, CT45.1","ENSG00000268940","Cancer/testis antigen family 45 member A1","X","135713453-135723539","Predicted intracellular proteins","Evidence at protein level","HPA044735, HPA044757, HPA046872, HPA046987","Supported",NA,"Approved","Nucleus<br>Nucleoli",NA,"Mixed","Tissue enriched",42,"testis: 12.5","cerebral cortex,lung: 0.2","Group enriched",6,"HMC-1: 202.8;Karpas-707: 77.5"
"CT45A10",NA,"ENSG00000269586","Cancer/testis antigen family 45 member A10","X","135881063-135889086","Predicted intracellular proteins","Evidence at protein level","HPA044735, HPA044757, HPA046872, HPA046987","Supported",NA,"Approved","Nucleus<br>Nucleoli",NA,"Mixed","Tissue enriched",23,"testis: 16.5","cerebral cortex: 0.7","Cell line enhanced",NA,"AN3-CA: 78.6;K-562: 23.7;Karpas-707: 67.5;U-266/84: 58.7"
"CT45A2","CT45-2, CT45.2","ENSG00000271449","Cancer/testis antigen family 45 member A2","X","135811668-135820012","Predicted intracellular proteins","Evidence at protein level","HPA044735, HPA044757, HPA046872, HPA046987","Supported",NA,"Approved","Nucleus<br>Nucleoli",NA,"Not detected","Tissue enriched",14,"testis: 1.4","all non-specific tissues: 0.0","Group enriched",5,"AN3-CA: 10.0;HMC-1: 43.4"
"CT45A3","CT45-3, CT45-4, CT45.3, CT45.4, CT45A4","ENSG00000269096","Cancer/testis antigen family 45 member A3","X","135759846-135768191","Predicted intracellular proteins","Evidence at protein level","HPA044735, HPA044757, HPA046872, HPA046987","Supported",NA,"Approved","Nucleus<br>Nucleoli",NA,"Not detected","Tissue enriched",15,"testis: 20.5","lung: 1.3","Group enriched",6,"HMC-1: 108.1;T-47d: 68.5;U-266/84: 279.7"
"CT45A5","CT45-5, CT45.5","ENSG00000228836","Cancer/testis antigen family 45 member A5","X","135777130-135785298","Predicted intracellular proteins","Evidence at protein level","HPA044735, HPA044757, HPA046872, HPA046987","Supported",NA,"Approved","Nucleus<br>Nucleoli",NA,"Not detected","Tissue enriched",62,"testis: 8.6","cerebral cortex: 0.1","Cell line enhanced",NA,"HMC-1: 47.9;Karpas-707: 27.5;U-266/84: 147.8"
"CT45A6","CT45-6, CT45.6","ENSG00000278289","Cancer/testis antigen family 45 member A6","X","135794706-135802656","Predicted intracellular proteins","Evidence at protein level","HPA044735, HPA044757, HPA046872, HPA046987","Supported",NA,"Approved","Nucleus<br>Nucleoli",NA,"Not detected","Not detected",NA,NA,"testis: 0.7","Cell line enriched",7,"U-266/84: 72.2"
"CT45A7",NA,"ENSG00000273696","Cancer/testis antigen family 45 member A7","X","135829247-135837268","Predicted intracellular proteins","Evidence at protein level","HPA044735, HPA044757, HPA046872, HPA046987","Supported",NA,"Approved","Nucleus<br>Nucleoli",NA,"Not detected","Tissue enriched",6,"testis: 1.5","cerebral cortex,lung: 0.2","Not detected",NA,NA
"CT45A8",NA,"ENSG00000278085","Cancer/testis antigen family 45 member A8","X","135846499-135854538","Predicted intracellular proteins","Evidence at protein level","HPA044735, HPA044757, HPA046872, HPA046987","Supported",NA,"Approved","Nucleus<br>Nucleoli",NA,"Not detected","Tissue enriched",12,"testis: 1.2","all non-specific tissues: 0.0","Group enriched",6,"AN3-CA: 18.9;HMC-1: 39.4"
"CT45A9",NA,"ENSG00000270946","Cancer/testis antigen family 45 member A9","X","135863776-135871812","Predicted intracellular proteins","Evidence at protein level","HPA044735, HPA044757, HPA046872, HPA046987","Supported",NA,"Approved","Nucleus<br>Nucleoli",NA,"Not detected","Tissue enriched",13,"testis: 1.2","all non-specific tissues: 0.0","Cell line enriched",8,"HMC-1: 113.9"
"CTD-2207O23.3",NA,"ENSG00000268861",NA,"19","7382834-7472477","Predicted intracellular proteins","Evidence at protein level","HPA042689, HPA071867","Supported",NA,"Uncertain","Cytosol",NA,"Not detected","Tissue enhanced",NA,"lymph node: 17.2","spleen: 11.9","Cell line enhanced",NA,"Daudi: 18.2;MOLT-4: 13.4;REH: 12.3;THP-1: 12.9"
"CTD-3088G3.8",NA,"ENSG00000188897",NA,"16","11359845-11523588","Predicted intracellular proteins","Evidence at transcript level","HPA042154","Uncertain",NA,NA,NA,NA,"Not detected","Tissue enhanced",NA,"appendix: 5.3;skin: 4.3","testis: 2.8","Cell line enhanced",NA,"Daudi: 2.2;HDLM-2: 3.2"
"CUL4B",NA,"ENSG00000158290","Cullin 4B","X","120524609-120575794","Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA003046, HPA011880, CAB017786, HPA058979","Enhanced",NA,"Enhanced","Nucleoplasm",NA,"Expressed in all","Expressed in all",NA,NA,"testis: 68.3","Expressed in all",NA,NA
"CUL7","dJ20C7.5, KIAA0076","ENSG00000044090","Cullin 7","6","43037617-43053945","Disease related genes, Predicted intracellular proteins","Evidence at protein level","CAB015449, HPA030095, HPA030096","Approved",NA,NA,NA,"Renal cancer:2.19e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"fallopian tube: 26.3","Expressed in all",NA,NA
"CUTC","CGI-32","ENSG00000119929","CutC copper transporter","10","99702558-99756134","Predicted intracellular proteins, Transporters","Evidence at protein level","HPA038619","Approved",NA,"Supported","Nucleoplasm<br>Cytosol","Renal cancer:3.81e-7 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"skeletal muscle: 131.6","Expressed in all",NA,NA
"CXorf58","FLJ25444","ENSG00000165182","Chromosome X open reading frame 58","X","23907801-23939507","Predicted intracellular proteins","Evidence at protein level","HPA031542, HPA031543, HPA031544","Uncertain",NA,NA,NA,NA,"Not detected","Tissue enriched",9,"testis: 6.2","fallopian tube: 0.6","Not detected",NA,NA
"CYP4X1","MGC40051","ENSG00000186377","Cytochrome P450 family 4 subfamily X member 1","1","47023568-47050751","Enzymes, Predicted membrane proteins","Evidence at protein level","HPA017661","Approved",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"cervix, uterine: 52.7","breast: 18.7","Cell line enhanced",NA,"CACO-2: 3.6;NTERA-2: 2.0;SCLC-21H: 3.0;T-47d: 8.7"
"CYYR1","C21orf95","ENSG00000166265","Cysteine and tyrosine rich 1","21","26466209-26573284","Predicted membrane proteins","Evidence at transcript level","CAB034921, HPA067685","Uncertain",NA,"Approved","Nucleoplasm",NA,"Expressed in all","Expressed in all",NA,NA,"adrenal gland: 60.2","Cell line enhanced",NA,"AF22: 13.8;NTERA-2: 39.4;RH-30: 16.1;SCLC-21H: 39.7"
"DAO","DAMOX","ENSG00000110887","D-amino acid oxidase","12","108858932-108901043","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA038653, HPA038654","Enhanced",NA,NA,NA,"Renal cancer:4.11e-4 (favourable)","Tissue enriched","Group enriched",36,"kidney: 89.8;liver: 74.1","rectum: 2.2","Not detected",NA,NA
"DAP",NA,"ENSG00000112977","Death associated protein","5","10679230-10761272","Predicted intracellular proteins","Evidence at protein level","HPA029456","Uncertain",NA,"Approved","Nucleoplasm<br>Vesicles<br>Mitochondria","Liver cancer:2.15e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 156.6","Expressed in all",NA,NA
"DARS2","FLJ10514","ENSG00000117593","Aspartyl-tRNA synthetase 2, mitochondrial","1","173824503-173858546","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA026506, HPA026528","Enhanced",NA,"Supported","Nucleus<br>Mitochondria","Renal cancer:1.74e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 24.9","Expressed in all",NA,NA
"DCUN1D4","KIAA0276","ENSG00000109184","Defective in cullin neddylation 1 domain containing 4","4","51843000-51916837","Predicted intracellular proteins","Evidence at protein level","HPA036483, HPA036484","Uncertain",NA,"Supported","Nucleus<br>Vesicles",NA,"Expressed in all","Expressed in all",NA,NA,"testis: 28.9","Expressed in all",NA,NA
"DDX54","APR-5, DP97, MGC2835","ENSG00000123064","DEAD-box helicase 54","12","113157174-113185479","Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA028244, HPA070786","Approved",NA,"Approved","Nucleus<br>Nucleoli<br>Golgi apparatus","Liver cancer:1.39e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"appendix: 38.8","Expressed in all",NA,NA
"DENND5B","MGC24039","ENSG00000170456","DENN domain containing 5B","12","31382223-31591097","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA038865","Approved",NA,"Approved","Nucleoli<br>Microtubules",NA,"Expressed in all","Mixed",NA,NA,"testis: 29.6","Mixed",NA,NA
"DFFA","DFF-45, DFF1, DFF45, ICAD","ENSG00000160049","DNA fragmentation factor subunit alpha","1","10456522-10472526","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB002679, HPA018859, HPA019938, HPA025230","Supported",NA,"Supported","Plasma membrane<br>Cytosol","Renal cancer:1.57e-9 (favourable), Liver cancer:9.46e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 28.8","Expressed in all",NA,NA
"DGAT1","ARGP1, DGAT","ENSG00000185000","Diacylglycerol O-acyltransferase 1","8","144314584-144326910","Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins","Evidence at protein level","CAB032853","Enhanced",NA,"Approved","Nucleoli<br>Endoplasmic reticulum",NA,"Expressed in all","Tissue enhanced",NA,"duodenum: 71.3;small intestine: 75.1","adipose tissue: 20.0","Cell line enhanced",NA,"PC-3: 35.6"
"DGKG","DAGK3","ENSG00000058866","Diacylglycerol kinase gamma","3","186105668-186362237","Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA036577","Approved",NA,"Approved","Vesicles<br>Plasma membrane",NA,"Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 21.4","placenta: 11.3","Cell line enhanced",NA,"HDLM-2: 22.1;U-87 MG: 13.9"
"DGKQ","DAGK, DAGK4, DAGK7","ENSG00000145214","Diacylglycerol kinase theta","4","958887-986895","Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA026797, CAB033835","Uncertain",NA,NA,NA,NA,"Expressed in all","Expressed in all",NA,NA,"small intestine: 26.0","Mixed",NA,NA
"DHPS","MIG13","ENSG00000095059","Deoxyhypusine synthase","19","12675717-12681902","Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA014461, HPA029413","Approved",NA,"Approved","Nucleoplasm<br>Plasma membrane<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"fallopian tube: 64.5","Expressed in all",NA,NA
"DHRS12","FLJ13639, SDR40C1","ENSG00000102796","Dehydrogenase/reductase 12","13","51767993-51804157","Predicted intracellular proteins","Evidence at protein level","CAB034238, HPA057028, HPA058315","Uncertain",NA,"Supported","Nucleoplasm<br>Golgi apparatus<br>Vesicles","Renal cancer:2.22e-16 (favourable), Breast cancer:1.41e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"epididymis: 22.0","Mixed",NA,NA
"DHX30","DDX30, FLJ11214, KIAA0890","ENSG00000132153","DExH-box helicase 30","3","47802909-47850195","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA034806","Supported",NA,"Supported","Mitochondria<br>Cytosol","Renal cancer:1.37e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 46.2","Expressed in all",NA,NA
"DMP1",NA,"ENSG00000152592","Dentin matrix acidic phosphoprotein 1","4","87650307-87664361","Disease related genes, Predicted secreted proteins","Evidence at protein level","HPA037465","Approved",NA,NA,NA,NA,"Not detected","Not detected",NA,NA,"testis: 0.8","Not detected",NA,NA
"DNAJC12","JDP1","ENSG00000108176","DnaJ heat shock protein family (Hsp40) member C12","10","67796665-67838166","Predicted intracellular proteins","Evidence at protein level","HPA036289","Enhanced",NA,NA,NA,"Renal cancer:1.97e-10 (unfavourable)","Tissue enhanced","Tissue enhanced",NA,"adrenal gland: 57.7","breast: 39.4","Cell line enhanced",NA,"Daudi: 66.4;SCLC-21H: 86.3"
"DNHD1","C11orf47, CCDC35, DHCD1, DKFZp686J0796, DNHD1L, FLJ32752, FLJ35709, FLJ46184","ENSG00000179532","Dynein heavy chain domain 1","11","6497260-6593758","Predicted intracellular proteins","Evidence at protein level","HPA039698, HPA040267, HPA057639","Uncertain",NA,"Approved","Nucleoplasm<br>Cytokinetic bridge",NA,"Mixed","Tissue enriched",6,"testis: 19.5","bone marrow: 3.5","Mixed",NA,NA
"DOCK3","KIAA0299, MOCA, PBP","ENSG00000088538","Dedicator of cytokinesis 3","3","50675241-51384198","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA037543, HPA037544","Approved",NA,"Enhanced","Cytosol",NA,"Tissue enhanced","Group enriched",6,"cerebral cortex: 33.7;parathyroid gland: 12.6;testis: 8.5;thyroid gland: 15.1","adrenal gland: 3.0","Cell line enhanced",NA,"AN3-CA: 5.9;U-87 MG: 8.0"
"DPM3","MGC125904, MGC125905, MGC34275","ENSG00000179085","Dolichyl-phosphate mannosyltransferase subunit 3","1","155139891-155140595","Disease related genes, Predicted membrane proteins","Evidence at protein level","HPA014667","Approved",NA,NA,NA,"Endometrial cancer:7.09e-5 (favourable), Ovarian cancer:8.97e-5 (favourable), Urothelial cancer:8.64e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"adrenal gland: 78.5","Expressed in all",NA,NA
"DPP7","DPP2, DPPII","ENSG00000176978","Dipeptidyl peptidase 7","9","137110542-137115177","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA021282, CAB025541, HPA059381","Supported",NA,"Enhanced","Golgi apparatus<br>Vesicles","Colorectal cancer:6.07e-6 (unfavourable), Pancreatic cancer:8.31e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"adrenal gland: 70.7","Mixed",NA,NA
"DPY19L3",NA,"ENSG00000178904","Dpy-19 like 3 (C. elegans)","19","32405543-32485895","Predicted membrane proteins","Evidence at protein level","HPA008325","Approved",NA,"Approved","Microtubules","Pancreatic cancer:1.70e-4 (favourable), Head and neck cancer:5.55e-4 (favourable)","Expressed in all","Mixed",NA,NA,"cerebral cortex: 20.3","Expressed in all",NA,NA
"DSG2","CDHF5","ENSG00000046604","Desmoglein 2","18","31498043-31549008","Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA004896, CAB025122","Enhanced",NA,"Enhanced","Plasma membrane<br>Cell Junctions","Renal cancer:3.14e-10 (favourable), Pancreatic cancer:4.94e-5 (unfavourable), Lung cancer:2.43e-4 (unfavourable), Head and neck cancer:5.63e-4 (unfavourable), Colorectal cancer:7.81e-4 (favourable), Cervical cancer:8.22e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"parathyroid gland: 251.3","rectum: 106.9","Cell line enhanced",NA,"HaCaT: 233.0;hTERT-HME1: 159.3"
"DTNBP1","BLOC1S8, DBND, Dysbindin, HPS7, My031","ENSG00000047579","Dystrobrevin binding protein 1","6","15522801-15663058","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA028053, HPA029615, HPA029616","Enhanced",NA,"Supported","Microtubules<br>Midbody","Lung cancer:6.34e-5 (favourable), Cervical cancer:2.82e-4 (favourable), Liver cancer:8.72e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"lymph node: 32.7","Expressed in all",NA,NA
"DUOXA1","FLJ32334, mol, NIP, NUMBIP","ENSG00000140254","Dual oxidase maturation factor 1","15","45117367-45129938","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA041578","Approved",NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"esophagus: 122.2;skin: 107.9;thyroid gland: 112.0","epididymis: 60.3","Cell line enriched",9,"HaCaT: 92.0"
"DYDC1","bA36D19.5, DPY30D1","ENSG00000170788","DPY30 domain containing 1","10","80336105-80356755","Predicted intracellular proteins","Evidence at protein level","HPA037790, HPA037791","Uncertain",NA,NA,NA,NA,"Tissue enhanced","Tissue enriched",21,"testis: 200.6","fallopian tube: 9.5","Not detected",NA,NA
"ECHDC1","dJ351K20.2","ENSG00000093144","Ethylmalonyl-CoA decarboxylase 1","6","127288710-127343609","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA035445, HPA035446","Uncertain",NA,"Approved","Vesicles",NA,"Expressed in all","Expressed in all",NA,NA,"adipose tissue: 98.5","Mixed",NA,NA
"ECT2L","ARHGEF32, C6orf91, FBXO49, LFDH","ENSG00000203734","Epithelial cell transforming 2 like","6","138795926-138904070","Cancer-related genes, Predicted intracellular proteins","Evidence at protein level","HPA035488","Uncertain",NA,NA,NA,NA,"Not detected","Tissue enriched",7,"fallopian tube: 18.3","lung: 2.7","Not detected",NA,NA
"EDN1","ET1","ENSG00000078401","Endothelin 1","6","12290363-12297194","Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","HPA031976, CAB032500, CAB037291","Approved",NA,"Approved","Nucleus<br>Nucleoli<br>Golgi apparatus",NA,"Expressed in all","Mixed",NA,NA,"lung: 43.5","Group enriched",6,"EFO-21: 622.7;HUVEC TERT2: 372.8;T-47d: 129.1;TIME: 272.4"
"EGR3","PILOT","ENSG00000179388","Early growth response 3","8","22687659-22693302","Predicted intracellular proteins, Transcription factors","Evidence at transcript level","HPA006206, CAB009373","Uncertain",NA,"Uncertain","Nucleus<br>Vesicles","Breast cancer:1.83e-4 (favourable), Melanoma:4.78e-4 (favourable)","Mixed","Mixed",NA,NA,"gallbladder: 49.6","Cell line enhanced",NA,"HMC-1: 8.5;MCF7: 25.2;SK-MEL-30: 17.0"
"ELMO3","CED-12, CED12, ELMO-3, FLJ13824","ENSG00000102890","Engulfment and cell motility 3","16","67199111-67204029","Predicted intracellular proteins","Evidence at protein level","HPA021484","Approved",NA,"Approved","Plasma membrane<br>Cell Junctions","Renal cancer:2.77e-5 (favourable)","Expressed in all","Mixed",NA,NA,"skin: 39.3","Cell line enhanced",NA,"BEWO: 31.7;CAPAN-2: 43.1;HaCaT: 41.1;T-47d: 42.8"
"ERI2","EXOD1, KIAA1504, MGC16943, ZGRF5","ENSG00000196678","ERI1 exoribonuclease family member 2","16","20780193-20900349","Predicted intracellular proteins","Evidence at protein level","HPA035384, HPA035385","Uncertain",NA,"Supported","Nucleus<br>Golgi apparatus",NA,"Expressed in all","Expressed in all",NA,NA,"testis: 23.0","Expressed in all",NA,NA
"ERMARD","C6orf70, dJ266L20.3, FLJ11152","ENSG00000130023","ER membrane associated RNA degradation","6","169751622-169781584","Disease related genes, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA041741","Approved",NA,"Approved","Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"testis: 33.2","Expressed in all",NA,NA
"ETHE1","HSCO, YF13H12","ENSG00000105755","ETHE1, persulfide dioxygenase","19","43506719-43527244","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA028360, HPA029028, HPA029029","Enhanced",NA,"Enhanced","Mitochondria","Lung cancer:9.58e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"colon: 240.2","Mixed",NA,NA
"F2RL1","GPR11, PAR2","ENSG00000164251","F2R like trypsin receptor 1","5","76818933-76835315","G-protein coupled receptors, Predicted membrane proteins, Transporters","Evidence at protein level","CAB012989, HPA014091","Approved",NA,"Approved","Plasma membrane","Renal cancer:5.86e-7 (favourable), Colorectal cancer:3.88e-4 (favourable), Head and neck cancer:5.88e-4 (unfavourable), Lung cancer:8.92e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"colon: 58.9","Cell line enhanced",NA,"PC-3: 113.9;RPTEC TERT1: 152.3"
"FAM114A2","133K02, C5orf3","ENSG00000055147","Family with sequence similarity 114 member A2","5","153990128-154038936","Predicted intracellular proteins","Evidence at protein level","HPA035869, HPA035870","Approved",NA,"Approved","Vesicles",NA,"Expressed in all","Expressed in all",NA,NA,"testis: 68.7","Expressed in all",NA,NA
"FAM135B","C8ORFK32","ENSG00000147724","Family with sequence similarity 135 member B","8","138130023-138496822","Predicted intracellular proteins","Evidence at transcript level","HPA023911, HPA023950, HPA024815","Uncertain",NA,"Approved","Nucleoplasm<br>Nuclear membrane",NA,"Tissue enhanced","Group enriched",8,"adrenal gland: 3.6;cerebral cortex: 8.3;testis: 7.3","colon: 0.8","Cell line enriched",11,"RH-30: 8.5"
"FAM169A","KIAA0888, SLAP75","ENSG00000198780","Family with sequence similarity 169 member A","5","74777574-74866951","Predicted intracellular proteins","Evidence at protein level","HPA041574","Enhanced",NA,"Supported","Nuclear membrane<br>Cytosol",NA,"Mixed","Tissue enhanced",NA,"cerebral cortex: 29.2;testis: 25.4","epididymis: 23.2","Cell line enhanced",NA,"BEWO: 35.3"
"FAM185A","MGC35361","ENSG00000222011","Family with sequence similarity 185 member A","7","102748971-102809225","Predicted intracellular proteins","Evidence at protein level","HPA020470, HPA029883","Uncertain",NA,"Enhanced","Cytosol","Renal cancer:9.36e-5 (favourable)","Expressed in all","Mixed",NA,NA,"parathyroid gland: 4.5","Mixed",NA,NA
"FAM204A","bA319I23.1, C10orf84, FLJ13188","ENSG00000165669","Family with sequence similarity 204 member A","10","118297930-118342328","Predicted intracellular proteins","Evidence at protein level","HPA038182, HPA062025","Approved",NA,"Supported","Nucleus<br>Nucleoli","Renal cancer:8.59e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 89.3","Expressed in all",NA,NA
"FAM214A","FLJ10980, KIAA1370","ENSG00000047346","Family with sequence similarity 214 member A","15","52581317-52709817","Predicted intracellular proteins","Evidence at protein level","HPA039369, HPA040180","Approved",NA,"Approved","Nucleoplasm","Endometrial cancer:7.27e-6 (favourable), Lung cancer:8.68e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 57.9","Expressed in all",NA,NA
"FAM35A","bA163M19.1, FAM35A1, MGC5560","ENSG00000122376","Family with sequence similarity 35 member A","10","87094161-87191468","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA036582","Uncertain",NA,"Approved","Nucleoplasm<br>Actin filaments","Glioma:5.44e-4 (favourable), Colorectal cancer:6.06e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 38.8","Expressed in all",NA,NA
"FAM53B","bA12J10.2, KIAA0140, smp","ENSG00000189319","Family with sequence similarity 53 member B","10","124619292-124744269","Predicted intracellular proteins","Evidence at protein level","HPA037751, HPA037752","Approved",NA,"Approved","Cytosol","Renal cancer:4.81e-7 (favourable), Pancreatic cancer:7.00e-6 (favourable), Head and neck cancer:1.97e-4 (favourable), Stomach cancer:3.26e-4 (favourable), Cervical cancer:4.96e-4 (favourable)","Expressed in all","Mixed",NA,NA,"lymph node: 37.9","Expressed in all",NA,NA
"FAM98A","DKFZP564F0522","ENSG00000119812","Family with sequence similarity 98 member A","2","33583658-33599382","Predicted intracellular proteins","Evidence at protein level","HPA036250, HPA036251","Uncertain",NA,"Supported","Vesicles","Liver cancer:4.86e-7 (unfavourable), Thyroid cancer:8.18e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 127.4","Expressed in all",NA,NA
"FBXO42","Fbx42, KIAA1332","ENSG00000037637","F-box protein 42","1","16246839-16352454","Predicted intracellular proteins","Evidence at protein level","HPA025071","Approved",NA,"Approved","Nucleoplasm","Liver cancer:3.72e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"skin: 29.9","Expressed in all",NA,NA
"FEZ2",NA,"ENSG00000171055","Fasciculation and elongation protein zeta 2","2","36531805-36646087","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA035978","Uncertain",NA,"Approved","Nucleoli<br>Golgi apparatus<br>Cytosol","Liver cancer:7.79e-6 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 78.6","Expressed in all",NA,NA
"FGD5","FLJ00274, FLJ39957, ZFYVE23","ENSG00000154783","FYVE, RhoGEF and PH domain containing 5","3","14810853-14934565","Predicted intracellular proteins","Evidence at protein level","HPA014536, HPA019191","Uncertain",NA,NA,NA,"Urothelial cancer:7.50e-4 (favourable)","Expressed in all","Mixed",NA,NA,"spleen: 35.0","Group enriched",8,"HUVEC TERT2: 80.3;TIME: 64.8;U-2197: 19.8"
"FGF11","FHF3, FLJ16061, MGC102953, MGC45269","ENSG00000161958","Fibroblast growth factor 11","17","7438273-7444937","Predicted intracellular proteins, RAS pathway related proteins","Evidence at protein level","HPA066605, HPA075188","Enhanced",NA,"Approved","Centrosome",NA,"Mixed","Tissue enhanced",NA,"adrenal gland: 17.3;skin: 13.7","cerebral cortex: 10.3","Cell line enhanced",NA,"HaCaT: 16.3"
"FH","fumarase","ENSG00000091483","Fumarate hydratase","1","241497603-241519761","Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","CAB017785, HPA025770, HPA025948, HPA027341","Enhanced","Approved","Enhanced","Mitochondria","Renal cancer:2.76e-7 (favourable)","Expressed in all","Expressed in all",NA,NA,"liver: 142.2","Expressed in all",NA,NA
"FNDC3A","bA203I16.5, FNDC3, KIAA0970","ENSG00000102531","Fibronectin type III domain containing 3A","13","48975912-49209779","Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA008927, HPA012825","Approved",NA,"Approved","Endoplasmic reticulum","Renal cancer:4.25e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 85.7","Expressed in all",NA,NA
"FOXRED2","ERFAD, FLJ23322","ENSG00000100350","FAD dependent oxidoreductase domain containing 2","22","36487190-36507101","Predicted secreted proteins","Evidence at protein level","HPA031611, HPA031612","Approved",NA,NA,NA,"Cervical cancer:4.86e-5 (favourable), Thyroid cancer:9.32e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"cerebral cortex: 30.8","Cell line enhanced",NA,"SiHa: 155.2"
"FPR2","ALXR, FMLP-R-II, FMLPX, FPR2A, FPRH2, FPRL1, HM63, LXA4R","ENSG00000171049","Formyl peptide receptor 2","19","51752026-51770526","G-protein coupled receptors, Predicted membrane proteins","Evidence at protein level","HPA029154","Approved",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"appendix: 69.7","spleen: 19.7","Cell line enriched",21,"U-937: 23.5"
"FREM3",NA,"ENSG00000183090","FRAS1 related extracellular matrix 3","4","143577302-143700675","Predicted secreted proteins","Evidence at protein level","HPA041641","Uncertain",NA,NA,NA,NA,"Not detected","Tissue enhanced",NA,"cerebral cortex: 1.6","lung: 0.6","Not detected",NA,NA
"FUK","FLJ39408","ENSG00000157353","Fucokinase","16","70454421-70480274","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA041971","Approved",NA,"Approved","Vesicles","Urothelial cancer:8.38e-4 (favourable), Renal cancer:8.91e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 13.9","Mixed",NA,NA
"GABPB2","MGC29891","ENSG00000143458","GA binding protein transcription factor beta subunit 2","1","151070578-151125542","Predicted intracellular proteins","Evidence at protein level","HPA028471, HPA058483","Uncertain",NA,"Supported","Nucleoplasm<br>Cytosol",NA,"Expressed in all","Mixed",NA,NA,"testis: 20.1","Mixed",NA,NA
"GAK","DNAJC26","ENSG00000178950","Cyclin G associated kinase","4","849276-932373","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA027405, HPA027459, HPA027463","Approved",NA,"Enhanced","Golgi apparatus<br>Vesicles","Renal cancer:1.70e-6 (favourable), Urothelial cancer:7.41e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"duodenum: 51.5","Expressed in all",NA,NA
"GCNA","ACRC, NAAR1","ENSG00000147174","Germ cell nuclear acidic peptidase","X","71578411-71613583","Predicted intracellular proteins","Evidence at protein level","HPA023476","Enhanced",NA,"Approved","Vesicles",NA,"Mixed","Group enriched",5,"adrenal gland: 5.9;testis: 20.6","spleen: 2.4","Mixed",NA,NA
"GCNT1","C2GNT, NACGT2, NAGCT2","ENSG00000187210","Glucosaminyl (N-acetyl) transferase 1, core 2","9","76419850-76507416","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA003522, HPA003523, HPA031151","Uncertain",NA,"Supported","Nuclear speckles","Urothelial cancer:4.96e-4 (unfavourable), Endometrial cancer:8.44e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"parathyroid gland: 186.4","duodenum: 50.1","Cell line enhanced",NA,"HHSteC: 38.9"
"GNA12","gep","ENSG00000146535","G protein subunit alpha 12","7","2728112-2844324","Predicted intracellular proteins","Evidence at protein level","CAB010046","Approved",NA,"Supported","Cytosol","Liver cancer:1.20e-6 (unfavourable), Renal cancer:4.71e-5 (unfavourable), Urothelial cancer:2.27e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 34.5","Expressed in all",NA,NA
"GNAI1",NA,"ENSG00000127955","G protein subunit alpha i1","7","80133955-80219402","Cancer-related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB022449, HPA042141","Approved",NA,"Supported","Nucleus<br>Nucleoli<br>Centrosome","Melanoma:5.09e-4 (unfavourable), Stomach cancer:6.47e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 94.5","Mixed",NA,NA
"GNS",NA,"ENSG00000135677","Glucosamine (N-acetyl)-6-sulfatase","12","64713445-64759447","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA013695, CAB026011, HPA048508","Enhanced",NA,NA,NA,"Liver cancer:1.94e-5 (unfavourable), Glioma:4.17e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"adrenal gland: 172.9","Expressed in all",NA,NA
"GPATCH3","FLJ12455, GPATC3","ENSG00000198746","G-patch domain containing 3","1","26890488-26900466","Predicted intracellular proteins","Evidence at protein level","HPA032078, HPA054973","Approved",NA,"Approved","Nucleoplasm<br>Cytosol","Liver cancer:1.23e-7 (unfavourable), Pancreatic cancer:6.42e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"bone marrow: 15.3","Expressed in all",NA,NA
"GPBP1L1","SP192","ENSG00000159592","GC-rich promoter binding protein 1 like 1","1","45627304-45688113","Predicted intracellular proteins","Evidence at protein level","HPA028593","Approved",NA,"Approved","Nucleoplasm<br>Plasma membrane<br>Focal adhesion sites",NA,"Expressed in all","Expressed in all",NA,NA,"testis: 107.1","Expressed in all",NA,NA
"GSDMB","GSDML, PRO2521","ENSG00000073605","Gasdermin B","17","39904595-39919854","Predicted intracellular proteins, Transporters","Evidence at protein level","CAB013681, HPA023925, HPA052407","Enhanced",NA,NA,NA,"Renal cancer:5.13e-11 (unfavourable), Urothelial cancer:5.91e-9 (favourable), Cervical cancer:3.41e-5 (favourable)","Expressed in all","Tissue enhanced",NA,"duodenum: 67.0;small intestine: 85.1","rectum: 62.6","Cell line enriched",7,"SK-BR-3: 342.4"
"H2AFY2","macroH2A2","ENSG00000099284","H2A histone family member Y2","10","70052796-70112280","Predicted intracellular proteins","Evidence at protein level","HPA035865, HPA041189","Enhanced",NA,"Enhanced","Nucleoplasm",NA,"Expressed in all","Expressed in all",NA,NA,"endometrium: 31.3","Cell line enhanced",NA,"AF22: 166.7;SCLC-21H: 146.5;SH-SY5Y: 128.2"
"HDAC5","FLJ90614, KIAA0600, NY-CO-9","ENSG00000108840","Histone deacetylase 5","17","44076746-44123702","Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins","Evidence at protein level","CAB019400, HPA030991","Approved",NA,"Supported","Nuclear speckles<br>Golgi apparatus<br>Cytosol","Liver cancer:3.12e-5 (unfavourable), Renal cancer:3.30e-5 (favourable), Cervical cancer:6.14e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 60.0","Mixed",NA,NA
"HIF3A","bHLHe17, IPAS, MOP7, PASD7","ENSG00000124440","Hypoxia inducible factor 3 alpha subunit","19","46297046-46343433","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA041141","Approved",NA,"Supported","Nucleoplasm<br>Plasma membrane<br>Cytosol","Endometrial cancer:6.90e-9 (unfavourable)","Mixed","Tissue enhanced",NA,"placenta: 39.8","spleen: 19.9","Cell line enhanced",NA,"ASC TERT1: 6.5;HHSteC: 16.0;HSkMC: 12.2;TIME: 13.1"
"HKR1","ZNF875","ENSG00000181666","HKR1, GLI-Kruppel zinc finger family member","19","37312837-37369365","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA036126, HPA044855","Approved",NA,"Supported","Nucleoplasm<br>Golgi apparatus<br>Mitochondria","Prostate cancer:5.18e-5 (unfavourable), Pancreatic cancer:4.41e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 54.6","Expressed in all",NA,NA
"HMGN3","TRIP7","ENSG00000118418","High mobility group nucleosomal binding domain 3","6","79201245-79234738","Predicted intracellular proteins","Evidence at protein level","CAB018370, HPA027971, HPA063572","Enhanced",NA,"Enhanced","Nucleus<br>Cytosol","Renal cancer:1.02e-7 (unfavourable), Lung cancer:2.76e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"fallopian tube: 335.7","Mixed",NA,NA
"HOXA11","HOX1, HOX1I","ENSG00000005073","Homeobox A11","7","27181510-27185223","Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA006770, HPA035623","Enhanced",NA,"Supported","Nucleoplasm","Renal cancer:2.57e-5 (unfavourable)","Mixed","Tissue enhanced",NA,"endometrium: 96.3;smooth muscle: 68.5","cervix, uterine: 17.9","Cell line enhanced",NA,"HEK 293: 46.1;U-937: 37.5"
"HPDL","4-HPPD-L, GLOXD1, MGC15668","ENSG00000186603","4-hydroxyphenylpyruvate dioxygenase like","1","45326905-45328533","Predicted intracellular proteins","Evidence at protein level","HPA031997, HPA057346","Approved",NA,"Supported","Mitochondria","Endometrial cancer:1.60e-5 (unfavourable), Ovarian cancer:1.03e-4 (favourable), Breast cancer:1.81e-4 (favourable)","Mixed","Mixed",NA,NA,"colon: 3.8","Cell line enhanced",NA,"BEWO: 118.1;SK-BR-3: 58.4"
"HSPB11","C1orf41, HSPCO34, IFT25, PP25","ENSG00000081870","Heat shock protein family B (small) member 11","1","53916574-53945929","Predicted intracellular proteins","Evidence at protein level","HPA030140","Uncertain",NA,"Approved","Nucleoplasm<br>Cytosol","Liver cancer:9.58e-7 (unfavourable), Renal cancer:1.03e-6 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 116.6","Expressed in all",NA,NA
"IBA57","C1orf69, FLJ12734","ENSG00000181873","IBA57 homolog, iron-sulfur cluster assembly","1","228165815-228182257","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA030555, HPA030556, HPA030557","Approved",NA,"Supported","Mitochondria","Renal cancer:1.71e-9 (favourable)","Expressed in all","Mixed",NA,NA,"parathyroid gland: 4.1","Mixed",NA,NA
"IER5",NA,"ENSG00000162783","Immediate early response 5","1","181088712-181092899","Predicted intracellular proteins","Evidence at protein level","HPA029894","Uncertain","Approved","Supported","Nucleus<br>Nucleoli","Endometrial cancer:2.42e-7 (favourable), Lung cancer:1.18e-4 (unfavourable), Renal cancer:2.36e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"bone marrow: 31.1","Expressed in all",NA,NA
"IL17RD","FLJ35755, IL-17RD, IL17RLM, SEF","ENSG00000144730","Interleukin 17 receptor D","3","57089982-57170306","Disease related genes, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA039577, HPA043550","Approved",NA,"Supported","Nucleoplasm<br>Golgi apparatus","Renal cancer:2.92e-9 (favourable)","Mixed","Mixed",NA,NA,"parathyroid gland: 26.8","Group enriched",7,"AF22: 24.6;AN3-CA: 62.9;NTERA-2: 39.0;SH-SY5Y: 108.1"
"IL25","IL-17E, IL-25, IL17E","ENSG00000166090","Interleukin 25","14","23372809-23376403","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB024864","Approved",NA,NA,NA,NA,"Not detected","Not detected",NA,NA,"testis: 0.3","Not detected",NA,NA
"ING2","ING1L, p33ING2","ENSG00000168556","Inhibitor of growth family member 2","4","183504994-183511096","Predicted intracellular proteins","Evidence at protein level","HPA019486, HPA021517","Enhanced",NA,"Supported","Nucleoplasm<br>Golgi apparatus<br>Cytosol","Breast cancer:5.43e-4 (favourable), Liver cancer:8.87e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"ovary: 63.3","Expressed in all",NA,NA
"INHA",NA,"ENSG00000123999","Inhibin alpha subunit","2","219569162-219575713","Predicted secreted proteins","Evidence at protein level","CAB000047, HPA019141","Enhanced",NA,"Approved","Vesicles","Renal cancer:4.03e-5 (unfavourable)","Mixed","Tissue enhanced",NA,"adrenal gland: 51.5;ovary: 38.0;testis: 106.3","placenta: 14.9","Cell line enhanced",NA,"HEL: 3.7;SK-BR-3: 6.8"
"IPCEF1","KIAA0403, PIP3-E","ENSG00000074706","Interaction protein for cytohesin exchange factors 1","6","154154496-154356792","Predicted intracellular proteins","Evidence at protein level","HPA028708, HPA028710","Approved",NA,"Approved","Nucleoli<br>Nuclear speckles<br>Plasma membrane<br>Cytoplasmic bodies",NA,"Mixed","Tissue enhanced",NA,"thyroid gland: 66.3","cerebral cortex: 24.9","Cell line enhanced",NA,"HMC-1: 17.9;THP-1: 7.2;U-937: 8.8"
"IRF8","ICSBP, ICSBP1, IRF-8","ENSG00000140968","Interferon regulatory factor 8","16","85898803-85922609","Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA002267, HPA002531, CAB013480","Enhanced",NA,"Enhanced","Nucleoplasm",NA,"Expressed in all","Tissue enhanced",NA,"lymph node: 297.7;spleen: 205.7;tonsil: 232.5","appendix: 118.0","Cell line enhanced",NA,"Daudi: 177.0;THP-1: 280.9;U-698: 672.1;U-937: 108.3"
"ITFG2","MDS028","ENSG00000111203","Integrin alpha FG-GAP repeat containing 2","12","2812622-2859791","Predicted intracellular proteins","Evidence at protein level","HPA038664, HPA038665","Uncertain",NA,"Approved","Nucleoplasm<br>Endoplasmic reticulum<br>Cytokinetic bridge",NA,"Expressed in all","Expressed in all",NA,NA,"thyroid gland: 46.0","Expressed in all",NA,NA
"IZUMO2","C19orf41, MGC33947, SCRL","ENSG00000161652","IZUMO family member 2","19","50152548-50163195","Predicted membrane proteins, Transporters","Evidence at transcript level","HPA042143","Uncertain",NA,NA,NA,NA,"Not detected","Tissue enriched",250,"testis: 56.1","prostate,skin,thyroid gland: 0.2","Not detected",NA,NA
"KCNH5","eag2, H-EAG2, Kv10.2","ENSG00000140015","Potassium voltage-gated channel subfamily H member 5","14","62699454-63102037","Predicted membrane proteins, Voltage-gated ion channels","Evidence at protein level","HPA030487","Uncertain",NA,"Uncertain","Microtubules<br>Mitotic spindle",NA,"Not detected","Tissue enhanced",NA,"adrenal gland: 1.4;cerebral cortex: 3.6","testis: 0.7","Cell line enhanced",NA,"BEWO: 1.5;HeLa: 5.0;RT4: 7.9"
"KCNJ8","Kir6.1","ENSG00000121361","Potassium voltage-gated channel subfamily J member 8","12","21764955-21775581","Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels","Evidence at protein level","HPA031066","Uncertain",NA,NA,NA,"Renal cancer:1.62e-6 (unfavourable), Colorectal cancer:9.29e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"seminal vesicle: 32.0","Cell line enhanced",NA,"CACO-2: 71.9;SH-SY5Y: 31.1"
"KCTD14","MGC2376","ENSG00000151364","Potassium channel tetramerization domain containing 14","11","78015715-78046191","Predicted intracellular proteins","Evidence at protein level","HPA041118, HPA042181","Enhanced",NA,NA,NA,"Melanoma:3.96e-5 (unfavourable), Renal cancer:6.92e-5 (favourable), Pancreatic cancer:1.05e-4 (unfavourable), Thyroid cancer:5.93e-4 (favourable), Ovarian cancer:8.01e-4 (favourable)","Expressed in all","Mixed",NA,NA,"seminal vesicle: 27.0","Cell line enhanced",NA,"HBEC3-KT: 18.6;Hep G2: 19.7;RPTEC TERT1: 34.1;U-2 OS: 21.2"
"KCTD6","KCASH3, MGC27385","ENSG00000168301","Potassium channel tetramerization domain containing 6","3","58492114-58502360","Predicted intracellular proteins","Evidence at protein level","HPA036100, HPA036101","Uncertain",NA,"Approved","Nucleoli<br>Mitochondria","Liver cancer:4.57e-4 (unfavourable), Renal cancer:8.63e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 40.2","Expressed in all",NA,NA
"KDM1B","AOF1, bA204B7.3, C6orf193, dJ298J15.2, FLJ33898, FLJ34109, FLJ43328, LSD2","ENSG00000165097","Lysine demethylase 1B","6","18155329-18223853","Predicted intracellular proteins","Evidence at protein level","HPA031269","Uncertain",NA,"Approved","Nucleus","Colorectal cancer:6.94e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 65.1","Expressed in all",NA,NA
"KERA","CNA2, SLRR2B","ENSG00000139330","Keratocan","12","91050491-91057983","Disease related genes, Predicted secreted proteins","Evidence at protein level","HPA039321","Uncertain",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"gallbladder: 1.5","breast,fallopian tube: 0.8","Not detected",NA,NA
"KIAA0825","C5orf36, DKFZp686F0372, MGC34713","ENSG00000185261","KIAA0825","5","94152966-94618597","Predicted intracellular proteins","Evidence at protein level","HPA038030, HPA038031","Uncertain",NA,NA,NA,NA,"Not detected","Mixed",NA,NA,"testis: 5.4","Cell line enhanced",NA,"HeLa: 6.1"
"KIAA1147","LCHN","ENSG00000257093","KIAA1147","7","141656728-141702153","Predicted intracellular proteins","Evidence at protein level","HPA029467, HPA061437","Approved",NA,"Approved","Golgi apparatus","Head and neck cancer:6.24e-4 (favourable), Renal cancer:8.01e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 21.1","Mixed",NA,NA
"KIAA1257",NA,"ENSG00000114656","KIAA1257","3","128909866-129002690","Predicted intracellular proteins","Evidence at transcript level","HPA042811, HPA048445","Uncertain",NA,"Approved","Cell Junctions<br>Cytosol",NA,"Mixed","Tissue enriched",7,"testis: 34.5","placenta: 5.1","Cell line enhanced",NA,"AF22: 6.0;BEWO: 11.3;HL-60: 9.2;THP-1: 5.6"
"KIAA1429","DKFZP434I116, fSAP121","ENSG00000164944","KIAA1429","8","94487693-94553529","Predicted intracellular proteins","Evidence at protein level","HPA031530","Approved",NA,"Supported","Nucleoplasm<br>Nuclear bodies","Renal cancer:7.90e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 30.2","Expressed in all",NA,NA
"KIAA1614",NA,"ENSG00000135835","KIAA1614","1","180913154-180951614","Predicted intracellular proteins","Evidence at protein level","HPA028227, HPA061684","Approved",NA,"Approved","Nuclear membrane<br>Vesicles",NA,"Mixed","Mixed",NA,NA,"thyroid gland: 9.2","Cell line enhanced",NA,"RH-30: 17.2;SH-SY5Y: 47.3"
"KIF2B",NA,"ENSG00000141200","Kinesin family member 2B","17","53822901-53825213","Predicted intracellular proteins","Evidence at protein level","HPA023081, HPA023103, HPA024795","Uncertain",NA,"Uncertain","Nucleoli<br>Microtubules<br>Cytokinetic bridge<br>Mitotic spindle",NA,"Not detected","Tissue enriched",1329,"testis: 132.9","all non-specific tissues: 0.0","Not detected",NA,NA
"KIF9","MGC104186","ENSG00000088727","Kinesin family member 9","3","47228026-47283451","Predicted intracellular proteins","Evidence at protein level","HPA022031, HPA022033, HPA030429","Approved",NA,"Approved","Nucleus<br>Nucleoli","Renal cancer:5.95e-6 (favourable), Colorectal cancer:2.26e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 87.6","Expressed in all",NA,NA
"KLC4","bA387M24.3, KNSL8","ENSG00000137171","Kinesin light chain 4","6","43040777-43075099","Predicted intracellular proteins","Evidence at protein level","HPA030168, HPA030169","Enhanced",NA,"Approved","Mitochondria<br>Cytosol","Renal cancer:6.99e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"duodenum: 70.0","Expressed in all",NA,NA
"KLHL18","FLJ13703, KIAA0795","ENSG00000114648","Kelch like family member 18","3","47282917-47346816","Predicted intracellular proteins","Evidence at protein level","HPA035027, HPA035028","Approved",NA,"Approved","Nucleoplasm<br>Nuclear bodies","Liver cancer:3.13e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"skin: 14.2","Expressed in all",NA,NA
"KLHL7","KLHL6, RP42, SBBI26","ENSG00000122550","Kelch like family member 7","7","23105758-23177914","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA029491, HPA029492","Uncertain",NA,"Supported","Nucleoplasm<br>Cytosol","Renal cancer:8.98e-5 (favourable), Liver cancer:7.96e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 76.1","Expressed in all",NA,NA
"KY","FLJ33207","ENSG00000174611","Kyphoscoliosis peptidase","3","134603138-134651636","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA036492, HPA036668","Uncertain",NA,"Approved","Nucleoplasm",NA,"Mixed","Tissue enhanced",NA,"skin: 11.0","parathyroid gland: 9.3","Cell line enhanced",NA,"Karpas-707: 1.6;U-2197: 2.7;U-87 MG: 8.6"
"LACTB","FLJ14902, MRPL56","ENSG00000103642","Lactamase beta","15","63121800-63142061","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA036361, HPA036362","Enhanced",NA,"Supported","Mitochondria",NA,"Expressed in all","Expressed in all",NA,NA,"testis: 39.7","Expressed in all",NA,NA
"LAGE3","CVG5, DXS9879E, DXS9951E, ESO3, ITBA2, Pcc1","ENSG00000196976","L antigen family member 3","X","154477769-154479257","Predicted intracellular proteins","Evidence at protein level","HPA036122, HPA036123","Approved",NA,"Supported","Nucleoplasm<br>Nuclear bodies","Cervical cancer:5.29e-6 (favourable), Renal cancer:5.42e-5 (unfavourable), Liver cancer:8.63e-5 (unfavourable), Endometrial cancer:7.60e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 26.9","Expressed in all",NA,NA
"LCLAT1","AGPAT8, ALCAT1, FLJ37965, LYCAT","ENSG00000172954","Lysocardiolipin acyltransferase 1","2","30447226-30644225","Enzymes, Predicted membrane proteins","Evidence at protein level","HPA031880, HPA049217","Uncertain",NA,"Supported","Endoplasmic reticulum<br>Cytosol","Liver cancer:8.72e-4 (unfavourable), Head and neck cancer:9.67e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 18.8","Expressed in all",NA,NA
"LGALS4","GAL4","ENSG00000171747","Galectin 4","19","38801671-38813364","Cancer-related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB025653, HPA031184, HPA031185, HPA031186","Enhanced",NA,"Uncertain","Plasma membrane","Renal cancer:2.28e-4 (unfavourable), Urothelial cancer:3.21e-4 (favourable)","Group enriched","Tissue enhanced",NA,"colon: 736.0;duodenum: 526.9;rectum: 640.3;small intestine: 493.5","gallbladder: 138.8","Cell line enhanced",NA,"CACO-2: 1.0;RT4: 2.2;SH-SY5Y: 1.0"
"LGR4","GPR48","ENSG00000205213","Leucine rich repeat containing G protein-coupled receptor 4","11","27365961-27472775","Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA030267, HPA054350","Uncertain",NA,"Approved","Microtubule organizing center","Renal cancer:2.00e-7 (favourable)","Expressed in all","Expressed in all",NA,NA,"kidney: 56.2","Cell line enhanced",NA,"HAP1: 86.6"
"LIPT1","MGC12290, MGC13378","ENSG00000144182","Lipoyltransferase 1","2","99154955-99163157","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA034802","Approved",NA,NA,NA,"Urothelial cancer:9.60e-8 (favourable), Lung cancer:5.70e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 24.3","Expressed in all",NA,NA
"LMOD1","1D, 64kD, D1","ENSG00000163431","Leiomodin 1","1","201896452-201946588","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA028325, HPA028435, HPA030097","Enhanced",NA,"Approved","Cytosol","Liver cancer:2.52e-5 (favourable), Renal cancer:1.05e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"seminal vesicle: 331.2","Group enriched",10,"ASC diff: 10.7;BJ: 17.8;BJ hTERT+: 27.6;fHDF/TERT166: 13.3;HSkMC: 10.4"
"LONRF1","FLJ23749, RNF191","ENSG00000154359","LON peptidase N-terminal domain and ring finger 1","8","12721894-12756073","Predicted intracellular proteins","Evidence at protein level","HPA023584, HPA024814","Uncertain",NA,"Approved","Plasma membrane<br>Centrosome<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"skin: 30.8","Cell line enhanced",NA,"Karpas-707: 47.8;SCLC-21H: 45.0"
"LRP5L","DKFZp434O0213","ENSG00000100068","LDL receptor related protein 5 like","22","25351418-25405377","Predicted intracellular proteins","Evidence at transcript level","HPA028717","Uncertain",NA,"Approved","Nucleoplasm","Urothelial cancer:6.93e-6 (favourable)","Expressed in all","Mixed",NA,NA,"thyroid gland: 9.7","Mixed",NA,NA
"LRRC2",NA,"ENSG00000163827","Leucine rich repeat containing 2","3","46515423-46580099","Predicted intracellular proteins","Evidence at protein level","HPA039138, HPA040096","Approved",NA,NA,NA,NA,"Tissue enhanced","Group enriched",5,"heart muscle: 30.0;skeletal muscle: 55.9;thyroid gland: 37.0","endometrium: 7.8","Cell line enhanced",NA,"fHDF/TERT166: 5.6;HEL: 3.8;LHCN-M2: 3.4"
"LRRC56","DKFZp761L1518, FLJ00101","ENSG00000161328","Leucine rich repeat containing 56","11","537527-554916","Predicted intracellular proteins","Evidence at transcript level","HPA038728","Uncertain",NA,NA,NA,"Lung cancer:6.19e-4 (favourable), Pancreatic cancer:6.32e-4 (favourable), Endometrial cancer:7.39e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"testis: 3.9","epididymis,fallopian tube: 1.5","Cell line enhanced",NA,"AN3-CA: 1.7;Karpas-707: 1.8;T-47d: 1.8"
"LRRC63","RP11-139H14.4","ENSG00000173988","Leucine rich repeat containing 63","13","46211943-46277366","Predicted intracellular proteins","Evidence at transcript level","HPA039318, HPA039763","Uncertain",NA,"Approved","Golgi apparatus",NA,"Not detected","Group enriched",6,"cerebral cortex: 1.1;epididymis: 1.7;testis: 2.4","fallopian tube: 0.3","Cell line enhanced",NA,"HDLM-2: 1.1"
"LSG1","FLJ11301","ENSG00000041802","Large 60S subunit nuclear export GTPase 1","3","194640788-194672477","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA037704, HPA037705","Approved",NA,"Supported","Nucleus<br>Nuclear bodies<br>Cytosol","Liver cancer:3.21e-7 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 24.8","Expressed in all",NA,NA
"LYRM4","C6orf149, CGI-203, ISD11","ENSG00000214113","LYR motif containing 4","6","5102593-5260939","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA030362","Approved",NA,"Supported","Nuclear bodies",NA,"Expressed in all","Expressed in all",NA,NA,"ovary: 29.5","Expressed in all",NA,NA
"LZIC","MGC15436","ENSG00000162441","Leucine zipper and CTNNBIP1 domain containing","1","9922113-9943407","Predicted intracellular proteins","Evidence at protein level","HPA028184, HPA058614","Approved",NA,"Approved","Nucleoplasm<br>Cytosol","Liver cancer:2.47e-5 (unfavourable), Renal cancer:3.56e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 120.1","Expressed in all",NA,NA
"MACF1","ABP620, ACF7, FLJ45612, FLJ46776, KIAA0465, KIAA1251, MACF","ENSG00000127603","Microtubule-actin crosslinking factor 1","1","39081316-39487177","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA013713, HPA068064, HPA068103","Approved",NA,"Supported","Plasma membrane<br>Cell Junctions<br>Actin filaments","Renal cancer:2.77e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"lung: 137.2","Expressed in all",NA,NA
"MAPK12","ERK6, p38gamma, PRKM12, SAPK-3, SAPK3","ENSG00000188130","Mitogen-activated protein kinase 12","22","50245450-50261825","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","CAB025483, HPA054562","Enhanced",NA,"Approved","Nuclear speckles<br>Cytosol","Renal cancer:5.00e-6 (unfavourable)","Mixed","Tissue enriched",6,"skeletal muscle: 91.5","cerebral cortex: 15.7","Mixed",NA,NA
"MAPK7","BMK1, ERK5, PRKM7","ENSG00000166484","Mitogen-activated protein kinase 7","17","19377721-19383544","Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","CAB018561, HPA031031","Uncertain",NA,"Enhanced","Nucleus<br>Cytosol","Liver cancer:1.86e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"testis: 10.6","Mixed",NA,NA
"MAPKAP1","MGC2745, MIP1, SIN1","ENSG00000119487","Mitogen-activated protein kinase associated protein 1","9","125437393-125707234","Predicted intracellular proteins","Evidence at protein level","HPA029091, HPA029092","Enhanced",NA,"Supported","Nucleoplasm<br>Cytosol","Renal cancer:7.23e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 79.7","Expressed in all",NA,NA
"MAPKAPK5","PRAK","ENSG00000089022","Mitogen-activated protein kinase-activated protein kinase 5","12","111841978-111902238","Enzymes, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","CAB004546, HPA015515","Supported",NA,"Supported","Nucleoplasm<br>Cytosol","Liver cancer:2.98e-8 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"rectum: 33.8","Expressed in all",NA,NA
"MAT2B","MATIIbeta, SDR23E1","ENSG00000038274","Methionine adenosyltransferase 2B","5","163503114-163519336","Predicted intracellular proteins","Evidence at protein level","HPA037721, HPA037722","Uncertain",NA,NA,NA,"Renal cancer:4.51e-7 (favourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 133.5","Expressed in all",NA,NA
"MDP1","FN6Pase, MGC5987","ENSG00000213920","Magnesium dependent phosphatase 1","14","24213937-24216070","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA003064, HPA070338","Uncertain",NA,"Approved","Nucleoplasm","Renal cancer:5.96e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 20.3","Mixed",NA,NA
"MICALCL","FLJ14966","ENSG00000133808","MICAL C-terminal like","11","12276080-12359144","Cancer-related genes, Predicted intracellular proteins","Evidence at protein level","HPA039895, HPA040438","Uncertain",NA,"Approved","Nucleoplasm<br>Plasma membrane<br>Cytosol",NA,"Mixed","Tissue enhanced",NA,"skin: 17.3;testis: 13.4","lung: 10.3","Cell line enhanced",NA,"HBEC3-KT: 18.3;RT4: 12.1;U-2 OS: 9.9"
"MID1IP1","FLJ10386, G12-like, MIG12, STRAIT11499, THRSPL","ENSG00000165175","MID1 interacting protein 1","X","38801432-38806537","Predicted intracellular proteins","Evidence at protein level","HPA038816","Uncertain",NA,NA,NA,"Renal cancer:1.15e-4 (favourable), Liver cancer:2.20e-4 (unfavourable), Urothelial cancer:8.06e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"bone marrow: 66.2","Expressed in all",NA,NA
"MIOS","FLJ20323, MIO, Sea4","ENSG00000164654","Meiosis regulator for oocyte development","7","7566872-7608929","Predicted intracellular proteins","Evidence at protein level","HPA042928, HPA052223","Approved",NA,"Enhanced","Nucleoplasm<br>Cytosol","Renal cancer:3.28e-6 (favourable), Endometrial cancer:6.51e-4 (favourable), Liver cancer:9.14e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 54.8","Expressed in all",NA,NA
"MKRN3","D15S9, MGC88288, RNF63, ZFP127, ZNF127","ENSG00000179455","Makorin ring finger protein 3","15","23565678-23630075","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA029494","Uncertain",NA,"Approved","Nucleoplasm<br>Plasma membrane<br>Cytosol","Glioma:9.23e-4 (favourable)","Mixed","Tissue enhanced",NA,"cerebral cortex: 5.9;placenta: 4.1;testis: 3.6","epididymis: 1.1","Cell line enhanced",NA,"K-562: 22.8"
"MLYCD","hMCD, MCD","ENSG00000103150","Malonyl-CoA decarboxylase","16","83899126-83927026","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA031625","Enhanced",NA,NA,NA,"Renal cancer:2.61e-7 (favourable)","Expressed in all","Mixed",NA,NA,"heart muscle: 3.2","Mixed",NA,NA
"MMP11","STMY3","ENSG00000099953","Matrix metallopeptidase 11","22","23768226-23784316","Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins","Evidence at protein level","CAB002593, HPA068864","Approved",NA,NA,NA,"Renal cancer:2.62e-4 (unfavourable)","Expressed in all","Group enriched",9,"cervix, uterine: 31.6;endometrium: 123.1;placenta: 28.0","smooth muscle: 6.9","Cell line enhanced",NA,"AN3-CA: 17.4;REH: 7.4"
"MOB4","2C4D, CGI-95, DKFZP564M112, MOB3, MOBKL3, PHOCN, PREI3","ENSG00000115540","MOB family member 4, phocein","2","197515571-197553699","Predicted intracellular proteins","Evidence at protein level","CAB034082, HPA044125","Approved",NA,NA,NA,"Renal cancer:4.68e-4 (unfavourable), Liver cancer:8.29e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"adrenal gland: 79.6","Expressed in all",NA,NA
"MON2","KIAA1040","ENSG00000061987","MON2 homolog, regulator of endosome-to-Golgi trafficking","12","62466817-62600479","Predicted intracellular proteins","Evidence at protein level","HPA038697, HPA057607","Uncertain",NA,"Approved","Nucleoplasm<br>Nucleoli fibrillar center","Head and neck cancer:2.03e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 34.8","Expressed in all",NA,NA
"MPP3","DLG3","ENSG00000161647","Membrane palmitoylated protein 3","17","43800799-43833170","Predicted intracellular proteins","Evidence at protein level","HPA021818, HPA024742","Uncertain",NA,"Approved","Nucleoplasm<br>Cytosol",NA,"Expressed in all","Mixed",NA,NA,"cerebral cortex: 2.9","Cell line enhanced",NA,"SCLC-21H: 11.2"
"MRPL15","HSPC145, L15mt, MRP-L15, MRP-L7, RPML7","ENSG00000137547","Mitochondrial ribosomal protein L15","8","54135210-54147901","Predicted intracellular proteins, Ribosomal proteins","Evidence at protein level","HPA044425","Enhanced",NA,NA,NA,"Endometrial cancer:5.37e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"heart muscle: 84.8","Expressed in all",NA,NA
"MRPL18","HSPC071","ENSG00000112110","Mitochondrial ribosomal protein L18","6","159789812-159798436","Predicted intracellular proteins, Ribosomal proteins","Evidence at protein level","HPA028774, HPA028775","Enhanced",NA,NA,NA,"Renal cancer:9.02e-5 (unfavourable), Liver cancer:3.61e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"fallopian tube: 85.9","Expressed in all",NA,NA
"MTBP",NA,"ENSG00000172167","MDM2 binding protein","8","120445400-120542133","Predicted intracellular proteins","Evidence at protein level","HPA025694, HPA050594","Uncertain",NA,"Approved","Nucleus",NA,"Mixed","Mixed",NA,NA,"testis: 9.1","Mixed",NA,NA
"MTFR2","DUFD1, FAM54A","ENSG00000146410","Mitochondrial fission regulator 2","6","136231024-136250335","Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA029792, HPA029794","Approved",NA,"Uncertain","Vesicles","Lung cancer:8.28e-4 (unfavourable), Endometrial cancer:9.64e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"testis: 12.7","bone marrow: 10.2","Mixed",NA,NA
"MTMR3","FYVE-DSP1, KIAA0371, ZFYVE10","ENSG00000100330","Myotubularin related protein 3","22","29883155-30030866","Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA034515, HPA034516, HPA061399","Uncertain",NA,"Supported","Nucleoplasm<br>Cytosol",NA,"Mixed","Expressed in all",NA,NA,"bone marrow: 52.3","Expressed in all",NA,NA
"MTX2",NA,"ENSG00000128654","Metaxin 2","2","176269395-176338025","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA031550, HPA031551, HPA031552","Approved","Approved","Supported","Nucleoli<br>Mitochondria","Endometrial cancer:5.06e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 116.5","Mixed",NA,NA
"MYOZ2","C4orf5, CS-1","ENSG00000172399","Myozenin 2","4","119135784-119187789","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA035763, HPA035764","Enhanced",NA,"Approved","Nucleus<br>Cytosol",NA,"Tissue enhanced","Tissue enriched",8,"heart muscle: 500.2","skeletal muscle: 63.4","Cell line enhanced",NA,"HSkMC: 1.6;SK-MEL-30: 4.7;U-87 MG: 6.0"
"N4BP2L1","CG018","ENSG00000139597","NEDD4 binding protein 2 like 1","13","32400723-32428311","Predicted intracellular proteins","Evidence at protein level","HPA038971","Approved",NA,"Uncertain","Nucleoplasm<br>Cytosol","Liver cancer:3.11e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"ovary: 47.8","Cell line enhanced",NA,"HEL: 21.3;NB-4: 38.0"
"NAA25","C12orf30, FLJ13089","ENSG00000111300","N(alpha)-acetyltransferase 25, NatB auxiliary subunit","12","112026689-112109022","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA039322","Approved",NA,"Supported","Golgi apparatus<br>Cytosol","Renal cancer:1.32e-8 (unfavourable), Liver cancer:5.53e-5 (unfavourable), Endometrial cancer:2.26e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 9.5","Expressed in all",NA,NA
"NAA60","FLJ14154, NAT15","ENSG00000122390","N(alpha)-acetyltransferase 60, NatF catalytic subunit","16","3443611-3486963","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA040916","Approved",NA,"Uncertain","Actin filaments<br>Cytosol","Endometrial cancer:3.14e-4 (favourable), Pancreatic cancer:4.30e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 86.3","Expressed in all",NA,NA
"NADK2","C5orf33, FLJ30596, MNADK, NADKD1","ENSG00000152620","NAD kinase 2, mitochondrial","5","36192592-36242279","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA038366, HPA038367, HPA061492","Enhanced",NA,NA,NA,NA,"Expressed in all","Expressed in all",NA,NA,"liver: 173.0","Expressed in all",NA,NA
"NAGK","GNK","ENSG00000124357","N-acetylglucosamine kinase","2","71064344-71079805","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA035206, HPA035207","Enhanced",NA,"Approved","Nucleus<br>Cytosol","Renal cancer:4.35e-4 (unfavourable), Head and neck cancer:5.87e-4 (favourable), Endometrial cancer:6.88e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"esophagus: 148.0","Expressed in all",NA,NA
"NCKAP5","ERIH1, ERIH2, NAP5","ENSG00000176771","NCK associated protein 5","2","132671799-133568463","Predicted intracellular proteins","Evidence at protein level","HPA034639, HPA044859","Uncertain",NA,"Approved","Nucleoli<br>Golgi apparatus<br>Plasma membrane<br>Cytosol",NA,"Mixed","Tissue enhanced",NA,"lung: 17.3","cerebral cortex,kidney: 4.4","Cell line enriched",7,"AF22: 45.7"
"NCR3LG1","B7-H6, DKFZp686O24166","ENSG00000188211","Natural killer cell cytotoxicity receptor 3 ligand 1","11","17351726-17377341","Predicted membrane proteins","Evidence at protein level","HPA024137","Uncertain",NA,NA,NA,"Renal cancer:4.21e-12 (favourable)","Mixed","Tissue enhanced",NA,"parathyroid gland: 12.9","rectum: 5.6","Cell line enhanced",NA,"HL-60: 42.1"
"NECAP2","FLJ10420","ENSG00000157191","NECAP endocytosis associated 2","1","16440672-16460078","Predicted intracellular proteins","Evidence at protein level","HPA028077","Approved",NA,"Approved","Endoplasmic reticulum","Liver cancer:6.13e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"spleen: 86.0","Expressed in all",NA,NA
"NEDD8-MDP1",NA,"ENSG00000255526","NEDD8-MDP1 readthrough","14","24213955-24232352","Predicted intracellular proteins","Evidence at protein level","HPA003064, HPA060254","Uncertain",NA,"Approved","Nucleoplasm",NA,"Not detected","Tissue enhanced",NA,"parathyroid gland: 2.7","testis: 1.8","Cell line enhanced",NA,"MOLT-4: 6.6"
"NHS",NA,"ENSG00000188158","NHS actin remodeling regulator","X","17375420-17735994","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA031497, HPA076257","Uncertain",NA,"Supported","Cell Junctions","Endometrial cancer:1.68e-4 (favourable)","Mixed","Mixed",NA,NA,"endometrium: 7.9","Cell line enhanced",NA,"EFO-21: 12.0;RPTEC TERT1: 14.5"
"NIPBL","DKFZp434L1319, FLJ11203, FLJ12597, FLJ13354, FLJ13648, IDN3, Scc2","ENSG00000164190","NIPBL, cohesin loading factor","5","36876759-37066413","Disease related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA040834, HPA058239","Approved",NA,"Supported","Nucleoplasm<br>Vesicles",NA,"Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 43.0","Expressed in all",NA,NA
"NKX6-3","FLJ25169","ENSG00000165066","NK6 homeobox 3","8","41645178-41650669","Predicted intracellular proteins, Transcription factors","Evidence at transcript level","HPA042790","Uncertain",NA,NA,NA,NA,"Group enriched","Tissue enhanced",NA,"duodenum: 17.3;stomach: 50.6","parathyroid gland: 7.3","Group enriched",7,"Daudi: 4.2;THP-1: 1.8"
"NME1","NDPKA, NM23, NM23-H1","ENSG00000239672","NME/NM23 nucleoside diphosphate kinase 1","17","51153536-51162428","Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA008467, CAB040571, HPA041113","Supported",NA,"Enhanced","Nucleoplasm<br>Cytosol","Renal cancer:2.07e-9 (unfavourable), Liver cancer:2.60e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 89.3","Expressed in all",NA,NA
"NOTCH1","TAN1","ENSG00000148400","Notch 1","9","136494444-136545862","Cancer-related genes, Disease related genes, Plasma proteins, Predicted membrane proteins","Evidence at protein level","CAB008112, CAB022466, HPA067168","Supported",NA,"Approved","Nucleoplasm","Renal cancer:5.45e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"skin: 24.0","Cell line enhanced",NA,"MOLT-4: 77.4"
"NPC2","EDDM1, HE1, NP-C2","ENSG00000119655","NPC intracellular cholesterol transporter 2","14","74476192-74494177","Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters","Evidence at protein level","HPA000835","Enhanced",NA,NA,NA,"Colorectal cancer:4.83e-5 (unfavourable), Stomach cancer:2.66e-4 (unfavourable), Liver cancer:3.13e-4 (unfavourable), Thyroid cancer:6.55e-4 (favourable)","Expressed in all","Tissue enriched",19,"epididymis: 16336.0","lung: 849.0","Expressed in all",NA,NA
"NPLOC4","FLJ20657, KIAA1499, NPL4","ENSG00000182446","NPL4 homolog, ubiquitin recognition factor","17","81556887-81648465","Predicted intracellular proteins, Transporters","Evidence at protein level","HPA021560, HPA023295","Enhanced",NA,"Supported","Nucleoplasm<br>Cytosol","Renal cancer:6.95e-7 (unfavourable), Liver cancer:1.16e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 67.6","Expressed in all",NA,NA
"NR1H3","LXR-a, RLD-1","ENSG00000025434","Nuclear receptor subfamily 1 group H member 3","11","47248300-47269032","Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA036443, CAB037109","Approved",NA,NA,NA,"Renal cancer:1.40e-5 (unfavourable), Urothelial cancer:3.40e-4 (favourable), Endometrial cancer:5.05e-4 (favourable), Liver cancer:5.60e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"adipose tissue: 55.2","Mixed",NA,NA
"NT5DC1","dJ486I3.1, MGC24302, NT5C2L1","ENSG00000178425","5'-nucleotidase domain containing 1","6","116100849-116249497","Predicted intracellular proteins","Evidence at protein level","HPA030352","Uncertain",NA,NA,NA,"Renal cancer:7.49e-7 (favourable), Colorectal cancer:2.61e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 47.2","Expressed in all",NA,NA
"NUBP2","CFD1","ENSG00000095906","Nucleotide binding protein 2","16","1782901-1789191","Predicted intracellular proteins","Evidence at protein level","HPA041704","Uncertain",NA,"Approved","Nucleus<br>Cytosol","Renal cancer:9.63e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"spleen: 17.4","Expressed in all",NA,NA
"NUDT13","DKFZp586P2219","ENSG00000166321","Nudix hydrolase 13","10","73110375-73131828","Predicted intracellular proteins","Evidence at transcript level","HPA040636","Approved",NA,"Approved","Nucleus",NA,"Mixed","Mixed",NA,NA,"epididymis,parathyroid gland: 4.7","Mixed",NA,NA
"NUDT22","MGC13045","ENSG00000149761","Nudix hydrolase 22","11","64225941-64230686","Predicted intracellular proteins","Evidence at protein level","HPA039334, HPA053464","Approved",NA,"Enhanced","Nucleoplasm","Renal cancer:2.18e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"duodenum: 31.1","Expressed in all",NA,NA
"OBSL1","KIAA0657","ENSG00000124006","Obscurin like 1","2","219550729-219571859","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA036404, HPA036405","Approved",NA,"Approved","Centrosome","Glioma:8.52e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"ovary: 220.5","Cell line enhanced",NA,"BEWO: 148.8"
"OGFOD2","FLJ13491, FLJ37501","ENSG00000111325","2-oxoglutarate and iron dependent oxygenase domain containing 2","12","122974580-122980043","Predicted intracellular proteins","Evidence at protein level","HPA039448, HPA040306","Approved",NA,"Supported","Nucleoplasm<br>Nuclear bodies",NA,"Mixed","Expressed in all",NA,NA,"testis: 23.1","Expressed in all",NA,NA
"OSBPL2","DFNA67, KIAA0772, ORP-2","ENSG00000130703","Oxysterol binding protein like 2","20","62231922-62296213","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA041127, HPA042659","Uncertain",NA,"Approved","Cytosol","Renal cancer:4.20e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"skin: 49.7","Expressed in all",NA,NA
"OTOL1","C1QTNF15","ENSG00000182447","Otolin 1","3","161496808-161503942","Predicted secreted proteins","No evidence","HPA041030","Uncertain",NA,NA,NA,NA,"Not detected","Not detected",NA,NA,"cerebral cortex: 0.8","Not detected",NA,NA
"PATE4","FLJ41047, PATE-B","ENSG00000237353","Prostate and testis expressed 4","11","125833316-125840069","Predicted secreted proteins","Evidence at protein level","HPA045632","Approved",NA,NA,NA,NA,"Not detected","Tissue enriched",8,"seminal vesicle: 148.4","epididymis: 18.3","Not detected",NA,NA
"PCBD1","DCOH, PCBD, PCD","ENSG00000166228","Pterin-4 alpha-carbinolamine dehydratase 1","10","70882280-70888784","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA037575, HPA061723","Approved",NA,"Enhanced","Nucleoplasm<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"liver: 157.7","Mixed",NA,NA
"PCSK2","NEC2, PC2, SPC2","ENSG00000125851","Proprotein convertase subtilisin/kexin type 2","20","17226107-17484578","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA049627","Enhanced",NA,"Approved","Vesicles",NA,"Group enriched","Tissue enhanced",NA,"adrenal gland: 37.5;cerebral cortex: 31.7","skin: 16.5","Group enriched",6,"AF22: 59.2;SCLC-21H: 18.5"
"PDE1B","PDES1B","ENSG00000123360","Phosphodiesterase 1B","12","54549350-54579239","Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA018492","Approved",NA,NA,NA,"Renal cancer:4.77e-6 (unfavourable)","Mixed","Tissue enhanced",NA,"cerebral cortex: 18.4","parathyroid gland: 11.9","Cell line enhanced",NA,"HDLM-2: 10.6;HL-60: 5.1;HMC-1: 10.2;NB-4: 5.1;THP-1: 5.1;U-937: 5.0"
"PDE7B",NA,"ENSG00000171408","Phosphodiesterase 7B","6","135851696-136195574","Enzymes, FDA approved drug targets, Predicted intracellular proteins","Evidence at protein level","HPA023967","Uncertain",NA,"Approved","Nucleoplasm","Renal cancer:1.59e-4 (favourable)","Mixed","Mixed",NA,NA,"ovary: 16.2","Cell line enhanced",NA,"EFO-21: 15.3;HSkMC: 16.3;U-2197: 10.6"
"PEAR1","FLJ00193, JEDI, MEGF12","ENSG00000187800","Platelet endothelial aggregation receptor 1","1","156893698-156916434","Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA035217","Approved",NA,"Approved","Nucleoplasm<br>Cell Junctions<br>Centrosome","Renal cancer:4.31e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"placenta: 16.9","Cell line enhanced",NA,"HBEC3-KT: 21.4;HUVEC TERT2: 43.6;TIME: 69.3"
"PGBD2",NA,"ENSG00000185220","PiggyBac transposable element derived 2","1","248906196-248919946","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA029888, HPA029889, HPA029890","Uncertain",NA,"Supported","Vesicles","Urothelial cancer:2.05e-4 (favourable), Head and neck cancer:6.08e-4 (favourable), Renal cancer:7.86e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"thyroid gland: 13.4","Expressed in all",NA,NA
"PGLYRP3","PGLYRPIalpha, PGRP-Ialpha, PGRPIA","ENSG00000159527","Peptidoglycan recognition protein 3","1","153297862-153310718","Predicted secreted proteins","Evidence at protein level","HPA030369","Uncertain",NA,NA,NA,NA,"Tissue enhanced","Group enriched",9,"esophagus: 42.8;skin: 87.1","tonsil: 6.8","Group enriched",15,"HaCaT: 3.4;HDLM-2: 1.4;hTCEpi: 1.0"
"PHACTR2","C6orf56, KIAA0680","ENSG00000112419","Phosphatase and actin regulator 2","6","143536845-143831185","Predicted intracellular proteins","Evidence at protein level","HPA031719, HPA031720, HPA031725","Approved",NA,NA,NA,"Renal cancer:1.99e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"placenta: 120.1","Cell line enhanced",NA,"TIME: 66.9"
"PHF20","C20orf104, dJ1121G12.1, TDRD20A","ENSG00000025293","PHD finger protein 20","20","35771974-35950381","Cancer-related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA029619, HPA029620, HPA029621","Approved",NA,"Supported","Nucleoplasm<br>Nuclear membrane<br>Cytosol","Liver cancer:2.49e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 22.4","Expressed in all",NA,NA
"PHF20L1","CGI-72, FLJ13649, FLJ21615, MGC64923, TDRD20B","ENSG00000129292","PHD finger protein 20-like 1","8","132775358-132848807","Predicted intracellular proteins","Evidence at protein level","HPA025060, HPA028417","Uncertain",NA,"Approved","Nucleoplasm<br>Plasma membrane",NA,"Expressed in all","Expressed in all",NA,NA,"thyroid gland: 38.1","Expressed in all",NA,NA
"PHYHIPL","Em:AC025038.1, KIAA1796","ENSG00000165443","Phytanoyl-CoA 2-hydroxylase interacting protein like","10","59176590-59247774","Predicted intracellular proteins","Evidence at protein level","HPA038746","Uncertain",NA,"Approved","Cytosol","Renal cancer:1.60e-7 (favourable)","Group enriched","Tissue enhanced",NA,"cerebral cortex: 89.4","adrenal gland: 22.4","Cell line enhanced",NA,"Hep G2: 22.4;SCLC-21H: 6.7;SH-SY5Y: 20.0;SK-BR-3: 6.0"
"PIGN","MDC4, PIG-N","ENSG00000197563","Phosphatidylinositol glycan anchor biosynthesis class N","18","61905255-62187118","Disease related genes, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA039922, HPA040374","Approved",NA,"Supported","Plasma membrane<br>Cytosol","Colorectal cancer:6.51e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 33.4","Expressed in all",NA,NA
"PKDCC","SgK493, Vlk","ENSG00000162878","Protein kinase domain containing, cytoplasmic","2","42048020-42058528","Enzymes, Predicted secreted proteins","Evidence at protein level","HPA026427, HPA026442, HPA026526","Uncertain",NA,NA,NA,NA,"Expressed in all","Mixed",NA,NA,"adipose tissue: 27.4","Cell line enhanced",NA,"AN3-CA: 72.7;ASC diff: 41.5;CACO-2: 78.1;HHSteC: 43.5"
"PLA2G12A","PLA2G12","ENSG00000123739","Phospholipase A2 group XIIA","4","109709989-109730077","Enzymes, Predicted secreted proteins, RAS pathway related proteins","Evidence at protein level","HPA035908, HPA035909","Approved",NA,NA,NA,"Renal cancer:2.54e-9 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 34.0","Expressed in all",NA,NA
"PLEKHG6","FLJ10665, MYOGEF","ENSG00000008323","Pleckstrin homology and RhoGEF domain containing G6","12","6310436-6328506","Predicted intracellular proteins","Evidence at protein level","HPA041459, HPA058230","Uncertain",NA,"Supported","Cell Junctions<br>Centrosome",NA,"Mixed","Tissue enhanced",NA,"small intestine: 47.7","duodenum: 36.5","Cell line enhanced",NA,"BEWO: 147.7;CACO-2: 41.4;RT4: 42.4"
"PLEKHM3","DAPR, PLEKHM1L","ENSG00000178385","Pleckstrin homology domain containing M3","2","207821288-208025560","Predicted intracellular proteins","Evidence at protein level","HPA035046","Uncertain",NA,"Approved","Vesicles<br>Cytosol",NA,"Mixed","Mixed",NA,NA,"parathyroid gland: 18.9","Mixed",NA,NA
"PLEKHO2","DKFZp761K2312, PLEKHQ1, PP1628, pp9099","ENSG00000241839","Pleckstrin homology domain containing O2","15","64841883-64868007","Predicted intracellular proteins","Evidence at protein level","HPA040055","Approved",NA,"Approved","Nucleoplasm<br>Plasma membrane<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"spleen: 119.5","Mixed",NA,NA
"PNRC1","B4-2, PROL2, PRR2","ENSG00000146278","Proline rich nuclear receptor coactivator 1","6","89080751-89085160","Predicted intracellular proteins","Evidence at protein level","HPA029839, HPA066513","Approved",NA,"Approved","Nucleus<br>Nucleoli","Renal cancer:6.88e-6 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"ovary: 272.4","Expressed in all",NA,NA
"PPIP5K1","HISPPD2A, IPS1, KIAA0377, VIP1","ENSG00000168781","Diphosphoinositol pentakisphosphate kinase 1","15","43533462-43590253","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA039380","Approved",NA,"Supported","Cytosol","Renal cancer:7.14e-8 (favourable), Ovarian cancer:8.57e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 53.1","Expressed in all",NA,NA
"PPP1R1B","DARPP-32, FLJ20940","ENSG00000131771","Protein phosphatase 1 regulatory inhibitor subunit 1B","17","39626740-39636626","Predicted intracellular proteins","Evidence at protein level","CAB004026, HPA048630, HPA061142","Approved","Approved",NA,NA,NA,"Mixed","Tissue enhanced",NA,"rectum: 219.9","colon: 209.5","Cell line enhanced",NA,"CAPAN-2: 11.0;HSkMC: 23.1;SCLC-21H: 31.9"
"PPP1R3D","PPP1R6","ENSG00000132825","Protein phosphatase 1 regulatory subunit 3D","20","59936668-59940297","Predicted intracellular proteins","Evidence at protein level","HPA041146","Approved",NA,"Approved","Nucleoli<br>Vesicles<br>Mitochondria","Stomach cancer:9.14e-4 (favourable)","Expressed in all","Mixed",NA,NA,"parathyroid gland: 11.1","Mixed",NA,NA
"PPP5C","PP5, PPP5","ENSG00000011485","Protein phosphatase 5 catalytic subunit","19","46346994-46392981","Enzymes, Predicted intracellular proteins","Evidence at protein level","CAB022641, HPA029065, HPA056933","Approved",NA,"Supported","Vesicles<br>Cytosol","Liver cancer:3.45e-6 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 44.3","Expressed in all",NA,NA
"PRSS1","TRY1","ENSG00000204983","Protease, serine 1","7","142749468-142753076","Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","CAB025487, CAB025538, HPA062452, HPA063471","Enhanced",NA,NA,NA,"Endometrial cancer:6.41e-6 (unfavourable), Thyroid cancer:4.91e-4 (favourable), Ovarian cancer:7.05e-4 (favourable)","Tissue enriched","Tissue enriched",318,"pancreas: 81683.0","ovary: 257.2","Cell line enhanced",NA,"EFO-21: 1.3;RPMI-8226: 2.0;U-2 OS: 1.7"
"PRSS16","TSSP","ENSG00000112812","Protease, serine 16","6","27247701-27256624","Enzymes, Predicted intracellular proteins, Predicted secreted proteins","Evidence at transcript level","HPA017743","Uncertain",NA,NA,NA,"Ovarian cancer:6.46e-5 (favourable)","Mixed","Tissue enhanced",NA,"thyroid gland: 22.0","epididymis: 16.5","Cell line enhanced",NA,"hTCEpi: 14.7;RPMI-8226: 7.9"
"PRSS36","FLJ90661","ENSG00000178226","Protease, serine 36","16","31138925-31150094","Enzymes, Predicted secreted proteins","Evidence at protein level","HPA036079","Uncertain",NA,NA,NA,"Cervical cancer:2.97e-7 (favourable)","Mixed","Mixed",NA,NA,"skin: 1.2","Cell line enhanced",NA,"HeLa: 1.4"
"PRSS38","MPN2","ENSG00000185888","Protease, serine 38","1","227815693-227846470","Enzymes, Predicted secreted proteins","Evidence at protein level","HPA028003, HPA055809","Enhanced",NA,NA,NA,NA,"Not detected","Tissue enriched",41,"testis: 4.2","epididymis: 0.1","Not detected",NA,NA
"PSMC6","p42","ENSG00000100519","Proteasome 26S subunit, ATPase 6","14","52707172-52728587","Predicted intracellular proteins","Evidence at protein level","HPA042823","Approved",NA,"Approved","Nucleoplasm<br>Plasma membrane<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"thyroid gland: 91.8","Expressed in all",NA,NA
"PSMG2","CLAST3, HCCA3, HsT1707, MDS003, MGC15092, PAC2, TNFSF5IP1","ENSG00000128789","Proteasome assembly chaperone 2","18","12658043-12725740","Predicted intracellular proteins","Evidence at protein level","HPA041517, HPA046741","Uncertain",NA,"Approved","Nucleus<br>Nuclear bodies","Ovarian cancer:3.09e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 172.4","Expressed in all",NA,NA
"PSPN","PSP","ENSG00000125650","Persephin","19","6375148-6379058","Predicted secreted proteins","Evidence at transcript level","CAB025366","Approved",NA,NA,NA,NA,"Expressed in all","Mixed",NA,NA,"cerebral cortex,epididymis,parathyroid gland,thyroid gland: 1.4","Mixed",NA,NA
"PTER",NA,"ENSG00000165983","Phosphotriesterase related","10","16436943-16513745","Predicted intracellular proteins","Evidence at protein level","HPA038044, HPA038045","Approved",NA,"Approved","Nucleoplasm<br>Cytosol","Renal cancer:6.52e-6 (favourable), Liver cancer:2.11e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 42.7","Mixed",NA,NA
"PTK6","BRK","ENSG00000101213","Protein tyrosine kinase 6","20","63528001-63537370","Cancer-related genes, Enzymes, Predicted intracellular proteins","Evidence at protein level","CAB032952, HPA036070, HPA036071","Approved",NA,"Supported","Nucleoplasm<br>Nuclear bodies<br>Plasma membrane<br>Cytosol","Renal cancer:1.26e-9 (unfavourable), Pancreatic cancer:1.96e-4 (unfavourable)","Mixed","Tissue enhanced",NA,"esophagus: 61.0;skin: 60.4","duodenum: 29.2","Cell line enhanced",NA,"A-431: 19.4;CAPAN-2: 36.5;HaCaT: 30.0;hTCEpi: 32.5;RT4: 21.3;T-47d: 23.7"
"PTPN23","DKFZP564F0923, HD-PTP, KIAA1471","ENSG00000076201","Protein tyrosine phosphatase, non-receptor type 23","3","47381011-47413441","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA016845","Approved",NA,"Supported","Nucleoplasm<br>Nuclear bodies","Renal cancer:1.82e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 56.9","Expressed in all",NA,NA
"QPCT","GCT, QC","ENSG00000115828","Glutaminyl-peptide cyclotransferase","2","37344574-37373322","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA008406","Enhanced",NA,"Approved","Cytosol",NA,"Expressed in all","Tissue enhanced",NA,"adrenal gland: 158.9;epididymis: 121.6","skin: 41.1","Cell line enhanced",NA,"SCLC-21H: 130.6;SK-MEL-30: 299.7;U-266/84: 218.7"
"QTRT1","TGT","ENSG00000213339","Queuine tRNA-ribosyltransferase catalytic subunit 1","19","10701430-10713437","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA042695, HPA048651, HPA049440","Approved",NA,"Approved","Mitochondria","Renal cancer:1.13e-6 (unfavourable), Cervical cancer:7.63e-5 (favourable), Pancreatic cancer:2.13e-4 (favourable), Head and neck cancer:4.90e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 25.5","Expressed in all",NA,NA
"RAB21","KIAA0118","ENSG00000080371","RAB21, member RAS oncogene family","12","71754874-71800285","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA016988, CAB037048","Approved",NA,NA,NA,"Renal cancer:5.39e-8 (favourable)","Expressed in all","Mixed",NA,NA,"parathyroid gland: 12.2","Expressed in all",NA,NA
"RAB32",NA,"ENSG00000118508","RAB32, member RAS oncogene family","6","146543693-146554965","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA025731","Approved",NA,"Approved","Cytosol","Liver cancer:1.08e-7 (unfavourable), Colorectal cancer:1.56e-4 (favourable), Endometrial cancer:6.51e-4 (unfavourable), Renal cancer:8.62e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"bone marrow: 91.9","Mixed",NA,NA
"RABGAP1L","FLJ38519, HHL, KIAA0471, TBC1D18","ENSG00000152061","RAB GTPase activating protein 1 like","1","174159410-174995308","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA054695","Uncertain",NA,"Approved","Nucleoli<br>Cytosol","Lung cancer:1.16e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"heart muscle: 76.6","Expressed in all",NA,NA
"RABGGTB",NA,"ENSG00000137955","Rab geranylgeranyltransferase beta subunit","1","75786197-75795079","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA026585, HPA027167, HPA030793","Approved","Approved","Supported","Vesicles","Renal cancer:1.12e-5 (unfavourable), Liver cancer:9.80e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"kidney: 69.4","Expressed in all",NA,NA
"RASAL1","RASAL","ENSG00000111344","RAS protein activator like 1","12","113098819-113136239","Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins","Evidence at protein level","HPA041650","Uncertain",NA,"Approved","Plasma membrane<br>Cell Junctions<br>Cytosol","Endometrial cancer:3.26e-5 (unfavourable)","Mixed","Tissue enriched",6,"parathyroid gland: 118.8","cerebral cortex: 19.4","Cell line enhanced",NA,"EFO-21: 18.2;REH: 20.3;RPMI-8226: 34.6;RPTEC TERT1: 14.4;U-698: 28.8"
"RASGRF1","CDC25, CDC25L, GNRP, GRF1, GRF55, H-GRF55, PP13187","ENSG00000058335","Ras protein specific guanine nucleotide releasing factor 1","15","78959947-79090773","Predicted intracellular proteins, RAS pathway related proteins","Evidence at protein level","CAB010413, HPA041965","Approved",NA,"Supported","Golgi apparatus","Endometrial cancer:6.14e-6 (favourable)","Mixed","Group enriched",14,"cerebral cortex: 30.5;lung: 11.3","lymph node: 1.5","Cell line enhanced",NA,"A-431: 7.3;BEWO: 7.5;Karpas-707: 7.5;RPMI-8226: 9.0;U-2 OS: 15.8"
"RBMXL2","HNRNPG-T, HNRPGT","ENSG00000170748","RNA binding motif protein, X-linked like 2","11","7089027-7090900","Predicted intracellular proteins","Evidence at protein level","HPA038912, HPA051842","Enhanced",NA,NA,NA,NA,"Tissue enriched","Tissue enriched",499,"testis: 49.8","all non-specific tissues: 0.0","Not detected",NA,NA
"RBP1","CRABP-I, CRBP, CRBP1, CRBPI, RBPC","ENSG00000114115","Retinol binding protein 1","3","139517434-139539829","Predicted intracellular proteins","Evidence at protein level","HPA007338, CAB018603, CAB019276","Enhanced",NA,"Approved","Nucleoplasm<br>Cytosol",NA,"Expressed in all","Tissue enhanced",NA,"fallopian tube: 634.8;ovary: 1297.7","adrenal gland: 376.4","Cell line enriched",6,"SH-SY5Y: 887.3"
"RC3H1","KIAA2025, RNF198, roquin, RP5-1198E17.5","ENSG00000135870","Ring finger and CCCH-type domains 1","1","173931214-174022297","Predicted intracellular proteins","Evidence at protein level","HPA027428, HPA027434, HPA027448","Approved",NA,"Supported","Plasma membrane<br>Cytosol","Renal cancer:7.96e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"bone marrow: 12.9","Mixed",NA,NA
"RFX7","FLJ12994, RFXDC2","ENSG00000181827","Regulatory factor X7","15","56087280-56243266","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA035462","Supported",NA,"Approved","Nucleus<br>Nuclear membrane","Renal cancer:1.12e-5 (unfavourable)","Expressed in all","Mixed",NA,NA,"testis: 8.2","Expressed in all",NA,NA
"RHCG","C15orf6, PDRC2, RHGK, SLC42A3","ENSG00000140519","Rh family C glycoprotein","15","89471398-89496613","Predicted membrane proteins, Transporters","Evidence at protein level","HPA041874, HPA043317","Enhanced",NA,NA,NA,"Lung cancer:3.80e-4 (unfavourable)","Tissue enhanced","Tissue enriched",7,"esophagus: 2901.8","tonsil: 420.3","Cell line enhanced",NA,"A549: 3.3;hTCEpi: 1.4;RT4: 1.6;SK-MEL-30: 1.0"
"RHPN1","KIAA1929, ODF5, RHPN","ENSG00000158106","Rhophilin Rho GTPase binding protein 1","8","143368887-143384220","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA024288, HPA024671","Approved",NA,"Approved","Nucleoplasm",NA,"Expressed in all","Tissue enhanced",NA,"cerebral cortex: 7.1","parathyroid gland: 4.8","Cell line enhanced",NA,"MCF7: 21.9;MOLT-4: 21.1;T-47d: 42.5"
"RIDA","HRSP12, P14.5, PSP, UK114","ENSG00000132541","Reactive intermediate imine deaminase A homolog","8","98102344-98117241","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA022856, HPA023489","Enhanced",NA,NA,NA,"Liver cancer:9.61e-6 (favourable)","Expressed in all","Group enriched",9,"kidney: 454.6;liver: 698.7","cerebral cortex: 62.3","Expressed in all",NA,NA
"RNF217","C6orf172, dJ84N20.1, IBRDC1, MGC26996","ENSG00000146373","Ring finger protein 217","6","124962545-125092633","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA029598","Uncertain",NA,NA,NA,"Renal cancer:4.60e-5 (unfavourable), Urothelial cancer:1.92e-4 (unfavourable)","Expressed in all","Tissue enriched",8,"parathyroid gland: 95.7","testis: 12.5","Mixed",NA,NA
"RNF25","AO7, FLJ13906","ENSG00000163481","Ring finger protein 25","2","218663864-218672411","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA036420, HPA036421","Uncertain",NA,"Approved","Nucleoplasm<br>Cytosol","Liver cancer:6.58e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 14.6","Expressed in all",NA,NA
"RNF6","DKFZp686P0776","ENSG00000127870","Ring finger protein 6","13","26132115-26222493","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA039343, HPA040048","Approved",NA,"Supported","Nuclear membrane","Cervical cancer:3.07e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 61.0","Mixed",NA,NA
"RPP14","P14","ENSG00000163684","Ribonuclease P/MRP subunit p14","3","58306247-58324695","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA036194","Uncertain",NA,"Approved","Nucleoplasm<br>Cytosol","Renal cancer:3.07e-10 (favourable), Thyroid cancer:2.96e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"skeletal muscle: 21.1","Expressed in all",NA,NA
"RPUSD3","MGC29784","ENSG00000156990","RNA pseudouridylate synthase domain containing 3","3","9837849-9844602","Predicted intracellular proteins","Evidence at protein level","HPA037551, HPA037552","Uncertain",NA,"Approved","Nucleus","Liver cancer:1.73e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 54.0","Expressed in all",NA,NA
"RTN4IP1","NIMP","ENSG00000130347","Reticulon 4 interacting protein 1","6","106571971-106629487","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA036357","Approved",NA,NA,NA,"Renal cancer:8.55e-6 (favourable), Breast cancer:9.18e-6 (unfavourable)","Expressed in all","Mixed",NA,NA,"parathyroid gland: 11.4","Expressed in all",NA,NA
"RUFY4","FLJ46536, ZFYVE31","ENSG00000188282","RUN and FYVE domain containing 4","2","218034960-218090581","Predicted intracellular proteins","Evidence at protein level","HPA037980","Uncertain",NA,NA,NA,NA,"Mixed","Tissue enhanced",NA,"spleen: 2.5","lymph node: 1.3","Cell line enriched",12,"Karpas-707: 7.6"
"RWDD1","PTD013","ENSG00000111832","RWD domain containing 1","6","116571367-116597675","Predicted intracellular proteins","Evidence at protein level","HPA028712, HPA028713","Approved",NA,NA,NA,"Liver cancer:5.16e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"adrenal gland: 61.8","Expressed in all",NA,NA
"RWDD4","FAM28A, MGC10198, RWDD4A","ENSG00000182552","RWD domain containing 4","4","183639635-183659225","Predicted intracellular proteins","Evidence at protein level","HPA036501, HPA036502","Approved",NA,"Approved","Intermediate filaments","Renal cancer:1.01e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"adrenal gland: 68.2","Expressed in all",NA,NA
"SARM1","KIAA0524, SAMD2, SARM","ENSG00000004139","Sterile alpha and TIR motif containing 1","17","28364356-28404049","Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA024359, HPA024759","Uncertain",NA,"Approved","Vesicles",NA,"Mixed","Mixed",NA,NA,"duodenum: 7.5","Cell line enhanced",NA,"CACO-2: 26.9"
"SBNO2","FLJ00173, KIAA0963, Sno, Stno","ENSG00000064932","Strawberry notch homolog 2","19","1107636-1174283","Predicted intracellular proteins","Evidence at protein level","HPA041867","Approved",NA,NA,NA,"Renal cancer:7.98e-8 (unfavourable)","Expressed in all","Mixed",NA,NA,"adipose tissue: 13.9","Cell line enhanced",NA,"HDLM-2: 61.0"
"SCAF11","CASP11, SFRS2IP, SIP1, SRRP129, SRSF2IP","ENSG00000139218","SR-related CTD associated factor 11","12","45919131-45992120","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA038862, HPA045456, HPA046345","Enhanced",NA,"Enhanced","Nucleoplasm<br>Nuclear bodies",NA,"Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 84.9","Expressed in all",NA,NA
"SCML1",NA,"ENSG00000047634","Sex comb on midleg-like 1 (Drosophila)","X","17737449-17754988","Predicted intracellular proteins","Evidence at protein level","HPA035270, HPA035271, HPA061397","Enhanced",NA,"Approved","Nucleus",NA,"Expressed in all","Expressed in all",NA,NA,"testis: 54.2","Cell line enhanced",NA,"U-2197: 82.3"
"SDC3","N-syndecan, SYND3","ENSG00000162512","Syndecan 3","1","30869467-30908761","Predicted membrane proteins","Evidence at protein level","HPA017087, CAB025786, HPA048085","Approved",NA,"Approved","Nucleoplasm<br>Mitochondria","Renal cancer:1.71e-4 (unfavourable), Melanoma:2.36e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 136.4","Cell line enhanced",NA,"SK-MEL-30: 167.1;WM-115: 290.3"
"SEC13","D3S1231E, npp-20, SEC13L1, SEC13R","ENSG00000157020","SEC13 homolog, nuclear pore and COPII coat complex component","3","10293131-10321178","Predicted intracellular proteins, Transporters","Evidence at protein level","HPA035292, HPA057943","Approved",NA,"Supported","Nucleoplasm<br>Vesicles","Liver cancer:1.73e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cervix, uterine: 120.0","Expressed in all",NA,NA
"SEC31B","DKFZP434M183, SEC31B-1, SEC31L2","ENSG00000075826","SEC31 homolog B, COPII coat complex component","10","100486642-100519864","Predicted intracellular proteins","Evidence at protein level","HPA035882, HPA040819, HPA060052","Uncertain",NA,"Approved","Nucleus<br>Nucleoli<br>Vesicles<br>Cytosol","Renal cancer:6.41e-7 (unfavourable)","Mixed","Mixed",NA,NA,"testis: 3.2","Mixed",NA,NA
"SEMA3F","Sema4, SEMAK","ENSG00000001617","Semaphorin 3F","3","50155045-50189075","Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA035008","Approved",NA,NA,NA,"Liver cancer:5.15e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"skin: 89.1","Cell line enhanced",NA,"HUVEC TERT2: 156.4;SK-BR-3: 129.8;TIME: 276.8"
"SERPINB9","CAP3, PI9","ENSG00000170542","Serpin family B member 9","6","2887266-2903280","Predicted intracellular proteins","Evidence at protein level","HPA030067","Uncertain",NA,"Approved","Nucleoplasm<br>Cytosol","Renal cancer:1.66e-6 (unfavourable)","Expressed in all","Tissue enhanced",NA,"placenta: 74.8","appendix: 48.4","Cell line enhanced",NA,"BEWO: 219.1;U-698: 69.6"
"SGSH","HSS, MPS3A, SFMD","ENSG00000181523","N-sulfoglucosamine sulfohydrolase","17","80206716-80220923","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Evidence at protein level","HPA023436, HPA023451","Enhanced",NA,NA,NA,"Renal cancer:2.66e-4 (unfavourable), Lung cancer:2.72e-4 (favourable), Pancreatic cancer:3.10e-4 (favourable), Testis cancer:5.37e-4 (unfavourable), Liver cancer:7.71e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"adrenal gland: 36.3","Mixed",NA,NA
"SH3TC2","CMT4C, KIAA1985","ENSG00000169247","SH3 domain and tetratricopeptide repeats 2","5","148923639-149063163","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA037683, HPA037684","Uncertain",NA,"Approved","Nucleoplasm<br>Cytosol",NA,"Mixed","Group enriched",6,"cerebral cortex: 3.0;placenta: 2.8;testis: 8.8","cervix, uterine,heart muscle: 0.7","Cell line enhanced",NA,"RT4: 6.6;SK-MEL-30: 5.9;WM-115: 8.2"
"SHROOM1","APXL2, KIAA1960","ENSG00000164403","Shroom family member 1","5","132822141-132830898","Predicted intracellular proteins","Evidence at protein level","HPA037690, HPA037691","Uncertain",NA,"Approved","Vesicles","Renal cancer:5.72e-6 (unfavourable)","Expressed in all","Tissue enhanced",NA,"prostate: 54.5","seminal vesicle: 21.3","Mixed",NA,NA
"SIGLEC10","MGC126774, PRO940, SIGLEC-10, SLG2","ENSG00000142512","Sialic acid binding Ig like lectin 10","19","51410021-51417803","Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","CAB025807, HPA027093","Enhanced",NA,"Supported","Plasma membrane<br>Actin filaments<br>Cytosol","Renal cancer:4.74e-5 (unfavourable)","Expressed in all","Tissue enhanced",NA,"appendix: 48.4;spleen: 36.9","lymph node: 22.1","Cell line enhanced",NA,"Daudi: 21.0;HEL: 13.5;HMC-1: 10.2;U-698: 14.8;U-937: 9.7"
"SLC10A1","NTCP","ENSG00000100652","Solute carrier family 10 member 1","14","69775417-69797289","Predicted membrane proteins, Transporters","Evidence at protein level","HPA042727","Approved",NA,NA,NA,"Liver cancer:9.53e-6 (favourable)","Tissue enriched","Tissue enriched",394,"liver: 212.4","gallbladder: 0.5","Not detected",NA,NA
"SLC16A1","MCT, MCT1","ENSG00000155380","Solute carrier family 16 member 1","1","112911847-112957013","Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters","Evidence at protein level","HPA003324, CAB017489, HPA071055, CAB079035","Enhanced","Supported","Enhanced","Plasma membrane<br>Cell Junctions","Renal cancer:6.78e-8 (unfavourable), Endometrial cancer:8.37e-6 (unfavourable), Pancreatic cancer:2.10e-4 (unfavourable), Lung cancer:4.05e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"testis: 31.4","Mixed",NA,NA
"SLC20A2","Glvr-2, GLVR2, MLVAR, PiT-2, Ram-1","ENSG00000168575","Solute carrier family 20 member 2","8","42416475-42541926","Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters","Evidence at protein level","HPA026540","Approved",NA,NA,NA,"Renal cancer:1.01e-4 (favourable), Breast cancer:7.67e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 138.4","Expressed in all",NA,NA
"SLC25A41","APC4, FLJ40442, MGC34725","ENSG00000181240","Solute carrier family 25 member 41","19","6426037-6433779","Predicted intracellular proteins, Transporters","Evidence at transcript level","HPA043591","Uncertain",NA,NA,NA,NA,"Not detected","Tissue enhanced",NA,"cerebral cortex: 1.0;testis: 1.9","esophagus: 0.4","Cell line enhanced",NA,"HMC-1: 2.4;U-937: 1.3"
"SLC26A11",NA,"ENSG00000181045","Solute carrier family 26 member 11","17","80219699-80253500","Predicted intracellular proteins, Predicted membrane proteins, Transporters","Evidence at protein level","HPA029893","Approved",NA,"Supported","Nucleoplasm<br>Golgi apparatus<br>Vesicles","Liver cancer:1.82e-6 (unfavourable), Pancreatic cancer:1.43e-5 (favourable), Endometrial cancer:1.55e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"adrenal gland: 34.4","Mixed",NA,NA
"SLC29A1","ENT1","ENSG00000112759","Solute carrier family 29 member 1 (Augustine blood group)","6","44219505-44234151","Predicted membrane proteins, Transporters","Evidence at protein level","HPA012384","Approved",NA,NA,NA,"Renal cancer:2.96e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"adrenal gland: 124.4","Expressed in all",NA,NA
"SLC2A8","GLUT8, GLUTX1","ENSG00000136856","Solute carrier family 2 member 8","9","127397138-127408424","Predicted membrane proteins, Transporters","Evidence at protein level","HPA011935","Uncertain",NA,"Approved","Vesicles","Cervical cancer:2.57e-6 (favourable), Renal cancer:6.55e-6 (favourable), Pancreatic cancer:9.86e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 50.0","Cell line enhanced",NA,"CACO-2: 101.8"
"SLC35D3","FRCL1","ENSG00000182747","Solute carrier family 35 member D3","6","136922264-136925639","Predicted membrane proteins, Transporters","Evidence at protein level","HPA030431, HPA067497","Uncertain",NA,"Approved","Microtubule organizing center",NA,"Tissue enhanced","Tissue enhanced",NA,"adrenal gland: 1.2","lung,stomach: 0.6","Group enriched",16,"SCLC-21H: 4.2;SH-SY5Y: 16.3"
"SLC37A4","G6PT1, G6PT2, G6PT3, GSD1b, GSD1c, GSD1d","ENSG00000137700","Solute carrier family 37 member 4","11","119024114-119030906","Predicted membrane proteins","Evidence at protein level","HPA038939, HPA038940","Enhanced",NA,"Approved","Mitochondria",NA,"Expressed in all","Tissue enhanced",NA,"kidney: 36.6","duodenum: 30.8","Cell line enhanced",NA,"HEK 293: 24.3"
"SLC38A1","ATA1, NAT2, SAT1","ENSG00000111371","Solute carrier family 38 member 1","12","46183063-46270017","Predicted intracellular proteins, Predicted membrane proteins, Transporters","Evidence at protein level","HPA039460, HPA052272","Uncertain","Supported",NA,NA,"Liver cancer:6.95e-8 (unfavourable), Endometrial cancer:4.76e-6 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 154.6","Mixed",NA,NA
"SLC6A11","GAT3","ENSG00000132164","Solute carrier family 6 member 11","3","10816200-10940733","Predicted membrane proteins, Transporters","Evidence at protein level","HPA037981","Supported","Supported",NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 18.1;skin: 6.7","esophagus: 5.5","Cell line enhanced",NA,"HaCaT: 11.8;Hep G2: 10.7;hTCEpi: 8.5;NTERA-2: 6.6"
"SLC7A10","asc-1","ENSG00000130876","Solute carrier family 7 member 10","19","33208664-33225850","Predicted membrane proteins, Transporters","Evidence at transcript level","HPA041884, HPA057036","Uncertain",NA,"Uncertain","Nucleus<br>Nucleoli",NA,"Mixed","Group enriched",24,"adipose tissue: 31.6;cerebral cortex: 6.5","breast: 0.8","Cell line enhanced",NA,"BEWO: 1.8;HSkMC: 1.2;THP-1: 2.6;U-2 OS: 1.1"
"SLF1","ANKRD32, BRCTD1, BRCTx, DKFZp564C0469, DKFZp761C121","ENSG00000133302","SMC5-SMC6 complex localization factor 1","5","94618347-94739436","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA040793, HPA054213","Uncertain",NA,"Approved","Nucleus",NA,"Expressed in all","Tissue enhanced",NA,"testis: 12.9","cerebral cortex: 4.4","Cell line enhanced",NA,"HeLa: 34.7"
"SLU7","9G8","ENSG00000164609","SLU7 homolog, splicing factor","5","160401641-160421711","Predicted intracellular proteins","Evidence at protein level","HPA035907, HPA058120","Uncertain",NA,"Enhanced","Nucleoplasm<br>Nuclear speckles","Renal cancer:1.98e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 50.1","Expressed in all",NA,NA
"SMAGP","hSMAGP, MGC149453, MGC149454","ENSG00000170545","Small cell adhesion glycoprotein","12","51244558-51270890","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA039711","Enhanced",NA,"Supported","Nucleoplasm<br>Plasma membrane","Renal cancer:2.24e-4 (favourable), Pancreatic cancer:4.38e-4 (unfavourable), Glioma:7.05e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"placenta: 145.7","esophagus: 83.3","Cell line enhanced",NA,"BEWO: 126.2"
"SOCS5","CIS6, Cish5, CISH6, KIAA0671, SOCS-5","ENSG00000171150","Suppressor of cytokine signaling 5","2","46698952-46763129","Predicted intracellular proteins","Evidence at protein level","HPA020884, CAB025510","Approved",NA,"Approved","Nucleoplasm<br>Plasma membrane<br>Cytosol","Liver cancer:7.28e-4 (unfavourable), Ovarian cancer:7.53e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"ovary: 31.1","Expressed in all",NA,NA
"SORD",NA,"ENSG00000140263","Sorbitol dehydrogenase","15","45023104-45077185","Enzymes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA040260, HPA040621","Enhanced",NA,"Approved","Cytosol","Liver cancer:6.14e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"cervix, uterine: 404.7","Mixed",NA,NA
"SP3","SPR-2","ENSG00000172845","Sp3 transcription factor","2","173906459-173965702","Predicted intracellular proteins, Transcription factors","Evidence at protein level","CAB004580, HPA032145, HPA032146","Supported","Supported",NA,NA,"Renal cancer:2.46e-5 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cervix, uterine: 91.7","Expressed in all",NA,NA
"SPAG1","CILD28, CT140, FLJ32920, HSD-3.8, SP75, TPIS","ENSG00000104450","Sperm associated antigen 1","8","100157906-100259278","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA023748, HPA053682","Enhanced",NA,"Supported","Cytosol","Urothelial cancer:2.62e-4 (favourable), Renal cancer:3.87e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"testis: 34.1","rectum: 20.0","Mixed",NA,NA
"SPATA13","ARHGEF29, FLJ31208","ENSG00000182957","Spermatogenesis associated 13","13","23979805-24307074","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA040185, HPA041208","Approved",NA,"Supported","Nucleoplasm<br>Cytosol","Urothelial cancer:1.16e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"spleen: 90.2","lymph node: 27.2","Cell line enhanced",NA,"HDLM-2: 43.0"
"SPP1","BNSP, BSPI, ETA-1, OPN","ENSG00000118785","Secreted phosphoprotein 1","4","87975650-87983426","Cancer-related genes, Plasma proteins, Predicted secreted proteins","Evidence at protein level","CAB002212, HPA027540, HPA027541","Enhanced",NA,"Supported","Golgi apparatus","Liver cancer:2.84e-6 (unfavourable), Pancreatic cancer:5.89e-4 (unfavourable), Cervical cancer:9.52e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"gallbladder: 3987.0;kidney: 2404.4;placenta: 4045.7","cerebral cortex: 795.2","Group enriched",6,"EFO-21: 4669.3;Hep G2: 1742.5;RPTEC TERT1: 8242.5"
"SPPL2A","IMP3, PSL2","ENSG00000138600","Signal peptide peptidase like 2A","15","50702266-50765808","Enzymes, Plasma proteins, Predicted membrane proteins, Transporters","Evidence at protein level","HPA036062, HPA067304","Enhanced",NA,"Supported","Vesicles",NA,"Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 291.5","Expressed in all",NA,NA
"SPRY1","hSPRY1","ENSG00000164056","Sprouty RTK signaling antagonist 1","4","123396795-123403760","Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","CAB013538, HPA051369, HPA070554","Approved",NA,"Approved","Nucleoplasm<br>Golgi apparatus<br>Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"gallbladder: 132.0","Cell line enhanced",NA,"AF22: 94.2;AN3-CA: 180.0"
"SPTLC1","hLCB1, HSAN1, HSN1, LCB1, SPTI","ENSG00000090054","Serine palmitoyltransferase long chain base subunit 1","9","92031999-92115384","Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins","Evidence at protein level","HPA010860, CAB018747, HPA063907","Supported",NA,"Supported","Endoplasmic reticulum","Renal cancer:1.36e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 108.3","Expressed in all",NA,NA
"SQLE",NA,"ENSG00000104549","Squalene epoxidase","8","124998497-125022283","Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA018038, HPA020762","Enhanced",NA,"Uncertain","Vesicles<br>Cytosol","Pancreatic cancer:2.73e-4 (unfavourable), Lung cancer:4.67e-4 (unfavourable), Renal cancer:5.70e-4 (unfavourable), Head and neck cancer:7.42e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"testis: 107.8","Expressed in all",NA,NA
"ST7","ETS7q, FAM4A, FAM4A1, HELG, RAY1, SEN4, TSG7","ENSG00000004866","Suppression of tumorigenicity 7","7","116953238-117230103","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA038325, HPA038326","Approved",NA,"Supported","Nucleoplasm<br>Cytosol","Renal cancer:3.39e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 51.0","Mixed",NA,NA
"STRA6","FLJ12541","ENSG00000137868","Stimulated by retinoic acid 6","15","74179466-74212267","Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters","Evidence at protein level","HPA040839","Approved",NA,"Approved","Nucleus<br>Cytosol",NA,"Mixed","Tissue enhanced",NA,"cervix, uterine: 37.0;placenta: 20.4","endometrium: 13.2","Cell line enhanced",NA,"CAPAN-2: 162.1;SH-SY5Y: 119.5;WM-115: 273.5"
"STT3B","FLJ90106, SIMP, STT3-B","ENSG00000163527","STT3B, catalytic subunit of the oligosaccharyltransferase complex","3","31532638-31637622","Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins","Evidence at protein level","HPA036448, HPA036646","Approved",NA,"Supported","Endoplasmic reticulum","Colorectal cancer:7.91e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 165.5","Expressed in all",NA,NA
"STXBP6","amisyn, HSPC156","ENSG00000168952","Syntaxin binding protein 6","14","24809656-25050297","Predicted intracellular proteins","Evidence at protein level","HPA003552","Approved",NA,NA,NA,NA,"Mixed","Mixed",NA,NA,"placenta: 61.2","Cell line enhanced",NA,"HBF TERT88: 62.1"
"STYX",NA,"ENSG00000198252","Serine/threonine/tyrosine interacting protein","14","52730180-52774998","Predicted intracellular proteins","Evidence at protein level","HPA040290","Uncertain",NA,"Approved","Nucleoplasm",NA,"Expressed in all","Expressed in all",NA,NA,"testis: 20.5","Expressed in all",NA,NA
"SULT2A1","DHEA-ST, STD","ENSG00000105398","Sulfotransferase family 2A member 1","19","47870466-47886397","Enzymes, Predicted intracellular proteins","Evidence at protein level","CAB018755, HPA041487, HPA063633","Enhanced",NA,"Supported","Cytosol",NA,"Tissue enriched","Tissue enhanced",NA,"adrenal gland: 189.9;liver: 514.2","small intestine: 91.1","Group enriched",30,"Hep G2: 25.8;RT4: 20.3"
"SUOX",NA,"ENSG00000139531","Sulfite oxidase","12","55997180-56006641","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA038208, HPA038209","Approved",NA,NA,NA,"Renal cancer:4.77e-7 (favourable), Urothelial cancer:8.32e-5 (favourable), Pancreatic cancer:6.28e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 108.9","Mixed",NA,NA
"SUPT7L","KIAA0764, SPT7L, STAF65, STAF65gamma","ENSG00000119760","SPT7-like STAGA complex gamma subunit","2","27650812-27663840","Predicted intracellular proteins","Evidence at protein level","HPA039565, HPA063643","Uncertain",NA,"Approved","Nucleoplasm","Liver cancer:4.46e-7 (unfavourable), Renal cancer:1.53e-4 (unfavourable), Endometrial cancer:2.28e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"endometrium: 45.6","Expressed in all",NA,NA
"SYNC","SYNC1, SYNCOILIN","ENSG00000162520","Syncoilin, intermediate filament protein","1","32680360-32703596","Predicted intracellular proteins","Evidence at protein level","HPA028311","Approved",NA,"Approved","Golgi apparatus<br>Vesicles<br>Plasma membrane",NA,"Mixed","Tissue enhanced",NA,"smooth muscle: 74.1","skeletal muscle: 36.1","Cell line enhanced",NA,"BJ hTERT+: 65.1;fHDF/TERT166: 91.5;U-138 MG: 98.1;WM-115: 67.5"
"SYNJ2BP","Arip2","ENSG00000213463","Synaptojanin 2 binding protein","14","70366496-70417061","Predicted membrane proteins","Evidence at protein level","HPA000866","Approved","Supported","Approved","Mitochondria","Renal cancer:1.11e-16 (favourable)","Expressed in all","Mixed",NA,NA,"parathyroid gland: 40.9","Mixed",NA,NA
"SYNJ2BP-COX16",NA,"ENSG00000258644","SYNJ2BP-COX16 readthrough","14","70326064-70417074","Predicted intracellular proteins","Evidence at protein level","HPA000866, HPA062659","Approved","Supported","Enhanced","Mitochondria",NA,"Not detected","Tissue enhanced",NA,"testis: 39.7","skeletal muscle: 15.1","Mixed",NA,NA
"TBC1D12","KIAA0608","ENSG00000108239","TBC1 domain family member 12","10","94402504-94535930","Cancer-related genes, Predicted intracellular proteins","Evidence at protein level","HPA038277, HPA038645","Uncertain",NA,"Approved","Nucleoplasm<br>Nuclear speckles","Colorectal cancer:1.79e-5 (favourable)","Expressed in all","Mixed",NA,NA,"parathyroid gland: 19.4","Mixed",NA,NA
"TBC1D14","KIAA1322","ENSG00000132405","TBC1 domain family member 14","4","6909242-7033118","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA036930, HPA067398","Approved",NA,"Supported","Nucleoplasm<br>Golgi apparatus<br>Vesicles","Renal cancer:5.28e-10 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 67.5","Expressed in all",NA,NA
"TBC1D25","OATL1","ENSG00000068354","TBC1 domain family member 25","X","48539457-48562609","Predicted intracellular proteins","Evidence at protein level","HPA029197","Approved","Supported",NA,NA,NA,"Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 12.9","Expressed in all",NA,NA
"TBC1D7","dJ257A7.3, FLJ32666","ENSG00000145979","TBC1 domain family member 7","6","13266542-13328583","Disease related genes, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA034748","Approved",NA,NA,NA,"Renal cancer:2.03e-7 (unfavourable), Ovarian cancer:4.98e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"epididymis: 24.4","Expressed in all",NA,NA
"TBC1D9","GRAMD9, KIAA0882, MDR1","ENSG00000109436","TBC1 domain family member 9","4","140620765-140756120","Predicted intracellular proteins","Evidence at protein level","HPA000262, HPA006317, HPA006503","Uncertain","Supported","Approved","Nucleoplasm<br>Cytosol","Renal cancer:1.61e-6 (favourable)","Tissue enriched","Mixed",NA,NA,"breast: 65.6","Mixed",NA,NA
"TBCC","CFC","ENSG00000124659","Tubulin folding cofactor C","6","42744481-42746096","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA035073, HPA035074","Approved",NA,"Enhanced","Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"lymph node: 32.8","Expressed in all",NA,NA
"TCF7L2","TCF-4, TCF4","ENSG00000148737","Transcription factor 7 like 2","10","112950250-113167678","Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors","Evidence at protein level","CAB013535, HPA038800","Supported","Approved","Supported","Nucleoplasm<br>Nuclear bodies",NA,"Expressed in all","Expressed in all",NA,NA,"endometrium: 30.9","Mixed",NA,NA
"TCTEX1D1","FLJ40873","ENSG00000152760","Tctex1 domain containing 1","1","66752459-66778787","Predicted intracellular proteins","Evidence at protein level","HPA028420","Uncertain",NA,NA,NA,NA,"Tissue enriched","Tissue enhanced",NA,"fallopian tube: 16.6;placenta: 9.6","liver: 4.0","Group enriched",6,"HEL: 14.3;HUVEC TERT2: 13.0;THP-1: 12.0"
"TDRD7","PCTAIRE2BP","ENSG00000196116","Tudor domain containing 7","9","97411950-97496125","Disease related genes, Predicted intracellular proteins","Evidence at protein level","CAB020800, HPA022250, HPA024529","Approved",NA,"Supported","Nucleoplasm<br>Cytoplasmic bodies","Renal cancer:4.76e-5 (favourable), Liver cancer:5.91e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 64.1","Cell line enhanced",NA,"HDLM-2: 49.4"
"TK2","SCA31","ENSG00000166548","Thymidine kinase 2, mitochondrial","16","66508003-66552544","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA041162","Uncertain",NA,NA,NA,"Renal cancer:2.18e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 89.9","Mixed",NA,NA
"TLDC1","KIAA1609","ENSG00000140950","TBC/LysM-associated domain containing 1","16","84476421-84554033","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA041020","Approved",NA,"Approved","Nucleus<br>Nucleoli<br>Cytosol","Lung cancer:1.03e-5 (unfavourable), Pancreatic cancer:7.05e-5 (unfavourable)","Expressed in all","Mixed",NA,NA,"placenta: 15.5","Mixed",NA,NA
"TM7SF2","ANG1, DHCR14A, NET47","ENSG00000149809","Transmembrane 7 superfamily member 2","11","65111845-65116384","Enzymes, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA030691, HPA072704","Approved",NA,"Supported","Endoplasmic reticulum<br>Vesicles","Renal cancer:8.49e-8 (favourable)","Expressed in all","Expressed in all",NA,NA,"adrenal gland: 160.5","Cell line enhanced",NA,"T-47d: 122.6"
"TMEM173","ERIS, FLJ38577, MITA, MPYS, NET23, STING","ENSG00000184584","Transmembrane protein 173","5","139475534-139482935","Disease related genes, Predicted membrane proteins","Evidence at protein level","HPA038116, HPA038534","Enhanced",NA,NA,NA,"Renal cancer:3.59e-8 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"fallopian tube: 70.7","Cell line enhanced",NA,"EFO-21: 150.4;HDLM-2: 331.0"
"TMEM259","ASBABP1, C19orf6, MBRL, MGC4022","ENSG00000182087","Transmembrane protein 259","19","1009648-1021179","Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA042669, HPA054801","Approved",NA,"Approved","Nuclear speckles<br>Endoplasmic reticulum","Stomach cancer:8.92e-6 (favourable), Endometrial cancer:1.01e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"spleen: 129.7","Expressed in all",NA,NA
"TMEM40","FLJ11036","ENSG00000088726","Transmembrane protein 40","3","12733525-12769457","Predicted membrane proteins","Evidence at protein level","HPA044165","Enhanced",NA,"Approved","Cytosol",NA,"Tissue enhanced","Group enriched",8,"esophagus: 88.8;placenta: 23.3;skin: 55.5;tonsil: 23.7","urinary bladder: 6.1","Cell line enhanced",NA,"HBEC3-KT: 182.0;hTCEpi: 40.5;hTERT-HME1: 54.0"
"TMEM63C","C14orf171, CSC1, DKFZp434P0111, hsCSC1","ENSG00000165548","Transmembrane protein 63C","14","77116568-77259495","Predicted intracellular proteins, Predicted membrane proteins, Transporters","Evidence at protein level","HPA030657","Uncertain",NA,"Approved","Centrosome",NA,"Mixed","Tissue enhanced",NA,"adrenal gland: 12.9;cerebral cortex: 18.5;testis: 13.8","epididymis: 5.6","Cell line enhanced",NA,"Daudi: 13.3;Karpas-707: 17.4;SCLC-21H: 38.5;SK-BR-3: 21.9"
"TMEM70","FLJ20533","ENSG00000175606","Transmembrane protein 70","8","73972437-73982783","Disease related genes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA023187, CAB034226","Uncertain",NA,"Supported","Nucleoplasm<br>Mitochondria",NA,"Expressed in all","Expressed in all",NA,NA,"skeletal muscle: 30.2","Expressed in all",NA,NA
"TMX3","FLJ20793, KIAA1830, PDIA13, TXNDC10","ENSG00000166479","Thioredoxin related transmembrane protein 3","18","68673688-68715298","Enzymes, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA014157","Uncertain",NA,NA,NA,"Renal cancer:2.87e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"lymph node: 31.4","Expressed in all",NA,NA
"TNFRSF1A","CD120a, TNF-R, TNF-R-I, TNF-R55, TNFAR, TNFR1, TNFR60","ENSG00000067182","TNF receptor superfamily member 1A","12","6328757-6342114","Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Evidence at protein level","HPA004102, CAB010309","Approved",NA,NA,NA,"Renal cancer:2.70e-7 (unfavourable), Head and neck cancer:3.68e-4 (unfavourable), Endometrial cancer:8.22e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"smooth muscle: 141.2","Mixed",NA,NA
"TPGS2","C18orf10, DKFZP586M1523, HsT3006","ENSG00000134779","Tubulin polyglutamylase complex subunit 2","18","36777647-36829216","Predicted intracellular proteins","Evidence at protein level","HPA040596, HPA040617, HPA061753","Uncertain",NA,"Supported","Nucleoli","Liver cancer:1.24e-5 (unfavourable), Ovarian cancer:1.93e-5 (favourable), Cervical cancer:4.09e-4 (favourable), Testis cancer:7.74e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"testis: 367.2","Expressed in all",NA,NA
"TPRKB","CGI-121, CGI121","ENSG00000144034","TP53RK binding protein","2","73729104-73737400","Predicted intracellular proteins","Evidence at protein level","HPA035712","Approved",NA,"Supported","Cytosol",NA,"Expressed in all","Expressed in all",NA,NA,"testis: 79.9","Expressed in all",NA,NA
"TRAF7","DKFZp586I021, MGC7807, RFWD1, RNF119","ENSG00000131653","TNF receptor associated factor 7","16","2155698-2178129","Cancer-related genes, Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA041229","Approved",NA,"Supported","Vesicles<br>Plasma membrane",NA,"Expressed in all","Expressed in all",NA,NA,"skin: 40.6","Expressed in all",NA,NA
"TRMT112","HSPC152, HSPC170, hTrm112, TRM112, TRMT11-2","ENSG00000173113","TRNA methyltransferase 11-2 homolog (S. cerevisiae)","11","64316460-64318084","Predicted intracellular proteins","Evidence at protein level","HPA039901, HPA040006","Uncertain",NA,"Approved","Nucleus<br>Microtubules","Head and neck cancer:1.62e-4 (unfavourable), Renal cancer:2.78e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"fallopian tube: 306.4","Expressed in all",NA,NA
"TRUB1","PUS4","ENSG00000165832","TruB pseudouridine synthase family member 1","10","114938193-114977676","Predicted intracellular proteins","Evidence at protein level","HPA037914, HPA057552","Approved",NA,"Supported","Vesicles<br>Actin filaments",NA,"Expressed in all","Expressed in all",NA,NA,"adrenal gland: 38.5","Expressed in all",NA,NA
"TTC7A","KIAA1140, TTC7","ENSG00000068724","Tetratricopeptide repeat domain 7A","2","46916157-47076137","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA036781, HPA036782","Enhanced",NA,NA,NA,"Ovarian cancer:1.36e-4 (unfavourable)","Expressed in all","Tissue enhanced",NA,"testis: 40.9","lung: 17.7","Expressed in all",NA,NA
"TTLL8",NA,"ENSG00000138892","Tubulin tyrosine ligase like 8","22","50015123-50056935","Predicted intracellular proteins","Evidence at transcript level","HPA016882","Uncertain",NA,NA,NA,NA,"Not detected","Tissue enriched",42,"testis: 4.2","all non-specific tissues: 0.0","Not detected",NA,NA
"TUBD1","FLJ12709, TUBD","ENSG00000108423","Tubulin delta 1","17","59859482-59892945","FDA approved drug targets, Predicted intracellular proteins","Evidence at protein level","CAB004609, HPA023980, HPA027090","Approved",NA,"Enhanced","Nucleoplasm<br>Cytosol","Liver cancer:1.00e-5 (unfavourable), Colorectal cancer:2.04e-4 (favourable), Renal cancer:6.06e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 12.5","Expressed in all",NA,NA
"TUBE1","dJ142L7.2, FLJ22589, TUBE","ENSG00000074935","Tubulin epsilon 1","6","112070777-112087529","FDA approved drug targets, Predicted intracellular proteins","Evidence at protein level","HPA032073, HPA032074","Approved",NA,NA,NA,NA,"Expressed in all","Expressed in all",NA,NA,"testis: 55.3","Expressed in all",NA,NA
"TUBGCP6","DJ402G11.6, GCP6, KIAA1669","ENSG00000128159","Tubulin gamma complex associated protein 6","22","50217689-50244992","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA043928","Approved",NA,NA,NA,"Urothelial cancer:3.18e-5 (favourable), Pancreatic cancer:5.75e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 28.2","Expressed in all",NA,NA
"UBE3C","KIAA0010, KIAA10","ENSG00000009335","Ubiquitin protein ligase E3C","7","157138913-157269372","Enzymes, Predicted intracellular proteins","Evidence at protein level","HPA039915","Approved",NA,"Approved","Nucleoplasm<br>Plasma membrane<br>Mitochondria","Renal cancer:9.18e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 51.1","Expressed in all",NA,NA
"UBL7","BMSC-UbP, MGC14421","ENSG00000138629","Ubiquitin like 7","15","74445977-74461182","Predicted intracellular proteins","Evidence at protein level","HPA040423, HPA041897","Approved",NA,"Approved","Nucleoplasm<br>Cytosol","Cervical cancer:6.37e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 76.4","Expressed in all",NA,NA
"UBR2","bA49A4.1, C6orf133, dJ392M17.3, KIAA0349","ENSG00000024048","Ubiquitin protein ligase E3 component n-recognin 2","6","42564062-42693504","Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Evidence at protein level","HPA027869, HPA027880","Approved",NA,"Approved","Nucleoplasm<br>Plasma membrane","Ovarian cancer:1.65e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 30.5","Expressed in all",NA,NA
"UBXN2B","p37","ENSG00000215114","UBX domain protein 2B","8","58411264-58451501","Predicted intracellular proteins","Evidence at protein level","HPA045278","Uncertain",NA,"Approved","Nucleoplasm",NA,"Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 27.0","Expressed in all",NA,NA
"UFSP2","C4orf20, FLJ11200","ENSG00000109775","UFM1 specific peptidase 2","4","185399540-185425985","Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins","Evidence at protein level","HPA039985, HPA043298","Approved",NA,"Approved","Nucleus<br>Cytosol","Renal cancer:1.07e-8 (favourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 53.0","Expressed in all",NA,NA
"UPK1B","TSPAN20, UPK1","ENSG00000114638","Uroplakin 1B","3","119173517-119205153","Predicted membrane proteins, Transporters","Evidence at protein level","HPA031799, HPA031800","Enhanced",NA,NA,NA,"Endometrial cancer:3.87e-5 (favourable), Stomach cancer:7.76e-4 (unfavourable)","Tissue enhanced","Tissue enhanced",NA,"stomach: 33.1;urinary bladder: 36.1","tonsil: 15.4","Cell line enhanced",NA,"CACO-2: 33.3;RPTEC TERT1: 27.6;RT4: 115.3"
"USB1","C16orf57, FLJ13154, HVSL1, Mpn1","ENSG00000103005","U6 snRNA biogenesis phosphodiesterase 1","16","57999546-58021618","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA041791, HPA059854","Approved",NA,"Supported","Nucleus","Liver cancer:6.69e-7 (unfavourable), Renal cancer:2.02e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"appendix: 37.4","Expressed in all",NA,NA
"VPS26B","MGC10485, Pep8b","ENSG00000151502","VPS26, retromer complex component B","11","134224645-134247792","Predicted intracellular proteins","Evidence at protein level","HPA038172","Uncertain",NA,NA,NA,NA,"Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 60.4","Expressed in all",NA,NA
"VPS37D","MGC35352, WBSCR24","ENSG00000176428","VPS37D, ESCRT-I subunit","7","73667825-73672112","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA040978","Uncertain",NA,"Approved","Vesicles","Renal cancer:5.80e-9 (favourable), Pancreatic cancer:2.07e-5 (favourable)","Expressed in all","Mixed",NA,NA,"cerebral cortex: 6.3","Cell line enhanced",NA,"SH-SY5Y: 12.4"
"VWA3A","FLJ40941, FLJ46765","ENSG00000175267","Von Willebrand factor A domain containing 3A","16","22092538-22156966","Predicted intracellular proteins","Evidence at protein level","HPA041696, HPA042044","Uncertain",NA,NA,NA,"Endometrial cancer:8.15e-4 (favourable)","Tissue enhanced","Tissue enhanced",NA,"fallopian tube: 10.8;testis: 3.3","lung: 2.8","Not detected",NA,NA
"WASHC3","CCDC53, CGI-116","ENSG00000120860","WASH complex subunit 3","12","102012927-102062149","Predicted intracellular proteins","Evidence at protein level","HPA038338, HPA038339","Approved",NA,"Approved","Vesicles",NA,"Expressed in all","Expressed in all",NA,NA,"testis: 165.7","Expressed in all",NA,NA
"WDFY3","ALFY, KIAA0993, ZFYVE25","ENSG00000163625","WD repeat and FYVE domain containing 3","4","84669610-84966391","Predicted intracellular proteins","Evidence at protein level","HPA042734, HPA048572","Approved",NA,"Approved","Nucleoli<br>Plasma membrane<br>Cytosol","Renal cancer:3.64e-5 (favourable), Stomach cancer:9.35e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 36.2","Mixed",NA,NA
"WDR26","FLJ21016, GID7","ENSG00000162923","WD repeat domain 26","1","224385143-224437033","Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA028539, HPA061094","Enhanced",NA,"Enhanced","Nucleoplasm<br>Cytosol","Renal cancer:3.31e-6 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 53.9","Expressed in all",NA,NA
"WDR35","IFT121, IFTA1, KIAA1336, MGC33196","ENSG00000118965","WD repeat domain 35","2","19910260-19990131","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA044147","Approved",NA,NA,NA,NA,"Expressed in all","Mixed",NA,NA,"parathyroid gland: 26.2","Mixed",NA,NA
"WDR47","KIAA0893","ENSG00000085433","WD repeat domain 47","1","108970214-109042113","Predicted intracellular proteins","Evidence at protein level","HPA027287, HPA027289","Approved",NA,"Approved","Actin filaments","Head and neck cancer:9.86e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 73.3","Expressed in all",NA,NA
"WDR6",NA,"ENSG00000178252","WD repeat domain 6","3","49007062-49015953","Predicted intracellular proteins","Evidence at protein level","HPA042622","Approved",NA,"Supported","Plasma membrane<br>Cytosol","Liver cancer:2.97e-6 (unfavourable), Renal cancer:4.52e-5 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 204.8","Expressed in all",NA,NA
"WRAP73","WDR8","ENSG00000116213","WD repeat containing, antisense to TP73","1","3630767-3652761","Predicted intracellular proteins","Evidence at protein level","HPA026893","Uncertain",NA,"Approved","Nucleoplasm<br>Cell Junctions","Liver cancer:1.37e-4 (unfavourable), Renal cancer:1.42e-4 (unfavourable), Pancreatic cancer:3.49e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"lymph node: 20.4","Expressed in all",NA,NA
"WWC1","KIAA0869, KIBRA, PPP1R168","ENSG00000113645","WW and C2 domain containing 1","5","168291651-168472303","Predicted intracellular proteins","Evidence at protein level","HPA038016, HPA038017","Approved",NA,"Approved","Golgi apparatus","Renal cancer:1.95e-8 (favourable)","Expressed in all","Mixed",NA,NA,"salivary gland: 61.5","Cell line enhanced",NA,"RPTEC TERT1: 195.6"
"WWC3","BM042, KIAA1280","ENSG00000047644","WWC family member 3","X","10015562-10144478","Predicted intracellular proteins","Evidence at protein level","HPA039814","Uncertain",NA,"Approved","Actin filaments<br>Cytosol","Renal cancer:1.06e-5 (unfavourable), Colorectal cancer:1.31e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"seminal vesicle: 39.8","Cell line enhanced",NA,"T-47d: 129.2"
"XIRP2","CMYA3","ENSG00000163092","Xin actin binding repeat containing 2","2","166888487-167259753","Cancer-related genes, Plasma proteins, Predicted intracellular proteins","Evidence at protein level","HPA034813, HPA074599","Uncertain",NA,"Approved","Nucleoplasm<br>Plasma membrane",NA,"Tissue enriched","Group enriched",22,"heart muscle: 84.0;skeletal muscle: 301.6","prostate: 8.8","Cell line enhanced",NA,"AN3-CA: 1.4;HUVEC TERT2: 3.5;U-2197: 2.7"
"XPO6","FLJ22519, KIAA0370, RANBP20","ENSG00000169180","Exportin 6","16","28097979-28211920","Predicted intracellular proteins","Evidence at protein level","HPA038246","Uncertain",NA,"Approved","Nucleus<br>Nucleoli<br>Plasma membrane<br>Cytosol","Liver cancer:3.68e-4 (unfavourable), Urothelial cancer:8.80e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 93.8","Expressed in all",NA,NA
"YBX1","BP-8, CSDA2, CSDB, DBPB, MDR-NF1, NSEP-1, NSEP1, YB-1, YB1","ENSG00000065978","Y-box binding protein 1","1","42682427-42702349","Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors","Evidence at protein level","CAB005875, HPA040304, HPA057159","Supported",NA,"Enhanced","Vesicles<br>Cytosol","Liver cancer:9.87e-10 (unfavourable), Renal cancer:3.59e-7 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 1542.9","Expressed in all",NA,NA
"YKT6",NA,"ENSG00000106636","YKT6 v-SNARE homolog (S. cerevisiae)","7","44200968-44214294","Predicted intracellular proteins","Evidence at protein level","HPA030817, HPA030818","Approved",NA,"Approved","Mitochondria<br>Cytosol","Liver cancer:1.02e-4 (unfavourable), Head and neck cancer:4.64e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 61.8","Expressed in all",NA,NA
"ZC3H12A","FLJ23231, MCPIP1","ENSG00000163874","Zinc finger CCCH-type containing 12A","1","37474552-37484379","Disease related genes, Predicted intracellular proteins","Evidence at protein level","HPA032052, HPA032053","Uncertain",NA,"Supported","Nucleoplasm<br>Cytoplasmic bodies","Renal cancer:5.95e-5 (unfavourable), Endometrial cancer:9.67e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"bone marrow: 84.3","gallbladder: 55.5","Cell line enhanced",NA,"RT4: 48.1"
"ZC3H6","FLJ41410, FLJ45877, KIAA2035, ZC3HDC6","ENSG00000188177","Zinc finger CCCH-type containing 6","2","112275594-112340063","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA036019, HPA036020, HPA076065","Uncertain",NA,"Approved","Nucleoplasm<br>Golgi apparatus",NA,"Expressed in all","Mixed",NA,NA,"ovary: 7.6","Mixed",NA,NA
"ZCCHC10","FLJ20094","ENSG00000155329","Zinc finger CCHC-type containing 10","5","132996985-133026604","Predicted intracellular proteins","Evidence at protein level","HPA038944","Approved",NA,"Approved","Nucleus<br>Nucleoli",NA,"Expressed in all","Expressed in all",NA,NA,"testis: 43.5","Expressed in all",NA,NA
"ZCCHC12","FLJ16123, PNMA7A, SIZN, SIZN1","ENSG00000174460","Zinc finger CCHC-type containing 12","X","118823790-118826968","Predicted intracellular proteins","Evidence at protein level","HPA031016, HPA034940","Uncertain",NA,"Approved","Nuclear bodies","Thyroid cancer:3.42e-5 (favourable)","Tissue enriched","Group enriched",8,"endometrium: 167.0;fallopian tube: 184.1;smooth muscle: 203.5","cerebral cortex: 24.3","Cell line enhanced",NA,"HAP1: 4.0;HEK 293: 9.1;NTERA-2: 3.1;SH-SY5Y: 2.6"
"ZCCHC18","PNMA7B, SIZN2","ENSG00000166707","Zinc finger CCHC-type containing 18","X","104112131-104115846","Predicted intracellular proteins","Evidence at transcript level","HPA034940","Uncertain",NA,NA,NA,NA,"Tissue enhanced","Tissue enhanced",NA,"cerebral cortex: 5.6","ovary: 4.2","Cell line enhanced",NA,"Karpas-707: 3.3;SH-SY5Y: 3.2"
"ZDHHC4","FLJ10479, ZNF374","ENSG00000136247","Zinc finger DHHC-type containing 4","7","6577434-6589374","Enzymes, Predicted membrane proteins","Evidence at protein level","HPA032124, HPA064358","Approved",NA,"Approved","Nuclear bodies","Renal cancer:1.18e-7 (favourable), Head and neck cancer:3.95e-6 (unfavourable), Urothelial cancer:8.94e-4 (unfavourable), Cervical cancer:9.35e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"thyroid gland: 77.7","Mixed",NA,NA
"ZFP69","FLJ16030, ZFP69A, ZKSCAN23A, ZNF642, ZSCAN54A","ENSG00000187815","ZFP69 zinc finger protein","1","40477215-40496343","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA027808, HPA054942","Uncertain",NA,"Approved","Nucleus","Renal cancer:5.00e-6 (unfavourable), Head and neck cancer:9.31e-4 (favourable)","Expressed in all","Mixed",NA,NA,"testis: 6.7","Cell line enhanced",NA,"THP-1: 39.0"
"ZKSCAN5","ZFP95, ZNF914, ZSCAN37","ENSG00000196652","Zinc finger with KRAB and SCAN domains 5","7","99504651-99534700","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA003201","Uncertain",NA,"Approved","Intermediate filaments","Liver cancer:7.59e-6 (unfavourable), Thyroid cancer:1.13e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"testis: 15.1","Expressed in all",NA,NA
"ZMAT2","FLJ31121, hSNU23, Snu23","ENSG00000146007","Zinc finger matrin-type 2","5","140698680-140706676","Predicted intracellular proteins","Evidence at protein level","HPA036518","Approved",NA,"Approved","Nucleus<br>Mitochondria","Colorectal cancer:7.96e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"cerebral cortex: 103.3","Expressed in all",NA,NA
"ZMYM4","KIAA0425, MYM, ZNF198L3, ZNF262","ENSG00000146463","Zinc finger MYM-type containing 4","1","35268967-35422058","Predicted intracellular proteins","Evidence at protein level","HPA051301, HPA054802","Approved",NA,"Supported","Nucleoplasm<br>Cytosol","Liver cancer:9.75e-9 (unfavourable), Renal cancer:8.10e-4 (unfavourable)","Expressed in all","Expressed in all",NA,NA,"testis: 63.9","Expressed in all",NA,NA
"ZNF124","HZF-16, HZF16","ENSG00000196418","Zinc finger protein 124","1","247121975-247172016","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA031127","Uncertain",NA,"Approved","Nucleus<br>Nuclear membrane","Urothelial cancer:1.03e-4 (favourable)","Expressed in all","Mixed",NA,NA,"salivary gland: 16.8","Mixed",NA,NA
"ZNF407","FLJ13839, FLJ20307, KIAA1703","ENSG00000215421","Zinc finger protein 407","18","74597870-75065671","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA028255, HPA041673","Uncertain",NA,"Approved","Nucleoplasm<br>Plasma membrane","Renal cancer:9.79e-5 (favourable)","Expressed in all","Mixed",NA,NA,"parathyroid gland: 9.0","Mixed",NA,NA
"ZNF426","MGC2663","ENSG00000130818","Zinc finger protein 426","19","9523224-9538645","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA029342","Approved",NA,"Approved","Nucleoplasm","Renal cancer:2.57e-6 (favourable), Urothelial cancer:1.81e-4 (favourable), Head and neck cancer:3.74e-4 (favourable)","Expressed in all","Mixed",NA,NA,"esophagus: 22.7","Mixed",NA,NA
"ZNF503","FLJ45745, MGC2555, Nlz2","ENSG00000165655","Zinc finger protein 503","10","75397830-75401906","Predicted intracellular proteins","Evidence at protein level","HPA026848","Approved",NA,"Approved","Nucleoplasm<br>Plasma membrane<br>Cytosol","Renal cancer:1.97e-4 (favourable), Prostate cancer:3.50e-4 (unfavourable)","Expressed in all","Mixed",NA,NA,"adrenal gland: 25.7","Cell line enhanced",NA,"HEK 293: 100.8;PC-3: 132.2"
"ZNF577","MGC4400","ENSG00000161551","Zinc finger protein 577","19","51804816-51890950","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA041499, HPA046761","Uncertain",NA,"Supported","Nucleus<br>Nucleoli","Urothelial cancer:2.03e-4 (favourable)","Mixed","Mixed",NA,NA,"ovary: 28.9","Mixed",NA,NA
"ZNF582","FLJ30927","ENSG00000018869","Zinc finger protein 582","19","56375846-56393545","Predicted intracellular proteins, Transcription factors","Evidence at transcript level","HPA028858","Uncertain",NA,"Approved","Nucleoplasm<br>Cytosol",NA,"Mixed","Mixed",NA,NA,"thyroid gland: 12.4","Cell line enhanced",NA,"HEK 293: 26.0"
"ZNF598","FLJ00086","ENSG00000167962","Zinc finger protein 598","16","1997654-2009823","Predicted intracellular proteins","Evidence at protein level","HPA041760, HPA041896","Approved",NA,"Approved","Plasma membrane<br>Cytosol",NA,"Expressed in all","Mixed",NA,NA,"spleen: 11.5","Expressed in all",NA,NA
"ZNF606","FLJ14260, KIAA1852, ZNF328","ENSG00000166704","Zinc finger protein 606","19","57977053-58003349","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA041712, HPA043584","Uncertain",NA,"Supported","Nucleoplasm","Urothelial cancer:4.75e-6 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 18.9","Cell line enhanced",NA,"HEK 293: 21.5"
"ZNF641","FLJ31295","ENSG00000167528","Zinc finger protein 641","12","48337180-48351414","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA035189","Uncertain",NA,"Supported","Nucleoplasm","Pancreatic cancer:8.30e-5 (favourable), Ovarian cancer:3.91e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"adrenal gland: 28.8","Expressed in all",NA,NA
"ZNF678","MGC42493","ENSG00000181450","Zinc finger protein 678","1","227563543-227677443","Predicted intracellular proteins, Transcription factors","Evidence at transcript level","HPA028507","Uncertain",NA,"Approved","Nucleoli<br>Mitochondria<br>Cytosol",NA,"Expressed in all","Mixed",NA,NA,"thyroid gland: 8.9","Expressed in all",NA,NA
"ZNF710","DKFZp547K1113, FLJ00306, FLJ37393","ENSG00000140548","Zinc finger protein 710","15","90001392-90082206","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA030226, HPA030227, HPA030228","Enhanced",NA,"Approved","Nucleoplasm<br>Mitochondria",NA,"Expressed in all","Expressed in all",NA,NA,"appendix: 20.4","Expressed in all",NA,NA
"ZNF711","CMPX1, dJ75N13.1, MRX97, Zfp711, ZNF4, ZNF5, ZNF6","ENSG00000147180","Zinc finger protein 711","X","85244032-85273362","Disease related genes, Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA030654","Enhanced",NA,"Approved","Nucleoplasm",NA,"Mixed","Tissue enhanced",NA,"testis: 69.8","cerebral cortex: 32.7","Cell line enhanced",NA,"AF22: 34.0;HAP1: 51.8;HEK 293: 42.5;RH-30: 40.6"
"ZNF749","FLJ16360","ENSG00000186230","Zinc finger protein 749","19","57435329-57445485","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA042082, HPA042091, HPA056001","Uncertain",NA,"Approved","Nucleoplasm<br>Nuclear membrane",NA,"Expressed in all","Mixed",NA,NA,"parathyroid gland: 4.2","Expressed in all",NA,NA
"ZNF772","DKFZp686I1569","ENSG00000197128","Zinc finger protein 772","19","57466663-57477570","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA031312","Uncertain",NA,"Approved","Cytosol","Renal cancer:1.02e-6 (favourable)","Mixed","Mixed",NA,NA,"parathyroid gland: 20.0","Cell line enhanced",NA,"BJ hTERT+ SV40 Large T+ RasG12V: 28.4"
"ZNF821",NA,"ENSG00000102984","Zinc finger protein 821","16","71859680-71895336","Predicted intracellular proteins","Evidence at protein level","HPA036372, HPA042742","Enhanced",NA,"Supported","Nucleoplasm<br>Nuclear speckles","Renal cancer:6.32e-10 (favourable), Pancreatic cancer:4.27e-5 (favourable), Glioma:1.55e-4 (favourable)","Expressed in all","Tissue enhanced",NA,"testis: 33.2","cerebral cortex: 13.7","Cell line enhanced",NA,"SCLC-21H: 15.5"
"ZNF85","HPF4, HTF1","ENSG00000105750","Zinc finger protein 85","19","20923222-20950697","Predicted intracellular proteins, Transcription factors","Evidence at protein level","HPA044760","Uncertain",NA,"Supported","Nucleus","Ovarian cancer:6.45e-6 (favourable), Endometrial cancer:5.20e-5 (unfavourable)","Mixed","Tissue enhanced",NA,"testis: 28.0","thyroid gland: 12.0","Mixed",NA,NA
"ZNF862",NA,"ENSG00000106479","Zinc finger protein 862","7","149838367-149867479","Predicted intracellular proteins","Evidence at protein level","HPA024154","Uncertain",NA,"Approved","Mitochondria","Urothelial cancer:8.66e-4 (favourable)","Expressed in all","Expressed in all",NA,NA,"parathyroid gland: 23.7","Mixed",NA,NA

